var images_info;if (!images_info) images_info =[]; images_info["67"]={"67000":{"type":"graphic_diagnosticimage","displayName":"FAST Morisons pouch normal","title":"FAST: Hepatorenal (Morisons) space","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">FAST: Hepatorenal (Morisons) space</div><div class=\"cntnt\"><img style=\"width:504px; height:397px;\" src=\"images/EM/67000_FAST_Morisons_pouch_normal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This image, obtained as part of a FAST examination, reveals normal juxtaposition of the liver and kidney without free fluid.</div><div class=\"graphic_footnotes\">FAST: Focused Assessment with Sonography for Trauma; L: liver; K: kidney.</div><div class=\"graphic_reference\">Courtesy of Greg Snead, MD.</div><div id=\"graphicVersion\">Graphic 67000 Version 2.0</div></div></div>"},"67001":{"type":"graphic_figure","displayName":"HBV cirrhosis and HCC","title":"Hepatocellular carcinoma in HBV-related cirrhosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hepatocellular carcinoma in HBV-related cirrhosis</div><div class=\"cntnt\"><img style=\"width:359px; height:230px;\" src=\"images/GAST/67001_HBV_cirrhosis_and_HCC.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cumulative probability of developing hepatocellular carcinoma in patients with compensated cirrhosis related to hepatitis B virus (HBV) infection.</div><div class=\"graphic_reference\">Data from: Fattovich G, Giustina G, Schalm SW, et al. Hepatology 1995; 21:77.</div><div id=\"graphicVersion\">Graphic 67001 Version 3.0</div></div></div>"},"67005":{"type":"graphic_diagnosticimage","displayName":"Blood in fetal stomach","title":"Intraamniotic bleeding and gastric pseudomass in fetus at 21 weeks' gestational age, 2 weeks after transplacental amniocentesis","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Intraamniotic bleeding and gastric pseudomass in fetus at 21 weeks' gestational age, 2 weeks after transplacental amniocentesis</div><div class=\"cntnt\"><img style=\"width:512px; height:226px;\" src=\"images/OBGYN/67005_Blood_in_fetal_stomach.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Transverse transabdominal sonogram shows echogenic particles floating in amniotic fluid (arrow) that were not present before amniocentesis. Until third trimester, echogenic particles in amniotic fluid should raise possibility of bleeding. Later in pregnancy, particles are most commonly the result of shed epithelial cells (vernix caseosa). (B) Transverse sonogram of fetal abdomen shows echogenic material (arrow) in stomach that results from fetus swallowing echogenic blood particles that resulted from recent amniocentesis. Gastric pseudomasses resolve on follow-up examination. To our knowledge, no gastric neoplasms have been reported on prenatal sonography.</div><div class=\"graphic_reference\">Reproduced with permission from: Trop I, Levine D. Hemorrage During Pregnancy: Sonography and MR Imaging. AJR Am J.</div><div id=\"graphicVersion\">Graphic 67005 Version 3.0</div></div></div>"},"67006":{"type":"graphic_table","displayName":"Vitamin preparations for CF, water-soluble and zinc","title":"Vitamin preparations for cystic fibrosis, water-soluble vitamin content","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Vitamin preparations for cystic fibrosis, water-soluble vitamin content</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">AquADEKs<br /> (drops, chewables)<sup>*</sup></td> <td class=\"subtitle1\">DEKAs&nbsp;Plus<sup>*&#182;</sup> (liquid, chewables, softgels)&nbsp;&nbsp;</td> <td class=\"subtitle1\">Libertas ABDEK<br /> (drops, chewables, softgels)</td> <td class=\"subtitle1\">MVW Complete Formulation<br /> (drops, chewables, softgels<sup>&#916;</sup>)</td> <td class=\"subtitle1\"> <p>Poly-Vi-Sol<br /> (drops, no iron)</p> Centrum Kids<br /> (chewable, tablet)&nbsp;</td> <td class=\"subtitle1\">Vitamax<br /> (drops, chewables)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Thiamin (vitamin B1); mg</td> </tr> <tr> <td class=\"indent1\">0 to 12 months</td> <td>0.6 mg/1 mL</td> <td>0.6 mg/1 mL&nbsp;</td> <td>0.5 mg/1 mL</td> <td>0.5 mg/0.5 mL</td> <td>0.5 mg/1 mL&nbsp;</td> <td>0.5 mg/1 mL</td> </tr> <tr> <td class=\"indent1\">1 to 3 years</td> <td>1.2 mg/2 mL</td> <td>1.2 mg/2 mL&nbsp;</td> <td>1 mg/2 mL</td> <td>1 mg/1 mL</td> <td>1 mg/2 mL&nbsp;</td> <td>1 mg/2 mL</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">4 to 10 years</td> <td rowspan=\"2\">1.5 mg/2 chewables</td> <td rowspan=\"2\">1.5 mg/1 chewable&nbsp;<br /> <strong>or</strong> 1 softgel</td> <td rowspan=\"2\">1.5 mg/1 chewable</td> <td> <p>Ages 4 to 8 years:</p> 1.5 mg/1 chewable</td> <td> <p>Ages 4 to 8 years:</p> 1.5 mg/1 chewable&nbsp;</td> <td rowspan=\"2\">1.5 mg/1 chewable</td> </tr> <tr> <td> <p>Ages 9 years and older:</p> <p>3 mg/2 chewables</p> <strong>or</strong> 3 mg/2 softgels</td> <td> <p>Ages 9 years and older:</p> 3 mg/2 tablets&nbsp;</td> </tr> <tr> <td class=\"indent1\">11 years and older</td> <td>3 mg/4 chewables</td> <td>3 mg/2 chewables<br /> <strong>or </strong>2 softgels&nbsp;</td> <td>3 mg/2 softgels</td> <td> <p>3 mg/2 chewables</p> <strong>or</strong> 3 mg/2 softgels</td> <td>3 mg/2 tablets&nbsp;</td> <td>3 mg/2 chewables</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Riboflavin (vitamin B2); mg</td> </tr> <tr> <td class=\"indent1\">0 to 12 months</td> <td>0.6 mg/1 mL</td> <td>0.6 mg/1 mL&nbsp;</td> <td>0.6 mg/1 mL</td> <td>0.6 mg/0.5 mL</td> <td>0.6 mg/1 mL&nbsp;</td> <td>0.6 mg/1 mL</td> </tr> <tr> <td class=\"indent1\">1 to 3 years</td> <td>1.2 mg/2 mL</td> <td>1.2 mg/2 mL&nbsp;</td> <td>1.2 mg/2 mL</td> <td>1.2 mg/1 mL</td> <td>1.2 mg/2 mL&nbsp;</td> <td>1.2 mg/2 mL</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">4 to 10 years</td> <td rowspan=\"2\">1.7 mg/2 chewables</td> <td rowspan=\"2\">1.7 mg/1 chewable<br /> <strong>or </strong>1 softgel&nbsp;</td> <td rowspan=\"2\">1.7 mg/1 chewable</td> <td> <p>Ages 4 to 8 years:</p> 1.7 mg/1 chewable</td> <td> <p>Ages 4 to 8 years:</p> 1.7 mg/1 chewable&nbsp;</td> <td rowspan=\"2\">1.7 mg/1 chewable</td> </tr> <tr> <td> <p>Ages 9 years and older:</p> <p>3.4 mg/2 chewables</p> <strong>or</strong> 3.4 mg/2 softgels</td> <td> <p>Ages 9 years and older:</p> 3.4 mg/2 tablets&nbsp;</td> </tr> <tr> <td class=\"indent1\">11 years and older</td> <td>3.4 mg/4 chewables</td> <td>3.4&nbsp;mg/1 chewables<br /> <strong>or </strong>2 softgels&nbsp;&nbsp;</td> <td>3.4 mg/2 softgels</td> <td> <p>3.4 mg/2 chewables</p> <strong>or</strong> 3.4 mg/2 softgels</td> <td>3.4 mg/2 tablets&nbsp;</td> <td>3.4 mg/2 chewables</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Niacin; mg</td> </tr> <tr> <td class=\"indent1\">0 to 12 months</td> <td>6 mg/1 mL</td> <td>6 mg/1 mL&nbsp;</td> <td>6 mg/1 mL</td> <td>6 mg/0.5 mL</td> <td>8 mg/1 mL&nbsp;</td> <td>6 mg/1 mL</td> </tr> <tr> <td class=\"indent1\">1 to 3 years</td> <td>12 mg/2 mL</td> <td>12 mg/2 mL&nbsp;</td> <td>12 mg/2 mL</td> <td>12 mg/1 mL</td> <td>16 mg/2 mL&nbsp;</td> <td>12 mg/2 mL</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">4 to 10 years</td> <td rowspan=\"2\">10 mg/2 chewables</td> <td rowspan=\"2\">10 mg/1 chewable<br /> <strong>or</strong> 1 softgel&nbsp;</td> <td rowspan=\"2\">10 mg/1 chewable</td> <td> <p>Ages 4 to 8 years:</p> 10 mg/1 chewable</td> <td> <p>Ages 4 to 8 years:</p> 20 mg/1 chewable&nbsp;</td> <td rowspan=\"2\">20 mg/1 chewable</td> </tr> <tr> <td> <p>Ages 9 years and older:</p> <p>20 mg/2 chewables</p> <strong>or</strong> 40 mg/2 softgels</td> <td> <p>Ages 9 years and older:</p> 40 mg/2 tablets&nbsp;</td> </tr> <tr> <td class=\"indent1\">11 years and older</td> <td>20 mg/4 chewables</td> <td>20&nbsp;mg/2 chewables<br /> <strong>or </strong>2 softgels&nbsp;</td> <td>40 mg/2 softgels</td> <td> <p>20 mg/2 chewables</p> <strong>or</strong> 40 mg/2 softgels</td> <td>40 mg/2 tablets&nbsp;</td> <td>40 mg/2 chewables</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Pyridoxine (vitamin B6); mg</td> </tr> <tr> <td class=\"indent1\">0 to 12 months</td> <td>0.6 mg/1 mL</td> <td>0.6 mg/1 mL&nbsp;</td> <td>0.6 mg/1 mL</td> <td>0.6 mg/0.5 mL</td> <td>0.4 mg/1 mL&nbsp;</td> <td>0.6 mg/1 mL</td> </tr> <tr> <td class=\"indent1\">1 to 3 years</td> <td>1.2 mg/2 mL</td> <td>1.2 mg/2 mL&nbsp;</td> <td>1.2 mg/2 mL</td> <td>1.2 mg/1 mL</td> <td>0.8 mg/2 mL&nbsp;</td> <td>1.2 mg/2 mL</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">4 to 10 years</td> <td rowspan=\"2\">1.9 mg/2 chewables</td> <td rowspan=\"2\">1.9 mg/1 chewable<br /> <strong>or</strong>&nbsp;1 softgel&nbsp;</td> <td rowspan=\"2\">1.9 mg/1 chewable</td> <td> <p>Ages 4 to 8 years:</p> 1.9 mg/1 chewable</td> <td> <p>Ages 4 to 8 years:</p> 2 mg/1 chewable&nbsp;</td> <td rowspan=\"2\">2 mg/1 chewable</td> </tr> <tr> <td> <p>Ages 9 years and older:</p> <p>3.8 mg/2 chewables</p> <strong>or</strong> 3.8 mg/2 softgels</td> <td> <p>Ages 9 years and older:</p> 4 mg/2 tablets&nbsp;</td> </tr> <tr> <td class=\"indent1\">11 years and older</td> <td>3.8 mg/4 chewables</td> <td>3.8 mg/2 chewables<br /> <strong>or </strong>2 softgels&nbsp;</td> <td>3.8 mg/2 softgels</td> <td> <p>3.8 mg/2 chewables</p> <strong>or</strong> 3.8 mg/2 softgels</td> <td>4 mg/2 tablets&nbsp;</td> <td>4 mg/2 chewables</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Vitamin B12; mcg</td> </tr> <tr> <td class=\"indent1\">0 to 12 months</td> <td>0 mcg</td> <td>0 mcg&nbsp;</td> <td>4 mcg/1 mL</td> <td>4 mcg/0.5 mL</td> <td>2 mcg/1 mL&nbsp;</td> <td>4 mcg/1 mL</td> </tr> <tr> <td class=\"indent1\">1 to 3 years</td> <td>0 mcg</td> <td>0 mcg&nbsp;</td> <td>8 mcg/2 mL</td> <td>8 mcg/1 mL</td> <td>4 mcg/2 mL&nbsp;</td> <td>8 mcg/2 mL</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">4 to 10 years</td> <td rowspan=\"2\">12 mcg/2 chewables</td> <td rowspan=\"2\">12 mcg/1 chewable<br /> <strong>or </strong>1 softgel&nbsp;</td> <td rowspan=\"2\">6&nbsp;mcg/1 chewable</td> <td> <p>Ages 4 to 8 years:</p> 6 mcg/1 chewable</td> <td> <p>Ages 4 to 8 years:</p> 6 mcg/1 chewable&nbsp;</td> <td rowspan=\"2\">6 mcg/1 chewable</td> </tr> <tr> <td> <p>Ages 9 years and older:</p> <p>12 mcg/2 chewables</p> <strong>or</strong> 12 mcg/2 softgels</td> <td> <p>Ages 9 years and older:</p> 12 mcg/2 tablets&nbsp;</td> </tr> <tr> <td class=\"indent1\">11 years and older</td> <td>24 mcg/4 chewables</td> <td>24 mcg/2 chewables<br /> <strong>or </strong>2 softgels&nbsp;</td> <td>12&nbsp;mcg/2 softgels</td> <td> <p>12 mcg/2 chewables</p> <strong>or</strong> 12 mcg/2 softgels</td> <td>12 mcg/2 tablets&nbsp;</td> <td>12 mcg/2 chewables</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Biotin; mcg</td> </tr> <tr> <td class=\"indent1\">0 to 12 months</td> <td>15 mcg/1 mL</td> <td>15 mcg/1 mL&nbsp;</td> <td>15 mcg/1 mL</td> <td>15 mcg/0.5 mL</td> <td>0 mcg&nbsp;</td> <td>15 mcg/1 mL</td> </tr> <tr> <td class=\"indent1\">1 to 3 years</td> <td>30 mcg/2 mL</td> <td>30 mcg/2 mL&nbsp;</td> <td>30 mcg/2 mL</td> <td>30 mcg/1 mL</td> <td>0 mcg&nbsp;</td> <td>30 mcg/2 mL</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">4 to 10 years</td> <td rowspan=\"2\">100 mcg/2 chewables</td> <td rowspan=\"2\">100 mcg/1 chewable<br /> <strong>or </strong>1 softgel&nbsp;</td> <td rowspan=\"2\">100 mcg/1 chewable</td> <td> <p>Ages 4 to 8 years:</p> 100 mcg/1 chewable</td> <td> <p>Ages 4 to 8 years:</p> 45 mcg/1 chewable&nbsp;</td> <td rowspan=\"2\">300 mcg/1 chewable</td> </tr> <tr> <td> <p>Ages 9 years and older:</p> <p>200 mcg/2 chewables</p> <strong>or</strong> 200 mcg/2 softgels</td> <td> <p>Ages 9 years and older:</p> 60 mcg/2 tablets&nbsp;</td> </tr> <tr> <td class=\"indent1\">11 years and older</td> <td>200 mcg/4 chewables</td> <td>200 mcg/2 chewables<br /> <strong>or&nbsp;2</strong> softgels&nbsp;&nbsp;</td> <td>200 mcg/2 softgels</td> <td> <p>200 mcg/2 chewables</p> <strong>or</strong> 200 mcg/2 softgels</td> <td>60 mcg/2 tablets&nbsp;</td> <td>600 mcg/2 chewables</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Folic acid; mcg</td> </tr> <tr> <td class=\"indent1\">0 to 12 months</td> <td>0 mcg</td> <td>0 mcg&nbsp;</td> <td>0 mcg</td> <td>0 mcg</td> <td>0 mcg&nbsp;</td> <td>0 mcg</td> </tr> <tr> <td class=\"indent1\">1 to 3 years</td> <td>0 mcg</td> <td>0 mcg&nbsp;</td> <td>0 mcg</td> <td>0 mcg</td> <td>0 mcg&nbsp;</td> <td>0 mcg</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">4 to 10 years</td> <td rowspan=\"2\">200 mcg/2 chewables</td> <td rowspan=\"2\">200 mcg/1 chewable<br /> <strong>or </strong>1 softgel&nbsp;</td> <td rowspan=\"2\">200 mcg/1 chewable</td> <td> <p>Ages 4 to 8 years:</p> 200 mcg/1 chewable</td> <td> <p>Ages 4 to 8 years:</p> 400 mcg/1 chewable&nbsp;</td> <td rowspan=\"2\">200 mcg/1 chewable</td> </tr> <tr> <td> <p>Ages 9 years and older:</p> <p>400 mcg/2 chewables</p> <strong>or</strong> 400 mcg/2 softgels</td> <td> <p>Ages 9 years and older:</p> 800 mcg/2 tablets&nbsp;</td> </tr> <tr> <td class=\"indent1\">11 years and older</td> <td>400 mcg/4 chewables</td> <td>400 mcg/2 chewables<br /> <strong>or </strong>2 softgels&nbsp;&nbsp;</td> <td>400 mcg/2 softgels</td> <td> <p>400 mcg/2 chewables</p> <strong>or</strong> 400 mcg/2 softgels</td> <td>800 mcg/2 tablets&nbsp;</td> <td>400 mcg/2 chewables</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Ascorbic acid (vitamin C); mg</td> </tr> <tr> <td class=\"indent1\">0 to 12 months</td> <td>45 mg/1 mL</td> <td>45 mg/1 mL&nbsp;</td> <td>45 mg/1 mL</td> <td>45 mg/0.5 mL</td> <td>35 mg/1 mL&nbsp;</td> <td>45 mg/1 mL</td> </tr> <tr> <td class=\"indent1\">1 to 3 years</td> <td>90 mg/2 mL</td> <td>90 mg/2 mL&nbsp;</td> <td>90 mg/2 mL</td> <td>90 mg/1 mL</td> <td>70 mg/2 mL&nbsp;</td> <td>90 mg/2 mL</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">4 to 10 years</td> <td rowspan=\"2\">70 mg/2 chewables</td> <td rowspan=\"2\">70 mg/1 chewable<br /> <strong>or </strong>75 mg/1 softgel&nbsp;</td> <td rowspan=\"2\">100&nbsp;mg/1 chewable</td> <td> <p>Ages 4 to 8 years:</p> 100 mg/1 chewable</td> <td> <p>Ages 4 to 8 years:</p> 60 mg/1 chewable&nbsp;</td> <td rowspan=\"2\">60 mg/1 chewable</td> </tr> <tr> <td> <p>Ages 9 years and older:</p> <p>200 mg/2 chewables</p> <strong>or</strong> 200 mg/2 softgels</td> <td> <p>Ages 9 years and older:</p> 120 mg/2 tablets&nbsp;</td> </tr> <tr> <td class=\"indent1\">11 years and older</td> <td>140 mg/4 chewables</td> <td>140&nbsp;mg/2 chewables<br /> <strong>or&nbsp;</strong>150 mg/2 softgels&nbsp;&nbsp;</td> <td>200&nbsp;mg/2 softgels</td> <td> <p>200 mg/2 chewables</p> <strong>or</strong> 200 mg/2 softgels</td> <td>120 mg/2 tablets&nbsp;</td> <td>120 mg/2 chewables</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Pantothenic acid; mg</td> </tr> <tr> <td class=\"indent1\">0 to 12 months</td> <td>3 mg/1 mL</td> <td>3 mg/1 mL&nbsp;</td> <td>3 mg/1 mL</td> <td>3 mg/0.5 mL</td> <td>0 mg&nbsp;</td> <td>3 mg/1 mL</td> </tr> <tr> <td class=\"indent1\">1 to 3 years</td> <td>6 mg/2 mL</td> <td>6 mg/2 mL&nbsp;</td> <td>6 mg/2 mL</td> <td>6 mg/1 mL</td> <td>0 mg&nbsp;</td> <td>6 mg/2 mL</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">4 to 10 years</td> <td rowspan=\"2\">12 mg/2 chewables</td> <td rowspan=\"2\">12 mg/1 chewable<br /> <strong>or </strong>1 softgel&nbsp;</td> <td rowspan=\"2\">12 mg/1 chewable</td> <td> <p>Ages 4 to 8 years:</p> 12 mg/1 chewable</td> <td> <p>Ages 4 to 8 years:</p> 10 mg/1 chewable&nbsp;</td> <td rowspan=\"2\">10 mg/1 chewable</td> </tr> <tr> <td> <p>Ages 9 years and older:</p> <p>24 mg/2 chewables</p> <strong>or</strong> 24 mg/2 softgels</td> <td> <p>Ages 9 years and older:</p> 20 mg/2 tablets&nbsp;</td> </tr> <tr> <td class=\"indent1\">11 years and older</td> <td>24 mg/4 chewables</td> <td>24&nbsp;mg/2 chewables<br /> <strong>or</strong>&nbsp;2 softgels&nbsp;&nbsp;</td> <td>24 mg/2 softgels</td> <td> <p>24 mg/2 chewables</p> <strong>or</strong> 24 mg/2 softgels</td> <td>20 mg/2 tablets&nbsp;</td> <td>20 mg/2 chewables</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Zinc; mg</td> </tr> <tr> <td class=\"indent1\">0 to 12 months</td> <td>5 mg/1 mL</td> <td>5 mg/1 mL&nbsp;</td> <td>5 mg/1 mL</td> <td>5 mg/0.5 mL</td> <td>0 mg&nbsp;</td> <td>7.5 mg/1 mL</td> </tr> <tr> <td class=\"indent1\">1 to 3 years</td> <td>10 mg/2 mL</td> <td>10 mg/2 mL&nbsp;</td> <td>10 mg/2 mL</td> <td>10 mg/1 mL</td> <td>0 mg&nbsp;</td> <td>15 mg/2 mL</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">4 to 10 years</td> <td rowspan=\"2\">10 mg/2 chewables</td> <td rowspan=\"2\">10 mg/1 chewable<br /> <strong>or </strong>1 softgel&nbsp;</td> <td rowspan=\"2\">15 mg/1 chewable</td> <td> <p>Ages 4 to 8 years:</p> 15 mg/1 chewable</td> <td> <p>Ages 4 to 8 years:</p> 15 mg/1 chewable&nbsp;</td> <td rowspan=\"2\">7.5 mg/1 chewable</td> </tr> <tr> <td> <p>Ages 9 years and older:</p> <p>30 mg/2 chewables</p> <strong>or</strong> 20 mg/2 softgels</td> <td> <p>Ages 9 years and older:</p> 22 mg/2 tablets&nbsp;</td> </tr> <tr> <td class=\"indent1\">11 years and older</td> <td>20 mg/4 chewables</td> <td>20 mg/2 chewables<br /> <strong>or</strong>&nbsp;2 softgels&nbsp;&nbsp;</td> <td>30 mg/2 softgels</td> <td> <p>30 mg/2 chewables</p> <strong>or</strong> 20 mg/2 softgels</td> <td>22 mg/2 tablets&nbsp;</td> <td>15 mg/2 chewables</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI>All of the formulations listed above also contain vitamins A,E,D, and K, in addition to the vitamins listed here.</LI>&#xD;&#xA;<LI>AquADEKs is a registered trademark of Yasoo Health. DEKAs products is a registered trademark of Callion Pharma. Libertas is a registered trademark of Libertas Pharma. MVW Complete Formulation is a registered trademark of MVW Nutritionals. Vitamax is a registered trademark of Shear/Kershman Labs. Poly-Vi-Sol is a registered trademark of Mead Johnson and Company. Centrum is a registered trademark of Wyeth Consumer Care. </LI></UL></div><div class=\"graphic_footnotes\">* AquADEK and DEKAs plus also contain selenium&nbsp;and Coenzyme Q10.<br />¶ A different formulation of DEKAs is also available (DEKAs Essentials), which includes only vitamins A,E,D, and K, in different doses from those in DEKAs Plus. DEKAs Essentials&nbsp;can be used to boost intake of the fat-soluble vitamins for patients with unusually high requirements.<br />Δ MVW Complete softgels are available as regular (1500 IU vitamin D);&nbsp;D3000 (3000 IU vitamin D), or D5000 (5000 IU vitamin D). The other components of these softgels are identical.&nbsp;A chewable form is also available (3000 IU vitamin D in 2 chewables).</div><div class=\"graphic_reference\">Modified with permission from: Eurand Pharmaceuticals, Inc. All rights reserved. Available at: http://www.sourcecf.com/pdf/VitaminComparisonTablenew.pdf.<br />Updated 12/13/16 with information from manufacturers' websites.</div><div id=\"graphicVersion\">Graphic 67006 Version 8.0</div></div></div>"},"67007":{"type":"graphic_figure","displayName":"Survival by residual tumor vol","title":"Estimated five-year survival for epithelial ovarian carcinoma by residual tumor volume after adjusting for age and International Federation of Gynecology and Obstetrics (FIGO) stage","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Estimated five-year survival for epithelial ovarian carcinoma by residual tumor volume after adjusting for age and International Federation of Gynecology and Obstetrics (FIGO) stage</div><div class=\"cntnt\"><img style=\"width:478px; height:420px;\" src=\"images/OBGYN/67007_Survival_by_residual_tumor.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Data from: Tingulstad S, Skjeldestad E, Halvorsen TB, Hagen B. Survival and prognostic factors in patients with ovarian cancer. Obstet Gynecol 2003; 101:885.</div><div id=\"graphicVersion\">Graphic 67007 Version 4.0</div></div></div>"},"67008":{"type":"graphic_figure","displayName":"Breakthrough pain","title":"Preventing overmedication in patients with breakthrough pain","html":"<div class=\"graphic\"><div style=\"width: 507px\" class=\"figure\"><div class=\"ttl\">Preventing overmedication in patients with breakthrough pain</div><div class=\"cntnt\"><img style=\"width:487px; height:321px;\" src=\"images/HEME/67008_ATC-treat_shortcomings_edt2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Breakthrough pain is treated with a continuous hourly dose (solid black line) plus&nbsp;immediate access to additional smaller doses of&nbsp;pain medication when needed, preferably by patient-controlled analgesia (PCA). If the total hourly dose is raised higher (dotted black line)&nbsp;to eliminate all breakthrough pain, the patient is likely to become overmedicated and have increased opioid side effects. Refer to UpToDate content on sickle cell pain treatment for&nbsp;further details.&nbsp;&nbsp;</div><div class=\"graphic_reference\">Coluzzi PH, Fairbairn BS. The management of pain in terminally ill cancer patients with difficulty swallowing. Am J Hosp Palliat Care 1999; 16:731. Copyright © 2010 by Sage Publications. Reprinted by permission of Sage Publications.</div><div id=\"graphicVersion\">Graphic 67008 Version 9.0</div></div></div>"},"67009":{"type":"graphic_table","displayName":"Screening ECG features SCD B","title":"ECG features of the cardiac diseases detectable at pre-participation screening in young competitive athletes (continued)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ECG features of the cardiac diseases detectable at pre-participation screening in young competitive athletes (continued)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">QTc interval</td> <td class=\"subtitle1\">P wave</td> <td class=\"subtitle1\">PR interval</td> <td class=\"subtitle1\">QRS complex</td> <td class=\"subtitle1\">ST interval</td> <td class=\"subtitle1\">T wave</td> <td class=\"subtitle1\">Arrhythmias</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Brugada syndrome</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Normal</td> <td>&nbsp;</td> <td>Prolonged &#8805;0.21 s</td> <td>S1S2S3 pattern; (RBBB/LAD)</td> <td>Up-sloping in coved-type right precordial leads</td> <td>Inverted in right precordial leads</td> <td>(Polymorphic VT); (atrial fibrillation) (sinus bradycardia)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Lenegre disease</td> </tr> <tr> <td class=\"divider_bottom indent1\" rowspan=\"2\">Normal</td> <td class=\"divider_bottom\" rowspan=\"2\">Normal</td> <td class=\"divider_bottom\" rowspan=\"2\">Prolonged &#8805;0.21 s</td> <td>RBBB; RBBB/LAD</td> <td class=\"divider_bottom\" rowspan=\"2\">Normal</td> <td class=\"divider_bottom\" rowspan=\"2\">Secondary changes</td> <td class=\"divider_bottom\" rowspan=\"2\">(2nd or 3rd degree AV block)</td> </tr> <tr class=\"divider_bottom\"> <td>LBBB</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Short QT syndrome</td> </tr> <tr> <td class=\"indent1\">Shortened</td> <td class=\"divider_bottom\" rowspan=\"2\">Normal</td> <td class=\"divider_bottom\" rowspan=\"2\">Normal</td> <td class=\"divider_bottom\" rowspan=\"2\">Normal</td> <td class=\"divider_bottom\" rowspan=\"2\">Normal</td> <td class=\"divider_bottom\" rowspan=\"2\">Normal</td> <td class=\"divider_bottom\" rowspan=\"2\">Atrial fibrillation (polymorphic VT)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&#60;300 ms</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Pre-excitation syndrome (WPW)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Normal</td> <td>Normal</td> <td>Shortened &#60;0.12 s</td> <td>Delta wave</td> <td>Secondary changes</td> <td>Secondary changes</td> <td>Supraventricular tachycardia; (atrial fibrillation)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Coronary artery*</td> </tr> <tr> <td class=\"indent1\">(Prolonged)</td> <td>Normal</td> <td>Normal</td> <td>(Abnormal Q waves)<sup>&#182;</sup></td> <td>(Down- or up-sloping)</td> <td>Inverted in &#8805;2 leads</td> <td>PVB; (VT)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Less common or uncommon ECG findings are reported in brackets.</div><div class=\"graphic_footnotes\">QTc: QT interval corrected for heart rate by Bazett's formula; LBBB: left bundle branch block; RBBB: right bundle branch block; LAD: left axis deviation of -30&ordm; or more; PVB: either single or coupled premature ventricular beats; VT: either non-sustained or sustained ventricular tachycardia.<br />* Coronary artery diseases: either premature coronary atherosclerosis or congenital coronary anomalies.<br />&para; Abnormal Q waves.</div><div class=\"graphic_reference\">Reproduced with permission from: Corrado D, Pelliccia A, Bjornstad HH, et al. Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol. Consensus Statement of the Study Group of Sport Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J 2005; 26:516. Copyright&copy; 2005 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 67009 Version 4.0</div></div></div>"},"67010":{"type":"graphic_table","displayName":"Pathologic skin picking diagnosis","title":"Diagnostic criteria for pathologic skin picking","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for pathologic skin picking</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Criteria</td> </tr> <tr> <td><strong>A.</strong> Maladaptive skin excoriation (eg, scratching, picking, gouging, lancing, digging, rubbing, or squeezing skin) or maladaptive preoccupation with skin excoriation as indicated by at least 1 of the following: <ul> <li>Preoccupation with skin excoriation and/or recurrent impulses to excoriate the skin that is/are experienced as irresistible, intrusive, and/or senseless</li> <li>Recurrent excoriation of the skin resulting in noticeable skin damage</li> </ul> </td> </tr> <tr> <td><strong>B.</strong> The preoccupation, impulses, or behaviors associated with skin excoriation cause marked distress, are time-consuming, significantly interfere with social or occupational activities, or result in medical problems (eg, infections)</td> </tr> <tr> <td><strong>C.</strong> The disturbance is not better accounted for by another mental disorder and is not due to a general medical condition</td> </tr> <tr> <td class=\"subtitle1_single\">Subtypes</td> </tr> <tr> <td class=\"subtitle2_single\">Compulsive type</td> </tr> <tr> <td class=\"indent1\">Skin excoriation is performed to avoid increased anxiety or to prevent a dreaded event or situation and/or is elicited by an obsession (eg, obsession about contamination of the skin)</td> </tr> <tr> <td class=\"indent1\">It is performed in full awareness</td> </tr> <tr> <td class=\"indent1\">It is associated with some resistance to performing the behavior</td> </tr> <tr> <td class=\"indent1\">There is some insight into its senselessness or harmfulness</td> </tr> <tr> <td class=\"subtitle2_single\">Impulsive type</td> </tr> <tr> <td class=\"indent1\">Skin excoriation is associated with arousal, pleasure, or reduction of tension</td> </tr> <tr> <td class=\"indent1\">It is performed at times with minimal awareness (eg, automatically)</td> </tr> <tr> <td class=\"indent1\">It is associated with little resistance to performing the behavior</td> </tr> <tr> <td class=\"indent1\">There is little insight into its senselessness or harmfulness</td> </tr> <tr> <td class=\"subtitle2_single\">Mixed type</td> </tr> <tr> <td class=\"indent1\">Skin excoriation has both compulsive and impulsive features</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Arnold LM, Auchenbach MB, McElroy SL. Psychogenic excoriation. Clinical features, proposed diagnostic criteria, epidemiology and approaches to treatment. CNS Drugs 2001; 15:351, with permission from Adis, a Wolters Kluwer business. Copyright © Adis Data Information BV 2001. All rights reserved.</div><div id=\"graphicVersion\">Graphic 67010 Version 2.0</div></div></div>"},"67011":{"type":"graphic_diagnosticimage","displayName":"Inlet VSD 4 chamber 2D still frame","title":"Inlet VSD 4 chamber 2D still frame","html":"<div class=\"graphic\"><div style=\"width: 580px\" class=\"figure\"><div class=\"ttl\">Inlet VSD 4 chamber 2D still frame</div><div class=\"cntnt\"><img style=\"width:560px; height:440px;\" src=\"images/CARD/67011_Inlet_VSD_4_chamber_2D.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This apical four chamber image (inverted) shows the inlet ventricular septal defect (VSD; arrow) at the juncture of the atrioventricular valves. Note that there is no apical displacement of the tricuspid valve hinge point relative to the mitral valve hinge point as is usually seen in normal hearts. With an intact inlet septum, the tricuspid valve is displaced apically when compared with the position of the mitral valve.</div><div class=\"graphic_footnotes\">RA: right atrium; LA: left atrium; TV: tricuspid valve; MV: mitral valve; RV: right ventricle; LV: left ventricle; IVS: intraventricular septum; arrow: VSD.</div><div id=\"graphicVersion\">Graphic 67011 Version 4.0</div></div></div>"},"67012":{"type":"graphic_picture","displayName":"Actinic cheilitis 2","title":"Actinic cheilitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Actinic cheilitis</div><div class=\"cntnt\"><img style=\"width:504px; height:327px;\" src=\"images/DERM/67012_Actinic_cheilitis_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Superficial (porcelain-like) scale on lower lip.</div><div id=\"graphicVersion\">Graphic 67012 Version 2.0</div></div></div>"},"67013":{"type":"graphic_picture","displayName":"Hip abduction PI","title":"Hip abduction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hip abduction</div><div class=\"cntnt\"><img style=\"width:322px; height:432px;\" src=\"images/PI/67013_Hip_abduction_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">As above, you will need a piece of rubber tubing or elastic band. Stand with the legs shoulder width apart, with the &quot;good&quot; leg closest to the furniture or door. The tubing should loop around the outside of the injured leg. Lift the affected leg to the side, 18 to 24 inches away from the body, stretching the tubing. Hold for 5 seconds, then slowly release. Rest as needed. Repeat 10 to 15 times (one set). Perform a total of 3 sets.</div><div id=\"graphicVersion\">Graphic 67013 Version 3.0</div></div></div>"},"67015":{"type":"graphic_picture","displayName":"Marfan syndrome dislocated lens","title":"Ectopia lentis (dislocated lens) in Marfan syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ectopia lentis (dislocated lens) in Marfan syndrome</div><div class=\"cntnt\"><img style=\"width:396px; height:269px;\" src=\"images/PEDS/67015_Marfan_syndr_ectopia_lentis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Slit-lamp photomicrography shows ectopia lentis with microspherophakia; the lens is completely luxated into the anterior chamber, predisposing to pupillary block glaucoma.</div><div class=\"graphic_reference\">Reproduced with permission from: Gold DH, MD, and Weingeist TA, MD, PhD. Color Atlas of the Eye in Systemic Disease. Baltimore: Lippincott Williams &amp; Wilkins, 2001. Copyright &#169; 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 67015 Version 2.0</div></div></div>"},"67017":{"type":"graphic_diagnosticimage","displayName":"CT findings in elevated ICP","title":"Radiographic findings suggestive of elevated ICP","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radiographic findings suggestive of elevated ICP</div><div class=\"cntnt\"><img style=\"width:304px; height:337px;\" src=\"images/PULM/67017_Elevated_ICP_head_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Evidence of contusions with surrounding edema (top arrow), effacement of cisterns (middle arrow), and effacement of sulci (lowest arrow).</div><div id=\"graphicVersion\">Graphic 67017 Version 3.0</div></div></div>"},"67019":{"type":"graphic_figure","displayName":"Pressure support ventilation","title":"Pressure support ventilation","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Pressure support ventilation</div><div class=\"cntnt\"><img style=\"width:512px; height:137px;\" src=\"images/PULM/67019_Pressure_support_ventilatio.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Changes in airway pressure, flow, and volume as measured in the distal endotracheal tube during unsupported and pressure-supported spontaneous breaths in intubated patients. The unsupported patient (blue lines) must first generate an initial negative pressure &quot;spike&quot; to open the ventilator demand valves and then must maintain a small amount of negative pressure during inspiration to produce flow through the ventilator circuitry. The addition of increasing levels of pressure support (green lines) provides plateaus of positive pressure that augment the spontaneous tidal volume in accordance with the patient's spontaneous respiratory flow demand and inspiratory time pattern.</div><div class=\"graphic_reference\">Redrawn from Respir Care 1987; 32:447.</div><div id=\"graphicVersion\">Graphic 67019 Version 1.0</div></div></div>"},"67020":{"type":"graphic_picture","displayName":"Knee hypermobility","title":"Knee hypermobility","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Knee hypermobility</div><div class=\"cntnt\"><img style=\"width:146px; height:253px;\" src=\"images/RHEUM/67020_Knee_hypermobility.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Laxity of the knee with greater than 10 degrees of joint extension.</div><div class=\"graphic_reference\">Reproduced with permission from Sheon, RP, Moskowitz, RW, Goldberg, VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996.</div><div id=\"graphicVersion\">Graphic 67020 Version 1.0</div></div></div>"},"67024":{"type":"graphic_diagnosticimage","displayName":"Anterior needle bx bone tumor","title":"Anterior biopsy approach for a bone tumor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anterior biopsy approach for a bone tumor</div><div class=\"cntnt\"><img style=\"width:320px; height:320px;\" src=\"images/ONC/67024_Anterior_needle_bx_bone_tum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT-guided needle biopsy of this posterior soft tissue mass was accomplished using an anterior approach, which would not have compromised a planned limb-sparing procedure because the needle track could be entirely excised with the resection specimen.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Daniel Rosenthal, MD.</div><div id=\"graphicVersion\">Graphic 67024 Version 4.0</div></div></div>"},"67026":{"type":"graphic_table","displayName":"Etiology life or limb threatening limp in children","title":"Life- or limb-threatening causes of limp in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Life- or limb-threatening causes of limp in children</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td>Septic arthritis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Osteomyelitis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   Tumor\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Leukemia\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Metastatic neuroblastoma\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Osteogenic sarcoma\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Ewing's tumor\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Torsion of the testicle</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Slipped capital femoral epiphysis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Fracture</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Appendicitis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Discitis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Developmental dysplasia of the hip</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Meningitis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Epidural abscess of the spine</td>\r\n  \r\n   </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 67026 Version 2.0</div></div></div>"},"67027":{"type":"graphic_table","displayName":"High-risk patients with neutropenic fever","title":"Patients with neutropenic fever who are at high risk for serious complications","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Patients with neutropenic fever who are at high risk for serious complications</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Patients with <strong>any</strong> of the following characteristics are considered to be at high risk for serious complications during episodes of neutropenic fever:</td> </tr> <tr> <td class=\"indent1\">Neutropenia (absolute neutrophil count &#60;500 cells/microL) anticipated to last &#62;7 days*</td> </tr> <tr> <td class=\"indent1\">Presence of any comorbid medical problems, including, but not limited to: <ul> <li>Hemodynamic instability </li> <li>Oral or gastrointestinal mucositis that interferes with swallowing or causes severe diarrhea </li> <li>Gastrointestinal symptoms, including abdominal pain, nausea and vomiting, or diarrhea </li> <li>Neurologic or mental status changes of new onset </li> <li>Intravascular catheter infection, especially catheter tunnel infection </li> <li>New pulmonary infiltrate or hypoxemia </li> <li>Underlying chronic lung disease </li> <li>Complex infection at the time of presentation </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Alemtuzumab use within the past two months</td> </tr> <tr> <td class=\"indent1\">Inpatient status at the time of development of fever</td> </tr> <tr> <td class=\"indent1\">Uncontrolled or progressive cancer<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Evidence of hepatic insufficiency (defined as aminotransferase levels &#62;5 times normal values) or renal insufficiency (defined as a creatinine clearance of &#60;30 mL/min)</td> </tr> <tr> <td class=\"indent1\">Multinational Association for Supportive Care in Cancer (MASCC) risk index score &#60;21<sup>&#916;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The authors consider patients with an absolute neutrophil count &lt;500 cells/microL for &gt;7 days to be at high risk for serious complications. It should be noted that in the Infectious Diseases Society of America, the National Comprehensive Cancer Network, and the American Society of Clinical Oncology guidelines, patients with an absolute neutrophil count ≤100 cells/microL for &gt;7 days are considered to be at high risk for serious complications<SUP>[1,2,3]</SUP>.<br />¶ Defined as any leukemic patient not in complete remission or a non-leukemic patient with evidence of disease progression after more than two courses of chemotherapy.<br />Δ Refer to the associated topic review for details about the MASCC risk index.</div><div class=\"graphic_reference\">Data adapted from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52:e56. </li>&#xD;&#xA;    <li>National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Prevention and treatment of cancer-related infections. Version 1.2012. http://www.nccn.org (Accessed on January 03, 2013).</li>&#xD;&#xA;    <li>Flowers CR, Seidenfeld J, Bow EJ, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2013.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 67027 Version 11.0</div></div></div>"},"67033":{"type":"graphic_diagnosticimage","displayName":"Fracture of the first metacarpal base: Type II (Rolando)","title":"Fracture of the first metacarpal base: Type II (Rolando)","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Fracture of the first metacarpal base: Type II (Rolando)</div><div class=\"cntnt\"><img style=\"width:542px; height:754px;\" src=\"images/EM/67033_Rolandosfractureofthumb.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A comminuted fracture of the base of the thumb that extends into the articular surface is a more serious type of Bennett fracture, which has been termed a Rolando fracture.</div><div class=\"graphic_reference\">Reproduced from: Helms CA. Fundamentals of Skeletal Radiology, 4th ed, Saunders, Philadelphia 2014. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 67033 Version 5.0</div></div></div>"},"67034":{"type":"graphic_figure","displayName":"Foot fasciotomy","title":"Fasciotomy of the foot","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Fasciotomy of the foot</div><div class=\"cntnt\"><img style=\"width:518px; height:334px;\" src=\"images/SURG/67034_Right-foot-fasciotomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two dorsal longitudinal incisions are made to access the foot compartments. The incisions are positioned medial to the second metatarsal shaft and lateral to the fourth metatarsal shaft. Each of the four sub-compartments of the interosseous compartment (turquoise) are opened between the metatarsal bones through the dorsal incisions. The calcaneal compartment (purple), which lies beneath the metatarsals, is opened directly. The lateral compartment (green) is decompressed through the lateral dorsal incision. The medial compartment (red) may be accessed by dissecting medial to the second metatarsal. Alternatively, the medial compartment can be accessed through another incision along the medial foot, immediately posterior to the first metatarsal.</div><div id=\"graphicVersion\">Graphic 67034 Version 2.0</div></div></div>"},"67037":{"type":"graphic_diagnosticimage","displayName":"Doppler pulmonary regurgitation","title":"Pulmonary regurgitation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary regurgitation</div><div class=\"cntnt\"><img style=\"width:321px; height:238px;\" src=\"images/CARD/67037_Dopplerpulmonaryregurgita.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In most normal individuals, pulmonary regurgitant can be detected with color flow Doppler, and a well-defined signal of pulmonary regurgitation can be recorded using pulsed or continuous wave Doppler. In this pulsed wave study, the forward flow in the pulmonary artery during systole is laminar. The regurgitant diastolic flow has a relatively slow slope of decay (arrows). In severe pulmonary regurgitation, the diastolic decay can be very rapid and the systolic signal dense. Respiratory variation in the slope of the diastolic signal can be seen. The velocity of end diastolic flow signal can be used to calculate end diastolic pulmonary pressure by applying the Bernoulli equation and adding the right atrial pressure.</div><div id=\"graphicVersion\">Graphic 67037 Version 3.0</div></div></div>"},"67038":{"type":"graphic_diagnosticimage","displayName":"Myelomeningocele","title":"Myelomeningocele at 36<sup>5/7th</sup> weeks of gestation","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Myelomeningocele at 36<sup>5/7th</sup> weeks of gestation</div><div class=\"cntnt\"><img style=\"width:514px; height:201px;\" src=\"images/OBGYN/67038_Myelomeningocele.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Lumbo-sacral myelomeningocele. Note the bulging neural tissue into the amniotic cavity. B) Three-dimensional reconstruction of the same defect demonstrating a bulge, which corresponds to the spinal lesion.</div><div class=\"graphic_reference\">Courtesy of Ana Monteagudo, MD.</div><div id=\"graphicVersion\">Graphic 67038 Version 3.0</div></div></div>"},"67039":{"type":"graphic_figure","displayName":"Int classification VUR","title":"International classification of vesicoureteral reflux (VUR)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">International classification of vesicoureteral reflux (VUR)</div><div class=\"cntnt\"><img style=\"width:504px; height:215px;\" src=\"images/PEDS/67039_Int_classification_VUR.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Modified from: International Reflux Committee. Medical versus surgical treatment of primary vesicoureteral reflux. Pediatrics 1981; 67:392.</div><div id=\"graphicVersion\">Graphic 67039 Version 3.0</div></div></div>"},"67040":{"type":"graphic_table","displayName":"Education in pulmonary rehab","title":"Educational components of pulmonary rehabilitation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Educational components of pulmonary rehabilitation</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Anatomy and physiology of the lung</td>\n</tr>\n<tr>\n<td>Pathophysiology of lung disease</td>\n</tr>\n<tr>\n<td>Airway management</td>\n</tr>\n<tr>\n<td>Breathing training strategies</td>\n</tr>\n<tr>\n<td>Energy conservation and work simplification techniques</td>\n</tr>\n<tr>\n<td>Medications</td>\n</tr>\n<tr>\n<td>Self-management skills</td>\n</tr>\n<tr>\n<td>Benefits of exercise and safety guidelines</td>\n</tr>\n<tr>\n<td>Oxygen therapy</td>\n</tr>\n<tr>\n<td>Environmental irritant avoidance</td>\n</tr>\n<tr>\n<td>Respiratory and chest therapy techniques</td>\n</tr>\n<tr>\n<td>Symptom management</td>\n</tr>\n<tr>\n<td>Psychological factors, coping, anxiety, panic control</td>\n</tr>\n<tr>\n<td>Stress management</td>\n</tr>\n<tr>\n<td>End of life planning</td>\n</tr>\n<tr>\n<td>Smoking cessation</td>\n</tr>\n<tr>\n<td>Travel/leisure/sexuality</td>\n</tr>\n<tr>\n<td>Nutrition</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 67040 Version 2.0</div></div></div>"},"67041":{"type":"graphic_diagnosticimage","displayName":"Angiogram showing postpartum hemorrhage","title":"Right hypogastric angiogram","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Right hypogastric angiogram</div><div class=\"cntnt\"><img style=\"width:248px; height:226px;\" src=\"images/OBGYN/67041_Postpartum_hemorrhage_7a.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Right hypogastric angiogram on a 34-year-old woman with postpartum hemorrhage shows an area of extravasation (arrow).</div><div id=\"graphicVersion\">Graphic 67041 Version 4.0</div></div></div>"},"67042":{"type":"graphic_picture","displayName":"Polychromatophilia","title":"Polychromatophilia due to increased reticulocytes","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Polychromatophilia due to increased reticulocytes</div><div class=\"cntnt\"><img style=\"width:447px; height:288px;\" src=\"images/HEME/67042_Polychromatophilia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral blood smear taken from a patient with increased reticulocytes. Unlike mature red cells (arrows), which have central pallor and are the same size as the nucleus of a small lymphocyte (arrowhead), reticulocytes (dashed arrows) are larger, have a blue tint, and lack central pallor because they are not biconcave discs. (Wright-Giemsa stain.)</div><div class=\"graphic_reference\">Courtesy of Stanley Schrier, MD.</div><div id=\"graphicVersion\">Graphic 67042 Version 5.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal peripheral blood smear</div><div class=\"cntnt\"><img style=\"width:393px; height:257px;\" src=\"images/HEME/59683_Normal_blood_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view of a normal peripheral blood smear. Several platelets (arrows) and a normal lymphocyte (arrowhead) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (dashed arrow) should equal one-third of its diameter.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 59683 Version 4.0</div></div></div>"},"67045":{"type":"graphic_figure","displayName":"Anatomy of the cervical esophagus - longitudinal","title":"Longitudinal section of the anatomy of the cervical esophagus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Longitudinal section of the anatomy of the cervical esophagus</div><div class=\"cntnt\"><img style=\"width:446px; height:502px;\" src=\"images/SURG/67045_Anatomy-of-the-cervical-esophagus-logitudinal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows a longitudinal section of the anatomy of the cervical esophagus at the level of the sixth cervical vertebrae. Note the space between the oblique inferior constrictor muscle and the cricopharyngeum muscle, called Killian's triangle.</div><div id=\"graphicVersion\">Graphic 67045 Version 4.0</div></div></div>"},"67046":{"type":"graphic_table","displayName":"Scorpion envenomation with neuromuscular toxicity treatment","title":"Scorpion envenomation with neuromuscular toxicity: Grading of severity and treatment","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Scorpion envenomation with neuromuscular toxicity: Grading of severity and treatment</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"5%\"></colgroup><colgroup span=\"2\" width=\"47%\"></colgroup> <tbody> <tr> <td class=\"divider_bottom\" style=\"color: red;\" colspan=\"3\">For assistance in managing a patient with a suspected scorpion envenomation, contact a regional poison control center (WHO list of <a href=\"http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/\" target=\"_blank\">international poison control centers</a>, or, in the United States, call 1-800-222-1222). A list of major scorpion antivenoms with manufacturer contact information is available <a href=\"http://wikitoxin.toxicology.wikispaces.net/Scorpions\" target=\"_blank\">here</a>.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1\">Grade</td> <td class=\"subtitle1\">Clinical findings</td> <td class=\"subtitle1\">Treatment</td> </tr> <tr> <td>I</td> <td>Localized pain or paresthesias at site</td> <td> <p>Pain management (eg, ibuprofen)</p> <p>Local wound care</p> <p>Tetanus prophylaxis</p> </td> </tr> <tr> <td>II</td> <td>Local and remote pain or paresthesias</td> <td>As above, regional anesthesia (eg, digital block) for severe local pain; intravenous opioids (eg, fentanyl) for severe remote pain</td> </tr> <tr> <td rowspan=\"2\">III</td> <td>As above, and:</td> <td rowspan=\"3\"> <p>Antivenom, if available*</p> Supportive care: <ul class=\"decimal_heading\"> <li>Frequent suctioning of oral secretions </li> <li>Endotracheal intubation if airway compromise or pulmonary edema with hypoxemia </li> <li>Monitor for and treat myocardial ischemia, heart failure, and rhabdomyolysis<sup>&#182;</sup> </li> <li>Treat pain with intravenous opioids (eg, fentanyl<sup>&#916;</sup>) </li> <li>If antivenom is <strong>not </strong>available, treat muscle activity and anxiety with short-acting benzodiazepines (eg, midazolam)<sup>&#9674;</sup> </li> <li>Provide local wound care as above </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <p><strong>Cranial nerve dysfunction</strong>: Abnormal eye movements, dysphagia, drooling, and/or slurred speech</p> <p class=\"indent2\"><strong>OR</strong></p> <p><strong>Somatic skeletal neuromuscular dysfunction</strong>: Undulating and writhing restlessness, fasciculations, extremity shaking and jerking, opisthotonos (arching of the back), and emprosthotonos (tetanic forward body flexion) with preservation of alertness.</p> <p><strong>Autonomic dysfunction</strong>:</p> <p class=\"indent2\"><em>Centruoides</em>: Salivation, vomiting, bronchoconstriction, diaphoresis, and tachycardia most frequent.</p> <p class=\"indent2\"><em>Parabuthus</em>: Salivation, vomiting, and urinary retention most frequent.</p> </td> </tr> <tr> <td>IV</td> <td>All above features present</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Grading scale and treatment following envenomation with <EM>Centruroides</EM> species (southwestern United States, Mexico, and Central America) and <EM>Parabuthus</EM> species (southern Africa).</div><div class=\"graphic_footnotes\">* To obtain antivenom in the United States, contact the nearest regional poison control center at 1-800-222-1222. <br />​¶ Refer to UpToDate topics on the recognition and emergency treatment of myocardial infarction, heart failure, and rhabdomyolysis.<br />​Δ If antivenom administration is planned, fentanyl is preferred because it promotes less antihistamine release than morphine.<br /><FONT class=lozenge>◊</FONT> Benzodiazepines should be used carefully or avoided if antivenom administration is planned because antivenom reverses the excitatory effects of scorpion venom and patients who have received high doses of benzodiazepines may develop excessive sedation and respiratory compromise.</div><div id=\"graphicVersion\">Graphic 67046 Version 7.0</div></div></div>"},"67047":{"type":"graphic_algorithm","displayName":"Topical pain control in children","title":"Algorithm for topical anesthetic use* in children","html":"<div class=\"graphic\"><div style=\"width: 595px\" class=\"figure\"><div class=\"ttl\">Algorithm for topical anesthetic use* in children</div><div class=\"cntnt\"><img style=\"width:575px; height:490px;\" src=\"images/EM/67047_Topical_pain_control.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IV: intravenous; LP: lumbar puncture.<br />* For example: Lidocaine/prilocaine 2.5 percent/2.5 percent (EMLA); Liposomal lidocaine 4 percent (LMX<SUB>4</SUB>); Tetracaine gel (40 mg tetracaine per 1 g of gel, Ametop). Tetracaine gel is an ester-type local anesthetic that is not available in the USA.<br />• For patients with an emergent need for a procedure or with non-intact skin, infiltrative anesthetic is suggested. For patients with an allergy to amide anesthetics, refer to UpToDate topics on&nbsp;allergic reactions to local anesthetics.<br />Δ Methemoglobinemia is only a contraindication for lidocaine/prilocaine (EMLA). (refer to UpToDate topics on clinical features, diagnosis, and treatment of methemoglobinemia.<br />◊ Topical anesthetic should be applied as soon as the need for a procedure is evident.&nbsp;Refer to UpToDate topics on topical anesthetics in children.</div><div class=\"graphic_reference\">Data from: Zempsky, WT, Cravero, JP, Committee on Pediatric Emergency Medicine, and Section on Anesthesiology and Pain Medicine. Relief of pain and anxiety in pediatric patients in emergency medical systems. Pediatrics 2004; 114:1348.</div><div id=\"graphicVersion\">Graphic 67047 Version 3.0</div></div></div>"},"67048":{"type":"graphic_algorithm","displayName":"Glucocorticoid-induced osteoporosis","title":"Glucocorticoid-induced osteoporosis: Mechanisms of bone loss","html":"<div class=\"graphic\"><div style=\"width: 515px\" class=\"figure\"><div class=\"ttl\">Glucocorticoid-induced osteoporosis: Mechanisms of bone loss</div><div class=\"cntnt\"><img style=\"width:495px; height:388px;\" src=\"images/ENDO/67048_Steroid_induced_osteoporosi.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the mechanisms of bone loss in patients with glucocorticoid-induced osteoporosis.</div><div class=\"graphic_footnotes\">PTH: parathyroid hormone.</div><div class=\"graphic_reference\">Adapted from Libanati CS, Baylink DJ. Prevention and treatment of glucocorticoid-induced osteoporosis: A pathogenetic perspective.&nbsp;Chest 1992; 102:1426.</div><div id=\"graphicVersion\">Graphic 67048 Version 4.0</div></div></div>"},"67050":{"type":"graphic_table","displayName":"Interpretations serum CRP","title":"Interpretations of serum CRP levels and atherosclerotic cardiovascular disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Interpretations of serum CRP levels and atherosclerotic cardiovascular disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Serum CRP levels </td> <td class=\"subtitle1\">Interpretation </td> </tr> <tr> <td>&#60;1</td> <td>Normal</td> </tr> <tr> <td>1 to 3</td> <td>Possibly increased cardiovascular risk (grey zone)</td> </tr> <tr> <td>3 to 10</td> <td>Highly likely increased cardiovascular risk, common in moderate CKD</td> </tr> <tr> <td>10 to 50</td> <td>Common in maintenance dialysis patients</td> </tr> <tr> <td>&#62;50</td> <td>Acute infection/inflammation (usually temporary)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CRP: C-reactive protein; CKD: chronic kidney disease.</div><div class=\"graphic_reference\">Reproduced with permission from: Kalantar-Zadeh K. Inflammatory marker mania in chronic kidney disease: pentraxins at the crossroad of universal soldiers of inflammation. Clin J Am Soc Nephrol 2007; 2:872. Copyright ©2007 American Society of Nephrology.</div><div id=\"graphicVersion\">Graphic 67050 Version 2.0</div></div></div>"},"67051":{"type":"graphic_figure","displayName":"Bone sarcoma incidence SEER","title":"Bone cancer age-specific incidence rates by histology, all races, both sexes, SEER 1976-84 and 1986-94 combined","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Bone cancer age-specific incidence rates by histology, all races, both sexes, SEER 1976-84 and 1986-94 combined</div><div class=\"cntnt\"><img style=\"width:539px; height:375px;\" src=\"images/ONC/67051_Bone_sarcoma_SEER_2_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Malignant bone tumors. Bleyer A, O'Leary M, Barr R, Ries LAG (eds): Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, Including SEER Incidence and Survival: 1975-2000. National Cancer Institute, NIH Pub. No. 06-5767. Bethesda, MD 2006.</div><div id=\"graphicVersion\">Graphic 67051 Version 6.0</div></div></div>"},"67053":{"type":"graphic_figure","displayName":"ICD pacemaker comparison PI","title":"ICDs and pacemakers compared","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">ICDs and pacemakers compared</div><div class=\"cntnt\"><img style=\"width:445px; height:297px;\" src=\"images/PI/67053_ICD_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Implantable cardioverter defibrillators (ICDs)&nbsp;work differently than pacemakers do. Both devices are implanted under the skin and have wires called \"electrodes\" leading to the heart. Both devices send electrical signals to the heart to keep it beating normally. But ICDs can give a much more powerful jolt to the heart if it starts to beat in a dangerous way. Pacemakers cannot do that.</div><div class=\"graphic_reference\">http://www.nhlbi.nih.gov/health/dci/Diseases/icd/icd_whatis.html.</div><div id=\"graphicVersion\">Graphic 67053 Version 8.0</div></div></div>"},"67055":{"type":"graphic_table","displayName":"Classification angiodysplasias","title":"Classification of gastrointestinal angiodysplasia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of gastrointestinal angiodysplasia</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Location</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Gastric</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Duodenal</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Jejunal</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Ileal</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Colonic</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Size</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Minute (&#60;2 mm in diameter)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Intermediate (2 to 5 mm)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Large (&#62;5 mm)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Number of lesions</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Unique (n = 1)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Multiple (n = 2 to 10)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Diffuse (n &#62;10)</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div class=\"graphic_footnotes\">As an example. &quot;J - S2 - N2,&quot; signifies multiple angiodysplasias of intermediate size in the jejunum.</div><div class=\"graphic_reference\">Proposed by the European Endoscopy Club in: Schmit A, van Gossum A. Proposal for an endoscopic classification of digestive angiodysplasias for therapeutic trials. Gastrointest Endosc 1998; 48:659.</div><div id=\"graphicVersion\">Graphic 67055 Version 3.0</div></div></div>"},"67057":{"type":"graphic_diagnosticimage","displayName":"Oriental cholangiohep ERCP","title":"Recurrent pyogenic cholangitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Recurrent pyogenic cholangitis</div><div class=\"cntnt\"><img style=\"width:369px; height:276px;\" src=\"images/GAST/67057_Oriental_cholangiohep_ERCP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cholangiogram obtained during endoscopic retrograde cholangiopancreatography showing a massively dilated left hepatic system and common bile duct both of which are filled with stones (appearing as round lucencies).</div><div class=\"graphic_reference\">Courtesy of Hannah M Lee, MD.</div><div id=\"graphicVersion\">Graphic 67057 Version 4.0</div></div></div>"},"67060":{"type":"graphic_figure","displayName":"High-resolution manometry achalasia","title":"High-resolution manometry achalasia","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">High-resolution manometry achalasia</div><div class=\"cntnt\"><img style=\"width:464px; height:337px;\" src=\"images/SURG/67060_High_res_manom_achalasia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This high-resolution manometry depicts the findings of achalasia.</div><div id=\"graphicVersion\">Graphic 67060 Version 2.0</div></div></div>"},"67062":{"type":"graphic_figure","displayName":"Surgical repair TOF","title":"Repair of tetralogy of Fallot","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Repair of tetralogy of Fallot</div><div class=\"cntnt\"><img style=\"width:411px; height:307px;\" src=\"images/CARD/67062_Surgical_repair_TOF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These figures depict two options for the surgical correction of right ventricular outflow tract (RVOT) obstruction in patients with tetralogy of Fallot. In figure A, the RVOT is enlarged by opening the RVOT and pulmonary valve, resecting the subinfundibular muscle bundles, and patching the area open. In figure B, a conduit containing a prosthetic valve is inserted to connect the right ventricle and the main pulmonary artery, bypassing the RVOT.</div><div id=\"graphicVersion\">Graphic 67062 Version 2.0</div></div></div>"},"67067":{"type":"graphic_movie","displayName":"TEE contrast atrial septal aneurysm and defect","title":"Atrial septal aneurysm and defect","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atrial septal aneurysm and defect</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/67067_teeasancconv.mp4\" style=\"width:324px;height:236px\"></div><img style=\"width:383px; height:419px;\" src=\"images/CARD/67067_teeasanc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transesophageal echocardiogram was performed with contrast. Panel A shows an aneurysm of the atrial septum. Immediately after the injection of agitated saline, contrast (yellow arrow) can be seen in the right atrium (RA) (panel B). With complete filling of the RA, a small amount of contrast is seen entering the left atrium (LA) as a result of a right to left shunt through an atrial septal defect (panel C). The contrast is then seen diffusely within the LA (panel D).</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 67067 Version 2.0</div></div></div>"},"67068":{"type":"graphic_figure","displayName":"Fetal station","title":"Assessing descent of the fetal head by vaginal examination","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Assessing descent of the fetal head by vaginal examination</div><div class=\"cntnt\"><img style=\"width:461px; height:354px;\" src=\"images/OBGYN/67068_Fetal_station.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The fetus is at -2 station signifying that the leading bony edge of the presenting part is&nbsp;2 centimeters above the ischial spines. The head is engaged at 0 station.</div><div class=\"graphic_footnotes\">Sp: ischial spine.</div><div id=\"graphicVersion\">Graphic 67068 Version 5.0</div></div></div>"},"67069":{"type":"graphic_figure","displayName":"ECG complex and intervals","title":"ECG complexes and intervals","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">ECG complexes and intervals</div><div class=\"cntnt\"><img style=\"width:201px; height:143px;\" src=\"images/CARD/67069_ECG_complex_and_intervals.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">ECG waves are labeled alphabetically starting with the P wave, followed by the QRS complex, and the ST-T complex (ST segment and T wave). The J point is the junction between the end of the QRS and the beginning of the ST segment. The PR interval is measured from the beginning of the P wave to the first part of the QRS complex. The QT interval consists of the QRS complex which represents only a brief part of the interval, and the ST segment and T wave which are of longer duration.</div><div id=\"graphicVersion\">Graphic 67069 Version 1.0</div></div></div>"},"67071":{"type":"graphic_diagnosticimage","displayName":"Unstable midshaft fracture 1","title":"Unstable midshaft forearm fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Unstable midshaft forearm fracture</div><div class=\"cntnt\"><img style=\"width:406px; height:453px;\" src=\"images/EM/67071_Unstable_midshaft_fx_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This nine-year-old child sustained an unstable midforearm fracture of the radius and ulna. There is approximately 25 degrees of volar angulation of the greenstick fracture of the radius on the lateral view (A) with dorsal displacement and shortening of the completely fractured distal ulnar fragment on the anterior posterior view (B).</div><div class=\"graphic_reference\">Courtesy of Paula Schweich, MD.</div><div id=\"graphicVersion\">Graphic 67071 Version 3.0</div></div></div>"},"67072":{"type":"graphic_figure","displayName":"Tanner staging breasts","title":"Tanner staging of breast development in girls","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Tanner staging of breast development in girls</div><div class=\"cntnt\"><img style=\"width:535px; height:284px;\" src=\"images/ENDO/67072_Tannerstagingbreasts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stage 1: Prepubertal.<br> Stage 2: Breast bud stage with elevation of breast and papilla; enlargement of areola.<br> Stage 3: Further enlargement of breast and areola; no separation of their contour.<br> Stage 4: Areola and papilla form a secondary mound above level of breast.<br> Stage 5: Mature stage with projection of papilla only, related to recession of areola.</div><div id=\"graphicVersion\">Graphic 67072 Version 4.0</div></div></div>"},"67073":{"type":"graphic_table","displayName":"Treatment recs for IFG, IGT, or both","title":"Treatment recommendation for individuals with IFG, IGT, or elevated A1C","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment recommendation for individuals with IFG, IGT, or elevated A1C</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Population</td> <td class=\"subtitle1\">Treatment</td> </tr> <tr class=\"divider_bottom\"> <td>IFG, IGT, or A1C (5.7 to 6.4%)</td> <td>Lifestyle modification (ie, 5 to 10% weight loss and moderate-intensity physical activity, approximately 30 min/day)</td> </tr> <tr> <td class=\"sublist1_start\">Individuals with IFG, IGT, or A1C 5.7 to 6.4%, especially for those:</td> <td class=\"sublist_other_start\" rowspan=\"4\">Lifestyle modification (as above) and/or metformin*</td> </tr> <tr> <td class=\"sublist1\">&#60;60 years of age</td> </tr> <tr> <td class=\"sublist1\">BMI &#8805;35 kg/m<sup>2</sup></td> </tr> <tr> <td class=\"sublist1\">Women with prior gestational diabetes</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IFG: impaired fasting glucose; IGT: impaired glucose tolerance; A1C: glycated hemoglobin; BMI: body mass index.<br />*&nbsp;Metformin 850 mg twice per day.</div><div class=\"graphic_reference\">Reproduced with permission from: Nathan DM, Davidson MB, DeFronzo RA, et al. Impaired fasting glucose and impaired glucose tolerance. Diabetes Care 2007; 30:753. Copyright © 2007 American Diabetes Association. Updated information from American Diabetes Association. Standards of medical care in diabetes—2013. Diabetes Care 2013; 36 Suppl 1:S11. The content within this table is still current as of the 2017 version of the Standards of Medical Care in Diabetes.</div><div id=\"graphicVersion\">Graphic 67073 Version 9.0</div></div></div>"},"67078":{"type":"graphic_picture","displayName":"Skin biopsy lichen sclerosis","title":"Skin biopsy of lichen sclerosis et atrophicus","html":"<div class=\"graphic\"><div style=\"width: 592px\" class=\"figure\"><div class=\"ttl\">Skin biopsy of lichen sclerosis et atrophicus</div><div class=\"cntnt\"><img style=\"width:572px; height:224px;\" src=\"images/RHEUM/67078_Skin_biopsy_lichen_sclerosi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Skin biopsy in lichen sclerosis et atrophicus showing attenuation of the epidermis which is surmounted by a dense or hyperkeratotic scale (left panel). There is also homogenization of the dermis with hypovascularity (right panel).</div><div class=\"graphic_reference\">Courtesy of Cynthia Magro, MD.</div><div id=\"graphicVersion\">Graphic 67078 Version 2.0</div></div></div>"},"67079":{"type":"graphic_figure","displayName":"Plication technique for Peyronies disease","title":"Plication technique for Peyronies disease","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Plication technique for Peyronies disease</div><div class=\"cntnt\"><img style=\"width:512px; height:691px;\" src=\"images/SURG/67079_PD_plication.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Straightening the penis with plication is achieved by shortening the convex side of the penis (ie, opposite the plaque). Plication is generally performed in men with adequate penile length.</div><div id=\"graphicVersion\">Graphic 67079 Version 2.0</div></div></div>"},"67080":{"type":"graphic_table","displayName":"Medical complications of anorexia nervosa","title":"Medical complications of anorexia nervosa","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medical complications of anorexia nervosa</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Constitution/whole body</td> </tr> <tr> <td>Cachexia and low body mass index</td> </tr> <tr> <td>Arrested growth</td> </tr> <tr> <td>Hypothermia</td> </tr> <tr> <td class=\"subtitle1_single\">Cardiovascular</td> </tr> <tr> <td>Myocardial atrophy</td> </tr> <tr> <td>Mitral valve prolapse</td> </tr> <tr> <td>Pericardial effusion</td> </tr> <tr> <td>Bradycardia</td> </tr> <tr> <td>Arrhythmia, which may cause sudden death</td> </tr> <tr> <td class=\"sublist1_start\">Electrocardiogram (ECG) changes</td> </tr> <tr> <td class=\"sublist1\">Increased PR interval</td> </tr> <tr> <td class=\"sublist1\">First-degree heart block</td> </tr> <tr> <td class=\"sublist1\">ST-T wave abnormalities</td> </tr> <tr> <td>Hypotension</td> </tr> <tr> <td>Acrocyanosis</td> </tr> <tr> <td class=\"subtitle1_single\">Gynecologic and reproductive</td> </tr> <tr> <td>Amenorrhea</td> </tr> <tr> <td>Unplanned pregnancy and neonatal complications</td> </tr> <tr> <td class=\"subtitle1_single\">Endocrine</td> </tr> <tr> <td>Osteoporosis and pathologic stress fractures</td> </tr> <tr> <td>Euthyroid sick syndrome</td> </tr> <tr> <td>Hypercortisolemia</td> </tr> <tr> <td>Hypoglycemia</td> </tr> <tr> <td>Neurogenic diabetes insipidus</td> </tr> <tr> <td>Poor diabetes control</td> </tr> <tr> <td class=\"subtitle1_single\">Gastrointestinal</td> </tr> <tr> <td>Gastroparesis (delayed gastric emptying)</td> </tr> <tr> <td>Constipation</td> </tr> <tr> <td>Gastric dilatation</td> </tr> <tr> <td>Increased colonic transit time</td> </tr> <tr> <td>Hepatitis</td> </tr> <tr> <td>Superior mesenteric artery syndrome</td> </tr> <tr> <td>&nbsp;Diarrhea</td> </tr> <tr> <td class=\"subtitle1_single\">Renal and electrolytes</td> </tr> <tr> <td>Decreased glomerular filtration rate</td> </tr> <tr> <td>Renal calculi</td> </tr> <tr> <td>Impaired concentration of urine</td> </tr> <tr> <td>Dehydration</td> </tr> <tr> <td>Hypokalemia</td> </tr> <tr> <td>Hypomagnesemia</td> </tr> <tr> <td>Hypovolemic nephropathy</td> </tr> <tr> <td class=\"subtitle1_single\">Pulmonary</td> </tr> <tr> <td>Pulmonary muscle wasting</td> </tr> <tr> <td>Decreased pulmonary capacity</td> </tr> <tr> <td>Respiratory failure</td> </tr> <tr> <td>Spontaneous pneumothorax and pneumomediastinum</td> </tr> <tr> <td>Enlargement of peripheral lung units without alveolar septa destruction</td> </tr> <tr> <td class=\"subtitle1_single\">Hematologic</td> </tr> <tr> <td>Anemia (normocytic, microcytic, or macrocytic)</td> </tr> <tr> <td>Leukopenia</td> </tr> <tr> <td>Thrombycytopenia</td> </tr> <tr> <td class=\"subtitle1_single\">Neurologic</td> </tr> <tr> <td>Cerebral atrophy (decreased gray and white matter)</td> </tr> <tr> <td>Enlarged ventricles</td> </tr> <tr> <td>Cognitive impairment</td> </tr> <tr> <td>Peripheral neuropathy</td> </tr> <tr> <td>Seizures</td> </tr> <tr> <td class=\"subtitle1_single\">Dermatologic</td> </tr> <tr> <td>Xerosis (dry skin)</td> </tr> <tr> <td>Lanugo hair (fine, downy, dark hair)</td> </tr> <tr> <td>Telogen effluvium (hair loss)</td> </tr> <tr> <td>Carotenoderma (yellowing)</td> </tr> <tr> <td>Scars from self-injurious behavior (cuts and burns)</td> </tr> <tr> <td class=\"subtitle1_single\">Muscular</td> </tr> <tr> <td>Muscle wasting</td> </tr> <tr> <td class=\"subtitle1_single\">Vitamin deficiencies</td> </tr> <tr> <td class=\"subtitle1_single\">Refeeding syndrome</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 67080 Version 4.0</div></div></div>"},"67082":{"type":"graphic_picture","displayName":"Grade III infiltrating ductal carcinoma of the breast","title":"Grade III infiltrating ductal carcinoma of the breast","html":"<div class=\"graphic\"><div style=\"width: 603px\" class=\"figure\"><div class=\"ttl\">Grade III infiltrating ductal carcinoma of the breast</div><div class=\"cntnt\"><img style=\"width:583px; height:230px;\" src=\"images/ONC/67082_Grade_3_breast_ca_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panel A) Low power view of a poorly differentiated breast carcinoma shows that the tumor is composed of solid nests of neoplastic cells without evidence of gland formation.<br />(Panel B) The high power view demonstrates marked nuclear atypia in the tumor cells with considerable mitotic activity.</div><div class=\"graphic_reference\">Courtesy of Stuart Schnitt, MD.</div><div id=\"graphicVersion\">Graphic 67082 Version 4.0</div></div></div>"},"67084":{"type":"graphic_picture","displayName":"Dry powder inhalers PI","title":"Examples of dry powder inhalers","html":"<div class=\"graphic\"><div style=\"width: 586px\" class=\"figure\"><div class=\"ttl\">Examples of dry powder inhalers</div><div class=\"cntnt\"><img style=\"width:566px; height:460px;\" src=\"images/PI/67084_Dry_powder_inhalers_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These are pictures of some of the different dry powder inhalers. The inhalers shown are: (A) Aerolizer, (B) HandiHaler, (C) Neohaler, (D) Tobi Podhaler, (E) Flexhaler, (F) Diskus, (G) Twisthaler, and (H) Breo Ellipta. There are two main types of dry powder inhalers, called single-dose inhalers and multiple-dose inhalers. The Aerolizer, HandiHaler, Neohaler, and Tobi Podhaler are single-dose inhalers. The others in the picture are multiple-dose inhalers.</div><div class=\"graphic_reference\">Panels A, B, E, F, and G: Courtesy of Dean Hess, RRT, PhD.<br />Panel C: Image used with permission. Copyright &copy; 2012 Novartis Pharmaceuticals Corporation.<br />Panel D: Image used with permission. Copyright &copy; 2013 Novartis Pharmaceuticals Corporation.<br />Panel H: Reproduced with permission. Copyright &copy; 2014 GlaxoSmithKline. All rights reserved.</div><div id=\"graphicVersion\">Graphic 67084 Version 8.0</div></div></div>"},"67087":{"type":"graphic_table","displayName":"Bosniak criteria renal cysts","title":"Definition of Bosniak classification of cystic renal masses by CT scanning","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Definition of Bosniak classification of cystic renal masses by CT scanning</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Category I - Simple benign cyst with the following features:</td> </tr> <tr> <td>Hairline thin wall.</td> </tr> <tr> <td>Density less than 20 Hounsfield units (similar to water).</td> </tr> <tr> <td>Does not contain septa, calcification, or solid components.</td> </tr> <tr> <td>Does not enhance.</td> </tr> <tr> <td class=\"subtitle1_single\">Category II - Cystic lesions with the following features:</td> </tr> <tr> <td>A few hairline thin septa.</td> </tr> <tr> <td>\"Perceived\" enhancement may be present. There is no measurable enhancement.</td> </tr> <tr> <td>Uniformly high attenuation lesions &#60;3 cm that are well marginated and do not enhance fall into this category.</td> </tr> <tr> <td class=\"subtitle1_single\">Category IIF - Minimally complicated cysts that do not neatly fall into category II. These lesions are generally well marginated but have some suspicious features that require follow-up:</td> </tr> <tr> <td>Multiple hairline thin septa or minimal smooth thickening of the wall or septa.</td> </tr> <tr> <td>\"Perceived\" enhacement of septa or wall may be present.</td> </tr> <tr> <td>Thick and nodular calcification of the wall or septa, but no measurable contrast enhancement is present.</td> </tr> <tr> <td>Totally intrarenal, nonenhancing, high attenuation lesions &#62;3 cm in diameter fall in this category.</td> </tr> <tr> <td class=\"subtitle1_single\">Category III - True indeterminate cystic masses that typically undergo surgical evaluation, although many lesions are benign. These lesions show the following: </td> </tr> <tr> <td>Thickened irregular or smooth walls or septa in which measurable enhancement is present.</td> </tr> <tr> <td class=\"subtitle1_single\">Category IV - These mostly malignant lesions have the following features: </td> </tr> <tr> <td>All category III criteria.</td> </tr> <tr> <td>Enhancing soft-tissue components adjacent to, but independent of, the wall or septum.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from Israel GM, Bosniak MA. An update of the Bosniak Renal Cyst Classification System. Urology 2005; 66:484.</div><div id=\"graphicVersion\">Graphic 67087 Version 3.0</div></div></div>"},"67090":{"type":"graphic_table","displayName":"Risk of childhood leukemia after in-utero exposure to radiation ","title":"Risk of childhood leukemia after in-utero exposure to radiation compared to other risk groups","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk of childhood leukemia after in-utero exposure to radiation compared to other risk groups</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Group</td>\n<td class=\"subtitle1\">Approximate risk</td>\n<td class=\"subtitle1\">Increase in risk above baseline</td>\n</tr>\n<tr>\n<td>Identical twin of leukemic twin</td>\n<td>1/3</td>\n<td>1000</td>\n</tr>\n<tr>\n<td>Irradiation-treated polycythemia</td>\n<td>1/6</td>\n<td>500</td>\n</tr>\n<tr>\n<td>Bloom syndrome</td>\n<td>1/8</td>\n<td>375</td>\n</tr>\n<tr>\n<td>Hiroshima survivors who were within 1000 meters of the hypocenter</td>\n<td>1/60</td>\n<td>50</td>\n</tr>\n<tr>\n<td>Down's syndrome</td>\n<td>1/95</td>\n<td>30</td>\n</tr>\n<tr>\n<td>Irradiation-treated ankylosing spondylitis</td>\n<td>1/270</td>\n<td>10</td>\n</tr>\n<tr>\n<td>Siblings of leukemic children</td>\n<td>1/720</td>\n<td>4</td>\n</tr>\n<tr>\n<td>Children exposed to in-utero pelvimetry</td>\n<td>1/2000</td>\n<td>1.5</td>\n</tr>\n<tr>\n<td>US white children &#60;15 years old</td>\n<td>1/2800</td>\n<td>1</td>\n</tr>\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">19.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=43288&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>In_utero_radiation_leukemia.htm</title></head></div><div class=\"graphic_reference\">Data from: Miller, RW. Epidemiologic conclusions from radiation toxicity studies. In: Late Effects of Radiation, Fry, RJM,Grahn, D, Griem, ML, et al (Eds). Taylor and Francis, London, 1970.</div><div id=\"graphicVersion\">Graphic 67090 Version 2.0</div></div></div>"},"67092":{"type":"graphic_figure","displayName":"Ethnicity foster care","title":"Race/ethnicity of children in foster care*, United States, 2015","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">Race/ethnicity of children in foster care*, United States, 2015</div><div class=\"cntnt\"><img style=\"width:490px; height:521px;\" src=\"images/PEDS/67092_Ethnicityfostercare.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* All races exclude children of Hispanic origin. Children of Hispanic ethnicity may be any race.</div><div class=\"graphic_reference\">Data from: Adoption and Foster Care Analysis and Reporting System (AFCARS) FY 2015 data. Available at: <A href=\"http://www.acf.hhs.gov/programs/cb/research-data-technology/statistics-research/afcars\" target=_blank>www.acf.hhs.gov/programs/cb/research-data-technology/statistics-research/afcars</A> (Accessed on October 17, 2017).</div><div id=\"graphicVersion\">Graphic 67092 Version 5.0</div></div></div>"},"67095":{"type":"graphic_algorithm","displayName":"Evaluation of dyspnea","title":"Approach to the patient with dyspnea","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Approach to the patient with dyspnea</div><div class=\"cntnt\"><img style=\"width:461px; height:394px;\" src=\"images/PULM/67095_Evaluation_of_dyspnea.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An efficient stepwise method of determining the cause of chronic dyspnea using pulmonary function tests.</div><div class=\"graphic_footnotes\">WNL: within normal limits; VC: vital capacity; FEV<SUB>1</SUB>: forced expiratory volume in one second; TLC: total lung capacity; DLCO: diffusing capacity; Pimax: peak inspiratory pressure.</div><div id=\"graphicVersion\">Graphic 67095 Version 2.0</div></div></div>"},"67096":{"type":"graphic_figure","displayName":"Physiologic progression of the thigh-foot angle","title":"Physiologic progression of the thigh-foot angle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Physiologic progression of the thigh-foot angle</div><div class=\"cntnt\"><img style=\"width:422px; height:284px;\" src=\"images/PEDS/67096_Progthighfootangle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The mean (line) and normal range (two standard deviations) of the thigh-foot angle according to age (years).</div><div class=\"graphic_reference\">Reproduced with permission from: Staheli LT. Lower limb. In: Fundamentals of Pediatric Orthopedics, 4<sup>th</sup> ed, Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 67096 Version 10.0</div></div></div>"},"67097":{"type":"graphic_figure","displayName":"Surgical treatment of acute eponychia","title":"Surgical treatment of acute eponychia","html":"<div class=\"graphic\"><div style=\"width: 609px\" class=\"figure\"><div class=\"ttl\">Surgical treatment of acute eponychia</div><div class=\"cntnt\"><img style=\"width:589px; height:302px;\" src=\"images/SURG/67097_Surg_treatment_eponychia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Surgical drainage is indicated for patients with acute eponychia who present late and have an abscess cavity. The drawings illustrate the appropriate drainage procedure.<br> (Left) Preoperative appearance and incision.<br> (Center) Eponychium elevated as a flap to drain the underlying abscess.<br> (Right) A small piece of xeroform is inserted into the wound to keep the eponychial flap open and allow the wound to drain.</div><div id=\"graphicVersion\">Graphic 67097 Version 2.0</div></div></div>"},"67098":{"type":"graphic_picture","displayName":"Angiolipoma","title":"Angiolipoma of the forearm","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Angiolipoma of the forearm</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/67098_Angiolipoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 67098 Version 3.0</div></div></div>"},"67102":{"type":"graphic_table","displayName":"Causes abd pain","title":"Classification of causes of abdominal pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of causes of abdominal pain</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td class=\"container\"><table cellspacing=\"0\">\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Visceral\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_single\">\r\n  \r\n   1. Mechanical obstruction of hollow viscera\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   a. Obstruction of the small or large intestine\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   b. Obstruction of the biliary tree\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   c. Obstruction of the ureter\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_single\">\r\n  \r\n   2. Distention of visceral surfaces, eg, hepatic or renal capsules\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_single\">\r\n  \r\n   3. Vascular disturbances\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   a. Embolism or thrombosis\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   b. Vascular rupture\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   c. Pressure or torsional occlusion\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   d. Sickle cell anemia\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_single\">\r\n  \r\n   4. Referred from non-abdominal viscera\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   a. Thorax, eg, pneumonia, referred pain from coronary occlusion\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_single\">\r\n  \r\n   5. Metabolic causes\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   a. Black widow spider bite\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   b. Lead poisoning and others\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   c. Uremia\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   b. Diabetic ketoacidosis\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   c. Porphyria\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   d. Allergic factors (C'1 esterase inhibitor deficiency)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   </table></td>\r\n  \r\n   <td class=\"container\"><table cellspacing=\"0\">\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Somatic\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_single\">\r\n  \r\n   1. Parietal peritoneal inflammation\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   a. Bacterial contamination, eg, perforated appendix, pelvic inflammatory disease\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   b. Chemical irritation, eg, perforated ulcer, pancreatitis, mittelschmerz\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_single\">\r\n  \r\n   2. Abdominal wall\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   a. Distortion or traction of mesentery\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   b. Trauma or infection of muscles\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_single\">\r\n  \r\n   3. Spine, eg, radiculitis from arthritis\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_single\">\r\n  \r\n   4. Neurogenic causes\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   a. Tabes dorsalis\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   b. Herpes zoster\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   c. Causalgia and others\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   d. Functional\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   </table></td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_reference\">Reproduced with permission from: Howard, FM. Acute Abdominal Pain. In: Primary Care for Women., Leppert, PC, Peipert, P (Eds), Lippincott, Williams and Wilkins 2004. Copyright &#169;2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 67102 Version 1.0</div></div></div>"},"67103":{"type":"graphic_picture","displayName":"Histology nevoid melanoma","title":"Nevoid melanoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nevoid melanoma</div><div class=\"cntnt\"><img style=\"width:375px; height:258px;\" src=\"images/ONC/67103_Histology_nevoid_melanoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power light photomicrograph. Note the resemblance to a dermal nevus on low power.</div><div class=\"graphic_reference\">Courtesy of Vincent Liu, MD and April Wang Armstrong, MD.</div><div id=\"graphicVersion\">Graphic 67103 Version 1.0</div></div></div>"},"67105":{"type":"graphic_picture","displayName":"Atrophie blanche lipodermatosclerosis","title":"Atrophie blanche lipodermatosclerosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atrophie blanche lipodermatosclerosis</div><div class=\"cntnt\"><img style=\"width:289px; height:194px;\" src=\"images/PC/67105_Atrophie_blanche_lipodermat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atrophie blanche of the medial ankle in a patient with lipodermatosclerosis consists of several white macular areas measuring 3 to 4 mm in diameter (arrows). These changes are caused by avascular fibrotic scars.</div><div class=\"graphic_reference\">Courtesy of Patrick C Alguire, MD.</div><div id=\"graphicVersion\">Graphic 67105 Version 4.0</div></div></div>"},"67106":{"type":"graphic_figure","displayName":"Axillary artery puncture","title":"Axillary artery puncture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Axillary artery puncture</div><div class=\"cntnt\"><img style=\"width:332px; height:306px;\" src=\"images/PULM/67106_Axillary_artery_puncture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Technique of axillary artery puncture. The arm should be hyperabducted and externally rotated. The needle should be inserted into the artery as high as possible within the axilla.</div><div class=\"graphic_reference\">Adapted from American Heart Association. Textbook of Advanced Cardiac Life Support, 1994.</div><div id=\"graphicVersion\">Graphic 67106 Version 1.0</div></div></div>"},"67108":{"type":"graphic_picture","displayName":"Gross appearance of allergic mucin","title":"Gross appearance of allergic mucin","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gross appearance of allergic mucin</div><div class=\"cntnt\"><img style=\"width:360px; height:151px;\" src=\"images/ALLRG/67108_Allergicmucin.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Mark S Schubert, MD, PhD.</div><div id=\"graphicVersion\">Graphic 67108 Version 3.0</div></div></div>"},"67109":{"type":"graphic_diagnosticimage","displayName":"Thyroid suppression scan","title":"Thyroid suppression scan","html":"<div class=\"graphic\"><div style=\"width: 730px\" class=\"figure\"><div class=\"ttl\">Thyroid suppression scan</div><div class=\"cntnt\"><img style=\"width:710px; height:605px;\" src=\"images/ENDO/67109_Thrd_sppr_scn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">123-I thyroid scan of the indeterminate thyroid nodule shown in the previous radiograph, after four weeks of T4 therapy. The nodule (outlined in white) overlies an area of relatively increased isotope concentration, indicating autonomy, since uptake is suppressed in the rest of the gland.</div><div class=\"graphic_footnotes\">123-I: iodine-123; SSN: suprasternal notch; T4: levothyroxine.</div><div class=\"graphic_reference\">Courtesy of Douglas Ross, MD.</div><div id=\"graphicVersion\">Graphic 67109 Version 4.0</div></div></div>"},"67110":{"type":"graphic_diagnosticimage","displayName":"Ovarian torsion sonogram","title":"Ovarian torsion sonogram","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ovarian torsion sonogram</div><div class=\"cntnt\"><img style=\"width:396px; height:289px;\" src=\"images/OBGYN/67110_Ovarian_torsion_sonogram.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound with color Doppler image of ovarian torsion in a pregnant woman. Arrow shows ovary with no vascularity. Arrowhead shows the fetus.</div><div class=\"graphic_reference\">Courtesy of Charles C Kilpatrick, MD and Francisco J Orejuela, MD.</div><div id=\"graphicVersion\">Graphic 67110 Version 3.0</div></div></div>"},"67112":{"type":"graphic_picture","displayName":"Erysipelas of the face","title":"Erysipelas","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erysipelas</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/ID/67112_Erysipelas_face_new.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erysipelas lesions are raised above the level of surrounding skin, and there is a clear line of demarcation between involved and uninvolved tissue.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 67112 Version 5.0</div></div></div>"},"67113":{"type":"graphic_table","displayName":"Local recurr breast CA in pts with occult primary breast CA","title":"Local recurrence of breast cancer in patients with occult primary breast cancer not undergoing local therapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Local recurrence of breast cancer in patients with occult primary breast cancer not undergoing local therapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Author, year</td> <td class=\"subtitle1\">Breast failures (percent)</td> <td class=\"subtitle1\">Delay in months</td> </tr> <tr> <td>Atkins H; 1960</td> <td>5/9 (56)</td> <td>9 to 17</td> </tr> <tr> <td>Feuerman L; 1962</td> <td>0/1 (0)</td> <td>-</td> </tr> <tr> <td>Haagensen C; 1974</td> <td>3/5 (60)</td> <td>5 to 64</td> </tr> <tr> <td>Kemeny M; 1986</td> <td>0/7 (0)</td> <td>-</td> </tr> <tr> <td>Campana F; 1989</td> <td>2/2 (100)</td> <td>9 to 67</td> </tr> <tr> <td>Ellerbroek N; 1990</td> <td>7/13 (54)</td> <td>11 to 47</td> </tr> <tr> <td>Merson M; 1992</td> <td>9/17 (53)</td> <td>2 to 34</td> </tr> <tr> <td>Van Ooijen B; 1993</td> <td>3/14 (21)</td> <td>16 to 56</td> </tr> <tr> <td>Fouroudi F; 2000</td> <td>5/6 (83)</td> <td>7 (median)</td> </tr> <tr> <td>Feigenberg S; 2003</td> <td>0/4 (0)</td> <td>-</td> </tr> <tr> <td>Blanchard D; 2004</td> <td>12/16 (75)</td> <td>-</td> </tr> <tr class=\"divider_top\"> <td><strong>Total</strong></td> <td><strong>46/94 (49)</strong></td> <td><strong>-</strong></td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 67113 Version 4.0</div></div></div>"},"67114":{"type":"graphic_figure","displayName":"Stool diary sample PI","title":"Stool diary (sample)","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Stool diary (sample)</div><div class=\"cntnt\"><img style=\"width:542px; height:602px;\" src=\"images/PI/67114_Stool_diary_sample_PI.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 67114 Version 1.0</div></div></div>"},"67117":{"type":"graphic_diagnosticimage","displayName":"Normal foot oblique","title":"Standard oblique radiograph of foot","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Standard oblique radiograph of foot</div><div class=\"cntnt\"><img style=\"width:233px; height:534px;\" src=\"images/EM/67117_Normal_foot_oblique.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The oblique angle provides a better view of the Lisfranc joint. In this view, the medial border of the fourth metatarsal should be colinear with the medial border of the cuboid.</div><div class=\"graphic_reference\">Courtesy of Robert L Hatch, MD, MPH.</div><div id=\"graphicVersion\">Graphic 67117 Version 3.0</div></div></div>"},"67119":{"type":"graphic_table","displayName":"RR vs absolute risk fx","title":"Relative risk versus absolute risk estimates of fracture","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Relative risk versus absolute risk estimates of fracture</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Age</td>\n<td class=\"subtitle1\">Hip T-score</td>\n<td class=\"subtitle1\">Relative risk</td>\n<td class=\"subtitle1\">10-year fracture probability, percent</td>\n</tr>\n<tr>\n<td>50</td>\n<td>-2.5</td>\n<td>17.6</td>\n<td>1.7</td>\n</tr>\n<tr><td>80</td><td>-2.5</td><td>17.6</td><td>11.5</td></tr>\n\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">4.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=15961&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>RR_vs_absolute_risk_fx.htm</title></head></div><div class=\"graphic_lgnd\">Relative&nbsp;risk compared to age-matched women with normal BMD. <br />(RR per SD change in BMD)<SUP>T-score Difference</SUP> = (2.6)<SUP>2.5</SUP> = 17.6.</div><div class=\"graphic_footnotes\">BMD: bone mineral density; RR: relative risk; SD: standard deviation.</div><div class=\"graphic_reference\">10-year fracture probability from Swedish National Bureau of Statistics.<br />Data from: Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312:1254 and Kanis JA, Johnell O, Oden A, et al. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporosis International 2001; 12:989.</div><div id=\"graphicVersion\">Graphic 67119 Version 2.0</div></div></div>"},"67121":{"type":"graphic_table","displayName":"Test results bleeding disorders","title":"Expected results of tests for hemostatic function in representative bleeding disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Expected results of tests for hemostatic function in representative bleeding disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup span=\"5\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disorder</td> <td class=\"subtitle1\">Platelet count</td> <td class=\"subtitle1\">PT</td> <td class=\"subtitle1\">aPTT</td> <td class=\"subtitle1\">TT</td> <td class=\"subtitle1\">Fibrinogen</td> </tr> <tr> <td>Vasculopathies, connective tissue diseases, or collagen disorders affecting skin</td> <td>Normal</td> <td>Normal</td> <td>Normal</td> <td>Normal</td> <td>Normal or increased*</td> </tr> <tr> <td>Thrombocytopenia</td> <td>Low</td> <td>Normal</td> <td>Normal</td> <td>Normal</td> <td>Normal</td> </tr> <tr> <td>Qualitative platelet abnormalities</td> <td>Normal or low<sup>&#182;</sup></td> <td>Normal</td> <td>Normal</td> <td>Normal</td> <td>Normal</td> </tr> <tr> <td>Hemophilia A (factor VIII deficiency)</td> <td>Normal</td> <td>Normal</td> <td>Long</td> <td>Normal</td> <td>Normal</td> </tr> <tr> <td>von Willebrand disease</td> <td>Normal<sup>&#916;</sup></td> <td>Normal</td> <td>Normal or long<sup>&#9674;</sup></td> <td>Normal</td> <td>Normal</td> </tr> <tr> <td>Disseminated intravascular coagulation</td> <td>Low</td> <td>Long</td> <td>Long</td> <td>Long</td> <td>Low</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate topics on the evaluation of unexplained bleeding or&nbsp;bruising for a discussion of these findings and our approach to the evaluation.</div><div class=\"graphic_footnotes\">PT: prothrombin time; aPTT: activated partial thromboplastin time; TT: thrombin time.<br />* Fibrinogen may be elevated as an acute phase reactant in disorders of inflammation.<br />¶ The platelet count in myeloproliferative disorders is usually high (eg, essential thrombocythemia) and platelets may also be qualitatively abnormal, predisposing to hemorrhagic and thrombotic diatheses.<br />Δ The platelet count may be low in some patients with type 2B von Willebrand disease.<br /><FONT class=lozenge>◊</FONT> The aPTT may be normal in those with Factor VIII activity &gt;40 percent.</div><div id=\"graphicVersion\">Graphic 67121 Version 12.0</div></div></div>"},"67123":{"type":"graphic_picture","displayName":"Psoriatic arthritis foot","title":"Psoriatic arthritis","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Psoriatic arthritis</div><div class=\"cntnt\"><img style=\"width:468px; height:351px;\" src=\"images/RHEUM/67123_Psoriatic_arthritis_foot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph of the foot of a patient with psoriatic arthritis shows the early separation of the nails (onycholysis), swelling of the entire second toe (dactylitis), and some psoriatic skin lesions.</div><div class=\"graphic_reference\">Reproduced with permission from Daniel Z Sands, MD, MPH.</div><div id=\"graphicVersion\">Graphic 67123 Version 1.0</div></div></div>"},"67124":{"type":"graphic_figure","displayName":"Comparison of OCT and IVUS","title":"Comparison of OCT and IVUS","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Comparison of OCT and IVUS</div><div class=\"cntnt\"><img style=\"width:445px; height:452px;\" src=\"images/CARD/67124_Comparison_OCT_IVUS_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Comparison of intracoronary Fourier domain OCT (St. Jude/Lightlab Imaging Inc, Westford, MA, USA) specifications and conventional intravascular ultrasound, as typically used in the catheterization laboratory.</div><div class=\"graphic_footnotes\">* Based on specifications of the current generations of Volcano, Boston Scientific, and Terumo IVUS systems.</div><div class=\"graphic_reference\">Courtesy of Dr. Evelyn Regar, Thoraxcenter.</div><div id=\"graphicVersion\">Graphic 67124 Version 1.0</div></div></div>"},"67127":{"type":"graphic_picture","displayName":"Schambergs disease","title":"Schamberg's disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Schamberg's disease</div><div class=\"cntnt\"><img style=\"width:339px; height:396px;\" src=\"images/DERM/67127_Schambergs_disease.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Brown macules and patches with red-brown (cayenne-pepper-like) pinpoint macules are present in this patient with Schamberg's disease, a variant of pigmented purpuric dermatosis.</div><div class=\"graphic_reference\">Reproduced with permission from: Stedman's Medical Dictionary. Copyright &#169; 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 67127 Version 2.0</div></div></div>"},"67129":{"type":"graphic_figure","displayName":"Potassium adaptation","title":"Increased potassium secretion in potassium adaptation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Increased potassium secretion in potassium adaptation</div><div class=\"cntnt\"><img style=\"width:419px; height:215px;\" src=\"images/NEPH/67129_Potassium_adaptation.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relationship between the plasma potassium concentration (which is raised by potassium chloride infusion) and distal potassium secretion in normal animals (dashed line) and those treated with a high-potassium diet for four weeks (solid line). A high-potassium diet leads to potassium adaptation: at any plasma potassium concentration, distal potassium secretion is two to four times higher in adapted animals compared to normals.</div><div class=\"graphic_reference\">Data from: Stanton BA. Am J Physiol 1989; 257:R989.</div><div id=\"graphicVersion\">Graphic 67129 Version 2.0</div></div></div>"},"67130":{"type":"graphic_picture","displayName":"Chorangioma","title":"Chorangioma","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Chorangioma</div><div class=\"cntnt\"><img style=\"width:590px; height:442px;\" src=\"images/OBGYN/67130_Chorioangioma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arrows point to vessels within the mass.</div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 67130 Version 2.0</div></div></div>"},"67131":{"type":"graphic_table","displayName":"Causes death children","title":"10 leading causes of death, United States (<1 to 24 years) 2015, all races, both sexes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">10 leading causes of death, United States (&lt;1 to 24 years) 2015, all races, both sexes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"6\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Rank</td> <td class=\"subtitle1\" colspan=\"6\">Age groups (years)</td> </tr> <tr> <td class=\"subtitle2\">&#60;1</td> <td class=\"subtitle2\">1 to 4</td> <td class=\"subtitle2\">5 to 9</td> <td class=\"subtitle2\">10 to 14</td> <td class=\"subtitle2\">15 to 19</td> <td class=\"subtitle2\">20 to 24</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">1</td> <td> <p>Congenital anomalies</p> 4825</td> <td> <p><span class=\"blue\" style=\"color: #0000ff;\"><strong>Unintentional injury</strong></span></p> <strong><span class=\"blue\" style=\"color: #0000ff;\">1235*</span></strong></td> <td> <p><strong><span class=\"blue\" style=\"color: #0000ff;\">Unintentional injury</span></strong></p> <strong><span class=\"blue\" style=\"color: #0000ff;\">755*</span></strong></td> <td> <p><strong><span class=\"blue\" style=\"color: #0000ff;\">Unintentional injury</span></strong></p> <strong><span class=\"blue\" style=\"color: #0000ff;\">763*</span></strong></td> <td> <p><strong><span class=\"blue\" style=\"color: #0000ff;\">Unintentional injury</span></strong></p> <strong><span class=\"blue\" style=\"color: #0000ff;\">3919*</span></strong></td> <td> <p><strong><span class=\"blue\" style=\"color: #0000ff;\">Unintentional injury</span></strong></p> <strong><span class=\"blue\" style=\"color: #0000ff;\">8595*</span></strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">2</td> <td> <p>Short gestation</p> 4084</td> <td> <p>Congenital anomalies</p> 435</td> <td> <p>Malignant neoplasms</p> 437</td> <td> <p>Malignant neoplasms</p> 428</td> <td> <p><span class=\"green\" style=\"color: #008000;\"><strong>Suicide</strong></span></p> <strong><span class=\"green\" style=\"color: #008000;\">2061<sup>&#182;</sup></span></strong></td> <td> <p><strong><span class=\"green\" style=\"color: #008000;\">Suicide</span></strong></p> <strong><span class=\"green\" style=\"color: #008000;\"><strong>3430<sup>&#182;</sup></strong></span></strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">3</td> <td> <p>SIDS</p> 1568</td> <td> <p><span class=\"red\" style=\"color: #ff0000;\"><strong>Homicide</strong></span></p> <span class=\"red\" style=\"color: #ff0000;\"><strong>369<sup>&#916;</sup></strong></span></td> <td> <p>Congenital anomalies</p> 181</td> <td> <p><span class=\"green\" style=\"color: #008000;\"><strong>Suicide</strong></span></p> <span class=\"green\" style=\"color: #008000;\"><strong>409<sup>&#182;</sup></strong></span></td> <td> <p><span class=\"red\" style=\"color: #ff0000;\"><strong>Homicide</strong></span></p> <strong><span class=\"red\" style=\"color: #ff0000;\">1587<sup>&#916;</sup></span></strong></td> <td> <p><strong><span class=\"red\" style=\"color: #ff0000;\">Homicide</span></strong></p> <strong><span class=\"red\" style=\"color: #ff0000;\"><strong>3146<sup>&#916;</sup></strong></span></strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">4</td> <td> <p>Maternal pregnancy complications</p> <p>1522</p> </td> <td> <p>Malignant neoplasms</p> 354</td> <td> <p><span class=\"red\" style=\"color: #ff0000;\"><strong>Homicide</strong></span></p> <strong><span class=\"red\" style=\"color: #ff0000;\">140<sup>&#916;</sup></span></strong></td> <td> <p><strong><span style=\"color: #ff0000;\">Homicide</span></strong></p> <strong><span style=\"color: #ff0000;\"><strong>158<sup>&#916;</sup></strong></span></strong></td> <td> <p>Malignant neoplasms</p> 583</td> <td> <p>Malignant neoplasms</p> 886</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">5</td> <td> <p><span class=\"blue\" style=\"color: #0000ff;\"><strong>Unintentional injury</strong></span></p> <span class=\"blue\" style=\"color: #0000ff;\"><strong>1291*</strong></span></td> <td> <p>Heart disease</p> 147</td> <td> <p>Heart disease</p> 85</td> <td> <p><span class=\"red\" style=\"color: #000000;\">Congenital anomalies</span></p> <span class=\"red\" style=\"color: #000000;\">156</span></td> <td> <p>Heart disease</p> 306</td> <td> <p>Heart disease</p> 691</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">6</td> <td> <p>Placenta cord membranes</p> 910</td> <td> <p>Influenza and&nbsp;pneumonia</p> 88</td> <td> <p>Chronic lower respiratory disease</p> 80</td> <td> <p>Heart disease</p> 125</td> <td> <p>Congenital anomalies</p> 195</td> <td> <p>Congenital anomalies</p> 191</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">7</td> <td> <p>Bacterial sepsis</p> 599</td> <td> <p>Septicemia</p> 54</td> <td> <p>Influenza and pneumonia</p> 44</td> <td> <p>Chronic lower respiratory disease</p> 93</td> <td> <p>Influenza and pneumonia</p> 72</td> <td> <p>Diabetes mellitus</p> 144</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">8</td> <td> <p>Respiratory distress</p> 462</td> <td> <p>Perinatal period</p> 50</td> <td> <p>Cerebrovascular</p> 42</td> <td> <p>Cerebrovascular</p> 42</td> <td> <p>Chronic lower respiratory disease</p> 63</td> <td> <p>Chronic lower respiratory disease</p> 139</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">9</td> <td> <p>Circulatory system disease</p> 428</td> <td> <p>Cerebrovascular</p> 42</td> <td> <p>Benign neoplasms</p> 39</td> <td> <p>Influenza&nbsp;and pneumonia</p> 39</td> <td> <p>Cerebrovascular</p> 61</td> <td> <p>Complicated pregnancy</p> 120</td> </tr> <tr> <td class=\"centered\">10</td> <td> <p>Neonatal hemorrhage</p> 406</td> <td> <p>Chronic lower respiratory disease</p> 40</td> <td> <p>Septicemia</p> 31</td> <td> <p>Two tied<sup>&#9674;</sup></p> 33</td> <td> <p>Diabetes mellitus</p> 52</td> <td> <p>Influenza&nbsp;and pneumonia</p> 112</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SIDS: sudden infant death syndrome.<br />* Unintentional injury.<br />¶ Suicide.<br />Δ Homicide.<br />◊ Benign neoplasms and septicemia.</div><div class=\"graphic_reference\">Reproduced from: National Center for Health Statistics (NCHS), National Vital Statistics System. Available at: <A spellcheck=true href=\"https://webappa.cdc.gov/sasweb/ncipc/leadcause.html\" target=_blank>https://webappa.cdc.gov/sasweb/ncipc/leadcause.html</A>. Accessed on June 26, 2017.</div><div id=\"graphicVersion\">Graphic 67131 Version 11.0</div></div></div>"},"67132":{"type":"graphic_table","displayName":"Genetic classification of CMD","title":"Genetic classification of congenital muscular dystrophies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Genetic classification of congenital muscular dystrophies</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Disease/phenotypes</td> <td class=\"subtitle1\">Designation</td> <td class=\"subtitle1\">Gene location</td> <td class=\"subtitle1\">Gene</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Protein defects</td> </tr> <tr> <td class=\"indent1\">Primary merosin deficiency</td> <td>MDC1A</td> <td>6q22-q23</td> <td>LAMA2</td> </tr> <tr> <td class=\"indent1\">Secondary merosin deficiency</td> <td>MDC1B</td> <td>1q42</td> <td>?</td> </tr> <tr> <td class=\"indent1\">Rigid spine syndrome (rigid spine muscular dystrophy 1)</td> <td>RSMD1</td> <td>1p35-p36</td> <td>SEPN1</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Ullrich muscular dystrophy and Bethlem myopathy</td> <td rowspan=\"3\">&nbsp;</td> <td>21q22.3</td> <td>COL6A1</td> </tr> <tr> <td>21q22.3</td> <td>COL6A2</td> </tr> <tr> <td>2q37</td> <td>COL6A3</td> </tr> <tr> <td class=\"indent1\">Lamin A-related congenital muscular dystrophy</td> <td>&nbsp;</td> <td>1q21.2</td> <td>LMNA</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Dystroglycanopathies</td> </tr> <tr> <td class=\"subtitle3_left\">Congenital muscular dystrophy-dystroglycanopathy with brain and eye anomalies (type A)</td> <td class=\"subtitle3_left\" colspan=\"3\">MDDGA series</td> </tr> <tr> <td class=\"indent2\">POMT1-related Walker-Warburg syndrome and muscle-eye-brain disease</td> <td class=\"indent2\">MDDGA1</td> <td>9q34.1</td> <td>POMT1</td> </tr> <tr> <td class=\"indent2\">POMT2-related Walker-Warburg syndrome and muscle-eye-brain disease</td> <td class=\"indent2\">MDDGA2</td> <td>14q24.3</td> <td>POMT2</td> </tr> <tr> <td class=\"indent2\">POMGNT1-related muscle-eye-brain disease and Walker-Warburg syndrome</td> <td class=\"indent2\">MDDGA3</td> <td>1p34-p33</td> <td>POMGNT1</td> </tr> <tr> <td class=\"indent2\">FKTN-related Fukuyama congenital muscular dystrophy and Walker-Warburg syndrome</td> <td class=\"indent2\">MDDGA4</td> <td>9q31-q33</td> <td>FKTN</td> </tr> <tr> <td class=\"indent2\">FKRP-related Walker-Warburg syndrome and muscle-eye-brain disease</td> <td class=\"indent2\">MDDGA5</td> <td>19q13.32</td> <td>FKRP</td> </tr> <tr> <td class=\"indent2\">LARGE-related Walker-Warburg syndrome and muscle-eye-brain disease</td> <td class=\"indent2\">MDDGA6</td> <td>22q12.3-q13.1</td> <td>LARGE</td> </tr> <tr> <td class=\"indent2\">ISPD-related Walker-Warburg syndrome and muscle-eye-brain disease</td> <td class=\"indent2\">MDDGA7</td> <td>7p21.2</td> <td>ISPD</td> </tr> <tr> <td class=\"indent2\">GTDC2-related Walker-Warburg syndrome and muscle-eye-brain disease</td> <td class=\"indent2\">MDDGA8</td> <td>3p22.1</td> <td>GTDC2</td> </tr> <tr> <td class=\"indent2\">TMEM5-related Walker-Warburg syndrome and muscle-eye-brain disease</td> <td class=\"indent2\">MDDGA10</td> <td>12q14.2</td> <td>TMEM5</td> </tr> <tr> <td class=\"indent2\">B3GALNT2-related Walker-Warburg syndrome and muscle-eye-brain disease</td> <td class=\"indent2\">MDDGA11</td> <td>1q42.3</td> <td>B3GALNT2</td> </tr> <tr> <td class=\"indent2\">POMK-related Walker-Warburg syndrome and muscle-eye-brain disease</td> <td class=\"indent2\">MDDGA12</td> <td>8p11.21</td> <td>POMK</td> </tr> <tr> <td class=\"indent2\">B3GNT1-related Walker-Warburg syndrome and muscle-eye-brain disease</td> <td class=\"indent2\">MDDGA13</td> <td>11q13.2</td> <td>B3GNT1&nbsp;</td> </tr> <tr> <td class=\"indent2\">GMPPB-related Walker-Warburg syndrome and muscle-eye-brain disease</td> <td class=\"indent2\">MDDGA14</td> <td>3p21.31</td> <td>GMPPB</td> </tr> <tr> <td class=\"subtitle3_left\">Congenital muscular dystrophy-dystroglycanopathy with or without mental retardation (type B)</td> <td class=\"subtitle3_left\" colspan=\"3\">MDDGB series</td> </tr> <tr> <td class=\"indent2\">POMT1-related</td> <td class=\"indent2\">MDDGB1</td> <td>9q34.1</td> <td>POMT1</td> </tr> <tr> <td class=\"indent2\">POMT2-related</td> <td class=\"indent2\">MDDGB2</td> <td>14q24.3</td> <td>POMT2</td> </tr> <tr> <td class=\"indent2\">POMGNT1-related</td> <td class=\"indent2\">MDDGB3</td> <td>1p34-p33</td> <td>POMGNT1</td> </tr> <tr> <td class=\"indent2\">FKTN-related</td> <td class=\"indent2\">MDDGB4</td> <td>9q31-q33</td> <td>FKTN</td> </tr> <tr> <td class=\"indent2\">FKRP-related</td> <td class=\"indent2\">MDDGB5</td> <td>19q13.32</td> <td>FKRP</td> </tr> <tr> <td class=\"indent2\">LARGE-related</td> <td class=\"indent2\">MDDGB6</td> <td>22q12.3-q13.1</td> <td>LARGE</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from:<BR>1. Jones K, North K. The congenital muscular dystrophies. In: Neuromuscular Disorders of Infancy, Childhood, and Adolescence: A Clinician's Approach. Jones HR, De Vivo DC, Darras BT (Eds). Butterworth Heinemann, Philadelphia 2003.<BR>2. Online Mendelian Inheritance in Man. <A href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?db=omim\" target=_blank>www.ncbi.nlm.nih.gov/sites/entrez?db=omim</A> (Accessed on January 19, 2011).</div><div id=\"graphicVersion\">Graphic 67132 Version 7.0</div></div></div>"},"67133":{"type":"graphic_algorithm","displayName":"Inflammatory diarrhea child","title":"Algorithm for evaluation of a child with inflammatory diarrhea","html":"<div class=\"graphic\"><div style=\"width: 716px\" class=\"figure\"><div class=\"ttl\">Algorithm for evaluation of a child with inflammatory diarrhea</div><div class=\"cntnt\"><img style=\"width:696px; height:443px;\" src=\"images/PEDS/67133_Inflammadiarrheachild.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm shows a typical diagnostic pathway for many patients in this age group. Other sequences of testing may be appropriate in some cases.</div><div class=\"graphic_footnotes\">C. difficile: Clostridium difficile; CT: computerized tomography; MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 67133 Version 7.0</div></div></div>"},"67134":{"type":"graphic_table","displayName":"Uses for vagal maneuvers","title":"Conditions in which vagal maneuvers may be useful diagnostically or therapeutically","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions in which vagal maneuvers may be useful diagnostically or therapeutically</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Tachyarrhythmias</td> </tr> <tr> <td>Narrow, regular supraventricular tachycardias</td> </tr> <tr> <td>Sinus tachycardia</td> </tr> <tr> <td>Atrial fibrillation and flutter</td> </tr> <tr> <td>Ventricular tachycardia</td> </tr> <tr> <td class=\"subtitle1_single\">Conduction abnormalities</td> </tr> <tr> <td>2:1&nbsp;atrioventricular block</td> </tr> <tr> <td>Bundle branch blocks</td> </tr> <tr> <td>Pre-excitation</td> </tr> <tr> <td class=\"subtitle1_single\">Other cardiovascular uses</td> </tr> <tr> <td>Carotid sinus hypersensitivity</td> </tr> <tr> <td>Pulmonary edema</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Peter J Zimetbaum, MD and Daniel Frisch, MD.</div><div id=\"graphicVersion\">Graphic 67134 Version 3.0</div></div></div>"},"67135":{"type":"graphic_figure","displayName":"Placement of King LT laryngeal tube airway device","title":"Placement of King LT laryngeal tube airway device","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Placement of King LT laryngeal tube airway device</div><div class=\"cntnt\"><img style=\"width:454px; height:372px;\" src=\"images/EM/67135_King_LT_anatomy_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The King LT is an example of a laryngeal tube, which are commonly used for emergency airway management. Laryngeal tubes include two balloon cuffs, one pharyngeal and one esophageal, with ventilation fenestrations in between that align with the glottic opening.</div><div class=\"graphic_reference\">Reproduced with permission from: King Systems Corporation. Copyright © 2008 King Systems Corporation.</div><div id=\"graphicVersion\">Graphic 67135 Version 3.0</div></div></div>"},"67136":{"type":"graphic_figure","displayName":"Protein sequence PP family","title":"Protein sequence of the human pancreatic polypeptide family","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Protein sequence of the human pancreatic polypeptide family</div><div class=\"cntnt\"><img style=\"width:427px; height:608px;\" src=\"images/GAST/67136_Protein_seq_PP_family_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Top) Protein sequence of the human pancreatic polypeptide family.<br />(Bottom) Illustration of the \"PP-fold.\"</div><div class=\"graphic_footnotes\">PP: pancreatic peptide; PYY: peptide YY; NPY: neuropeptide Y.</div><div class=\"graphic_reference\">Modified from: Cabrele C, Beck-Sickinger AG. Molecular characterization of the ligand-receptor interaction of the neuropeptide Y family. J Pept Sci 2000; 6:97.</div><div id=\"graphicVersion\">Graphic 67136 Version 5.0</div></div></div>"},"67141":{"type":"graphic_table","displayName":"Tips for sleeping better at night PI","title":"Tips for sleeping better at night","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Tips for sleeping better at night</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">During the day</td> </tr> <tr> <td>Exercise on a regular basis, even if it's only a 20-minute walk each day. Don't exercise in the evening.</td> </tr> <tr> <td>Limit naps if you can. If you must nap, don't nap more than 30 minutes.</td> </tr> <tr> <td class=\"subtitle1_single\">Before bedtime</td> </tr> <tr> <td>Avoid alcohol, caffeine, chocolate, and nicotine (cigarettes) in the late afternoon and evening.</td> </tr> <tr> <td>Limit liquids in the evening before going to bed.</td> </tr> <tr> <td>Turn off the TV 1 hour before bedtime. Listen to quiet music or take a warm bath.</td> </tr> <tr> <td>If you worry or \"can't turn your brain off\" when you try to sleep, write out a list of the things you need to do before you go to bed. Then stop thinking about them.</td> </tr> <tr> <td class=\"subtitle1_single\">At bedtime</td> </tr> <tr> <td>Go to bed and get up at the same time every day, even on weekends.</td> </tr> <tr> <td>A bedtime snack of warm milk, turkey, or a banana might make you sleepy.</td> </tr> <tr> <td>Use your bedroom only for sleep and sex. Do not read, watch TV, or work in the bedroom.</td> </tr> <tr> <td>If you are a \"clock watcher,\" turn your clock so that you cannot see its face.</td> </tr> <tr> <td>To fall asleep, lie in the position that you are normally in when you wake up.</td> </tr> <tr> <td>Go to bed at the same time as your spouse.</td> </tr> <tr> <td class=\"subtitle1_single\">If you can't fall asleep</td> </tr> <tr> <td>If you haven't fallen asleep in 15 minutes, go to another room. Listen to quiet music or read a self-help book. Avoid watching TV or reading an exciting book. Go back to bed when you feel sleepy. If you still can't fall asleep, get up again and repeat as needed.</td> </tr> <tr> <td class=\"subtitle1_single\">If you wake up during the night</td> </tr> <tr> <td>If you can't get back to sleep, follow the steps above (under \"If you can't fall asleep\").</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 67141 Version 3.0</div></div></div>"},"67142":{"type":"graphic_picture","displayName":"Lymph node LCH","title":"Lymph node biopsy in Langerhans cell histiocytosis","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Lymph node biopsy in Langerhans cell histiocytosis</div><div class=\"cntnt\"><img style=\"width:584px; height:238px;\" src=\"images/HEME/67142_LymphnodeLCH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Langerhans cell histiocytosis extensively involving lymph node in a patient with widespread disease and symptoms. The Langerhans cells have inconspicuous nucleoli, thin nuclear membranes, and prominent folding of their nuclear contours, imparting a &quot;twisted towel&quot; appearance.<br> (A) Low-power view showing subtotal replacement of lymph node.<br> (B) High-power magnification showing cytologic features of Langerhans cells and a mitotic figure. Hematoxylin-eosin stains.</div><div class=\"graphic_reference\">Reproduced with permission from: Ioachim HL, Medeiros LJ. Dendritic cell neoplasms. In: Ioachim's Lymph Node Pathology, 4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright © 2009 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 67142 Version 8.0</div></div></div>"},"67143":{"type":"graphic_table","displayName":"Estimated prevalence rates of intermittent explosive disorder","title":"Estimated prevalence rates of intermittent explosive disorder from nationally representative surveys","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Estimated prevalence rates of intermittent explosive disorder from nationally representative surveys</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Lifetime percent</td> <td class=\"subtitle1\">12-month percent</td> </tr> <tr> <td><strong>China</strong></td> <td class=\"centered\">2</td> <td class=\"centered\">2</td> </tr> <tr> <td><strong>Iraq</strong></td> <td class=\"centered\">2</td> <td class=\"centered\">1</td> </tr> <tr> <td><strong>Japan</strong></td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> </tr> <tr> <td><strong>South Africa</strong></td> <td class=\"centered\">Not reported</td> <td class=\"centered\">2</td> </tr> <tr> <td><strong>Ukraine</strong></td> <td class=\"centered\">4</td> <td class=\"centered\">3</td> </tr> <tr> <td><strong>United States</strong></td> <td class=\"centered\">4</td> <td class=\"centered\">2</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Shen YC, Zhang MY, Huang Yq, et al. Twelve month prevalence, severity, and unmet need for treatment of mental disorders in metropolitan China. </LI>&#xD;&#xA;<LI>Lee S, Tsang A, Zhang MY, et al. Lifetime prevalence and inter-cohort variation in DSM-IV disorders in metropolitan China. Psychol Med 2007; 37:61. </LI>&#xD;&#xA;<LI>Yoshimasu K, Kawakami N, WMH-J 2002-2006 Survey Group. Epidemiological aspects of intermittent explosive disorder in Japan; prevalence and psychosocial comorbidity: findings from the World Mental Health Japan Survey 2002-2006. Psychiatry Res 2011; 186:384. </LI>&#xD;&#xA;<LI>Bromet EJ, Gluzman SF, Paniotto VI, et al. Epidemiology of psychiatric and alcohol disorders in Ukraine: findings from the Ukraine World Mental Health survey. Soc Psychiatry Psychiatr Epidemiol 2005; 40:681. </LI>&#xD;&#xA;<LI>Fincham D, Grimsrud A, Corrigall J, et al. Intermittent explosive disorder in South Africa: prevalence, correlates and the role of traumatic exposures. Psychopathology 2009; 42:92. </LI>&#xD;&#xA;<LI>Al-Hamzawi A, Al-Diwan JK, Al-Hasnawi SM, et al. The prevalence and correlates of intermittent explosive disorder in Iraq. Acta Psychiatr Scand 2012; 126:219.</LI>&#xD;&#xA;<LI>Coccaro EF, Fanning JR, Lee R. Intermittent Explosive Disorder and Substance Use Disorder: Analysis of the National Comorbidity Survey Replication Sample. J Clin Psychiatry 2017.</LI></OL></div><div id=\"graphicVersion\">Graphic 67143 Version 5.0</div></div></div>"},"67144":{"type":"graphic_picture","displayName":"Subcorneal pustular dermatosis histopathology","title":"Subcorneal pustular dermatosis (Sneddon-Wilkinson disease)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Subcorneal pustular dermatosis (Sneddon-Wilkinson disease)</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/67144_Subcorn_pust_derm_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subcorneal blister formation in subcorneal pustular dermatosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 67144 Version 5.0</div></div></div>"},"67147":{"type":"graphic_algorithm","displayName":"Algorithm for cough evaluation","title":"Evaluation of subacute or chronic cough in adults","html":"<div class=\"graphic\"><div style=\"width: 585px\" class=\"figure\"><div class=\"ttl\">Evaluation of subacute or chronic cough in adults</div><div class=\"cntnt\"><img style=\"width:565px; height:816px;\" src=\"images/PULM/67147_Algorithm_for_cough_evaluat.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">GERD: gastroesophageal reflux disease; ACE: angiotensin-converting enzyme.<br />* Also consider post-infectious etiology for subacute cough (3 to 8 weeks duration).</div><div id=\"graphicVersion\">Graphic 67147 Version 5.0</div></div></div>"},"67150":{"type":"graphic_figure","displayName":"Pulmonary function histogram","title":"Pulmonary function histogram","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Pulmonary function histogram</div><div class=\"cntnt\"><img style=\"width:488px; height:271px;\" src=\"images/PULM/67150_Pulmonary_function_histogra.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histogram showing representative values of pulmonary function for patients with ankylosing spondylitis (AS), kyphoscoliosis (KS), pectus excavatum (Pectus), and thoracoplasty (TP).</div><div class=\"graphic_reference\">Adapted from McCool, FD, Rochester, DF. The lungs and chest Wall diseases. In: Textbook of Respiratory Medicine, 2nd ed, Vol 2, Murray, JF, Nadel, JA (Eds), WB Saunders, Philadelphia 1994.</div><div id=\"graphicVersion\">Graphic 67150 Version 1.0</div></div></div>"},"67152":{"type":"graphic_table","displayName":"E coli diarrhea syndromes","title":"Clinical syndromes associated with diarrheagenic Escherichia coli","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical syndromes associated with diarrheagenic Escherichia coli</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">Strain</td>\n\n      <td class=\"subtitle1\">Syndrome</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Enterotoxigenic E. coli (ETEC)</td>\n\n      <td>Watery diarrhea</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Enteropathogenic E. coli (EPEC)</td>\n\n      <td>Infantile diarrhea</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Enterohemorrhagic E. coli (EHEC)</td>\n\n      <td>Hemorrhagic colitis and hemolytic uremic syndrome</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Enteroinvasive E. coli (EIEC)</td>\n\n      <td>Dysentery</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Enteroaggregative E. coli (EAEC)</td>\n\n      <td>Persistent diarrhea in children and patients infected\nwith HIV</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 67152 Version 1.0</div></div></div>"},"67153":{"type":"graphic_waveform","displayName":"Basic case 1","title":"Basic case 1","html":"<div class=\"graphic normal\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Basic case 1</div><div class=\"cntnt\"><img style=\"width:540px; height:328px;\" src=\"images/CARD/67153_Basic_case_1.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 67153 Version 2.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"67155":{"type":"graphic_table","displayName":"Rx cytotoxic drug extravasation","title":"Recommended treatment regimens for cytotoxic drug extravasations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended treatment regimens for cytotoxic drug extravasations</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"15%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Treatment</td> <td class=\"subtitle1\">Route</td> <td class=\"subtitle1\">Frequency</td> <td class=\"subtitle1\">Duration</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"> <p>Vinca alkaloids (vinblastine, vincristine, vinorelbine)</p> <p>&nbsp;</p> <p>&nbsp;</p> </td> <td>Heat</td> <td>Topical</td> <td>15 to 20 minutes at least four times daily</td> <td class=\"divider_bottom\" rowspan=\"2\">24 to 48 hours</td> </tr> <tr class=\"divider_bottom\"> <td>Hyaluronidase</td> <td>Subcutaneously</td> <td>One time dose: 1 mL (150 units) as five separate injections of 0.2 mL each, each injected subcutaneously into the extravasated site using a separate 25 gauge or smaller needle</td> </tr> <tr> <td class=\"divider_bottom\">Etoposide</td> <td>Heat&nbsp;</td> <td>Topical&nbsp;</td> <td>&nbsp;15 to 20 minutes at least four times daily</td> <td class=\"divider_bottom\">&nbsp;24 to 48 hours</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Anthracyclines (daunorubicin, doxorubicin, epirubicin, idarubicin)</td> <td>Cold</td> <td>Topical</td> <td>30 to 60 minutes, then every 15 minutes; discontinue at least 15 minutes prior to dexrazoxane therapy</td> <td>Day 1 only</td> </tr> <tr> <td>Dexrazoxane</td> <td>Over 1 to 2 hours IV in a large vein away from the extravasation area<sup>[1,2]</sup></td> <td>1000 mg/m<sup>2</sup> within six hours, 1000 mg/m<sup>2</sup> after 24 hours, and 500 mg/m<sup>2</sup> after 48 hours</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>DMSO</td> <td>Topical</td> <td>For peripheral line extravasations if dexrazoxane unavailable or cannot be started within 6 hours: apply few drops of 50% DMSO to the site using a sterile gauze pad every 8 hours. Allow to air dry; do not cover site.</td> <td>7 days</td> </tr> <tr class=\"divider_bottom\"> <td>Liposomal anthracyclines (daunorubicin, doxorubicin)</td> <td>Cold</td> <td>Topical</td> <td>15 to 20 minutes at least four times daily</td> <td>24 hours</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Mitomycin</td> <td>Cold</td> <td>Topical</td> <td>15 to 20 minutes at least four times daily</td> <td>24 hours</td> </tr> <tr class=\"divider_bottom\"> <td>DMSO</td> <td>Topical</td> <td>Apply few drops of 50% DMSO to the site using a sterile gauze pad every 8 hours. Allow to air dry; do not cover site.</td> <td>7 days</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Taxanes (docetaxel, paclitaxel)</td> <td>Heat</td> <td>Topical</td> <td>15 to 20 minutes at least four times daily</td> <td>24 hours</td> </tr> <tr class=\"divider_bottom\"> <td>Hyaluronidase*</td> <td>Subcutaneously</td> <td>One time dose: 1 mL (150 units) as five separate injections of 0.2 mL each, each injected subcutaneously into the extravasated site using a separate 25 gauge or smaller needle</td> <td>&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"> <p>Mechlorethamine</p> <p>Bendamustine</p> <p>Carboplatin</p> <p>Cisplatin</p> Dacarbazine</td> <td>Cold</td> <td>Topical</td> <td>For 6 to 12 hours following sodium thiosulfate antidote injection<sup>&#182;</sup></td> <td>6 to 12 hours</td> </tr> <tr class=\"divider_bottom\"> <td>Sodium thiosulfate<sup>&#916;</sup></td> <td>Subcutaneously</td> <td>One time dose: inject 2 mL of the 1/6 Molar solution for each mg of mechlorethamine suspected to have extravasated<sup>&#182;</sup>. Inject solution subcutaneously into the extravasation site using a 25 gauge or smaller needle.</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Oxaliplatin</td> <td>Corticosteroids</td> <td>Oral</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td>Heat</td> <td>Topical&nbsp;</td> <td>&nbsp;15 to 20 minutes at least four times per day</td> <td>One to two days. Exposure to cold may precipitate or worsen the acute neuropathy associated with oxaliplatin</td> </tr> <tr> <td>Other agents</td> <td>Cold</td> <td>Topical</td> <td>15 to 20 minutes at least four times daily</td> <td>24 hours</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DMSO: Dimethylsulfoxide; EONS: European Oncology Nurses Society; ONS: US Oncology Nursing Society.<br />* Use of hyaluronidase for taxane extravasation recommended in guidelines from the EONS but not ONS.<br />¶&nbsp;Sodium thiosulfate recommendation from ONS and EONS covers mechlorethamine extravasation only.<br />Δ Freshly prepared 1/6 Molar solution (approximately 4 percent; 4 mL 10 percent sodium thiosulfate + 6 mL sterile water); recommended in guidelines from the ONS and EONS.</div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Perez Fidalgo JA, et al. Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. Ann Oncol 2012; 23 (7 suppl): vii:167.</li>&#xD;&#xA;    <li>Polovich M, Whitford JM, Olsen M. Chemotherapy and biotherapy guidelines and recommendations for practice, 3rd ed, Oncology Nursing Society, Pittsburgh, PA, 2009. Section V: Immediate Complications of cytotoxic therapy, p.105.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 67155 Version 16.0</div></div></div>"},"67156":{"type":"graphic_table","displayName":"High-potassium food PI","title":"Foods with high levels of potassium","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Foods with high levels of potassium</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"85%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td><strong>Grains</strong></td> <td>Whole-grain breads, wheat bran, granola and granola bars</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Beverages</strong></td> <td>Sports drinks (Gatorade, etc), instant breakfast mix, soy milk, coffee/tea (limit to 16 fluid ounces)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Snack foods/sweets</strong></td> <td>Fig cookies, chocolate (1.5 to 2 ounces), molasses (1 tablespoon)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Fruits</strong></td> <td>Apricots, avocado (&#188; whole), bananas (&#189; whole), coconut, melon (cantaloupe and honeydew), kiwi, mango, nectarines, oranges, orange juice, papaya, pears (fresh), plantains, pomegranate (and juice), dried fruits (apricots [5 halves], dates [5], figs, prunes, raisins), prune juice, yams</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Vegetables</strong></td> <td>Bamboo shoots, baked or refried beans, beets, broccoli (cooked), Brussels sprouts, cabbage (raw), carrots (raw), chard, greens (except kale), kohlrabi, olives, mushrooms (canned), potatoes (white and sweet), parsnips, pickles, pumpkin, rutabaga, sauerkraut, spinach (cooked), squash (acorn, butternut, hubbard), tomato, tomato sauce, tomato juice, and vegetable juice cocktail</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Dairy products</strong></td> <td>Milk and milk products, buttermilk, yogurt</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Proteins</strong></td> <td>(3-ounce serving) Clams, sardines, scallops, lobster, whitefish, salmon (and most other fish), ground beef, sirloin steak (and most other beef products), pinto beans, kidney beans, black beans, navy beans (and most other peas and beans, serving size is &#189; cup)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Soups</strong></td> <td>Read label for potassium as many low-sodium soups and bouillon cubes or&nbsp;broth may have added potassium</td> </tr> <tr> <td><strong>Condiments</strong></td> <td>Imitation bacon bits, salt substitutes, or lite salt made with potassium</td> </tr> <tr> <td><strong>Nuts, seeds, and legumes</strong></td> <td>Tofu, lentils, adzuki beans, most legumes, peanut butter, most nuts, and most seeds (including sunflower seeds)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Unless noted, one serving is ½ cup (4 ounces). These foods have more than 200 mg of potassium per serving, and should be avoided or eaten in very small portions if you are limiting potassium.</div><div id=\"graphicVersion\">Graphic 67156 Version 5.0</div></div></div>"},"67158":{"type":"graphic_diagnosticimage","displayName":"Calcific tendonitis AP view","title":"Calcific tendonitis","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Calcific tendonitis</div><div class=\"cntnt\"><img style=\"width:500px; height:330px;\" src=\"images/RHEUM/67158_Calcific_tendonitis_AP_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anteroposterior view of the right shoulder demonstrates prominent dystrophic calcification within the tendon of the rotator cuff, superior to the humeral head.</div><div class=\"graphic_reference\">Courtesy of Cecilia M Jude, MD.</div><div id=\"graphicVersion\">Graphic 67158 Version 2.0</div></div></div>"},"67161":{"type":"graphic_picture","displayName":"Captive bead ring","title":"Captive bead ring","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Captive bead ring</div><div class=\"cntnt\"><img style=\"width:372px; height:275px;\" src=\"images/PEDS/67161_Captive_bead_ring.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of R Michelle Schmidt, MD and Myrna L Armstrong, EdD, RN, FAAN.</div><div id=\"graphicVersion\">Graphic 67161 Version 1.0</div></div></div>"},"67162":{"type":"graphic_table","displayName":"DMD post anesthesia","title":"Summary of the American College of Chest Physicians (ACCP) consensus statement suggestions for the management of patients with Duchenne muscular dystrophy (DMD) after general anesthesia or procedural sedation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of the American College of Chest Physicians (ACCP) consensus statement suggestions for the management of patients with Duchenne muscular dystrophy (DMD) after general anesthesia or procedural sedation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">Consider extubating patients with DMD who have a forced vital capacity (FVC) &#60;50% of predicted, and especially those with FVC &#60;30% of predicted, directly to noninvasive positive pressure ventilation (NPPV)</td> </tr> <tr> <td class=\"sublist1\">&#8226; Consider delaying extubation until respiratory secretions are well-controlled and oxyhemoglobin saturation measured by pulse oximetry (SpO<sub>2</sub>) is normal or baseline in room air; continuous use of NPPV can then be weaned as tolerated</td> </tr> <tr> <td class=\"sublist1\">&#8226; When applicable, try to utilize the patient's home interface after extubation</td> </tr> <tr> <td class=\"sublist1_start\">Use supplemental oxygen therapy cautiously</td> </tr> <tr> <td class=\"sublist1\">&#8226; Monitor SpO<sub>2</sub> continuously after general anesthesia or procedural sedation</td> </tr> <tr> <td class=\"sublist1\">&#8226; Whenever possible, monitor blood or end-tidal carbon dioxide levels</td> </tr> <tr> <td class=\"sublist1\">&#8226; Assess if hypoxemia is due to hypoventilation, atelectasis, or airway secretions, and treat appropriately</td> </tr> <tr> <td class=\"sublist1_start\">Use manually assisted cough and postoperatively in patients with DMD who have impaired cough, defined in adults as peak cough flow (PCF) &#60;270 L/min or maximum expiratory pressure (MEP) &#60;60 cmH<sub>2</sub>O</td> </tr> <tr> <td class=\"sublist1_start\">Optimize postoperative pain control in patients with DMD</td> </tr> <tr> <td class=\"sublist1\">&#8226; If sedation and/or hypoventilation occurs, delay endotracheal extubation for 24 to 48 hours or use NPPV</td> </tr> <tr> <td class=\"sublist1_start\">Obtain a cardiology consultation and closely monitor cardiac and fluid status postoperatively</td> </tr> <tr> <td class=\"sublist1_start\">Initiate bowel regimens to avoid and treat constipation and consider prokinetic gastrointestinal (GI) medications</td> </tr> <tr> <td class=\"sublist1\">&#8226; Consider gastric decompression with a nasogastric tube in patients with GI dysmotility</td> </tr> <tr> <td class=\"sublist1\">&#8226; Start parenteral nutrition or enteral feeding via a small-diameter tube if oral feeding is delayed for &#62;24 to 48 hours postoperatively</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Birnkrant, DJ, Panitch, HB, Benditt, JO, et al. American College of Chest Physicians consensus statement on the respiratory and related management of patients with Duchenne muscular dystrophy undergoing anesthesia or sedation. Chest 2007; 132:1977.</div><div id=\"graphicVersion\">Graphic 67162 Version 2.0</div></div></div>"},"67163":{"type":"graphic_figure","displayName":"Ear tube PI","title":"Surgery to treat fluid in the ear (tympanostomy tube)","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Surgery to treat fluid in the ear (tympanostomy tube)</div><div class=\"cntnt\"><img style=\"width:517px; height:331px;\" src=\"images/PI/67163_Tympanostomy_tube_PI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This surgery might be done when fluid in the middle ear does not go away. This treatment can also be used to prevent more ear infections in children who get them a lot. The figure on the left shows an eardrum before the tube is inserted. The figure on the right shows fluid draining from the middle ear in a child who got an ear infection after the tube was inserted.</div><div id=\"graphicVersion\">Graphic 67163 Version 12.0</div></div></div>"},"67164":{"type":"graphic_table","displayName":"Clinical questions","title":"Clinical questions in daily practice","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical questions in daily practice</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Is the finding abnormal?</td>\n</tr>\n<tr>\n<td>What is the diagnosis?</td>\n</tr>\n<tr>\n<td>How often does it occur?</td>\n</tr>\n<tr>\n<td>What are the risk factors for the disease?</td>\n</tr>\n<tr>\n<td>What is the pathogenesis?</td>\n</tr>\n<tr>\n<td>What is the natural history?</td>\n</tr>\n<tr>\n<td>How effective (and harmful) is treatment?</td>\n</tr>\n<tr>\n<td>How effective (and harmful) are preventive interventions?</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 67164 Version 1.0</div></div></div>"},"67165":{"type":"graphic_picture","displayName":"Hypertrophic scars acne","title":"Hypertrophic scars","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hypertrophic scars</div><div class=\"cntnt\"><img style=\"width:284px; height:396px;\" src=\"images/PC/67165_Hypertrophic_scars_acne.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These lesions are characteristic of acne scars that occur on the trunk.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP, MD. Goodheart's Photoguide of Common Skin Disorders, 2nd ed. Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright ©2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 67165 Version 3.0</div></div></div>"},"67166":{"type":"graphic_picture","displayName":"Pleural lymphatic lacunae","title":"Pleural lymphatic lacunae","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pleural lymphatic lacunae</div><div class=\"cntnt\"><img style=\"width:360px; height:235px;\" src=\"images/PULM/67166_Pleural_lymphatic_lacunae.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Drainage of pleural lymphatics. Each pleural lymphatic vessel joins others, forming a lake or lacuna (L). From the lacunae, collecting lymphatics join intercostal trunk lymphatics which travel to the parasternal and periaortic lymph nodes.</div><div class=\"graphic_reference\">Courtesy of Kurt H Albertine, MD.</div><div id=\"graphicVersion\">Graphic 67166 Version 2.0</div></div></div>"},"67168":{"type":"graphic_table","displayName":"Clinical features of selective IgM deficiency","title":"Clinical features of selective IgM deficiency","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of selective IgM deficiency</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Primary presentation</td> </tr> <tr> <td>Sepsis and bacteremia (gram-negative bacteria, encapsulated pathogens)</td> </tr> <tr> <td>Diarrhea</td> </tr> <tr> <td>Dermatitis</td> </tr> <tr> <td>Frequent upper respiratory infections</td> </tr> <tr> <td>Meningitis</td> </tr> <tr> <td class=\"subtitle1_single\">Other reported presentations</td> </tr> <tr> <td>Elevated IgE</td> </tr> <tr> <td>Allergic disease</td> </tr> <tr> <td>Chronic idiopathic/immune thrombocytopenic purpura</td> </tr> <tr> <td>Large warts (epidermodysplasia verruciformis)</td> </tr> <tr> <td>Splenomegaly</td> </tr> <tr> <td>Growth retardation in children</td> </tr> <tr> <td class=\"subtitle1_single\">Possible presentations</td> </tr> <tr> <td>Autoimmunity (increased response to self-antigens?)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IgM: immunoglobulin M; IgE: immunoglobulin E.</div><div id=\"graphicVersion\">Graphic 67168 Version 5.0</div></div></div>"},"67171":{"type":"graphic_diagnosticimage","displayName":"Retrograde pyelogram showing retroperitoneal fibrosis","title":"Retrograde pyelogram showing retroperitoneal fibrosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Retrograde pyelogram showing retroperitoneal fibrosis</div><div class=\"cntnt\"><img style=\"width:315px; height:375px;\" src=\"images/NEPH/67171_RP_fibrosis_retrograde.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Retrograde pyelogram of the right kidney from a patient with biopsy-proven retroperitoneal fibrosis. There is marked hydronephrosis with blunted calyces and dilatation of the upper ureter. At the level of the L3 and L4 vertebral bodies, there is medial deviation of the ureter (arrow) and the lower ureter a normal caliber.</div><div class=\"graphic_reference\">Courtesy of Jonathan R Diamond, MD.</div><div id=\"graphicVersion\">Graphic 67171 Version 4.0</div></div></div>"},"67172":{"type":"graphic_table","displayName":"Marshall scale for TBI","title":"Marshall CT (computed tomography) classification of traumatic brain injury","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Marshall CT (computed tomography) classification of traumatic brain injury</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n  <tr>\n    <td class=\"subtitle1\">Category</td>\n    <td class=\"subtitle1\">Definition</td>\n  </tr>\n  <tr>\n    <td>Diffuse injury I (no visible pathology)</td>\n    <td>No visible intracranial pathology seen on CT scan</td>\n  </tr>\n  <tr>\n    <td>Diffuse injury II</td>\n    <td>Cisterns are present with midline shift of 0-5 mm and/or lesions densities present; no high or mixed density lesion &#62;25 cm<sup>3</sup>  may include bone fragments and foreign bodies</td>\n  </tr>\n  <tr>\n    <td>Diffuse injury III (swelling)</td>\n    <td>Cisterns compressed or absent with midline shift 0-5 mm; no high or mixed density lesion &#62;25 cm<sup>3</sup></td>\n  </tr>\n  <tr>\n    <td>Diffuse injury IV (shift)</td>\n    <td>Midline shift &#62;5 mm; no high or mixed density lesion &#62;25 cm<sup>3</sup></td>\n  </tr>\n  <tr>\n    <td>Evacuated mass lesion V</td>\n    <td>Any lesion surgically evacuated</td>\n  </tr>\n  <tr>\n    <td>Non-evacuated mass lesion VI</td>\n    <td>High or mixed density lesion &#62;25 cm<sup>3</sup>; not surgically evacuated</td>\n  </tr>\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">10.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Media_Notes msdt:dt=\"string\">1/6/2010--Permission granted via Rightslink; figure to Terrence (JD).</mso:Media_Notes>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=40919&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Marshall_scale_for_TBI.htm</title></head></div><div class=\"graphic_reference\">Reproduced with permission from: Adelson PD, Bratton SL, Carney NA, et al. Guidelines for the acute medical management of severe traumatic brain injury in infants, children, and adolescents. Chapter 1: Introduction. Pediatr Crit Care Med 2003; 4:S2. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 67172 Version 11.0</div></div></div>"},"67174":{"type":"graphic_table","displayName":"Hormones inhibited by somatostatin","title":"Hormones inhibited by somatostatin","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hormones inhibited by somatostatin</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Acetylcholine</td> </tr> <tr> <td>Arginine vasopressin</td> </tr> <tr> <td>Cholecystokinin</td> </tr> <tr> <td>Epidermal growth hormone</td> </tr> <tr> <td>Glucagon</td> </tr> <tr> <td>Glucose-dependent insulinotropic peptide</td> </tr> <tr> <td>Gastrin</td> </tr> <tr> <td>Growth hormone</td> </tr> <tr> <td>Insulin</td> </tr> <tr> <td>Motilin</td> </tr> <tr> <td>Neurotensin</td> </tr> <tr> <td>Pancreatic polypeptide</td> </tr> <tr> <td>Secretin</td> </tr> <tr> <td>Serotonin</td> </tr> <tr> <td>Substance P</td> </tr> <tr> <td>Thyrotropin</td> </tr> <tr> <td>Vasoactive intestinal polypeptide</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 67174 Version 3.0</div></div></div>"},"67176":{"type":"graphic_figure","displayName":"Soft tissue emphysema","title":"Soft tissue emphysema following alveolar disruption","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Soft tissue emphysema following alveolar disruption</div><div class=\"cntnt\"><img style=\"width:376px; height:331px;\" src=\"images/PULM/67176_Soft_tissue_emphysema.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Air from torn alveolus first enters perivascular interstitium (A), dissecting proximally within the bronchovascular sheath toward the mediastinum (B). As airway pressure rises, decompression occurs into cervical (C), subcutaneous (D), and pericardial (E) tissue spaces. Pleural rupture may result in pneumothorax (F). Small arrows indicate the direction of air movement.</div><div class=\"graphic_reference\">Redrawn from Maunder RJ, Pierson DJ, Hudson LD, Arch Intern Med 1984; 144:1449.</div><div id=\"graphicVersion\">Graphic 67176 Version 1.0</div></div></div>"},"67177":{"type":"graphic_diagnosticimage","displayName":"CT of a benign femoral bone tumor","title":"CT of a benign femoral bone tumor","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">CT of a benign femoral bone tumor</div><div class=\"cntnt\"><img style=\"width:504px; height:372px;\" src=\"images/RADIOL/67177_Benign_tumor_of_femoral_nec.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Benign femoral bone tumor. Coronal reconstruction image from a CT of the pelvis shows a well-defined soft tissue density lesion of the left femoral neck with sclerotic border consistent with a benign tumor.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Shahla Modarresi, MD.</div><div id=\"graphicVersion\">Graphic 67177 Version 4.0</div></div></div>"},"67179":{"type":"graphic_picture","displayName":"Black tongue Addison","title":"Black tongue in Addison disease","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Black tongue in Addison disease</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/67179_Black_tongue_addison.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 67179 Version 3.0</div></div></div>"},"67180":{"type":"graphic_picture","displayName":"Glioblastoma","title":"Glioblastoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Glioblastoma</div><div class=\"cntnt\"><img style=\"width:504px; height:375px;\" src=\"images/ONC/67180_Glioblastoma_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dense cellularity, anaplastic nuclei, mitotic figures and necrosis with palisading of nuclei (left) in an astrocytic glioma are diagnostic of glioblastoma.</div><div class=\"graphic_reference\">Courtesy of Dr. David Louis.</div><div id=\"graphicVersion\">Graphic 67180 Version 1.0</div></div></div>"},"67181":{"type":"graphic_waveform","displayName":"12 lead WPW","title":"ECG in Wolff-Parkinson-White","html":"<div class=\"graphic normal\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">ECG in Wolff-Parkinson-White</div><div class=\"cntnt\"><img style=\"width:538px; height:365px;\" src=\"images/CARD/67181_12leadWPW.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The 12-lead ECG shows the typical features of Wolff-Parkinson-White; the PR interval is short (*) and the QRS duration prolonged as a result of a delta wave (arrow), indicating ventricular preexcitation.</div><div class=\"graphic_reference\">Courtesy of Martin Burke, DO.</div><div id=\"graphicVersion\">Graphic 67181 Version 3.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"67183":{"type":"graphic_picture","displayName":"Gonococcal skin lesion PI","title":"Disseminated gonococcal infection","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Disseminated gonococcal infection</div><div class=\"cntnt\"><img style=\"width:540px; height:351px;\" src=\"images/PI/67183_Gonococcal_skin_lesion_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typical small pustular skin lesion in a patient with disseminated gonococcal infection.</div><div class=\"graphic_reference\">Courtesy of Don L Goldenberg, MD.</div><div id=\"graphicVersion\">Graphic 67183 Version 1.0</div></div></div>"},"67185":{"type":"graphic_table","displayName":"Indications for skin biopsy","title":"Indications for skin biopsy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for skin biopsy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Indication</td> <td class=\"subtitle1\">Clinical presentation</td> <td class=\"subtitle1\">Possible diagnosis</td> <td class=\"subtitle1\">Biopsy technique</td> </tr> <tr> <td rowspan=\"10\">Diagnosis</td> <td rowspan=\"9\">Rashes or blisters involving dermis</td> <td>Drug reaction</td> <td rowspan=\"9\">Punch</td> </tr> <tr> <td>Cutaneous lymphoma</td> </tr> <tr> <td>Deep tissue infection</td> </tr> <tr> <td>Erythema multiforme </td> </tr> <tr> <td>Kaposi's sarcoma</td> </tr> <tr> <td>Lupus erythematosus</td> </tr> <tr> <td>Pemphigoid </td> </tr> <tr> <td>Psoriasis</td> </tr> <tr> <td>Vasculitis</td> </tr> <tr> <td>Processes involving the subcutis</td> <td>Panniculitis (eg, erythema nodosum)</td> <td>Excision</td> </tr> <tr> <td rowspan=\"9\">Diagnosis and treatment</td> <td rowspan=\"2\">Atypical moles and pigmented lesions</td> <td>Dysplastic nevi&nbsp;</td> <td rowspan=\"2\">Excision or punch (for small lesions)</td> </tr> <tr> <td>Malignant melanoma</td> </tr> <tr> <td rowspan=\"7\">Superficial lesions</td> <td>Actinic keratoses</td> <td rowspan=\"7\">Shave (into dermis for suspected malignancy) or excision</td> </tr> <tr> <td>Basal cell carcinoma</td> </tr> <tr> <td>Seborrheic keratosis</td> </tr> <tr> <td>Pyogenic granuloma</td> </tr> <tr> <td>Skin tags</td> </tr> <tr> <td>Squamous cell carcinoma</td> </tr> <tr> <td>Warts</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Alguire PC, Mathes BM. Skin biopsy techniques for the internist. J Gen Intern Med&nbsp;1998; 13:46. Copyright © 1998 Society of General Internal Medicine.</div><div id=\"graphicVersion\">Graphic 67185 Version 2.0</div></div></div>"},"67188":{"type":"graphic_diagnosticimage","displayName":"Angioplasty in RA stenosis","title":"Percutaneous transluminal renal angioplasty for renal artery stenosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Percutaneous transluminal renal angioplasty for renal artery stenosis</div><div class=\"cntnt\"><img style=\"width:378px; height:271px;\" src=\"images/NEPH/67188_Angioplasty_in_RA_stenosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Renal arteriogram after percutaneous transluminal renal angioplasty (PTRA) has largely corrected the stenotic lesion in the right renal artery (arrow).</div><div class=\"graphic_reference\">From: Rose BD. Pathophysiology of Renal Disease, 2d ed, McGraw-Hill, New York 1987.</div><div id=\"graphicVersion\">Graphic 67188 Version 4.0</div></div></div>"},"67192":{"type":"graphic_picture","displayName":"Eosinophilic folliculitis histology","title":"Eosinophilic folliculitis histology","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eosinophilic folliculitis histology</div><div class=\"cntnt\"><img style=\"width:360px; height:271px;\" src=\"images/PC/67192_Eosin_folliculitis_histol_h.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This high-power photomicrograph demonstrates the preponderance of eosinophils within the follicular inflammatory infiltrate in the infundibulum and sebaceous gland. Eventually, the number of eosinophils becomes so numerous that an infundibular eosinophilic pustule may develop.</div><div class=\"graphic_reference\">Courtesy of Whitney High, MD.</div><div id=\"graphicVersion\">Graphic 67192 Version 2.0</div></div></div>"},"67193":{"type":"graphic_table","displayName":"Side effects of antitrypanosomal drugs","title":"Estimated percentage of patients (all age groups) that experience adverse effects of benznidazole and nifurtimox","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Estimated percentage of patients (all age groups) that experience adverse effects of benznidazole and nifurtimox</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"35%\"></colgroup><colgroup width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Side effects</td> <td class=\"subtitle1\">Approximate percentage (range) of patients with adverse effect*</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"12\">Nifurtimox</td> <td>Anorexia and weight loss</td> <td>50 (17 to 70)</td> </tr> <tr> <td>Polyneuropathy<sup>&#182;</sup></td> <td>25 (15 to 36)</td> </tr> <tr> <td>Nausea/vomiting</td> <td>15 (5 to 33)</td> </tr> <tr> <td>Abdominal discomfort</td> <td>15 (9 to 25)</td> </tr> <tr> <td>Headache</td> <td>15 (13 to 19)</td> </tr> <tr> <td>Dizziness/vertigo</td> <td>15 (9 to 25)</td> </tr> <tr> <td>Insomnia</td> <td>12 (10 to 19)</td> </tr> <tr> <td>Nervous excitation, mood changes</td> <td>15 (9 to 27)</td> </tr> <tr> <td>Myalgia</td> <td>12 (11 to 14)</td> </tr> <tr> <td>Disorientation</td> <td>7 (6 to 10)</td> </tr> <tr> <td>Paresthesia</td> <td>3 (2 to 3)</td> </tr> <tr class=\"divider_bottom\"> <td>Leukopenia</td> <td>&#60;3</td> </tr> <tr> <td rowspan=\"8\">Benznidazole</td> <td>Allergic dermatitis<sup>&#916;</sup></td> <td>30 (14 to 50)</td> </tr> <tr> <td>Peripheral neuropathy<sup>&#182;</sup></td> <td>30 (0 to 43)</td> </tr> <tr> <td>Anorexia and weight loss</td> <td>15 (6 to 24)</td> </tr> <tr> <td>Insomnia</td> <td>5 (0 to 6)</td> </tr> <tr> <td>Nausea and/or vomiting</td> <td>4 (2 to 6)</td> </tr> <tr> <td>Leukopenia<sup>&#9674;</sup></td> <td>Rare</td> </tr> <tr> <td>Thrombocytopenia<sup>&#9674;</sup></td> <td>Rare</td> </tr> <tr> <td>Dysgeusia<sup>&#167;</sup></td> <td>Rare</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Based on reported frequences from retrospective case series and clinical trials in which standard drug doses were given.<br />&para; Dose dependent, usually occurs late in course. Reversible but may take months.<br />&Delta; Not dose dependent. Discontinue drug if severe. Stevens Johnson syndrome reported.<br /><span class=\"lozenge\">&loz;</span> Requires discontinuation.<br />&sect; Reversible but may take weeks.<br /></div><div id=\"graphicVersion\">Graphic 67193 Version 5.0</div></div></div>"},"67194":{"type":"graphic_diagnosticimage","displayName":"Bone scan stress fracture distal fibula","title":"Bone scan showing a stress fracture of the distal fibula","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bone scan showing a stress fracture of the distal fibula</div><div class=\"cntnt\"><img style=\"width:418px; height:609px;\" src=\"images/EM/67194_Stress_fracture_distal_fibu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A bone scan shows increased activity in the distal right fibula (arrow).</div><div class=\"graphic_reference\">Courtesy of Scott M Koehler, MD.</div><div id=\"graphicVersion\">Graphic 67194 Version 5.0</div></div></div>"},"67197":{"type":"graphic_figure","displayName":"Cervical dysgenesis","title":"Congenital cervical dysgenesis","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Congenital cervical dysgenesis</div><div class=\"cntnt\"><img style=\"width:526px; height:547px;\" src=\"images/OBGYN/67197_Cervical_dysgenesis_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The cervical body is intact (A) with obstruction of the cervical os. The cervical body (B) consists of a fibrous band of variable diameter that may contain endocervical glands. Fragmented portions of the cervix are noted (C) with no connection to the uterine body. Hypoplasia of the uterine cavity may be associated with cervical cords or fragmentation. The midportion of the cervix (D) is hypoplastic with a bulbous tip. No cervical lumen is identified.</div><div class=\"graphic_reference\">Redrawn with permission from: Rock, JA, Carpenter, SE, Wheeless, CR, Jones, Jr., HW. The clinical management of maldevelopment of the uterine cervix. Journal of Pelvic Surgery 1995; 1:129.</div><div id=\"graphicVersion\">Graphic 67197 Version 5.0</div></div></div>"},"67199":{"type":"graphic_picture","displayName":"Megakaryocytes and platelets","title":"Platelets originate from bone marrow megakaryocytes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Platelets originate from bone marrow megakaryocytes</div><div class=\"cntnt\"><img style=\"width:237px; height:481px;\" src=\"images/HEME/67199_Megakaryocytes_and_platelet.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Top panel: A large bone marrow megakaryocyte (thick arrow) adjacent to a bone marrow sinusoid has staining characteristics identical to those of the platelets (thin arrow) in the lumen of the sinusoid. <br />Middle panel: A megakaryocyte is extending a portion of its cytoplasm into the lumen of the sinusoid with the suggestion of platelets (arrow) budding off. <br />Bottom panel: An entire megakaryocyte (thick arrow) has entered the sinusoid with a portion of its cytoplasm streaming ahead and forming a long proplatelet extension from the end of which platelets (thin arrow) appear to be shedding.</div><div class=\"graphic_reference\">Water color drawings by James Homer Wright using the camera lucida. From: Wright JH. The histogenesis of the blood platelets.&nbsp;J Morphol 1910; 21:263.</div><div id=\"graphicVersion\">Graphic 67199 Version 2.0</div></div></div>"},"67200":{"type":"graphic_diagnosticimage","displayName":"Rock of Gibraltar sign","title":"Subpulmonic effusions with Rock of Gibraltar sign","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Subpulmonic effusions with Rock of Gibraltar sign</div><div class=\"cntnt\"><img style=\"width:514px; height:416px;\" src=\"images/PULM/67200_RockGibraltarsignPR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bilateral subpulmonic pleural effusions, larger on the right side: Chest frontal (panel A) and lateral (panel B) views and image of the Rock of Gibraltar (panel C). The elevation of the lung bases with an abrupt drop-off laterally on the frontal view and posteriorly on the lateral view has been dubbed the &quot;Rock of Gibraltar sign.&quot; This finding is best seen on the right side on the frontal view and bilaterally on the lateral view.</div><div id=\"graphicVersion\">Graphic 67200 Version 5.0</div></div></div>"},"67202":{"type":"graphic_table","displayName":"Junctional epidermolysis bullosa variants","title":"Genotypic and phenotypic variants of junctional epidermolysis bullosa (lucidolytic)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Genotypic and phenotypic variants of junctional epidermolysis bullosa (lucidolytic)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Subtype</td> <td class=\"subtitle1\"> <p>Inheritance</p> <p>Mutated gene</p> <p>Targeted gene product</p> </td> <td class=\"subtitle1\">Clinical features</td> </tr> <tr> <td>JEB, generalized severe (formerly&nbsp;Herlitz)</td> <td> <p>Autosomal recessive</p> <p><em>LAMA3</em>, <em>LAMB3</em>, <em>LAMC2</em></p> <p>Laminin-alpha-3 chain of laminin-332</p> <p>Laminin-beta-3 chain of laminin-332<br /> Laminin-gamma-2 chain of laminin-332</p> </td> <td> <ul> <li>Varying degrees of mechanical fragility at birth with generalized, recurrent, often persistent blistering, erosions, and&nbsp;crusting covering not only particularly exposed skin areas (like palms and soles) but most or almost all of the body surface </li> <li>Periungual inflammation, onychodystrophy, and nail loss&nbsp;&nbsp; </li> <li>Exuberant granulation tissue, often periorificial&nbsp; </li> <li>Involvement of oral cavity (blisters, erosions); teeth (enamel hypoplasia, excessive caries); gastrointestinal (protein-losing enteropathy, diarrhea), respiratory, and&nbsp;genitourinary tract; conjunctivae </li> <li>Anemia, growth retardation, high lethality (survival past one year of age uncommon) </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td>JEB, generalized intermediate (formerly non-Herlitz)</td> <td> <p>Autosomal recessive</p> <p><em>COL17A1</em>, <em>LAMA3</em>, <em>LAMB3</em>, <em>LAMC2</em></p> <p>Type XVII collagen<br /> Laminin-alpha-3 chain of laminin-332<br /> Laminin-beta-3 chain of laminin-332<br /> Laminin-gamma-2 chain of laminin-332</p> </td> <td> <ul> <li>Generalized blistering from birth, atrophic scarring, milia; \"male-pattern\" alopecia; nail dystrophy and loss </li> <li>Involvement of oral cavity and teeth (excessive caries, teeth loss, enamel hypoplasia); gastrointestinal, respiratory, and genitourinary tract; conjunctivae </li> <li>Anemia, growth retardation, protein losing enteropathy,&nbsp;diarrhea </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td>JEB, localized</td> <td> <p>Autosomal recessive</p> <p><em>COL17A1, </em><em>ITGB4, </em><em>LAMA3, LAMB3, LAMC2</em></p> <p>Type XVII collagen</p> <p>Integrin-beta-4</p> <p>Laminin-alpha-3 chain of laminin-332</p> <p>Laminin-beta-3 chain of laminin-332</p> <p>Laminin-gamma-2 chain of laminin-332</p> </td> <td> <ul> <li>Localized disease of lesser extent and lesser severity, onset at birth; milia, nail dystrophy, and loss </li> <li>Involvement of oral cavity and teeth (excessive caries, enamel hypoplasia) </li> <li>Extensive atrophic scarring, hair loss, anemia, impairments of growth and development, ocular abnormalities or alterations affecting gastrointestinal, genitourinary, and&nbsp;respiratory tract mostly absent<sup>[1]</sup> </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td>JEB with pyloric atresia</td> <td> <p>Autosomal recessive</p> <p><em>ITGA6</em>, <em>ITGB4</em></p> <p>Integrin-alpha-6</p> <p>Integrin-beta-4</p> </td> <td> <ul> <li>Gestational hydramnion </li> <li>Generalized and profound blistering from birth, occasionally age-associated amelioration; atrophic scarring; nail dystrophy and loss </li> <li>Association with aplasia cutis congenita </li> <li>Enamel hypoplasia </li> <li>Pyloric atresia </li> <li>Congenital genitourinary malformations </li> <li>Sporadically rudimentary ear anlage </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td>JEB, inversa</td> <td> <p>Autosomal recessive</p> <p><em>LAMA3</em>, <em>LAMB3</em>, <em>LAMC2</em></p> <p>Laminin-alpha-3 chain of laminin-332<br /> Laminin-beta-3 chain of laminin-332<br /> Laminin-gamma-2 chain of laminin-332</p> </td> <td> <ul> <li>Blistering predominantly located in intertriginous areas/sites, typically displaying an overall extent that exceeds that observed in patients with JEB, localized<sup>[1]</sup> </li> <li>Atrophic scarring, milia, hypo-/hyperpigmentation, dystrophic (or absent) nails </li> <li>Moderate oral mucosal lesions; dental enamel hypoplasia, caries and gastrointestinal abnormalities to a lesser extent as compared&nbsp;with other JEB variants </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td>JEB, late onset</td> <td> <p>Autosomal recessive</p> <p><em>COL17A1</em></p> <p>Type XVII collagen</p> </td> <td> <ul> <li>Mild form of JEB developing in young adulthood or later </li> <li>Dystrophic (or absent) nails, dental enamel hypoplasia and caries to a lesser severity than JEB, generalized intermediate </li> <li>Hyperhidrosis </li> <li>Absence of dermatoglyphs on fingers, palms, toes, and soles </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td>JEB-LOC (laryngo-onycho-cutaneous) syndrome<sup>[2-11]</sup></td> <td> <p>Autosomal recessive</p> <p><em>LAMA3A</em></p> <p>Laminin-alpha-3a chain of laminin-332</p> </td> <td> <ul> <li>High incidence in Punjab but Caucasian cases reported&nbsp; </li> <li>Minimal skin blistering, erosions </li> <li>Extensive aberrant production of granulation tissue with delayed healing, atrophic scarring </li> <li>Involvement of larynx (altered cry) at birth or later, skin (face, nuchal) and conjunctiva (granulomatous papules, symblepharon) in infancy </li> <li>Nail dystrophy and loss </li> <li>Enamel hypoplasia, caries </li> <li>High childhood mortality due to laryngeal, gastrointestinal, and urethral strictures </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td><span style=\"font-size: 11pt; font-family: calibri,sans-serif; line-height: 115%;\">JEB with respiratory and renal involvement (JEB-RR)<sup>[10-12]</sup></span></td> <td> <p><span style=\"font-size: 11pt; font-family: calibri,sans-serif; line-height: 115%;\">Autosomal recessive</span></p> <p><span style=\"font-size: 11pt; font-family: calibri,sans-serif; line-height: 115%;\"><em>ITGA3</em></span></p> <p><span style=\"font-size: 11pt; font-family: calibri,sans-serif; line-height: 115%;\">Integrin-alpha-3</span></p> </td> <td> <ul> <li>Congenital nephrotic syndrome (small kidneys, atrophic glomeruli, focal segmental glomerulosclerosis, diffuse interstitial fibrosis, tubular atrophy and loss) </li> <li>Interstitial lung disease (tachypnea, respiratory distress, cyanosis in first days of life; secondary aspiration with respiratory tract infections) </li> <li>Mild skin fragility (small blisters and erosions beginning at age of&nbsp;two to&nbsp;four months </li> <li>Fine and sparse scalp hair, eyebrows, eyelashes </li> <li>Nail dystrophy, distal onycholysis </li> <li>Delayed reepithelialization; healing with residual erythema </li> <li>No scarring; no mucosal involvement&nbsp; </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">JEB: junctional epidermolysis bullosa.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Fine JD, Eady RA, Bauer EA, et al. The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol 2008; 58:931. </LI>&#xD;&#xA;<LI>Shabbir G, Hassan M, Kazmi A. Laryngo-onycho-cutaneous syndrome: A study of 22 cases. Biomedica 1986; 2:15. </LI>&#xD;&#xA;<LI>Ainsworth JR, Spencer AF, Dudgeon J, et al. Laryngeal and ocular granulation tissue formation in two Punjabi children: LOGIC syndrome. Eye (Lond) 1991; 5:717. </LI>&#xD;&#xA;<LI>Ainsworth JR, Shabbir G, Spencer AF, Cockburn F. Multisystem disorder of Punjabi children exhibiting spontaneous dermal and submucosal granulation tissue formation: LOGIC syndrome. Clin Dysmorphol 1992; 1:3. </LI>&#xD;&#xA;<LI>Phillips RJ, Atherton DJ, Gibbs ML, et al. Laryngo-onycho-cutaneous syndrome: An inherited epithelial defect. Arch Dis Child 1994; 70:319. </LI>&#xD;&#xA;<LI>Murrell DF, Hamil K, Pfendner E, et al. Is Laryngo-Onycho-Cutaneous Syndrome a form of junctional epidermolysis bullosa? Oral paper.&nbsp;Australasian College of Dermatologists' Spring Meeting, Cairns, Australia, September 2005.</LI>&#xD;&#xA;<LI>Figueira EC, Crotty A, Challinor CJ, et al. Granulation tissue in the eyelid margin and conjunctiva in junctional epidermolysis bullosa with features of laryngo-onycho-cutaneous syndrome. Clin Exp Ophthalmol 2007; 25:163.</LI>&#xD;&#xA;<LI>Hamil K, Uitto J, Figueira EC, et al. Novel N-terminal mutation in LAMA3a isoform causing late-onset Herlitz junctional epidermolysis bullosa with features of laryngo-onycho-cutaneous syndrome. Poster. Society for Investigative Dermatology, Los Angeles, CA, May 2007.</LI>&#xD;&#xA;<LI>Cohn HI, Murrell DF. Laryngo-onycho-cutaneous syndrome. Dermatol Clin 2010; 28:89.</LI>&#xD;&#xA;<LI>Nicolaou N, Margadant C, Lilen MR, et al. Gain of glycosylation in integrin α3 causes lung disease and nephrotic syndrome. J Clin Invest 2012; 122:4375.</LI>&#xD;&#xA;<LI>Yalcin EG, He Y, Orhan D, et al. Crucial role of posttranslational modifications of integrin α3 in interstitial lung disease and nephrotic syndrome. Hum Mol Genet 2015; 24:3679.</LI>&#xD;&#xA;<LI>Has C, Spartà G, Kiritsi D,&nbsp;et al.&nbsp;Integrin α3 mutations with kidney, lung, and skin disease. N Engl J Med 2012; 366:1508.</LI></OL></div><div id=\"graphicVersion\">Graphic 67202 Version 6.0</div></div></div>"},"67204":{"type":"graphic_table","displayName":"Femoral shaft fracture treatment in children and adolescents","title":"Treatment options for femoral shaft fractures in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment options for femoral shaft fractures in children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Age </td> <td class=\"subtitle1\">Treatment </td> </tr> <tr> <td rowspan=\"3\">Birth to 24 mo </td> <td>Pavlik harness (newborn to 6 mo)</td> </tr> <tr> <td>Immediate spica cast</td> </tr> <tr> <td>Traction &#8594; spica cast</td> </tr> <tr> <td rowspan=\"4\">24 mo to 5 yr </td> <td>Immediate spica cast</td> </tr> <tr> <td>Traction &#8594; spica cast</td> </tr> <tr> <td>External fixation (rare)</td> </tr> <tr> <td>Flexible intramedullary rod (rare)</td> </tr> <tr> <td rowspan=\"4\">6-11 yr </td> <td>Traction &#8594; spica cast</td> </tr> <tr> <td>Flexible intramedullary rod</td> </tr> <tr> <td>Compression or submuscular plate</td> </tr> <tr> <td>External fixation</td> </tr> <tr> <td rowspan=\"4\">12 yr to maturity </td> <td>Flexible intramedullary rod</td> </tr> <tr> <td>Compression or submuscular&nbsp;plate</td> </tr> <tr> <td>Locked intramedullary rod</td> </tr> <tr> <td>External fixation</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Treatment choices are influenced by the presence of multiple trauma (vs. an isolated femoral shaft fracture) or an open fracture with soft tissue trauma.</div><div class=\"graphic_reference\">Reproduced with permission from: Kasser JR, Beaty JH. Femoral Shaft Fractures. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 67204 Version 15.0</div></div></div>"},"67205":{"type":"graphic_table","displayName":"Results of cephalosporin challenges in patients","title":"Results of cephalosporin challenges in patients with histories of penicillin allergy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Results of cephalosporin challenges in patients with histories of penicillin allergy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Study</td> <td class=\"subtitle1\" colspan=\"2\">Cephalosporin reaction rate</td> <td class=\"subtitle1\" rowspan=\"2\">Cephalosporins administered</td> <td class=\"subtitle1\" rowspan=\"2\">Type of reaction<br /> (causative drug)</td> </tr> <tr> <td class=\"subtitle2\">History of penicillin allergy (%)</td> <td class=\"subtitle2\">No history of penicillin allergy (%)</td> </tr> <tr class=\"divider_bottom\"> <td>Dash (1975)<sup>[1]</sup></td> <td>25 of 324 (7.7%)</td> <td>140 of 17,216 (0.8%)</td> <td>Cephalexin and cephaloridine</td> <td>No details given</td> </tr> <tr class=\"divider_bottom\"> <td>Petz (1978)<sup>[2]</sup></td> <td>57 of 701 (8.1%)</td> <td>285 of 15,007 (1.9%)</td> <td>Cephalexin, cephaloridine, cephalothin, cefazolin, and cefamandole</td> <td>No details given</td> </tr> <tr class=\"divider_bottom\"> <td>Goodman (2001)<sup>[3]</sup></td> <td>1 of 300 (0.3%)</td> <td>1 of 2431 (0.04%)</td> <td>Cefazolin (in all but one patient)</td> <td>Reaction was questionable</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Daulat (2004)<sup>[4]</sup></td> <td class=\"divider_bottom\" rowspan=\"3\">1 of 606 (0.17%)</td> <td class=\"divider_bottom\" rowspan=\"3\">15 of 22,664 (0.07%)</td> <td>First generation (42%)</td> <td> <p>Reaction was eczema</p> (cefazolin)</td> </tr> <tr> <td>Second generation (21%)</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Third/fourth generation (37%)</td> <td>&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Fonacier (2005)<sup>[5]</sup></td> <td class=\"divider_bottom\" rowspan=\"4\">7 of 83 (8.4%)</td> <td class=\"divider_bottom\" rowspan=\"4\">Not applicable</td> <td>First generation (59%)</td> <td> <p>Reactions were convincing:</p> (Cephalexin-1)</td> </tr> <tr> <td>Second generation (8.4%)</td> <td>(Cefaclor-2, cefuroxime-2)</td> </tr> <tr> <td>Third generation (25%)</td> <td>(Cefixime-1, ceftriaxone-1)</td> </tr> <tr class=\"divider_bottom\"> <td>Fourth generation (7%)</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>MacPherson (2006)<sup>[6]</sup></td> <td>0 of 84 (0)</td> <td>Not applicable</td> <td>Cefazolin, cefotetan, ceftriaxone</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Crotty (2015)<sup>[7]</sup></td> <td>7 of 186 (3.8%)</td> <td>Not applicable</td> <td>Cephalexin, cefoxitin, ceftriaxone, and cefepime</td> <td>Six of seven reactions were due to cefepime; three of seven reactions were immediate</td> </tr> <tr> <td>Beltran (2015)<sup>[8]</sup></td> <td>1 of 153 (0.7%)</td> <td>Not applicable</td> <td> <p>Cefazolin (84%)</p> Cefoxitin (17%)</td> <td> <p>Reaction was urticarial</p> (cefazolin)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Summary of studies of cephalosporin challenges in patients with a history of penicillin allergy without preceding penicillin allergy testing.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Dash CH. Penicillin allergy and the cephalosporins. J Antimicrob Chemother 1975; 1:107.</li>&#xD;&#xA;    <li>Petz LD. Immunologic cross-reactivity between penicillins and cephalosporins: a review. J Infect Dis 1978; 137 Suppl:S74.</li>&#xD;&#xA;    <li>Goodman EJ, Morgan MJ, Johnson PA, et al. Cephalosporins can be given to penicillin-allergic patients who do not exhibit an anaphylactic response. J Clin Anesth 2001; 13:561.</li>&#xD;&#xA;    <li>Daulat S, Solensky R, Earl HS, et al. Safety of cephalosporin administration to patients with histories of penicillin allergy. J Allergy Clin Immunol 2004; 113:1220.</li>&#xD;&#xA;    <li>Fonacier L, Hirschberg R, Gerson S. Adverse drug reactions to a cephalosporins in hospitalized patients with a history of penicillin allergy. Allergy Asthma Proc 2005; 26:135.</li>&#xD;&#xA;    <li>MacPherson RD, Willcox C, Chow C, Wang A. Anaesthetist's responses to patients' self-reported drug allergies. Br J Anaesth 2006; 97:634.</li>&#xD;&#xA;    <li>Crotty DJ, Chen XJ, Scipione MR, et al. Allergic Reactions in Hospitalized Patients With a Self-Reported Penicillin Allergy Who Receive a Cephalosporin or Meropenem. J Pharm Pract 2015.</li>&#xD;&#xA;    <li>Beltran RJ, Kako H, Chovanec T, et al. Penicillin allergy and surgical prophylaxis: Cephalosporin cross-reactivity risk in a pediatric tertiary care center. J Pediatr Surg 2015; 50:856.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 67205 Version 9.0</div></div></div>"},"67206":{"type":"graphic_table","displayName":"Bacterial flora and resolution","title":"Resolution of pneumonia caused by different bacteria","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Resolution of pneumonia caused by different bacteria</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Infectious Agent</td> <td class=\"subtitle1\">Frequency of transient radiographic deterioration</td> <td class=\"subtitle1\">Time until full radiographic resolution</td> <td class=\"subtitle1\">Residual radiographic abnormalities</td> </tr> <tr> <td><em>Legionella</em> species</td> <td>Majority</td> <td>2 to 6 months</td> <td>25 percent</td> </tr> <tr> <td><em>Staphylococcus aureus</em></td> <td>Majority</td> <td>3 to 5 months</td> <td>Common</td> </tr> <tr> <td><em>Streptococcus pneumoniae</em> with sepsis</td> <td>Majority</td> <td>3 to 5 months</td> <td>25 to 35 percent</td> </tr> <tr> <td><em>Streptococcus pneumoniae </em>(nonbacteremic)</td> <td>Occasional</td> <td>1 to 3 months</td> <td>Rare</td> </tr> <tr> <td>Gram-negative</td> <td>Occasional</td> <td>3 to 5 months</td> <td>10 to 20 percent</td> </tr> <tr> <td><em>Haemophilus influenzae</em></td> <td>Occasional</td> <td>1 to 5 months</td> <td>Occasional</td> </tr> <tr> <td><em>Chlamydia </em>species</td> <td>Rare</td> <td>1 to 3 months</td> <td>10 to 20 percent</td> </tr> <tr> <td><em>Mycoplasma pneumoniae</em></td> <td>Rare</td> <td>2 to 4 weeks</td> <td>Rare</td> </tr> <tr> <td><em>Moraxella catarrhalis</em></td> <td>Rare</td> <td>1 to 3 months</td> <td>Unusual</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 67206 Version 2.0</div></div></div>"},"67209":{"type":"graphic_table","displayName":"Cisplatin plus pemetrexed NSCLC regimen","title":"Cisplatin plus pemetrexed for chemotherapy-naïve patients with advanced nonsquamous, non-small cell lung cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cisplatin plus pemetrexed for chemotherapy-naïve patients with advanced nonsquamous, non-small cell lung cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 21 days, for a maximum of six cycles.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Pemetrexed</td> <td>500 mg/m<sup>2</sup> IV</td> <td>Dilute in 100 mL normal saline (NS) and administer over 10 minutes. Do not administer with calcium-containing IV fluids such as Lactated Ringer's solution.</td> <td>Day 1</td> </tr> <tr class=\"divider_bottom\"> <td>Cisplatin</td> <td>75 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL NS and administer over 120 minutes, beginning 30 minutes after pemetrexed. Do not administer with aluminum needles or sets.</td> <td>Day 1</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Hydration</strong></td> <td colspan=\"3\"> <ul> <li>IV fluid to establish a urine flow of at least 100 mL/hour for at least two hours prior to and two hours after cisplatin administration. </li> <li>Refer to UpToDate topic on \"Cisplatin nephrotoxicity\", section on prevention. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>HIGH. </li> <li>Refer to UpToDate topics on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for skin rashes</strong></td> <td colspan=\"3\"> <ul> <li>Premedication with dexamethasone (4 mg orally twice daily for three days starting the day before drug administration) is recommended to reduce cutaneous toxicity.<sup>[2]</sup> </li> <li>Refer to UpToDate topic on \"Cutaneous complications of conventional chemotherapy agents\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Cisplatin is an irritant but can cause significant tissue damage; avoid extravasation. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with hematopoietic growth factors is not recommended (incidence of neutropenic fever approximately 2%<sup>[1]</sup>). </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>The optimal approach to cisplatin therapy in patients with preexisting renal impairment is unknown. Such patients were excluded from the original trial.<sup>[1]</sup> With pemetrexed, avoid use if creatinine clearance is &#60;45 mL/min. There are recommendations for avoidance of NSAIDs in the days prior to and immediately following each dose of pemetrexed in patients with mild to moderate renal dysfunction (CrCl 45 to 79 mL/min) because of the potential for decreased clearance of pemetrexed. </li> <li>Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\", \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\", and \"Pemetrexed: Drug information\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Vitamin supplementation</strong></td> <td colspan=\"3\"> <ul> <li>Vitamin supplementation with folic acid and intramuscular B12 is recommended prior to administration of pemetrexed and during treatment to reduce both hematologic and nonhematologic side effects.<sup>[1,2]</sup> </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count weekly during treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Electrolytes, renal, and liver function weekly during treatment. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for hearing loss prior to each dose of cisplatin; audiometry as clinically indicated. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Each cycle should not begin until the WBC count is &#62;1500 cells/microL and platelet count is &#62;100,000/microL.<sup>[1]</sup> During treatment, if nadir ANC &#60;500/microL and nadir platelet count &#8805;50,000/microL, reduce dose of both pemetrexed and cisplatin by 25%. Regardless of the ANC, reduce dose of both pemetrexed and cisplatin by 25% if nadir platelet count &#60;50,000/microL without bleeding. If nadir platelet count &#60;50,000/microL with bleeding, reduce dose of both pemetrexed and cisplatin by 50%.<sup>[1,2]</sup> </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurologic toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Neuropathy usually is seen only after cumulative doses of cisplatin beyond 400 mg/m<sup>2</sup>, although there is marked interindividual variation. </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Nephrotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Hold cisplatin until serum creatinine &#60;1.5 mg/dL and/or blood urea nitrogen &#60;25 mg/dL. For grade &#8805;2 nephrotoxicity during treatment (creatinine &#62;1.5 times normal value despite adequate hydration), creatinine clearance should be determined prior to next cycle and cisplatin dose reduced if &#60;60 mL/min. Treatment with pemetrexed should not begin unless creatinine clearance is &#8805;45 mL/min. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Mucositis, hepatotoxicity, and other severe non-hematologic toxicity</strong></td> <td colspan=\"3\"> <ul> <li>The dose of pemetrexed should be reduced 50% for grade 3 or 4 mucositis. The doses of pemetrexed and cisplatin should be decreased to 75% of previous level for any other grade 3 or 4 toxicities or for any diarrhea requiring hospitalization. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; NSAIDs: nonsteroidal anti-inflammatory drugs; CrCl: creatinine clearance; CBC: complete blood count; WBC: white blood cell; ANC: absolute neutrophil count.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Scagliotti GV, et al. J Clin Oncol 2008; 26:3543.</LI>&#xD;&#xA;<LI>Pemetrexed disodium injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 7, 2011).</LI></OL></div><div id=\"graphicVersion\">Graphic 67209 Version 27.0</div></div></div>"},"67210":{"type":"graphic_table","displayName":"Drugs palliative care child","title":"Pediatric palliative care: Medications used to treat common symptoms in children*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pediatric palliative care: Medications used to treat common symptoms in children*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup span=\"4\" width=\"21%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Symptoms</td> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Oral dose and frequency</td> <td class=\"subtitle1\">Intravenous dose and frequency</td> <td class=\"subtitle1\">Other routes</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Dyspnea</strong></td> <td>Morphine</td> <td>0.1 mg/kg every three to four hours as needed</td> <td>0.05 mg/kg every three to four hours as needed</td> <td>0.1 mg/kg sublingual (concentrated oral solution) every three to four hours as needed; 0.05 mg/kg subcutaneous every three to four hours as needed</td> </tr> <tr class=\"divider_bottom\"> <td>Lorazepam</td> <td>0.025 to 0.05 mg/kg every six hours as needed (maximum initial dose 2 mg)</td> <td>0.025 to 0.05 mg/kg every six hours as needed (maximum initial dose 2 mg)</td> <td>0.025 to 0.05 mg/kg subcutaneous every six hours as needed (maximum initial dose 2 mg)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\"><strong>Respiratory secretions (\"death rattle\")</strong></td> <td>Glycopyrrolate</td> <td>0.04 to 0.1 mg/kg every four to eight hours (maximum initial dose 1 to 2 mg)</td> <td>4 mcg/kg every four hours as needed (maximum initial dose 0.1 mg)</td> <td>&nbsp;</td> </tr> <tr> <td rowspan=\"3\">Hyoscyamine</td> <td>Age &#60;2 years: 0.03 mg/dose every four hours as needed</td> <td rowspan=\"3\">&nbsp;</td> <td>Age &#60;2 years: 0.03 mg/dose sublingual every four hours as needed</td> </tr> <tr> <td>Age 2 to 12 years: 0.06 to 0.125 mg/dose every four hours as needed</td> <td>Age 2 to 12 years: 0.06 to 0.125 mg/dose sublingual every four hours as needed</td> </tr> <tr> <td>Age &#62;12 years: 0.125 to 0.25 mg/dose every four hours as needed</td> <td>Age &#62;12 years: 0.125 to 0.25 mg/dose sublingual every six hours as needed</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Scopolamine hydrobromide<sup>&#182;</sup></td> <td class=\"divider_bottom\" rowspan=\"2\">Adolescents: 0.4 mg/dose every eight hours as needed</td> <td class=\"divider_bottom\" rowspan=\"2\">6 mcg/kg every eight hours as needed (maximum initial dose 0.3 mg)</td> <td>6 mcg/kg subcutaneous every eight hours as needed (maximum initial dose 0.3 mg)</td> </tr> <tr class=\"divider_bottom\"> <td>Adolescents: 1.5 mg transdermal patch behind ear every 72 hours</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Fatigue</strong></td> <td>Methylphenidate (immediate release)</td> <td>Age &#8805;6 years: 0.05 to 0.1 mg/kg per dose given in the morning and at noon (maximum 2.5 mg per dose initially)</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\"><strong>Anorexia/weight loss</strong></td> <td rowspan=\"3\">Megestrol acetate</td> <td>Use only in children &#62;10 years old</td> <td rowspan=\"3\">&nbsp;</td> <td rowspan=\"3\">&nbsp;</td> </tr> <tr> <td>Initial dose: 3.75 mg/kg twice a day (maximum initial dose 100 mg)</td> </tr> <tr> <td>If no effect in two weeks: increase to 5 mg/kg twice a day (maximum 200 mg per dose)</td> </tr> <tr> <td>Dexamethasone</td> <td>0.15 mg/kg per dose twice a day (maximum initial dose 8 mg)</td> <td>0.15 mg/kg per dose twice a day (maximum initial dose 8 mg)</td> <td>&nbsp;</td> </tr> <tr> <td>Dronabinol</td> <td>Age &#8805;6 years: 2.5 mg/m<sup>2</sup> per dose every six hours</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Cyproheptadine</td> <td>Age &#8805;8 years: 2 mg every eight hours</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"14\"><strong>Constipation</strong></td> <td rowspan=\"2\">Polyethylene glycol 3350</td> <td>0.7 gram/kg (up to 8.5 grams initially) once daily</td> <td rowspan=\"2\">&nbsp;</td> <td rowspan=\"2\">&nbsp;</td> </tr> <tr> <td>Increase to 1.5 gram/kg (maximum 17 grams) once daily as needed</td> </tr> <tr> <td rowspan=\"3\">Senna (Syrup [8.8 mg sennosides per 5 mL strength syrup] or tablet [8.6 mg sennosides])</td> <td>Six months to two years: 2.2 mg (1.25 mL) to 4.4 mg (2.5 mL) at bedtime</td> <td rowspan=\"3\">&nbsp;</td> <td rowspan=\"3\">&nbsp;</td> </tr> <tr> <td>Two to six years: 4.4 mg (2.5 mL) to 6.6 mg (3.75 mL) at bedtime, or half tablet at bedtime</td> </tr> <tr> <td>6 to 12 years: 8.8 mg (5 mL) to 13.2 mg (7.5 mL) at bedtime, or one tablet at bedtime</td> </tr> <tr> <td>Lactulose (10 gram per 15 mL strength solution)</td> <td>7.5 mL once daily as needed or 5 to 10 mL every two hours until bowel movement (maximum 60 mL per 24 hours)</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td rowspan=\"2\">Bisacodyl</td> <td rowspan=\"2\">3 to 12 years: 0.3 mg/kg/24 hours (10 mg maximum) once daily as needed (onset six hours)</td> <td rowspan=\"2\">&nbsp;</td> <td>Six months to two years: 5 mg per rectum once daily as needed</td> </tr> <tr> <td>2 to 11 years: 5 to 10 mg per rectum once daily as needed</td> </tr> <tr> <td rowspan=\"2\">Glycerin</td> <td rowspan=\"2\">&nbsp;</td> <td rowspan=\"2\">&nbsp;</td> <td>Six months to six years: 2 to 5 mL rectal solution or one infant suppository per rectum once daily as needed</td> </tr> <tr> <td>&#62;6 years: 5 to 15 mL rectal solution or one adult suppository per rectum once daily as needed</td> </tr> <tr> <td rowspan=\"3\">Docusate</td> <td>Six months to three years: 10 mg once to twice daily</td> <td rowspan=\"3\">&nbsp;</td> <td rowspan=\"3\">&nbsp;</td> </tr> <tr> <td>Three to six years: 20 mg once to twice daily</td> </tr> <tr> <td>6 to 12 years: 40 mg once to twice daily</td> </tr> <tr class=\"divider_bottom\"> <td>Mineral oil enema (Fleet)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>2 to 11 years: 30 to 60 mL per rectum once daily as needed</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"13\"><strong>Nausea/vomiting</strong></td> <td>Metoclopramide<sup>&#916;</sup></td> <td>0.1 to 0.2 mg/kg per dose three times daily before meals as needed (maximum initial dose 10 mg)</td> <td>0.1 to 0.2 mg/kg per dose three times daily before meals as needed (maximum initial dose 10 mg)</td> <td>&nbsp;</td> </tr> <tr> <td>Prochlorperazine</td> <td>&#62;10 years: 0.1 mg/kg per dose every eight hours as needed (maximum initial dose 5)</td> <td>&#62;10 years: 0.1 to 0.15 mg/kg per dose every eight hours as needed (maximum initial dose 5)</td> <td>&#62;10 years: 0.1 mg/kg per dose as a suppository per rectum every eight hours as needed (maximum initial dose 5)</td> </tr> <tr> <td>Promethazine</td> <td>&#8805;2 years: 0.25 to 0.5 mg/kg per dose every four to six hours as needed (maximum initial dose 12.5 mg)</td> <td>Not recommended due to risk of tissue injury depending on IV line placement and condition</td> <td>&#8805;2 years: 0.25 to 0.5 mg/kg per dose as a suppository per rectum every four to six hours as needed (maximum initial dose 12.5 mg)</td> </tr> <tr> <td rowspan=\"5\">Ondansetron</td> <td>&#60;0.3 m<sup>2</sup>: 1 mg every eight hours as needed</td> <td rowspan=\"5\">0.15 mg/kg every eight hours as needed (maximum initial dose 8 mg)</td> <td rowspan=\"5\">&nbsp;</td> </tr> <tr> <td>0.3 to 0.6 m<sup>2</sup>: 2 mg every eight hours as needed</td> </tr> <tr> <td>0.6 to 1 m<sup>2</sup>: 3 mg every eight hours as needed</td> </tr> <tr> <td>&#62;1 m<sup>2</sup>: 4 to 8 mg every eight hours as needed</td> </tr> <tr> <td>&#62;11 years: 8 mg every eight hours as needed</td> </tr> <tr> <td>Haloperidol<sup>&#9674;</sup></td> <td>0.01 mg/kg per dose three times daily as needed (maximum initial dose 0.5 mg)</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Diphenhydramine<sup>&#167;</sup></td> <td>1 mg/kg per dose every six hours as needed</td> <td>1 mg/kg per dose every six hours as needed</td> <td>&nbsp;</td> </tr> <tr> <td>Lorazepam<sup>&#9674;</sup></td> <td>0.025 to 0.05 mg/kg every six hours as need (maximum initial dose 2 mg)</td> <td>0.02 to 0.05 mg/kg every six hours as need (maximum initial dose 2 mg)</td> <td>0.02 to 0.05 mg/kg sublingual every six hours as need (maximum initial dose 2 mg)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Dexamethasone<sup>&#9674;</sup></td> <td class=\"divider_bottom\" rowspan=\"2\">0.1 mg/kg three times a day (maximum initial dose 5 mg)</td> <td>0.1 mg/kg three times a day (maximum initial dose 5 mg)</td> <td class=\"divider_bottom\" rowspan=\"2\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Dosing to prevent nausea/vomiting due to emetogenic chemotherapy or radiotherapy:</p> Initial dose 10 mg/m<sup>2</sup> (maximum initial dose 20 mg); then 5 mg/m<sup>2</sup> (maximum initial dose 5 mg) every six hours</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Fever</strong></td> <td>Acetaminophen</td> <td>15 mg/kg per dose every four to six hours as needed</td> <td>&nbsp;</td> <td>15 mg/kg per rectum every four to six hours as needed</td> </tr> <tr class=\"divider_bottom\"> <td>Ibuprofen</td> <td>10 mg/kg every six to eight hours as needed</td> <td>Adolescent &#8805;17 years: 100 to 200 mg every four to six hours as needed</td> <td>&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Insomnia</strong></td> <td>Melatonin</td> <td>2 to 3 mg at bedtime</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Trazodone</td> <td>&#8805;6 years: 0.75 to 1 mg/kg at bedtime (12.5 to 50 mg)</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Anxiety</strong></td> <td>Lorazepam</td> <td>0.025 to 0.05 mg/kg every six hours as needed (maximum initial dose 2 mg)</td> <td>0.02 to 0.05 mg/kg every six hours as needed (maximum initial dose 2 mg)</td> <td>0.02 to 0.05 mg/kg sublingual every six hours as needed (maximum initial dose 2 mg)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\"><strong>Agitation/delirium</strong></td> <td rowspan=\"2\">Haloperidol</td> <td>0.01 mg/kg three times a day as needed (maximum initial dose 0.5 mg)</td> <td>0.01 mg/kg three times a day as needed (maximum initial dose 0.5 mg)</td> <td>&nbsp;</td> </tr> <tr> <td>For acute agitation: 0.02 to 0.05 mg/kg, may repeat with a dose of 0.025 mg/kg in one hour as needed</td> <td>For acute agitation: 0.02 to 0.05 mg/kg, may repeat with a dose of 0.025 mg/kg in one hour as needed</td> <td>&nbsp;</td> </tr> <tr> <td>Clonazepam</td> <td>0.005 to 0.01 mg/kg every 8 to 12 hours (maximum initial dose 0.5 mg)</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Olanzapine</td> <td>Adolescents: 2.5 to 5 mg once daily</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Muscle spasm</strong></td> <td>Diazepam</td> <td>0.04 to 0.2 mg/kg per dose every six to eight hours as needed (up to 2.5 mg per dose initially)</td> <td>0.04 to 0.2 mg/kg per dose every six to eight hours as needed (up to 2.5 mg per dose initially)</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Baclofen</td> <td>&#8805;2 years: 5 mg three times a day, may increase every three days by 5 to 15 mg/day to a maximum dose of 40 mg/day</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"8\"><strong>Seizures</strong><sup>&#165;</sup></td> <td>Lorazepam</td> <td>&nbsp;</td> <td>0.05 to 0.1 mg/kg per dose; may repeat in 10 to 15 minutes (maximum cumulative dose 10 mg over 20 minutes)</td> <td>&nbsp;</td> </tr> <tr> <td rowspan=\"2\">Midazolam</td> <td rowspan=\"2\">&nbsp;</td> <td rowspan=\"2\">Second line (refractory seizures): 0.15 mg/kg loading dose followed by continuous infusion of 1 mcg/kg/minute gradually titrated to effect</td> <td>0.2 mg/kg intranasal may repeat in 10 minutes<sup>&#135;</sup> <strong>OR</strong></td> </tr> <tr> <td>0.3 mg/kg buccal may repeat in 10 minutes<sup>&#135;</sup></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Diazepam</td> <td class=\"divider_bottom\" rowspan=\"5\">Adjunct for prevention of seizures: 0.04 to 0.2 mg/kg per dose every six hours (up to 2.5 mg per dose initially)</td> <td class=\"divider_bottom\" rowspan=\"5\">&nbsp;</td> <td class=\"sublist1_start\">Rectal gel formulation (Diastat)</td> </tr> <tr> <td class=\"sublist1\">Two to five years: 0.5 mg/kg per rectum</td> </tr> <tr> <td class=\"sublist1\">6 to 11 years: 0.3 mg/kg per rectum</td> </tr> <tr> <td class=\"sublist1\">&#62;12 years: 0.2 mg/kg per rectum</td> </tr> <tr class=\"divider_bottom\"> <td>Doses should be rounded to 2.5, 5, 7.5, 10, 12.5, 15, 17.5 or 20 mg/dose. Dose may be repeated in 4 to 12 hours if needed<sup>&#134;</sup>.</td> </tr> <tr> <td rowspan=\"8\"><strong>Neuropathic pain</strong></td> <td rowspan=\"5\">Gabapentin**</td> <td class=\"sublist1_start\">&#8805;3 years of age:</td> <td rowspan=\"5\">&nbsp;</td> <td rowspan=\"5\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Day one to three: 5 mg/kg at bedtime</td> </tr> <tr> <td class=\"sublist1\">Day four to six: 5 mg/kg twice a day</td> </tr> <tr> <td class=\"sublist1\">Day seven to nine: 5 mg/kg/dose three times a day</td> </tr> <tr> <td class=\"sublist1\">Day 10 to 12: 5 mg/kg/dose in the morning and midday, and 10 mg/kg at bedtime</td> </tr> <tr> <td rowspan=\"3\">Nortriptyline<sup>&#182;&#182;</sup></td> <td class=\"sublist1_start\">&#8805;6 years of age:</td> <td rowspan=\"3\">&nbsp;</td> <td rowspan=\"3\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Day one to four: 0.2 mg/kg at bedtime</td> </tr> <tr> <td class=\"sublist1\">Day four to eight: 0.4 mg/kg at bedtime</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Doses are for individuals over six months of age (except where shown otherwise) with a maximum weight of 50 kg.<br />&para; Dosing shown is for scopolamine hydrobromide (oral, parenteral). Scopolamine butylbromide, widely available outside US, is not equivalent to and is dosed differently than dosing shown.<br />&Delta; Dosing shown is for nausea-vomiting related to gastrointestinal dysmotility. Higher doses (in conjunction with diphenhydramine to prevent extrapyramidal symptoms) used for chemotherapy-induced emesis.<br /><span class=\"lozenge\">&loz;</span> Most data for antiemetic use of this agent is as adjunct for prevention of nausea-vomiting due to emetogenic chemotherapy or radiotherapy.<br />&sect; Also appropriate for management of opioid induced pruritis or insomnia.<br />&yen; Refer to UpToDate topics on treatment of seizures and epileptic syndromes in children and management of status epilepticus in children.<br />&Dagger; Use based on limited experience and case descriptions as adjunct. Refer to UpToDate topics on treatment of seizures and epileptic syndromes in children, section on transmucosal administration.<br />&dagger; Rectal diazepam gel has been repeated as frequently as every 15 minutes up to three doses total (in absence of IV access) to control prolonged seizure activity based on limited experience in palliative care.<br />** Gabapentin dosing is increased until effective analgesia is achieved, side effects occur, or a maximum daily dose of 60 mg/kg/day is reached. Once a daily dose is established, half of the total daily dose may be given in the evening. Dose increases may be made more frequently (eg, every one to three days) as tolerated.<br />&para;&para; Nortriptyline dosing is increased as tolerated until effective analgesia is achieved, or a maximum daily dose of 1 mg/kg per day (50 mg maximum) is reached. Prior to dose escalation beyond these parameters, plasma levels and obtaining an ECG should be considered.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Custer JW, Rau RE, Lee C. The Harriet Lane Handbook, 18th ed, Elsevier Mosby, Philadelphia 2009. </LI>&#xD;&#xA;<LI>Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved.</LI>&#xD;&#xA;<LI>Schechter NL, Berde CB, Yaster M, eds. Pain in infants, children, and adolescents, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. </LI></OL></div><div id=\"graphicVersion\">Graphic 67210 Version 16.0</div></div></div>"},"67211":{"type":"graphic_table","displayName":"Etiology short term problems","title":"Environmental and occupational causes of health problems: Immediate or short-term effects","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Environmental and occupational causes of health problems: Immediate or short-term effects</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Immediate or short-term effects</td>\n\n      <td class=\"subtitle1\">Agent</td>\n\n      <td class=\"subtitle1\">Potential exposures</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Dermatoses (allergic or irritant)</td>\n\n      <td>Metals (chromium, nickel), fibrous glass, epoxy resin, cutting oils, solvents, caustic alkali, soaps</td>\n\n      <td>Electroplating, metal cleaning, plastics, machining, leather tanning, housekeeping</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Headache</td>\n\n      <td>Carbon monoxide, solvents</td>\n\n      <td>Firefighting, automobile exhaust, foundry, wood finishing, dry cleaning</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Behavioral changes</td>\n\n      <td>Lead (especially organic), mercury, carbon disulfide manganese</td>\n\n      <td>Handling gasoline, fungicide, wood preserving, viscose, rayon industry, mining</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Asthma or dry cough</td>\n\n      <td>Formaldehyde, toluene diisocyanate, animal dander, latex, chemical irritants</td>\n\n      <td>Textiles, plastics, polyurethane kits, car painting, lacquer use, animal handling, latex glove use</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pulmonary edema, pneumonitis</td>\n\n      <td>Nitrogen oxides, phosgene, halogen gases, cadmium</td>\n\n      <td>Welding, farming (\"silo filler's disease\"), chemical operations, smelting</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cardiac arrhythmias</td>\n\n      <td>Solvents, fluorocarbons, carbon monoxide</td>\n\n      <td>Metal cleaning, solvent use, refrigerator maintenance, automobile exhaust</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Angina</td>\n\n      <td>Carbon monoxide</td>\n\n      <td>Car repair, traffic exhaust, foundry, wood finishing</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Abdominal pain</td>\n\n      <td>Lead</td>\n\n      <td>Battery making, enameling, smelting, painting, welding, ceramics, plumbing, radiator repair</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hepatitis (may become a long-term effect)</td>\n\n      <td>Halogenated hydrocarbons (eg, carbon tetrachloride), dimethylformanide, viral infection</td>\n\n      <td>Solvent use, lacquer use, hospital work, electroplating, plastic manufacturing</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Tendonitis, carpal tunnel syndrome, \"repetitive strain disorder\" (may become a long-term effect)</td>\n\n      <td>Repetitive motions, awkward postures, pinching motions, wrist flexion</td>\n\n      <td>Assembly work, keyboarding, data entry, material handling</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Goldman RH, Peters JM. JAMA 1981; 246:2831.</div><div id=\"graphicVersion\">Graphic 67211 Version 2.0</div></div></div>"},"67213":{"type":"graphic_diagnosticimage","displayName":"Pancoast tumor PA","title":"Superior sulcus tumor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Superior sulcus tumor</div><div class=\"cntnt\"><img style=\"width:283px; height:337px;\" src=\"images/PULM/67213_Pancoast_tumor_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior chest radiograph reveals opacification at the right apex due to a superior sulcus (Pancoast) tumor.</div><div class=\"graphic_reference\">Courtesy of David Midthun, MD.</div><div id=\"graphicVersion\">Graphic 67213 Version 2.0</div></div></div>"},"67214":{"type":"graphic_picture","displayName":"Dermatofibroma dermoscopy","title":"Dermoscopic structures of dermatofibroma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Dermoscopic structures of dermatofibroma</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/67214_Dermatofibroma_dermoscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral delicate pigment network with a central scar-like area.</div><div class=\"graphic_reference\">Reproduced with permission from Drs. Ashfaq Marghoob and Natalia Jaimes.</div><div id=\"graphicVersion\">Graphic 67214 Version 3.0</div></div></div>"},"67215":{"type":"graphic_picture","displayName":"Allergic contact dermatitis face","title":"Allergic contact dermatitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Allergic contact dermatitis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/67215_Allergiccontactdermaface.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An intense, inflammatory eruption is present on the face.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 67215 Version 4.0</div></div></div>"},"67216":{"type":"graphic_picture","displayName":"Polymorphic light eruption B","title":"Polymorphic light eruption","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Polymorphic light eruption</div><div class=\"cntnt\"><img style=\"width:263px; height:396px;\" src=\"images/ALLRG/67216_Polymorphic_light_eruptionB.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Clusters of pruritic papules and vesicles on the dorsal wrist and arm and an erythematous plaque on the dorsum of the hand following first sun exposure of the season. The face and dorsal hand are typically spared.</div><div class=\"graphic_reference\">Reproduced with permission from: Fitzpatrick T, Johnson R, Wolff K, et al. Color atlas and synopsis of clinical dermatology: Common and Serious Diseases, Third Edition, McGraw Hill, New York, 1997. Copyright © 1997 McGraw-Hill Companies, Inc.</div><div id=\"graphicVersion\">Graphic 67216 Version 16.0</div></div></div>"},"67218":{"type":"graphic_figure","displayName":"Clamping uteroovarian ligament","title":"Clamping of the utero-ovarian ligament during vaginal hysterectomy","html":"<div class=\"graphic\"><div style=\"width: 478px\" class=\"figure\"><div class=\"ttl\">Clamping of the utero-ovarian ligament during vaginal hysterectomy</div><div class=\"cntnt\"><img style=\"width:458px; height:393px;\" src=\"images/OBGYN/67218_Clamping_uteroovarian_ligam.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 67218 Version 2.0</div></div></div>"},"67222":{"type":"graphic_table","displayName":"TNM group prostate CA","title":"TNM anatomic stage prognostic groups for prostate cancer*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">TNM anatomic stage prognostic groups for prostate cancer*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Primary tumor (T)</td> <td class=\"subtitle1\">Regional lymph nodes (N)</td> <td class=\"subtitle1\">Distant metastasis (M)</td> <td class=\"subtitle1\">PSA</td> <td class=\"subtitle1\">Gleason</td> </tr> <tr> <td rowspan=\"3\">I</td> <td>T1a-c</td> <td>N0</td> <td>M0</td> <td>PSA &#60;10</td> <td>Gleason &#8804;6</td> </tr> <tr> <td>T2a</td> <td>N0</td> <td>M0</td> <td>PSA &#60;10</td> <td>Gleason &#8804;6</td> </tr> <tr> <td>T1-2a</td> <td>N0</td> <td>M0</td> <td>PSA X</td> <td>Gleason X</td> </tr> <tr> <td rowspan=\"6\">IIA</td> <td>T1a-c</td> <td>N0</td> <td>M0</td> <td>PSA &#60;20</td> <td>Gleason 7</td> </tr> <tr> <td>T1a-c</td> <td>N0</td> <td>M0</td> <td>PSA &#8805;10&#60;20</td> <td>Gleason &#8804;6</td> </tr> <tr> <td>T2a</td> <td>N0</td> <td>M0</td> <td>PSA &#8805;10&#60;20</td> <td>Gleason &#8804;6</td> </tr> <tr> <td>T2a</td> <td>N0</td> <td>M0</td> <td>PSA &#60;20</td> <td>Gleason 7</td> </tr> <tr> <td>T2b</td> <td>N0</td> <td>M0</td> <td>PSA &#60;20</td> <td>Gleason &#8804;7</td> </tr> <tr> <td>T2b</td> <td>N0</td> <td>M0</td> <td>PSA X</td> <td>Gleason X</td> </tr> <tr> <td rowspan=\"3\">IIB</td> <td>T2c</td> <td>N0</td> <td>M0</td> <td>Any PSA</td> <td>Any Gleason</td> </tr> <tr> <td>T1-2</td> <td>N0</td> <td>M0</td> <td>PSA &#8805;20</td> <td>Any Gleason</td> </tr> <tr> <td>T1-2</td> <td>N0</td> <td>M0</td> <td>Any PSA</td> <td>Gleason &#8805;8</td> </tr> <tr> <td>III</td> <td>T3a-b</td> <td>N0</td> <td>M0</td> <td>Any PSA</td> <td>Any Gleason</td> </tr> <tr> <td rowspan=\"3\">IV</td> <td>T4</td> <td>N0</td> <td>M0</td> <td>Any PSA</td> <td>Any Gleason</td> </tr> <tr> <td>Any T</td> <td>N1</td> <td>M0</td> <td>Any PSA</td> <td>Any Gleason</td> </tr> <tr> <td>Any T</td> <td>Any N</td> <td>M1</td> <td>Any PSA</td> <td>Any Gleason</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">11</mso:Specialty>\r\n<mso:Media_Notes msdt:dt=\"string\">4/1/2010--These are in the AJCC folder and should be renewed annually for the life of the 7th Edition; this has been paid for 2010 (JD). The total fee of $&amp;quot;160.00&amp;quot;was originally charged to TNM_staging_adrenal_CA TNM_staging_ampullary_CA anal_cancer_TNM_stage anal_cancer_stage_group Anal_outcome_hist_AJCC TNM_stage_append_CA TNM_stage_append_carcinoid Surv_rates_appendix_CA TNM_staging_bone_tumors TNM_stage_breast_cancer Breast_reg_lymph_nodes 2002_TNM_breast_cancer Staging_cervical_cancer TNM_staging_colorec_CA CRC_tumor_regression_grade SEER_surv_adeno_colon SEER_surv_adeno_rectum Reg_nodes_colorec_CA CRC_resection_margin Staging_uterine_carcinoma Staging_uterine_sarcoma TNM_distal_cholangio TNM_staging_esoph_SCC TNM_staging_esoph_EGJ_adenoCA Esoph_CA_site T_stage_esophageal_cancer Staging_fallopian_cancer TNM_staging_gallbladder_CA OS_gallbladder_CA TNM_staging_GIST Dis_prog_gastric_GIST Dis_prog_small_int_GIST Staging_gest_trop_neoplas TNM_stage_hypopharynx TNM_small_bowel_cancer TNM_intrahep_cholangio SEER_surv_intrahep_cholang TNM_staging_RCC TNM_stage_larynx TNM_stage_oral_cavity TNM_staging_HCC 7th_TNM_lung_stage system Lung_CA staging_6th_TNM 7th_TNM_lung_CA_changes TNM_path_staging_mel_conj TNM_clin_staging_mel_conj Melanoma_7thTNM_stage_group Melanoma_7th_TNM_staging TNM_staging_muc_melanoma_HN Muc_melanoma_HN_stage_group Ciliary_choroid_thickness TNM_stage_uveal_melanoma TNM_stage_Merkel_cell_CA TNM_stage_sinonasal_sites TNM_stage_nasopharynx TNM_stage_gastric_carcinoid TNM_gastrointest_carcinoid TNM_amp_sm_bowel_carcinoid TNM_staging_CRC_carcinoid Surv_rates_GI_neuroendo Staging_ovar_prim_perit_ca TNM_panc_endo_exo_CA NCDB_no_surg_surv_panc NCDB_surg_surv_panc Prog_panc_neuroendo_tum TNM_staging_penile_cancer TNM_perihilar_cholangio TNM_stage_oropharynx TNM_stage_mesothelioma TNM_staging_prostate_CA TNM_group_prostate_CA TNM_staging_renal_pelvis TNM_stage_salivary_glands TNM_stage_sarcoma_orbit TNM_staging_soft_tis_sarc 2010_TNM_staging_STS TNM_stage_cutan_SCC 2010_TNM_staging_stomach_CA SEER_survival_gast_CA TMN_staging_testicular_CA Stage_group_testicular_CA TNM_staging_thyroid_cancer Urethral_CA_TNM_women TNM_stage_group_urethra Urethral_CA_TNM_men TNM_staging_bladder_CA Staging_vaginal_cancer Staging_vulvar_cancer</mso:Media_Notes>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=48362&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_lgnd\">Note: cTNM is the clinical classification, pTNM is the pathologic classification.</div><div class=\"graphic_footnotes\">PSA: prostate specific antigen.<br />* When either PSA or Gleason is not available, grouping should be determined by T stage and/or either PSA or Gleason as available.</div><div class=\"graphic_reference\">Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.</div><div id=\"graphicVersion\">Graphic 67222 Version 14.0</div></div></div>"},"67223":{"type":"graphic_table","displayName":"72h fecal fat test","title":"Seventy-two hour fecal fat collection and calculation of coefficient of fat absorption","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Seventy-two hour fecal fat collection and calculation of coefficient of fat absorption</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>1.&nbsp;48 to 72&nbsp;hours prior to the beginning of stool collection, subject is started on a high fat diet.*</td> </tr> <tr> <td>2. All stools are collected into a single container for a full 72 hours. Stool container is kept refrigerated during collection.</td> </tr> <tr> <td>3. During the collection, all food and fluid intake is recorded. A record of all bowel movements is kept. Intake record is analyzed for total dietary fat intake.</td> </tr> <tr> <td>4. Collected stool is homogenized and analyzed for fat by the method of van de Kamer.<sup>[1]</sup> Medium chain triglyceride will not be measured by this method.</td> </tr> <tr> <td>5. Coefficient of fat absorption (CFA) is calculated from the following equation:</td> </tr> <tr> <td class=\"indent2\"> <p>CFA = Dietary fat - Stool fat</p> <p>------------------------</p> <p>Dietary fat</p> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This protocol is intended for clinical use. This protocol is not sufficiently precise to be used for research purposes.</div><div class=\"graphic_footnotes\">* For children, a high fat diet consists of&nbsp;&gt;2 g/kg/day and minimum of 50 g/day fat. For adolescents and adults, the high-fat diet is 100 g fat daily.<SUP>[2] </SUP>&nbsp;Medium-chain triglyceride (MCT) fat in the diet should not be counted towards this total fat intake (eg, from MCT supplements or formula). </div><div class=\"graphic_reference\">Courtesy of Robert D Baker, MD.<br /><OL>&#xD;&#xA;<LI>​Van de Kamer, JH, et al. Rapid method for the determination of fat in feces. J Biol Chem 1949; 177:347.</LI>&#xD;&#xA;<LI>Taylor CJ, Chen K, Horvath K, et al. ESPGHAN and NASPGHAN Report on the Assessment of Exocrine Pancreatic Function and Pancreatitis in Children. J Pediatr Gastroenterol Nutr 2015; 61:144.</LI></OL></div><div id=\"graphicVersion\">Graphic 67223 Version 5.0</div></div></div>"},"67225":{"type":"graphic_table","displayName":"Example of fire ant rush protocol","title":"Example of fire ant rush protocol","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Example of fire ant rush protocol</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Day</td> <td class=\"subtitle1\">Volume (mL)</td> <td class=\"subtitle1\">Dilution</td> <td class=\"subtitle1\">Color vial</td> </tr> <tr> <td rowspan=\"8\">1</td> <td>0.1</td> <td>1:100,000</td> <td>&nbsp;</td> </tr> <tr> <td>0.3</td> <td>1:100,000</td> <td>&nbsp;</td> </tr> <tr> <td>0.1</td> <td>1:10,000</td> <td>Silver</td> </tr> <tr> <td>0.3</td> <td>1:10,000</td> <td>Silver</td> </tr> <tr> <td>0.1</td> <td>1:1000</td> <td>Green</td> </tr> <tr> <td>0.3</td> <td>1:1000</td> <td>Green</td> </tr> <tr> <td>0.1</td> <td>1:100</td> <td>Blue</td> </tr> <tr> <td>0.3</td> <td>1:100</td> <td>Blue</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"8\">2</td> <td>0.1</td> <td>1:10</td> <td>Yellow</td> </tr> <tr> <td>0.2</td> <td>1:10</td> <td>Yellow</td> </tr> <tr> <td>0.3</td> <td>1:10</td> <td>Yellow</td> </tr> <tr> <td>0.4</td> <td>1:10</td> <td>Yellow</td> </tr> <tr> <td>0.5</td> <td>1:10</td> <td>Yellow</td> </tr> <tr> <td>0.1</td> <td>1:1</td> <td>Red</td> </tr> <tr> <td>0.2</td> <td>1:1</td> <td>Red</td> </tr> <tr> <td>0.3</td> <td>1:1</td> <td>Red</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This protocol (Willford Hall protocol) was developed for administration of immunotherapy using whole body extract of imported fire ants.</div><div class=\"graphic_reference\">Data from: Tankersley MS, Walker RL, Butler WK, et al. Safety and efficacy of an imported fire ant rush immunotherapy protocol with and without prophylactic treatment. J Allergy Clin Immunol 2002; 109:556.</div><div id=\"graphicVersion\">Graphic 67225 Version 4.0</div></div></div>"},"67226":{"type":"graphic_table","displayName":"Causes of neck stiffness in children","title":"Causes of neck stiffness in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of neck stiffness in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Trauma</td> </tr> <tr> <td class=\"indent1\">Clavicular fracture*</td> </tr> <tr> <td class=\"indent1\">Epidural hematoma of the cervical spine<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Fracture of the cervical spine<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Muscular contusion or neck spasm*</td> </tr> <tr> <td class=\"indent1\">SCIWORA syndrome<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Subarachnoid hemorrhage<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Subluxation of the cervical spine<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle1_single\">Infectious or inflammatory</td> </tr> <tr> <td class=\"indent1\">Bacterial meningitis<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Branchial cleft or thyroglossal duct cyst abscess</td> </tr> <tr> <td class=\"indent1\">Cervical lymphadenitis*</td> </tr> <tr> <td class=\"indent1\">Collagen vascular disease (eg, systemic JIA, ankylosing spondylitis, psoriatic arthritis)</td> </tr> <tr> <td class=\"indent1\">Infections of the spine: vertebral osteomyelitis, infectious discitis, epidural abscess<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Intervertebral disc calcification</td> </tr> <tr> <td class=\"indent1\">Kawasaki disease with cervical lymphadenopathy</td> </tr> <tr> <td class=\"indent1\">Lyme meningitis</td> </tr> <tr> <td class=\"indent1\">Muscle strain*</td> </tr> <tr> <td class=\"indent1\">Otitis media and mastoiditis</td> </tr> <tr> <td class=\"indent1\">Pharyngitis or tonsillitis*</td> </tr> <tr> <td class=\"indent1\">Retropharyngeal abscess<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Rotary atlantoaxial subluxation as a result of local inflammation or procedure (Grisel's syndrome)</td> </tr> <tr> <td class=\"indent1\">Upper lobe pneumonia</td> </tr> <tr> <td class=\"indent1\">Viral meningitis*</td> </tr> <tr> <td class=\"indent1\">Viral myositis</td> </tr> <tr> <td class=\"subtitle1_single\">Tumors, other space-occupying and vascular lesions of the central nervous system</td> </tr> <tr> <td class=\"indent1\">Brain tumor<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Other space-occupying lesions of the spinal cord (neurenteric cyst, arteriovenous malformation, syringomyelia)<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Other tumors of the head and neck (osteoid osteoma, eosinophilic granuloma, orbital tumor, acoustic neuroma, osteoblastoma, metastatic tumor to the spine, nasopharyngeal carcinoma, bone cyst)<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Spinal cord tumor<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Subarachnoid hemorrhage (aneurysm rupture-congenital, sickle cell disease)<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle1_single\">Congenital conditions</td> </tr> <tr> <td class=\"indent1\">Atlantoaxial instability secondary to congenital conditions (Down's syndrome, Klippel-Feil syndrome, os odontoideum, Morquio's syndrome)</td> </tr> <tr> <td class=\"indent1\">Benign paroxysmal torticollis</td> </tr> <tr> <td class=\"indent1\">Congenital muscular torticollis*</td> </tr> <tr> <td class=\"indent1\">Skeletal malformations (Klippel-Feil syndrome, Sprengel's deformity, hemiatlas, basilar impression, occipitocervical synostosis)</td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous</td> </tr> <tr> <td class=\"indent1\">Dystonic reaction</td> </tr> <tr> <td class=\"indent1\">Guillain-Barre syndrome</td> </tr> <tr> <td class=\"indent1\">Myasthenia gravis</td> </tr> <tr> <td class=\"indent1\">Ophthalmologic, neurologic, and/or vestibular causes (strabismus, cranial nerve palsies, extraocular muscle palsies, refractive errors, myasthenia gravis, Guillain-Barre syndrome, migraine headaches)</td> </tr> <tr> <td class=\"indent1\">Pseudo-tumor cerebri</td> </tr> <tr> <td class=\"indent1\">Psychogenic</td> </tr> <tr> <td class=\"indent1\">Sandifer syndrome</td> </tr> <tr> <td class=\"indent1\">Spasmus nutans</td> </tr> <tr> <td class=\"indent1\">Spontaneous pneumomediastinum</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">JIA: juvenile idiopathic arthritis; SCIWORA: spinal cord injury without radiographic abnormality.<br />* Common condition.<br />¶ Life-threatening condition.</div><div id=\"graphicVersion\">Graphic 67226 Version 10.0</div></div></div>"},"67228":{"type":"graphic_table","displayName":"Suicide risk assessment2","title":"Suicide risk assessment for children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suicide risk assessment for children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Factors related to intent (motivation)</td> </tr> <tr> <td class=\"sublist1_start\">How strong is the intent (motivation)?</td> </tr> <tr> <td class=\"sublist1\">If all the things you needed to kill yourself were available right here and you were alone, would you kill yourself right now?</td> </tr> <tr> <td class=\"sublist1_start\">Has the child or adolescent done anything to prepare?</td> </tr> <tr> <td class=\"sublist1\">Have you already written a note to your loved ones?</td> </tr> <tr> <td class=\"sublist1\">Have you practiced or come close already?</td> </tr> <tr> <td class=\"subtitle1_single\">Factors related to emotional/behavioral regulation</td> </tr> <tr> <td>What is the level of hopelessness and helplessness? Despair?</td> </tr> <tr> <td>Are intoxicants present?</td> </tr> <tr> <td>Does the child or adolescent have any psychiatric disorders or comorbidities?</td> </tr> <tr> <td>Does the child or adolescent have the capacity for self-regulation or is he or she impulsive?</td> </tr> <tr> <td>Is the child or adolescent able to cope and solve problems?</td> </tr> <tr> <td class=\"subtitle1_single\">Factors related to stressors</td> </tr> <tr> <td>Are there any recent or anticipated stressors?</td> </tr> <tr> <td class=\"subtitle1_single\">Factors related to support systems</td> </tr> <tr> <td class=\"sublist1_start\">Does the child or adolescent have a strong support system?</td> </tr> <tr> <td class=\"sublist1\">Among your family and friends, is there anyone who makes you feel less likely to kill yourself? More?</td> </tr> <tr> <td class=\"sublist1_start\">Can the child or adolescent build an alliance? Is he or she ready to participate in treatment?</td> </tr> <tr> <td class=\"sublist1\">If I asked you to promise me or your family members to tell one of us when you were thinking about killing yourself, would you be able to keep that promise?</td> </tr> <tr> <td class=\"sublist1\">Are you willing to promise to tell one of us if you are feeling worse?</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Jacobs DG, Brewer M, Klein-Benheim M. Suicide assessment: An overview and recommended protocol. In: Harvard Medical School Guide to Assessment and Intervention in Suicide, Jacob D (Ed), Jossey-Bass, San Francisco 1998. p.3.</div><div id=\"graphicVersion\">Graphic 67228 Version 3.0</div></div></div>"},"67231":{"type":"graphic_figure","displayName":"Flexible bronchoscope","title":"Diagram of a flexible bronchoscope","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diagram of a flexible bronchoscope</div><div class=\"cntnt\"><img style=\"width:383px; height:516px;\" src=\"images/PULM/67231_Flex_bronchoscope_PI_edt.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 67231 Version 4.0</div></div></div>"},"67232":{"type":"graphic_figure","displayName":"Maximal flow volume curve IPF","title":"Maximal expiratory flow volume (MEFV curve) in idiopathic pulmonary fibrosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Maximal expiratory flow volume (MEFV curve) in idiopathic pulmonary fibrosis</div><div class=\"cntnt\"><img style=\"width:425px; height:368px;\" src=\"images/PULM/67232_Maximal_flow_volume_curve_I.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A: shown are the MEFV curves at presentation in a 42-year old nonsmoking man with a normal chest roentgenogram and lung biopsy-proven idiopathic pulmonary fibrosis. The FEV1 and FVC values are low relative to the predicted values, but the FEV1 to FVC ratio is increased. However, at any given lung volume, the flow rates are higher than expected because of elevated driving pressure due to an increased elastic recoil. B: shows the MEFV curve for a patient with chronic obstructive lung disease. The FEV1 and FVC values are low relative to the predicted values, and the lung volumes are increased.</div><div id=\"graphicVersion\">Graphic 67232 Version 1.0</div></div></div>"},"67233":{"type":"graphic_figure","displayName":"DNA-based HLA typing","title":"DNA-based method of HLA typing","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">DNA-based method of HLA typing</div><div class=\"cntnt\"><img style=\"width:346px; height:562px;\" src=\"images/RHEUM/67233_DNA_based_HLA_typing.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Summary of DNA-based method of HLA typing, showing the main steps of DNA denaturation per amplification, and specific sequence detection by SSOP.</div><div class=\"graphic_reference\">Courtesy of Barbara S Nepom, MD.</div><div id=\"graphicVersion\">Graphic 67233 Version 2.0</div></div></div>"},"67234":{"type":"graphic_picture","displayName":"Gram stain sputum - Pulmonary tuberculosis","title":"Pulmonary tuberculosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary tuberculosis</div><div class=\"cntnt\"><img style=\"width:356px; height:240px;\" src=\"images/ID/67234_Gramstainsputum9Canswer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low-power light micrograph of a lung biopsy from a patient with tuberculosis shows multiple granulomas (hematoxylin and eosin stain).</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 67234 Version 3.0</div></div></div>"},"67235":{"type":"graphic_diagnosticimage","displayName":"Osteo in hip prosthesis","title":"Osteomyelitis in the setting of hip prosthesis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Osteomyelitis in the setting of hip prosthesis</div><div class=\"cntnt\"><img style=\"width:396px; height:400px;\" src=\"images/ID/67235_Osteo_in_hip_prosthesis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Coronal-reformatted&nbsp;computed tomography&nbsp;image demonstrates marked beam hardening artifact about a metallic left hip prosthesis (arrow).<br />(B) Despite extensive artifact in image A, on lung windows, a region of air can be identified adjacent to the lesser trochanter (arrow).<br />(C) Fluoroscopic-guided aspiration (arrow indicates needle) yielded 3 cc of pus. Initial Gram stain was positive for gram-negative rods; cultures subsequently grew<EM> Bacteroides fragilis</EM>.</div><div class=\"graphic_reference\">Courtesy of Perry Horwich, MD.</div><div id=\"graphicVersion\">Graphic 67235 Version 4.0</div></div></div>"},"67236":{"type":"graphic_figure","displayName":"SEER incidence breast cancer","title":"Age-specific SEER incidence, rates of female breast cancer per 100,000, 2000-2003","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Age-specific SEER incidence, rates of female breast cancer per 100,000, 2000-2003</div><div class=\"cntnt\"><img style=\"width:343px; height:328px;\" src=\"images/ONC/67236_SEER_incidence_breast_cance.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 67236 Version 3.0</div></div></div>"},"67237":{"type":"graphic_figure","displayName":"Periodontal disease","title":"Gingivitis and periodontitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gingivitis and periodontitis</div><div class=\"cntnt\"><img style=\"width:326px; height:683px;\" src=\"images/PEDS/67237_Periodontaldiseaseedt3.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A is an illustration of a healthy periodontium. Note that the epithelial attachment is located at the junction of the tooth enamel and the root. Panel B shows the changes occurring in gingivitis. Note the edema and erythema of the gingiva, and no change in bone or attachment level. Panel C shows the loss of supporting structures that occurs in periodontitis. The gingival sulcus has deepened, creating a \"periodontal pocket\". Note that the attachment has moved apically and that gingiva and bone have been lost, exposing the root surface.</div><div id=\"graphicVersion\">Graphic 67237 Version 5.0</div></div></div>"},"67238":{"type":"graphic_table","displayName":"Strength training guideline","title":"Summary of strength-training recommendations for children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of strength-training recommendations for children and adolescents</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_left\">\r\n  \r\n   Individualization\r\n  \r\n   </td>\r\n  \r\n   <td>Determined by age; physical, emotional, and cognitive limitations; personal goals and objectives.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_left\">\r\n  \r\n   Warm-up and cool-down\r\n  \r\n   </td>\r\n  \r\n   <td>Warm up with 5 to 10 minutes of stretching, aerobic exercise, and no-load or light weight repetitions. Cool down with light aerobic activity.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_left\">\r\n  \r\n   Specificity\r\n  \r\n   </td>\r\n  \r\n   <td>A well-rounded general strength training program can meet the needs of most children and adolescents.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_left\" rowspan=\"7\">\r\n  \r\n   Overload\r\n  \r\n   </td>\r\n  \r\n   <td><strong>Choice of exercises:</strong> Six to eight exercises that train the major muscle groups (chest, shoulders, back, arms, legs, abdomen, lower back) with appropriate balance between flexors and extensors and between upper and lower body muscle groups.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td><strong>Order of exercises:</strong> Perform large-muscle-mass exercises before small-muscle-mass exercises; complex exercises before simple exercises; multijoint exercises before single-joint exercises.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td><strong>Load:</strong> Select a resistance that allows 6 to 15 repetitions. Initially use a lower load that permits higher repetitions.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td><strong>Sets:</strong> Begin with 1 to 2 sets.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td><strong>Repetitions:</strong> 6 to 15 repetitions of each exercise per set.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td><strong>Rest:</strong> 1 to 3 minutes between sets.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td><strong>Frequency:</strong> 2 to 3 days per week.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_left\">\r\n  \r\n   Adaptation\r\n  \r\n   </td>\r\n  \r\n   <td>Strength gains can occur in children without significant enlargement of skeletal muscle mass. Strength training increases the number of motor units recruited and improves the coordinated recruitment of motor units, the firing rate or firing pattern of activated motor neurons, and coordination. Increased neural response may facilitate injury prevention in other sports and activities of daily living. During adolescence, strength training results in neurological adaptations, as well as hypertrophy.</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_left\">\r\n  \r\n   Progression\r\n  \r\n   </td>\r\n  \r\n   <td>Increase variety of the program and introduce new movement patterns and motor skills (coordination, skill technique, balance and stabilization) by adding both single- and multijoint exercises. Increase resistance by 5 to 10 percent when 20 repetitions become easy. Before increasing the number of sets or resistance, participants should be able to correctly demonstrate proper technique. Progress to performing 2 to 3 exercises per muscle group for 1 to 3 sets of 10 to 15 repetitions performed 3 days per week.</td>\r\n  \r\n   </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 67238 Version 1.0</div></div></div>"},"67239":{"type":"graphic_picture","displayName":"Planar xanthoma","title":"Planar xanthoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Planar xanthoma</div><div class=\"cntnt\"><img style=\"width:269px; height:381px;\" src=\"images/PC/67239_Planar_xanthoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Planar xanthoma in the antecubital fossa of a patient with homozygous familial hypercholesterolemia.</div><div class=\"graphic_reference\">Reproduced with permission from: Durrington P. Dyslipidaemia. Lancet 2003; 362:717. Copyright &#169; 2003 Elsevier.</div><div id=\"graphicVersion\">Graphic 67239 Version 2.0</div></div></div>"},"67242":{"type":"graphic_figure","displayName":"Insulin glargine versus NPH","title":"Time-action profiles for NPH and insulin glargine","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Time-action profiles for NPH and insulin glargine</div><div class=\"cntnt\"><img style=\"width:370px; height:342px;\" src=\"images/ENDO/67242_Insulin_glargine_versus_NPH.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Serum insulin concentrations after subcutaneous injection of 0.4 U/kg body weight of insulin glargine (solid line) or NPH human insulin (dashed line) on two different study days in 15 normal subjects. In contrast to NPH insulin, the time-action profile for insulin glargine has virtually no peak, which may make it an ideal basal insulin for intensive insulin therapy in patients with type 1 diabetes. To convert serum insulin values to µU/mL, divide by 6.</div><div class=\"graphic_footnotes\">NPH: neutral protamine hagedorn.</div><div class=\"graphic_reference\">Data from: Heinemann L, Linkeschova R, Rave K, et al. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000; 23:644.</div><div id=\"graphicVersion\">Graphic 67242 Version 5.0</div></div></div>"},"67243":{"type":"graphic_picture","displayName":"DLBCL path","title":"Diffuse large B-cell lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diffuse large B-cell lymphoma</div><div class=\"cntnt\"><img style=\"width:396px; height:292px;\" src=\"images/HEME/67243_DLBCLpath.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse large B-cell lymphoma. The majority of cases contain a mixture of large cells that resemble centroblasts with peripheral nucleoli and a minority of large cells that resemble immunoblasts with central nucleoli.</div><div class=\"graphic_reference\">Reproduced with permission from: Armitage JO, Mauch PM, Harris NL, et al. Non-Hodgkin Lymphomas, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 67243 Version 11.0</div></div></div>"},"67244":{"type":"graphic_table","displayName":"Religious position medical therapy","title":"Jehovah's witness religious position on medical therapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Jehovah's witness religious position on medical therapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Unacceptable treatment</td> </tr> <tr> <td class=\"indent1\">Transfusion of allogeneic whole blood, red blood cells, white cells, platelets, or plasma</td> </tr> <tr> <td class=\"indent1\">Preoperative autologous blood donation (PAD or predeposit)</td> </tr> <tr> <td class=\"subtitle1_single\">Acceptable treatment</td> </tr> <tr> <td class=\"indent1\">Most surgical and anesthesiological blood conservation measures (eg, hemostatic surgical instruments, controlled hypotension/hypotensive hemostasis, regional anesthesia, minimally invasive surgery, endovascular therapy, intraoperative positioning, maintenance of normothermia, meticulous hemostasis and surgical technique)</td> </tr> <tr> <td class=\"indent1\">Most diagnostic and therapeutic procedures (eg, phlebotomy for laboratory testing, angiographic embolization)</td> </tr> <tr> <td class=\"indent1\">Synthetic oxygen therapeutics (eg, perfluorochemicals)</td> </tr> <tr> <td class=\"indent1\">Nonblood volume expanders (eg, saline, lactated Ringer's, hydroxyethyl starches)</td> </tr> <tr> <td class=\"sublist2_start\">Pharmacologic agents that do not contain blood components or fractions:</td> </tr> <tr> <td class=\"sublist2\">Drugs to enhance hemostasis (eg, tranexamic acid, epsilon-aminocaproic acid, aprotinin, desmopressin, conjugated estrogens)</td> </tr> <tr> <td class=\"sublist2\">Hematopoietic growth factors and hematinics (eg, albumin-free erythropoietin, iron)</td> </tr> <tr> <td class=\"sublist2\">Recombinant products (eg, albumin-free coagulation factors)</td> </tr> <tr> <td class=\"sublist2\">Topical hemostatic agents (eg, collagen, gelatin-based hemostats, oxidized cellulose)</td> </tr> <tr> <td class=\"subtitle1_single\">Personal decision (acceptable to some, declined by others)</td> </tr> <tr> <td class=\"indent1\">Blood cell salvage* (intraoperative or postoperative autotransfusion)</td> </tr> <tr> <td class=\"indent1\">Acute normovolemic hemodilution*</td> </tr> <tr> <td class=\"indent1\">Intraoperative autologous blood component sequestration* (including intraoperative plateletpheresis, preparation of fibrin gel, platelet gel, platelet-rich plasma)</td> </tr> <tr> <td class=\"indent1\">Cardiopulmonary bypass<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Apheresis<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Hemodialysis<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Plasma-derived fractions (eg, immune globulins, vaccines, antivenins, albumin, cryoprecipitate<sup>&#916;</sup>)</td> </tr> <tr> <td class=\"indent1\">Hemostatic products containing blood fractions (eg, recombinant factor VIIa<sup>&#9674;</sup>, coagulation factor concentrates, prothrombin complex concentrate, fibrin glue/sealant, hemostatic bandages containing plasma fractions, thrombin sealants)</td> </tr> <tr> <td class=\"indent1\">Products containing plasma-derived blood fractions such as human serum albumin (eg, some formulations of erythropoietin, streptokinase, G-CSF, vaccines, recombinant clotting factors, nuclear imaging products)</td> </tr> <tr> <td class=\"indent1\">Oxygen therapeutics and other products containing a blood cell-derived fraction, whether from a human or animal source (eg, conjugated hemoglobin solutions, iron supplements, hematin, interferon alfa-N3 (leukocyte derived))</td> </tr> <tr> <td class=\"indent1\">Epidural blood patch</td> </tr> <tr> <td class=\"indent1\">Blood cell scintigraphy (eg, radionuclide tagging for localization of bleeding)</td> </tr> <tr> <td class=\"indent1\">Peripheral blood stem cell transplantation (autologous or allogeneic)</td> </tr> <tr> <td class=\"indent1\">Transplants (organ, marrow, bone)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Patients might request that continuity is maintained with their vascular system.<br />¶ Circuits not primed with allogeneic blood.<br />Δ Cryoprecipitate resuspended in 0.9 percent Sodium Chloride Injection (USP) diluent (ie, vast majority of cryoprecipitate preparations).<br /><FONT class=lozenge>◊</FONT> Recombinant activated Factor VII currently contains trace amounts of murine and bovine IgG from the manufacturing process.</div><div class=\"graphic_reference\">Reproduced with permission from: Bodnaruk ZM, Wong CJ, Thomas MJ. Meeting the clinical challenge of care for Jehovah's Witnesses. Transfusion Med Rev 2004; 18:105. Copyright &copy;2004 Elsevier Inc.</div><div id=\"graphicVersion\">Graphic 67244 Version 3.0</div></div></div>"},"67246":{"type":"graphic_figure","displayName":"Mechanism glucocorticoid action","title":"Mechanisms of glucocorticoid receptor action","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Mechanisms of glucocorticoid receptor action</div><div class=\"cntnt\"><img style=\"width:596px; height:444px;\" src=\"images/PULM/67246_Mech_glucocorticoid_action.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Glucocorticoids (GC) cross freely into the cytoplasm where they bind to and activate the glucocorticoid receptor (GR). Activated GR translocates into the nucleus where it can bind as a dimer to a glucocorticoid response element (GRE) and induce the expression of anti-inflammatory genes such as the IL-10 gene. This involves a change in local histone acetylation status and chromatin remodeling. Secondly, the GR dimer can bind to a negative GRE to prevent inflammatory gene expression preventing formation of an active transcriptional complex. Thirdly, GR, acting as a monomer, binds directly or indirectly with pro-inflammatory transcription factors such as nuclear factor kappaB (NF-kappaB) preventing its ability to switch on inflammatory gene expression. The increased expression of the GRbeta isoform found in some patients with glucocorticoid insensitive severe asthma can act as a dominant negative regulator of GRalpha.</div><div class=\"graphic_footnotes\">MKP-1:&nbsp;mitogen-activated protein kinase phosphatase-1; IL-10: interleukin-10.</div><div class=\"graphic_reference\">Reference:<br /><OL>&#xD;&#xA;<LI>Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43:343.</LI></OL></div><div id=\"graphicVersion\">Graphic 67246 Version 4.0</div></div></div>"},"67249":{"type":"graphic_figure","displayName":"Sternum, pericardium, and related anatomy","title":"Sternum, pericardium, and related anatomy","html":"<div class=\"graphic\"><div style=\"width: 630px\" class=\"figure\"><div class=\"ttl\">Sternum, pericardium, and related anatomy</div><div class=\"cntnt\"><img style=\"width:610px; height:512px;\" src=\"images/EM/67249_Sternpericardrelatanat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This dissection exposes the pericardial sac posterior to the body of the sternum from just superior to the sternal angle to the level of the xiphisternal joint. The pericardial sac lies approximately one-third to the right of the midsternal line and two-thirds to the left.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AF. Clinically oriented anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 67249 Version 13.0</div></div></div>"},"67251":{"type":"graphic_figure","displayName":"Anatomy of the parapharyngeal space","title":"Anatomy of the parapharyngeal space","html":"<div class=\"graphic\"><div style=\"width: 598px\" class=\"figure\"><div class=\"ttl\">Anatomy of the parapharyngeal space</div><div class=\"cntnt\"><img style=\"width:578px; height:563px;\" src=\"images/ID/67251_Parapharyngspace.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 67251 Version 5.0</div></div></div>"},"67253":{"type":"graphic_figure","displayName":"Mitochondrial pathways","title":"Metabolic reactions in the mitochondria","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Metabolic reactions in the mitochondria</div><div class=\"cntnt\"><img style=\"width:522px; height:373px;\" src=\"images/NEURO/67253_Mitochondrial_pathways_new.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The respiratory chain is composed of four multi-subunit complexes (I, II, III, and IV) linked by the mobile electron carriers coenzyme Q and cytochrome c. The reduced forms of nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide (FADH<SUB>2</SUB>) are formed from the citric acid cycle and the beta-oxidation of fatty acids in the mitochondrial matrix. The respiratory chain transfers electrons from NADH (via complex I) and from reduced flavoproteins (via complex II and electron transfer flavoprotein-coenzyme Q oxidoreductase [ETF-Qo]) to coenzyme Q, then complex III, cytochrome c and finally complex IV. At the same time, complexes I, III, and IV pump electrons across the inner mitochondrial membrane from the matrix to the intermembrane space. The influx of these electrons (protons) back into the mitochondrial matrix releases energy that is used in the phosphorylation of ADP to ATP by complex V (ATP synthetase), which is also embedded in the inner mitochondrial membrane.</div><div id=\"graphicVersion\">Graphic 67253 Version 10.0</div></div></div>"},"67254":{"type":"graphic_table","displayName":"Treatment of painful diabetic neuropathy","title":"Treatment options for painful diabetic neuropathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment options for painful diabetic neuropathy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Antidepressants</td> </tr> <tr> <td class=\"subtitle2_single\">Tricyclics</td> </tr> <tr> <td class=\"indent1\">Amitriptyline 25 to 100 mg at night</td> </tr> <tr> <td class=\"indent1\">Nortriptyline 25 to 100 mg at night</td> </tr> <tr> <td class=\"indent1\">Doxepin 25 to 100 mg at night</td> </tr> <tr> <td class=\"subtitle2_single\">Others</td> </tr> <tr> <td class=\"indent1\">Duloxetine 60 to 120 mg daily</td> </tr> <tr> <td class=\"indent1\">Venlafaxine 75 to 225 mg daily</td> </tr> <tr> <td class=\"subtitle1_single\">Anticonvulsants</td> </tr> <tr> <td>Pregabalin 300 to 600 mg daily</td> </tr> <tr> <td>Sodium valproate 500 to 1200 mg daily</td> </tr> <tr> <td class=\"subtitle1_single\">Others</td> </tr> <tr> <td>Capsaicin topical cream 0.075 percent</td> </tr> <tr> <td>Lidocaine patch</td> </tr> <tr> <td>Alpha-lipoic acid 600 mg once daily</td> </tr> <tr> <td>Isosorbide dinitrate spray</td> </tr> <tr> <td>Transcutaneous electrical nerve stimulation (TENS)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 67254 Version 5.0</div></div></div>"},"67255":{"type":"graphic_waveform","displayName":"Intermediate case 5 with answer","title":"Subendocardial ischemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Subendocardial ischemia</div><div class=\"cntnt\"><img style=\"width:422px; height:127px;\" src=\"images/CARD/67255_Intermediate_case_5_with_an.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sinus tachycardia with marked (5 mm) ST depression that is horizontal or downsloping. This finding is consistent with severe subendocardial ischemia.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 67255 Version 2.0</div></div></div>"},"67256":{"type":"graphic_figure","displayName":"Relationship of development to stem cell type","title":"Relationship of development to stem cell type","html":"<div class=\"graphic\"><div style=\"width: 608px\" class=\"figure\"><div class=\"ttl\">Relationship of development to stem cell type</div><div class=\"cntnt\"><img style=\"width:588px; height:294px;\" src=\"images/PC/67256_Rel_dev_stem_type.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Types of stem cells and their relationship to normal development. Totipotent stem cells are thought to exist only in the first several divisions of the zygote. Stem cells become more restricted as pluripotent cells once the blastocyst is formed. By the time the primitive streak forms, most cell types in the organism become further restricted to multipotent status, with the exception of embryonic germ cell lines. The cells derived from these later stages in development have been called &quot;embryonic&quot; or &quot;adult&quot; stem cells, to reflect their different potency as stem cells. The unilinear relationship of development to stem cell potential that is depicted here is no longer a rigid dictate as it appears that highly differentiated cells can be reprogrammed to become pluripotent cells.</div><div class=\"graphic_reference\">Redrawn based on information from The National Institutes of Health.</div><div id=\"graphicVersion\">Graphic 67256 Version 1.0</div></div></div>"},"67257":{"type":"graphic_table","displayName":"Drug induced diabetes","title":"Drugs that can impair glucose tolerance or cause overt diabetes mellitus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs that can impair glucose tolerance or cause overt diabetes mellitus</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Category</td> <td class=\"subtitle1\">Agents</td> <td class=\"subtitle1\">Mechanism*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Anti-infectives</td> </tr> <tr> <td class=\"indent1\">Fluoroquinolones</td> <td>Gatifloxacin<sup>&#182;</sup> (not available in United States), moxifloxacin</td> <td>Altered insulin secretion. Association with moxifloxacin is rare.</td> </tr> <tr> <td class=\"indent1\">HIV antiretrovirals</td> <td> <p>Protease inhibitors</p> Nucleoside reverse transcriptase inhibitors (NRTIs)</td> <td>Increased peripheral insulin resistance. Part of antiretroviral associated metabolic syndrome.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Other anti-infectives</td> <td>Pentamidine</td> <td>Altered pancreatic beta cell function. Following initial hypoglycemic effect, beta cell destruction can occur.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Antipsychotics</td> </tr> <tr> <td class=\"indent1\">1st generation</td> <td>Chlorpromazine<sup>&#182;</sup>, perphenazine, other phenothiazines</td> <td>Mechanism not established. Appears to involve increased insulin resistance and diminished insulin secretion.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">2nd generation</td> <td>Clozapine<sup>&#182;</sup>, iloperidone, olanzapine<sup>&#182;</sup>, paliperidone, quetiapine, risperidone</td> <td>Mechanism not established. Appears to involve increased insulin resistance and diminished insulin secretion.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Cardiovascular</td> </tr> <tr> <td class=\"indent1\">Beta-blockers</td> <td>Atenolol, metoprolol, propranolol<sup>[1]</sup></td> <td> <p>Decreased insulin sensitivity (moderate effect).</p> <p>Carvedilol does not appear to impair glucose tolerance.</p> Refer to UpToDate topic on treatment of hypertension in patients with diabetes mellitus.</td> </tr> <tr> <td class=\"indent1\">Hypolipidemic</td> <td>Niacin (nicotinic acid)<sup>&#182;</sup>, statins</td> <td> <p>Niacin: Altered hepatic glucose metabolism, probably greater with extended release form.</p> Statins: Evidence of impaired glucose tolerance due to statins is conflicting and overall risk appears low.</td> </tr> <tr> <td class=\"indent1\">Thiazide diuretics</td> <td>Hydrochlorothiazide, chlorthalidone, chlorothiazide, indapamide</td> <td> <p>Reduced total-body potassium, decreased insulin secretion and increased insulin resistance<sup>[2]</sup>.</p> <p>Infrequent with low dosages (ie, hydrochlorothiazide &#8804;25 mg or equivalent).</p> Potassium supplementation may decrease thiazide-associated glucose intolerance.</td> </tr> <tr> <td class=\"indent1\">Vasodilators</td> <td>Diazoxide</td> <td>Reduced insulin secretion and sensitivity, increased hepatic glucose production.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vasopressors</td> <td>Epinephrine<sup>&#182;</sup>, norepinephrine<sup>[3]</sup></td> <td>Activation of glycogenolysis, increased hepatic gluconeogenesis, stimulation of glucagon and cortisol, inhibition of insulin secretion.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Gonadotropin-releasing hormone agonists</strong></td> <td>Class effect in men receiving androgen deprivation therapy for metastatic prostate cancer</td> <td>Refer to UpToDate topic on side effects of androgen deprivation therapy.</td> </tr> <tr class=\"divider_bottom\"> <td> <p><strong>Glucocorticoids, systemic</strong>*</p> <p class=\"indent1\">NOTE: Glucocorticoids are a particularly common cause of clinically significant drug-induced hyperglycemia</p> </td> <td>Class effect</td> <td> <p>Multifactorial, including increased hepatic glucose production, increased insulin resistance, increased expression of peroxisome proliferator activated gamma receptors (PPAR-gamma).</p> Refer to UpToDate topic on major side effects of systemic glucocorticoids.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Hormones, sex</td> </tr> <tr> <td class=\"indent1\">Oral contraceptives</td> <td>Combination estrogen-progestogen oral contraceptives, progestin only contraceptives</td> <td class=\"divider_bottom\" rowspan=\"2\"> <p>Altered hepatic glucose metabolism, increased peripheral insulin resistance.</p> <p>Low-dose pills (&#8804;35 mcg ethinyl estradiol) have little effect on carbohydrate metabolism in most women.</p> Refer to UpToDate topics on pregnancy evaluation and management of women with diabetes mellitus.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Progestin</td> <td>Megestrol acetate</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Hormones, growth</strong></td> <td>Somatropin, tesamorelin</td> <td> <p>Increased counter-regulatory responses.</p> Refer to UpToDate topics on treatment of growth hormone deficiency and treatment of HIV-associated lipodystrophy.</td> </tr> <tr> <td><strong>Immunosuppressants</strong></td> <td>Cyclosporine (ciclosporin), sirolimus, tacrolimus</td> <td> <p>Decreased insulin synthesis and release.</p> Refer to UpToDate topic on new onset diabetes after transplant in renal transplant recipients.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus.<br />* Degree or incidence of hyperglycemia is generally related to dose.<br />&para; Among agents listed, these have been more frequently associated with hyperglycemia and/or diabetes mellitus.</div><div class=\"graphic_reference\">Compiled with data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Sarafidis PA, Bakris GL. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. Q J Med 2006; 99:431.</li>&#xD;&#xA;    <li>Luna B, Feinglos MN. Drug-induced hyperglycemia. JAMA 2001; 286:1945.</li>&#xD;&#xA;    <li>Thomas Z, Bandali F, McCowen K, et al. Drug induced endocrine disorders in the intensive care unit. Crit Care Med 2010; 38:S219.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 67257 Version 9.0</div></div></div>"},"67258":{"type":"graphic_diagnosticimage","displayName":"Divertic obstruct Hypaque enema","title":"Diverticular obstruction on hypaque enema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diverticular obstruction on hypaque enema</div><div class=\"cntnt\"><img style=\"width:376px; height:289px;\" src=\"images/GAST/67258_Divertic_obstruct_Hypaque_e.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A hypaque enema in a 74-year-old woman with bloating and ribbon-like stools for several years reveals a persistent area of narrowing (arrow) in the mid-sigmoid colon measuring 2 cm in length. It is not possible to distinguish between a diverticular stricture and carcinoma radiographically; resection of the affected segment is mandatory.</div><div id=\"graphicVersion\">Graphic 67258 Version 2.0</div></div></div>"},"67260":{"type":"graphic_table","displayName":"Risk score CML transplantation","title":"European Group for Blood and Marrow Transplantation risk assessment score for allogeneic transplantation in chronic myeloid leukemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">European Group for Blood and Marrow Transplantation risk assessment score for allogeneic transplantation in chronic myeloid leukemia</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  colspan=\"1\" class=\"subtitle1\">Item</td>\n   <td  class=\"subtitle1\">Category</td>\n   <td  class=\"subtitle1\">Score</td>\n   </tr>\n\n   <tr>\n   <td rowspan=\"2\">Donor</td>\n   <td>HLA Identical sibling donor</td>\n   <td>0</td>\n   </tr>\n\n   <tr>\n   <td>Matched unrelated donor</td>\n   <td>1</td>\n   </tr>\n\n   <tr>\n   <td rowspan=\"3\">Stage</td>\n   <td>First chronic phase</td>\n   <td>0</td>\n   </tr>\n\n   <tr>\n   <td>Accelerated phase</td>\n   <td>1</td>\n   </tr>\n\n   <tr>\n   <td>Blast crisis or &#8805;2nd chronic phase</td>\n   <td>2</td>\n   </tr>\n\n   <tr>\n   <td rowspan=\"3\">Age</td>\n   <td>&#60;20 years</td>\n   <td>0</td>\n   </tr>\n\n   <tr>\n   <td>20 to 40 years</td>\n   <td>1</td>\n   </tr>\n\n   <tr>\n   <td>&#62;40 years</td>\n   <td>2</td>\n   </tr>\n\n   <tr>\n   <td rowspan=\"2\">Sex matching (donor/recipient)</td>\n   <td>All other matches</td>\n   <td>0</td>\n   </tr>\n\n   <tr>\n   <td>Female donor, male recipient</td>\n   <td>1</td>\n   </tr>\n\n   <tr>\n   <td rowspan=\"2\">Time to HCT from diagnosis</td>\n   <td>&#60;12 months</td>\n   <td>0</td>\n   </tr>\n\n   <tr>\n   <td>&#62;12 months</td>\n   <td>1</td>\n   </tr>\n\n   <tr>\n   <td  class=\"subtitle1\">Score</td>\n   <td  class=\"subtitle1\">Treatment-related mortality (%)</td>\n   <td  class=\"subtitle1\">5-year Overall Survival (%)</td>\n   </tr>\n\n   <tr>\n   <td>0</td>\n   <td>20</td>\n   <td>72</td>\n   </tr>\n\n   <tr>\n   <td>1</td>\n   <td>23</td>\n   <td>70</td>\n   </tr>\n\n   <tr>\n   <td>2</td>\n   <td>31</td>\n   <td>62</td>\n   </tr>\n\n   <tr>\n   <td>3</td>\n   <td>46</td>\n   <td>48</td>\n   </tr>\n\n   <tr>\n   <td>4</td>\n   <td>51</td>\n   <td>40</td>\n   </tr>\n\n   <tr>\n   <td>5</td>\n   <td>71</td>\n   <td>18</td>\n   </tr>\n\n   <tr>\n   <td>6</td>\n   <td>73</td>\n   <td>22</td>\n   </tr>\n\n   <tr>\n   <td>7</td>\n   <td>-</td>\n   <td>-</td>\n   </tr>\n\n </table></div><div class=\"graphic_lgnd\">Scoring: Scoring is from zero to a maximum of seven, with points scored for each of the five risk categories, as shown in the upper table. Treatment-related mortality and five-year overall survivals as a function of the score are shown in the lower table. There were too few patients with a score of seven to adequately assess TRM and OS.</div><div class=\"graphic_footnotes\">EGBMT: European Group for Blood and Marrow Transplantation; CML: chronic myelogenous leukemia; HCT: hematopoietic cell transplantation; %: percent.</div><div class=\"graphic_reference\">Data from: Gratwohl, A, et al. Lancet 1998; 352:1087.</div><div id=\"graphicVersion\">Graphic 67260 Version 2.0</div></div></div>"},"67262":{"type":"graphic_figure","displayName":"Anatomic features Amanita species","title":"Anatomic features of a juvenile and mature Amanita species mushroom","html":"<div class=\"graphic\"><div style=\"width: 493px\" class=\"figure\"><div class=\"ttl\">Anatomic features of a juvenile and mature Amanita species mushroom</div><div class=\"cntnt\"><img style=\"width:473px; height:372px;\" src=\"images/EM/67262_Anat_feats_Amanita_species.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anatomical development of a &quot;toadstool&quot;-type mushroom (Amanita species).<br> (A) Juvenile mushroom &quot;button.&quot;<br> (B) Mature mushroom &quot;toadstool.&quot;</div><div class=\"graphic_reference\">Reproduced with permission from: Diaz JH. Evolving global epidemiology, syndromic classification, general management, and prevention of unknown mushroom poisonings. Crit Care Med 2005; 33:419. Copyright © 2005 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 67262 Version 5.0</div></div></div>"},"67263":{"type":"graphic_figure","displayName":"TG LDL HDL and coronary risk","title":"Hypertriglyceridemia as a risk factor for coronary heart disease","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Hypertriglyceridemia as a risk factor for coronary heart disease</div><div class=\"cntnt\"><img style=\"width:524px; height:301px;\" src=\"images/CARD/67263_TG_LDL_HDL_and_coronary_ris.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Data from the Helsinki Heart Study, a randomized primary prevention trial in dyslipidemic men, showing the incidence of coronary events at five years according to the baseline serum triglyceride concentration and the LDL-to-HDL cholesterol ratio. The risk was markedly increased in patients with both a triglyceride concentration above 2.3 mmol/L [200 mg/dL]) and an elevated LDL-to-HDL ratio. A beneficial effect of gemfibrozil to lower the incidence of coronary events was limited to this group.</div><div class=\"graphic_reference\">Data from Manninen, V, Tenkanen, L, Koskinen, P, et al, Circulation 1992; 85:37.</div><div id=\"graphicVersion\">Graphic 67263 Version 1.0</div></div></div>"},"67264":{"type":"graphic_table","displayName":"Criteria for protein-energy wasting","title":"Criteria for diagnosis of kidney disease-related protein-energy wasting","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for diagnosis of kidney disease-related protein-energy wasting</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Criteria</td> </tr> <tr> <td class=\"subtitle2_single\">Serum chemistry</td> </tr> <tr> <td class=\"indent1\">Serum albumin &#60;3.8 g/dL (bromocresol green)*</td> </tr> <tr> <td class=\"indent1\">Serum prealbumin (transthyretin) &#60;30 mg/dL (for maintenance dialysis patients only; levels may vary according to GFR level for patients on CKD stages 2 to 5)*</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Serum cholesterol &#60;100 mg/dL*</td> </tr> <tr> <td class=\"subtitle2_single\">Body mass</td> </tr> <tr> <td class=\"indent1\">BMI &#60;23 kg/m<sup>2</sup><sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Unintentional weight loss over time: 5% over three months or 10% over six months</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Total body fat percentage &#60;10%</td> </tr> <tr> <td class=\"subtitle2_single\">Muscle mass</td> </tr> <tr> <td class=\"indent1\">Muscle wasting: reduced muscle mass 5% over three months or 10% over six months</td> </tr> <tr> <td class=\"indent1\">Reduced mid-arm muscle circumference area<sup>&#916;</sup> (reduction &#62;10% in relation to 50<sup>th</sup> percentile of reference population)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Creatinine appearance<sup>&#9674;</sup></td> </tr> <tr> <td class=\"subtitle2_single\">Dietary intake</td> </tr> <tr> <td class=\"indent1\">Unintentional low-dietary protein intake &#60;0.8 g/kg/day for at least two months<sup>&#167;</sup> for dialysis patients or &#60;0.6 g/kg/day for patients on CKD stages 2 to 5</td> </tr> <tr> <td class=\"indent1\">Unintentional low-dietary energy intake &#60;25 kcal/kg/day for at least two months<sup>&#167;</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">At least three out of the four listed categories (and at least one test in each of the selected categories) must be satisfied for the diagnosis of kidney disease-related PEW. Optimally, each criterion should be documented on at least three occasions, preferably two to three weeks apart.</div><div class=\"graphic_footnotes\">GFR: glomerular filtration rate; CKD: chronic kidney disease; BMI: body mass index; PEW: protein-energy wasting.<br />* Not valid if low concentrations are due to abnormally great urinary or gastrointestinal protein losses, to liver disease, or to cholesterol-lowering medicines.<br />¶ A lower BMI might be desirable for certain Asian populations; weight must be edema-free mass, for example, postdialysis dry weight. Refer to UpToDate topic on assessment of nutritional status in dialysis patients for the discussion about the BMI of the healthy population.<br />Δ Measurement must be performed by a trained anthropometrist.<br /><FONT class=lozenge>◊</FONT> Creatinine appearance is influenced by both muscle mass and meat intake.<br />§ Can be assessed by dietary diaries and interviews, or for protein intake by calculation of normalized protein equivalent of total nitrogen appearance (normalized protein nitrogen appearance or normalized protein catabolid rate) as determined by urea kinetic measurements.</div><div class=\"graphic_reference\">Reprinted by permission from: Macmillan Publishers Ltd: Fouque D, Pelletier S, Mafra D, Chauveau P. Nutrition and chronic kidney disease. Kidney Int 2011; 80:348. Copyright &copy; 2011.</div><div id=\"graphicVersion\">Graphic 67264 Version 7.0</div></div></div>"},"67265":{"type":"graphic_picture","displayName":"Paraneoplastic pemphigus bullae","title":"Paraneoplastic pemphigus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Paraneoplastic pemphigus</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/67265_Paraneopemphibulla.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vesicles and flaccid bullae are present on the skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 67265 Version 5.0</div></div></div>"},"67266":{"type":"graphic_figure","displayName":"Proximal tibia intraosseous site","title":"Proximal tibial intraosseous access site","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Proximal tibial intraosseous access site</div><div class=\"cntnt\"><img style=\"width:510px; height:459px;\" src=\"images/EM/67266_ProximaltibiaIOsite.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Entry site at the proximal tibia.</div><div class=\"graphic_reference\">Reproduced with permission from: Hodge Dee III. Intraosseous infusion. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 67266 Version 11.0</div></div></div>"},"67272":{"type":"graphic_figure","displayName":"Notched tongue","title":"Notched tongue","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Notched tongue</div><div class=\"cntnt\"><img style=\"width:524px; height:586px;\" src=\"images/PEDS/67272_Notched-tongue.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Notched or heart shape of the tongue when it is protruded.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 67272 Version 3.0</div></div></div>"},"67274":{"type":"graphic_waveform","displayName":"Intraventricular conduction delay","title":"Intraventricular conduction delay","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Intraventricular conduction delay</div><div class=\"cntnt\"><img style=\"width:535px; height:225px;\" src=\"images/CARD/67274_Intraventric_delay_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The QRS duration is &gt;0.10 seconds, but the QRS morphology does not resemble a left or right bundle branch block.</div><div id=\"graphicVersion\">Graphic 67274 Version 3.0</div></div></div>"},"67277":{"type":"graphic_table","displayName":"Oral antibiotics used in exit-site and tunnel infection","title":"Dosing (adult) of oral antibiotics used in peritoneal catheter exit-site and tunnel infections","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dosing (adult) of oral antibiotics used in peritoneal catheter exit-site and tunnel infections</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Amoxicillin</td> <td>250 to 500 mg two times per day</td> </tr> <tr> <td>Cephalexin</td> <td>500 mg two to three times per day</td> </tr> <tr> <td>Ciprofloxacin*</td> <td>250 to 500 mg two times per day<sup>&#182;</sup></td> </tr> <tr> <td>Clarithromycin</td> <td>500 mg loading dose, then 250 mg once or two times per day</td> </tr> <tr> <td>Clindamycin</td> <td>300 to 450 mg three to four times per day</td> </tr> <tr> <td>Dicloxacillin</td> <td>500 mg four times per day</td> </tr> <tr> <td>Erythromycin</td> <td>500 mg four times per day</td> </tr> <tr> <td>Flucloxacillin (or cloxacillin)</td> <td>500 mg four times per day</td> </tr> <tr> <td>Fluconazole</td> <td>200 mg once per day for&nbsp;two days, then 100 mg once per day</td> </tr> <tr> <td>Flucytosine</td> <td>0.5 to 1 g/day titrated to response and serum trough levels (25 to 50 mcg/mL)</td> </tr> <tr> <td>Isoniazid</td> <td>200 to 300 mg once per day</td> </tr> <tr> <td>Linezolid</td> <td>400 to 600 mg two times per day</td> </tr> <tr> <td>Metronidazole</td> <td>400 mg three times per day</td> </tr> <tr> <td>Moxifloxacin*</td> <td>400 mg once per day</td> </tr> <tr> <td>Ofloxacin*</td> <td>400 mg first day, then 200 mg once per day</td> </tr> <tr> <td>Pyrazinamide</td> <td>25 to 35 mg/kg up to 3 g per dose three times per week</td> </tr> <tr> <td>Rifampin (rifampicin)<sup>&#916;</sup></td> <td> <p>Patients weighing less than 50 kg: 450 mg once per day</p> Patients weighing greater than or equal to 50 kg: 600 mg once per day</td> </tr> <tr> <td>Trimethoprim-sulfamethoxazole (co-trimoxazole)</td> <td>80 to 400 mg (one single-strength tablet) once per day</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Slowly resolving or recurrent <EM>Pseudomonas</EM> exit-site infections should be treated with a second antipseudomonal drug. Refer to UpToDate topics on tunnel and peritoneal catheter exit site infections in continuous peritoneal dialysis.<br />¶ The preferred dose for ciprofloxacin is 250 mg two times per day. 500 mg two times per day may be used for patients who have significant residual renal function or are very large.<br />Δ Rifampin (rifampicin) is reserved for combination treatment with an oral penicillin or first-generation cephalosporin for slowly resolving and severe <EM>Staphylococcus aureus</EM> exit-site infections. Due to rapid emergence of resistance, rifampin is not appropriate for use as a single agent.</div><div class=\"graphic_reference\">Adapted with permission from: Li PK, Szeto CC, Piraino B, et al. Peritoneal Dialysis-Related Infections Recommendations: 2010 Update. Perit Dial Int 2010; 30:393. Published in Peritoneal Dialysis International. Copyright © 2010.</div><div id=\"graphicVersion\">Graphic 67277 Version 7.0</div></div></div>"},"67278":{"type":"graphic_figure","displayName":"Tilt test in syncope","title":"Determinants of tilt table positivity in syncope","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Determinants of tilt table positivity in syncope</div><div class=\"cntnt\"><img style=\"width:430px; height:600px;\" src=\"images/CARD/67278_Tilt_test_in_syncope.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The results of the tilt table test are dependent upon the clinical characteristics of the patient being studied. Of importance are age (greater or less than 50), presence of structural heart disease (SHD) or noncardiovascular abnormality that might result in sudden diminished consciousness (SDC), or a single syncopal episode or single or multiple episodes of presyncope without loss of consciousness (&lt;2 syncope). As an example, the tilt test was negative in all patients under age 50 who had SHD or SDC and less than two syncopal episodes (top row).</div><div class=\"graphic_reference\">Data from Fitzpatrick, AP, Lee, RJ, Epstein, LM, et al, Heart 1996; 76:406.</div><div id=\"graphicVersion\">Graphic 67278 Version 1.0</div></div></div>"},"67279":{"type":"graphic_figure","displayName":"Endocrine glands PI","title":"Endocrine glands","html":"<div class=\"graphic\"><div style=\"width: 495px\" class=\"figure\"><div class=\"ttl\">Endocrine glands</div><div class=\"cntnt\"><img style=\"width:475px; height:556px;\" src=\"images/PI/67279_Endocrine_glands_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing shows the location of the adrenal glands, hypothalamus, and pituitary gland. These are all part of the body's \"endocrine system.\"</div><div id=\"graphicVersion\">Graphic 67279 Version 5.0</div></div></div>"},"67280":{"type":"graphic_table","displayName":"Specimen collection methods III","title":"Microbiology specimen handling and collection - III","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Microbiology specimen handling and collection - III</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Specimen</td> <td class=\"subtitle1\">Method</td> <td class=\"subtitle1\">Volume</td> <td class=\"subtitle1\">Storage temperature*</td> <td class=\"subtitle1\">Comments</td> <td class=\"subtitle1\">Refer to UpToDate topic review</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Lower respiratory</td> </tr> <tr> <td class=\"indent1\">Expectorated sputum</td> <td>Sterile container</td> <td>&nbsp;</td> <td>25&#176;C</td> <td>Rinse mouth first, use Gram stain to screen for suitability</td> <td>Sputum cultures</td> </tr> <tr> <td class=\"indent1\">Bronchoscopy fluid</td> <td>Sterile container</td> <td>&nbsp;</td> <td>25&#176;C</td> <td>&nbsp;</td> <td>Sputum cultures</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Upper respiratory</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Nasal</td> <td>Insert premoistened swab into nares</td> <td rowspan=\"2\">&nbsp;</td> <td rowspan=\"2\">25&#176;C</td> <td rowspan=\"2\">For detection of nasal carriage of&nbsp;<em><span class=\"st\">Staphylococcus</span> aureus</em> or group A streptococci only</td> <td rowspan=\"2\">&nbsp;</td> </tr> <tr> <td>Place into transport media</td> </tr> <tr> <td class=\"indent1\">Nasopharynx</td> <td>Insert swab into posterior nasopharynx via nose, inoculate medium at bedside or transport swab</td> <td>&nbsp;</td> <td>25&#176;C</td> <td> <p>Use swab and transport device compatible with the test used.</p> <p>For culture: Routine swabs may not support growth of some organisms (eg, <em><span class=\"st\">Bordetella</span> pertussis</em>); use calcium alginate or dacron/rayon swab</p> <p>For nucleic acid amplification testing (polymerase chain reaction&nbsp;and other): do NOT use calcium alginate swab</p> </td> <td>Routine swabs</td> </tr> <tr> <td class=\"indent1\">Throat</td> <td>Swab posterior pharynx and tonsils</td> <td>&nbsp;</td> <td>25&#176;C</td> <td>Inform laboratory if identification of organisms other than group A beta-hemolytic streptococci is indicated (eg,&nbsp;<em><span class=\"st\">Neisseria</span> gonorrhoeae</em>)</td> <td>Throat cultures</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Stool</td> </tr> <tr> <td class=\"indent1\">Routine culture</td> <td>Sterile wide-mouth container or enteric transport system</td> <td>&#62;2 grams</td> <td>4&#176;C (25&#176;C if enteric transport system used)</td> <td>Do not send specimens for routine culture on patients who develop diarrhea after&nbsp;three days of hospitalization; only send for <em>Clostridium difficile</em> toxin</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Multiplex molecular testing</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Use manufacturer's recommended transport media</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\"><em>Clostridium difficile</em> toxin</td> <td>Sterile wide-mouth container</td> <td>&#62;5 mL (soft or liquid)</td> <td>4&#176;C for &#8804;24h, -20&#176;C for &#62;24h</td> <td>Test of choice for patients who develop diarrhea after&nbsp;three days of hospitalization</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Ova and parasite examination</td> <td>Sterile wide-mouth container or commercial transport system</td> <td>&nbsp;</td> <td>25&#176;C in fixative</td> <td>Fresh specimens should be examined immediately; do not send specimens on inpatients who develop diarrhea after&nbsp;three days of hospitalization</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* If immediate processing is not possible.</div><div id=\"graphicVersion\">Graphic 67280 Version 3.0</div></div></div>"},"67281":{"type":"graphic_movie","displayName":"Aortic valve bioprosthesis short axis echocardiogram","title":"Bioprosthetic aortic valve","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bioprosthetic aortic valve</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/67281_shaxbiavconv.mp4\" style=\"width:312px;height:224px\"></div><img style=\"width:269px; height:204px;\" src=\"images/CARD/67281_shaxbiav.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The short axis view from a 2-D echocardiogram shows a bioprosthetic valve in the aortic position. The sewing ring of the valve can be seen within the aortic root.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 67281 Version 2.0</div></div></div>"},"67283":{"type":"graphic_picture","displayName":"VIN histology","title":"Vulvar intraepithelial neoplasia histology","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vulvar intraepithelial neoplasia histology</div><div class=\"cntnt\"><img style=\"width:395px; height:690px;\" src=\"images/OBGYN/67283_VIN_histology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">2004 International Society for the Study of Vulvar Diseases (ISSVD) modified terminology for vulvar intraepithelial neoplasia (VIN): the term VIN applies only to histologically high grade squamous lesions (former terms, VIN 2 and VIN 3 and differentiated VIN 3).</div><div id=\"graphicVersion\">Graphic 67283 Version 3.0</div></div></div>"},"67285":{"type":"graphic_figure","displayName":"Confidentiality agreement","title":"Confidentiality agreement for adolescent health care","html":"<div class=\"graphic\"><div style=\"width: 629px\" class=\"figure\"><div class=\"ttl\">Confidentiality agreement for adolescent health care</div><div class=\"cntnt\"><img style=\"width:609px; height:430px;\" src=\"images/PEDS/67285_Confidentiality_agreement.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Confidentiality in adolescent health care. ACOG educational bulletin #249. Int J Gynecol Obstet 1998; 63:295. Copyright &#169;1998 Elsevier.</div><div id=\"graphicVersion\">Graphic 67285 Version 2.0</div></div></div>"},"67287":{"type":"graphic_figure","displayName":"Uterine descent","title":"Uterine prolapse","html":"<div class=\"graphic\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">Uterine prolapse</div><div class=\"cntnt\"><img style=\"width:492px; height:410px;\" src=\"images/OBGYN/67287_Uterine_descent.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Prolapse of the Uterus Prolapse of the uterus results from weakness of the supporting structures of the pelvic floor, and is often associated with a cystocele and rectocele. In progressive stages, the uterus becomes retroverted and descends down the vaginal canal to the outside. In first-degree prolapse, the cervix is still well within the vagina. In second-degree prolapse, it is at the introitus. In third-degree prolapse (procidentia), the cervix and vagina are outside the introitus.</div><div class=\"graphic_reference\">Reproduced with permission from: Bickley, LS, Szilagyi, P. Bates' Guide to Physical Examination and History Taking, Eighth Edition. Philadelphia: Lippincott Williams &amp; Wilkins 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 67287 Version 3.0</div></div></div>"},"67291":{"type":"graphic_figure","displayName":"Spermatocele","title":"Spermatocele","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Spermatocele</div><div class=\"cntnt\"><img style=\"width:329px; height:349px;\" src=\"images/PEDS/67291_Spermatocele.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A spermatocele epididymal cyst is a painless, fluid-filled cyst of the epididymis. It can be palpated as distinct from the testis and typically transilluminates as a cystic mass.</div><div id=\"graphicVersion\">Graphic 67291 Version 1.0</div></div></div>"},"67292":{"type":"graphic_diagnosticimage","displayName":"Congen pulm airways malform CT II","title":"Congenital pulmonary airways malformation of the right upper lobe in a 19-year-old patient with pneumonia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Congenital pulmonary airways malformation of the right upper lobe in a 19-year-old patient with pneumonia</div><div class=\"cntnt\"><img style=\"width:372px; height:226px;\" src=\"images/PULM/67292_Adenomatoid_malform_CT_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple small cysts are present in the axillary region of the right upper lobe. The gas-liquid interface is evidence for superimposed recent infection of&nbsp;congenital pulmonary airways&nbsp;malformation.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 67292 Version 3.0</div></div></div>"},"67293":{"type":"graphic_figure","displayName":"Effect of PGI2 and NO on PVR","title":"Effects of inhaled prostacyclin and inhaled nitric oxide on pulmonary hemodynamics","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Effects of inhaled prostacyclin and inhaled nitric oxide on pulmonary hemodynamics</div><div class=\"cntnt\"><img style=\"width:413px; height:224px;\" src=\"images/PULM/67293_Effect_of_PGI2_and_NO_on_PV.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The approximately equivalent efficacy of inhaled prostacyclin (PGI2) and inhaled nitric oxide (NO) was demonstrated in eight patients with severe ARDS who were treated sequentially with both agents.</div><div class=\"graphic_reference\">Redrawn from Zwissler, B, Kemming, G, Habler, O, et al, Am J Respir Crit Care Med 1996; 154:1671.</div><div id=\"graphicVersion\">Graphic 67293 Version 1.0</div></div></div>"},"67294":{"type":"graphic_table","displayName":"Laboratory findings in hypothermia","title":"Laboratory findings in hypothermia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laboratory findings in hypothermia</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td>Arterial blood gas</td>\r\n  \r\n   <td>Metabolic acidosis, respiratory alkalosis, or both</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Electrolytes</td>\r\n  \r\n   <td>No consistent abnormality</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Glucose</td>\r\n  \r\n   <td>Increased, decreased, or no change</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>White blood cell and platelets counts</td>\r\n  \r\n   <td>Decreased due to splenic sequestration</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Hemoglobin, hematocrit</td>\r\n  \r\n   <td>Increased due to hemoconcentration</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Lipase</td>\r\n  \r\n   <td>May be increased due to hypothermia-induced pancreatitis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Prothrombin and partial thromboplastin times</td>\r\n  \r\n   <td>Increased in vivo due to inhibition of coagulation cascade, despite normal reported values</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  colspan=\"1\" rowspan=\"4\">\r\n  \r\n   Electrocardiogram\r\n  \r\n   </td>\r\n  \r\n   <td>Prolongation of PR, QRS, QT intervals</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>ST segment elevation</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1_start\">\r\n  \r\n   T wave inversions; Osborn J wave\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"sublist1\">\r\n  \r\n   Atrial fibrillation or sinus bradycardia\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Chest radiograph</td>\r\n  \r\n   <td>Aspiration pneumonia, vascular congestion, pulmonary edema</td>\r\n  \r\n   </tr>\r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">14.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=65903&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Lab_findings_in_hypothermia.htm</title></head></div><div class=\"graphic_reference\">Redrawn from: Mechem CC. Hypothermia and hyperthermia. In: The Intensive Care Unit Manual, Lanken PN, Manaker S, Hanson CW III (Eds), WB Saunders, Philadelphia 2000. p.627.</div><div id=\"graphicVersion\">Graphic 67294 Version 4.0</div></div></div>"},"67295":{"type":"graphic_figure","displayName":"Pertussis by age group US","title":"Reported pertussis incidence by age group: 1990-2013","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Reported pertussis incidence by age group: 1990-2013</div><div class=\"cntnt\"><img style=\"width:543px; height:421px;\" src=\"images/ID/67295_Pertussis_age_group_US.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention, National Notifiable Diseases Surveillance System, 2013. Available at <a href=\"http://www.cdc.gov/pertussis/surv-reporting.html\" style=\"font-style: italic;\" target=\"_blank\">www.cdc.gov/pertussis/surv-reporting.html</a> (Accessed on October 24, 2014).</div><div id=\"graphicVersion\">Graphic 67295 Version 6.0</div></div></div>"},"67296":{"type":"graphic_diagnosticimage","displayName":"Computed tomography - Tuberculous lymphadenopathy","title":"Computed tomography (CT) - Tuberculous lymphadenopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computed tomography (CT) - Tuberculous lymphadenopathy</div><div class=\"cntnt\"><img style=\"width:449px; height:316px;\" src=\"images/ID/67296_TBlymphadenopathyHIV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan of neck showing large right supraclavicular node with central hypodensity and rim contrast enhancement (arrow).</div><div class=\"graphic_reference\">Courtesy of Gary Maartens, MBChB, MMed.</div><div id=\"graphicVersion\">Graphic 67296 Version 6.0</div></div></div>"},"67297":{"type":"graphic_figure","displayName":"Effect of weight on serum etonogestrel levels","title":"Effect of weight on serum etonogestrel levels","html":"<div class=\"graphic\"><div style=\"width: 612px\" class=\"figure\"><div class=\"ttl\">Effect of weight on serum etonogestrel levels</div><div class=\"cntnt\"><img style=\"width:592px; height:260px;\" src=\"images/OBGYN/67297_Effect_of_weight_serum.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Etonogestrel concentrations extrapolated to three years.</div><div class=\"graphic_reference\">Data from: Croxatto HB, Makarainen L. The pharmacodynamics and efficacy of Implanon&reg;: An overview of the data. Contraception 1998; 58:91S and Huber J. Pharmacokinetics of Implanon&reg;: An integrated analysis. Contraception 58:85S.</div><div id=\"graphicVersion\">Graphic 67297 Version 4.0</div></div></div>"},"67298":{"type":"graphic_figure","displayName":"Perineal anatomy","title":"Anatomy of the female perineum","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Anatomy of the female perineum</div><div class=\"cntnt\"><img style=\"width:526px; height:412px;\" src=\"images/OBGYN/67298_perineal_anatomy.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 67298 Version 2.0</div></div></div>"},"67299":{"type":"graphic_diagnosticimage","displayName":"Axial CT six months","title":"Axial CT six months","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Axial CT six months</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/ONC/67299_Axial_CT_six_months.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 77-year-old woman with biopsy-proven 1.8 cm left lower lobe adenocarcinoma (stage IA NSCLC) who was not considered a surgical candidate due to chronic obstructive pulmonary disease and cardiac risk factors. Contrast-enhanced axial CT at six-months. The area treated has decreased in size without evidence of enhancement (arrow), findings consistent with successful tumor ablation. A small calcified granuloma is present anteriorly.</div><div class=\"graphic_footnotes\">NSCLC: non-small cell lung cancer; CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Schirmang, T, MD and Dupuy, D, MD.</div><div id=\"graphicVersion\">Graphic 67299 Version 3.0</div></div></div>"},"67302":{"type":"graphic_picture","displayName":"Sucking blister","title":"Sucking blister","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Sucking blister</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/67302_Sucking_blister.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A blister is present on the thumb of this neonate.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 67302 Version 1.0</div></div></div>"},"67304":{"type":"graphic_picture","displayName":"Dubin Johnson Light","title":"Dubin-Johnson syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dubin-Johnson syndrome</div><div class=\"cntnt\"><img style=\"width:405px; height:252px;\" src=\"images/GAST/67304_Dubin_Johnson_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Cut surface of the liver of a patient with Dubin-Johnson syndrome showing macroscopic pigmentation; (B) Photomicrograph showing pigment granules within hepatocyte cytoplasm.</div><div class=\"graphic_reference\">Courtesy of Ajit Kadakol, MD, Jayanta Roy Chowdhury, MD, MRCP, and Namita Roy Chowdhury, PhD.</div><div id=\"graphicVersion\">Graphic 67304 Version 2.0</div></div></div>"},"67305":{"type":"graphic_table","displayName":"Drugs causing dyspareunia","title":"Medications or other treatments that are associated with dyspareunia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medications or other treatments that are associated with dyspareunia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Tamoxifen - in premenopausal women can&nbsp;have anti-estrogenic&nbsp;effect, causing vaginal dryness, pain&nbsp;with penetration, and issues with arousal; can have estrogenic effect in postmenopausal women, potentially resulting in Candidiasis</td> </tr> <tr> <td>Aromatase inhibitors - anti-estrogenic effect may cause vaginal dryness, pain with penetration, and issues with arousal</td> </tr> <tr> <td>Chemotherapeutic agents - mechanism is unclear, possibly mucosal irritant</td> </tr> <tr> <td>Bromocriptine - may result in loss of libido or may be associated with painful clitoral tumescence</td> </tr> <tr> <td>Immunosuppressants - may result in recurrent Candidiasis</td> </tr> <tr> <td>Antidepressants -&nbsp;may result in&nbsp;loss of libido, issues with arousal or orgasm; anticholinergic medications may result in vaginal dryness&nbsp;</td> </tr> <tr> <td>Antihistamines - may result in vaginal dryness</td> </tr> <tr> <td>Anticholinergics - may result in vaginal dryness</td> </tr> <tr> <td>Antibiotics - may result in Candidiasis</td> </tr> <tr> <td>Antihypertensives - may result in loss of libido or issues with arousal</td> </tr> <tr> <td>Estrogen-progestin contraceptives</td> </tr> <tr> <td>Depot medroxyprogesterone acetate -&nbsp;may result in&nbsp;vaginal dryness or&nbsp;issues with arousal&nbsp;&nbsp;</td> </tr> <tr> <td>Spermicides - may result in contact irritation or allergy</td> </tr> <tr> <td>Douches - may result in contact irritation</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 67305 Version 4.0</div></div></div>"},"67306":{"type":"graphic_diagnosticimage","displayName":"Chest wall extension MRI II","title":"Lung carcinoma with chest wall invasion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lung carcinoma with chest wall invasion</div><div class=\"cntnt\"><img style=\"width:310px; height:299px;\" src=\"images/PULM/67306_Chest_wall_extension_MRI_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal T1-weighted section shows that the large tumor in the previous image is invading the posteroapical chest wall (arrow).</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 67306 Version 2.0</div></div></div>"},"67309":{"type":"graphic_figure","displayName":"Types of lice PI","title":"Types of lice","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Types of lice</div><div class=\"cntnt\"><img style=\"width:267px; height:392px;\" src=\"images/PI/67309_Types_of_lice_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three types of lice can live on or close to people's bodies:<br />(A) Crab lice (also called pubic lice);<br />(B) Head lice;<br />(C) Body lice.</div><div class=\"graphic_reference\">Courtesy of John T Crissey, MD.</div><div id=\"graphicVersion\">Graphic 67309 Version 11.0</div></div></div>"},"67310":{"type":"graphic_figure","displayName":"Transcription","title":"Gene transcription","html":"<div class=\"graphic\"><div style=\"width: 614px\" class=\"figure\"><div class=\"ttl\">Gene transcription</div><div class=\"cntnt\"><img style=\"width:594px; height:709px;\" src=\"images/PC/67310_Transcription_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Genic structure.<br> (B) Transcription.<br> (C) Post-transcriptional modification.</div><div id=\"graphicVersion\">Graphic 67310 Version 3.0</div></div></div>"},"67311":{"type":"graphic_figure","displayName":"Mechanism of a clenched fist injury","title":"Mechanism of a clenched fist injury","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Mechanism of a clenched fist injury</div><div class=\"cntnt\"><img style=\"width:576px; height:352px;\" src=\"images/SURG/67311_Fight_bite.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fight bite injuries to the hand usually occur with the fist in a clenched position. When the fist makes contact with a victim's mouth, the teeth can easily penetrate the skin and extensor tendon that are stretched tightly over the metacarpal head, thus injuring the underlying bone and joint.</div><div id=\"graphicVersion\">Graphic 67311 Version 2.0</div></div></div>"},"67312":{"type":"graphic_diagnosticimage","displayName":"Epiglottitis - Lateral neck radiograph","title":"Epiglottitis: Lateral neck radiograph","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Epiglottitis: Lateral neck radiograph</div><div class=\"cntnt\"><img style=\"width:480px; height:362px;\" src=\"images/PEDS/67312_Epiglottitis_radiograph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A normal epiglottis on a lateral neck radiograph, with the structures illustrated in panel B. Epiglottitis is similarly depicted radiographically (C, D).</div><div class=\"graphic_reference\">Reproduced with permission from: Fleisher GR, Ludwig W, Baskin MN. Atlas of Pediatric Emergency Medicine. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 67312 Version 5.0</div></div></div>"},"67313":{"type":"graphic_table","displayName":"Low-fat low-sugar guide A","title":"Tips for maintaining a healthy weight: Low-fat, low-sugar eating guidelines","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Tips for maintaining a healthy weight: Low-fat, low-sugar eating guidelines</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Food group</td> <td class=\"subtitle1\">Food to choose more often</td> <td class=\"subtitle1\">Food to limit</td> </tr> <tr> <td>Breads, cereals, starches and starchy vegetables</td> <td>Barley, bulgur, buckwheat (kasha); whole grain breads, bagels, English muffins, hamburger buns, rolls, tortillas, crackers, cereals, pancakes, and waffles; brown rice, whole wheat pasta, whole wheat couscous, unflavored oatmeal, winter squash, sweet potatoes, corn, corn tortillas</td> <td>Biscuits; store brought muffins, croissants, sweet rolls, Danish, and donuts; sugar coated cereals, crackers made with saturated fats; pasta and rice dishes prepared in a butter cream sauce; baked, fried, mashed or scalloped potatoes</td> </tr> <tr> <td>Vegetables</td> <td>Any fresh or frozen vegetable such as artichoke and artichoke hearts, asparagus, beans (green, wax, Italian), bean sprouts, beets, broccoli, brussel sprouts, cabbage, carrots, cauliflower, celery, cucumber, eggplant, green onions, greens (collard, kale, mustard, turnip), mushrooms, okra, onions, pea pods, peppers, radishes, salad greens (endive, escarole, lettuce, romaine, spinach), sauerkraut, spinach, summer squash, tomatoes and tomato sauce, vegetable juices, water chestnuts, watercress, zucchini</td> <td>Any vegetables prepared in butter, cream, or cheese sauce; fried vegetables</td> </tr> <tr> <td>Fruits</td> <td>Whole fresh and frozen fruits such as apple, banana, blueberries, cantaloupe, cherries, grapefruit, grapes, honeydew melon, kiwi, mango, orange, peach, pear, pineapple, plums, and strawberries</td> <td>Canned fruit, fruit juices, dried fruit and fried fruits</td> </tr> <tr> <td>Meat, poultry, fish, dried beans, eggs</td> <td>Fish, shellfish, skinned white-meat chicken and turkey, beans, peas, lentils, egg substitutes, egg whites, soybeans, and tofu</td> <td>Regular beef, pork, lamb, veal, and luncheon meats; fried chicken and fish, eggs, sausage, hot dogs</td> </tr> <tr> <td>Milk, yogurt and cheese</td> <td>Skim and 1 percent milk, plain nonfat yogurt, nonfat yogurt sweetened with aspartame or nonnutritive sweetener; fat-free or low-fat cheese and cottage cheese</td> <td>2 percent and whole milk, 1 percent and whole chocolate milk, goat's milk, kefir, low-fat yogurt (plain or fruit flavored), custard-style yogurt, regular cheese and cottage cheese</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Texas Children's Hospital.</div><div id=\"graphicVersion\">Graphic 67313 Version 2.0</div></div></div>"},"67314":{"type":"graphic_figure","displayName":"Pincer mechanism","title":"Pincer mechanism","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pincer mechanism</div><div class=\"cntnt\"><img style=\"width:325px; height:200px;\" src=\"images/PEDS/67314_Pincer_mechanism.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pincer mechanism is one mechanism of injury that is proposed to explain the pathogenesis of cervical cord neurapraxia. It is hypothesized that during extension the cervical cord becomes compressed between the posterior margin of one vertebral body and the anterior margin of the spinous process of the vertebra below it. Such compression is most likely to occur in a hyperextension injury with axial loading.</div><div id=\"graphicVersion\">Graphic 67314 Version 1.0</div></div></div>"},"67315":{"type":"graphic_diagnosticimage","displayName":"Echo normal and dilated cardiomyopathy","title":"Echocardiogram of a normal heart and a case of dilated cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Echocardiogram of a normal heart and a case of dilated cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:301px; height:324px;\" src=\"images/CARD/67315_LV_normal_cardiomyopathy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A four-chamber view from the two-dimensional echocardiogram of a normal heart is shown in the panel A. In panel B, the echocardiogram from a patient with dilated cardiomyopathy is shown and diagrammed. Note the dilated cardiomyopathy heart is more spherical than its normal counterpart.</div><div class=\"graphic_footnotes\">LV: left ventricle; RV: right ventricle; RA: right atrium; LA: left atrium; aML: anterior mitral leaflet; pML: posterior mitral leaflet.</div><div id=\"graphicVersion\">Graphic 67315 Version 4.0</div></div></div>"},"67317":{"type":"graphic_diagnosticimage","displayName":"Bronchoalveolar ca nodule CT","title":"Nodule in bronchioloalveolar cell carcinoma (focal mucinous adenocarcinoma)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nodule in bronchioloalveolar cell carcinoma (focal mucinous adenocarcinoma)</div><div class=\"cntnt\"><img style=\"width:331px; height:267px;\" src=\"images/PULM/67317_Bronchoalveolar_ca_nodule_C.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ill-defined nodule in the superior segment of the lingula with a so-called rabbit tail extending towards the anterior aspect of the chest wall and an air-bronchogram. The bronchus extends into the lesion, assuring a high yield for bronchoscopy.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 67317 Version 3.0</div></div></div>"},"67318":{"type":"graphic_table","displayName":"Misc dermatologic disorders OLT","title":"Miscellaneous dermatologic complications after liver transplantation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Miscellaneous dermatologic complications after liver transplantation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"85%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">Comments</td> </tr> <tr class=\"divider_bottom\"> <td>Cutaneous calcinosis</td> <td>Complication linked to the deposition of calcium.</td> </tr> <tr class=\"divider_bottom\"> <td>Erythema elevatum diutinum</td> <td>Rare condition. It may improve in intensity with reduction of the cyclosporine dose.</td> </tr> <tr class=\"divider_bottom\"> <td>Photosensitivity</td> <td>Isolated reports: Pseudoporphyria after liver transplantation for congenital biliary atresia, transitory porphyrinemia with light sensitivity in a patient waiting for a second transplantation after necrosis of the hepatic graft.</td> </tr> <tr class=\"divider_bottom\"> <td>Porokeratosis</td> <td>Round or oval erythematous plaques with a sharp border. Porokeratosis lesions typically appear four to five years after liver transplantation, and their number varies from one to dozens. These lesions are due to the clonal proliferation of keratinocytes. Porokeratosis in a recipient of a liver transplantation is a sign of a strong immunosuppression. In the context of transplantation, porokeratosis is not a precancerous lesion.</td> </tr> <tr class=\"divider_bottom\"> <td>Immune thrombocytopenia</td> <td>Immune thrombocytopenia after liver transplantation can be due to the underlying liver disease (primary biliary cholangitis), an infection (varicella, herpes virus 6, parvovirus B19), the immunosuppression (tacrolimus), or the graft itself. Endogenous heparin-like molecules have been described after liver transplantation and may have a role.</td> </tr> <tr class=\"divider_bottom\"> <td>Graft-versus-host-disease</td> <td>Generally rare after transplantation of solid organs, but has been described after liver transplantation. The dermatologic and digestive manifestations are comparable to those observed in graft-versus-host-disease after bone marrow transplantation. The hepatic manifestations are usually mild, probably because the lymphocytes of the donor are immunotolerant to the graft. In the case of acute graft-versus-host-disease, the severity of the dermatologic manifestations range from a maculopapular rash localized to the extremities, to generalized erythroderma and toxic epidermal necrolysis. In the case of chronic graft-versus-host-disease, the lesions are polymorphic with the appearance of lichen planus, scleroderma, ichthyosis, vitiligo, and/or Shulman's fasciitis. Risk factors may include close matching of the donor and recipient HLA types and donor age older than 60 years or younger than 40 years. Fluorescent in situ hybridization can help to reach an early diagnosis in sex mismatched patients.</td> </tr> <tr> <td>Granuloma annulare</td> <td>Confluent rash with maculae on sun-exposed areas.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 67318 Version 6.0</div></div></div>"},"67319":{"type":"graphic_table","displayName":"Frequency biochem abnormalities","title":"Frequency of biochemical abnormalities in the urine by gender and stone formation status","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequency of biochemical abnormalities in the urine by gender and stone formation status</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n\r\n  <tbody>\r\n\r\n\r\n    <tr>\r\n\r\n      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">&nbsp;</td>\r\n\r\n      <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">Women</td>\r\n\r\n\r\n\r\n      <td colspan=\"2\" rowspan=\"1\" class=\"subtitle1\">Men</td>\r\n\r\n\r\n\r\n    </tr>\r\n\r\n    <tr>\r\n\r\n\r\n      <td class=\"subtitle2\">Cases, percent</td>\r\n\r\n\r\n      <td class=\"subtitle2\">Controls, percent</td>\r\n\r\n      <td class=\"subtitle2\">Cases, percent</td>\r\n\r\n\r\n      <td class=\"subtitle2\">Control, percent</td>\r\n\r\n    </tr>\r\n\r\n    <tr>\r\n\r\n      <td>Hypercalciuria</td>\r\n\r\n      <td>33 </td>\r\n\r\n\r\n      <td>27</td>\r\n\r\n      <td>25</td>\r\n\r\n\r\n      <td>14</td>\r\n\r\n    </tr>\r\n\r\n    <tr>\r\n\r\n      <td>Hyperuricosuria</td>\r\n\r\n      <td>9</td>\r\n\r\n\r\n      <td>8</td>\r\n\r\n      <td>29</td>\r\n\r\n\r\n      <td>40</td>\r\n\r\n    </tr>\r\n\r\n    <tr>\r\n\r\n      <td>Hyperoxaluria</td>\r\n\r\n      <td>13</td>\r\n\r\n\r\n      <td>14</td>\r\n\r\n      <td>47</td>\r\n\r\n\r\n      <td>43</td>\r\n\r\n    </tr>\r\n\r\n    <tr>\r\n\r\n      <td>Hypocitraturia</td>\r\n\r\n      <td>11</td>\r\n\r\n\r\n      <td>9</td>\r\n\r\n      <td>8</td>\r\n\r\n\r\n      <td>4</td>\r\n\r\n    </tr>\r\n\r\n  </tbody>\r\n</table></div><div class=\"graphic_reference\">Adapted from Curhan, GC, Willett, WC, Speizer, FE, et al. Twenty-four-hour urine chemistries and the risk of kidney stones among women and men. Kidney Int 2001; 59:2290.</div><div id=\"graphicVersion\">Graphic 67319 Version 1.0</div></div></div>"},"67321":{"type":"graphic_figure","displayName":"Audiograms in Cogans I","title":"Serial pure tone audiograms in Cogan's syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Serial pure tone audiograms in Cogan's syndrome</div><div class=\"cntnt\"><img style=\"width:432px; height:144px;\" src=\"images/RHEUM/67321_Audiograms_in_Cogans_I.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three audiograms are presented from a patient with Cogan's syndrome and hearing loss: A) Two months after the onset of Cogan's syndrome during initial corticosteroid therapy; B) Four and one-half years into disease course while taking alternate-day corticosteroid therapy; C) Eight years after onset of disease with stable to improved hearing acuity. _-----_, right ear; X-----X, left ear.</div><div class=\"graphic_reference\">Reproduced with permission from: Haynes, BF, Kaiser-Kupfer, MI, Mason, P, et al. Corgan syndrome: Studies in thirteen patients, long-term follow-up, and a review of the literature. Medicine 1980; 59:426. Copyright &#169;1980 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 67321 Version 1.0</div></div></div>"},"67322":{"type":"graphic_waveform","displayName":"ECG_2 Polymorphic VT in ischemia","title":"ECG_2 showing polymorphic ventricular tachycardia in ischemia","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">ECG_2 showing polymorphic ventricular tachycardia in ischemia</div><div class=\"cntnt\"><img style=\"width:541px; height:212px;\" src=\"images/CARD/67322_Polymorphic_VT_in_ischemi1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Continuous rhythm strip showing an episode of very rapid polymorphic ventricular tachycardia which is often referred to as ventricular flutter. The QT interval is normal and the QRS complex morphology is highly variable. The patient had an underlying sinus tachycardia, suggesting increased sympathetic activity secondary to an ischemic event.</div><div id=\"graphicVersion\">Graphic 67322 Version 3.0</div></div></div>"},"67323":{"type":"graphic_table","displayName":"Suggested supplies and equipment for the MH treatment cart","title":"Suggested supplies and equipment for the malignant hyperthermia (MH) treatment cart","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested supplies and equipment for the malignant hyperthermia (MH) treatment cart</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Quantity per cart*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Drugs</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\">Dantrolene</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Dantrium, Revonto: 20 mg vials (lyophilized powder); <strong>OR</strong> </li> </ul> </td> <td>36 vials (enough supply to prepare maximum recommended cumulative dose [ie, 10 mg/kg] for one 72 kg patient); <strong>OR</strong></td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Ryanodex: 250 mg vials (lyophilized powder) </li> </ul> </td> <td>3 vials (enough supply to prepare maximum recommended cumulative dose [ie, 10 mg/kg] for one 75 kg patient)</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\">Sterile water for injection (<strong>non</strong>-bacteriostatic)</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>100 mL vials for reconstitution of Dantrium or Revonto; <strong>OR</strong> </li> </ul> </td> <td>36 vials; <strong>OR</strong></td> </tr> <tr> <td class=\"indent2\"> <ul> <li>5 mL vials for reconstitution of Ryanodex </li> </ul> </td> <td>3 vials</td> </tr> <tr> <td class=\"indent1\">Sodium bicarbonate 8.4% (also labeled 1 mEq/mL or 1 mmol/mL), 50 mL<sup>&#182;</sup></td> <td>5 prefilled syringes or vials</td> </tr> <tr> <td class=\"indent1\">Dextrose 50%, 50 mL<sup>&#182;</sup></td> <td>2 prefilled syringes or vials</td> </tr> <tr> <td class=\"indent1\">Calcium chloride 10%, 10 mL<sup>&#182;</sup></td> <td>2 vials</td> </tr> <tr> <td class=\"indent1\">Lidocaine 2%, 100 mg/5 mL <strong>or</strong> 1% 100 mg/10 mL<sup>&#182;</sup></td> <td>4 prefilled syringes or vials</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Refrigerated drugs and solutions</td> </tr> <tr> <td class=\"indent1\">Insulin regular 100 units/mL, 10 mL</td> <td>1 vial</td> </tr> <tr> <td class=\"indent1\">0.9% normal saline, 1000 mL for IV cooling</td> <td>4 bags and sterile pour bottles</td> </tr> <tr> <td class=\"indent1\">Cold packs</td> <td>8</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">General equipment</td> </tr> <tr> <td class=\"indent1\">Syringes, 60 mL to dilute dantrolene (unnecessary if using Ryanodex)<sup>&#182;</sup></td> <td>5 syringes</td> </tr> <tr> <td class=\"indent1\">IV catheters (for IV access and arterial line): 16G, 18G, 20G 2-inch, 22G 1-inch, 24G &#190;-inch<sup>&#182;</sup></td> <td>4 each</td> </tr> <tr> <td class=\"indent1\">NG tubes<sup>&#182;</sup></td> <td>Various sized</td> </tr> <tr> <td class=\"indent1\">60 cc irrigation syringe<sup>&#182;</sup></td> <td>2</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Monitoring equipment</td> </tr> <tr> <td class=\"indent1\">Esophageal or other core temperature probes (eg, for nasopharyngeal, tympanic membrane, rectal, or bladder sites, or a pulmonary artery catheter)<sup>&#182;</sup></td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Central venous pressure kits (sizes appropriate to your patient population)<sup>&#182;</sup></td> <td>Sizes appropriate for patient population</td> </tr> <tr> <td class=\"indent1\">Transducer kits for arterial and central venous cannulation<sup>&#182;</sup></td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Nursing supplies</td> </tr> <tr> <td class=\"indent1\">Large sterile plastic drape (eg, Steri-Drape, for rapid drape of wound)<sup>&#182;</sup></td> <td>1</td> </tr> <tr> <td class=\"indent1\">Urine meter<sup>&#182;</sup></td> <td>1</td> </tr> <tr> <td class=\"indent1\">Irrigation tray with piston (60 cc irrigation) syringe<sup>&#182;</sup></td> <td>1</td> </tr> <tr> <td class=\"indent1\">Small and large clear plastic bags for ice<sup>&#182;</sup></td> <td>4 each</td> </tr> <tr> <td class=\"indent1\">Bucket for ice<sup>&#182;</sup></td> <td>1</td> </tr> <tr> <td class=\"indent1\">Test strips: urine analysis for hemoglobin and finger stick glucose<sup>&#182;</sup></td> <td>1 vial</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\"><strong>Laboratory testing supplies</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Syringes (3 mL) for blood gas analysis or ABG kits x 6 or point-of-care monitors; ISTAT with TB syringes (the point-of-care ISTAT device has replaced lab blood gene and electrolyte measurement)</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Blood specimen tubes for CK, myoglobin, SMA 19 (LDH, electrolytes, thyroid studies), PT/PTT, fibrinogen, Fibrin split products; and lactate, CBC, platelets. If no immediate laboratory analysis is available, samples should be kept on ice for later analysis. This may well prove useful on retrospective review and diagnosis. Blood cultures are very useful and should be included to rule out bacteremia.</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Urine collection container for myoglobin level. Pigmenturia (eg, brown or red urine and heme-positive dipstick) indicates that renal protection is mandated, when the urine is centrifuged or allow to settle, and the sample shows clear supernatant, ie, the coloration is due to red cells in the sample.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NG: nasogastric; IV: intravenous; G: gauge; CVP: central venous pressure; ABG: arterial blood gas.<br />* We suggest that institutions establish the number and location of MH treatment carts so that one or more carts are available immediately or within no more than 10 minutes to all anesthetizing locations in the facility including operating rooms and procedural suites.<br />¶ These supplies are only necessary if not already immediately accessible at all anesthetizing locations in the institution.</div><div class=\"graphic_reference\">Data from: FAQs: Stocking an MH Cart. The Malignant Hyperthermia Association of the United States. Available at: http://www.mhaus.org/faqs/stocking-an-mh-cart (Accessed August 25, 2014).</div><div id=\"graphicVersion\">Graphic 67323 Version 11.0</div></div></div>"},"67324":{"type":"graphic_figure","displayName":"CNS lymphoma flow study","title":"Flow cytometry of cerebrospinal fluid demonstrates lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Flow cytometry of cerebrospinal fluid demonstrates lymphoma</div><div class=\"cntnt\"><img style=\"width:397px; height:369px;\" src=\"images/HEME/67324_CNS_lymphoma_flow_study.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This flow cytometry study of a sample of lymphocytes obtained from the cerebrospinal fluid of a patient with suspected lymphoma shows a population of B-lymphocytes (green color, asterisk) which stains positive for kappa light chains (Y axis) and positive for CD19 expression (x axis). This same CD19 positive cell population stained negative for lambda light chain expression (not shown here), identifying this as a monoclonal population of lymphocytes, and suggesting that these cells represent involvement of the neuraxis with lymphoma.</div><div id=\"graphicVersion\">Graphic 67324 Version 2.0</div></div></div>"},"67326":{"type":"graphic_table","displayName":"Toxicity comparison for bisphosphonates versus denosumab","title":"Toxicity comparison for bisphosphonates versus denosumab","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Toxicity comparison for bisphosphonates versus denosumab</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Denosumab</td> <td class=\"subtitle1\">Bisphosphonates</td> </tr> <tr> <td>Route of administration</td> <td class=\"centered\">Subcutaneous</td> <td class=\"centered\">Intravenous</td> </tr> <tr> <td>Osteonecrosis of the jaw</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td>Hypocalcemia</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td>Nephrotoxicity</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr> <td>Atypical femoral fractures</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td>Renal elimination/need for dose adjustment in renal insufficiency</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr> <td>Flu-like symptoms (acute-phase reaction)</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr> <td>Bone, joint, muscle pain</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 67326 Version 5.0</div></div></div>"},"67327":{"type":"graphic_diagnosticimage","displayName":"Triplane fx child","title":"Triplane fracture in a 12-year-old boy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Triplane fracture in a 12-year-old boy</div><div class=\"cntnt\"><img style=\"width:326px; height:582px;\" src=\"images/EM/67327_Triplane_fx_child_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Frontal (A) and lateral (B) radiographs of the right ankle demonstrating a triplane fracture. The frontal view demonstrates faint visualization of the epiphyseal fracture (arrow) along the sagittal plane and the superior edge of the metaphyseal fracture in the coronal plane (arrowhead). The lateral view demonstrates the widening along the anterior margin of the physis (asterisk), a sagittal epiphyseal fracture (arrowhead), and posterior metaphyseal fracture extension (arrow). Oblique fracture across the distal fibular shaft is noted in both frontal and lateral views (curved arrow). Computed tomographic scans of the right ankle demonstrating in better detail the morphologic complexity of the triplane fracture. Axial image at the level of the distal tibial epiphysis (C) and axial image at the level of the distal tibial physis (D) show epiphyseal widening and displacement in the sagittal plane (arrow) with irregularity and multiple fracture fragments at the physis (curved arrow). Sagittal reformation (E) demonstrates both physeal (arrow) and posterior metaphyseal (curved arrow) fracture extension of a Salter-Harris type II fracture, in addition to a cortical fracture fragment (arrowhead) interposed along the posterior metaphyseal cortical fracture fragments, which could potentially interfere with surgical reduction. Three-dimensionally shaded surface reformation (F) show anterolateral displacement of the epiphysis and physeal fracture extension of a Salter-Harris type III fracture of the tibia (arrow), in addition to a distal fibular oblique fracture (arrowhead).</div><div class=\"graphic_reference\">Reproduced with permission from: Ho-Fung V, Pollock A. Triplane fracture. Pediatr Emerg Care 2011; 27:70. Copyright © 2011 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 67327 Version 12.0</div></div></div>"},"67328":{"type":"graphic_figure","displayName":"Survival with insulinoma","title":"Survival with insulinoma","html":"<div class=\"graphic\"><div style=\"width: 582px\" class=\"figure\"><div class=\"ttl\">Survival with insulinoma</div><div class=\"cntnt\"><img style=\"width:562px; height:250px;\" src=\"images/ENDO/67328_Survival_w_insulinoma_edit1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Survival of 224 patients with insulinomas in the Mayo Clinic cohort. Overall survival was equivalent to expected survival (left panel). However, survival was substantially reduced in the 13 patients with malignant insulinomas (right panel).</div><div class=\"graphic_reference\">Courtesy of F John Service, MD.</div><div id=\"graphicVersion\">Graphic 67328 Version 2.0</div></div></div>"},"67329":{"type":"graphic_table","displayName":"Treatment of adrenal crisis","title":"Treatment of acute adrenal insufficiency (adrenal crisis) in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of acute adrenal insufficiency (adrenal crisis) in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Emergency measures</td> </tr> <tr> <td>1. Establish intravenous access with a large-gauge needle.</td> </tr> <tr> <td>2. Draw blood for immediate serum electrolytes and glucose and routine measurement of plasma cortisol and ACTH. Do not wait for lab results.</td> </tr> <tr> <td>3. Infuse 2 to 3 liters of isotonic saline or 5 percent dextrose in isotonic saline as quickly as possible. Frequent hemodynamic monitoring and measurement of serum electrolytes should be performed to avoid iatrogenic fluid overload.</td> </tr> <tr> <td>4. Give 4 mg dexamethasone as intravenous bolus over one to five minutes and every 12 hours thereafter. Dexamethasone is the drug of choice because it does not interfere with the measurement of plasma cortisol. If dexamethasone is unavailable, intravenous hydrocortisone, 100 mg immediately and every six hours thereafter, may be used.</td> </tr> <tr> <td>5. Use supportive measures as needed.*</td> </tr> <tr> <td class=\"subtitle1_single\">Subacute measures after stabilization of the patient</td> </tr> <tr> <td>1. Continue intravenous isotonic saline at a slower rate for next 24 to 48 hours.</td> </tr> <tr> <td>2. Search for and treat possible infectious precipitating causes of the adrenal crisis.</td> </tr> <tr> <td>3. Perform a short ACTH stimulation test to confirm the diagnosis of adrenal insufficiency, if patient does not have known adrenal insufficiency.</td> </tr> <tr> <td>4. Determine the type of adrenal insufficiency and its cause if not already known.</td> </tr> <tr> <td>5. Taper parenteral glucocorticoid over one to three days, if precipitating or complicating illness permits, to oral glucocorticoid maintenance dose.</td> </tr> <tr> <td>6. Begin mineralocorticoid replacement with fludrocortisone, 0.1 mg by mouth daily, when saline infusion is stopped.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Electrolyte abnormalities may include hyponatremia, hyperkalemia or rarely hypercalcemia. Hyponatremia is rapidly corrected by cortisol and volume repletion.</div><div id=\"graphicVersion\">Graphic 67329 Version 6.0</div></div></div>"},"67333":{"type":"graphic_table","displayName":"NINDS-AIREN criteria for probable VaD","title":"NINDS-AIREN criteria for probable vascular dementia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NINDS-AIREN criteria for probable vascular dementia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">The criteria for the clinical diagnosis of probable vascular dementia include all of the following:</td> </tr> <tr> <td class=\"subtitle2_single\">Dementia</td> </tr> <tr> <td class=\"indent1\">Defined by cognitive decline from a previously higher level of functioning and manifested by impairment of memory and of two or more cognitive domains (orientation, attention, language, visuospatial functions, executive functions, motor control, and praxis), preferably established by clinical examination and documented by neuropsychological testing; deficits should be severe enough to interfere with activities of daily living not due to physical effects of stroke alone.</td> </tr> <tr> <td class=\"indent1\"><strong>Exclusion criteria:</strong> Cases with disturbance of consciousness, delirium, psychosis, severe aphasia, or major sensorimotor impairment precluding neuropsychological testing. Also excluded are systemic disorders or other brain diseases (such as AD) that in and of themselves could account for deficits in memory and cognition.</td> </tr> <tr> <td class=\"subtitle2_single\">Cerebrovascular disease</td> </tr> <tr> <td class=\"indent1\">Defined by the presence of focal signs on neurologic examination, such as hemiparesis, lower facial weakness, Babinski sign, sensory deficit, hemianopia, and dysarthria consistent with stroke (with or without history of stroke), and evidence of relevant CVD by brain imaging (CT or MRI) including multiple large vessel infarcts or a single strategically placed infarct (angular gyrus, thalamus, basal forebrain, or PCA or ACA territories), as well as multiple basal ganglia and white matter lacunes, or extensive periventricular white matter lesions, or combinations thereof.</td> </tr> <tr> <td class=\"subtitle2_single\">A relationship between the above two disorders</td> </tr> <tr> <td class=\"indent1\">Manifested or inferred by the presence of one or more of the following:</td> </tr> <tr> <td class=\"indent1\">(a) Onset of dementia within three months following a recognized stroke;</td> </tr> <tr> <td class=\"indent1\">(b) Abrupt deterioration in cognitive functions; or fluctuating, stepwise progression of cognitive deficits.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AD: Alzheimer disease; CVD: cerebrovascular disease; CT: computed tomography; MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 67333 Version 3.0</div></div></div>"},"67334":{"type":"graphic_diagnosticimage","displayName":"TTTS7","title":"TTTS7","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">TTTS7</div><div class=\"cntnt\"><img style=\"width:432px; height:313px;\" src=\"images/OBGYN/67334_TTTS7.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Doppler study of the fetal ductus venous in this recipient twin at&nbsp;approximately 25&nbsp;weeks of gestation. Fetal ascites&nbsp;can be&nbsp;noted in the top image.&nbsp;In the bottom image, the&nbsp;arrow points to the reversed \"a\" wave of the ductus venosus that occurs during diastole.</div><div class=\"graphic_reference\">Courtesy of Kenneth J Moise, Jr, MD &amp; Anthony Johnson, DO.</div><div id=\"graphicVersion\">Graphic 67334 Version 3.0</div></div></div>"},"67336":{"type":"graphic_picture","displayName":"Trichotillomania","title":"Trichotillomania","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Trichotillomania</div><div class=\"cntnt\"><img style=\"width:380px; height:301px;\" src=\"images/DERM/67336_Trichotillomania.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hairs tend to be broken at different lengths. The areas of alopecia are not completely devoid of hair.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 67336 Version 2.0</div></div></div>"},"67338":{"type":"graphic_diagnosticimage","displayName":"Celiac lymphoma UGI","title":"Lymphoma arising in celiac disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lymphoma arising in celiac disease</div><div class=\"cntnt\"><img style=\"width:336px; height:275px;\" src=\"images/GAST/67338_Celiac_lymphoma_UGI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small bowel follow through examination shows a large ulcerating extrinsic mass (white arrow) arising between and displacing loops of jejunum in a patient with celiac disease. Note the distended, featureless loops of jejunum, which have lost their normal fold pattern; these features are characteristic of celiac disease.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 67338 Version 2.0</div></div></div>"},"67339":{"type":"graphic_picture","displayName":"Nodular lymphocyte predominant HL","title":"Nodular lymphocyte predominant Hodgkin lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nodular lymphocyte predominant Hodgkin lymphoma</div><div class=\"cntnt\"><img style=\"width:238px; height:288px;\" src=\"images/HEME/67339_Nod_lymph_predom_HL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nodules larger than those typically seen in follicular lymphoma are present in this lymph node section.</div><div class=\"graphic_reference\">From Warnke, RA, Weiss, LM, Chan, JK, Cleary, ML, Dorfman, RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 67339 Version 3.0</div></div></div>"},"67341":{"type":"graphic_table","displayName":"Classic lacunar syndromes","title":"Classic lacunar syndromes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classic lacunar syndromes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Lacunar syndrome</td> <td class=\"subtitle1\">Location</td> <td class=\"subtitle1\">Clinical findings</td> <td class=\"subtitle1\">Positive predictive value</td> </tr> <tr> <td>Pure motor hemiparesis</td> <td>Internal capsule, corona radiata, basal pons, medial medulla</td> <td>Unilateral paralysis of face, arm and leg, no sensory signs, dysarthria and dysphagia may be present</td> <td>52-85 percent</td> </tr> <tr> <td>Pure sensory syndrome</td> <td>Thalamus, pontine tegmentum, corona radiata</td> <td>Unilateral numbness of face, arm and leg without motor deficit</td> <td>95-100 percent</td> </tr> <tr> <td>Ataxic hemiparesis</td> <td>Internal capsule-corona radiata, basal pons, thalamus</td> <td>Unilateral weakness and limb ataxia</td> <td>59-95 percent</td> </tr> <tr> <td>Sensorimotor syndrome</td> <td>Thalamocapsular, maybe basal pons or lateral medulla</td> <td>Hemiparesis or hemiplegia of face, arm and leg with ipsilateral sensory impairment</td> <td>51-87 percent</td> </tr> <tr> <td>Dysarthria-clumsy hand syndrome</td> <td>Basal pons, internal capsule, corona radiata</td> <td>Unilateral facial weakness, dysarthria and dysphagia, with mild hand weakness and clumsiness</td> <td>About 96 percent</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 67341 Version 3.0</div></div></div>"},"67346":{"type":"graphic_picture","displayName":"Idiopathic guttate hypomelanosis - arm","title":"Idiopathic guttate hypomelanosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Idiopathic guttate hypomelanosis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/67346_Idio_guttate_hypomel_arm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple small, hypopigmented macules are present on the arm.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 67346 Version 3.0</div></div></div>"},"67348":{"type":"graphic_figure","displayName":"Antigen in gut","title":"Antigen uptake in the gut","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Antigen uptake in the gut</div><div class=\"cntnt\"><img style=\"width:541px; height:518px;\" src=\"images/ALLRG/67348_Antigen_in_gut.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Antigens may be taken up from the gut lumen by three different cell types.<br />(A) Soluble antigen can cross the epithelium via transcellular (endocytosis) or paracellular routes.<br />(B) Dendritic cells can extend dendrites into the lumen and sample antigen.<br />(C) M cells in Peyer's patches take up particulate antigens.</div><div class=\"graphic_reference\">Modified with permission from: Chehade M, Mayer L. Oral tolerance and its relation to food hypersensitivities. J Allergy Clin Immunol 2005; 115:3. Illustration used with permission of Elsevier Inc. All rights reserved. Copyright © 2005 Elsevier Inc.</div><div id=\"graphicVersion\">Graphic 67348 Version 4.0</div></div></div>"},"67349":{"type":"graphic_figure","displayName":"Indirect inguinal hernia A","title":"Indirect inguinal hernia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Indirect inguinal hernia</div><div class=\"cntnt\"><img style=\"width:329px; height:331px;\" src=\"images/PEDS/67349_Indirect_inguinal_hernia_A.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A patent processus vaginalis allows open communication between the peritoneal cavity and the scrotum.</div><div class=\"graphic_reference\">Adapted from Langman J. Urogenital system. In: Medical Embryology, 4th ed, Williams and Wilkins, Baltimore 1981. p.264.</div><div id=\"graphicVersion\">Graphic 67349 Version 2.0</div></div></div>"},"67350":{"type":"graphic_picture","displayName":"Basal cell carcinoma eyelid","title":"Basal cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Basal cell carcinoma</div><div class=\"cntnt\"><img style=\"width:353px; height:285px;\" src=\"images/PC/67350_Basal_cell_carcinoma_eyelid.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">With permission from Slomovits TL (Ed), Basic and clinical science courses section, American Academy of Ophthalmology, San Francisco 1996.</div><div id=\"graphicVersion\">Graphic 67350 Version 2.0</div></div></div>"},"67351":{"type":"graphic_form","displayName":"Faces pain scale","title":"Faces pain scale","html":"<div class=\"graphic\"><div style=\"width: 589px\" class=\"figure\"><div class=\"ttl\">Faces pain scale</div><div class=\"cntnt\"><img style=\"width:569px; height:135px;\" src=\"images/PC/67351_Faces_pain_scale.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the faces pain scale, rated from 0 to 6 left to right.</div><div class=\"graphic_reference\">Bieri, D, Reeve, RA, Champion, GD, et al. Pain 1990; 41:139. Copyright © 1990 with permission from Elsevier Science.</div><div id=\"graphicVersion\">Graphic 67351 Version 4.0</div></div></div>"},"67353":{"type":"graphic_figure","displayName":"Benefit of LTOT in MRC","title":"Survival benefit of long-term oxygen therapy in COPD","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Survival benefit of long-term oxygen therapy in COPD</div><div class=\"cntnt\"><img style=\"width:420px; height:243px;\" src=\"images/PULM/67353_Benefit_of_LTOT_in_MRC.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Medical Research Council Trial in which 87 patients with chronic obstructive pulmonary disease, severe hypoxemia, hypercapnia, and a history of heart failure were randomized to treatment with oxygen therapy for at least 15 h/day (blue dashed line) or no oxygen (red line). Continuous oxygen therapy led to a significant survival benefit.</div><div class=\"graphic_reference\">Report of the Medical Research Council Working Party, Lancet 1981; 1:681.</div><div id=\"graphicVersion\">Graphic 67353 Version 2.0</div></div></div>"},"67355":{"type":"graphic_table","displayName":"Clues for chronic meningitis","title":"Clinically useful or important clues to the cause of chronic meningitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinically useful or important clues to the cause of chronic meningitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Clue</td> <td class=\"subtitle1\">Diagnosis</td> </tr> <tr> <td>Positive tuberculin skin test</td> <td>Tuberculosis</td> </tr> <tr> <td>Residence or travel to the southwestern United States, southern California, or Mexico</td> <td>Coccidioidomycosis</td> </tr> <tr> <td>Hypothalamic, optic, or pituitary lesions on cranial imaging</td> <td>Sarcoidosis</td> </tr> <tr> <td>Uveitis/iritis</td> <td>Sarcoidosis, Beh&#231;et's disease, Vogt-Koyanagi-Harada syndrome</td> </tr> <tr> <td>Radiculopathy and/or cranial nerve palsies</td> <td>Lyme disease</td> </tr> <tr> <td>Prior residence in Mexico, Central or South America, India, sub-Saharan Africa, or the Caribbean</td> <td>Cysticercosis</td> </tr> <tr> <td>Exposure to unpasturized milk or contact with cows, goats, swine, or sheep (including butchering or working in a packing house)</td> <td>Brucellosis</td> </tr> <tr> <td>Peripheral 7th nerve paralysis</td> <td>Sarcoidosis</td> </tr> <tr> <td>Diabetes insipidus</td> <td>Sarcoidosis</td> </tr> <tr> <td>Poliosis (whitening of the eyebrows and eyelashes and vitiligo)</td> <td>Vogt-Koyanagi-Harada syndrome</td> </tr> <tr> <td>Recurrent genital or oral ulcerations</td> <td>Beh&#231;et's disease</td> </tr> <tr> <td>A preexisting immunosuppressive condition or therapy</td> <td>Cryptococcosis, tuberculosis, toxoplasmosis, endemic mycoses</td> </tr> <tr> <td>Predominately neutrophilic CSF pleocytosis</td> <td>Nocardiosis, actinomycosis, aspergillosis, systemic lupus erythematosus, chemical or drug-induced meningitis</td> </tr> <tr> <td>Eosinophilic CSF pleocytosis</td> <td>Coccidioidomycosis, lymphoma, <em>Angiostrongylus</em>, cysticercosis, schistosomiasis</td> </tr> <tr> <td>Hypogammaglobulinemia</td> <td>Echovirus</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CSF: cerebrospinal fluid.</div><div id=\"graphicVersion\">Graphic 67355 Version 3.0</div></div></div>"},"67357":{"type":"graphic_table","displayName":"Tuberculin skin test interpretation","title":"Interpretation of tuberculin skin test","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Interpretation of tuberculin skin test</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Tuberculin skin test reaction size (mm)</td> <td class=\"subtitle1\">Situation in which reaction is considered positive*</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">&#60;5</td> <td>HIV infection plus close contact of active contagious case<sup>&#182;</sup></td> </tr> <tr> <td class=\"divider_bottom centered\" rowspan=\"4\">&#8805;5</td> <td>HIV infection</td> </tr> <tr> <td>Close contact of active contagious case</td> </tr> <tr> <td>Abnormal chest radiograph with fibrotic changes consistent with old TB</td> </tr> <tr class=\"divider_bottom\"> <td>Immunosuppressed patients: TNF-alpha inhibitors, chemotherapy, organ transplantation, glucocorticoid treatment (equivalent of &#8805;15 mg/day prednisone for &#8805;1 month)</td> </tr> <tr> <td class=\"divider_bottom centered\" rowspan=\"4\">&#8805;10 </td> <td>Persons with clinical conditions that increase the risk of reactivation, including silicosis<sup>&#916;</sup>, chronic renal failure requiring dialysis<sup>&#916;</sup>, diabetes mellitus, some malignancies (leukemias, lymphomas, carcinoma of the head, neck, or lung), underweight (&#8805;10 percent ideal body weight), jejunoileal bypass, injection drug users</td> </tr> <tr> <td>Children less than 4 years of age</td> </tr> <tr> <td>Foreign born from countries with incidence &#62;25/100,000<sup>&#9674;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Residents and employees in high-risk settings, such as prisons, jails, healthcare facilities, mycobacteriology labs, and homeless shelters</td> </tr> <tr> <td class=\"centered\">&#8805;15</td> <td>Healthy individuals age 4 years and older with low likelihood of true TB infection<sup>&#167;</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The table summarizes the approach to interpretation of initial TST; issues related to interpretation of repeat TST are discussed separately (refer to UpToDate topic on diagnosis of latent TB infection).</div><div class=\"graphic_footnotes\">TB: tuberculosis; TNF: tumor necrosis factor; TST: tuberculin skin test.<br />* The goal of testing for latent tuberculosis infection is to identify individuals who are at increased risk for the development of tuberculosis and therefore would benefit from treatment of latent TB infection. Only those who would benefit from treatment should be tested, so a decision to test presupposes a decision to treat if the test is positive. Refer to the UpToDate topic on diagnosis of latent TB infection for discussion of issues related to interpretation of repeat TST.<br />¶ The risk of active TB is high among human immunodeficiency virus (HIV)-positive patients who are close contacts of active contagious cases and are anergic.<br />Δ The United States Centers for Disease Control and Prevention (CDC) recommends a 10 mm induration definition for patients with silicosis or chronic renal failure. However, population-based studies demonstrate that the relative risk for development of active tuberculosis in this category is high (≥10x that of healthy individuals). For this reason, many favor a lower threshold for a positive test (≥5 mm).<br /><FONT class=lozenge>◊</FONT> The CDC indicates that only those foreign-born individuals who immigrated within the past five years should be tested (regardless of age), although others do not favor this practice since most recently arrived foreign born with positive TST have old (not recent) infection.<br />§ Persons with a low likelihood of true TB infection should not be tested routinely unless they are entering a high-risk setting such as starting employment at a healthcare facility. A threshold of 15 mm is used in the United States and is appropriate for healthy individuals with low likelihood of true TB infection and high likelihood of exposure to nontuberculous mycobacteria (eg, southern United States). However, Canadian guidelines use a threshold of 10 mm for healthy individuals given the lower likelihood of exposure to nontuberculous mycobacteria. (Refer to the UpToDate topic on epidemiology of nontuberculous mycobacterial infections.)</div><div id=\"graphicVersion\">Graphic 67357 Version 10.0</div></div></div>"},"67360":{"type":"graphic_table","displayName":"Neuropathic causes of tonic pupil","title":"Neuropathies causing a tonic pupil","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Neuropathies causing a tonic pupil</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Autonomic or peripheral neuropathy</td> </tr> <tr> <td class=\"indent1\">Acute sensorimotor polyneuropathy, tonic pupils and abduction deficit with polyarteritis nodosa</td> </tr> <tr> <td class=\"indent1\">Alcohol-related</td> </tr> <tr> <td class=\"indent1\">Amyloidosis</td> </tr> <tr> <td class=\"indent1\">Charcot-Marie-Tooth disease</td> </tr> <tr> <td class=\"indent1\">Chronic inflammatory demyelinating polyradiculoneuropathy</td> </tr> <tr> <td class=\"indent1\">Diabetes</td> </tr> <tr> <td class=\"indent1\">Familial dysautonomia</td> </tr> <tr> <td class=\"indent1\">Fisher syndrome</td> </tr> <tr> <td class=\"indent1\">Guillain-Barr&#233; syndrome</td> </tr> <tr> <td class=\"indent1\">Hereditary neuropathy</td> </tr> <tr> <td class=\"indent1\">Pandysautonomia</td> </tr> <tr> <td class=\"indent1\">Progressive autonomic failure</td> </tr> <tr> <td class=\"indent1\">Ross syndrome (tonic pupil, hyporeflexia, segmental anhidrosis)</td> </tr> <tr> <td class=\"indent1\">Shy-Drager syndrome</td> </tr> <tr> <td class=\"indent1\">Sjogren syndrome</td> </tr> <tr> <td class=\"indent1\">Syphilis (congenital or acquired)</td> </tr> <tr> <td class=\"indent1\">Systemic infectious</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 67360 Version 3.0</div></div></div>"},"67361":{"type":"graphic_figure","displayName":"Lateral pancreaticojej AGA","title":"Lateral pancreaticojejunostomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lateral pancreaticojejunostomy</div><div class=\"cntnt\"><img style=\"width:432px; height:317px;\" src=\"images/GAST/67361_Lateral_pancreaticojej_AGA.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: American Gastroenterological Association (AGA) GTP slide set (2003), Pancreatic Disease. Authors: Gorelick F, Pandol S, Topazian M. Artist: Schoendorf J. Copyright &#169; 2003 American Gastroenterological Association.</div><div id=\"graphicVersion\">Graphic 67361 Version 3.0</div></div></div>"},"67362":{"type":"graphic_picture","displayName":"Ess thrombocythemia marrow","title":"Bone marrow in essential thrombocythemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bone marrow in essential thrombocythemia</div><div class=\"cntnt\"><img style=\"width:376px; height:368px;\" src=\"images/HEME/67362_Ess_thrombocythemia_marrow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow biopsies from two different patients with essential thrombocythemia are shown here. Both patients met the Polycythemia Vera Study Group's criteria for this diagnosis. The most prominent finding in both cases is megakaryocytic hyperplasia, with clustering of megakaryocytes more prominent in the biopsy shown in the lower panel.</div><div class=\"graphic_reference\">Provided by Stephen A. Landaw, MD,PhD.</div><div id=\"graphicVersion\">Graphic 67362 Version 2.0</div></div></div>"},"67363":{"type":"graphic_waveform","displayName":"EP study tracings RF catheter ablation of the AV junction in AF","title":"Intracardiac and surface ECG recordings during electrophysiologic study and radiofrequency catheter ablation of the AV junction in atrial fibrillation (AF)","html":"<div class=\"graphic\"><div style=\"width: 581px\" class=\"figure\"><div class=\"ttl\">Intracardiac and surface ECG recordings during electrophysiologic study and radiofrequency catheter ablation of the AV junction in atrial fibrillation (AF)</div><div class=\"cntnt\"><img style=\"width:561px; height:389px;\" src=\"images/CARD/67363_RF_ablation_AV_node.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three surface ECG leads (I, aVF, V1) and intracardiac recordings from the region of the atrio- ventricular (AV) junction (HBE1-2, HBE3-4), and the right ventricular apex (RVA3- 4) in a patient with atrial fibrillation (AF). Application of radiofrequency (RF) energy from the tip of the mapping catheter (HBE1-2) causes complete AV nodal block; pacing (P) is initiated from the right ventricular apex. A permanent VVIR pacemaker was implanted, and the patient has noted a marked improvement in symptoms.</div><div id=\"graphicVersion\">Graphic 67363 Version 4.0</div></div></div>"},"67364":{"type":"graphic_figure","displayName":"Conduction block and slowing across the elbow","title":"Motor nerve conduction study of ulnar innervated hypothenar muscles with conduction block","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Motor nerve conduction study of ulnar innervated hypothenar muscles with conduction block</div><div class=\"cntnt\"><img style=\"width:463px; height:383px;\" src=\"images/NEURO/67364_Conduction_block_elbow_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure illustrates the typical findings for a motor nerve conduction study of the ulnar-innervated hypothenar muscles with conduction block and slowing across the elbow. The smaller response on the affected side is with stimulation above the elbow and reflects conduction block. In this case, the other two responses with stimulation at the wrist and below elbow are normal and the inset sensory response to the 5th digit is normal.</div><div id=\"graphicVersion\">Graphic 67364 Version 2.0</div></div></div>"},"67365":{"type":"graphic_figure","displayName":"Female genital tract infections","title":"Female genital tract infections","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Female genital tract infections</div><div class=\"cntnt\"><img style=\"width:520px; height:346px;\" src=\"images/OBGYN/67365_Female-genital-tract-infections-edit.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 67365 Version 4.0</div></div></div>"},"67366":{"type":"graphic_picture","displayName":"Xerosis","title":"Xerosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Xerosis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/67366_Xerosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dry, flaking skin is present.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 67366 Version 3.0</div></div></div>"},"67367":{"type":"graphic_figure","displayName":"Construction of a colostomy - proximal and distal ","title":"Construction of a colostomy - Hartmann's pouch","html":"<div class=\"graphic\"><div style=\"width: 487px\" class=\"figure\"><div class=\"ttl\">Construction of a colostomy - Hartmann's pouch</div><div class=\"cntnt\"><img style=\"width:467px; height:659px;\" src=\"images/SURG/67367_Colostomy-Hartmann's-pouch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the proximal limb of the colon brought onto the abdominal wall. The proximal bowel is opened with electrocautery. The distal limb will remain in the abdominal cavity and the suture line inverted with silk sutures, creating a Hartmann's pouch.</div><div id=\"graphicVersion\">Graphic 67367 Version 1.0</div></div></div>"},"67368":{"type":"graphic_algorithm","displayName":"ADA management patients HHS","title":"Protocol for the management of adult patients with HHS","html":"<div class=\"graphic\"><div style=\"width: 1214px\" class=\"figure\"><div class=\"ttl\">Protocol for the management of adult patients with HHS</div><div class=\"cntnt\"><img style=\"width:1194px; height:693px;\" src=\"images/ENDO/67368_ADA_mgmt_patients_HHS_edit1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">HHS diagnostic criteria: Serum glucose &gt;600 mg/dL, arterial pH &gt;7.3, serum bicarbonate &gt;15 mEq/L, and minimal ketonuria and ketonemia. Normal laboratory values vary; check local lab normal ranges for all electrolytes.</div><div class=\"graphic_footnotes\">HHS: hyperosmolar hyperglycemic state; IV: intravenous; NaCl: sodium chloride; K: potassium; Na: sodium; BUN: blood urea nitrogen; SC: subcutaneous.<br />* After history and physical exam, obtain capillary glucose and serum or urine ketones (nitroprusside method). Begin 1 liter of 0.9% NaCl over one hour, and draw arterial blood gases, complete blood count with differential, urinalysis, serum glucose, BUN, electrolytes, chemistry profile, and creatinine levels STAT. Obtain electrocardiogram, chest radiograph, and specimens for bacterial cultures, as needed.<br />¶ Serum Na<SUP>+</SUP> should be corrected for hyperglycemia (for each 100 mg/dL glucose &gt;100 mg/dL, add 2.0 mEq to sodium value for corrected serum sodium value).<br />Δ An alternative IV insulin regimen is to give a continuous intravenous infusion of regular insulin at 0.14 units/kg per hour; at this dose, an initial intravenous bolus is not necessary.</div><div class=\"graphic_reference\">Copyright © 2006 American Diabetes Association From Diabetes Care Vol 29, Issue 12, 2006. Modifications from Diabetes Care Vol 32, Issue 7, 2009. Reprinted with permission from the American Diabetes Association.</div><div id=\"graphicVersion\">Graphic 67368 Version 4.0</div></div></div>"},"67370":{"type":"graphic_table","displayName":"Causes of wheeze in children","title":"Causes of wheezing in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of wheezing in children</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Acute</td> </tr> <tr> <td class=\"indent1\">Asthma</td> </tr> <tr> <td class=\"indent1\">Bronchiolitis*</td> </tr> <tr> <td class=\"indent1\">Bronchitis</td> </tr> <tr> <td class=\"indent1\">Laryngotracheobronchitis<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Bacterial tracheitis</td> </tr> <tr> <td class=\"indent1\">Foreign body aspiration<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Esophageal foreign body</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Chronic or recurrent</td> </tr> <tr> <td class=\"subtitle2_single\">Structural abnormalities</td> </tr> <tr> <td class=\"indent1\">Tracheo-bronchomalacia*</td> </tr> <tr> <td class=\"indent1\">Vascular compression/rings*</td> </tr> <tr> <td class=\"indent1\">Tracheal stenosis/webs*</td> </tr> <tr> <td class=\"indent1\">Cystic lesions/masses</td> </tr> <tr> <td class=\"indent1\">Tumors/lymphadenopathy</td> </tr> <tr> <td class=\"indent1\">Cardiomegaly</td> </tr> <tr> <td class=\"subtitle2_single\">Functional abnormalities</td> </tr> <tr> <td class=\"indent1\">Asthma</td> </tr> <tr> <td class=\"indent1\">Gastroesophageal reflux</td> </tr> <tr> <td class=\"indent1\">Recurrent aspiration</td> </tr> <tr> <td class=\"indent1\">Cystic fibrosis</td> </tr> <tr> <td class=\"indent1\">Immunodeficiency</td> </tr> <tr> <td class=\"indent1\">Primary ciliary dyskinesia</td> </tr> <tr> <td class=\"indent1\">Bronchopulmonary dysplasia</td> </tr> <tr> <td class=\"indent1\">Retained foreign body (trachea or esophagus)</td> </tr> <tr> <td class=\"indent1\">Bronchiolitis obliterans</td> </tr> <tr> <td class=\"indent1\">Pulmonary edema</td> </tr> <tr> <td class=\"indent1\">Vocal cord dysfunction<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Interstitial lung disease</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* These disorders tend to present in infancy.<br />¶ These disorders are more commonly seen in young children (toddlers and preschoolers).<br />Δ These disorders are more commonly seen in teenagers.</div><div id=\"graphicVersion\">Graphic 67370 Version 4.0</div></div></div>"},"67371":{"type":"graphic_table","displayName":"Equipment tube thoracostomy","title":"Equipment list for tube thoracostomy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Equipment list for tube thoracostomy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>&#8226; 1 or 2 percent lidocaine</td> </tr> <tr> <td>&#8226; Needles (size 25 and size 18-21) and syringes for anesthetizing the skin</td> </tr> <tr> <td>&#8226; Scalpel, with No. 10 or 11 blade</td> </tr> <tr> <td>&#8226; Three Kelly clamps</td> </tr> <tr> <td>&#8226; Straight scissors</td> </tr> <tr> <td>&#8226; Chest tube</td> </tr> <tr> <td>&#8226; Silk suture (1 to 0)</td> </tr> <tr> <td>&#8226; Needle holder</td> </tr> <tr> <td>&#8226; Petroleum gauze</td> </tr> <tr> <td>&#8226; Drain sponges</td> </tr> <tr> <td>&#8226; Elastic tape</td> </tr> <tr> <td>&#8226; Sterile drapes, gown and gloves</td> </tr> <tr> <td>&#8226; Mask, protective eyewear</td> </tr> <tr> <td>&#8226; 2 percent chlorhexidine or povidone-iodine</td> </tr> <tr> <td>&#8226; Drainage system</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 67371 Version 2.0</div></div></div>"},"67374":{"type":"graphic_table","displayName":"Kidney pain in ADPKD","title":"Differential diagnosis and treatment of kidney pain in ADPKD","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis and treatment of kidney pain in ADPKD</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Pain characteristics</td> <td class=\"subtitle1\">Associated features</td> <td class=\"subtitle1\">U/A</td> <td class=\"subtitle1\">Cultures</td> <td class=\"subtitle1\">Imaging</td> <td class=\"subtitle1\">Treatment</td> </tr> <tr> <td rowspan=\"4\"><strong>Cyst hemorrhage</strong></td> <td>Sudden onset</td> <td>Usually afebrile</td> <td>+/- Hematuria</td> <td rowspan=\"4\">Negative</td> <td rowspan=\"4\">CT or MRI</td> <td>Analgesics</td> </tr> <tr> <td>Localized, unilateral</td> <td>Nausea/vomiting</td> <td rowspan=\"3\">Cultures negative</td> <td>Bed rest and hydration</td> </tr> <tr> <td>Sharp</td> <td rowspan=\"2\">Hematuria possible</td> <td>Compression on affected side</td> </tr> <tr> <td>Improves after a few days</td> <td>If shock: transfusions</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\"><strong>Pyelonephritis</strong></td> <td>Uni/bilateral</td> <td>High-grade fever</td> <td>WBCs/pyuria</td> <td>Urine positive</td> <td>Not indicated with positive cultures</td> <td rowspan=\"4\">IV antibiotics with good urine concentration (four weeks), followed by PO treatment</td> </tr> <tr> <td>Progressive</td> <td>Nausea/vomiting</td> <td>+/- Bacteria</td> <td rowspan=\"3\">+/- Positive Blood</td> <td rowspan=\"3\">CT or MRI</td> </tr> <tr> <td rowspan=\"2\">Diffuse ++</td> <td>Dysuria</td> <td rowspan=\"2\">+/- Hematuria</td> </tr> <tr> <td>Sepsis</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\"><strong>Cyst infection</strong></td> <td>Unilateral, localized</td> <td>Fever</td> <td rowspan=\"3\">Usually bland</td> <td>Urine negative</td> <td>CT or MRI</td> <td>Cyst penetrating antibiotics (four weeks minimum)</td> </tr> <tr> <td>Subacute</td> <td rowspan=\"2\">Nausea/vomiting</td> <td rowspan=\"2\">Blood positive in 50%</td> <td rowspan=\"2\">WBC tagging if uncertain</td> <td rowspan=\"2\">Longer recovery time</td> </tr> <tr> <td>Sharp ++</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\"><strong>Nephrolithiasis</strong></td> <td>Unilateral</td> <td>Usually afebrile unless infection</td> <td>Hematuria common</td> <td rowspan=\"5\">Usually negative unless infected stone</td> <td>Spiral CT</td> <td>IV hydration</td> </tr> <tr> <td>Acute, sharp +++</td> <td rowspan=\"4\">Nausea/vomiting</td> <td rowspan=\"4\">Crystals (uric acid and/or calcium oxalate)</td> <td rowspan=\"4\">Stone protocol</td> <td>Analgesics</td> </tr> <tr> <td>Paroxysmal</td> <td>Ureteroscopy</td> </tr> <tr> <td>Renal colic</td> <td>Percutaneous nephrolithotomy</td> </tr> <tr> <td>Radiation to pelvis or groin</td> <td>Open surgery</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\"><strong>Chronic cyst/renal pain</strong></td> <td>Diffuse</td> <td rowspan=\"4\">Afebrile</td> <td>Chronic hematuria possible</td> <td rowspan=\"4\">Negative</td> <td rowspan=\"4\">Usually negative</td> <td>Analgesics</td> </tr> <tr> <td>Constant</td> <td rowspan=\"3\">No WBC</td> <td>Cyst aspiration +/- sclerosis with ethanol or tetracyclines if few large cysts causing pain</td> </tr> <tr> <td>Variable intensity</td> <td>Cyst reduction surgery</td> </tr> <tr> <td>Positional in nature aggravated by inspiration, automobile, sudden impact movements</td> <td>Nephrectomy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">U/A: urinalysis; CT: computed tomography; MRI: magnetic resonance imaging; WBC: white blood cell; IV: intravenous; PO: orally.</div><div class=\"graphic_reference\">Original figure modified for this publication. Chapman AB, Rahbari-Oskoui F. Renal cystic disorders. In: Therapy in nephrology and hypertension, 3rd ed, Wilcox, CS (Ed). Saunders, Philadelphia 2008. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 67374 Version 2.0</div></div></div>"},"67375":{"type":"graphic_algorithm","displayName":"CGA groups BC Rx recommend","title":"Comprehensive geriatric assessment (CGA) and its implications for patients being treated for breast cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Comprehensive geriatric assessment (CGA) and its implications for patients being treated for breast cancer</div><div class=\"cntnt\"><img style=\"width:422px; height:389px;\" src=\"images/ONC/67375_CGA_groups_BC_Rx_recommend.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Balducci L. Geriatric oncology. Crit Rev Oncol Hematol 2003; 46:212. Copyright © 2003 Elsevier.</div><div id=\"graphicVersion\">Graphic 67375 Version 4.0</div></div></div>"},"67376":{"type":"graphic_picture","displayName":"Light microscopy embryonal CA","title":"Embryonal carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Embryonal carcinoma</div><div class=\"cntnt\"><img style=\"width:386px; height:259px;\" src=\"images/ONC/67376_Light_microscopy_embryonal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of a testicular embryonal carcinoma. Focus of embryonal carcinoma with central necrosis. Marked nuclear atypia characterizes the cells of embryonal carcinoma.</div><div class=\"graphic_reference\">Courtesy of Michael Weinstein, MD, PhD.</div><div id=\"graphicVersion\">Graphic 67376 Version 1.0</div></div></div>"},"67377":{"type":"graphic_table","displayName":"Clinical features HSAN","title":"Clinical features of the hereditary sensory and autonomic neuropathies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of the hereditary sensory and autonomic neuropathies</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disorder</td> <td class=\"subtitle1\">Gene</td> <td class=\"subtitle1\">Clinical features</td> </tr> <tr> <td rowspan=\"6\">HSAN1</td> <td rowspan=\"6\"> <p>SPTLC1</p> <p>SPTLC2</p> <p>ATL1</p> <p>DNMT1</p> <p>ATL3</p> </td> <td>Most are autosomal dominant</td> </tr> <tr> <td>Onset often in early adulthood but variable </td> </tr> <tr> <td>Distal sensory loss, foot ulcers</td> </tr> <tr> <td>Preservation of facial sensation</td> </tr> <tr> <td>Variable muscle wasting and weakness</td> </tr> <tr> <td>Variable neural deafness and dementia</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">HSAN2</td> <td rowspan=\"3\"> <p>WNK1/HSN2</p> <p>FAM134B</p> <p>KIF1A</p> </td> <td>Autosomal recessive</td> </tr> <tr> <td>Loss of pain, temperature, and tactile sensation</td> </tr> <tr> <td>Recurrent infection and fractures of the digits</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">HSAN3 (familial dysautonomia)</td> <td rowspan=\"4\">IKBKAP</td> <td>Autosomal recessive</td> </tr> <tr> <td>Progressive sensorimotor neuropathy</td> </tr> <tr> <td>Sympathetic autonomic dysfunction</td> </tr> <tr> <td>Smooth tongue without fungiform papillae</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"7\">HSAN4 (congenital insensitivity to pain with anhidrosis)</td> <td rowspan=\"7\">NTRK1</td> <td>Autosomal recessive</td> </tr> <tr> <td>Profound loss of pain sensitivity</td> </tr> <tr> <td>Defects in thermoregulation</td> </tr> <tr> <td>Anhydrosis</td> </tr> <tr> <td>Mild to moderate mental retardation</td> </tr> <tr> <td>Microcephaly</td> </tr> <tr> <td>Fungiform papillae are present</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\">HSAN5</td> <td rowspan=\"5\">NGFB</td> <td>Autosomal recessive</td> </tr> <tr> <td>Loss of pain and temperature sensation</td> </tr> <tr> <td>Normal muscle strength</td> </tr> <tr> <td>Normal reflexes</td> </tr> <tr> <td>Normal nerve conduction</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\"> <p>HSAN6</p> </td> <td rowspan=\"4\">DST</td> <td>Autosomal recessive; Ashkenazi Jewish</td> </tr> <tr class=\"divider_top\"> <td>Autonomic dysfunction</td> </tr> <tr class=\"divider_top\"> <td>Absent fungiform papillae</td> </tr> <tr class=\"divider_top\"> <td>Death by age 2 years</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\">HSAN7</td> <td rowspan=\"5\">SCN11A</td> <td>Autosomal dominant</td> </tr> <tr class=\"divider_top\"> <td>Congenital insensitivity to pain</td> </tr> <tr class=\"divider_top\"> <td>Self-mutilation, slow wound healing, painless bone fractures</td> </tr> <tr class=\"divider_top\"> <td>Gastrointestinal dysfunction</td> </tr> <tr class=\"divider_top\"> <td>Hyperhidrosis </td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">HSAN and dementia</td> <td rowspan=\"4\">PRNP</td> <td>Autosomal dominant</td> </tr> <tr class=\"divider_top\"> <td>Dementia</td> </tr> <tr class=\"divider_top\"> <td>Autonomic dysfunction</td> </tr> <tr class=\"divider_top\"> <td>Sensory loss</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Hereditary sensory neuropathy with spastic paraplegia</td> <td rowspan=\"3\">CCT5</td> <td>Autosomal recessive</td> </tr> <tr class=\"divider_top\"> <td>Spastic paraplegia</td> </tr> <tr class=\"divider_top\"> <td>Ulcerations of hands and feet</td> </tr> <tr class=\"divider_top\"> <td> <p>Insensitivity to pain</p> </td> <td rowspan=\"4\">SCN9A</td> <td rowspan=\"2\"> <p>Autosomal recessive:</p> <p>Insensitivity to pain</p> </td> </tr> <tr class=\"divider_top\"> <td>Paroxysmal extreme pain disorder</td> </tr> <tr class=\"divider_top\"> <td>Primary erythermalgia</td> <td rowspan=\"2\"> <p>Autosomal dominant:</p> <p>Paroxysmal extreme pain disorder</p> <p>Primary erythermalgia</p> <p>Small fiber neuropathy</p> </td> </tr> <tr class=\"divider_top\"> <td>Small fiber neuropathy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AD: autosomal dominant; AR: autosomal recessive; HSAN: hereditary sensory and autonomic neuropathy.</div><div id=\"graphicVersion\">Graphic 67377 Version 4.0</div></div></div>"},"67378":{"type":"graphic_table","displayName":"Etiology of rickets","title":"Etiology of rickets","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiology of rickets</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Deficient intake of minerals</td> </tr> <tr> <td>Inadequate calcium intake</td> </tr> <tr> <td>Inadequate phosphate intake</td> </tr> <tr> <td class=\"subtitle1_single\">Poor absorption of minerals</td> </tr> <tr> <td>Vitamin D deficiency</td> </tr> <tr> <td>25-hydroxylase deficiency&nbsp;</td> </tr> <tr> <td>1-alpha-hydroxylase deficiency (previously called vitamin D-dependent rickets type I or pseudovitamin D deficiency)</td> </tr> <tr> <td>Hereditary resistance to vitamin D&nbsp;(previously called vitamin D-dependent rickets type II)</td> </tr> <tr> <td>High phytin content (eg, soy formula)</td> </tr> <tr> <td>Antacids</td> </tr> <tr> <td>Anticonvulsants (eg, phenytoin, phenobarbital)</td> </tr> <tr> <td>Renal insufficiency</td> </tr> <tr> <td>Fanconi syndrome</td> </tr> <tr> <td>Hepatic insufficiency</td> </tr> <tr> <td>Fat malabsorption (eg, cystic fibrosis)</td> </tr> <tr> <td>Neocate brand&nbsp;formula (an&nbsp;elemental formula designed for children with multiple food allergies)</td> </tr> <tr> <td class=\"subtitle1_single\">Increased excretion of minerals</td> </tr> <tr> <td>Furosemide</td> </tr> <tr> <td class=\"sublist1_start\">Renal tubular dysfunction</td> </tr> <tr> <td class=\"sublist1\">Phosphaturia (eg, X-linked hypophosphatemic rickets, hereditary hypophosphatemic rickets with hypercalcuria, tumor-induced osteomalacia)</td> </tr> <tr> <td class=\"sublist1\">Renal tubular acidosis with hypercalciuria</td> </tr> <tr> <td class=\"sublist1\">Renal tubular damage (eg, cystinosis, tyrosinosis, galactosemia, fructose intolerance, Wilson disease, lead poisoning, other heavy metal poisoning)</td> </tr> <tr> <td>Tumors</td> </tr> <tr> <td class=\"subtitle1_single\">Local defect of bone cells</td> </tr> <tr> <td>Hypophosphatasia (alkaline phosphatase deficiency)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Bergstrom WH. Twenty ways to get rickets in the 1990's. Contemp Pediatr 1991; 8:88.</div><div id=\"graphicVersion\">Graphic 67378 Version 7.0</div></div></div>"},"67379":{"type":"graphic_picture","displayName":"TM air-fluid level","title":"Tympanic membrane with air-fluid levels","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tympanic membrane with air-fluid levels</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/PEDS/67379_TM_air_fluid_level.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An air-fluid level is appreciated when the tympanic membrane appears translucent above and opaque below a line demarcating the separation.</div><div id=\"graphicVersion\">Graphic 67379 Version 2.0</div></div></div>"},"67380":{"type":"graphic_table","displayName":"Warning signs of elder mistreatment","title":"History and warning signs for elder mistreatment/abuse","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">History and warning signs for elder mistreatment/abuse</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">History</td> </tr> <tr> <td class=\"indent1\">Advanced age (&#62;80 years)</td> </tr> <tr> <td class=\"indent1\">Disability in self-care</td> </tr> <tr> <td class=\"indent1\">Dementia</td> </tr> <tr> <td class=\"indent1\">Depression</td> </tr> <tr> <td class=\"indent1\">History of hip fracture</td> </tr> <tr> <td class=\"indent1\">History of stroke</td> </tr> <tr> <td class=\"indent1\">Social isolation</td> </tr> <tr> <td class=\"indent1\">Poor socioeconomic status</td> </tr> <tr> <td class=\"indent1\">External family stressors</td> </tr> <tr> <td class=\"indent1\">Unfavorable caretaker characteristics*</td> </tr> <tr> <td class=\"indent1\">Indicators of financial exploitation<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Institutional staffing shortages</td> </tr> <tr> <td class=\"indent1\">Inappropriate or excessive medications; failure to get needed medications; lack of appropriate monitoring of medications and their effects</td> </tr> <tr> <td class=\"indent1\">Substance abuse</td> </tr> <tr> <td class=\"subtitle1_single\">Physical/mental status examination</td> </tr> <tr> <td class=\"indent1\">Indicators of sexual abuse: pain, bruises, lacerations, bleeding in anal-genital areas; bruised breasts or abdomen; signs of venereal diseases</td> </tr> <tr> <td class=\"indent1\">Lacerations (including large skin tears, abrasions, burns, and bruises) without adequate explanation, especially on the trunk or other unusual locations</td> </tr> <tr> <td class=\"indent1\">Suspicious fractures in sites other than those seen in osteoporotic fractures, ie, wrist, hip, or vertebral body</td> </tr> <tr> <td class=\"indent1\">Malnutrition</td> </tr> <tr> <td class=\"indent1\">Focal findings on neurologic examination</td> </tr> <tr> <td class=\"indent1\">Signs of dehydration</td> </tr> <tr> <td class=\"indent1\">Pressure ulcers</td> </tr> <tr> <td class=\"indent1\">Dementia, psychiatric disorders, lack of mental capacity</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Unfavorable caretaker characteristics: mental illness, substance abuse, history of violent or antisocial behavior, depression, or financial dependency on the victim<SUP>[1,2]</SUP>.<br />¶ Indicators of financial exploitation: inability to pay for services (utilities, rent, medications, food) that the elder was previously able to pay for. Transfers of property when the elder lacks the capacity to consent<SUP>[3]</SUP>.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>​Lachs MS, Pillemer K. Elder abuse. Lancet 2004; 364:1265.</LI>&#xD;&#xA;<LI>Lachs MS, Pillemer K. Abuse and neglect of elderly persons. N Engl&nbsp;J Med 1995; 332:437.</LI>&#xD;&#xA;<LI>Reed K. When elders lose their cents: Financial abuse of the elderly.&nbsp;Clin Geriatr Med&nbsp;2005; 21:365.</LI></OL></div><div id=\"graphicVersion\">Graphic 67380 Version 4.0</div></div></div>"},"67381":{"type":"graphic_picture","displayName":"Biopsy specimen histo","title":"Biopsy specimen from a facial lesion (gomori methenamine silver stain; original magnification, x600)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Biopsy specimen from a facial lesion (gomori methenamine silver stain; original magnification, x600)</div><div class=\"cntnt\"><img style=\"width:504px; height:335px;\" src=\"images/ID/67381_Biopsy_specimen_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Lesho, E, Gunning, S, Wortmann, G. An AIDs patient with fever and rash. Clin Infect Dis 2005; 41:75. Copyright &#169;2005 University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 67381 Version 1.0</div></div></div>"},"67382":{"type":"graphic_figure","displayName":"Atrial flutter stroke risk","title":"Stroke risk in atrial flutter is related to concomitant atrial fibrillation","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Stroke risk in atrial flutter is related to concomitant atrial fibrillation</div><div class=\"cntnt\"><img style=\"width:500px; height:323px;\" src=\"images/CARD/67382_Atrial_flutter_stroke_risk.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Among 395,147 patients over 65 years of age, the risk of stroke in those with chronic atrial flutter is increased when atrial fibrillation (AF) is also present and is equivalent to the risk associated with only AF. The incidence of stroke in those with isolated atrial flutter is the same as the risk in the control patients who have no atrial arrhythmia.</div><div class=\"graphic_reference\">Data from Biblo LA, Yuan Z, Quan KJ, et al. Am J Cardiol 2001; 87:346.</div><div id=\"graphicVersion\">Graphic 67382 Version 2.0</div></div></div>"},"67383":{"type":"graphic_figure","displayName":"Left atrial compliance","title":"Left atrial pressure-volume relationship","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left atrial pressure-volume relationship</div><div class=\"cntnt\"><img style=\"width:328px; height:281px;\" src=\"images/CARD/67383_Left_atrial_compliance.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The relationship between the volume within a chamber and the resulting pressure defines chamber compliance or distensibility. The top curve (red) is from a left atrium with low compliance; small changes in volume result in marked changes in pressure. In this situation large &quot;v&quot; waves due to mitral regurgitation will be seen. The lower curve (blue) is from a left atrium that is very compliant; changes in volume result in only small changes in pressure. In this situation, the same degree of mitral regurgitation will cause small &quot;v&quot; waves.</div><div id=\"graphicVersion\">Graphic 67383 Version 1.0</div></div></div>"},"67386":{"type":"graphic_table","displayName":"Sarcoid monitoring","title":"Monitoring disease activity in sarcoidosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Monitoring disease activity in sarcoidosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Patients with active disease </td> </tr> <tr> <td class=\"subtitle2_single\">Every 3 to 4 months </td> </tr> <tr> <td class=\"indent1\">ROS including fever, fatigue, weight loss, visual disturbance, dyspnea, cough, palpitations, abdominal pain, numbness, tingling, lightheadedness, syncope </td> </tr> <tr> <td class=\"indent1\">PE including skin exam, palpation of lymph nodes, lung exam </td> </tr> <tr> <td class=\"indent1\">Lab tests based on sites of disease activity and medications </td> </tr> <tr> <td class=\"indent1\">Spirometry, diffusing capacity, ambulatory oximetry (or 6 minute walk) </td> </tr> <tr> <td class=\"subtitle2_single\">Every 6 months </td> </tr> <tr> <td class=\"indent1\">Ophthalmologic exam, if on hydroxychloroquine </td> </tr> <tr> <td class=\"subtitle2_single\">Every 12 months </td> </tr> <tr> <td class=\"indent1\">CBC and differential </td> </tr> <tr> <td class=\"indent1\">Creatinine </td> </tr> <tr> <td class=\"indent1\">Calcium </td> </tr> <tr> <td class=\"indent1\">AST, ALT, Alkaline phosphatase </td> </tr> <tr> <td class=\"indent1\">25 hydroxy vitamin D </td> </tr> <tr> <td class=\"indent1\">1,25 dihydroxy vitamin D </td> </tr> <tr> <td class=\"indent1\">EKG, sooner if palpitations, lightheadedness, syncope </td> </tr> <tr> <td class=\"indent1\">Ophthalmologic exam (slit lamp, fundoscopic, tonometric), sooner if visual disturbance </td> </tr> <tr> <td class=\"indent1\">Chest x-ray </td> </tr> <tr> <td class=\"subtitle1_single\">As indicated by symptoms or other tests </td> </tr> <tr> <td>HRCT</td> </tr> <tr> <td>Echocardiogram</td> </tr> <tr> <td>Holter monitoring</td> </tr> <tr> <td>Urinalysis</td> </tr> <tr> <td>TSH (association of thyroid autoimmunity and sarcoidosis)</td> </tr> <tr> <td>Bone density when glucocorticoid therapy initiated and then every 3 years</td> </tr> <tr> <td>MRI with gadolinium if neurologic symptoms (unless diabetic)</td> </tr> <tr> <td class=\"subtitle1_single\">Patients with inactive disease for 2 or more (?) years </td> </tr> <tr> <td class=\"subtitle2_single\">Every 12 to 18 months </td> </tr> <tr> <td class=\"indent1\">ROS including fever, fatigue, weight loss, visual disturbance, dyspnea, cough, palpitations, abdominal pain, numbness, tingling, lightheadedness, syncope </td> </tr> <tr> <td class=\"indent1\">PE including skin exam, palpation of lymph nodes, lung exam </td> </tr> <tr> <td class=\"indent1\">Spirometry, diffusing capacity, ambulatory oximetry (or 6 minute walk) </td> </tr> <tr> <td class=\"indent1\">CBC and differential </td> </tr> <tr> <td class=\"indent1\">Creatinine </td> </tr> <tr> <td class=\"indent1\">Calcium </td> </tr> <tr> <td class=\"indent1\">Liver enzymes </td> </tr> <tr> <td class=\"indent1\">1,25 dihydroxy vitamin D </td> </tr> <tr> <td class=\"indent1\">EKG, sooner if palpitations, lightheadedness, syncope </td> </tr> <tr> <td class=\"indent1\">Ophthalmologic exam, sooner if visual disturbance </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ROS: review of systems; PE: physical exam; CBC: complete blood count; AST: aspartate aminotransferase; ALT: alanine aminotransferase; EKG: electrocardiogram; HRCT: high resolution computed tomography; TSH: thyroid stimulating hormone; MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 67386 Version 3.0</div></div></div>"},"67387":{"type":"graphic_table","displayName":"Pesaro risk stratification","title":"Predictive variables of outcome after hematopoietic cell transplantation in pediatric patients with thalassemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Predictive variables of outcome after hematopoietic cell transplantation in pediatric patients with thalassemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Risk factor</td> <td class=\"subtitle1\">Adverse</td> <td class=\"subtitle1\">Favorable</td> </tr> <tr> <td>Hepatomegaly (cm from costal arch)</td> <td>&#62;2 cm</td> <td>&#8804;2 cm</td> </tr> <tr> <td>Liver fibrosis</td> <td>Presence</td> <td>Absence</td> </tr> <tr> <td>Iron chelation therapy</td> <td>Irregular</td> <td>Regular</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"3\">Risk class</td> </tr> <tr> <td colspan=\"3\">Class&nbsp;I patients have all three favorable risk factors</td> </tr> <tr> <td colspan=\"3\">Class&nbsp;II patients have one or two adverse risk factors</td> </tr> <tr> <td colspan=\"3\">Class&nbsp;III patients have all three adverse risk factors</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate topics on HCT for thalassemia and iron chelation therapy for details.</div><div class=\"graphic_footnotes\">HCT: hematopoietic cell transplantation.</div><div id=\"graphicVersion\">Graphic 67387 Version 4.0</div></div></div>"},"67388":{"type":"graphic_figure","displayName":"Troponin tropomyosin complex","title":"Troponin-tropomyosin complex","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Troponin-tropomyosin complex</div><div class=\"cntnt\"><img style=\"width:541px; height:346px;\" src=\"images/CARD/67388_Troponin_tropomyosin_comple.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Interaction of the troponin-tropomyosin complex with the myosin binding site in the actin strands. Top panel: Interaction of the myosin with actin is physically blocked by the presence of the protein tropomyosin, which lies in the groove of the thin filament formed by the two F-actin strands, occupying the myosin binding site. Bottom panel: Calcium (Ca2+) binds to troponin C, leading to a conformational change which moves the tropomyosin molecule and makes the myosin binding site accessible to the myosin head. The other troponins also contribute to this process. Troponin T serves to attach the troponin complex to actin and tropomyosin, and troponin I is an inhibitory protein which inhibits the ATPase of actomyosin.</div><div class=\"graphic_reference\">Courtesy of Timothy W Smith, MD, PhD.</div><div id=\"graphicVersion\">Graphic 67388 Version 1.0</div></div></div>"},"67389":{"type":"graphic_diagnosticimage","displayName":"Intramedullary nail treatment","title":"Femoral shaft fracture treated with flexible intramedullary nails","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Femoral shaft fracture treated with flexible intramedullary nails</div><div class=\"cntnt\"><img style=\"width:310px; height:504px;\" src=\"images/EM/67389_Intramedullary_nail_rx.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Klane White, MD.</div><div id=\"graphicVersion\">Graphic 67389 Version 3.0</div></div></div>"},"67391":{"type":"graphic_diagnosticimage","displayName":"Crohn nodular ileum SBFT","title":"Crohn disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Crohn disease</div><div class=\"cntnt\"><img style=\"width:300px; height:360px;\" src=\"images/GAST/67391_Crohns_nodular_ileum_SBFT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small bowel follow through examination demonstrates nodular filling defects arising on thickened folds in the terminal ileum (arrows). These features are characteristic of Crohn disease.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 67391 Version 3.0</div></div></div>"},"67393":{"type":"graphic_diagnosticimage","displayName":"Paraovarian cyst","title":"Paraovarian cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Paraovarian cyst</div><div class=\"cntnt\"><img style=\"width:432px; height:374px;\" src=\"images/OBGYN/67393_Paraovarian_cyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transvaginal ultrasound image of the left adnexa showing a paraovarian cyst. An anechoic structure is noted in the left adnexa separate from the left ovary. The cyst has a thin wall, as indicated by the arrow, with no identifiable ovarian tissue surrounding the cyst.</div><div class=\"graphic_reference\">Reproduced with permission from: Thomas D Shipp, MD. Copyright © Thomas D Shipp, MD.</div><div id=\"graphicVersion\">Graphic 67393 Version 2.0</div></div></div>"},"67394":{"type":"graphic_diagnosticimage","displayName":"Measuring angulation of a metacarpal shaft fracture","title":"Measuring angulation of a metacarpal shaft fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Measuring angulation of a metacarpal shaft fracture</div><div class=\"cntnt\"><img style=\"width:360px; height:281px;\" src=\"images/EM/67394_Measuring_MC_fx_angle_lat_v.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The amount of angulation of a metacarpal fracture is measured on a lateral radiograph. The angle (curved red line) between the axis of the proximal and the distal fragments is measured. This mid-shaft 5th metacarpal fracture is angulated about 70 degrees and will need orthopedic referral for probable surgical reduction and fixation.</div><div class=\"graphic_reference\">Courtesy of Kevin E Burroughs, MD.</div><div id=\"graphicVersion\">Graphic 67394 Version 3.0</div></div></div>"},"67395":{"type":"graphic_picture","displayName":"Pyogenic granuloma - chest","title":"Pyogenic granuloma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pyogenic granuloma</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/67395_Pyogenic_gran_chest.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A red, protruding vascular papule consistent with a pyogenic granuloma is present on the chest.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 67395 Version 3.0</div></div></div>"},"67396":{"type":"graphic_table","displayName":"SAC unscored portion","title":"Standardized assessment of concussion addendum<SUP>[1,2]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Standardized assessment of concussion addendum<SUP>[1,2]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"5\">Graded symptom checklist</td> </tr> <tr> <td><strong>Symptom</strong></td> <td><strong>None</strong></td> <td><strong>Mild</strong></td> <td><strong>Moderate</strong></td> <td><strong>Severe</strong></td> </tr> <tr class=\"divider_top\"> <td>Headache</td> <td>0</td> <td>1</td> <td>2</td> <td>3</td> </tr> <tr> <td>Nausea</td> <td>0</td> <td>1</td> <td>2</td> <td>3</td> </tr> <tr> <td>Vomiting</td> <td>0</td> <td>1</td> <td>2</td> <td>3</td> </tr> <tr> <td>Dizziness</td> <td>0</td> <td>1</td> <td>2</td> <td>3</td> </tr> <tr> <td>Poor balance</td> <td>0</td> <td>1</td> <td>2</td> <td>3</td> </tr> <tr> <td>Blurred/double vision</td> <td>0</td> <td>1</td> <td>2</td> <td>3</td> </tr> <tr> <td>Sensitivity to light</td> <td>0</td> <td>1</td> <td>2</td> <td>3</td> </tr> <tr> <td>Sensitivity to noise</td> <td>0</td> <td>1</td> <td>2</td> <td>3</td> </tr> <tr> <td>Ringing in the ears</td> <td>0</td> <td>1</td> <td>2</td> <td>3</td> </tr> <tr> <td>Poor concentration</td> <td>0</td> <td>1</td> <td>2</td> <td>3</td> </tr> <tr> <td>Memory problems</td> <td>0</td> <td>1</td> <td>2</td> <td>3</td> </tr> <tr> <td>Not feeling \"sharp\"</td> <td>0</td> <td>1</td> <td>2</td> <td>3</td> </tr> <tr> <td>Fatigue/sluggish</td> <td>0</td> <td>1</td> <td>2</td> <td>3</td> </tr> <tr> <td>Sadness/depression</td> <td>0</td> <td>1</td> <td>2</td> <td>3</td> </tr> <tr> <td>Irritability</td> <td>0</td> <td>1</td> <td>2</td> <td>3</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"5\">Amnesia</td> </tr> <tr> <td>Post-traumatic amnesia</td> <td>Yes</td> <td>No</td> <td colspan=\"2\">Length:</td> </tr> <tr> <td>Retrograde amnesia</td> <td>Yes</td> <td>No</td> <td colspan=\"2\">Length:</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"5\">Strength</td> </tr> <tr> <td>Right arm</td> <td colspan=\"2\">Normal</td> <td colspan=\"2\">Abnormal</td> </tr> <tr> <td>Right leg</td> <td colspan=\"2\">Normal</td> <td colspan=\"2\">Abnormal</td> </tr> <tr> <td>Left arm</td> <td colspan=\"2\">Normal</td> <td colspan=\"2\">Abnormal</td> </tr> <tr> <td>Left leg</td> <td colspan=\"2\">Normal</td> <td colspan=\"2\">Abnormal</td> </tr> <tr> <td>Sensation</td> <td colspan=\"2\">Normal</td> <td colspan=\"2\">Abnormal</td> </tr> <tr> <td>Coordination of limbs/gait</td> <td colspan=\"2\">Normal</td> <td colspan=\"2\">Abnormal</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">10</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=84612&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_lgnd\">The unscored portion of the Standardized Assessment of Concussion (SAC) includes a graded symptom checklist, a brief neurologic examination, and records the presence of post-traumatic and retrograde amnesia.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>McCrea M1, Kelly JP, Randolph C, et al. Standardized assessment of concussion (SAC): on-site mental status evaluation of the athlete. J Head Trauma Rehabil 1998; 13:27.</LI>&#xD;&#xA;<LI>Guskiewicz KM, Bruce SL, Cantu RC, et al. National Athletic Trainers' Association Position Statement: Management of Sport-Related Concussion. J Athl Train 2004; 39:280.</LI></OL></div><div id=\"graphicVersion\">Graphic 67396 Version 5.0</div></div></div>"},"67397":{"type":"graphic_figure","displayName":"Primary repair of urethral stricture","title":"Primary repair of urethral stricture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Primary repair of urethral stricture</div><div class=\"cntnt\"><img style=\"width:395px; height:558px;\" src=\"images/SURG/67397_Primary-repair-of-urethral-stricture.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 67397 Version 1.0</div></div></div>"},"67398":{"type":"graphic_diagnosticimage","displayName":"Fetal lissencephaly","title":"Fetal lissencephaly","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fetal lissencephaly</div><div class=\"cntnt\"><img style=\"width:244px; height:261px;\" src=\"images/PEDS/67398_Fetal_lissencephaly.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial magnetic resonance image of fetus at 29 weeks with diffusely smooth cortex, compatible with lissencephaly.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 67398 Version 1.0</div></div></div>"},"67399":{"type":"graphic_table","displayName":"Causes of goiter in adults","title":"Causes of goiter in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of goiter in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Multinodular goiter</td> </tr> <tr> <td>Iodine-deficiency goiter</td> </tr> <tr> <td class=\"sublist1_start\">Autoimmune/thyroiditis</td> </tr> <tr> <td class=\"sublist1\">Chronic autoimmune (Hashimoto's) thyroiditis</td> </tr> <tr> <td class=\"sublist1\">Painless thyroiditis</td> </tr> <tr> <td class=\"sublist1\">Subacute thyroiditis</td> </tr> <tr> <td class=\"sublist1\">Postpartum thyroiditis</td> </tr> <tr> <td class=\"sublist1\">Infectious thyroiditis</td> </tr> <tr> <td class=\"sublist1_start\">Ingestion of goitrogens</td> </tr> <tr> <td class=\"sublist1\">Iodine</td> </tr> <tr> <td class=\"sublist1\">Lithium carbonate</td> </tr> <tr> <td class=\"sublist1\">Foodstuffs (cassava, millet)</td> </tr> <tr> <td class=\"sublist1_start\">Thyroid infiltrative disease</td> </tr> <tr> <td class=\"sublist1\">Riedel's thyroiditis</td> </tr> <tr> <td class=\"sublist1\">Amyloid goiter</td> </tr> <tr> <td class=\"sublist1\">Histiocytosis</td> </tr> <tr> <td class=\"sublist1\">Cystinosis</td> </tr> <tr> <td class=\"sublist1\">Sarcoidosis</td> </tr> <tr> <td class=\"sublist1_start\">Toxic goiter</td> </tr> <tr> <td class=\"sublist1\">Graves' disease</td> </tr> <tr> <td class=\"sublist1\">Autonomously functioning thyroid adenoma</td> </tr> <tr> <td class=\"sublist1_start\">Thyroid cysts</td> </tr> <tr> <td class=\"sublist1\">Thyroglossal duct cysts</td> </tr> <tr> <td class=\"sublist1_start\">Thyroid adenomas</td> </tr> <tr> <td class=\"sublist1_start\">Thyroid carcinoma</td> </tr> <tr> <td class=\"sublist1\">Papillary carcinoma</td> </tr> <tr> <td class=\"sublist1\">Follicular carcinoma</td> </tr> <tr> <td class=\"sublist1\">Medullary carcinoma</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">4</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=99438&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div id=\"graphicVersion\">Graphic 67399 Version 2.0</div></div></div>"},"67402":{"type":"graphic_picture","displayName":"Pustules in pustular psoriasis","title":"Pustules in pustular psoriasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pustules in pustular psoriasis</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/67402_Psoriasis_pustules.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 67402 Version 6.0</div></div></div>"},"67403":{"type":"graphic_diagnosticimage","displayName":"Salter III fracture","title":"Salter III fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Salter III fracture</div><div class=\"cntnt\"><img style=\"width:362px; height:446px;\" src=\"images/EM/67403_Salter_III_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Oblique view of the right ankle. Salter Harris type III fracture of the medial aspect of the distal tibia in anatomic alignment (arrow).</div><div class=\"graphic_reference\">Courtesy of David Mathison, MD and Dewesh Agrawal, MD.</div><div id=\"graphicVersion\">Graphic 67403 Version 3.0</div></div></div>"},"67404":{"type":"graphic_figure","displayName":"Response to hypoglycemia","title":"Physiological and behavioral defenses against hypoglycemia","html":"<div class=\"graphic\"><div style=\"width: 639px\" class=\"figure\"><div class=\"ttl\">Physiological and behavioral defenses against hypoglycemia</div><div class=\"cntnt\"><img style=\"width:619px; height:505px;\" src=\"images/ENDO/67404_Response_to_hypoglycemia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Decrements in insulin and increments in glucagon are lost and increments in epinephrine and neurogenic symptoms are often attenuated in insulin-deficient - T1DM and advanced T2DM.</div><div class=\"graphic_footnotes\">SNS: sympathetic nervous system; PNS: parasympathetic nervous system; NE: norepinephrine; ACh: acetylcholine; α-cell: pancreatic islet α-cells; <sub>β</sub> -cell: pancreatic islet <sub>β</sub> -cells.</div><div class=\"graphic_reference\">Reproduced with permission from: Cryer PE. Mechanisms of sympathoadrenal failure and hypoglycemia in diabetes. J Clin Invest 2006; 116:1470. Copyright ©2006 American Society for Clinical Investigation.</div><div id=\"graphicVersion\">Graphic 67404 Version 3.0</div></div></div>"},"67406":{"type":"graphic_figure","displayName":"1st incision simple vulvectomy","title":"Incisions for total vulvectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Incisions for total vulvectomy</div><div class=\"cntnt\"><img style=\"width:242px; height:360px;\" src=\"images/OBGYN/67406_1stincissimplevulvecedt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Clitoris to be removed and (B) clitoris to be spared.</div><div id=\"graphicVersion\">Graphic 67406 Version 2.0</div></div></div>"},"67408":{"type":"graphic_figure","displayName":"Echinocandins target of activity","title":"Target of activity of echinocandins","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Target of activity of echinocandins</div><div class=\"cntnt\"><img style=\"width:404px; height:592px;\" src=\"images/ID/67408_Echinocandins_activity.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Fungal cell wall.<br> (B) Beta 1,3 glucan synthase complex.</div><div class=\"graphic_reference\">Courtesy of Russell Lewis, PharmD, FCCP, BCPS.</div><div id=\"graphicVersion\">Graphic 67408 Version 3.0</div></div></div>"},"67409":{"type":"graphic_table","displayName":"Common causes of syncope","title":"Common causes of syncope","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common causes of syncope</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Noncardiovascular</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Reflex mechanisms</td>\n\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Vasovagal and vasodepressor syncope (neurocardiogenic syncope)</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Micturition </td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Deglutition</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Cough</td>\n    </tr>\n    <tr>\n\n      <td class=\"sublist1_start\">Orthostatic hypotension</td>\n\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Dysautonomias</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Fluid depletion</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Illness, bedrest, deconditioning</td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Drugs - antidepressants, sympathetic blockers</td>\n    </tr>\n    <tr>\n\n      <td class=\"sublist1_start\">Psychogenic</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Hysterical</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Panic disorder</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Anxiety disorder</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Undiagnosed seizures</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Improperly diagnosed syncope - confusional states, eg, due to hypoglycemia, stroke</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td>Drug-induced loss of consciousness (consider alcohol, illicit drugs)</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Cardiovascular disease</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Arrhythmic causes</td>\n\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">AV block with bradycardia (structural changes, drugs) </td>\n    </tr>\n    <tr>\n\n      <td class=\"sublist1\">Sinus pauses/bradycardia (vagal causes, sick sinus syndrome, negative chronotropic drugs such as beta blockers and calcium channel blockers)</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1\">Ventricular tachycardia due to structural heart disease</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td class=\"sublist1_start\">Nonarrhythmic causes</td>\n\n\n    </tr>\n\n    <tr>\n      <td class=\"sublist1\">Hypertrophic cardiomyopathy </td>\n    </tr>\n    <tr>\n      <td class=\"sublist1\">Aortic stenosis</td>\n    </tr>\n    <tr>\n\n      <td class=\"subtitle1_single\">Syncope of unknown origin</td>\n\n\n    </tr>\n<tr>\n\n      <td>About 50 percent of patients presenting to the hospital</td>\n\n\n    </tr>\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 67409 Version 1.0</div></div></div>"},"67413":{"type":"graphic_table","displayName":"Motion sickness pharmacotherapy","title":"Common pharmacologic therapies for motion sickness","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common pharmacologic therapies for motion sickness</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Antidopaminergics </td> </tr> <tr> <td>Promethazine</td> </tr> <tr> <td>Metoclopramide</td> </tr> <tr> <td class=\"subtitle1_single\">Anticholinergic </td> </tr> <tr> <td>Scopolamine</td> </tr> <tr> <td class=\"subtitle1_single\">Antihistamines </td> </tr> <tr> <td>Meclizine</td> </tr> <tr> <td>Diphenhydramine</td> </tr> <tr> <td>Dimenhydrinate</td> </tr> <tr> <td>Cyclizine</td> </tr> <tr> <td>Buclizine</td> </tr> <tr> <td class=\"subtitle1_single\">Other </td> </tr> <tr> <td>Trimethobenzamide</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Information from: Gahlinger PM. Motion sickness: how to help your patients avoid travel travail. Postgraduate Medicine 1999; 106:177. Copyright ©1999 McGraw Hill Companies.</div><div id=\"graphicVersion\">Graphic 67413 Version 5.0</div></div></div>"},"67415":{"type":"graphic_picture","displayName":"GAVE endosc","title":"Gastric antral vascular ectasia (watermelon stomach)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastric antral vascular ectasia (watermelon stomach)</div><div class=\"cntnt\"><img style=\"width:320px; height:316px;\" src=\"images/GAST/67415_GAVE_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopy in a patient with gastric antral vascular ectasia (GAVE) shows the antrum and the pylorus (center) with erythematous radial stripes resembling the rind of a watermelon. The patient presented with iron deficiency anemia.</div><div class=\"graphic_reference\">Courtesy of Laurence Bailen, MD.</div><div id=\"graphicVersion\">Graphic 67415 Version 2.0</div></div></div>"},"67416":{"type":"graphic_table","displayName":"Causes of platelet transfusion refractoriness","title":"Causes of refractoriness to platelet transfusion","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of refractoriness to platelet transfusion</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Common</td> </tr> <tr> <td>Fever</td> </tr> <tr> <td>Sepsis and/or infection</td> </tr> <tr> <td>Active bleeding</td> </tr> <tr> <td>Splenomegaly</td> </tr> <tr> <td>Alloimmunization</td> </tr> <tr> <td class=\"subtitle1_single\">Less common</td> </tr> <tr> <td>Hematopoietic cell transplantation - autologous or allogeneic</td> </tr> <tr> <td>Disseminated intravascular coagulation</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate content on platelet refractoriness for additional discussion.</div><div id=\"graphicVersion\">Graphic 67416 Version 3.0</div></div></div>"},"67417":{"type":"graphic_diagnosticimage","displayName":"Smith Magenis syndrome","title":"Smith-Magenis syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Smith-Magenis syndrome</div><div class=\"cntnt\"><img style=\"width:446px; height:314px;\" src=\"images/HEME/67417_Smith_Magenis_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Smith-Magenis syndrome (SMS)&nbsp;is typified by a microdeletion of chromosome band 17p11.2. Fluorescence in situ hybridization (FISH) analysis of a patient's chromsomes is shown. The green control probe shows that an unrelated region of chromosome 17 is present in both chromosomes 17. The red probe, which detects the 17p11.2 region commonly deleted in SMS, only fluoresces on a single chromosome. This finding strongly supports the diagnosis of SMS.</div><div class=\"graphic_reference\">Courtesy of Athena Cherry, Stanford Hospital and Clinics.</div><div id=\"graphicVersion\">Graphic 67417 Version 3.0</div></div></div>"},"67418":{"type":"graphic_table","displayName":"Common drugs for external otitis","title":"Topical preparations for external otitis*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Topical preparations for external otitis*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"5\" width=\"12%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Topical preparation</td> <td class=\"subtitle1\">Trade name<br /> (United States)</td> <td class=\"subtitle1\">Antiseptic</td> <td class=\"subtitle1\">Glucocorticoid</td> <td class=\"subtitle1\">pH</td> <td class=\"subtitle1\">Preservative</td> <td class=\"subtitle1\">Notes</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Acidifying/antiseptic solution</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Acetic acid 2% otic solution</td> <td>Generic<br /> (formerly Acetasol)</td> <td>Acetic acid</td> <td>None</td> <td>3.5 to 5</td> <td>No additional</td> <td>Avoid use of acidifying antiseptic agents if tympanic membrane is known or suspected to be non-intact; contains boric acid</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Acidifying/antiseptic and glucocorticoid combination</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Acetic acid 2% and hydrocortisone 1% otic solution</td> <td>Acetasol HC, VoSol HC otic</td> <td>Acetic acid</td> <td>Hydrocortisone</td> <td>2 to 4</td> <td>No additional</td> <td>Avoid use of acidifying antiseptic agents if tympanic membrane is known or suspected to be non-intact; contains propylene glycol (drying agent) and benzethonium for promoting tissue penetration</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Antibiotic and glucocorticoid combinations</td> </tr> <tr> <td class=\"indent1\">Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension</td> <td>Ciprodex</td> <td>None</td> <td>Dexamethasone</td> <td>Buffered</td> <td>Benzalkonium chloride</td> <td>Contains boric acid</td> </tr> <tr> <td class=\"indent1\">Ciprofloxacin 0.2% and hydrocortisone 1% otic suspension</td> <td>Cipro HC otic</td> <td>None</td> <td>Hydrocortisone</td> <td>Buffered</td> <td>Benzyl alcohol</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Neomycin 0.35%, polymyxin B 10,000 units/mL, and hydrocortisone 0.5% otic solution</td> <td>Cortisporin otic</td> <td>None</td> <td>Hydrocortisone</td> <td>Acidic</td> <td>Potassium metabisulfite</td> <td>Avoid use of topical aminoglycosides if tympanic membrane is known or suspected to be non-intact</td> </tr> <tr> <td class=\"indent1\">Neomycin 0.33%, colistin 0.3%, and hydrocortisone 1% otic suspension</td> <td>Coly-Mycin S, Cortisporin TC</td> <td>None</td> <td>Hydrocortisone</td> <td>5</td> <td>Thimerosal</td> <td>Avoid use of topical aminoglycosides if tympanic membrane is known or suspected to be non-intact; contains thonzonium for promoting tissue penetration</td> </tr> <tr> <td class=\"indent1\">Gentamicin 0.3% and prednisolone 1% ophthalmic suspension<sup>&#182;</sup></td> <td>Pred-G</td> <td>None</td> <td>Prednisolone</td> <td>5.4 to 6.6</td> <td>Benzalkonium chloride</td> <td>Avoid use of topical aminoglycosides if tympanic membrane is known or suspected to be non-intact</td> </tr> <tr> <td class=\"indent1\">Tobramycin 0.3% and dexamethasone 0.1% ophthalmic suspension<sup>&#182;</sup></td> <td>TobraDex</td> <td>None</td> <td>Dexamethasone</td> <td>Buffered</td> <td>Benzalkonium chloride</td> <td>Avoid use of topical aminoglycosides if tympanic membrane is known or suspected to be non-intact</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Gentamicin 0.3% and betamethasone 0.1% otic solution</td> <td>Garasone<sup>&#916;</sup><br /> (not available in United States)</td> <td>None</td> <td>Betamethasone</td> <td>Buffered</td> <td>Benzalkonium chloride</td> <td>Avoid use of topical aminoglycosides if tympanic membrane is known or suspected to be non-intact; contains boric acid</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Antibiotic solutions</td> </tr> <tr> <td class=\"indent1\">Ciprofloxacin 0.2% otic solution</td> <td>Cetraxal otic</td> <td>None</td> <td>None</td> <td>Buffered</td> <td>None; single-use container</td> <td>Supplied as 0.5 mg per 0.25 mL individual use containers; contains povidone</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ofloxacin 0.3% otic solution</td> <td>Generic<br /> (formerly Floxin otic)</td> <td>None</td> <td>None</td> <td>6.5</td> <td>Benzalkonium chloride</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Glucocorticoid suspension</td> </tr> <tr> <td class=\"indent1\">Dexamethasone 0.1% ophthalmic suspension<sup>&#182;</sup></td> <td>Maxidex</td> <td>None</td> <td>Dexamethasone</td> <td>Buffered</td> <td>Benzalkonium chloride</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Topical preparations listed in chart are intended for use with an intact tympanic membrane. In cases where&nbsp;tympanic membrane&nbsp;is not intact, please refer to preparations discussed in UpToDate topics on suppurative otitis media.<br />¶&nbsp;These drugs or drug combinations are available only in ophthalmic preparations but can be applied directly to the ear to treat acute external otitis.&nbsp;<br />Δ Not available in the United States. Product shown is available in Canada and other countries.</div><div class=\"graphic_reference\">Prepared with data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Rosenfeld RM, Schwartz SR, Canon CR, et al. Clinical practice guideline: Acute otitis externa. Otolaryngol Head Neck Surg 2014; 150:S1.</li>&#xD;&#xA;    <li>United States prescribing information available at National Library of Medicine <a href=\"http://dailymed.nlm.nih.gov/dailymed/about.cfm\" target=\"_blank\">DailyMed</a> website (Accessed on March 17, 2014).</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 67418 Version 8.0</div></div></div>"},"67421":{"type":"graphic_figure","displayName":"Biliary reconstruction with Roux-en-Y hepaticojejunostomy","title":"Biliary reconstruction with Roux-en-Y hepaticojejunostomy","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Biliary reconstruction with Roux-en-Y hepaticojejunostomy</div><div class=\"cntnt\"><img style=\"width:538px; height:629px;\" src=\"images/SURG/67421_Biliary_reconstruction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The most common reconstruction for proximal bile duct injury is Roux-en-Y hepaticojejunostomy. Biliary stent placement helps reduce stricture at the anastomosis. Once a silastic stent has been positioned to replace the prior drainage catheter, the small bowel is divided and the distal small bowel (Roux limb) brought up and sutured to the bile duct (end-to-side hepaticojejunostomy). An end-to-side bowel-bowel anastomosis completes the Roux-en-Y reconstruction.</div><div id=\"graphicVersion\">Graphic 67421 Version 5.0</div></div></div>"},"67422":{"type":"graphic_picture","displayName":"Factitial dermatitis 3","title":"Factitial ulcerations","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Factitial ulcerations</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/67422_Factitial_dermatitis_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Self inflicted ulcerations. The lesions have a geometric shape and are at the same stage of development.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 67422 Version 3.0</div></div></div>"},"67423":{"type":"graphic_picture","displayName":"Example of intratumoral heterogeneity in digestive tract NETs","title":"Example of intratumoral heterogeneity in a digestive tract neuroendocrine tumor","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Example of intratumoral heterogeneity in a digestive tract neuroendocrine tumor</div><div class=\"cntnt\"><img style=\"width:548px; height:468px;\" src=\"images/ONC/67423_Exintratumoralheterogen.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Example of intratumoral heterogeneity on the same slide in a single tumor.<br />(A) A single high-power field (HPF) from one area shows no mitotic figures (H&amp;E, 400x original magnification).<br />(B) HPF from another area of the same tumor shows four mitotic figures (H&amp;E, 400x original magnification).<br />(C) Ki-67 staining in the same area as \"A\" shows a labeling index of &lt;1% (grade 1) (200x original magnification).<br />(D) Ki-67 staining in the same area as \"B\" shows a labeling index of 3.4% (grade 2) (200x original magnification).</div><div class=\"graphic_footnotes\">H&amp;E: hematoxylin and eosin stained.</div><div id=\"graphicVersion\">Graphic 67423 Version 3.0</div></div></div>"},"67424":{"type":"graphic_picture","displayName":"Vesicular erythema migrans","title":"Vesicular erythema migrans (EM)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vesicular erythema migrans (EM)</div><div class=\"cntnt\"><img style=\"width:370px; height:569px;\" src=\"images/ID/67424_EMvesicular.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) EM lesion in a patient with Lyme disease. The lesion has the complex \"bull's eye\" appearance with central clearing and vesicular lesions.<br />(B) Vesicles may appear near the center of an erythema migrans lesion. This patient subsequently developed facial nerve palsy and had positive serology for Lyme disease.</div><div class=\"graphic_reference\">Panel A courtesy of Robert Basow, MD; Panel B courtesy of Eugene D Shapiro, MD, FAAP.</div><div id=\"graphicVersion\">Graphic 67424 Version 4.0</div></div></div>"},"67425":{"type":"graphic_picture","displayName":"Murine typhus rash","title":"Murine typhus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Murine typhus</div><div class=\"cntnt\"><img style=\"width:184px; height:324px;\" src=\"images/ID/67425_Murine_typhus_rash.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Maculopapular rash in a man with serologically confirmed murine typhus acquired in northern India while on vacation.</div><div class=\"graphic_reference\">Courtesy of Daniel J Sexton, MD.</div><div id=\"graphicVersion\">Graphic 67425 Version 1.0</div></div></div>"},"67427":{"type":"graphic_table","displayName":"Zoonoses from dogs C","title":"Zoonoses dogs, continued","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Zoonoses dogs, continued</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Transmission</td>\n<td class=\"subtitle1\">Organism</td>\n<td class=\"subtitle1\">Human symptoms</td>\n<td class=\"subtitle1\">Canine symptoms</td>\n<td class=\"subtitle1\">Geographic distribution</td>\n</tr>\n<tr>\n<td colspan=\"1\" rowspan=\"2\">Aerosol</td>\n<td>Bordetella bronchiseptica</td>\n<td>Asymptomatic to upper respiratory tract infections to pneumonia</td>\n<td>Kennel cough</td>\n<td>Worldwide</td>\n</tr>\n<tr>\n\n<td>Coxiella burnetii</td>\n<td>Q fever, including A self-limited flu-like illness, +/- pneumonia, +/- hepatitis, +/- endocarditis</td>\n<td>Asymptomatic; infection may cause abortion or rapid death of newborn pups</td>\n<td>Worldwide</td>\n</tr>\n<tr>\n<td>Urine</td>\n<td>Leptospira interrogans</td>\n<td>Leptosiprosis, subclinical to severe, potentially fatal illness</td>\n<td>Similar to human disease</td>\n<td>Worldwide</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 67427 Version 1.0</div></div></div>"},"67428":{"type":"graphic_waveform","displayName":"Computing SAECG","title":"Computation of the signal averaged ECG","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computation of the signal averaged ECG</div><div class=\"cntnt\"><img style=\"width:320px; height:426px;\" src=\"images/CARD/67428_ComputingSAECGedt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Successive QRS complexes meeting a predetermined coefficient of similarity are aligned (within the window indicated by dashed lines) on an ongoing basis. Their rolling arithmetic mean is computed until a predetermined noise threshold is achieved (shown as the typical criterion of the standard deviation of the TP segment &lt;1 microvolts). The QRS complex is then filtered and analyzed for late potentials, defined when the filtered QRS duration is &gt;114 milliseconds, root mean square (RMS) voltage in the terminal 40 milliseconds is &lt;20 microvolts, and low amplitude signal (LAS) duration (the terminal signal duration from 40 mV to isopotential) is &gt;38 milliseconds.</div><div id=\"graphicVersion\">Graphic 67428 Version 5.0</div></div></div>"},"67429":{"type":"graphic_table","displayName":"Pagets nodal mets and survival","title":"Axillary node metastasis and survival in Paget disease of the breast with and without a palpable mass","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Axillary node metastasis and survival in Paget disease of the breast with and without a palpable mass</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  colspan=\"1\" class=\"subtitle1\">\r\n  \r\n   &nbsp;\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Palpable mass\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   No palpable mass\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Number of patients (percent)</td>\r\n  \r\n   <td>31 (62)</td>\r\n  \r\n   <td>19 (38)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Axillary node metastasis, percent</td>\r\n  \r\n   <td>64.5</td>\r\n  \r\n   <td>0</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Five-year survival, percent</td>\r\n  \r\n   <td>45</td>\r\n  \r\n   <td>100</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Ten-year survival, percent</td>\r\n  \r\n   <td>33.4</td>\r\n  \r\n   <td>100</td>\r\n  \r\n   </tr>\r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">11.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=47383&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Paget_nodal_mets_survival.htm</title></head></div><div class=\"graphic_reference\">Data from Paone JF, Baker RR. Pathogenesis and treatment of Paget's disease of the breast. Cancer 1981; 48:825.</div><div id=\"graphicVersion\">Graphic 67429 Version 3.0</div></div></div>"},"67431":{"type":"graphic_table","displayName":"Monoclonal gammopathies disease definitions","title":"Disease definitions for the monoclonal gammopathies: MGUS and related disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Disease definitions for the monoclonal gammopathies: MGUS and related disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type of monoclonal gammopathy</td> <td class=\"subtitle1\">Premalignancy with low risk of progression (1 to 2 percent per year)</td> <td class=\"subtitle1\">Premalignancy with high risk of progression (10 percent per year)</td> <td class=\"subtitle1\" colspan=\"2\">Malignancy</td> </tr> <tr class=\"divider_bottom\"> <td><strong>IgG and IgA (non-IgM)</strong>*</td> <td> <p><strong>Non-IgM MGUS</strong></p> <em>All criteria must be met:</em> <ol> <li>Serum monoclonal protein &#60;3 g/dL </li> <li>Clonal BM plasma cells &#60;10 percent </li> <li>Absence of end-organ damage such as CRAB that can be attributed to the PCPD&nbsp; and absence of myeloma defining biomarkers</li> </ol> </td> <td> <p><strong>Smoldering MM</strong></p> <em>Both criteria must be met:</em> <ol> <li>Serum monoclonal protein (IgG or IgA) &#8805;3 g/dL and/or clonal BM plasma cells &#8805;10 percent </li> <li>Absence of end-organ damage such as CRAB that can be attributed to a PCPD and absence of myeloma defining biomarkers</li> </ol> </td> <td colspan=\"2\"> <p><strong>MM</strong></p> <p>Clonal BM plasma cells &#8805;10 percent</p> <em>Plus one of the following:</em> <ol> <li>Evidence of end-organ damage that can be attributed to the underlying PCPD, specifically one or more of the following: <ul> <li>Hypercalcemia: serum calcium &#8805;11.5 mg/dL </li> <li>Renal insufficiency: serum creatinine &#62;2 mg/dL or estimated creatinine clearance &#60;40 mL/min </li> <li>Anemia: normochromic, normocytic with hemoglobin &#62;2 g/dL below lower limit of normal or hemoglobin &#60;10 g/dL </li> <li>Bone lesions: lytic lesions &#8805;5 mm attributed to a PCPD on skeletal radiography, MRI, CT, or PET/CT </li> </ul> </li> <li>Presence of one of the following biomarkers: <ul> <li>&#8805;60 percent clonal plasma cells in bone marrow </li> <li>Involved/uninvolved FLC ratio &#8805;100 </li> <li>MRI with &#62;1 focal bone lesion </li> </ul> </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>IgM</strong></td> <td> <p><strong>IgM MGUS</strong><sup>&#916;</sup></p> <em>All criteria must be met:</em> <ol> <li>Serum monoclonal protein &#60;3 g/dL </li> <li>Clonal BM lymphoplasmacytic cells &#60;10 percent </li> <li>Absence of end-organ damage such as anemia, constitutional symptoms, hyperviscosity, lymphadenopathy, or hepatosplenomegaly that can be attributed to the underlying lymphoproliferative disorder </li> </ol> </td> <td> <p><strong>Smoldering WM</strong></p> <em>Both criteria must be met:</em> <ol> <li>Serum IgM monoclonal protein &#8805;3 g/dL and/or BM lymphoplasmacytic infiltration &#8805;10 percent </li> <li>No evidence of anemia, constitutional symptoms, hyperviscosity, lymphadenopathy, or hepatosplenomegaly that can be attributed to the underlying lymphoproliferative disorder </li> </ol> </td> <td> <p><strong>WM</strong></p> <em>All criteria must be met:</em> <ol> <li>IgM monoclonal gammopathy (regardless of size of M protein) </li> <li>&#8805;10 percent BM lymphoplasmacytic infiltration (usual intertrabecular) by small lymphocytes that exhibit plasmacytoid or plasma cell differentiation and a typical immunophenotype (eg, surface IgM<sup>+</sup>, CD5<sup>&#177;</sup>, CD10<sup>&ndash;</sup>, CD19<sup>+</sup>, CD20<sup>+</sup>, CD23<sup>&ndash;</sup>) that satisfactorily excludes other lymphoproliferative disorders including chronic lymphocytic leukemia and mantle cell lymphoma </li> <li>Evidence of anemia, constitutional symptoms, hyperviscosity, lymphadenopathy, or hepatosplenomegaly that can be attributed to the underlying lymphoproliferative disorder </li> </ol> </td> <td> <p><strong>IgM myeloma</strong></p> <em>All criteria must be met:</em> <ol> <li>Symptomatic monoclonal PCPD characterized by a serum IgM monoclonal protein regardless of size </li> <li>Presence of &#8805;10 percent plasma cells on BM biopsy </li> <li>Presence of lytic bone lesions related to the underlying plasma cell disorder and/or translocation t(11:14) on FISH </li> </ol> </td> </tr> <tr> <td><strong>Light chain</strong></td> <td> <p><strong>Light chain MGUS</strong></p> <em>All criteria must be met:</em> <ol> <li>Abnormal FLC ratio (&#60;0.26 or &#62;1.65) </li> <li>Increased level of the appropriate involved light chain (increased &#954; FLC in patients with ratio &#62;1.65 and increased &#955; FLC in patients with ratio &#60;0.26) </li> <li>No immunoglobulin heavy chain expression on immunofixation </li> <li>Clonal BM plasma cells &#60;10 percent </li> <li>Absence of end-organ damage such as CRAB that can be attributed to the PCPD </li> </ol> </td> <td> <p><strong>Idiopathic Bence Jones proteinuria</strong></p> <em>All criteria must be met:</em> <ol> <li>Urinary monoclonal protein on urine protein electrophoresis &#8805;500 mg/24 h and/or clonal BM plasma cells &#8805;10 percent </li> <li>No immunoglobulin heavy chain expression on immunofixation </li> <li>Absence of end-organ damage such as CRAB that can be attributed to the PCPD </li> </ol> </td> <td colspan=\"2\"> <p><strong>Light chain MM</strong><sup>&#916;</sup></p> Same as MM except no evidence of immunoglobulin heavy chain expression on immunofixation</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BM: bone marrow; CRAB: hyper<strong>c</strong>alcemia, <strong>r</strong>enal insufficiency, <strong>a</strong>nemia, and <strong>b</strong>one lesions; FISH: fluorescent in situ hybridization; FLC: free light chain; MGUS: monoclonal gammopathy of undetermined significance; MM: multiple myeloma; PCPD: plasma cell proliferative disorder; WM: Waldenstr&ouml;m macroglobulinemia.<br />* Occasionally, patients with IgD and IgE monoclonal gammopathies have been described and will be considered part of this category as well.<br />&Delta; Note that conventionally IgM MGUS is considered a subtype of MGUS, and similarly light chain MM is considered a subtype of MM. Unless specifically distinguished, when the terms MGUS and MM are used in general, they include IgM MGUS and light chain MM, respectively.</div><div class=\"graphic_reference\">Modified&nbsp;with permission from: Rajkumar SV, Kyle RA, Buadi FK. Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence. Mayo Clin Proc 2010; 85:945. Copyright © 2010 Quadrant HealthCom, Inc.</div><div id=\"graphicVersion\">Graphic 67431 Version 6.0</div></div></div>"},"67432":{"type":"graphic_figure","displayName":"Biliopancreatic diversion","title":"Biliopancreatic diversion","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Biliopancreatic diversion</div><div class=\"cntnt\"><img style=\"width:502px; height:677px;\" src=\"images/SURG/67432_Biliopancreatic-diversion-NEW.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The biliopancreatic diversion procedure consists of a partial gastrectomy and gastroileostomy with a long segment of Roux limb and a short common channel (the part of the small bowel that receives both food and biliopancreatic secretions), resulting in fat and starch malabsorption. The use of this procedure results in high rates of protein malnutrition, anemia, diarrhea, and stomal ulceration, limiting its use.</div><div id=\"graphicVersion\">Graphic 67432 Version 2.0</div></div></div>"},"67434":{"type":"graphic_diagnosticimage","displayName":"Pediatric hip fracture","title":"Delbet type III hip fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Delbet type III hip fracture</div><div class=\"cntnt\"><img style=\"width:432px; height:338px;\" src=\"images/EM/67434_Hip_fx_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ten-year-old girl who fell from a tree.</div><div class=\"graphic_reference\">Courtesy of Klane White, MD.</div><div id=\"graphicVersion\">Graphic 67434 Version 3.0</div></div></div>"},"67436":{"type":"graphic_diagnosticimage","displayName":"Gastric bezoar after gastrectomy UGI","title":"Gastric bezoar","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastric bezoar</div><div class=\"cntnt\"><img style=\"width:258px; height:288px;\" src=\"images/GAST/67436_Bezoar_after_gastrectomy_UG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An upper gastrointestinal series in a patient status post-Billroth 2 gastrectomy and vagotomy shows a large bezoar in the distended stomach. The patient presented with gastric outlet obstruction that arose from a stricture at the gastrojejunal anastomosis (arrow) and from vagotomy-induced hypoperistalsis.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 67436 Version 4.0</div></div></div>"},"67437":{"type":"graphic_picture","displayName":"Fibroma","title":"Oral fibroma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oral fibroma</div><div class=\"cntnt\"><img style=\"width:360px; height:234px;\" src=\"images/PEDS/67437_Fibroma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A fibroma resulting from a chronic dental abscess in a five-year-old child.</div><div class=\"graphic_reference\">Reproduced with permission from: Caulfield PW, Griffen AL. Dental caries. An infectious and transmissible disease. Pediatr Clin North Am 2000: 47;1001. Copyright © 2000 W.B. Saunders.</div><div id=\"graphicVersion\">Graphic 67437 Version 3.0</div></div></div>"},"67438":{"type":"graphic_algorithm","displayName":"Pediatric tachycardia algorithm","title":"Pediatric tachycardia algorithm (with a pulse and poor perfusion)","html":"<div class=\"graphic\"><div style=\"width: 648px\" class=\"figure\"><div class=\"ttl\">Pediatric tachycardia algorithm (with a pulse and poor perfusion)</div><div class=\"cntnt\"><img style=\"width:628px; height:790px;\" src=\"images/EM/67438_Pediatrictachycardiaedt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IO: intraosseous; IV: intravenous; ECG: electrocardiogram.<br />* Vagal maneuvers: In infants or young children, place a plastic bag filled with ice and cold water over the face for 15 to 30 seconds or stimulate the rectum with a thermometer. In older children, encourage bearing down (Valsalva maneuver) for 15 to 20 seconds. Carotid massage and orbital pressure should not be performed in children.</div><div class=\"graphic_reference\">Reprinted with permission. Pediatric Advanced Life Support: 2010. American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. © 2010 American Heart Association, Inc. This algorithm remains unchanged in the 2015 update. </div><div id=\"graphicVersion\">Graphic 67438 Version 26.0</div></div></div>"},"67439":{"type":"graphic_figure","displayName":"Anatomy of the testicular appendages","title":"Anatomy of the testicular appendages","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anatomy of the testicular appendages</div><div class=\"cntnt\"><img style=\"width:381px; height:491px;\" src=\"images/PEDS/67439_Testicular-appendages-edit.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 67439 Version 3.0</div></div></div>"},"67440":{"type":"graphic_diagnosticimage","displayName":"Microdeletion FISH","title":"Microdeletion FISH","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Microdeletion FISH</div><div class=\"cntnt\"><img style=\"width:342px; height:291px;\" src=\"images/PC/67440_Microdeletion_FISH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">FISH of a patient with a deletion of chromosome 22q, the DiGeorge/VCF syndrome. As shown, the VCF probe only hybridizes with one chromosome 22 (red line and arrows). By comparison, the fluorescent green probe is a control probe that hybridizes to both chromosomes.</div><div class=\"graphic_footnotes\">FISH: fluorescence in situ hybridization; VCF: velocardiofacial. </div><div id=\"graphicVersion\">Graphic 67440 Version 3.0</div></div></div>"},"67441":{"type":"graphic_figure","displayName":"Central neck dissection","title":"Lymphadenectomy for thyroid cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lymphadenectomy for thyroid cancer</div><div class=\"cntnt\"><img style=\"width:442px; height:680px;\" src=\"images/SURG/67441_Central_neck_dissection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The extent of lymphadenectomy is based on the type of thyroid malignancy and the risk for lymph node metastasis.</div><div class=\"graphic_reference\">By permission of Mayo Foundation for Medical Education and Research. All rights reserved. Copyright &#169; 2010.</div><div id=\"graphicVersion\">Graphic 67441 Version 2.0</div></div></div>"},"67442":{"type":"graphic_picture","displayName":"Pathology of granuloma annulare - early lesion","title":"Pathology of granuloma annulare - early lesion (H&E 100x)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pathology of granuloma annulare - early lesion (H&amp;E 100x)</div><div class=\"cntnt\"><img style=\"width:426px; height:314px;\" src=\"images/DERM/67442_Earlylesion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This low-power view shows two areas of incomplete collagen degeneration in the left lower and left upper areas of this photomicrograph with broad areas of normal intervening dermal collagen (interstitial or incomplete granuloma annulare). Early lesions of this type fail to show central areas of acellular necrobiotic collagen (H&amp;E 100x).</div><div class=\"graphic_footnotes\">H&amp;E: hematoxylin and eosin.</div><div id=\"graphicVersion\">Graphic 67442 Version 2.0</div></div></div>"},"67443":{"type":"graphic_figure","displayName":"Transient ATN post AAA repair","title":"Serial changes in GFR after aortic aneurysm surgery","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Serial changes in GFR after aortic aneurysm surgery</div><div class=\"cntnt\"><img style=\"width:582px; height:222px;\" src=\"images/NEPH/67443_Transient_ATN_post_AAA_repa.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Serial changes in GFR after elective aortic aneurysm surgery involving an infrarenal clamp (left panel) or suprarenal clamp (right panel); the latter procedure was associated with 20 to 80 minutes of total renal ischemia. One to two hours after surgery with suprarenal clamping, there was a 60 percent reduction in GFR. By 24 hours, however, partial recovery had occurred, and the GFR was almost normal by 48 hours.</div><div class=\"graphic_footnotes\">GFR: glomerular filtration rate.</div><div class=\"graphic_reference\">Data from: Myers BD, Miller C, Mehigan JT, et al. Nature of the renal injury following total renal ischemia in man. J Clin Invest 1984; 73:329.</div><div id=\"graphicVersion\">Graphic 67443 Version 3.0</div></div></div>"},"67444":{"type":"graphic_table","displayName":"Unintended loss rate after MPR by starting number","title":"Unintended loss rate after MPR by starting number","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Unintended loss rate after MPR by starting number</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Starting number (n)</td> <td class=\"subtitle1\">Loss rate (percent)</td> </tr> <tr> <td class=\"centered\">2 (30)</td> <td class=\"centered\">2.5</td> </tr> <tr> <td class=\"centered\">3 (549)</td> <td class=\"centered\">5.3</td> </tr> <tr> <td class=\"centered\">4 (294)</td> <td class=\"centered\">5.4</td> </tr> <tr> <td class=\"centered\">5 (86)</td> <td class=\"centered\">4.7</td> </tr> <tr> <td class=\"centered\">&#8805;6</td> <td class=\"centered\">12.9</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Stone J, Eddleman K, Lynch L, Berkowitz RL. A single center experience with 1000 consecutive cases of multifetal pregnancy reduction. Am J Obstet Gynecol 2002; 187:1163. Copyright &copy; 2002 Elsevier.</div><div id=\"graphicVersion\">Graphic 67444 Version 3.0</div></div></div>"},"67445":{"type":"graphic_picture","displayName":"Adenoid cystic carcinoma Light","title":"Adenoid cystic carcinoma","html":"<div class=\"graphic\"><div style=\"width: 574px\" class=\"figure\"><div class=\"ttl\">Adenoid cystic carcinoma</div><div class=\"cntnt\"><img style=\"width:554px; height:249px;\" src=\"images/ONC/67445_Adenoid_cystic_carcinoma_Li.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left panel shows a low power representation of a well-differentiated adenoid cystic carcinoma. The cribriform spaces are filled with blue mucinous or pink hyalin material (black arrow). The right panel is a higher power view demonstrating bone invasion. Perineural invasion is also typical.</div><div class=\"graphic_reference\">Courtesy of G Kenneth Haines, MD.</div><div id=\"graphicVersion\">Graphic 67445 Version 5.0</div></div></div>"},"67448":{"type":"graphic_diagnosticimage","displayName":"Osteochondroma humerus","title":"Osteochondroma of the humerus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Osteochondroma of the humerus</div><div class=\"cntnt\"><img style=\"width:265px; height:540px;\" src=\"images/PEDS/67448_Osteochondroma_humerus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A radiograph of an osteochondroma of the humerus shows a lesion that is directly contiguous with the marrow space.</div><div class=\"graphic_reference\">Reproduced with permission from: Rubin R, Strayer DS. Rubin's Pathology: Clinicopathologic Foundations of Medicine, Fifth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 67448 Version 3.0</div></div></div>"},"67452":{"type":"graphic_diagnosticimage","displayName":"HAPE CT","title":"HAPE CT","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">HAPE CT</div><div class=\"cntnt\"><img style=\"width:432px; height:376px;\" src=\"images/EM/67452_HAPE_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With HAPE, chest CT often reveals patchy alveolar infiltrates, predominantly in the right central hemithorax, which become more confluent and bilateral as the illness progresses.</div><div class=\"graphic_footnotes\">HAPE: high altitude pulmonary edema; CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Scott A Gallagher, MD.</div><div id=\"graphicVersion\">Graphic 67452 Version 3.0</div></div></div>"},"67453":{"type":"graphic_figure","displayName":"Trendelenburg test","title":"Trendelenburg test","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Trendelenburg test</div><div class=\"cntnt\"><img style=\"width:356px; height:452px;\" src=\"images/EM/67453_Trendelenburg_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normally, the pelvis stays level when a patient stands on one leg. When standing on the affected leg, the pelvis tilts downward toward the unaffected side (as pictured in the abnormal patient above) because of gluteal muscle weakness on the affected side (right side in abnormal patient above).</div><div id=\"graphicVersion\">Graphic 67453 Version 3.0</div></div></div>"},"67454":{"type":"graphic_figure","displayName":"Sinuses and OMC external","title":"Location of the paranasal sinuses and ostiomeatal complex","html":"<div class=\"graphic\"><div style=\"width: 646px\" class=\"figure\"><div class=\"ttl\">Location of the paranasal sinuses and ostiomeatal complex</div><div class=\"cntnt\"><img style=\"width:626px; height:376px;\" src=\"images/ALLRG/67454_Sinuses_and_OMC_external.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic figure showing location of the frontal, ethmoid, maxillary, and sphenoid sinuses, as well as the ostiomeatal complex (also called the ostiomeatal unit).</div><div id=\"graphicVersion\">Graphic 67454 Version 3.0</div></div></div>"},"67457":{"type":"graphic_table","displayName":"Conditions needing ventilation","title":"Examples of conditions often requiring mechanical ventilation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of conditions often requiring mechanical ventilation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Alveolar filling processes</td> </tr> <tr> <td class=\"indent1\">Pneumonitis - infectious, aspiration</td> </tr> <tr> <td class=\"indent1\">Noncardiogenic pulmonary edema/ARDS (eg, due to infection, inhalation injury, near drowning, transfusion, contusion, high altitude)</td> </tr> <tr> <td class=\"indent1\">Cardiogenic pulmonary edema</td> </tr> <tr> <td class=\"indent1\">Pulmonary hemorrhage</td> </tr> <tr> <td class=\"indent1\">Tumor (eg, choriocarcinoma)</td> </tr> <tr> <td class=\"indent1\">Alveolar proteinosis</td> </tr> <tr> <td class=\"indent1\">Intravascular volume overload of any cause</td> </tr> <tr> <td class=\"subtitle1_single\">Pulmonary vascular disease</td> </tr> <tr> <td class=\"indent1\">Pulmonary thromboembolism</td> </tr> <tr> <td class=\"indent1\">Amniotic fluid embolism, tumor emboli</td> </tr> <tr> <td class=\"subtitle1_single\">Diseases causing airways obstruction: central</td> </tr> <tr> <td class=\"indent1\">Tumor</td> </tr> <tr> <td class=\"indent1\">Laryngeal angioedema</td> </tr> <tr> <td class=\"indent1\">Tracheal stenosis</td> </tr> <tr> <td class=\"subtitle1_single\">Diseases causing airways obstruction: distal</td> </tr> <tr> <td class=\"indent1\">Acute exacerbation of chronic obstructive pulmonary disease</td> </tr> <tr> <td class=\"indent1\">Acute, severe asthma</td> </tr> <tr> <td class=\"subtitle1_single\">Hypoventilation: decreased central drive</td> </tr> <tr> <td class=\"indent1\">General anesthesia</td> </tr> <tr> <td class=\"indent1\">Drug overdose</td> </tr> <tr> <td class=\"subtitle1_single\">Hypoventilation: peripheral nervous system/respiratory muscle dysfunction</td> </tr> <tr> <td class=\"indent1\">Amyotrophic lateral sclerosis</td> </tr> <tr> <td class=\"indent1\">Cervical quadriplegia</td> </tr> <tr> <td class=\"indent1\">Guillain-Barr&#233; syndrome</td> </tr> <tr> <td class=\"indent1\">Myasthenia gravis</td> </tr> <tr> <td class=\"indent1\">Tetanus, tick bite, ciguatera poisoning</td> </tr> <tr> <td class=\"indent1\">Toxins (eg, strychnine)</td> </tr> <tr> <td class=\"indent1\">Muscular dystrophy, myotonic dystrophy, myositis</td> </tr> <tr> <td class=\"subtitle1_single\">Hypoventilation: chest wall and pleural disease</td> </tr> <tr> <td class=\"indent1\">Kyphoscoliosis</td> </tr> <tr> <td class=\"indent1\">Trauma (eg, flail chest)</td> </tr> <tr> <td class=\"indent1\">Massive pleural effusion</td> </tr> <tr> <td class=\"indent1\">Pneumothorax</td> </tr> <tr> <td class=\"subtitle1_single\">Increased ventilatory demand</td> </tr> <tr> <td class=\"indent1\">Severe sepsis</td> </tr> <tr> <td class=\"indent1\">Septic shock</td> </tr> <tr> <td class=\"indent1\">Severe metabolic acidosis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ARDS: adult respiratory distress syndrome.</div><div id=\"graphicVersion\">Graphic 67457 Version 3.0</div></div></div>"},"67459":{"type":"graphic_figure","displayName":"Stepwise asthma Rx 5 to 11 years","title":"Stepwise approach for managing asthma in children 5 to 11 years of age","html":"<div class=\"graphic\"><div style=\"width: 637px\" class=\"figure\"><div class=\"ttl\">Stepwise approach for managing asthma in children 5 to 11 years of age</div><div class=\"cntnt\"><img style=\"width:617px; height:559px;\" src=\"images/PULM/67459_Stepwise_asthma_5_to_11_yrs.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The stepwise approach is meant to assist, not replace, the clinical decision making required to meet individual patient needs. If alternative treatment is used and response is inadequate, discontinue it and use the preferred treatment before stepping up. Theophylline is a less desirable alternative due to the need to monitor serum concentration levels. Step 1 and step 2 medications are based on evidence A. Step 3 inhaled glucocorticoids + adjunctive therapy and&nbsp;inhaled glucocorticoids&nbsp;are based on evidence B for efficacy of each treatment and extrapolation from comparator trials in older children and adults. Comparator trials are not available for this age group. Steps 4 to 6 are based on expert opinion and extrapolation from studies in older children and adults. Immunotherapy for steps 2 to 4 is based on evidence B for house dust mites, animal danders, and pollens. Evidence is weak or lacking for molds and cockroaches. Evidence is strongest for immunotherapy with single allergens. The role of allergy in asthma is greater in children than in adults. Clinicians who administer immunotherapy should be prepared and equipped to identify and treat anaphylaxis that may occur.<br /><STRONG>Alphabetical order is used when more than one treatment option is listed within either preferred or alternative therapy.</STRONG></div><div class=\"graphic_footnotes\">SABA: inhaled short-acting beta<SUB>2 </SUB>agonist; PRN: \"as needed\"; LTRA: leukotriene receptor antagonist; LABA: long-acting inhaled beta<SUB>2 </SUB>agonist; EIB: exercise-induced bronchospasm.</div><div class=\"graphic_reference\">Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.</div><div id=\"graphicVersion\">Graphic 67459 Version 10.0</div></div></div>"},"67460":{"type":"graphic_table","displayName":"Proposed ATPIII LDL goals","title":"Proposed modifications of ATP III LDL-cholesterol goals and cutpoints for therapeutic lifestyle changes and drug therapy in different risk categories","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Proposed modifications of ATP III LDL-cholesterol goals and cutpoints for therapeutic lifestyle changes and drug therapy in different risk categories</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Risk category</td> <td class=\"subtitle1\">LDL goal</td> <td class=\"subtitle1\">LDL level at which to initiate therapeutic lifestyle changes</td> <td class=\"subtitle1\">LDL level at which to consider drug therapy*</td> </tr> <tr class=\"divider_bottom\"> <td><strong>High risk:</strong> Coronary heart disease (CHD) or CHD risk equivalent (10-year risk &#62;20 percent)<sup>&#182;</sup></td> <td>&#60;100 mg/dL (2.58 mmol/L); optional goal &#60;70 mg/dL (1.82 mmol/L) in very high risk<sup>&#916;</sup></td> <td>&#8805;100 mg/dL (2.58 mmol/L)<sup>&#9674;</sup> &#8805;</td> <td>100 mg/dL (2.58 mmol/L)<sup>&#167;</sup>; &#60;100 mg/dL (2.58 mmol/L) consider drug options</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Moderately high risk:</strong> 2 or more risk factors (10-year risk 10 to 20 percent)<sup>&#165;</sup></td> <td>&#60;130 mg/dL (3.36 mmol/L)<sup>&#135;</sup></td> <td>&#8805;130 mg/dL (3.36 mmol/L)<sup>&#9674;</sup> &#8805;</td> <td>&#8805;130 mg/dL (3.36 mmol/L); 100 to 129 mg/dL consider drug options<sup>&#134;</sup></td> </tr> <tr class=\"divider_bottom\"> <td><strong>Moderate risk:</strong> 2 or more risk factors (10-year risk &#60;10 percent)<sup>&#165;</sup></td> <td>&#60;130 mg/dL (3.36 mmol/L)</td> <td>&#8805;130 mg/dL (3.36 mmol/L)</td> <td>&#8805;160 mg/dL (4.13 mmol/L)</td> </tr> <tr> <td><strong>Lower risk:</strong> 0 to 1 risk factor**</td> <td>&#60;160 mg/dL (4.13 mmol/L)</td> <td>&#8805;160 mg/dL (4.13 mmol/L)</td> <td>&#8805;190 mg/dL (4.91 mmol/L); 160 to 189 mg/dL consider drug options</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* When LDL lowering drug therapy is given, it is advised that the intensity of therapy be sufficient to achieve at least a 30 to 40 percent reduction in LDL levels.<br />¶ CHD risk equivalents include noncoronary forms of atherosclerotic disease (peripheral arterial disease, abdominal aortic aneurysm, and carotid artery disease), and diabetes. Ten-year risk defined by modified Framingham risk score.<br />Δ Very high risk favors the optional LDL goal of &lt;70 mg/dL (1.82 mmol/L) and, in patients with high triglycerides, non-HDL cholesterol goal of &lt;100 mg/dL.<br /><FONT class=lozenge>◊</FONT> ≥ Any individual at high or moderately high risk who has lifestyle-related risk factors (eg, obesity, physical inactivity, hypertriglyceridemia, low HDL-cholesterol [&lt;40 mg/dL (1.04 mmol/L)], or metabolic syndrome is a candidate for therapeutic lifestyle changes to modify these risk factors independent of LDL level.<br />§ If baseline LDL is &lt;100 mg/dL (2.58 mmol/L), institution of an LDL lowering drug is an option. This can be combined with a fibrate or nicotinic acid if a high-risk person has hypertriglyceridemia or low HDL (&lt;40 mg/dL (1.04 mmol/L).<br />¥ Risk factors that modify LDL goals include cigarette smoking; hypertension (BP ≥140/90 mmHg or on antihypertensive medication)s; low HDL-cholesterol (&lt;40 mg/dL [1.03 mmol/L]); family history of premature CHD (CHD in male first degree relative &lt;55 years or CHD in female first degree relative &lt;65 years); age (men ≥45 years; women ≥55 years). HDL-cholesterol ≥60 mg/dL (1.55 mmol/L) counts as a negative risk factor; its presence removes one risk factor from the total count.<br />‡ Optional LDL goal &lt;100 mg/dL (2.58 mmol/L).<br />† For moderately high risk persons with LDL of 100 to 129 mg/dL (2.58 to 3.35 mmol/L) at baseline or after lifestyle changes, initiation of an LDL lowering drug to achieve an LDL &lt;100 mg/L is an option.<br />** Almost all people with 0 to 1 risk factor have a 10-year risk &lt;10 percent; thus, 10-year risk assessment in people with 0 to 1 risk factor is not necessary.</div><div class=\"graphic_reference\">Adapted from: Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Circulation 2002; 106:3143; with modifications from Grundy SM, Cleeman JI, Merz CN, et al, Circulation 2004; 110:227.</div><div id=\"graphicVersion\">Graphic 67460 Version 4.0</div></div></div>"},"67461":{"type":"graphic_table","displayName":"Characteristics of abdominal endovascular devices","title":"Characteristics of abdominal endovascular devices","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of abdominal endovascular devices</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Endograft</td> <td class=\"subtitle1\">Materials graft/support</td> <td class=\"subtitle1\">Suprarenal fixation</td> <td class=\"subtitle1\">Active proximal fixation/hooks</td> <td class=\"subtitle1\">Native aortic neck diameter<br /> (range in mm)</td> <td class=\"subtitle1\">Native iliac diameter<br /> (range in mm)</td> <td class=\"subtitle1\">Maximum bifurcated main body device/introducer sheath diameter<br /> (French, OD)</td> <td class=\"subtitle1\">Potential advantages</td> </tr> <tr> <td>Endurant (Medtronic)</td> <td>Polyester/electropolished nitinol</td> <td>Yes</td> <td>Yes</td> <td>19 to 32</td> <td>8 to 25</td> <td>20</td> <td>Indications include short (10 mm) aortic neck, angulated neck</td> </tr> <tr> <td>Powerlink (Endologix)</td> <td>PTFE/cobalt chromium alloy</td> <td>Yes</td> <td>No</td> <td>18 to 32</td> <td>10 to 23</td> <td>17</td> <td>Anatomic fixation at native iliac bifurcation, low profile</td> </tr> <tr> <td>AFX2 (Endologix)</td> <td>PTFE/cobalt chromium alloy</td> <td>Yes</td> <td>No</td> <td>18 to 32</td> <td>10 to 23</td> <td>17</td> <td>Anatomic fixation at bifurcation, low profile</td> </tr> <tr> <td>Excluder (Gore)</td> <td>PTFE/nitinol</td> <td>No</td> <td>Yes</td> <td>19 to 29</td> <td>10 to 18.5</td> <td>20</td> <td>C3 delivery system, ability to recapture and reposition body, delivery sheath with hemostatic seal</td> </tr> <tr> <td>Zenith (Cook Medical)</td> <td>Polyester/stainless steel</td> <td>Yes</td> <td>Yes</td> <td>18 to 32</td> <td>8 to 20</td> <td>26</td> <td>Spiral Z flexible limbs</td> </tr> <tr> <td>Zenith fenestrated (Cook Medical)</td> <td>Polyester/stainless steel</td> <td>Yes</td> <td>Yes</td> <td>19 to 31</td> <td>9 to 21</td> <td>20</td> <td>Juxtarenal aneurysm</td> </tr> <tr> <td>Ovation (Trivascular)</td> <td>PTFE/nitinol</td> <td>Yes</td> <td>Yes</td> <td>16 to 30</td> <td>8 to 20</td> <td>15</td> <td>Low profile, proximal sealing ring</td> </tr> <tr> <td>Aorfix (Lombard)</td> <td>PTFE/nitinol</td> <td>No</td> <td>Yes</td> <td>19 to 29</td> <td>8 to 19</td> <td>22</td> <td>Flexibility, angulated neck</td> </tr> <tr> <td>Incraft&nbsp; (Cordis)</td> <td>Polyester/nitinol</td> <td>Yes</td> <td>No</td> <td>27 to 31</td> <td>10 to 24</td> <td>16</td> <td>Ultra low profile</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">OD: outer diameter; PTFE: polytetrafluoroethylene.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>http://www.goremedical.com.</LI>&#xD;&#xA;<LI>http://www.cookmedical.com.</LI>&#xD;&#xA;<LI>http://www.endologix.com.</LI>&#xD;&#xA;<LI>http://www.medtronic.com.</LI>&#xD;&#xA;<LI>http://www.trivascular.com.</LI>&#xD;&#xA;<LI>http://www.lombardmedical.com.</LI>&#xD;&#xA;<LI>http://www.emea.cordis.com.</LI></OL></div><div id=\"graphicVersion\">Graphic 67461 Version 8.0</div></div></div>"},"67464":{"type":"graphic_waveform","displayName":"Late decelerations","title":"Late decelerations","html":"<div class=\"graphic\"><div style=\"width: 572px\" class=\"figure\"><div class=\"ttl\">Late decelerations</div><div class=\"cntnt\"><img style=\"width:552px; height:321px;\" src=\"images/OBGYN/67464_Late_decelerations_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Late decelerations are characterized by a gradual decrease and return to baseline of the fetal heart rate associated with uterine contractions. The deceleration is delayed in timing, with the nadir of the deceleration occurring after the peak of the contraction. The onset, nadir, and recovery usually occur after the onset, peak, and termination of a contraction. In this example, variability is minimal.</div><div class=\"graphic_reference\">Courtesy of Robert L Barbieri, MD.</div><div id=\"graphicVersion\">Graphic 67464 Version 3.0</div></div></div>"},"67467":{"type":"graphic_picture","displayName":"Optic disc infiltration","title":"Leukemic and lymphomatous optic disc infiltration","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Leukemic and lymphomatous optic disc infiltration</div><div class=\"cntnt\"><img style=\"width:288px; height:483px;\" src=\"images/PEDS/67467_Optic_disc_infiltration.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Top: Leukemic infiltration. Bottom: Lymphomatous infiltration.</div><div class=\"graphic_reference\">Courtesy of Karl C Golnik, MD.</div><div id=\"graphicVersion\">Graphic 67467 Version 2.0</div></div></div>"},"67468":{"type":"graphic_table","displayName":"SMART mnemonic for difficult cricothyrotomy","title":"The SMART© mnemonic for difficult cricothyrotomy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The SMART© mnemonic for difficult cricothyrotomy</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td><strong>S</strong>urgery (recent or remote)</td>\r\n        </tr>\r\n        <tr>\r\n            <td><strong>M</strong>ass (hematoma, abscess, or other mass)</td>\r\n        </tr>\r\n        <tr>\r\n            <td><strong>A</strong>ccess or <strong>A</strong>natomy&nbsp;(obesity, poor landmarks, or otherwise poor access)</td>\r\n        </tr>\r\n        <tr>\r\n            <td><strong>R</strong>adiation (or other tissue deformity or scarring)</td>\r\n        </tr>\r\n        <tr>\r\n            <td><strong>T</strong>umor (including intrinsic airway tumor)</td>\r\n        </tr>\r\n    </tbody>\r\n</table>\r\n<!--[if gte mso 9]><xml>\r\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">3</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&#60;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=13102&#38;amp;Mode=Edit&quot;&#62;&#60;/a&#62;</mso:Edit_Table>\r\n<mso:Media_Notes msdt:dt=\"string\"></mso:Media_Notes>\r\n</mso:CustomDocumentProperties>\r\n</xml><![endif]--></div><div class=\"graphic_reference\">Adapted from: Brown III CA, Walls RM. Identification of the difficult and failed airway. In: The Walls Manual of Emergency Airway Management, 5th ed, Brown III CA, Sakles JC, Mick NW (Eds), Wolters Kluwer, Philadelphia&nbsp;2018.</div><div id=\"graphicVersion\">Graphic 67468 Version 7.0</div></div></div>"},"67469":{"type":"graphic_diagnosticimage","displayName":"Toddlers fracture tibia","title":"Nondisplaced toddler's fracture of the distal tibia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nondisplaced toddler's fracture of the distal tibia</div><div class=\"cntnt\"><img style=\"width:360px; height:320px;\" src=\"images/EM/67469_Toddlers_fx_tibia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This plain AP radiograph shows the characteristic faint fracture line indicating a nondisplaced spiral fracture (between black hash marks).</div><div class=\"graphic_reference\">Courtesy of Eglal Shalaby-Rana, MD.</div><div id=\"graphicVersion\">Graphic 67469 Version 3.0</div></div></div>"},"67470":{"type":"graphic_table","displayName":"Glucose transporters","title":"Glucose transporters","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Glucose transporters</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td><strong>Intestine, kidney</strong>: energy-dependent sodium/glucose co-transporters</td>\n\n\n    </tr>\n\n    <tr>\n\n      <td><strong>Other cells:</strong> diffusion via GLUTs 1 to 5</td>\n\n\n    </tr>\n\n    <tr>\n      <td>GLUT-1: All human tissues; high affinity; basal glucose uptake; central nervous system, vessels </td>\n    </tr>\n    <tr>\n\n      <td colspan=\"1\">GLUT-2: Beta cells, liver; low-affinity; post-prandial action</td>\n\n\n    </tr>\n    <tr>\n      <td>GLUT-3: All tissues; major transporter in neurons of central nervous system</td>\n    </tr>\n    <tr>\n      <td>GLUT-4: Skeletal muscle, fat cells; insulin stimulates translocation from cytosol to cell membranes</td>\n    </tr>\n    <tr>\n      <td>GLUT-5: Brush border of intestinal cells, liver, spermatozoa; primarily transports fructose</td>\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 67470 Version 1.0</div></div></div>"},"67471":{"type":"graphic_table","displayName":"CALGB regimen ALL adults","title":"Cancer and Leukemia Group B (CALGB) study 9111 chemotherapy regimen for acute lymphoblastic leukemia in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cancer and Leukemia Group B (CALGB) study 9111 chemotherapy regimen for acute lymphoblastic leukemia in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Course I: Induction (4 weeks)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">For patients &#60;60 years old:</td> </tr> <tr> <td class=\"indent1\">Cyclophosphamide</td> <td>IV</td> <td>1200 mg/m<sup>2</sup></td> <td>Day 1</td> </tr> <tr> <td class=\"indent1\">Daunorubicin</td> <td>IV</td> <td>45 mg/m<sup>2</sup>/day</td> <td>Days 1-3</td> </tr> <tr> <td class=\"indent1\">Vincristine</td> <td>IV</td> <td>2 mg</td> <td>Days 1, 8, 15, 22</td> </tr> <tr> <td class=\"indent1\">Prednisone</td> <td>PO</td> <td>60 mg/m<sup>2</sup>/day</td> <td>Days 1-21</td> </tr> <tr> <td class=\"indent1\">Asparaginase (E. coli)</td> <td>SC/IM</td> <td>6000 units/m<sup>2</sup></td> <td>Days 5, 8, 11, 15, 18, 22</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">For patients &#8805;60 years old:</td> </tr> <tr> <td class=\"indent1\">Cyclophosphamide</td> <td>IV</td> <td>800 mg/m<sup>2</sup></td> <td>Day 1</td> </tr> <tr> <td class=\"indent1\">Daunorubicin</td> <td>IV</td> <td>30 mg/m<sup>2</sup>/day</td> <td>Days 1-3</td> </tr> <tr> <td class=\"indent1\">Vincristine</td> <td>IV</td> <td>2 mg</td> <td>Days 1, 8, 15, 22</td> </tr> <tr> <td class=\"indent1\">Prednisone</td> <td>PO</td> <td>60 mg/m<sup>2</sup>/day</td> <td>Days 1-7</td> </tr> <tr> <td class=\"indent1\">Asparaginase (E. coli)</td> <td>SC/IM</td> <td>6000 units/m<sup>2</sup></td> <td>Days 5, 8, 11, 15, 18, 22</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">All patients receive filgrastim (G-CSF) 5 mcg/kg subcutaneously once per day starting on day 4 and continuing until the ANC is &#62;1000/microL on two consecutive determinations &#62;24 hours apart.</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Course IIA: Early intensification (4 weeks; repeat once for Course IIB)</td> </tr> <tr> <td>Intrathecal methotrexate</td> <td>IT</td> <td>15 mg</td> <td>Day 1</td> </tr> <tr> <td>Cyclophosphamide</td> <td>IV</td> <td>1000 mg/m<sup>2</sup></td> <td>Day 1</td> </tr> <tr> <td>Mercaptopurine</td> <td>PO</td> <td>60 mg/m<sup>2</sup>/day</td> <td>Days 1-14</td> </tr> <tr> <td>Cytarabine</td> <td>SC</td> <td>75 mg/m<sup>2</sup>/day</td> <td>Days 1-4, 8-11</td> </tr> <tr> <td>Vincristine</td> <td>IV</td> <td>2 mg</td> <td>Days 15, 22</td> </tr> <tr> <td>Asparaginase (E. coli)</td> <td>SC/IM</td> <td>6000 units/m<sup>2</sup></td> <td>Days 15, 18, 22, 25</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Course III: CNS prophylaxis and interim maintenance (12 weeks)</td> </tr> <tr> <td>Cranial irradiation</td> <td>&nbsp;</td> <td>2400 cGy</td> <td>Days 1-12</td> </tr> <tr> <td>Intrathecal methotrexate</td> <td>IT</td> <td>15 mg</td> <td>Days 1, 8, 15, 22, 29</td> </tr> <tr> <td>Mercaptopurine</td> <td>PO</td> <td>60 mg/m<sup>2</sup>/day</td> <td>Days 1-70</td> </tr> <tr> <td>Methotrexate</td> <td>PO</td> <td>20 mg/m<sup>2</sup></td> <td>Days 36, 43, 50, 57, 64</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Course IV: Late intensification (8 weeks)</td> </tr> <tr> <td>Doxorubicin</td> <td>IV</td> <td>30 mg/m<sup>2</sup></td> <td>Days 1, 8, 15</td> </tr> <tr> <td>Vincristine</td> <td>IV</td> <td>2 mg</td> <td>Days 1, 8, 15</td> </tr> <tr> <td>Dexamethasone</td> <td>PO</td> <td>10 mg/m<sup>2</sup>/day</td> <td>Days 1-14</td> </tr> <tr> <td>Cyclophosphamide</td> <td>IV</td> <td>1000 mg/m<sup>2</sup></td> <td>Day 29</td> </tr> <tr> <td>Thioguanine</td> <td>PO</td> <td>60 mg/m<sup>2</sup>/day</td> <td>Days 29-42</td> </tr> <tr> <td>Cytarabine</td> <td>SC</td> <td>75 mg/m<sup>2</sup>/day</td> <td>Days 29-32, 36-39</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Course V: Prolonged maintenance (until 24 months from diagnosis)</td> </tr> <tr> <td>Vincristine</td> <td>IV</td> <td>2 mg</td> <td>Day 1 of every 4 weeks</td> </tr> <tr> <td>Prednisone</td> <td>PO</td> <td>60 mg/m<sup>2</sup>/day</td> <td>Days 1-5 of every 4 weeks</td> </tr> <tr> <td>Mercaptopurine</td> <td>PO</td> <td>60 mg/m<sup>2</sup>/day</td> <td>Days 1-28</td> </tr> <tr> <td>Methotrexate</td> <td>PO</td> <td>20 mg/m<sup>2</sup></td> <td>Days 1, 8, 15, 22</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ANC: absolute neutrophil count; IT: intrathecal; IV: intravenous; IM: intramuscular; PO: oral; SC: subcutaneous.</div><div class=\"graphic_reference\">Data from: Acute Leukemias VI: Prognostic factors and treatment strategies, Buchner T, Hiddeman W, Wormann B (Eds), Springer-Verlag, Berlin 1997. p.677; Larson RA, Dodge RK, Burns CP, Blood 1995; 85:2025; and Larson RA, Dodge RK, Linker CA, et al. Blood 1998; 92:1556-1564.</div><div id=\"graphicVersion\">Graphic 67471 Version 10.0</div></div></div>"},"67473":{"type":"graphic_figure","displayName":"TIMI risk score for non-ST elevation ACS","title":"TIMI risk score for non-ST elevation ACS","html":"<div class=\"graphic\"><div style=\"width: 473px\" class=\"figure\"><div class=\"ttl\">TIMI risk score for non-ST elevation ACS</div><div class=\"cntnt\"><img style=\"width:453px; height:489px;\" src=\"images/CARD/67473_Risk_score_outcome_UAP_NSTE.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rates of all-cause mortality, myocardial infarction, and severe recurrent ischemia prompting urgent revascularization at 14 days after randomization according to the number of risk factors among patients with a non-ST elevation acute coronary syndrome (ACS) in TIMI 11B and ESSENCE. The risk factors were age &ge;65 years; presence of at least three risk factors for coronary disease; prior coronary stenosis of &ge;50 percent; presence of ST segment deviation on admission ECG; at least two anginal episodes in prior 24 hours; use of aspirin in prior seven days; and elevated serum cardiac biomarkers. Event rates increased significantly as the TIMI risk score rose. Patients are considered to be at low risk with a score of 0 to 2; intermediate risk with a score of 3 to 4; and high risk with a score of 5 to 7.</div><div class=\"graphic_reference\">Adapted from: Antman EM, Cohen M, Bernink PJ, et al. JAMA 2000; 284:835.</div><div id=\"graphicVersion\">Graphic 67473 Version 4.0</div></div></div>"},"67475":{"type":"graphic_picture","displayName":"Pressure-induced injury by stage","title":"Pressure-induced injury by stage","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Pressure-induced injury&nbsp;by stage</div><div class=\"cntnt\"><img style=\"width:512px; height:526px;\" src=\"images/SURG/67475_Pressureulcerstages.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pressure-induced injury staging​<SUP>[1]</SUP>.<br />(A)&nbsp;Stage&nbsp;1&nbsp;– Skin intact but with nonblanchable redness.<br />(B) Stage&nbsp;2&nbsp;– Partial-thickness loss of skin with exposed dermis. <br />(C) Stage&nbsp;3 – Full-thickness loss of skin, in which adipose (fat) is visible in the ulcer and granulation tissue and epibole (rolled wound edges) are often present. <br />(D) Stage&nbsp;4 –&nbsp;Full-thickness skin and tissue loss with exposed or directly palpable fascia, muscle, tendon, ligament, cartilage, or bone in the ulcer. <br />Not shown:<br />Unstageable&nbsp;pressure injury&nbsp;– Full-thickness skin and tissue loss in which the extent of tissue damage within the ulcer cannot be confirmed because it is obscured by slough or eschar.<br />Deep tissue pressure injury&nbsp;– Deep tissue pressure injury should be suspected whenever there is a localized area of skin (intact or non-intact) with persistent nonblanchable deep red, maroon, or purple discoloration or epidermal separation revealing a dark wound bed or blood-filled blister.</div><div class=\"graphic_reference\">Reference:<br /><OL>&#xD;&#xA;<LI>National Pressure Ulcer Advisory Panel. <A spellcheck=true href=\"http://www.npuap.org/\" target=_blank>www.npuap.org</A>.</LI></OL>Images reproduced with permission from: Nettina SM. The Lippincott manual of nursing practice, 7th ed. Philadelphia: Lippincott Williams &amp; Wilkins, 2001. Copyright © 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 67475 Version 5.0</div></div></div>"},"67476":{"type":"graphic_picture","displayName":"Occipital collateral","title":"Occipital collateral","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Occipital collateral</div><div class=\"cntnt\"><img style=\"width:256px; height:448px;\" src=\"images/SURG/67476_Occipita_collateral.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The distal vertebral and basilar artery being fed by an occipital collateral in a patient with proximal vertebral artery occlusion.</div><div id=\"graphicVersion\">Graphic 67476 Version 1.0</div></div></div>"},"67478":{"type":"graphic_figure","displayName":"Type II AC joint injury PI","title":"Type II acromioclavicular joint injury","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Type II acromioclavicular joint injury</div><div class=\"cntnt\"><img style=\"width:474px; height:440px;\" src=\"images/PI/67478_Grade_II_AC_joint_spr_PI.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 67478 Version 5.0</div></div></div>"},"67479":{"type":"graphic_table","displayName":"6As for smoking prevention and cessation in children","title":"Six \"A's\" to prevent smoking initiation or support smoking cessation among adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Six &quot;A's&quot; to prevent smoking initiation or support smoking cessation among adolescents</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Intervention\n   </td>\n   <td  class=\"subtitle1\">\n   Technique\n   </td>\n   </tr>\n   <tr>\n   <td>Anticipate</td>\n   <td>Routinely ask parents about smoking and discuss the health effects of tobacco use. Discuss the possibility of smoking onset in pre-teen and adolescent children, and the need for consistent messages from parents to prevent smoking initiation.</td>\n   </tr>\n   <tr>\n   <td>Ask</td>\n   <td>For all adolescents at every visit, ask about tobacco use without the parents in the room. For pre-teen children also inquire about tobacco use in an age-appropriate manner (eg, whether they have ever \"tried\" smoking or thought about trying). Also inquire about tobacco use among peers, as this may predict smoking initiation.</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"5\">\n   Advise\n   </td>\n   <td>Strongly urge all tobacco users to quit in a clear, strong, personalized manner. Advise all non-users to remain tobacco-free.</td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1_start\">\n   Advice should be:\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Clear - \"I think it is important for you to quit smoking now and I can help you.\" \"Cutting down is not enough.\" \"If you wait until you feel bad effects of smoking it will be too late.\"\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Strong - \"As your doctor, I want you to know that quitting smoking is the most important thing you can do to protect your health now and in the future. I will help you quit.\"\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   Personalized - Tie tobacco use to current and future health and athletic performance, its social and economic costs, motivation level/readiness to quit, and the impact of tobacco use on siblings and others in the household. Remind parents of their responsibility as role models.\n   </td>\n   </tr>\n   <tr>\n   <td  rowspan=\"5\">\n   Assess\n   </td>\n   <td  class=\"sublist1_start\">\n   Determine the patient's willingness to quit smoking within the next 30 days:\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   If the patient is willing to make a quit attempt at this time, provide assistance.\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   If the patient will participate in an intensive treatment, deliver such a treatment or refer to an intensive intervention.\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   If the patient clearly states he or she is unwilling to make a quit attempt at this time, provide a motivational intervention.\n   </td>\n   </tr>\n   <tr>\n   <td  class=\"sublist1\">\n   If the patient is a member of a special population (eg, pregnant smoker, racial or ethnic minority), consider providing additional information relevant to this population.\n   </td>\n   </tr>\n   <tr>\n   <td>Assist</td>\n   <td>Provide aid for the patient to quit (eg, set a quit date, provide counseling and self-help materials, refer to a quit line).</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"2\">\n   Arrange\n   </td>\n   <td>Schedule follow-up contact, either in person or by telephone. Follow-up contact should occur soon after the quit date, preferably during the first week. A second follow-up contact is recommended within the first month. Schedule further follow-up contacts as indicated.</td>\n   </tr>\n   <tr>\n   <td>Congratulate success during each follow-up. If tobacco use has occurred, review circumstances and elicit recommitment to total abstinence. Remind the patient that a lapse can be used as a learning experience. Identify problems already encountered and anticipate challenges in the immediate future. Assess pharmacotherapy use and problems. Consider use or referral to more intensive treatment.</td>\n   </tr>\n </table></div><div class=\"graphic_reference\">Adapted from: Fiore, MC, Bailey, WC, Cohen, SJ, et al. Treating Tobacco Use and Dependence. Quick Reference Guide for Clinicians. Rockville, MD: US Department of Health and Human Services. Public Health Service. October 2000 and Sims, TH. Pediatrics 2009; 124:e1045.</div><div id=\"graphicVersion\">Graphic 67479 Version 2.0</div></div></div>"},"67480":{"type":"graphic_table","displayName":"Symptoms of CNS tumors in children","title":"Signs and symptoms associated with central nervous system tumors in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Signs and symptoms&nbsp;associated with central nervous system tumors in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Infants and young children (&#60;4 years)</td> <td class=\"subtitle1_single\">All children (including older children and adolescents)</td> </tr> <tr> <td>Macrocephaly (41 percent)</td> <td>Headaches (33 percent)</td> </tr> <tr> <td>Nausea and vomiting (30 percent)</td> <td>Nausea and vomiting (32 percent)</td> </tr> <tr> <td>Irritability (24 percent)</td> <td>Abnormal gait or coordination (27 percent)</td> </tr> <tr> <td>Lethargy (21 percent)</td> <td>Seizures (13 percent)</td> </tr> <tr> <td>Abnormal gait or coordination (19 percent)</td> <td>Papilledema (13 percent)</td> </tr> <tr> <td>Weight loss / poor&nbsp;growth (14 percent)</td> <td>Unspecified symptoms of elevated ICP (10 percent)</td> </tr> <tr> <td>Bulging fontanelle and/or splayed sutures (13 percent)</td> <td>Squint (7 percent)</td> </tr> <tr> <td>Seizures (10 percent)</td> <td>Behavior changes and/or declining&nbsp;school performance (7 percent)</td> </tr> <tr> <td>Papilledema (10 percent)</td> <td>Macrocephaly (7 percent)</td> </tr> <tr> <td>Headache (10 percent)</td> <td>Cranial nerve palsies (7 percent)</td> </tr> <tr> <td>Unspecified focal neurologic signs (10 percent)</td> <td>Lethargy / fatigue (6 percent)</td> </tr> <tr> <td>Unspecified symptoms of elevated ICP (9 percent)</td> <td>Abnormal eye movements (6 percent)</td> </tr> <tr> <td>Focal motor weakness (7 percent)</td> <td>Hemiplegia (6 percent)</td> </tr> <tr> <td>Head tilt (7 percent)</td> <td>Altered level of consciousness (5 percent)</td> </tr> <tr> <td>Altered level of consciousness (7 percent)</td> <td>Weight loss (5 percent)</td> </tr> <tr> <td>Squint (6 percent)</td> <td>Unspecified visual or eye abnormalities (5 percent)</td> </tr> <tr> <td>Abnormal eye movements (6 percent)</td> <td>&nbsp;</td> </tr> <tr> <td>Developmental delay or loss of&nbsp;milestones (5 percent)</td> <td>&nbsp;</td> </tr> <tr> <td>Hemiplegia (5 percent)</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_reference\"><OL>&#xD;&#xA;<LI>Wilne SH, Dineen RA, Dommett RM, et al. Identifying brain tumours in children and young adults. BMJ 2013; 347:f5844.</LI>&#xD;&#xA;<LI>Wilne S, Collier J, Kennedy C, et al. Presentation of childhood CNS tumours: a systematic review and meta-analysis. Lancet Oncol 2007; 8:685.</LI></OL></div><div id=\"graphicVersion\">Graphic 67480 Version 2.0</div></div></div>"},"67481":{"type":"graphic_table","displayName":"Burn extent in children","title":"Modified Lund and Browder chart","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Modified Lund and Browder chart</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">Area</td>\n\n      <td class=\"subtitle1\">Birth to 1 year</td>\n\n      <td class=\"subtitle1\">1 to 4 years</td>\n\n      <td class=\"subtitle1\">5 to 9 years</td>\n\n      <td class=\"subtitle1\">10 to 14 years</td>\n\n      <td class=\"subtitle1\">15 years</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Head</td>\n\n      <td>19</td>\n\n      <td>17</td>\n\n      <td>13</td>\n\n      <td>11</td>\n\n      <td>9</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Neck</td>\n\n      <td>2</td>\n\n      <td>2</td>\n\n      <td>2</td>\n\n      <td>2</td>\n\n      <td>2</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Anterior trunk</td>\n\n      <td>13</td>\n\n      <td>13</td>\n\n      <td>13</td>\n\n      <td>13</td>\n\n      <td>13</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Posterior trunk</td>\n\n      <td>13</td>\n\n      <td>13</td>\n\n      <td>13</td>\n\n      <td>13</td>\n\n      <td>13</td>\n\n    </tr>\n\n    <tr>\n\n      <td>R buttock</td>\n\n      <td>2.5</td>\n\n      <td>2.5</td>\n\n      <td>2.5</td>\n\n      <td>2.5</td>\n\n      <td>2.5</td>\n\n    </tr>\n\n    <tr>\n\n      <td>L buttock</td>\n\n      <td>2.5</td>\n\n      <td>2.5</td>\n\n      <td>2.5</td>\n\n      <td>2.5</td>\n\n      <td>2.5</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Genitalia</td>\n\n      <td>1</td>\n\n      <td>1</td>\n\n      <td>1</td>\n\n      <td>1</td>\n\n      <td>1</td>\n\n    </tr>\n\n    <tr>\n\n      <td>R upper arm</td>\n\n      <td>4</td>\n\n      <td>4</td>\n\n      <td>4</td>\n\n      <td>4</td>\n\n      <td>4</td>\n\n    </tr>\n\n    <tr>\n\n      <td>L upper arm</td>\n\n      <td>4</td>\n\n      <td>4</td>\n\n      <td>4</td>\n\n      <td>4</td>\n\n      <td>4</td>\n\n    </tr>\n\n    <tr>\n\n      <td>R lower arm</td>\n\n      <td>3</td>\n\n      <td>3</td>\n\n      <td>3</td>\n\n      <td>3</td>\n\n      <td>3</td>\n\n    </tr>\n\n    <tr>\n\n      <td>L lower arm</td>\n\n      <td>3</td>\n\n      <td>3</td>\n\n      <td>3</td>\n\n      <td>3</td>\n\n      <td>3</td>\n\n    </tr>\n\n    <tr>\n\n      <td>R hand</td>\n\n      <td>2.5</td>\n\n      <td>2.5</td>\n\n      <td>2.5</td>\n\n      <td>2.5</td>\n\n      <td>2.5</td>\n\n    </tr>\n\n    <tr>\n\n      <td>L hand</td>\n\n      <td>2.5</td>\n\n      <td>2.5</td>\n\n      <td>2.5</td>\n\n      <td>2.5</td>\n\n      <td>2.5</td>\n\n    </tr>\n\n    <tr>\n\n      <td>R thigh</td>\n\n      <td>5.5</td>\n\n      <td>6.5</td>\n\n      <td>8</td>\n\n      <td>8.5</td>\n\n      <td>9</td>\n\n    </tr>\n\n    <tr>\n\n      <td>L thigh</td>\n\n      <td>5.5</td>\n\n      <td>6.5</td>\n\n      <td>8</td>\n\n      <td>8.5</td>\n\n      <td>9</td>\n\n    </tr>\n\n    <tr>\n\n      <td>R leg</td>\n\n      <td>5</td>\n\n      <td>5</td>\n\n      <td>5.5</td>\n\n      <td>6</td>\n\n      <td>6.5</td>\n\n    </tr>\n\n    <tr>\n\n      <td>L leg</td>\n\n      <td>5</td>\n\n      <td>5</td>\n\n      <td>5.5</td>\n\n      <td>6</td>\n\n      <td>6.5</td>\n\n    </tr>\n\n    <tr>\n\n      <td>R foot</td>\n\n      <td>3.5</td>\n\n      <td>3.5</td>\n\n      <td>3.5</td>\n\n      <td>3.5</td>\n\n      <td>3.5</td>\n\n    </tr>\n\n    <tr>\n\n      <td>L foot</td>\n\n      <td>3.5</td>\n\n      <td>3.5</td>\n\n      <td>3.5</td>\n\n      <td>3.5</td>\n\n      <td>3.5</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">Numbers refer to % total body surface area involved.</div><div class=\"graphic_reference\">Adapted from Lund, CC, Browder, NC, Surg Gynecol Obstet 1944; 79:352.</div><div id=\"graphicVersion\">Graphic 67481 Version 1.0</div></div></div>"},"67484":{"type":"graphic_figure","displayName":"Pulsed Doppler HCM","title":"Dynamic subaortic outflow tract obstruction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dynamic subaortic outflow tract obstruction</div><div class=\"cntnt\"><img style=\"width:275px; height:360px;\" src=\"images/CARD/67484_Pulsed_Doppler_HCM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pulsed Doppler echocardiogram&nbsp;is used to localize the subaortic jet (sj). The location of the sample volume is shown by the black crosshatch on the line running through the four-chamber views in panels A and B. In panel A, the sample volume is at the papillary muscle level, apical (ax) to the chordae, and intraventricular velocity of the sj is low (panel C). However, when the sample volume is moved basally (bs), below the contact point of the mitral valve with the septum (panel B) the sj suddenly accelerates (panel C). The high-velocity subaortic jet has the characteristic late systolic or \"horse's tail\" configuration, although this is partially obscured by aliasing at peak velocity.</div><div id=\"graphicVersion\">Graphic 67484 Version 2.0</div></div></div>"},"67487":{"type":"graphic_picture","displayName":"Meconium myonecrosis","title":"Meconium myonecrosis","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Meconium myonecrosis</div><div class=\"cntnt\"><img style=\"width:540px; height:384px;\" src=\"images/OBGYN/67487_Meconium_myonecrosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Black arrow shows orangophilic apoptotic smooth muscle cell, and red arrow shows meconium pigment.</div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 67487 Version 2.0</div></div></div>"},"67488":{"type":"graphic_picture","displayName":"NI proliferativ endometrium","title":"Proliferative endometrium","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Proliferative endometrium</div><div class=\"cntnt\"><img style=\"width:432px; height:288px;\" src=\"images/OBGYN/67488_NI_proliferativ_endometrium.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the straight non-convoluted glands, without glandular crowding.</div><div class=\"graphic_reference\">Courtesy of Russell S Vang, MD.</div><div id=\"graphicVersion\">Graphic 67488 Version 1.0</div></div></div>"},"67489":{"type":"graphic_diagnosticimage","displayName":"Typical carcinoid CXR","title":"Typical carcinoid radiographic imaging","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">Typical carcinoid radiographic imaging</div><div class=\"cntnt\"><img style=\"width:490px; height:226px;\" src=\"images/ONC/67489_Typical_carcinoid_CXR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Posterior-anterior (PA) chest radiograph demonstrating a nodular opacity (arrow) in the right middle lobe with volume loss on the right. The nodule is better visualized on the axial computed tomography (CT) image of the chest.<br />(B) Just below the level of the carina (arrow). At surgical resection the nodule proved to be a typical carcinoid.</div><div class=\"graphic_reference\">Courtesy of Charles F Thomas, Jr, MD.</div><div id=\"graphicVersion\">Graphic 67489 Version 5.0</div></div></div>"},"67491":{"type":"graphic_algorithm","displayName":"Management of acute colonic pseudo-obstruction ASGE","title":"Acute colonic dilation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute colonic dilation</div><div class=\"cntnt\"><img style=\"width:450px; height:651px;\" src=\"images/GAST/67491_Rx_pseudoobstruction_ASGE.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">NPO: nothing given by mouth; IVF: intravenous fluids; NG: nasogastric.</div><div class=\"graphic_reference\">Reproduced with permission from: Eisen GM, Baron TH, Dominitz JA, et al. Acute colonic pseudo-obstruction. Gastrointest Endosc 2002; 56:789. Copyright © 2002 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 67491 Version 3.0</div></div></div>"},"67492":{"type":"graphic_table","displayName":"Somatostatin physiology","title":"Somatostatin physiology","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Somatostatin physiology</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_left\" rowspan=\"2\">CNS</td> <td>Inhibits growth hormone release from pituitary</td> </tr> <tr> <td>Antinociception</td> </tr> <tr> <td class=\"subtitle1_left\" rowspan=\"3\">Liver </td> <td>Decreases blood flow</td> </tr> <tr> <td>Inhibits bile duct secretion</td> </tr> <tr> <td>Inhibits gallbladder contraction</td> </tr> <tr> <td class=\"subtitle1_left\" rowspan=\"2\">Pancreas </td> <td>Inhibits endocrine secretion</td> </tr> <tr> <td>Inhibits exocrine secretion</td> </tr> <tr> <td class=\"subtitle1_left\" rowspan=\"7\">Gastrointestinal </td> <td>Inhibits salivary amylase release</td> </tr> <tr> <td>Inhibits gastric acid secretion and gastric emptying</td> </tr> <tr> <td>Inhibits gastrointestinal hormone secretion</td> </tr> <tr> <td>Slows gastrointestinal motility</td> </tr> <tr> <td>Inhibits absorption (primarily carbohydrates)</td> </tr> <tr> <td>Reduces intestinal fluid volume</td> </tr> <tr> <td>Decreases splanchnic blood flow</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CNS: central nervous system.</div><div id=\"graphicVersion\">Graphic 67492 Version 3.0</div></div></div>"},"67493":{"type":"graphic_diagnosticimage","displayName":"HSG showing endometrial polyps","title":"Hysterosalpingogram showing multiple filling defects due to endometrial polyps","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Hysterosalpingogram showing multiple filling defects due to endometrial polyps</div><div class=\"cntnt\"><img style=\"width:468px; height:357px;\" src=\"images/OBGYN/67493_HSG_showing_endometrial_pol.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Baramki TA. Hysterosalpingography. Fertil Steril 2005; 83:1595. Copyright © 2005 Elsevier Science, Inc.</div><div id=\"graphicVersion\">Graphic 67493 Version 3.0</div></div></div>"},"67494":{"type":"graphic_table","displayName":"Composition ORS beverages","title":"Composition of oral rehydration solutions (ORS) and commonly used beverages","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Composition of oral rehydration solutions (ORS) and commonly used beverages</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" rowspan=\"2\">Carbohydrate<br /> (g/L)</td> <td class=\"subtitle1\" colspan=\"3\">mEq/L</td> <td class=\"subtitle1\" rowspan=\"2\">Osmolarity<br /> (mOSM/kg H<sub>2</sub>O)</td> </tr> <tr> <td class=\"subtitle2\">Sodium</td> <td class=\"subtitle2\">Potassium</td> <td class=\"subtitle2\">Base (HCO<sub>3</sub>&ndash;)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Oral rehydration solutions</td> </tr> <tr> <td class=\"indent1\">CeraLyte</td> <td class=\"centered\">40</td> <td class=\"centered\">70</td> <td class=\"centered\">20</td> <td class=\"centered\">10</td> <td class=\"centered\">235</td> </tr> <tr> <td class=\"indent1\">Enfalyte</td> <td class=\"centered\">30</td> <td class=\"centered\">50</td> <td class=\"centered\">25</td> <td class=\"centered\">30</td> <td class=\"centered\">200</td> </tr> <tr> <td class=\"indent1\">Pedialyte</td> <td class=\"centered\">25</td> <td class=\"centered\">45</td> <td class=\"centered\">20</td> <td class=\"centered\">30</td> <td class=\"centered\">250</td> </tr> <tr> <td class=\"indent1\">Rehydralyte</td> <td class=\"centered\">25</td> <td class=\"centered\">75</td> <td class=\"centered\">20</td> <td class=\"centered\">30</td> <td class=\"centered\">310</td> </tr> <tr> <td class=\"indent1\">WHO (1975)</td> <td class=\"centered\">20</td> <td class=\"centered\">90</td> <td class=\"centered\">30</td> <td class=\"centered\">30</td> <td class=\"centered\">310</td> </tr> <tr> <td class=\"indent1\">WHO (2002)</td> <td class=\"centered\">13.5</td> <td class=\"centered\">75</td> <td class=\"centered\">20</td> <td class=\"centered\">30</td> <td class=\"centered\">245</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Commonly Used Beverages (not appropriate for repletion therapy)</td> </tr> <tr> <td class=\"indent1\">Apple juice</td> <td class=\"centered\">100 to 150</td> <td class=\"centered\">3</td> <td class=\"centered\">20</td> <td class=\"centered\">0</td> <td class=\"centered\">700</td> </tr> <tr> <td class=\"indent1\">Chicken broth</td> <td class=\"centered\">0</td> <td class=\"centered\">250</td> <td class=\"centered\">5</td> <td class=\"centered\">0</td> <td class=\"centered\">450</td> </tr> <tr> <td class=\"indent1\">Colas</td> <td class=\"centered\">100 to 150</td> <td class=\"centered\">2</td> <td class=\"centered\">0.1</td> <td class=\"centered\">13</td> <td class=\"centered\">550</td> </tr> <tr> <td class=\"indent1\">Gatorade</td> <td class=\"centered\">45</td> <td class=\"centered\">20</td> <td class=\"centered\">3</td> <td class=\"centered\">3</td> <td class=\"centered\">330</td> </tr> <tr> <td class=\"indent1\">Ginger Ale</td> <td class=\"centered\">90</td> <td class=\"centered\">3.5</td> <td class=\"centered\">0.1</td> <td class=\"centered\">3.6</td> <td class=\"centered\">565</td> </tr> <tr> <td class=\"indent1\">Tea</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">5</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 67494 Version 4.0</div></div></div>"},"67495":{"type":"graphic_picture","displayName":"Livedo reticularis in lupus","title":"Livedo reticularis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Livedo reticularis</div><div class=\"cntnt\"><img style=\"width:353px; height:319px;\" src=\"images/RHEUM/67495_Livedo_reticularis_in_lupus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient with lupus and antiphospholipid antibodies with livedo reticularis (manifested by a reddish-cyanotic, reticular pattern of the skin) which has resulted in ulcer formation (arrows).</div><div class=\"graphic_reference\">Courtesy of Samuel Moschella, MD.</div><div id=\"graphicVersion\">Graphic 67495 Version 1.0</div></div></div>"},"67496":{"type":"graphic_picture","displayName":"Stingray envenomation","title":"Stingray envenomation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Stingray envenomation</div><div class=\"cntnt\"><img style=\"width:281px; height:549px;\" src=\"images/EM/67496_Sting_ray_envenomation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The stingrays of the <em>Dasyatis</em> genus are the most common marine stingrays.<br> (B) Note the serrated barb.<br> (C) A severe sting with total perforation of the foot of a fisherman.</div><div class=\"graphic_reference\">Reproduced from: Haddad V, Lupi O, Lonza JP, Tyring SK. Tropical dermatology: marine and aquatic dermatology. J Am Acad Derm 2009; 61:733. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 67496 Version 2.0</div></div></div>"},"67497":{"type":"graphic_picture","displayName":"Positive Siedel's test","title":"Positive Seidel's test","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Positive Seidel's test</div><div class=\"cntnt\"><img style=\"width:360px; height:259px;\" src=\"images/EM/67497_Siedel_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A small perforation will cause a clearing of the dense fluorescein that appears to be streaming away from the perforation site.</div><div id=\"graphicVersion\">Graphic 67497 Version 3.0</div></div></div>"},"67498":{"type":"graphic_figure","displayName":"Glycated hemoglobin and fetal malformations","title":"Deleterious effect of poor glycemic control on fetal outcome","html":"<div class=\"graphic\"><div style=\"width: 475px\" class=\"figure\"><div class=\"ttl\">Deleterious effect of poor glycemic control on fetal outcome</div><div class=\"cntnt\"><img style=\"width:455px; height:428px;\" src=\"images/ENDO/67498_HbA1c_fetal_malform_edit.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Combined incidence of major malformation and spontaneous abortion according to the hemoglobin A1 (HbA1) value during the first trimester of pregnancy in 303 women with type 1 diabetes. The risk rose markedly at HbA1 values above 11 percent (approximately equivalent to an&nbsp;AIC value of 8.5 percent). Other studies have found an increase in risk at&nbsp;A1C values above 9.5 percent.</div><div class=\"graphic_reference\">Data from: Greene MF, Hare JW, Cloherty JP, et al, Teratology 1989; 39:225.</div><div id=\"graphicVersion\">Graphic 67498 Version 4.0</div></div></div>"},"67500":{"type":"graphic_picture","displayName":"Body wall anomaly in neonate 2","title":"Body wall anomaly in neonate 2","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Body wall anomaly in neonate 2</div><div class=\"cntnt\"><img style=\"width:464px; height:250px;\" src=\"images/OBGYN/67500_Body_stalk_anomaly2_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Notice the severe scoliosis and chest wall deformity.</div><div class=\"graphic_reference\">Courtesy of Courtney D Stephenson, DO and A Hilton, MD.</div><div id=\"graphicVersion\">Graphic 67500 Version 4.0</div></div></div>"},"67503":{"type":"graphic_algorithm","displayName":"Algorithm Syst Rx desmoids","title":"Systemic therapy algorithm for desmoid tumors at MD Anderson Cancer Center","html":"<div class=\"graphic\"><div style=\"width: 814px\" class=\"figure\"><div class=\"ttl\">Systemic therapy algorithm for desmoid tumors at MD Anderson Cancer Center</div><div class=\"cntnt\"><img style=\"width:794px; height:842px;\" src=\"images/ONC/67503_algorithmRxdesmoids.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">DOXO: doxorubicin; DTIC: dacarbazine; MTX: methotrexate; VBL: vinblastine; NSAID: nonsteroidal antiinflammatory drug; PR: partial response; CR: complete response; SD: stable disease; PD: progressive disease; TKI: tyrosine kinase inhibitor; RT: radiation therapy.<br />* The urgency to induce a response is based on the severity of symptoms, tumor location and underlying disorder (ie, familial adenomatous polyposis [FAP]), and expected harm in the absence of rapid response.<br />¶ Includes most patients with a slowly growing intraabdominal desmoid in the setting of FAP that involves the mesentery or encases vessels and/or organs.<br />Δ Response may take &gt;6 months to appear.</div><div id=\"graphicVersion\">Graphic 67503 Version 6.0</div></div></div>"},"67504":{"type":"graphic_picture","displayName":"Common blue nevus","title":"Common blue nevus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Common blue nevus</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/PEDS/67504_Common_blue_nevus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blue nevus in a typical location on the dorsal hand.</div><div class=\"graphic_reference\">Courtesy of Jean L Bolognia, MD, and Julie V Schaffer, MD.</div><div id=\"graphicVersion\">Graphic 67504 Version 2.0</div></div></div>"},"67505":{"type":"graphic_table","displayName":"Laboratory tests in RPC","title":"Frequency of principal laboratory abnormalities in relapsing polychondritis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequency of principal laboratory abnormalities in relapsing polychondritis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Number of reported cases</td> <td class=\"subtitle1\">Percent positive</td> </tr> <tr> <td>Elevated sedimentation rate</td> <td>405</td> <td>86</td> </tr> <tr> <td>Anemia</td> <td>368</td> <td>56</td> </tr> <tr> <td>Leukocytosis</td> <td>283</td> <td>35</td> </tr> <tr> <td>Antinuclear antibody</td> <td>264</td> <td>22</td> </tr> <tr> <td>Rheumatoid factor</td> <td>250</td> <td>16</td> </tr> <tr> <td>Eosinophilia</td> <td>160</td> <td>11</td> </tr> <tr> <td>LE cell preparation</td> <td>118</td> <td>7</td> </tr> <tr> <td>Serologic test for syphilis</td> <td>107</td> <td>7</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Based on minimum of 100 reported observations</div><div id=\"graphicVersion\">Graphic 67505 Version 2.0</div></div></div>"},"67507":{"type":"graphic_picture","displayName":"Hemi-uterus1","title":"Laparoscopic view of left hemiuterus communicating with single cervix as demonstrated by flow of blue dye injected through the cervix \"freely spilling\" from left fallopian tube","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Laparoscopic view of left hemiuterus communicating with single cervix as demonstrated by flow of blue dye injected through the cervix &quot;freely spilling&quot; from left fallopian tube</div><div class=\"cntnt\"><img style=\"width:504px; height:357px;\" src=\"images/OBGYN/67507_Hemiuterus1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Right hemiuterus does not communicate with the cervix and should be removed laparoscopically.</div><div class=\"graphic_reference\">Reproduced with permission from:&nbsp;Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 67507 Version 12.0</div></div></div>"},"67508":{"type":"graphic_figure","displayName":"Patient positioning for thyroid and parathyroid surgery","title":"Patient positioning for thyroid and parathyroid surgery","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Patient positioning for thyroid and parathyroid surgery</div><div class=\"cntnt\"><img style=\"width:533px; height:325px;\" src=\"images/SURG/67508_Patientpositionthyroidparathyroid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For thyroid and parathyroid&nbsp;surgery, the patient is positioned supine in the semi-Fowler or beach chair position, with the neck in extension. A roll can be placed transversely under the scapulae to facilitate exposure of the anterior neck, and great care is taken to assure there is no neck hyperextension.</div><div id=\"graphicVersion\">Graphic 67508 Version 6.0</div></div></div>"},"67509":{"type":"graphic_picture","displayName":"Postirradiation morphea","title":"Postirradiation morphea on the breast","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Postirradiation morphea on the breast</div><div class=\"cntnt\"><img style=\"width:324px; height:300px;\" src=\"images/DERM/67509_Postirradiation_morphea.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Morpheaform changes occurred after breast reconstruction and radiation therapy in this patient with a history of breast cancer.</div><div id=\"graphicVersion\">Graphic 67509 Version 1.0</div></div></div>"},"67510":{"type":"graphic_table","displayName":"Risks and benefits of cough and cold medications for children","title":"Overview of the risks and benefits of prescription and over-the-counter medications marketed for the treatment of the common cold in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Overview of the risks and benefits of prescription and over-the-counter medications marketed for the treatment of the common cold in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Active ingredient</td> <td class=\"subtitle1\">Mechanism<sup>[1,2]</sup></td> <td class=\"subtitle1\">Potential benefits</td> <td class=\"subtitle1\">Potential risks*<sup>[1-3]</sup></td> </tr> <tr class=\"divider_top\"> <td> <p><strong>Antipyretics/analgesics</strong>:</p> <p>Acetaminophen<br /> Ibuprofen</p> </td> <td>&nbsp;</td> <td>Reduction in temperature; little evidence regarding effects on discomfort<sup>[4]</sup></td> <td>Acetaminophen may suppress the neutralizing antibody response, resulting in increased nasal secretions and prolonged viral shedding</td> </tr> <tr class=\"divider_top\"> <td> <p><strong>First generation antihistamines</strong><sup>&#182;</sup>:</p> <p>Diphenhydramine<br /> Hydroxyzine<br /> Chlorpheniramine<br /> Brompheniramine<br /> Clemastine</p> </td> <td>Anticholinergic effects decrease mucus secretion<sup>&#916;</sup></td> <td>No clinically significant benefits<sup>[5]</sup></td> <td> <ul> <li>Sedation </li> <li>Paradoxic excitability </li> <li>Dizziness </li> <li>Respiratory depression </li> <li>Hallucinations </li> <li>Tachycardia </li> <li>Heart block </li> <li>Arrhythmia </li> <li>Dry mouth </li> <li>Blurred vision </li> <li>Urinary retention </li> <li>Dystonic reactions </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td> <p><strong>Narcotic antitussives</strong><sup>&#182;&#9674;</sup>:</p> <p>Codeine<br /> Hydrocodone</p> </td> <td>Act on cough center in brainstem</td> <td>No more effective than placebo<sup>[5,6]</sup></td> <td> <ul> <li>Respiratory depression </li> <li>Nausea </li> <li>Vomiting </li> <li>Constipation </li> <li>Dizziness </li> <li>Palpitations </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td> <p><strong>Nonnarcotic antitussives</strong><sup>&#182;</sup>:</p> <p>Dextromethorphan</p> </td> <td>Act on cough center in brainstem</td> <td>No evidence of effectiveness<sup>[5-8]</sup></td> <td> <ul> <li>CNS effects </li> <li>Serotonin syndrome </li> <li>Hallucinations </li> <li>Respiratory depression (in overdose) </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td> <p><strong>Oral decongestants</strong><sup>&#182;</sup>:</p> <p>Pseudoephedrine<br /> Phenylephrine</p> </td> <td>Vasoconstriction</td> <td>No evidence of effectiveness in children &#60;12 years<sup> [9,10]</sup></td> <td> <ul> <li>Tachycardia </li> <li>Irritability </li> <li>Agitation </li> <li>Sleeplessness </li> <li>Hypertension </li> <li>Anorexia </li> <li>Headache </li> <li>Nausea </li> <li>Vomiting </li> <li>Palpitations </li> <li>Dysrhythmias </li> <li>Seizures </li> <li>Dystonic reactions </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td> <p><strong>Topical decongestants</strong><sup>&#182;</sup>:</p> <p>Oxymetazoline<br /> Xylometazoline<br /> Phenylephrine</p> </td> <td>Vasoconstriction</td> <td>No evidence of effectiveness in children &#60;12 years<sup>[10]</sup></td> <td> <ul> <li>Rebound nasal congestion </li> <li>Nosebleeds </li> <li>Drying of nasal membranes </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td><strong>Antihistamine-decongestant combination</strong><sup>&#182;</sup></td> <td> <p>Anticholinergic effects (antihistamine)</p> <p>Vasoconstriction (decongestant)</p> </td> <td>No more effective than placebo<sup>[5,9,11]</sup></td> <td>See potential risks for antihistamines and decongestants above</td> </tr> <tr class=\"divider_top\"> <td> <p><strong>Expectorant</strong><sup>&#182;</sup>:</p> <p>Guaifenesin</p> </td> <td>Increase mucus production to make secretions easier to remove with cough or mucociliary transport</td> <td>No studies of effectiveness in children<sup>[1,2,5]</sup></td> <td> <ul> <li>Mild GI irritation </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td> <p><strong>Mucolytics</strong><sup>&#182;</sup>:</p> <p>Acetylcysteine<br /> Bromhexine<br /> Letosteine</p> </td> <td>Thin secretions to make them easier to clear through coughing</td> <td>Some evidence of improvement compared with placebo<sup>[5]</sup></td> <td> <ul> <li>Bronchospasm </li> <li>GI disturbance </li> <li>Fever </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td> <p><strong>Topical aromatics</strong>:</p> <p>Menthol<br /> Camphor<br /> Eucalyptus oil</p> </td> <td>May act on TRPM8 cation channel to produce a cooling sensation</td> <td> <p>Subjective improvement of nasal patency without objective increase in air flow<sup>[12]</sup></p> <p>Parental report of symptomatic improvement in nocturnal cough and sleep in poorly blinded study<sup>&#167;</sup><sup>[13]</sup></p> </td> <td>GI and CNS effects may result from accidental ingestion</td> </tr> <tr class=\"divider_top\"> <td><strong>Ipratropium bromide</strong><sup>&#9674;&#165;</sup> (nasal)</td> <td>Decreases nasal discharge via anticholinergic activity</td> <td>May decrease nasal discharge but not nasal congestion<sup>[14]</sup></td> <td> <ul> <li>Nosebleeds </li> <li>Nasal dryness </li> <li>Headache </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CNS: central nervous system; GI: gastrointestinal.<br />* Overdose is a potential risk with all of these agents, particularly when combination products are used.<br />¶&nbsp;Because the risks outweigh the proven benefits, these medications generally are not recommended for children younger than six years of age. We suggest not using these medications in children 6 to 12 years of age.<br />Δ&nbsp;Histamine is not an inflammatory mediator in the common cold.<br />◊&nbsp;Requires a prescription.<br />§&nbsp;Significant placebo effect cannot be excluded.<br />¥&nbsp;For children older than five years.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Pappas DE, Hendley JO. The common cold and decongestant therapy. Pediatr Rev 2011; 32:47. </LI>&#xD;&#xA;<LI>Kelly LF. Pediatric cough and cold preparations. Pediatr Rev 2004; 25:115. </LI>&#xD;&#xA;<LI>World Health Organization. Cough and cold remedies for the treatment of acute respiratory infections in young children, 2001. <A spellcheck=true href=\"http://whqlibdoc.who.int/hq/2001/WHO_FCH_CAH_01.02.pdf\" target=_blank>http://whqlibdoc.who.int/hq/2001/WHO_FCH_CAH_01.02.pdf</A> (Accessed on August 30, 2011). </LI>&#xD;&#xA;<LI>Section on Clinical Pharmacology and Therapeutics, Committee on Drugs, Sullivan JE, Farrar HC. Fever and antipyretic use in children. Pediatrics 2011; 127:580. </LI>&#xD;&#xA;<LI>Smith SM, Schroeder K, Fahey T. Over-the-counter medications for acute cough in children and adults in ambulatory settings. Cochrane Database Syst Rev 2008; CD001831. </LI>&#xD;&#xA;<LI>Taylor JA, Novack AH, Almquist JR, Rogers JE. Efficacy of cough suppressants in children. J Pediatr 1993; 122:799. </LI>&#xD;&#xA;<LI>Paul IM, Beiler J, McMonagle A, et al. Effect of honey, dextromethorphan, and no treatment on nocturnal cough and sleep quality for coughing children and their parents. Arch Pediatr Adolesc Med 2007; 161:1140. </LI>&#xD;&#xA;<LI>Paul IM, Yoder KE, Crowell KR, et al. Effect of dextromethorphan, diphenhydramine, and placebo on nocturnal cough and sleep quality for coughing children and their parents. Pediatrics 2004; 114:e85. </LI>&#xD;&#xA;<LI>Clemens CJ, Taylor JA, Almquist JR, et al. Is an antihistamine-decongestant combination effective in temporarily relieving symptoms of the common cold in preschool children? J Pediatr 1997; 130:463. </LI>&#xD;&#xA;<LI>Taverner D, Latte J. Nasal decongestants for the common cold. Cochrane Database Syst Rev 2007; CD001953. </LI>&#xD;&#xA;<LI>Hutton N, Wilson MH, Mellits ED, et al. Effectiveness of an antihistamine-decongestant combination for young children with the common cold: a randomized, controlled clinical trial. J Pediatr 1991; 118:125. </LI>&#xD;&#xA;<LI>Kenia P, Houghton T, Beardsmore C. Does inhaling menthol affect nasal patency or cough? Pediatr Pulmonol 2008; 43:532. </LI>&#xD;&#xA;<LI>Paul IM, Beiler JS, King TS, et al. Vapor rub, petrolatum, and no treatment for children with nocturnal cough and cold symptoms. Pediatrics 2010; 126:1092. </LI>&#xD;&#xA;<LI>Albalawi ZH, Othman SS, Alfaleh K. Intranasal ipratropium bromide for the common cold. Cochrane Database Syst Rev 2011; CD008231. </LI></OL></div><div id=\"graphicVersion\">Graphic 67510 Version 4.0</div></div></div>"},"67511":{"type":"graphic_table","displayName":"SSRI kinetics","title":"SSRI kinetics","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">SSRI kinetics</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Peak serum concentration</td> <td class=\"subtitle1\">Elimination half-life</td> <td class=\"subtitle1\">Metabolism</td> <td class=\"subtitle1\">Active metabolites</td> <td class=\"subtitle1\">Protein binding, percent</td> </tr> <tr> <td rowspan=\"2\">Fluoxetine</td> <td rowspan=\"2\">6-8 hours</td> <td>Parent: 2-6 days</td> <td rowspan=\"2\">Liver (2D6, 2C9, 3A4)</td> <td rowspan=\"2\">Norfluoxetine</td> <td rowspan=\"2\">94.5</td> </tr> <tr> <td>Metabolite: 7-10 days</td> </tr> <tr> <td>Sertraline</td> <td>4.5-8.4 hours</td> <td>26 hours</td> <td>Liver (2C9, 2D6, 3A4)</td> <td>Desmethylsertraline (weakly active)</td> <td>98</td> </tr> <tr> <td>Paroxetine</td> <td>5.2 hours</td> <td>21 hours</td> <td>Liver (2D6)</td> <td>None</td> <td>95</td> </tr> <tr> <td>Fluvoxamine</td> <td>3-8 hours</td> <td>15.6 hours</td> <td>Liver (1A2, 2D6)</td> <td>None</td> <td>80</td> </tr> <tr> <td>Citalopram</td> <td>4 hours</td> <td>35 hours</td> <td>Liver (3A4, 2D6, 2C19)</td> <td>Desmethylcitalopram, didesmethylcitalopram (weakly active)</td> <td>80</td> </tr> <tr> <td>Escitalopram</td> <td>5 hours</td> <td>27-32 hours</td> <td>Liver (3A4, 2D6, 2C19)</td> <td>S-desmethylcitalopram, S-didesmethylcitalopram (weakly active)</td> <td>56</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 67511 Version 3.0</div></div></div>"},"67512":{"type":"graphic_figure","displayName":"Hungry bone syndrome after PTX","title":"Graph showing the time course of development of hypocalcemia following parathyroidectomy for primary hyperparathyroidism","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Graph showing the time course of development of hypocalcemia following parathyroidectomy for primary hyperparathyroidism</div><div class=\"cntnt\"><img style=\"width:356px; height:246px;\" src=\"images/ENDO/67512_Hungry_bone_syndrome_after.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Time course of development of hypocalcemia in 25 patients with hungry bone syndrome following parathyroidectomy for primary hyperparathyroidism. Most of the fall in the plasma calcium concentration occurred in the first 24 hours after surgery. To convert plasma calcium concentration from mg/dL to mmol/L, divide by 4.</div><div class=\"graphic_reference\">Data from Brasier AR, Nussbaum SR. Hungry bone syndrome:&nbsp;Clinical and biochemical predictors of its occurrence after parathyroid surgery.&nbsp;Am J Med 1988; 84:654.</div><div id=\"graphicVersion\">Graphic 67512 Version 3.0</div></div></div>"},"67514":{"type":"graphic_figure","displayName":"CA125 by diagnosis","title":"Box plots showing CA-125 serum levels by histologic diagnosis of adnexal masses.","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Box plots showing CA-125 serum levels by histologic diagnosis of adnexal masses.</div><div class=\"cntnt\"><img style=\"width:524px; height:644px;\" src=\"images/OBGYN/67514_CA125_by_diagnosis.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><strong>Box</strong>: range of the middle 50 percent of the CA-125 levels; <strong>line inside the box</strong>: median; <strong>whiskers</strong>: the 5th and 95th percentile; <strong>*</strong>: data points that lie outside the whiskers.</div><div class=\"graphic_reference\">Reproduced with permission from: Van Calster, B, Timmerman, D, Bourne, T, et al. Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125. J Natl Cancer Inst 2007; 99:1706. Copyright ©2007 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 67514 Version 2.0</div></div></div>"},"67516":{"type":"graphic_table","displayName":"Periph neurop cytotoxic agents","title":"Characteristics of peripheral neuropathy associated with cytotoxic chemotherapy agents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of peripheral neuropathy associated with cytotoxic chemotherapy agents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Drug</td> <td class=\"subtitle1\" colspan=\"4\">Clinical manifestations</td> <td class=\"subtitle1\" rowspan=\"2\">Recovery</td> </tr> <tr> <td class=\"subtitle2\">Sensory</td> <td class=\"subtitle2\">Motor</td> <td class=\"subtitle2\">Reflexes</td> <td class=\"subtitle2\">Autonomic</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Platinum compounds</td> </tr> <tr> <td class=\"indent1\">Cisplatin</td> <td>Distal, symmetric loss of sensation to all modalities, stocking glove distribution; painful paresthesias or numbness</td> <td>Normal</td> <td>In proportion to sensory loss</td> <td>Rare</td> <td>Partial; may progress for several months after drug is discontinued</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Carboplatin</td> <td>Similar but less severe than with cisplatin</td> <td>Normal</td> <td>Usually normal</td> <td>Rare</td> <td>Similar to cisplatin</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Oxaliplatin</td> </tr> <tr> <td class=\"indent1\">Acute</td> <td>Cold-induced dysesthesias in mouth, throat, and upper limbs</td> <td>Cramps and/or muscle spasm in throat muscles</td> <td>Usually normal</td> <td>None</td> <td>Gets better within one week, but persists between two-week cycles; improves after chemotherapy is completed</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Chronic</td> <td>Similar to cisplatin; symptoms worse in upper extremities during active therapy, but upper extremity neuropathy improves faster than lower extremity neuropathy after treatment completion. One year after treatment completion, there is more neuropathy in lower extremities.</td> <td>Normal</td> <td>Usually normal</td> <td>Rare</td> <td>Generally starts to improve approximately three months after completion of chemotherapy; can be a chronic problem for some patients.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Vinca alkaloids</td> </tr> <tr> <td class=\"indent1\">Vincristine</td> <td class=\"divider_bottom\" rowspan=\"4\">Distal sensory loss lower extremities, rarely affects upper extremities; vinblastine and vinorelbine are less neurotoxic; vincristine - rare mononeuropathies</td> <td class=\"divider_bottom\" rowspan=\"4\">Less common; distal symmetric weakness in lower limbs progressing to foot drop</td> <td class=\"divider_bottom\" rowspan=\"4\">Early decrease or absent</td> <td class=\"divider_bottom\" rowspan=\"4\">Constipation common (especially vincristine), orthostatic hypotension less common</td> <td class=\"divider_bottom\" rowspan=\"4\">Usually resolves within three months; may persist with vincristine</td> </tr> <tr> <td class=\"indent1\">Vinblastine</td> </tr> <tr> <td class=\"indent1\">Vinorelbine</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vindesine</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Taxanes</td> </tr> <tr> <td class=\"indent1\">Paclitaxel</td> <td class=\"divider_bottom\" rowspan=\"2\">Mild distal loss of sensation to all modalities, feet greater than hands, painful paresthesias</td> <td class=\"divider_bottom\" rowspan=\"2\">Occasional mild weakness in foot muscles; myalgia, myopathy</td> <td class=\"divider_bottom\" rowspan=\"2\">Reduced ankle reflexes</td> <td class=\"divider_bottom\" rowspan=\"2\">Rare</td> <td class=\"divider_bottom\" rowspan=\"2\">Usually improves after treatment, but persistent symptoms in about 50 percent of patients one year later</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Docetaxel</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Bortezomib</strong></td> <td>Mild to moderate distal symmetric loss of sensation to all modalities in distal extremities; painful paresthesias</td> <td>Occasional mild distal weakness in lower limbs; rare severe distal weakness; muscle cramps and fasciculations rare</td> <td>In proportion to sensory loss</td> <td>Occasional, including orthostatic hypotension, diarrhea, and constipation</td> <td>Usually resolves within three months; may persist</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Ixabepilone</strong></td> <td>Painful paresthesias; distal loss of sensation</td> <td>10 to 16 percent have weakness</td> <td>Rare</td> <td>Rare</td> <td>Usually improves after stopping</td> </tr> <tr> <td class=\"divider_bottom\"><strong>Thalidomide</strong></td> <td rowspan=\"3\">Symmetric mild to moderate distal loss to all sensory modalities</td> <td rowspan=\"3\">Weakness and tremor in 30 to 40 percent; muscle cramps and fasciculations common</td> <td rowspan=\"3\">In proportion to sensory loss</td> <td rowspan=\"3\">Constipation; other manifestations (impotence, bradycardia) are rare</td> <td rowspan=\"3\">Partially reversible; may persist for over one year</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Lenalidomide</strong></td> </tr> <tr> <td><strong>Pomalidomide</strong></td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 67516 Version 8.0</div></div></div>"},"67517":{"type":"graphic_table","displayName":"Antineoplastic drugs that act as vesicants or irritants","title":"Antineoplastic drugs that act as vesicants or irritants","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antineoplastic drugs that act as vesicants or irritants</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Vesicants</td> </tr> <tr> <td class=\"indent1\">Amsacrine</td> </tr> <tr> <td class=\"indent1\">Dactinomycin</td> </tr> <tr> <td class=\"indent1\">Daunorubicin</td> </tr> <tr> <td class=\"indent1\">Doxorubicin</td> </tr> <tr> <td class=\"indent1\">Epirubicin</td> </tr> <tr> <td class=\"indent1\">Idarubicin</td> </tr> <tr> <td class=\"indent1\">Mechlorethamine</td> </tr> <tr> <td class=\"indent1\">Mitomycin</td> </tr> <tr> <td class=\"indent1\">Trabectedin</td> </tr> <tr> <td class=\"indent1\">Vinblastine</td> </tr> <tr> <td class=\"indent1\">Vincristine and liposomal vincristine</td> </tr> <tr> <td class=\"indent1\">Vindesine</td> </tr> <tr> <td class=\"indent1\">Vinorelbine</td> </tr> <tr> <td class=\"subtitle1_single\">Irritants</td> </tr> <tr> <td class=\"indent1\">Ado-trastuzumab emtansine<sup>*</sup></td> </tr> <tr> <td class=\"indent1\">Bendamustine<sup><span style=\"font-size: 13px;\">&#182;</span></sup></td> </tr> <tr> <td class=\"indent1\">Bleomycin</td> </tr> <tr> <td class=\"indent1\">Bortezomib</td> </tr> <tr> <td class=\"indent1\">Busulfan</td> </tr> <tr> <td class=\"indent1\">Carboplatin</td> </tr> <tr> <td class=\"indent1\">Carmustine</td> </tr> <tr> <td class=\"indent1\">Cisplatin<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Cladribine</td> </tr> <tr> <td class=\"indent1\">Cyclophosphamide</td> </tr> <tr> <td class=\"indent1\">Cytarabine</td> </tr> <tr> <td class=\"indent1\">Dacarbazine<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Docetaxel</td> </tr> <tr> <td class=\"indent1\">Etoposide</td> </tr> <tr> <td class=\"indent1\">Fluorouracil/floxuridine</td> </tr> <tr> <td class=\"indent1\">Gemcitabine</td> </tr> <tr> <td class=\"indent1\">Ifosfamide</td> </tr> <tr> <td class=\"indent1\">Irinotecan<sup><span style=\"font-size: 13px;\">&#182;</span></sup></td> </tr> <tr> <td class=\"indent1\">Ixabepilone</td> </tr> <tr> <td class=\"indent1\">Liposomal daunorubicin<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Liposomal doxorubicin<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Melphalan<sup><span style=\"font-size: 13px;\">&#182;</span></sup></td> </tr> <tr> <td class=\"indent1\">Mitoxantrone<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Oxaliplatin<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Paclitaxel<span style=\"font-size: 13px;\"><sup>&#182;</sup></span></td> </tr> <tr> <td class=\"indent1\">Paclitaxel, nanoparticle albumin-bound (nab-paclitaxel)</td> </tr> <tr> <td class=\"indent1\">Streptozocin</td> </tr> <tr> <td class=\"indent1\">Teniposide</td> </tr> <tr> <td class=\"indent1\">Topotecan</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* A single case of skin necrosis after ado-trastuzumab emtansine extravasation has been reported<SUP>[1]</SUP><br />¶&nbsp;Irritants that may cause soft tissue injury when extravasated.<br />Δ&nbsp;May have vesicant properties depending on the concentration of volume of drug extravasated. As an example, extravasation of a large volume (&gt;20 mL) of concentrated cisplatin (&gt;0.5 mg/mL) may produce tissue necrosis.<br /></div><div class=\"graphic_reference\">Reference:&nbsp;<br /><OL>&#xD;&#xA;<LI>Shafaee MN, Salahudeen AA, Valero V. Skin Necrosis After Ado-Trastuzumab Emtansine Extravasation. J Oncol Pract 2017.</LI></OL></div><div id=\"graphicVersion\">Graphic 67517 Version 24.0</div></div></div>"},"67518":{"type":"graphic_figure","displayName":"Division isthmus","title":"Division isthmus","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Division isthmus</div><div class=\"cntnt\"><img style=\"width:463px; height:430px;\" src=\"images/SURG/67518_Division_isthmus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dandy clamps in place, with isthmus divided at its lateral aspect.</div><div class=\"graphic_reference\">Reproduced with permission from: Clark O. Fine needle aspiration biopsy of the thyroid: Thyroid lobectomy and subtotal and total thyroidectomy. In: Mastery of Surgery, Fischer JE, Bland KI, Callery MP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 67518 Version 9.0</div></div></div>"},"67520":{"type":"graphic_table","displayName":"Polyglandular autoimmune syndromes","title":"Types of endocrine and nonendocrine autoimmune syndromes associated with adrenal insufficiency","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Types of endocrine and nonendocrine autoimmune syndromes associated with adrenal insufficiency</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Disorder</td> <td class=\"subtitle1\">Prevalence (percent)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Polyglandular autoimmune syndrome type I</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\">Endocrine</td> </tr> <tr> <td class=\"sublist2\">Hypoparathyroidism</td> <td class=\"sublist_other_start_centered\">89</td> </tr> <tr> <td class=\"sublist2\">Chronic mucocutaneous candidiasis</td> <td class=\"sublist_other_centered\">75</td> </tr> <tr> <td class=\"sublist2\">Adrenal insufficiency</td> <td class=\"sublist_other_centered\">60</td> </tr> <tr> <td class=\"sublist2\">Primary hypogonadism</td> <td class=\"sublist_other_centered\">45</td> </tr> <tr> <td class=\"sublist2\">Hypothyroidism</td> <td class=\"sublist_other_centered\">12</td> </tr> <tr> <td class=\"sublist2\">Type 1 diabetes mellitus</td> <td class=\"sublist_other_centered\">1</td> </tr> <tr> <td class=\"sublist2\">Hypopituitarism</td> <td class=\"sublist_other_centered\">&#60;1</td> </tr> <tr> <td class=\"sublist2\">Diabetes insipidus</td> <td class=\"sublist_other_centered\">&#60;1</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\">Nonendocrine</td> </tr> <tr> <td class=\"sublist2\">Malabsorption syndromes</td> <td class=\"sublist_other_start_centered\">25</td> </tr> <tr> <td class=\"sublist2\">Alopecia totalis or areata</td> <td class=\"sublist_other_centered\">20</td> </tr> <tr> <td class=\"sublist2\">Pernicious anemia</td> <td class=\"sublist_other_centered\">16</td> </tr> <tr> <td class=\"sublist2\">Chronic active hepatitis</td> <td class=\"sublist_other_centered\">9</td> </tr> <tr> <td class=\"sublist2\">Vitiligo</td> <td class=\"sublist_other_centered\">4</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Polyglandular autoimmune syndrome type II</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\">Endocrine</td> </tr> <tr> <td class=\"sublist2\">Adrenal insufficiency</td> <td class=\"sublist_other_start_centered\">100</td> </tr> <tr> <td class=\"sublist2\">Autoimmune thyroid disease</td> <td class=\"sublist_other_centered\">70</td> </tr> <tr> <td class=\"sublist2\">Type 1 diabetes mellitus</td> <td class=\"sublist_other_centered\">50</td> </tr> <tr> <td class=\"sublist2\">Primary hypogonadism</td> <td class=\"sublist_other_centered\">5 to 50</td> </tr> <tr> <td class=\"sublist2\">Diabetes insipidus</td> <td class=\"sublist_other_centered\">&#60;1</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\">Nonendocrine</td> </tr> <tr> <td class=\"sublist2\">Vitiligo</td> <td class=\"sublist_other_start_centered\">4</td> </tr> <tr> <td class=\"sublist2\">Alopecia, pernicious anemia, myasthenia gravis, immune thrombocytopenia purpura, Sjogren's syndrome, rheumatoid arthritis</td> <td class=\"sublist_other_centered\">&#8804;1</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from:<br /><ol>&#xD;&#xA;    <li>Leshin M. Polyglandular autoimmune syndromes. Am J Med Sci 1985; 290:77.</li>&#xD;&#xA;    <li>Neufeld M, Maclaren NK, Blizzard RM. Two types of autoimmune Addison's disease associated with different polyglandular autoimmune (PGA) syndromes. Medicine (Baltimore) 1981; 60:355.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 67520 Version 4.0</div></div></div>"},"67522":{"type":"graphic_picture","displayName":"Cicumferential ES CA EGD","title":"Circumferential ulcerated esophageal cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Circumferential ulcerated esophageal cancer</div><div class=\"cntnt\"><img style=\"width:326px; height:252px;\" src=\"images/GAST/67522_Cicumferential_ES_CA_EGD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Circumferential ulcerated esophageal cancer seen on endoscopy.</div><div class=\"graphic_reference\">Courtesy of William Brugge, MD.</div><div id=\"graphicVersion\">Graphic 67522 Version 1.0</div></div></div>"},"67524":{"type":"graphic_picture","displayName":"Perianal abscess","title":"Perianal abscess","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Perianal abscess</div><div class=\"cntnt\"><img style=\"width:383px; height:265px;\" src=\"images/GAST/67524_Perianal_abscess.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A perianal abscess is apparent as an erythematous, fluctuant bulge with surrounding edema.</div><div class=\"graphic_reference\">Courtesy of David A Schwartz, MD and Maurits J Wiersema, MD.</div><div id=\"graphicVersion\">Graphic 67524 Version 1.0</div></div></div>"},"67527":{"type":"graphic_figure","displayName":"Normal lung anatomy PI","title":"Normal lungs","html":"<div class=\"graphic\"><div style=\"width: 578px\" class=\"figure\"><div class=\"ttl\">Normal lungs</div><div class=\"cntnt\"><img style=\"width:558px; height:560px;\" src=\"images/PI/67527_Normal_lung_anat_PI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The lungs sit in the chest, inside the ribcage. They are covered with a thin membrane called the \"pleura.\" The windpipe, or trachea, branches into two smaller airways called the left and right \"bronchi.\" The space between the lungs is called the \"mediastinum.\" Lymph nodes are located within and around the lungs and mediastinum.</div><div id=\"graphicVersion\">Graphic 67527 Version 13.0</div></div></div>"},"67528":{"type":"graphic_picture","displayName":"Urothelial CIS G","title":"Urothelial carcinoma in situ (CIS)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Urothelial carcinoma in situ (CIS)</div><div class=\"cntnt\"><img style=\"width:432px; height:261px;\" src=\"images/ONC/67528_Urothelial_CIS_G.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Cristina Magi-Galluzzi, MD, PhD.</div><div id=\"graphicVersion\">Graphic 67528 Version 1.0</div></div></div>"},"67529":{"type":"graphic_table","displayName":"Medications for acute asthma in pregnancy","title":"Pharmacologic management of acute asthma exacerbations during pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pharmacologic management of acute asthma exacerbations&nbsp;during pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">1. Beta<sub>2</sub>-agonist bronchodilator (nebulized or metered-dose inhaler)</td> </tr> <tr> <td class=\"sublist2\">Albuterol by MDI 4 to 8 puffs every 20 minutes up to&nbsp;1 hour, then every 1 to 4 hours, as needed</td> </tr> <tr> <td class=\"sublist2\">Albuterol by nebulizer 0.083 percent (2.5 mg/3 mL), 2.5 to 5 mg every 20 minutes for 3 doses and then 2.5 to 5 mg every 1 to 4 hours, as needed</td> </tr> <tr> <td class=\"sublist2\">Albuterol by continuous nebulization, administering 10 to 15 mg per hour</td> </tr> <tr> <td class=\"sublist1_start\">2. Ipratropium</td> </tr> <tr> <td class=\"sublist2\">By nebulizer, 500 mcg every 20 minutes for 3 doses, then as needed. Can be given simultaneously with beta<sub>2</sub>-agonist.</td> </tr> <tr> <td class=\"sublist2\">By MDI, 4 to 8 inhalations every 20 minutes for 3 doses, then as needed</td> </tr> <tr> <td class=\"sublist1_start\">3. Systemic glucocorticoids (for those with a poor response to treatment after one hour, or with initial therapy for patients on chronic oral glucocorticoids)</td> </tr> <tr> <td class=\"sublist2\">For patients who can be managed at home: prednisone 40 to 60 mg per day in a single or divided dose</td> </tr> <tr> <td class=\"sublist2\">For patients who require hospitalization: prednisone 40 to 80 mg daily in a single or divided dose (or the equivalent dose of methylprednisolone* intravenously) until peak flow reaches 70 percent of predicted or personal best, and then taper as patient improves</td> </tr> <tr> <td class=\"sublist2\">For patients who have a life-threatening exacerbation, a higher initial dose of methylprednisolone*, 60 to 80 mg every 6 to 12 hours, may be given intravenously, and then tapered as the patient improves, as above</td> </tr> <tr> <td class=\"sublist1_start\">4. For patients not responding to above therapies, consider adjunct therapies</td> </tr> <tr> <td class=\"sublist2\">Intravenous magnesium sulfate 2 g infused over 20 minutes, in absence of renal insufficiency<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist2\">Subcutaneous terbutaline 0.25 mg every 20 minutes for up to 3 doses</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MDI: metered dose inhaler.<br />* A conversion calculator is available in UpToDate. Refer to the calculator on corticosteroid medication dosing conversions (glucocorticoid effect).<br />¶ For patients with renal insufficiency, a baseline serum magnesium level is assessed. The decision to use intravenous magnesium requires consideration of the potential benefit in terms of asthma and the anticipated risk of hypermagnesemia based on the degree of renal insufficiency and baseline serum magnesium level.</div><div class=\"graphic_reference\">Adapted from: National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051) www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on May 12, 2011).</div><div id=\"graphicVersion\">Graphic 67529 Version 9.0</div></div></div>"},"67530":{"type":"graphic_figure","displayName":"Gastric band adjustment","title":"Gastric band adjustment","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastric band adjustment</div><div class=\"cntnt\"><img style=\"width:347px; height:454px;\" src=\"images/SURG/67530_Gastric_band_adjustment.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The gastric band consists of a soft, locking silicone ring connected to an infusion port placed in the subcutaneous tissue. The port may be accessed with relative ease by a syringe and needle. Injection of saline into the port leads to reduction in the band diameter, resulting in an increased degree of restriction.</div><div class=\"graphic_reference\">Reproduced with permission from: Jones DB, Schneider BE, Olbers T. Atlas of Metabolic and Weight Loss Surgery. Cine-Med, North Woodbury, Connecticut 2010. Copyright &#169; 2010 Cine-Med.</div><div id=\"graphicVersion\">Graphic 67530 Version 2.0</div></div></div>"},"67531":{"type":"graphic_picture","displayName":"Sarcoidosis of the lip","title":"Sarcoidosis involving the lip","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sarcoidosis involving the lip</div><div class=\"cntnt\"><img style=\"width:396px; height:349px;\" src=\"images/DERM/67531_Sarcoidosis_lip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Oral sarcoidosis. Diffused granulomatous infiltration of lips, with gross enlargement of the upper lip is present. Honeycomb post inflammatory pigmentary changes are present on the superior portion of the upper lip.</div><div id=\"graphicVersion\">Graphic 67531 Version 1.0</div></div></div>"},"67532":{"type":"graphic_picture","displayName":"Axillary freckling","title":"Axillary freckling in neurofibromatosis type 1","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Axillary freckling in neurofibromatosis type 1</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/67532_Axillary_freckling.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple hyperpigmented macules are present in the axilla.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 67532 Version 4.0</div></div></div>"},"67533":{"type":"graphic_table","displayName":"Prognostic factors thy ca","title":"Commonly used risk factors for stratification of risk of death from disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Commonly used risk factors for stratification of risk of death from disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Parameters </td> <td class=\"subtitle1\"> <p>EORTC<sup>[1]</sup></p> <p>(1979)</p> </td> <td class=\"subtitle1\"> <p>AGES<sup>[2]</sup></p> <p>(1987)</p> </td> <td class=\"subtitle1\"> <p>AMES<sup>[3]</sup></p> <p>(1988)</p> </td> <td class=\"subtitle1\"> <p>MACIS<sup>[4]</sup></p> <p>(1993)</p> </td> <td class=\"subtitle1\"> <p>OSU<sup>[5]</sup></p> <p>(1994)</p> </td> <td class=\"subtitle1\"> <p>MSKCC<sup>[6]</sup></p> <p>(1995)</p> </td> <td class=\"subtitle1\"> <p>NTCTCS<sup>[7]</sup></p> <p>(1998)</p> </td> <td class=\"subtitle1\"> <p>TNM<sup>[8]</sup></p> <p>(2017)</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"9\">Patient factors </td> </tr> <tr> <td class=\"indent1\">Age </td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> <td>-</td> <td>X</td> <td>X</td> <td>X</td> </tr> <tr> <td class=\"indent1\">Gender </td> <td>X</td> <td>-</td> <td>X</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"9\">Tumor factors </td> </tr> <tr> <td class=\"indent1\">Size of primary tumor </td> <td>-</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> </tr> <tr> <td class=\"indent1\">Multicentricity </td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> <td>X</td> <td>-</td> <td>X</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Tumor grade </td> <td>-</td> <td>X</td> <td>-</td> <td>-</td> <td>-</td> <td>X</td> <td>-</td> <td>-</td> </tr> <tr> <td class=\"indent1\">Extrathyroidal extension </td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> </tr> <tr> <td class=\"indent1\">Lymph node involvement </td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> </tr> <tr> <td class=\"indent1\">Distant metastasis </td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"9\">Operative factors </td> </tr> <tr> <td class=\"indent1\">Completeness of resection </td> <td>-</td> <td>-</td> <td>-</td> <td>X</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">X: variable used in defining risk group.<br> -: variable not used.</div><div class=\"graphic_footnotes\">EORTC: European Organization for Research on Treatment of Cancer; AGES: patient age, histologic grade of the tumor, tumor extent (extrathyroidal invasion or distant metastases), and size of the primary tumor; AMES: patient age, presence of distant metastases, extent and size of the primary tumor; MACIS: metastasis, patient age, completeness of resection, local invasion, and tumor size; OSU: Ohio State University; MSKCC: Memorial Sloan-Kettering Cancer Center; NTCTCS: National Thyroid Cancer Treatment Cooperative Study; TNM: American Joint Committee on Cancer staging system of tumor size (T), nodal metastases (N), and distant metastases (M).</div><div class=\"graphic_reference\">1. Byar DP, Green SB, Dor P, et al. A prognostic index for thyroid carcinoma:&nbsp;A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group. Eur J Cancer 1979; 15:1033.<br />2. Hay ID, Grant CS, Taylor WF, et al. Ipsilateral lobectomy versus bilateral lobar resection in papilliary thyroid carcinoma:&nbsp;A retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 1987; 102:1088.<br />3. Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 1988; 104:947.<br />4. Hay ID, Bergstralh EJ, Goellner JR, et al. Predicting outcome in papillary thyroid carcinoma: Development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993; 114:1050 [discussion: 1057-8].<br />5. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97:418.<br />6. Shaha AR, Loree TR, Shah JP. Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. Surgery 1995; 118:1131 [discussion: 1136-8].<br />7. Sherman SI, Brierley JD, Sperling M, et al. Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer 1998; 83:1012.<br />8. AJCC Cancer Staging Manual. 8th edition. New York: Springer; 2017.<br />Reproduced by permission from:<br />Cancer Control: Journal of the Moffitt Cancer Center. Dean DS, Hay ID. Prognostic indicators in differentiated thyroid carcinoma. Cancer Control. 2000; 7:229. Copyright ©2000.</div><div id=\"graphicVersion\">Graphic 67533 Version 3.0</div></div></div>"},"67534":{"type":"graphic_picture","displayName":"Boston Sci Res Clips endosc","title":"Treatment of a bleeding gastric ulcer with endoclips","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Treatment of a bleeding gastric ulcer with endoclips</div><div class=\"cntnt\"><img style=\"width:324px; height:323px;\" src=\"images/GAST/67534_Boston_Sci_Res_Clips_endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Treatment of an actively bleeding gastric ulcer using Boston Scientific Resolution Clips.</div><div class=\"graphic_reference\">Courtesy of Dennis M. Jensen, MD.</div><div id=\"graphicVersion\">Graphic 67534 Version 3.0</div></div></div>"},"67537":{"type":"graphic_picture","displayName":"Erb palsy","title":"Erb palsy after traction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erb palsy after traction</div><div class=\"cntnt\"><img style=\"width:260px; height:411px;\" src=\"images/NEURO/67537_Erb_palsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: O'Doherty, N. Atlas of the newborn. JB Lippincott, Philadelphia, 1979. p. 159. Copyright © 1979 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 67537 Version 2.0</div></div></div>"},"67538":{"type":"graphic_picture","displayName":"Postganglionic Horners syndrome","title":"Postganglionic right Horner's syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Postganglionic right Horner's syndrome</div><div class=\"cntnt\"><img style=\"width:289px; height:504px;\" src=\"images/NEURO/67538_Postganglionic_Horners_synd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) In the light, there is mild anisocoria, with the right pupil being smaller than the left pupil. There is also decreased palpebral fissure on the right. B) In the dark, the right pupil does not dilate well. C) After instillation of 1 percent hydroxyamphetamine in both eyes, only the left pupil dilates, suggesting a lesion involving the postganglionic oculosympathic pathways (third order Horner's syndrome).</div><div id=\"graphicVersion\">Graphic 67538 Version 1.0</div></div></div>"},"67539":{"type":"graphic_picture","displayName":"Arteriovenous anastomosis preablation","title":"Arteriovenous anastomosis preablation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Arteriovenous anastomosis preablation</div><div class=\"cntnt\"><img style=\"width:288px; height:292px;\" src=\"images/OBGYN/67539_Tx_TTTS4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The vessel at 11 o'clock is the recipient's vein, the vessel coming in at 5 o'clock is the donor artery, the &quot;green&quot; targeting light is focused on the donor vessel.</div><div class=\"graphic_reference\">Courtesy of Kenneth J Moise, Jr, MD and Anthony Johnson, DO.</div><div id=\"graphicVersion\">Graphic 67539 Version 4.0</div></div></div>"},"67540":{"type":"graphic_table","displayName":"Etiology epistaxis children","title":"Causes of epistaxis in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of epistaxis in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Local</td> </tr> <tr> <td class=\"indent1\">Trauma</td> <td> <p>Nose-picking*</p> <p>Foreign body</p> <p>Blunt or penetrating facial trauma</p> <p>Child abuse</p> <p>Postoperative; </p> <p>Nasotracheal intubation</p> <p>Nasogastric tube placement</p> </td> </tr> <tr> <td class=\"indent1\">Mucosal irritation</td> <td> <p>Dry air*</p> <p>Allergic rhinitis</p> <p>Inhaled irritants/drugs (inhaled corticosteroids*, tobacco, cocaine heroin, volatile inhalants of abuse)</p> <p>Upper respiratory infection or systemic infection with nasal congestion</p> <p>Localized skin or soft tissue infection</p> <p>Colonization with pathologic bacteria (eg, <em>Staphylococcus aureus</em>)</p> </td> </tr> <tr> <td class=\"indent1\">Anatomic</td> <td>Septal deviation or unilateral choanal atresia causing asymmetric airflow</td> </tr> <tr> <td class=\"indent1\">Tumors</td> <td> <p>Hemangioma</p> <p>Juvenile nasopharyngeal angiofibroma (particularly in adolescent males) </p> <p>Pyogenic granuloma</p> <p>Rhabdomyosarcoma</p> <p>Nasopharyngeal carcinoma</p> <p>Inverting papilloma</p> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Other</td> <td>Increased nasal venous pressure secondary to paroxysmal coughing</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Systemic</td> </tr> <tr> <td class=\"indent1\">Bleeding disorders</td> <td>Inherited or acquired coagulation disorders, platelet disorders, blood vessel disorders (eg, hereditary hemorrhagic telangiectasia)</td> </tr> <tr> <td class=\"indent1\">Medications</td> <td>Aspirin, ibuprofen, anticoagulants (including rodenticides), valproic acid</td> </tr> <tr> <td class=\"indent1\">Granulomatous disorders</td> <td>Granulomatosis with polyangiitis (Wegener's), sarcoidosis, tuberculosis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hypertension</td> <td>Primary hypertension, secondary hypertension (renal disease, corticosteroids), increased venous pressure (exertion, superior vena cava syndrome)</td> </tr> <tr> <td class=\"subtitle1_single\">Recurrent</td> <td> <p>Usually related to recurrent/chronic nasal trauma (eg, nose picking)&nbsp;or irritation, but may be the presenting symptom of:</p> <p>Bleeding disorder</p> <p>Hereditary hemorrhagic telangiectasia </p> <p>Nasopharyngeal carcinoma</p> <p>Posttraumatic pseudoaneurysm of internal carotid artery</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Most common causes.</div><div id=\"graphicVersion\">Graphic 67540 Version 5.0</div></div></div>"},"67542":{"type":"graphic_diagnosticimage","displayName":"Colles fracture child","title":"Complete distal radius and ulna fracture (Colles fracture) in 11 year old child","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Complete distal radius and ulna fracture (Colles fracture) in 11 year old child</div><div class=\"cntnt\"><img style=\"width:515px; height:347px;\" src=\"images/EM/67542_Colles_fx_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This common pediatric fracture is described as follows: 100 percent dorsally displaced distal radius and ulna fracture with volar angulation.</div><div class=\"graphic_reference\">Courtesy of Paula Schweich, MD.</div><div id=\"graphicVersion\">Graphic 67542 Version 2.0</div></div></div>"},"67544":{"type":"graphic_table","displayName":"DBA physical findings","title":"Physical exam findings in Diamond-Blackfan anemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Physical exam findings in Diamond-Blackfan anemia</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"container\">\r\n                    <table cellspacing=\"0\">\r\n                        <tbody>\r\n                            <tr>\r\n                                <td class=\"sublist1_start\">Craniofacial</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td class=\"sublist1\">Hypertelorism</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td class=\"sublist1\">Microcephaly</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td class=\"sublist1\">Congenital cataracts/glaucoma</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td class=\"sublist1\">Strabismus</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td class=\"sublist1\">Microophthalmos</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td class=\"sublist1\">Blue sclera</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td class=\"sublist1\">High arched palate</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td class=\"sublist1\">Ear malformations</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td class=\"sublist1_start\">Neck</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td class=\"sublist1\">Fusion of the vertebrae with flaring of the trapezius muscle (Turner like appearance)</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td class=\"sublist1\">Elevation of the scapula (Sprengel deformity)</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td class=\"sublist1_start\">Thumb</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td class=\"sublist1\">Bifid thumb</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td class=\"sublist1\">Duplication</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td class=\"sublist1\">Subluxation</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td class=\"sublist1\">Hypoplasia</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td class=\"sublist1\">Absence</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td class=\"sublist1\">Flat hypoplastic thenar eminence</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td class=\"sublist1\">Weak/absent radial pulses</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td class=\"sublist1\">Triphalangeal thumb*</td>\r\n                            </tr>\r\n                        </tbody>\r\n                    </table>\r\n                    </td>\r\n                    <td class=\"container\">\r\n                    <table cellspacing=\"0\">\r\n                        <tbody>\r\n                            <tr>\r\n                                <td class=\"sublist1_start\">Urogenital</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td class=\"sublist1\">Dysplastic or horseshoe kidney</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td class=\"sublist1\">Duplication of the ureters</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td class=\"sublist1\">Renal tubular acidosis</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td class=\"sublist1_start\">Cardiopulmonary</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td class=\"sublist1\">Ventricular and atrial septal defects</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Hypogonadism</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Mental retardation</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Other skeletal abnormalities</td>\r\n                            </tr>\r\n                            <tr>\r\n                                <td>Other anomalies</td>\r\n                            </tr>\r\n                        </tbody>\r\n                    </table>\r\n                    </td>\r\n                </tr>\r\n            </tbody>\r\n        </table>\r\n        <!--[if gte mso 9]><xml>\r\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">7.00000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&#60;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=25160&#38;amp;Mode=Edit&quot;&#62;&#60;/a&#62;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\r\n</xml><![endif]--></div><div class=\"graphic_footnotes\">* Triphalangeal thumbs are a characteristic of Aase syndrome, which is probably a variant of Diamond-Blackfan anemia.</div><div class=\"graphic_reference\">Data from: <br /><OL>&#xD;&#xA;<LI>Alter BP, Young NS. The Bone Marrow Failure Syndromes. In: Nathan and Oski's Hematology of Infancy and Childhood, Nathan DG, Orkin SH (Eds), W.B. Saunders Company, 1998, p.237.</LI>&#xD;&#xA;<LI>Halperin DS, Freedman MH, Am J Pediatr Hematol Oncol 1989; 11:380.</LI></OL></div><div id=\"graphicVersion\">Graphic 67544 Version 4.0</div></div></div>"},"67547":{"type":"graphic_figure","displayName":"Kasai hepatoportoenterostomy","title":"Kasai hepatoportoenterostomy","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Kasai hepatoportoenterostomy</div><div class=\"cntnt\"><img style=\"width:512px; height:696px;\" src=\"images/PEDS/67547_Kasai-hepatoportoenterostomy-edit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the Kasai hepatoportoenterostomy the bile ducts are excised and a limb of jejunum is anastamosed to the liver. The distal duodenum is anastomosed to the jejunal limb to create a Roux-en-Y configuration.</div><div id=\"graphicVersion\">Graphic 67547 Version 3.0</div></div></div>"},"67548":{"type":"graphic_table","displayName":"Food records standard","title":"Food records standard","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Food records standard</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"6\">Instructions for monitoring</td> </tr> <tr> <td colspan=\"6\"><strong>Column 1 (Time):</strong> Note the time when you had anything to eat or drink. Do your best to be accurate.</td> </tr> <tr> <td colspan=\"6\"> <p><strong>Column 2 (Food/drink consumed):</strong> Record exactly what you eat and drink, including any binge eating. Don't leave anything out. Instead of recording calories, write down a simple description of what you eat and drink. Write down each item you eat or drink as soon as possible after you eat it. Trying to remember what it was that you ate or drank later is not a good idea, because it can be unreliable and won't help you change.</p> <p>Monitoring at the time of eating is extremely important. For example, if you are eating out, it can be helpful to record what you are eating during the meal by monitoring in private, like in the restaurant's bathroom.</p> <p>Episodes of eating that you consider to be meals should be bracketed. Do not bracket snacks or other episodes of overeating.</p> </td> </tr> <tr> <td colspan=\"6\"><strong>Column 3 (Place):</strong> Write down where you consumed the food or drink. If you are eating or drinking at home, specify the room.</td> </tr> <tr> <td colspan=\"6\"><strong>Column 4 (Loss of control?):</strong> Place an asterisk (*) in this column if you feel like you were out of control (like you couldn't stop eating or control what, or how much you were eating).</td> </tr> <tr> <td colspan=\"6\"><strong>Column 5 (V/L/D):</strong> Record if and when you vomit or use laxatives or diuretics.</td> </tr> <tr> <td colspan=\"6\"><strong>Column 6 (Context/comments):</strong> Use this column like a diary. You should note anything that is going on while you are eating, or anything that is influencing your eating. For example, if you note in column 4 that you felt out of control, record in column 6 the circumstances at the time you were eating. This will help to identify triggers of any times you feel like you overate.</td> </tr> <tr class=\"divider_top\"> <td colspan=\"5\">&nbsp;</td> <td> <p><strong>Day:</strong></p> </td> </tr> <tr> <td class=\"subtitle1\">Time</td> <td class=\"subtitle1\">Food/drink consumed</td> <td class=\"subtitle1\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Place&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td> <td class=\"subtitle1\">Loss of control?</td> <td class=\"subtitle1\">V/L/D</td> <td class=\"subtitle1\">Context/comments</td> </tr> <tr> <td><br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> </td> <td><br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> </td> <td><br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> </td> <td><br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> </td> <td><br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> </td> <td><br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> <br /> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Fairburn (2008).</div><div id=\"graphicVersion\">Graphic 67548 Version 6.0</div></div></div>"},"67549":{"type":"graphic_diagnosticimage","displayName":"Acetabular fracture of anterior and posterior columns","title":"Acetabular fracture of anterior and posterior columns","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acetabular fracture of anterior and posterior columns</div><div class=\"cntnt\"><img style=\"width:360px; height:381px;\" src=\"images/EM/67549_Acetab_fx_2_column.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This anterior-posterior (AP) radiograph demonstrates a right acetabular fracture involving both the anterior and posterior columns and mild central hip dislocation.</div><div class=\"graphic_reference\">Courtesy of Jim Fiechtl, MD.</div><div id=\"graphicVersion\">Graphic 67549 Version 4.0</div></div></div>"},"67550":{"type":"graphic_picture","displayName":"Mold spores","title":"Mold spores","html":"<div class=\"graphic\"><div style=\"width: 489px\" class=\"figure\"><div class=\"ttl\">Mold spores</div><div class=\"cntnt\"><img style=\"width:469px; height:724px;\" src=\"images/ALLRG/67550_Mold_spores.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) <EM>Cladosporium</EM> spp B) <EM>Alternaria</EM>&nbsp;spp C) <EM>Aspergillus</EM> spp D) <EM>Penicillium</EM> spp E) Various fungi (<EM>Aspergillus</EM> and <EM>Penicillium</EM>) in culture.</div><div id=\"graphicVersion\">Graphic 67550 Version 2.0</div></div></div>"},"67551":{"type":"graphic_figure","displayName":"AS survival and jet velocity","title":"Event free survival in asymptomatic aortic stenosis","html":"<div class=\"graphic\"><div style=\"width: 513px\" class=\"figure\"><div class=\"ttl\">Event free survival in asymptomatic aortic stenosis</div><div class=\"cntnt\"><img style=\"width:493px; height:298px;\" src=\"images/CARD/67551_ASsurvivalandjetvelocit.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Event free survival in patients with aortic stenosis who are initially asymptomatic is related to the aortic jet velocity (V<SUB>max</SUB>) at entry. Aortic jet velocity varies inversely with valve area.</div><div class=\"graphic_reference\">Data from Otto CM, Burwash IG, Legget ME, et al. Circulation 1997; 95:2262.</div><div id=\"graphicVersion\">Graphic 67551 Version 3.0</div></div></div>"},"67553":{"type":"graphic_picture","displayName":"Skin lesions sporotrichosis","title":"Skin lesions sporotrichosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Skin lesions sporotrichosis</div><div class=\"cntnt\"><img style=\"width:504px; height:250px;\" src=\"images/ID/67553_Skin_lesions_sporotrichosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of www.doctorfungus.org. Copyright &#169; 2006.</div><div id=\"graphicVersion\">Graphic 67553 Version 1.0</div></div></div>"},"67557":{"type":"graphic_diagnosticimage","displayName":"Membranous VSD short axis color still frame","title":"Membranous VSD short axis color still frame","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Membranous VSD short axis color still frame</div><div class=\"cntnt\"><img style=\"width:546px; height:369px;\" src=\"images/CARD/67557_Membr_VSD_short_axis_color.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These paired short axis images show a large membranous ventricular septal defect (VSD) (arrow) beneath the septal leaflet of the tricuspid valve. The jet of systolic left-to-right flow across the defect is well demonstrated by Doppler color flow mapping in the left hand panel.</div><div class=\"graphic_footnotes\">LA: left atrium; RA: right atrium; RV: right ventricle; LVOT: left ventricular outflow tract; PA: pulmonary artery; arrow: VSD.</div><div id=\"graphicVersion\">Graphic 67557 Version 3.0</div></div></div>"},"67558":{"type":"graphic_table","displayName":"LMA size","title":"Weight based laryngeal mask airway (LMA) sizing","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Weight based laryngeal mask airway (LMA) sizing</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">LMA size</td> <td class=\"subtitle1\">Patient weight (kg)</td> </tr> <tr> <td>1</td> <td>up to 5 </td> </tr> <tr> <td>1.5</td> <td>5 to 10 </td> </tr> <tr> <td>2</td> <td>10 to 20 </td> </tr> <tr> <td>2.5</td> <td>20 to 30 </td> </tr> <tr> <td>3</td> <td>30 to 50 </td> </tr> <tr> <td>4</td> <td>50 to 70 </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 67558 Version 2.0</div></div></div>"},"67560":{"type":"graphic_diagnosticimage","displayName":"Mediastinal air Boerhaaves","title":"Esophageal perforation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Esophageal perforation</div><div class=\"cntnt\"><img style=\"width:202px; height:324px;\" src=\"images/GAST/67560_Mediastinal_air_Boerhaaves.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest film from a patient with Boerhaave syndrome reveals free mediastinal air along the esophageal contour (arrow).</div><div class=\"graphic_reference\">Courtesy of Robert E Mindelzun, MD, Department of Radiology, Stanford University.</div><div id=\"graphicVersion\">Graphic 67560 Version 3.0</div></div></div>"},"67561":{"type":"graphic_figure","displayName":"Superfic inguinal lymph nodes","title":"Anatomic view of the superficial inguinal lymph nodes","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Anatomic view of the superficial inguinal lymph nodes</div><div class=\"cntnt\"><img style=\"width:501px; height:409px;\" src=\"images/OBGYN/67561_Superfic_inguinal_lymph_nod.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Mann WJ, Stovall TG. Gynecologic Surgery. Churchill Livingstone, New York 1996. Copyright © 1996 Elsevier.</div><div id=\"graphicVersion\">Graphic 67561 Version 2.0</div></div></div>"},"67562":{"type":"graphic_table","displayName":"Choice of influenza vaccine for children","title":"Choice of influenza vaccine for children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Choice of influenza vaccine for children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Category</td> <td class=\"subtitle1\">Type of influenza vaccine</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">NOTE: LAIV is not recommended for use in children or adults during the&nbsp;2017-2018 influenza season in the United States. <sup>[1,2]</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Age</td> </tr> <tr> <td class=\"indent1\">0 to 6 months</td> <td>Vaccine not licensed for this age group; household contacts and out-of-home caregivers should receive IIV or LAIV*</td> </tr> <tr> <td class=\"indent1\">6 to 24 months</td> <td>IIV</td> </tr> <tr> <td class=\"indent1\">&#8805;24 months</td> <td>IIV or LAIV*</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"2\">Chronic medical disorders</td> </tr> <tr> <td class=\"indent1\">Pulmonary (including asthma in children of all ages and history of wheezing in the previous 12 months for children aged 2 through 4 years)</td> <td rowspan=\"8\">IIV</td> </tr> <tr> <td class=\"indent1\">Cardiovascular disease (including pulmonary hypertension, but excluding systemic hypertension)</td> </tr> <tr> <td class=\"indent1\">Congenital heart disease with physiologically significant abnormalities</td> </tr> <tr> <td class=\"indent1\">Renal</td> </tr> <tr> <td class=\"indent1\">Hepatic</td> </tr> <tr> <td class=\"indent1\">Hematologic</td> </tr> <tr> <td class=\"indent1\">Metabolic (including diabetes mellitus)</td> </tr> <tr> <td class=\"indent1\">Neurologic, neuromuscular, and neurodevelopmental disorders (including disorders of the brain, spinal cord, and peripheral nerve and muscle such as cerebral palsy, epilepsy, stroke, intellectual disability [mental retardation], moderate-to-severe developmental delay, muscular dystrophy, or spinal cord injury), particularly those that compromise respiratory function or the handling of secretions, or that increase the risk of aspiration</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"2\">Other conditions</td> </tr> <tr> <td class=\"indent1\">Immunosuppression, including immunosuppression due to medications or human immunodeficiency virus</td> <td>IIV</td> </tr> <tr> <td class=\"indent1\">Long-term aspirin or salicylate therapy (for children 6 months to 18 years of age)</td> <td>IIV</td> </tr> <tr> <td class=\"indent1\">Residents of long-term-care facilities</td> <td>IIV</td> </tr> <tr> <td class=\"indent1\">Women who will be pregnant during the influenza season</td> <td>IIV</td> </tr> <tr> <td class=\"indent1\">Severe obesity (body mass index [BMI] &#8805;40 for adults or BMI &#62;2.33 standard deviations above the mean for children)</td> <td>IIV or LAIV*</td> </tr> <tr> <td class=\"indent1\">Native Americans, including Alaska Natives</td> <td>IIV or LAIV*</td> </tr> <tr> <td class=\"indent1\">Household or close contact of infant younger than six months or individual with chronic medical disorder or other condition with increased risk of severe or complicated influenza infection, except severely immunocompromised hospitalized person who requires protected environment</td> <td>IIV or LAIV*</td> </tr> <tr> <td class=\"indent1\">Contact of severely immunocompromised hospitalized person who requires protected environment</td> <td>IIV</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IIV: inactivated influenza vaccine; LAIV: live attenuated influenza vaccine.<br />* LAIV may be administered to individuals who are healthy, nonpregnant, and 2 through 49 years of age.</div><div class=\"graphic_reference\">References: <br /><OL>&#xD;&#xA;<LI>American Academy of Pediatrics. Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2017–2018. Pediatrics 2017; 140:e20172550.</LI>&#xD;&#xA;<LI>Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices&nbsp;– United States, 2017-18 influenza season. MMWR Recomm Rep 2017; 66:1.</LI></OL></div><div id=\"graphicVersion\">Graphic 67562 Version 15.0</div></div></div>"},"67564":{"type":"graphic_table","displayName":"Air embolism differential dx","title":"Differential diagnosis of air embolism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of air embolism</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Pulmonary diseases</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pulmonary thromboembolism</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pneumothorax</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Acute bronchospasm</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Acute pulmonary edema</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Cardiovascular\ndecompensation</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hypovolemia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cardiogenic shock</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Myocardial infarction</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Septic shock</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Electromechanical dissociation</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Neurological\ndisorders</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cerebral hypoperfusion</td>\n\n    </tr>\n    <tr>\n      <td>Stroke</td>\n    </tr>\n    <tr>\n      <td>Intraparenchymal or\nsubarachnoid hemorrhage </td>\n    </tr>\n    <tr>\n      <td>Hypoxic brain injury </td>\n    </tr>\n    <tr>\n      <td>Head trauma</td>\n    </tr>\n    <tr>\n      <td>Metabolic\ndisorders (eg, hypoglycemia)</td>\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Orebaugh, SL, Crit Care Med 1992; 20:1169.</div><div id=\"graphicVersion\">Graphic 67564 Version 1.0</div></div></div>"},"67566":{"type":"graphic_picture","displayName":"Confluent and reticulated papillomatosis - back","title":"Confluent and reticulated papillomatosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Confluent and reticulated papillomatosis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/67566_Conflu_retic_papill_back.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Reticulated, hyperpigmented patches and thin plaques with fine scale are present on the upper back.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 67566 Version 3.0</div></div></div>"},"67567":{"type":"graphic_table","displayName":"Questions used to assess possibility of pregnancy","title":"Excluding pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Excluding pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_left\">The provider can be reasonably certain that the woman is not pregnant if she has no symptoms or signs of pregnancy and meets any of the following criteria:</td> </tr> <tr> <td> <ol> <li>She has not had intercourse since her last normal menses. </li> <li>She has been correctly and consistently using a reliable method of contraception. </li> <li>She is within the first&nbsp;seven days after normal menses.&nbsp; </li> <li>She is within&nbsp;four weeks postpartum (for nonlactating women). </li> <li>She is within the first&nbsp;seven days postabortion or miscarriage. </li> <li>She is fully or nearly fully breastfeeding, amenorrhoeic, and less than six months postpartum. </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">A systematic review of studies evaluating the performance of a pregnancy checklist compared with urine pregnancy test to rule out pregnancy concluded the negative predictive value of a checklist similar to the one above was 99 to 100 percent.</div><div class=\"graphic_reference\">Data&nbsp;from:<br /><br /><UL>&#xD;&#xA;<LI>Tepper NK, Marchbanks PA, Curtis KM. Use of a checklist to rule out pregnancy:&nbsp;A systematic review. Contraception 2013; 87:661.</LI>&#xD;&#xA;<LI>Curtis KM, Tepper NK, Jatlaoui TC, et al. United States Medical&nbsp;Eligibility Criteria for Contraceptive Use, 2016.&nbsp;MMWR Recomm Rep 2016; 65:1.</LI></UL></div><div id=\"graphicVersion\">Graphic 67567 Version 12.0</div></div></div>"},"67568":{"type":"graphic_diagnosticimage","displayName":"Right hepatic radoca bile leak","title":"Right hepatic radical bile leak after cholecystectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Right hepatic radical bile leak after cholecystectomy</div><div class=\"cntnt\"><img style=\"width:288px; height:313px;\" src=\"images/GAST/67568_Right_hepatic_radicle_bile.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic retrograde cholangiopancreatography shows extravasation of contrast from a right hepatic bile duct radical (arrow).</div><div class=\"graphic_reference\">Courtesy of Michael J Bourke, MBBS, FRACP.</div><div id=\"graphicVersion\">Graphic 67568 Version 5.0</div></div></div>"},"67569":{"type":"graphic_table","displayName":"Anaerobic bacteria in lung infx","title":"Bacteriology of anaerobic infections of the lung","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bacteriology of anaerobic infections of the lung</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"50%\"></colgroup><colgroup span=\"2\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Earlier series<sup>[1]</sup></td> <td class=\"subtitle1\">Later series<sup>[2]</sup></td> </tr> <tr> <td><strong>Period reviewed</strong></td> <td class=\"centered\">1968 to 1975</td> <td class=\"centered\">1976 to 1991</td> </tr> <tr> <td><strong>Number of cases</strong></td> <td class=\"centered\">193</td> <td class=\"centered\">110</td> </tr> <tr> <td><strong>Total anaerobic isolates</strong></td> <td class=\"centered\">461</td> <td class=\"centered\">404</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Average anaerobic isolates per case</strong></td> <td class=\"centered\">2.4</td> <td class=\"centered\">3.5</td> </tr> <tr> <td class=\"subtitle2 highlight_gray_text\">&nbsp;</td> <td class=\"subtitle2\" colspan=\"2\">Number of isolates*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Gram-negative bacilli</td> </tr> <tr> <td class=\"indent1\"><em>Fusobacterium nucleatum</em></td> <td class=\"centered\">56</td> <td class=\"centered\">34</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"3\">Former <em>Bacteroides</em> species</td> </tr> <tr> <td class=\"sublist2\"><em>B. fragilis</em> group</td> <td class=\"sublist_other_centered\">38</td> <td class=\"sublist_other_centered\">18</td> </tr> <tr> <td class=\"sublist2\">Pigmented <em>Prevotella</em></td> <td class=\"sublist_other_centered\">76</td> <td class=\"sublist_other_centered\">63</td> </tr> <tr> <td class=\"sublist2\">Nonpigmented <em>Prevotella</em></td> <td class=\"sublist_other_centered\">&ndash;</td> <td class=\"sublist_other_centered\">40</td> </tr> <tr> <td class=\"sublist2\"><em>B. ureolyticus</em></td> <td class=\"sublist_other_centered\">&ndash;</td> <td class=\"sublist_other_centered\">23</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist2\">Other</td> <td class=\"sublist_other_centered\">37</td> <td class=\"sublist_other_centered\">38</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Gram-negative cocci</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><em>Veillonella</em></td> <td class=\"centered\">23</td> <td class=\"centered\">18</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Gram-positive bacilli</td> </tr> <tr> <td class=\"indent1\"><em>Clostridium</em> species</td> <td class=\"centered\">18</td> <td class=\"centered\">12</td> </tr> <tr> <td class=\"indent1\"><em>Eubacterium</em> species</td> <td class=\"centered\">18</td> <td class=\"centered\">22</td> </tr> <tr> <td class=\"indent1\"><em>Actinomyces</em></td> <td class=\"centered\">5</td> <td class=\"centered\">19</td> </tr> <tr> <td class=\"indent1\"><em>Lactobacillus</em> species</td> <td class=\"centered\">8</td> <td class=\"centered\">22</td> </tr> <tr> <td class=\"indent1\"><em>Cutibacterium</em> (formerly <em>Propionibacterium</em>) species</td> <td class=\"centered\">10</td> <td class=\"centered\">9</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><em>Bifidobacterium</em> species</td> <td class=\"centered\">9</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Gram-positive cocci</td> </tr> <tr> <td class=\"indent1\">Peptostreptococci</td> <td class=\"centered\">87</td> <td class=\"centered\">39</td> </tr> <tr> <td class=\"indent1\">Peptococci</td> <td class=\"centered\">39</td> <td class=\"centered\">&ndash;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Differences in the two series partially reflect taxonomic changes and variations in microbiologic methods. In the earlier series, the \"black pigmented <em>Bacteroides</em> species\" were reported as <em>B. melaninogenicus</em>, whereas the later series reported these according to reclassification as <em>Prevotella melaninogenicus</em>, <em>P. intermedia</em>, and <em>P. asaccharolytica</em>. For gram-positive cocci, the clinically important organisms formerly classified as <em>Peptococcus</em> have nearly all been reclassified as <em>Peptostreptococcus</em>.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Bartlett JG. Anaerobic bacterial infections of the lung and pleural space. Clin Infect Dis 1993; 16:S248.</LI>&#xD;&#xA;<LI>Marina M, Strong CA, Civen R,&nbsp;et al. Bacteriology of anaerobic pleuropulmonary infections: preliminary report. Clin Infect Dis 1993; 16:S256.</LI></OL></div><div id=\"graphicVersion\">Graphic 67569 Version 6.0</div></div></div>"},"67573":{"type":"graphic_diagnosticimage","displayName":"CT diffuse axonal injury after TBI","title":"Diffuse axonal injury","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diffuse axonal injury</div><div class=\"cntnt\"><img style=\"width:380px; height:417px;\" src=\"images/NEURO/67573_Diffuseaxonalinjury.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan of the brain showing diffuse axonal injury (DAI). Note the deep shearing-type injury in or near the white matter of the left internal capsule (arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: J Claude Hemphill II, MD and Nicholas Phan, MD, FRCSC.</div><div id=\"graphicVersion\">Graphic 67573 Version 4.0</div></div></div>"},"67576":{"type":"graphic_picture","displayName":"Dutcher body","title":"Dutcher body","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dutcher body</div><div class=\"cntnt\"><img style=\"width:324px; height:224px;\" src=\"images/HEME/67576_Dutcher_body_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow smear from a patient with lymphoplasmacytic lymphoma and an IgM spike (Waldenstrom macroglobulinemia). There is an intranuclear inclusion in a lymphocyte (arrow) that represents precipitated IgM.</div><div class=\"graphic_reference\">From Brunning, RD, McKenna, RW. Tumors of the bone marrow. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 9, 1994, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 67576 Version 3.0</div></div></div>"},"67577":{"type":"graphic_picture","displayName":"Inward rotation exercise PI","title":"Inward rotation exercise","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Inward rotation exercise</div><div class=\"cntnt\"><img style=\"width:532px; height:304px;\" src=\"images/PI/67577_Inward_rotation_exercise_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hold your elbow at 90 degrees, close to your side. Hook the rubber band onto a door handle and grasp with only one hand. Rotate your forearm towards the body two or three inches and hold for five seconds. The forearm swings like a door.</div><div id=\"graphicVersion\">Graphic 67577 Version 5.0</div></div></div>"},"67578":{"type":"graphic_figure","displayName":"Proximal humerus fractures","title":"Displaced fractures of the proximal humerus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Displaced fractures of the proximal humerus</div><div class=\"cntnt\"><img style=\"width:331px; height:442px;\" src=\"images/RHEUM/67578_Proximal_humerus_fractures.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Bigliani, LU. Fractures of the proximal humerus. In: Rockwood, CA, Matsen, FA (Eds). The Shoulder. Philadelphia, W.B. Saunders, 1990, pp. 278-334. Copyright &#169; 1990 Elsevier.</div><div id=\"graphicVersion\">Graphic 67578 Version 3.0</div></div></div>"},"67579":{"type":"graphic_picture","displayName":"Open globe laceration with a teardrop pupil","title":"Open globe laceration with a teardrop pupil","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Open globe laceration with a teardrop pupil</div><div class=\"cntnt\"><img style=\"width:432px; height:288px;\" src=\"images/EM/67579_Open_globe_laceration_teardrop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Picture demonstrating a globe laceration and teardrop pupil.</div><div class=\"graphic_reference\">Reproduced with permission from: Hoff AM Stead LG, Smith VD. Traumatic globe laceration. J Trauma 2010; 68:746. Copyright © 2010 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 67579 Version 7.0</div></div></div>"},"67581":{"type":"graphic_picture","displayName":"Anetoderma","title":"Anetoderma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anetoderma</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/DERM/67581_Anetoderma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple circumscribed, wrinkled lesions are present on the chest.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 67581 Version 3.0</div></div></div>"},"67582":{"type":"graphic_picture","displayName":"H and E stain of chronic sclerosing sialadenitis","title":"H and E stain of chronic sclerosing sialadenitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">H and E stain of chronic sclerosing sialadenitis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/RHEUM/67582_HE_stain_chron_scler_sialad.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chronic sclerosing sialadenitis (Küttner's tumor). This IgG4-related disease shows large germinal centers (arrow), dense lymphoplasmacytic inflammation, and fibrosis. The cellular fibroinflammatory stroma is typical of this disease (arrowhead) (H&amp;E stain).</div><div class=\"graphic_reference\">Reproduced with permission from: Geyer J, Deshpande V. IgG4-associated sialadenitis. Curr Opinion Rheum 2011; 23:95. Copyright © 2011 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 67582 Version 7.0</div></div></div>"},"67583":{"type":"graphic_figure","displayName":"Norm autoregulation cereb","title":"Normal autoregulation of cerebral blood flow","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal autoregulation of cerebral blood flow</div><div class=\"cntnt\"><img style=\"width:447px; height:259px;\" src=\"images/NEURO/67583_Norm_autoregulation_cereb.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 67583 Version 1.0</div></div></div>"},"67584":{"type":"graphic_picture","displayName":"Signet ring carcinoma Light","title":"Histologic appearance of a signet ring colon carcinoma","html":"<div class=\"graphic\"><div style=\"width: 519px\" class=\"figure\"><div class=\"ttl\">Histologic appearance of a signet ring colon carcinoma</div><div class=\"cntnt\"><img style=\"width:499px; height:316px;\" src=\"images/ONC/67584_Signet_ring_carcinoma_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Focus of signet ring carcinoma arising within an adenomatous polyp. Left panel: low power view; right panel, higher power view demonstrating typical signet ring cells, which are identified by black arrows.</div><div class=\"graphic_reference\">Courtesy of Carolyn C Compton, MD, PhD.</div><div id=\"graphicVersion\">Graphic 67584 Version 2.0</div></div></div>"},"67585":{"type":"graphic_figure","displayName":"Histology healthy vs RP retina","title":"Histological appearance of healthy human retina (left) and retina of a patient with retinitis pigmentosa at a mid-stage of disease (right)","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Histological appearance of healthy human retina (left) and retina of a patient with retinitis pigmentosa at a mid-stage of disease (right)</div><div class=\"cntnt\"><img style=\"width:548px; height:292px;\" src=\"images/PC/67585_Healthy_retina_vs_retina_RP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The space between the retinal pigment epithelium and the outer nuclear layer in the diseased retina is a processing artifact.</div><div class=\"graphic_reference\">Reproduced with permission from: Hartong, DT, Berson, EL, Dryja, TP. Retinitis pigmentosa. The Lancet 2006; 368:1795. Copyright &#169;2006 Elsevier.</div><div id=\"graphicVersion\">Graphic 67585 Version 2.0</div></div></div>"},"67587":{"type":"graphic_diagnosticimage","displayName":"Postoperative liver shift CT","title":"Postpneumonectomy shift of the liver","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Postpneumonectomy shift of the liver</div><div class=\"cntnt\"><img style=\"width:360px; height:238px;\" src=\"images/PULM/67587_Postoperative_liver_shift_C.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest CT demonstrates the postoperative change in location of the liver, showing the potential risk of hepatic injury with blind chest tube or needle placement into the postpneumonectomy space. The liver (closed arrow) abuts the chest wall; the open arrow denotes fluid in the postpneumonectomy space.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Richard Irwin, MD.</div><div id=\"graphicVersion\">Graphic 67587 Version 5.0</div></div></div>"},"67588":{"type":"graphic_algorithm","displayName":"Diagnostic approach to weakness","title":"Approach to the adult patient with the complaint of weakness","html":"<div class=\"graphic\"><div style=\"width: 674px\" class=\"figure\"><div class=\"ttl\">Approach to the adult patient with the complaint of weakness</div><div class=\"cntnt\"><img style=\"width:654px; height:358px;\" src=\"images/RHEUM/67588_Dgnstc_apprch_wknss.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 67588 Version 3.0</div></div></div>"},"67591":{"type":"graphic_picture","displayName":"Granulomatous ISN","title":"Light micrograph of kidney biopsy of a patient with granulomatous acute interstitial nephritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Light micrograph of kidney biopsy of a patient with granulomatous acute interstitial nephritis</div><div class=\"cntnt\"><img style=\"width:378px; height:255px;\" src=\"images/NEPH/67591_Granulomatous_ISN.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph shows granulomatous change in acute interstitial nephritis. The interstitial infiltrate is seen on the left, while the granuloma is on the right. The granuloma consists of both giant cells (arrows) and epithelioid cells with abundant cytoplasm, which has an amorphous red appearance. Although these findings are characteristic of sarcoid involvement in the kidney, they can be seen with any cause (drug or infection) of acute interstitial nephritis.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 67591 Version 4.0</div></div></div>"},"67592":{"type":"graphic_figure","displayName":"Regional citrate in HD","title":"Schematic diagram showing regional citrate regimen for anticoagulation in hemodialysis","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Schematic diagram showing regional citrate regimen for anticoagulation in hemodialysis</div><div class=\"cntnt\"><img style=\"width:540px; height:453px;\" src=\"images/NEPH/67592_Regional_citrate_in_HD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of regional citrate regimen for anticoagulation during hemodialysis. Citrate is infused into the arterial side of the dialyzer to lower the free calcium concentration; calcium is infused into the venous return line to return the calcium concentration to the plasma level.</div><div id=\"graphicVersion\">Graphic 67592 Version 4.0</div></div></div>"},"67595":{"type":"graphic_table","displayName":"Ovar granulosa cell tumor progn","title":"Survival of ovarian granulosa cell tumor according to stage at diagnosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Survival of ovarian granulosa cell tumor according to stage at diagnosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"55%\"></colgroup><colgroup span=\"2\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">FIGO* stage</td> <td class=\"subtitle1\">Definition</td> <td class=\"subtitle1\">Five-year survival, percent</td> <td class=\"subtitle1\">Ten-year survival, percent</td> </tr> <tr> <td>I</td> <td>Growth limited to one or both ovaries</td> <td>90 to 100</td> <td>84 to 95</td> </tr> <tr> <td>II</td> <td>Growth involving one or both ovaries with pelvic extension</td> <td>55 to 75</td> <td>50 to 65</td> </tr> <tr> <td>III</td> <td>Growth involving one or both ovaries, with peritoneal implants involving upperabdomen and/or positive nodes</td> <td>22 to 50<sup>&#182;</sup></td> <td>17 to 33<sup>&#182;</sup></td> </tr> <tr> <td>IV</td> <td>Growth involving one or both ovaries with distant metastases</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* International Federation of Gynecology and Obstetrics.<br />¶ Combined data for stage III and IV disease.</div><div class=\"graphic_reference\">Modified from Schumer S, et al. J Clin Oncol 2003; 21:1180.</div><div id=\"graphicVersion\">Graphic 67595 Version 3.0</div></div></div>"},"67596":{"type":"graphic_figure","displayName":"Porphyria oxidation","title":"Postulated mechanism whereby uroporphrinogen is oxidized to uroporphyrin","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Postulated mechanism whereby uroporphrinogen is oxidized to uroporphyrin</div><div class=\"cntnt\"><img style=\"width:302px; height:375px;\" src=\"images/HEME/67596_Porphyria_oxidation.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Postulated mechanism for UROD inhibition in porphyria cutanea tarda.&nbsp;Uroporphrinogen is oxidized by cytochrome P450 enzymes (especially CYP1A2) in the presence of iron&nbsp;to uroporphomethene, a specific UROD inhibitor, and uroporphyrin, which accumulates in the liver.</div><div class=\"graphic_footnotes\">ALAS1: housekeeping form of ALA synthase; UROD: uroporphyrinogen decarboxylase; CYP1A2: cytochrome P450 1A2.</div><div class=\"graphic_reference\">Reproduced with permission from: Anderson, KE. Porphyria cutanea tarda: a possible role for ascorbic acid. Hepatology 2007; 45:6. Copyright © 2007 John Wiley &amp; Sons.</div><div id=\"graphicVersion\">Graphic 67596 Version 5.0</div></div></div>"},"67597":{"type":"graphic_table","displayName":"Etiology of easy bruising ","title":"Etiology of easy bruising and characteristic signs and symptoms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiology of easy bruising and characteristic signs and symptoms</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Etiology</td> <td class=\"subtitle1\">Characteristic signs and symptoms</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">A. Disorders of blood vessels and surrounding tissue</td> </tr> <tr> <td class=\"indent1\">Idiopathic*</td> <td>Bruises typically found on upper arms and legs, more common in women</td> </tr> <tr> <td class=\"indent1\">Physical abuse*</td> <td>Bruises that pattern after objects, in nonmobile subjects, a history inconsistent with patient's injuries</td> </tr> <tr> <td class=\"indent1\">Aging (senile purpura)*</td> <td>Dark ecchymosis in aged, thin skin; typically over extensor surfaces of forearms</td> </tr> <tr> <td class=\"indent1\">Glucocorticoids*</td> <td>Patients at risk with long-term use (eg, polymyalgia rheumatica)</td> </tr> <tr> <td class=\"indent1\">Alcohol abuse*</td> <td>History of heavy alcohol intake; signs of cirrhotic liver disease</td> </tr> <tr> <td class=\"indent1\">Wasting, malnutrition*</td> <td>Dietary history, cachetic on examination</td> </tr> <tr> <td class=\"indent1\">Hypercortisolism, Cushing's syndrome</td> <td>Supraclavicular fat pads, skin atrophy, wide purplish striae, and proximal muscle weakness</td> </tr> <tr> <td class=\"indent1\">Ehlers-Danlos syndrome</td> <td>Hypermobility of joints; skin hyperelasticity</td> </tr> <tr> <td class=\"indent1\">Pseudoxanthoma elasticum</td> <td>Characteristic skin findings: 2 to 5 mm yellow to orange papules</td> </tr> <tr> <td class=\"indent1\">Amyloidosis</td> <td>Multiple manifestations depending on type of amyloidosis</td> </tr> <tr> <td class=\"indent1\">Hereditary hemorrhagic telangiectasia</td> <td>Mucocutaneous telangiectasias and gastrointestinal arteriovenous malformations</td> </tr> <tr> <td class=\"indent1\">Vitamin C deficiency (scurvy)</td> <td>Dietary history; dental deterioration, impaired wound healing, coiled hairs</td> </tr> <tr> <td class=\"indent1\">Marfan syndrome</td> <td>Tall and thin; stretch marks; pectus excavatum; mitral valve prolapse; dilated aortic root</td> </tr> <tr> <td class=\"indent1\">Osteogenesis imperfecta</td> <td>Short stature, multiple fractures, increased laxity of ligaments and skin</td> </tr> <tr> <td class=\"indent1\">Connective tissue disease, cryoglobulinemia, or vasculitis (eg, immunoglobulin A vasculitis [Henoch-Sch&#246;nlein purpura])</td> <td>Systemic symptoms, presence of palpable purpura</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">B. Platelet abnormalities</td> </tr> <tr> <td class=\"indent1\">Drugs*</td> <td>Possible temporal relationship to symptom onset</td> </tr> <tr> <td class=\"indent1\">Renal disease*</td> <td>Decreased glomerular filtration rate</td> </tr> <tr> <td class=\"indent1\">Autoimmune disorders</td> <td>Multi-system disease including joint inflammation, abnormal antibody testing</td> </tr> <tr> <td class=\"indent1\">Von Willebrand disease* (VWF)</td> <td>Reduced VWF antigen and ristocetin cofactor</td> </tr> <tr> <td class=\"indent1\">Leukemia</td> <td>Abnormal complete blood count, peripheral smear, and bone marrow biopsy</td> </tr> <tr> <td class=\"indent1\">Lymphoid malignancy</td> <td>Lymphadenopathy</td> </tr> <tr> <td class=\"indent1\">May-Hegglin anomaly</td> <td>Autosomal dominant trait characterized by mild bruising/bleeding</td> </tr> <tr> <td class=\"indent1\">Thrombocytopenia Absent Radius (TAR) syndrome</td> <td>Autosomal recessive disorder with severe thrombocytopenia and absent radii bones</td> </tr> <tr> <td class=\"indent1\">Storage pool disease</td> <td>Bleeding after trauma or surgery</td> </tr> <tr> <td class=\"indent1\">Bernard-Soulier syndrome</td> <td>Autosomal recessive disorder leading to absence of platelet glycoprotein Ib-IX-V, circulating giant platelets, immediate bleeding (not delayed bleeding as in coagulation disorders)</td> </tr> <tr> <td class=\"indent1\">Glanzmann thrombasthenia</td> <td>Autosomal recessive disorder leading to absence of platelet glycoprotein IIb/IIIa, circulating giant platelets; no platelet clumping on platelet aggregation studies</td> </tr> <tr> <td class=\"indent1\">Gaucher disease</td> <td>Autosomal recessive disorder presenting in childhood with varying symptoms depending on type 1, 2, 3a, 3b, or 3c</td> </tr> <tr> <td class=\"indent1\">Wiskott-Aldrich syndrome</td> <td>X-linked disorder characterized by hemorrhagic diathesis, recurrent infection, extensive eczema</td> </tr> <tr> <td class=\"indent1\">Myeloproliferative disorders</td> <td>Abnormal bone marrow biopsy with increased platelets and positive for JAK 2</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">C. Coagulation protein disorders</td> </tr> <tr> <td class=\"indent1\">Liver disease*</td> <td>History of alcohol abuse, modestly-elevated liver function tests, hepatomegaly, ascites, stigmata of chronic liver disease (spider angiomata, palmar erythema, gynecomastia)</td> </tr> <tr> <td class=\"indent1\">Vitamin K deficiency, warfarin therapy*</td> <td>Antibiotic administration, poor nutritional status, vitamin K binding drugs (cholestyramine)</td> </tr> <tr> <td class=\"indent1\">Hemophilia (factor VIII, IX, deficiency)</td> <td>Males affected, family history, delayed bleeding</td> </tr> <tr> <td class=\"indent1\">Circulating anticoagulant or inhibitor</td> <td>Similar to hemophilia but onset is sudden and no patient or family history</td> </tr> <tr> <td class=\"indent1\">Dysfibrinogenemia</td> <td>Diagnosis of exclusion, identified with fibrinogen tests</td> </tr> <tr> <td class=\"indent1\">Plasminogen activator deficiency or inhibitor</td> <td>Delayed bleeding</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Denotes frequently seen cause.</div><div id=\"graphicVersion\">Graphic 67597 Version 6.0</div></div></div>"},"67599":{"type":"graphic_movie","displayName":"Parasternal long view tamponade","title":"Parasternal long view of cardiac tamponade","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Parasternal long view of cardiac tamponade</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/67599_Parastlongviewtampmovie.mp4\" style=\"width:496px;height:320px\"></div><img style=\"width:504px; height:364px;\" src=\"images/EM/67599_Parastlongviewtampimage.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This video clip shows a large pericardial effusion causing tamponade as seen from a parasternal long axis view.</div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">Courtesy of Greg Snead, MD.</div><div id=\"graphicVersion\">Graphic 67599 Version 1.0</div></div></div>"},"67600":{"type":"graphic_figure","displayName":"Hand-sewn ileocolic anastomosis - Lembert sutures","title":"Hand-sewn ileocolic anastomosis - Lembert sutures","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hand-sewn ileocolic anastomosis - Lembert sutures</div><div class=\"cntnt\"><img style=\"width:265px; height:244px;\" src=\"images/SURG/67600_Hand-sewn-Lembert.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 67600 Version 1.0</div></div></div>"},"67602":{"type":"graphic_diagnosticimage","displayName":"Jones fracture operative healing","title":"Operative healing of a Jones fracture in an adolescent","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Operative healing of a Jones fracture in an adolescent</div><div class=\"cntnt\"><img style=\"width:438px; height:586px;\" src=\"images/EM/67602_Jonesfxoperative.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 15-year-old high-level basketball player sustained a proximal fifth metatarsal fracture at the metaphyseal-diaphyseal junction. The patient chose intramedullary screw fixation because of his desire to return to sport as promptly as possible, lessen his time in immobilization, and lessen the risk of delayed union or nonunion. A) X-ray at time of injury. B and C) After intramedullary screw fixation. (Courtesy of Keith S. Hechtman, MD.)</div><div class=\"graphic_reference\">Reproduced with permission from: Jarvis JG, Moroz PJ. Fractures and Dislocations of the Foot. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 67602 Version 11.0</div></div></div>"},"67603":{"type":"graphic_figure","displayName":"Metaphyseal variants","title":"Normal metaphyseal variants","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Normal metaphyseal variants</div><div class=\"cntnt\"><img style=\"width:532px; height:535px;\" src=\"images/PEDS/67603_Metaphyseal_variants.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Step-off. Note acute angulation (arrow) of the distal femur. (B) Beak. A dense medial projection (arrow) is noted arising from proximal humerus. (C) Proximal tibial cortical irregularity. A slightly raised area with indistinct cortical margins (open arrow) is noted along medial aspect of the proximal tibia. (D) Spur. A discrete longitudinal projection of bone (arrow) that is continuous with the cortex and extends beyond the metaphyseal margin of the base of the fifth metatarsal.</div><div class=\"graphic_reference\">Adapted from Kleinman, PK, Belanger, PL, Karellas, A, Spevak, MR. Normal metaphyseal radiologic variants not to be confused with findings of infant abuse. AJR Am J Roentgenol 1991; 156:781.</div><div id=\"graphicVersion\">Graphic 67603 Version 1.0</div></div></div>"},"67606":{"type":"graphic_diagnosticimage","displayName":"Small nodules PA","title":"Small, rounded nodules","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Small, rounded nodules</div><div class=\"cntnt\"><img style=\"width:377px; height:350px;\" src=\"images/PULM/67606_Silicosis_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Standard ILO film for small rounded opacities, 3 to 10 mm in diameter.</div><div class=\"graphic_footnotes\">ILO: International Labour Organization.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 67606 Version 5.0</div></div></div>"},"67608":{"type":"graphic_figure","displayName":"Pulmonary function with age","title":"Pulmonary function with age","html":"<div class=\"graphic\"><div style=\"width: 565px\" class=\"figure\"><div class=\"ttl\">Pulmonary function with age</div><div class=\"cntnt\"><img style=\"width:545px; height:353px;\" src=\"images/PC/67608_Pulm_func_w_age_ed2.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">TLC: total lung capacity; VC: vital capacity; IC: inspiratory capacity; ERV: expiratory reserve volume; RV: residual volume; FRC: functional residual capacity.</div><div class=\"graphic_reference\">Modified and reproduced with permission from: Janssens JP, Pache JC, Nicod LP. Physiological changes in respiratory function associated with ageing. Eur Respir J 1999; 13:197. Copyright © 1999 European Respiratory Society. All rights reserved.</div><div id=\"graphicVersion\">Graphic 67608 Version 6.0</div></div></div>"},"67609":{"type":"graphic_figure","displayName":"Course of chronic HBV","title":"Course of chronic HBV infection","html":"<div class=\"graphic\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Course of chronic HBV infection</div><div class=\"cntnt\"><img style=\"width:519px; height:340px;\" src=\"images/GAST/67609_Course_of_chronic_HBV.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The course of chronic HBV infection is considered to consist of&nbsp;four phases: immune tolerance, immune clearance (HBeAg-positive chronic hepatitis), inactive carrier, and reactivation (HBeAg-negative chronic hepatitis), although not all patients go through every phase. HBeAg, hepatitis B e antigen; anti-HBe, antibody to HBeAg; HBV, hepatitis B virus; ALT, alanine aminotransferase.</div><div class=\"graphic_reference\">Reproduced with permission from: Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 2006; 43:S173. Copyright &#169; 2006 John Wiley &amp; Sons, Inc.</div><div id=\"graphicVersion\">Graphic 67609 Version 2.0</div></div></div>"},"67611":{"type":"graphic_figure","displayName":"Classification of leprosy","title":"Classification of leprosy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Classification of leprosy</div><div class=\"cntnt\"><img style=\"width:432px; height:328px;\" src=\"images/ID/67611_Classification_of_leprosy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diagram representing the different clinical classifications of leprosy using both the World Health Organization and the Ridley-Jopling system. The increase in number of acid-fast bacilli and defects in cell-mediated immunity are represented in the continuum from paucibacillary to multibacillary disease.</div><div class=\"graphic_footnotes\">TT: tuberculoid; BT: borderline tuberculoid; BB: mid-borderline; BL: borderline lepromatous; LL: lepromatous; CMI: cell-mediated immunity; AFB: acid-fast bacilli; PB: paucibacillary; MB: multibacillary.</div><div class=\"graphic_reference\">Reproduced with permission from Jacobson R, and Krahenbuhl JL. Leprosy. Lancet 1999; 353:655.</div><div id=\"graphicVersion\">Graphic 67611 Version 2.0</div></div></div>"},"67616":{"type":"graphic_figure","displayName":"Rigby vaginal retractor","title":"Rigby vaginal retractor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rigby vaginal retractor</div><div class=\"cntnt\"><img style=\"width:160px; height:449px;\" src=\"images/OBGYN/67616_Rigby_vaginal_retractor.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 67616 Version 1.0</div></div></div>"},"67618":{"type":"graphic_table","displayName":"Causes intermenstrual bleeding","title":"Causes of intermenstrual bleeding","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of intermenstrual bleeding</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Drugs</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Oral contraceptives</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Infection</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cervicitis*</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Endometritis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Sexually transmitted ulcerations*</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Vaginitis</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Benign growths</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cervical polyps*</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Endometrial polyps</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Ectropion*</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Uterine fibroids</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Vulvar skin tags, sebaceous cysts, condylomata</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Vaginal Gartner's duct cysts, polyps, adenosis</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Cancer</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Uterine</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cervical*</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Vaginal</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Vulvar</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Rarely ovarian or fallopian tube</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Trauma</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Previous cesarean delivery incision</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">* Often cause postcoital bleeding.</div><div id=\"graphicVersion\">Graphic 67618 Version 1.0</div></div></div>"},"67621":{"type":"graphic_picture","displayName":"Cotton wool spots","title":"Cotton wool spots","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cotton wool spots</div><div class=\"cntnt\"><img style=\"width:413px; height:297px;\" src=\"images/RHEUM/67621_Cotton_wool_spots.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cotton wool spots are indicative of retinal ischemia. The differential diagnosis includes diabetes, hypertension, AIDS, and the retinal vascular changes of systemic lupus erythematosus.</div><div class=\"graphic_reference\">Courtesy of James T Rosenbaum, MD.</div><div id=\"graphicVersion\">Graphic 67621 Version 1.0</div></div></div>"},"67622":{"type":"graphic_waveform","displayName":"ECG of right ventricular hypertrophy","title":"Electrocardiogram showing right ventricular hypertrophy","html":"<div class=\"graphic normal\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram showing right ventricular hypertrophy</div><div class=\"cntnt\"><img style=\"width:576px; height:378px;\" src=\"images/CARD/67622_Rightventricularhypertrop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Right ventricular hypertrophy due, in this case, to&nbsp;idiopathic pulmonary arterial&nbsp;hypertension. The characteristic features include marked right axis deviation (+210º which is equal to -150º), tall R wave in V1 (as part of a qR complex), delayed precordial transition zone with prominent S waves in leads V5 and V6, inverted T waves and ST depression in V1 to V3 consistent with right ventricular \"strain,\" and peaked P waves in lead II consistent with concomitant right atrial enlargement.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 67622 Version 5.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"67623":{"type":"graphic_picture","displayName":"Bacillary angiomatosis EM","title":"Electron micrograph of cutaneous bacillary angiomatosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electron micrograph of cutaneous bacillary angiomatosis</div><div class=\"cntnt\"><img style=\"width:360px; height:237px;\" src=\"images/ID/67623_Bacillary_angiomatosis_EM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph of cutaneous bacillary angiomatosis shows organisms characterized by an outer trilaminar cell wall and an inner membrane.</div><div class=\"graphic_reference\">Courtesy of David H Spach, MD.</div><div id=\"graphicVersion\">Graphic 67623 Version 2.0</div></div></div>"},"67626":{"type":"graphic_movie","displayName":"Mobile aortic dissection flap on TEE","title":"Mobile aortic dissection flap on transesophageal echocardiography","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mobile aortic dissection flap on transesophageal echocardiography</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/67626_teeaodisconv.mp4\" style=\"width:431px;height:322px\"></div><img style=\"width:262px; height:300px;\" src=\"images/CARD/67626_teeaodis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transesophageal echocardiogram shows a large dissection of the aorta. The intimal flap (arrow) is flail, moving widely within the aorta and spontaneous echo contrast can be seen within the false lumen, suggesting turbulent blood flow.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 67626 Version 3.0</div></div></div>"},"67630":{"type":"graphic_table","displayName":"Blistering disorders with mucous membrane involvement","title":"Blistering disorders with mucous membrane involvement","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Blistering disorders with mucous membrane involvement</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Disorder</td> <td class=\"subtitle1\">Associated conditions</td> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Pathology</td> <td class=\"subtitle1\">Laboratory findings</td> </tr> <tr> <td><strong>Herpes simplex virus (HSV)</strong></td> <td>None</td> <td>Recurrent, grouped vesicles; most commonly found on lips or genitalia</td> <td>H&#38;E: intraepidermal blister; ballooning of keratinocyte cytoplasm and margination of chromatin to form intranuclear inclusion bodies; mixed inflammatory infiltrate</td> <td>Viral culture, Tzanck smear, HSV DFA, PCR</td> </tr> <tr class=\"divider_top\"> <td><strong>Erythema multiforme</strong></td> <td>HSV or <em>Mycoplasma pneumoniae</em> infection, occasionally drug exposure</td> <td>Mucosal erythema and erosions, most frequently involving oral cavity; target lesions on skin</td> <td>H&#38;E: vacuolar interface dermatitis, necrotic keratinocytes, subepidermal clefts and vesiculation</td> <td>HSV testing on active lesions, serology, or biopsy specimen; testing for <em>M. pneumoniae</em> infection</td> </tr> <tr class=\"divider_top\"> <td><strong>Pemphigus vulgaris</strong></td> <td>None</td> <td>Vesicles, erosions and desquamative gingivitis</td> <td> <p>H&#38;E: intraepidermal vesicle, acantholysis</p> <p>DIF: intercellular epidermal IgG deposition</p> </td> <td>IIF: intercellular IgG staining of skin substrate, IgG antidesmoglein 3</td> </tr> <tr class=\"divider_top\"> <td><strong>Mucous membrane pemphigoid</strong>*</td> <td>Reflects a diverse group of subepidermal blistering disorders with mucous membranes as the primary site of involvement</td> <td>Vesicles and erosions, desquamative gingivitis; can have ocular involvement and symblepharon</td> <td>H&#38;E: subepidermal blisters; inflammatory infiltrate and DIF findings vary with subtype</td> <td>IIF: varies with subtype</td> </tr> <tr class=\"divider_top\"> <td><strong>Stevens-Johnson syndrome and toxic epidermal necrolysis</strong></td> <td>Medication, M<em>ycoplasma</em> infection</td> <td>Exudative erosions of lips, oral mucosa, eyes, genital mucosa; targetoid papulovesicles of skin, skin sloughing, skin pain</td> <td>H&#38;E: vacuolar interface dermatitis or epidermal necrosis</td> <td>None</td> </tr> <tr class=\"divider_top\"> <td><strong>Paraneoplastic pemphigus</strong></td> <td>Underlying malignancy</td> <td>Targetoid papulovesicles; erythema multiforme-like cutaneous lesions; exudative erosions of lips, oral mucosal, eyes, genital mucosa</td> <td> <p>H&#38;E: mixed histology; overlapping features of pemphigus vulgaris, erythema multiforme, and lichen planus</p> <p>DIF: intercellular IgG deposition; basement membrane zone IgG deposition also may be present </p> </td> <td> <p>IIF: intercellular IgG deposition on transitional epithelium (rodent bladder)</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HSV: herpes simplex virus; H&amp;E: hematoxylin and eosin pathology stain; DFA: direct fluorescent antibody; PCR: polymerase chain reaction; DIF: direct immunofluorescence; IgG: immunoglobulin G; IIF: indirect immunofluorescence.<br />* Skin-predominant forms of bullous pemphigoid, linear IgA bullous dermatosis, and epidermolysis bullosa acquisita may also present with mucosal involvement.</div><div id=\"graphicVersion\">Graphic 67630 Version 2.0</div></div></div>"},"67631":{"type":"graphic_table","displayName":"Indoor fungi","title":"Common indoor fungi","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common indoor fungi</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t    <td><em>Cladosporium</em></td>\n\t  </tr>\n\t  <tr>\n\t    <td><em>Alternaria</em></td>\n\t  </tr>\n\t  <tr>\n\t    <td><em>Epicoccum</em></td>\n\t  </tr>\n\t  <tr>\n\t    <td><em>Fusarium</em></td>\n\t  </tr>\n\t  <tr>\n\t    <td><em>Penicillium</em></td>\n\t  </tr>\n\t  <tr>\n\t    <td><em>Aspergillus</em></td>\n\t  </tr>\n\t  <tr>\n\t    <td><em>Geotrichum</em></td>\n\t  </tr>\n\t  <tr>\n\t    <td><em>Rhodotorula</em></td>\n\t  </tr>\n\t  <tr>\n\t    <td><em>Chaetomium</em></td>\n\t  </tr>\n\n</tbody>\n</table></div><div class=\"graphic_reference\">Courtesy of Robert Bush, MD.</div><div id=\"graphicVersion\">Graphic 67631 Version 1.0</div></div></div>"},"67632":{"type":"graphic_picture","displayName":"Cutaneous changes of Stevens-Johnson syndrome (SJS)","title":"Cutaneous changes of Stevens-Johnson syndrome (SJS)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cutaneous changes of Stevens-Johnson syndrome (SJS)</div><div class=\"cntnt\"><img style=\"width:396px; height:364px;\" src=\"images/ALLRG/67632_Stevens_Johnson_syndrome_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Generalized eruption of lesions that initially had a target-like appearance but then became confluent, brightly erythematous, and bullous. The patient had extensive mucous membrane involvement and tracheobronchitis.</div><div class=\"graphic_reference\">Reproduced with permission from: Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. In: Color Atlas and Synopsis of Clinical Dermatology: Common and Serious Diseases, 3rd edition, Fitzpatrick TB, Johnson RA, Wolff K, et al (Eds), McGraw-Hill, New York 1997. Copyright &copy; 1997 McGraw-Hill.</div><div id=\"graphicVersion\">Graphic 67632 Version 18.0</div></div></div>"},"67633":{"type":"graphic_figure","displayName":"Short-term effects of MI on blood lipids","title":"Short-term effects of MI on blood lipids","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Short-term effects of MI on blood lipids</div><div class=\"cntnt\"><img style=\"width:209px; height:251px;\" src=\"images/CARD/67633_Acute_phase_lipoprotein.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sequential changes in LDL and HDL cholesterol and total TG following an acute MI. The reductions in LDL and HDL cholesterol and rise in&nbsp;TG begin within a few days and do not resolve for up to 30 days.</div><div class=\"graphic_footnotes\">MI: myocardial infarction; LDL: low-density lipoprotein; TG: triglycerides; HDL: high-density lipoprotein.</div><div class=\"graphic_reference\">Redrawn from Rosenson RS. J Am Coll Cardiol 1993; 22:933.</div><div id=\"graphicVersion\">Graphic 67633 Version 3.0</div></div></div>"},"67634":{"type":"graphic_table","displayName":"Early TPN extremely premature infants","title":"Early total parenteral solution (TPN) for extremely premature infants*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Early total parenteral solution (TPN) for extremely premature infants*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Component</td> <td class=\"subtitle1\">Quantity</td> <td class=\"subtitle1\">Approximate intake, unit/kg/day</td> </tr> <tr> <td>Amino acids</td> <td>3.5 g/100 mL</td> <td>3.5 g</td> </tr> <tr> <td>Glucose</td> <td>5 to 10 g/100 mL</td> <td>5 to 10 g</td> </tr> <tr> <td>Calcium gluconate</td> <td>650 mg/100 mL</td> <td>650 mg</td> </tr> <tr> <td>Multivitamin-Pediatric</td> <td>2 mL/kg/day</td> <td>2 mL</td> </tr> <tr> <td>Zinc</td> <td>400 micrograms/kg/day</td> <td>400 micrograms</td> </tr> <tr> <td>Selenium</td> <td>2 micrograms/kg/day</td> <td>2 micrograms</td> </tr> <tr> <td>Heparin</td> <td>1 unit/mL</td> <td>100 units</td> </tr> <tr> <td>Lipid<sup>&#182;</sup> (by separate infusion)</td> <td>5 mL/kg/day</td> <td>1 g</td> </tr> <tr> <td>Water</td> <td>&nbsp;</td> <td>100 + 5 = 105 mL</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* This initial TPN solution contains no electrolytes, phosphorus, magnesium, or cysteine. Ongoing monitoring is required for serum glucose (determine whether to increase glucose infusion rate), and electrolytes, phosphorus, magnesium (determine when these are to be added). When phosphorus is added, ensure that cysteine has been added so that solubility of minerals is optimized.<br />&#182; Lipid is administered intravenously through a separate site.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Nutrition &amp; Gastroenterology Clinical Review Committee. Nutrition support. In: Guidelines for the Acute Care of the Neonate, Adams JM, Garcia-Prats JA, Schanler RJ, et al (Eds), Newborn Section, Department of Pediatrics, Baylor College of Medicine, Houston 2002. p.43.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 67634 Version 5.0</div></div></div>"},"67636":{"type":"graphic_figure","displayName":"Audiogram noise hearing loss","title":"A typical audiogram of noise-induced sensorineural hearing loss","html":"<div class=\"graphic\"><div style=\"width: 579px\" class=\"figure\"><div class=\"ttl\">A typical audiogram of noise-induced sensorineural hearing loss</div><div class=\"cntnt\"><img style=\"width:559px; height:741px;\" src=\"images/PC/67636_Audiogram_noise_hearing_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A typical audiogram of early noise-induced sensorineural hearing loss. Hearing is normal through 2000 Hz. There is an abrupt drop at 4000 Hz with recovery at 8000 Hz. With additional injury over time, this \"drop\" generalizes to involve more frequencies and becomes more noticeable to the child.</div><div class=\"graphic_footnotes\">ANSI-1969: American National Standards Institute, standard reference threshold sound-pressure levels for audiometers; AC: air conduction; BC: bone conduction; L: left; C: center; R: right; Hz: Hertz; NML: normal; NEG: negative pressure; VOL: volume; ART: acoustic reflex threshold; CR: contralateral R; CL: contralateral L; SRT: speech reception threshold; DISCM: speech discrimination; dB: decibel; MCL: most comfortable listening (loudness) level; LCL: loudness comfort level.</div><div id=\"graphicVersion\">Graphic 67636 Version 8.0</div></div></div>"},"67640":{"type":"graphic_picture","displayName":"Endosc stone extraction","title":"Endoscopic bile duct stone extraction","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Endoscopic bile duct stone extraction</div><div class=\"cntnt\"><img style=\"width:524px; height:189px;\" src=\"images/GAST/67640_Endosc_stone_extraction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">ERCP showing an impacted stone in the major papilla (Panel A, arrow) in a patient with fever, pain, abnormal liver enzymes, and elevated amylase and lipase. Biliary sphincterotomy was performed with stone extraction using a balloon. Pus was noted soon after stone extraction (Panel B, ellipse). Multiple additional stones were then extracted (Panel C, arrows). Two days after stone extraction, the liver enzymes, amylase, and lipase normalized and the pain and fever resolved.</div><div class=\"graphic_reference\">Courtesy of Andres Gelrud, MD.</div><div id=\"graphicVersion\">Graphic 67640 Version 2.0</div></div></div>"},"67641":{"type":"graphic_picture","displayName":"Erythematous nodule","title":"A tender, erythematous nodule on the patient's middle finger","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">A tender, erythematous nodule on the patient's middle finger</div><div class=\"cntnt\"><img style=\"width:504px; height:334px;\" src=\"images/ID/67641_Erythematous_nodule.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Lesho, E, Gunning, S, Wortmann, G. An AIDs patient with fever and rash. Clin Infect Dis 2005; 41:75. Copyright &#169;2005 University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 67641 Version 1.0</div></div></div>"},"67642":{"type":"graphic_table","displayName":"Rx nonfalcip malaria","title":"Treatment of uncomplicated non-falciparum malaria","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of uncomplicated non-falciparum malaria</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"10%\"></colgroup><colgroup span=\"2\" width=\"35%\"></colgroup><colgroup width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Adult dosing</td> <td class=\"subtitle1\">Pediatric dosing</td> <td class=\"subtitle1\">Pregnancy*</td> </tr> <tr class=\"divider_bottom\"> <td> <p><strong><em>P. vivax</em></strong></p> <p><strong><em>P. ovale</em></strong></p> (chloroquine-sensitive)</td> <td> <p><strong>Chloroquine</strong></p> <p>OR</p> <p><strong>Hydroxy-chloroquine<sup>&#182;</sup></strong></p> <p>PLUS</p> <strong>Primaquine<sup>&#916;</sup></strong></td> <td> <p><strong>Chloroquine</strong> 600 mg base (=1000 mg salt) orally immediately, followed by 300 mg base (=500 mg salt) orally at 6, 24, and 48 hours. Total dose: 1500 mg base (=2500 mg salt)</p> <p><strong>Hydroxychloroquine</strong> 620 mg base (=800 mg salt) orally immediately, followed by 310 mg base (=400 mg salt) orally at 6, 24, and 48 hours. Total dose: 1550 mg base (=2000 mg salt)</p> <strong>Primaquine<sup>&#916;</sup><sup>&#9674;</sup></strong> 30 mg base orally once daily for 14 days</td> <td> <p><strong>Chloroquine</strong> 10 mg base/kg orally immediately, followed by 5 mg base/kg orally at 6, 24, and 48 hours. Total dose: 25 mg base/kg</p> <p><strong>Hydroxychloroquine</strong> 10 mg base/kg orally immediately, followed by 5 mg base/kg orally at 6, 24, and 48 hours. Total dose: 25 mg base/kg</p> <strong>Primaquine<sup>&#916;</sup><sup>&#9674;</sup></strong> 30 mg base orally once daily for 14 days</td> <td> <p><strong>Chloroquine</strong></p> <p>OR</p> <strong>Hydroxy-chloroquine<sup>&#182;</sup></strong></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"> <p><strong>Chloroquine-resistant <em>P. vivax</em><sup>&#167;</sup></strong></p> (Papua New Guinea and Indonesia)</td> <td> <p><strong>A. Mefloquine</strong></p> <p>OR</p> <p><strong>Atovaquone-proguanil (Malarone)</strong></p> <p>PLUS</p> <strong>Primaquine<sup>&#916;</sup></strong></td> <td> <p><strong>A. Mefloquine</strong> 648 mg base (=750 mg salt) orally as initial dose, followed by 456 mg base (=500 mg salt) orally given 6 to 12 hours after initial dose (total dose = 1250 mg salt)</p> <p><strong>Atovaquone-proguanil (Malarone)</strong> Adult tab = 250 mg atovaquone / 100 mg proguanil. </p> <p>4 adult tabs orally once daily for 3 days</p> <strong>Primaquine</strong> (as above)</td> <td> <p><strong>A. Mefloquine</strong> 13.7 mg base/kg (=15 mg salt/kg) orally as initial dose, followed by 9.1 mg base/kg (=10 mg salt//kg) orally given 6 to 12 hours after initial dose (total dose = 25 mg salt/kg)</p> <p><strong>Atovaquone-proguanil (Malarone)</strong> Peds tab=62.5 mg atovaquone/ 25 mg proguanil. </p> <p>All doses administered orally once daily for 3 days: 5 to 8 kg: 2 peds tabs; 9 to 10 kg: 3 peds tabs; 11 to 20 kg: 1 adult tab; 21 to 30 kg: 2 adult tabs; 31 to 40 kg: 3 adult tabs; &#62;40kg: 4 adult tabs </p> <strong>Primaquine</strong> (as above)</td> <td><strong>A. Mefloquine</strong> (only)</td> </tr> <tr class=\"divider_bottom\"> <td> <p><strong>B. Quinine</strong></p> <p>PLUS one of the following:</p> <p><strong>Doxycycline</strong></p> <p><strong>Tetracycline</strong></p> <p>PLUS</p> <strong>Primaquine<sup>&#916;</sup></strong></td> <td> <p><strong>B. Quinine<sup>&#165;</sup></strong> 542 mg base (=650 mg salt) orally three times daily x 3 to 7 days</p> <p><strong>Doxycycline</strong> 100 mg orally twice daily x 7 days</p> <p><strong>Tetracycline</strong> 250 mg orally four times daily x 7 days</p> <strong>Primaquine</strong> (as above)</td> <td> <p><strong>B. Quinine<sup>&#165;</sup></strong> 8.3 mg base/kg (=10 mg salt/kg) orally three times daily x 3 to 7 days</p> <p><strong>Doxycycline<sup>&#135;</sup></strong> 2.2 mg/kg orally twice daily x 7 days</p> <p><strong>Tetracycline<sup>&#135;</sup></strong> 25 mg/kg/day orally divided four times daily x 7 days</p> <strong>Primaquine</strong> (as above)</td> <td><strong>B. Quinine</strong> (only)</td> </tr> <tr> <td> <p><strong><em>P. malariae</em></strong></p> <strong><em>P. knowlesii</em></strong></td> <td> <p><strong>Chloroquine</strong></p> <p>OR</p> <strong>Hydroxy-chloroquine<sup>&#182;</sup></strong></td> <td> <p><strong>Chloroquine</strong> (as above)</p> <strong>Hydroxychloroquine</strong> (as above)</td> <td> <p><strong>Chloroquine</strong> (as above)</p> <strong>Hydroxychloroquine</strong> (as above)</td> <td> <p><strong>Chloroquine</strong></p> <p>OR</p> <strong>Hydroxy-chloroquine<sup>&#182;</sup></strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Dosing as for adults. Primaquine, doxycycline, and tetracycle are contraindicated in pregnancy.<br />¶ Hydroxychloroquine is a second line alternative to chloroquine.<br />Δ Primaquine is used to prevent <EM>P. vivax</EM> and <EM>P. ovale </EM>relapse by eradicating hypnozoite forms that may remain dormant in the liver. Because primaquine can cause hemolytic anemia in persons with G6PD deficiency, screening for G6PD deficiency is required prior to starting treatment with primaquine. Primaquine is contraindicated in pregnancy given uncertain neonatal G6PD status.<br /><FONT class=lozenge>◊</FONT> To prevent relapse of <EM>P. vivax</EM>, primaquine should be dosed 30 mg/day for 14 days. To prevent relapse of <EM>P. ovale</EM>, primaquine should be dosed 15 mg base/day for 14 days. Primaquine therapy should begin on the same day of treatment with chloroquine.<br />§ For treatment of uncomplicated malaria due to chloroquine-resistant <EM>P. vivax,</EM> there are two options (A or B) that are equally recommended. Individuals with <EM>P. vivax </EM>infection acquired outside of Papua New Guinea or Indonesia should be started on chloroquine; if the patient does not respond, the treatment should be changed to a chloroquine-resistant <EM>P. vivax </EM>regimen.<br />¥ For infections acquired in Southeast Asia, quinine treatment should continue for&nbsp;seven days. For infections acquired in Africa and South America, quinine treatment should continue for&nbsp;three days. In the United States, quinine is encapsulated in a 324 mg dose; therefore, for adult dosing, two capsules are sufficient. For pediatric dosing, if non-capsule forms are not available, atovaquone-proguanil or mefloquine may be used. Dosing for atovaquone-proguanil is outlined separately (see \"Treatment of malaria\").<br />‡ Doxycycline and tetracycline are not indicated for use in children &lt;8 years. For children &lt;8 years with chloroquine-resistant <EM>P. vivax</EM>, quinine (given alone for&nbsp;seven days) or mefloquine may be used. If these options are not available or not tolerated and if treatment benefits outweigh the risks, doxycycline or tetracycline may be given to children &lt;8 years.</div><div id=\"graphicVersion\">Graphic 67642 Version 3.0</div></div></div>"},"67644":{"type":"graphic_figure","displayName":"Nonallelic homologous recombination","title":"Nonallelic homologous recombination (NAHR)","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Nonallelic homologous recombination (NAHR)</div><div class=\"cntnt\"><img style=\"width:584px; height:326px;\" src=\"images/PC/67644_Nonhomologous_recombination.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Upper panel) Balanced recombination (normal process) &ndash; The round circles labeled A and B represent low copy repeats (LCRs), defined as repetitive DNA sequences &gt;10kb in size with 97% sequence identity. LCRs are located in the same chromosomes and arranged directly oriented and separated 5 Mb from each other. Recombination will proceed correctly and cause genetic information A and B (blue rectangles) to swap places (ie, move to opposite deoxyribonucleic acid [DNA] strands).<br />(Middle panel) Meiotic error &ndash; A and B, representing LCRs with similar homology, pair erroneously and lead to duplicated material on the upper strand and deleted material on the lower strand.<br />(Lower panel) Abnormal PMP22 recombination &ndash; Aberrant recombination, resulting in an imbalanced swap of DNA leading to PMP22 duplication and Charcot-Mary-Tooth disease, while deletions of PMP22 lead to tomaculous neuropathy.</div><div class=\"graphic_footnotes\">PMP22: peripheral myelin protein-22.</div><div id=\"graphicVersion\">Graphic 67644 Version 9.0</div></div></div>"},"67647":{"type":"graphic_figure","displayName":"Penicillin: Major and minor determinants","title":"Penicillin: Major and minor determinants","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Penicillin: Major and minor determinants</div><div class=\"cntnt\"><img style=\"width:428px; height:349px;\" src=\"images/ALLRG/67647_PCN_major_minor_det.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Penicillin-allergic patients may form IgE molecules against the beta-lactam core or against the R groups (shown in red).</div><div class=\"graphic_footnotes\">IgE: immunoglobulin E.</div><div id=\"graphicVersion\">Graphic 67647 Version 3.0</div></div></div>"},"67648":{"type":"graphic_table","displayName":"Infectious mimics of IBD","title":"Infectious mimics of inflammatory bowel disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Infectious mimics of inflammatory bowel disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Infectious agents causing colitis and/or ileitis</td> </tr> <tr> <td class=\"subtitle2_single\">Bacteria</td> </tr> <tr> <td class=\"indent1\">Shigella species</td> </tr> <tr> <td class=\"indent1\">Enterohemorrhagic Escherichia coli</td> </tr> <tr> <td class=\"indent1\">Enteroinvasive Escherichia coli</td> </tr> <tr> <td class=\"indent1\">Campylobacter jejuni</td> </tr> <tr> <td class=\"indent1\">Salmonella species (gastroenteritis and typhoid fever)</td> </tr> <tr> <td class=\"indent1\">Yersinia enterocolitica</td> </tr> <tr> <td class=\"indent1\">Mycobacterium tuberculosis</td> </tr> <tr> <td class=\"indent1\">Clostridium difficile</td> </tr> <tr> <td class=\"indent1\">Vibrio parahaemolyticus</td> </tr> <tr> <td class=\"indent1\">Chlamydia trachomatis (lymphogranuloma venereum serotypes)</td> </tr> <tr> <td class=\"subtitle2_single\">Parasites</td> </tr> <tr> <td class=\"indent1\">Entamoeba histolytica</td> </tr> <tr> <td class=\"indent1\">Schistosoma species</td> </tr> <tr> <td class=\"indent1\">Balantidium coli</td> </tr> <tr> <td class=\"indent1\">Trichinella spiralis</td> </tr> <tr> <td class=\"subtitle2_single\">Viruses</td> </tr> <tr> <td class=\"indent1\">Cytomegalovirus</td> </tr> <tr> <td class=\"subtitle1_single\">Infectious agents causing proctitis</td> </tr> <tr> <td>Neisseria gonorrhoeae</td> </tr> <tr> <td>Herpes simplex virus</td> </tr> <tr> <td>Chlamydia trachomatis</td> </tr> <tr> <td>Treponema pallidum</td> </tr> <tr> <td>Cytomegalovirus</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Guerrant RL, Lima AA. Inflammtory enteritides. In: Principles and Practice of Infectious Diseases, 5th ed, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, Philadelphia 2000. p.1127.</div><div id=\"graphicVersion\">Graphic 67648 Version 3.0</div></div></div>"},"67651":{"type":"graphic_figure","displayName":"Reversal of diabetic nephropathy after pancreas TPL","title":"Reversal of diabetic nephropathy after pancreas transplantation","html":"<div class=\"graphic\"><div style=\"width: 502px\" class=\"figure\"><div class=\"ttl\">Reversal of diabetic nephropathy after pancreas transplantation</div><div class=\"cntnt\"><img style=\"width:482px; height:541px;\" src=\"images/NEPH/67651_DM_nephropathy_and_pancreas.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The thickness of the glomerular (A) and tubular (B) basement membranes, mesangial fractional volume (C), and mesangial-matrix fractional volume (D) at baseline, 5, and 10 years after pancreas transplantation. All four parameters fell toward or reached the normal range (shaded areas) at 10 years. The mesangial fractional volume is the proportion of the glomerulus occupied by the mesangium; the mesangial-matrix fractional volume is that fraction of the glomerulus consisting of the mesangial matrix.</div><div class=\"graphic_reference\">Data from Fioretto P, Steffes MW, Sutherland DER, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998; 339:69.</div><div id=\"graphicVersion\">Graphic 67651 Version 3.0</div></div></div>"},"67654":{"type":"graphic_figure","displayName":"Loop diuretic dose response","title":"Dose-response relationship between furosemide and sodium excretion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dose-response relationship between furosemide and sodium excretion</div><div class=\"cntnt\"><img style=\"width:392px; height:268px;\" src=\"images/NEPH/67654_Loopdiureticdoseresponse.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relation between the rate of furosemide excretion and the increase in sodium excretion in normals (solid line) and patients with HF (dashed line). A diuresis is not seen until a threshold rate of furosemide excretion is reached. Patients with HF show relative resistance at a given rate of diuretic excretion due to increased sodium reabsorption in other nephron segments.</div><div class=\"graphic_footnotes\">HF: heart failure.</div><div class=\"graphic_reference\">Data from: Brater DC, Day B, Burdette A, et al. Kidney Int 1984; 26:183.</div><div id=\"graphicVersion\">Graphic 67654 Version 3.0</div></div></div>"},"67655":{"type":"graphic_table","displayName":"Framingham risk score men","title":"Framingham risk score for men*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Framingham risk score for men*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" colspan=\"3\">Age</td> <td class=\"subtitle1\" colspan=\"3\">Diabetes</td> </tr> <tr> <td class=\"subtitle2\">Years</td> <td class=\"subtitle2\" colspan=\"2\">Points</td> <td class=\"subtitle2\">&nbsp;</td> <td class=\"subtitle2\" colspan=\"2\">Points&nbsp;</td> </tr> <tr> <td>30 to 34</td> <td colspan=\"2\">-1</td> <td>No</td> <td colspan=\"2\">0</td> </tr> <tr> <td>35&nbsp;to 39</td> <td colspan=\"2\">0</td> <td>Yes</td> <td colspan=\"2\">2</td> </tr> <tr> <td>40&nbsp;to 44</td> <td colspan=\"2\">1</td> <td class=\"subtitle1\" colspan=\"3\">Smoker</td> </tr> <tr> <td>45&nbsp;to 49</td> <td colspan=\"2\">2</td> <td class=\"subtitle2\">&nbsp;&nbsp;</td> <td class=\"subtitle2\" colspan=\"2\">Points </td> </tr> <tr> <td>50&nbsp;to 54</td> <td colspan=\"2\">3</td> <td>No</td> <td colspan=\"2\">0</td> </tr> <tr> <td>55&nbsp;to 59</td> <td colspan=\"2\">4</td> <td>Yes</td> <td colspan=\"2\">2</td> </tr> <tr> <td>60&nbsp;to 64</td> <td colspan=\"2\">5</td> <td rowspan=\"3\" colspan=\"3\">&nbsp;</td> </tr> <tr> <td>65&nbsp;to 69</td> <td colspan=\"2\">6</td> </tr> <tr> <td>70&nbsp;to 74</td> <td colspan=\"2\">7</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"3\">LDL cholesterol</td> <td class=\"subtitle1\" colspan=\"3\">HDL cholesterol</td> </tr> <tr> <td class=\"subtitle2\">mg/dL</td> <td class=\"subtitle2\">mmol/L</td> <td class=\"subtitle2\">Points</td> <td class=\"subtitle2\">mg/dL</td> <td class=\"subtitle2\">mmol/L</td> <td class=\"subtitle2\">Points</td> </tr> <tr> <td>&#60;100</td> <td>&#60;2.59</td> <td>-3</td> <td>&#60;35</td> <td>&#60;0.90</td> <td>2</td> </tr> <tr> <td>100&nbsp;to 129</td> <td>2.60&nbsp;to 3.36</td> <td>0</td> <td>35&nbsp;to 44</td> <td>0.91&nbsp;to 1.16</td> <td>1</td> </tr> <tr> <td>130&nbsp;to 159</td> <td>3.37&nbsp;to 4.14</td> <td>0</td> <td>45&nbsp;to 49</td> <td>1.17&nbsp;to 1.29</td> <td>0</td> </tr> <tr> <td>160&nbsp;to 190</td> <td>4.50&nbsp;to 4.92</td> <td>1</td> <td>50&nbsp;to 54</td> <td>1.30&nbsp;to 1.55</td> <td>0</td> </tr> <tr> <td>&#62;190</td> <td>&#62;4.92</td> <td>2</td> <td>&#62;60</td> <td>&#62;1.56</td> <td>-1</td> </tr> <tr> <td class=\"subtitle1\">Systolic blood pressure, mmHg</td> <td class=\"subtitle1\">Diastolic &#60;80 mmHg</td> <td class=\"subtitle1\">Diastolic 80 to 84</td> <td class=\"subtitle1\">Diastolic 85 to 89</td> <td class=\"subtitle1\">Diastolic 90 to 99</td> <td class=\"subtitle1\">Diastolic &#8805;100</td> </tr> <tr> <td>&#60;120</td> <td>0</td> <td>0</td> <td>1</td> <td>2</td> <td>3</td> </tr> <tr> <td>120&nbsp;to 129</td> <td>0</td> <td>0</td> <td>1</td> <td>2</td> <td>3</td> </tr> <tr> <td>130&nbsp;to 139</td> <td>1</td> <td>1</td> <td>1</td> <td>2</td> <td>3</td> </tr> <tr> <td>140&nbsp;to 159</td> <td>2</td> <td>2</td> <td>2</td> <td>2</td> <td>3</td> </tr> <tr> <td>&#8805;160</td> <td>3</td> <td>3</td> <td>3</td> <td>3</td> <td>3</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"6\">CHD risk </td> </tr> <tr> <td class=\"subtitle2\">Total points</td> <td class=\"subtitle2\" colspan=\"2\">10-year CHD risk, percent</td> <td class=\"subtitle2\">Total points</td> <td class=\"subtitle2\" colspan=\"2\">10-year CHD risk, percent</td> </tr> <tr> <td>&#60;-3</td> <td colspan=\"2\">1</td> <td>6</td> <td colspan=\"2\">11</td> </tr> <tr> <td>-2</td> <td colspan=\"2\">2</td> <td>7</td> <td colspan=\"2\">14</td> </tr> <tr> <td>-1</td> <td colspan=\"2\">2</td> <td>8</td> <td colspan=\"2\">18</td> </tr> <tr> <td>0</td> <td colspan=\"2\">3</td> <td>9</td> <td colspan=\"2\">22</td> </tr> <tr> <td>1</td> <td colspan=\"2\">4</td> <td>10</td> <td colspan=\"2\">27</td> </tr> <tr> <td>2</td> <td colspan=\"2\">5</td> <td>11</td> <td colspan=\"2\">33</td> </tr> <tr> <td>3</td> <td colspan=\"2\">6</td> <td>12</td> <td colspan=\"2\">40</td> </tr> <tr> <td>4</td> <td colspan=\"2\">7</td> <td>13</td> <td colspan=\"2\">47</td> </tr> <tr> <td>5</td> <td colspan=\"2\">9</td> <td>14</td> <td colspan=\"2\">56</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LDL: low-density lipoprotein; HDL: high-density lipoprotein; CHD: coronary heart disease; MI: myocardial infarction.<br />* Framingham risk scoring system for men. Use to calculate the risk of developing clinical CHD in men who do not have known CHD. Clinical CHD includes angina pectoris, recognized or unrecognized MI, coronary insufficiency (prolonged chest discomfort associated with transient repolarization abnormalities without criteria for MI), or CHD death.<br />To calculate the Framingham risk estimate, add points for age, presence of diabetes, smoking status, LDL cholesterol, HDL cholesterol, and blood pressure. Find the total point score on the bottom table to determine the 10-year risk of CHD.</div><div class=\"graphic_reference\">Adapted with permission from Wilson PW, D'Agostino R, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837. Copyright © 1998 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 67655 Version 3.0</div></div></div>"},"67656":{"type":"graphic_figure","displayName":"M mode mitral valve motion","title":"M-mode echocardiogram of the normal mitral valve","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">M-mode echocardiogram of the normal mitral valve</div><div class=\"cntnt\"><img style=\"width:528px; height:322px;\" src=\"images/CARD/67656_M_mode_mitral_valve_motion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The position of the beam relative to the long axis precordial plane anatomy is shown in panel A; a diagram of the M-mode pattern of the mitral valve echo is seen in panel B. During diastole the movement of the anterior leaflet (AL) of the valve has an M-shape pattern, while the posterior mitral valve leaflet (PML) moves in the opposite direction (panels C and D). The initial opening, the D-point, reaches a peak at the E point; this represents maximal opening of the valve associated with rapid filling after which there is temporary equilization of pressure and the valve leaflets move back to or near their closed position at the F-point. The speed with which the leaflets close from E to F is known as the E to F slope. The A wave is the peak opening during atrial contraction after which the valve closes (C-point). If the PR interval is prolonged and atrial contraction delayed, the leaflets may &quot;float&quot; back to an opened position (GH in panel D). During systole the segment between C and D represents the coapted leaflets and their migration from posterior to anterior with the descent of the base and the torsion of the longitudinal myocardial segments (panels E and F). Panel E is from a patient with cardiomyopathy; the reduced E to F slope and B notch in diastole indicate elevated left ventricular filling pressure and diastolic dysfunction. Panel F is recorded from a normal individual.</div><div id=\"graphicVersion\">Graphic 67656 Version 1.0</div></div></div>"},"67657":{"type":"graphic_picture","displayName":"Granulomatous cheilitis 1","title":"Granulomatous cheilitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Granulomatous cheilitis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/ALLRG/67657_Gran_cheilitis_1_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Granulomatous cheilitis is a rare disorder in which recurrent swelling of the lips leads to permanent areas of enlargement.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 67657 Version 5.0</div></div></div>"},"67660":{"type":"graphic_figure","displayName":"JC virus granule cell neuronopathy in PML","title":"JC virus granule cell neuronopathy in progressive multifocal leukoencephalopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">JC virus granule cell neuronopathy in progressive multifocal leukoencephalopathy</div><div class=\"cntnt\"><img style=\"width:372px; height:732px;\" src=\"images/NEURO/67660_JVC_GCN_in_PML.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Types of demyelinating lesions in the cerebellar white matter (WM) and focal cell loss of granule cell neurons (GCNs) in the GC layer (GCL) of patients with progressive multifocal leukoencephalopathy. <STRONG>(A, C, E, G)</STRONG> Double immunohistochemistry (IHC) for myelin and oligodendrocytes (CNPase, brown) and JC virus (JCV) VP1 capsid (PAB597, dark blue), displayed in 25,000,000 pixel pictures of 1 cm<SUP>2</SUP> representative portions of cerebellum, shows areas of demyelination and JCV-infected cells (dark blue, marked by arrows in all insets). <STRONG>(B, D, F, H)</STRONG> Double IHC for neurons (NeuN, brown) and JCV VP1 capsid (PAB597, dark blue). <STRONG>(A)</STRONG> Type I, an isolated JCV infected cell is present in the GCL (arrow, inset) in the absence of a PML lesion in the cerebellar WM. This cell is not visible in the adjacent section <STRONG>(B)</STRONG>, which shows an intact GCL. <STRONG>(C)</STRONG> Type II, a small demyelinating lesion at the GCL/WM junction contains JCV-infected cells at the periphery (arrows, inset). <STRONG>(D)</STRONG> The JCV-infected cells are detected in a preserved GCL in the same area. <STRONG>(E)</STRONG> Type III, numerous confluent demyelinating lesions penetrating the GCL harbor JCV-infected cells (arrows, inset), whereas rare JCV-infected cells (arrows, inset) are present in the GCL, which has no to limited focal GCN loss <STRONG>(F)</STRONG>. <STRONG>(G)</STRONG> Type IV, a cavitated PML lesion shows almost complete disappearance of myelin and oligodendrocytes in both the folia and the GCL. Almost all JCV-infected cells disappeared and only rare apoptotic JCV-infected cells or debris of JCV-infected cells (arrows, inset) are still present at the border of the demyelinated areas. These cells and debris are not visible in the inset of the adjacent section <STRONG>(H)</STRONG>, which shows some areas of focal GCN loss (arrowheads, inset).</div><div class=\"graphic_footnotes\">CNPase: Monoclonal antibody to cyclic nucleotide phosphodiesterase;&nbsp;IHC: immunohistochemistry; GCL: granule cell layer; GCNs: granule cell neurons; JCV: JC virus; ML: molecular layer;&nbsp;NeuN: Monoclonal antibody to neuronal nuclei; WM: white matter</div><div class=\"graphic_reference\">Reproduced with permission from: Wuthrich C, Cheng YM, Joseph JT, et al. Frequent infection of cerebellar granule cell neurons by polyomavirus JC in progressive multifocal leukoencephalopathy. J Neuropathol Exp Neurol 2009; 68:15. Copyright © 2009 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 67660 Version 10.0</div></div></div>"},"67663":{"type":"graphic_diagnosticimage","displayName":"CXR MRI scimitar syndrome","title":"CXR MRI scimitar syndrome","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">CXR MRI scimitar syndrome</div><div class=\"cntnt\"><img style=\"width:517px; height:299px;\" src=\"images/PEDS/67663_CXRMRIscimitarsyndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiography of a patient with scimitar syndrome showing a right-side anomalous pulmonary vein (Panel A), which was confirmed by magnetic resonance imaging (Panel B).</div><div class=\"graphic_reference\">Courtesy of George Taylor, MD.</div><div id=\"graphicVersion\">Graphic 67663 Version 4.0</div></div></div>"},"67664":{"type":"graphic_table","displayName":"Factors causing nocturia","title":"Factors potentially causative of nocturia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Factors potentially causative of nocturia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Mechanism </td> <td class=\"subtitle1\">Condition </td> <td class=\"subtitle1\">Diagnostic criteria </td> </tr> <tr> <td rowspan=\"4\">Small-volume bladder voids </td> <td>Urgency, sometimes with urge incontinence, urinary frequency (&#62;8 voids/24 hours), and/or nocturia</td> <td>Daytime voids &#8805;8, urgency, nocturia, and urge incontinence</td> </tr> <tr> <td>Benign prostatic hyperplasia (BPH) or bladder outlet obstruction (BOO)</td> <td>BPH: AUA-7 SI &#62;8 and peak uroflow between 4 and 15 mL/sec; BOO: evidence of obstruction, including peak uroflow less than 15 mL/sec</td> </tr> <tr> <td>Urinary tract infection</td> <td>Leukocyte esterase on U/A; presence of white blood cells &#62;5 HPF on microscopic examination; &#62;1000 colony-forming units by culture</td> </tr> <tr> <td>Low bladder capacity</td> <td>Cystometric capacity less than 150 mL</td> </tr> <tr> <td rowspan=\"6\">Increased urine output at night </td> <td>Nocturnal polyuria</td> <td>35 percent or more of 24-hour urine output occurring during sleep hours, may be related to loss of diurnal variation or deficiency for arginine vasopressin</td> </tr> <tr> <td>Peripheral edema (without heart failure)</td> <td>Presence of pitting edema 10 cm above ankle</td> </tr> <tr> <td>Congestive heart failure (HF)</td> <td>Echocardiographic evidence of a LVEF &#60;35 percent; presence of S3; bilateral lung crackles; use of an ACE inhibitor&nbsp;for HF</td> </tr> <tr> <td>Poor control of diabetes mellitus</td> <td>Random glucose &#62;200 mg/dL (11.1 mmol/L); glucosuria on urine dipstick</td> </tr> <tr> <td>Excessive fluid intake throughout day or large fluid intake immediately prior to bedtime</td> <td>Analysis of self-reported intake or recorded voiding diary or fluid intake record</td> </tr> <tr> <td>Intake of diuretic substances</td> <td>Analysis of self-reported intake</td> </tr> <tr> <td rowspan=\"3\">Sleep-related disorders </td> <td>Difficulty with sleep maintenance</td> <td>Self-reported sleep latency of &#62;30 minutes following first awakening for nocturia</td> </tr> <tr> <td>Sleep apnea</td> <td>Daytime sleepiness, loud snoring, witnessed breathing interruptions, or awakenings due to gasping or choking in the presence of at least five obstructive respiratory events per hour of sleep*</td> </tr> <tr> <td>Restless leg syndrome or periodic limb movements</td> <td>History, partner report, or nighttime sleep study</td> </tr> <tr> <td>Unknown mechanism</td> <td>Hypertension</td> <td>&#62;140/90 mmHg supine</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AUA SI: American Urological Association Symptom Index; U/A: urinalysis; HPF: high powered field; ACE: angiotensin-converting enzyme; LVEF: left-ventricular ejection fraction.<br />* Epstein, LJ, Kristo, D, Strollo, PJ, et al. Clinical guidelines for the evaluation, management, and long-term treatment of obstructive sleep apnea in adults. J Clin Sleep Med 2009; 5:263.</div><div id=\"graphicVersion\">Graphic 67664 Version 3.0</div></div></div>"},"67666":{"type":"graphic_table","displayName":"Detailed criteria for the diagnosis of FMF","title":"Detailed criteria for the diagnosis of familial Mediterranean fever","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Detailed criteria for the diagnosis of familial Mediterranean fever</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Major criteria</td> </tr> <tr> <td><strong>Typical attacks</strong></td> </tr> <tr> <td>1. Peritonitis (generalized)</td> </tr> <tr> <td>2. Pleuritis (unilateral) or pericarditis</td> </tr> <tr> <td>3. Monoarthritis (hip, knee, ankle)</td> </tr> <tr> <td>4. Fever alone</td> </tr> <tr> <td class=\"subtitle1_single\">Minor criteria</td> </tr> <tr> <td>1-3. <strong>Incomplete</strong> attacks involving one or more of the following sites:</td> </tr> <tr> <td class=\"sublist2\">1. Abdomen</td> </tr> <tr> <td class=\"sublist2\">2. Chest</td> </tr> <tr> <td class=\"sublist2\">3. Joint</td> </tr> <tr> <td>4. Exertional leg pain</td> </tr> <tr> <td>5. Favorable response to colchicine</td> </tr> <tr> <td class=\"subtitle1_single\">Supportive criteria</td> </tr> <tr> <td>1. Family history of FMF</td> </tr> <tr> <td>2. Appropriate ethnic origin</td> </tr> <tr> <td>3. Age &#60;20 years at disease onset</td> </tr> <tr> <td class=\"sublist1_start\">4-7. Features of attacks:</td> </tr> <tr> <td class=\"sublist2\">4. Severe, requiring bed rest</td> </tr> <tr> <td class=\"sublist2\">5. Spontaneous remission</td> </tr> <tr> <td class=\"sublist2\">6. Symptom-free interval</td> </tr> <tr> <td class=\"sublist2\">7. Transient inflammatory response, with one or more abnormal test result(s) for the white blood cell count, erythrocyte sedimentation rate, serum amyloid A, and/or fibronogen</td> </tr> <tr> <td>8. Episodic proteinuria/hematuria</td> </tr> <tr> <td>9. Negative laparotomy or removal of normal appendix</td> </tr> <tr> <td>10. Consanguinity of parents</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FMF: familial Mediterranean fever.</div><div class=\"graphic_reference\">Adapted from: Livneh A, Langevitz P, Zemer D, et al. Arthritis Rheum 1997; 40:1879.</div><div id=\"graphicVersion\">Graphic 67666 Version 7.0</div></div></div>"},"67667":{"type":"graphic_figure","displayName":"HL neoplast cell variants","title":"Neoplastic cell variants of Hodgkin lymphoma","html":"<div class=\"graphic\"><div style=\"width: 626px\" class=\"figure\"><div class=\"ttl\">Neoplastic cell variants of Hodgkin lymphoma</div><div class=\"cntnt\"><img style=\"width:606px; height:599px;\" src=\"images/HEME/67667_HL_neoplast_cell_variants.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mononuclear&#160;Reed-Sternberg cell variants are not diagnostic of Hodgkin's disease. However, these cells, in the appropriate environment, indicate involvement either in the staging work-up or in relapse.</div><div class=\"graphic_footnotes\">* Formalin fixation artifact: they cytoplasm of these cells may retract and the cell appears to lie in a clear space (lacuna or lake).<br> &#8226; Pleomorphic large cell lymphoma of T-cell type must be ruled out.<br> &#916; Similar cells may occasionally be seen in mixed cellularity.</div><div class=\"graphic_reference\">Modified with permission from: Rubin E MD and Farber JL MD. Pathology, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 1999. Copyright &#169; 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 67667 Version 2.0</div></div></div>"},"67668":{"type":"graphic_table","displayName":"Myelopoiesis knockouts","title":"Phenotypes of mice lacking specific hematopoietic growth factors or growth factor receptors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Phenotypes of mice lacking specific hematopoietic growth factors or growth factor receptors</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Phenotype</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Missing hematopoietic growth factor or growth factor receptor</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">GM-CSF</td> <td>Normal hematopoiesis and progenitors</td> </tr> <tr> <td>Progressive accumulation of pulmonary surfactant</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">G-CSF</td> <td>Circulating neutrophils 25 percent of normal</td> </tr> <tr> <td>Progenitors 50 percent of normal</td> </tr> <tr> <td>Impaired response to Listeria monocytogenes infection</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">IL-3/GM-CSF/IL-5 (bc) receptor</td> <td>Similar to mice lacking GM-CSF</td> </tr> <tr> <td>Low eosinophils and impaired eosinophil response to N. brasiliensis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Missing transcription factor</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">PU.1</td> <td>Embryonically lethal</td> </tr> <tr> <td>Absence of granulocytes, monocytes, T and B lymphocytes</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">C/EBP-alpha</td> <td>Death soon after birth</td> </tr> <tr> <td>Absent neutrophils and eosinophils</td> </tr> <tr> <td>Impaired glucose metabolism</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">C/EBP-beta</td> <td>Defective monocytes</td> </tr> <tr> <td>Myelodysplasia</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">C/EBP-epsilon</td> <td>Early death from opportunistic infection and myelodysplasia</td> </tr> <tr> <td>Specific granule deficiency and abnormal neutrophil function</td> </tr> <tr> <td class=\"indent1\">AML1 or CBF-beta</td> <td>Embryonically lethal due to failure of hematopoiesis</td> </tr> </tbody></table></div><div class=\"graphic_reference\">For references, please refer to the UpToDate topic on the regulation of myelopoiesis.</div><div id=\"graphicVersion\">Graphic 67668 Version 4.0</div></div></div>"},"67670":{"type":"graphic_picture","displayName":"Portuguese man of war","title":"Portuguese man-of-war","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Portuguese man-of-war</div><div class=\"cntnt\"><img style=\"width:245px; height:426px;\" src=\"images/PC/67670_Portuguese_man_of_war.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note that the nematocysts on this species of jellyfish are on the tentacles, not on the bell.</div><div class=\"graphic_reference\">Courtesy of Richard Weisman, PhD.</div><div id=\"graphicVersion\">Graphic 67670 Version 1.0</div></div></div>"},"67672":{"type":"graphic_diagnosticimage","displayName":"Doppler ultrasound nuchal cord","title":"Doppler ultrasound of the nuchal cord","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Doppler ultrasound of the nuchal cord</div><div class=\"cntnt\"><img style=\"width:432px; height:371px;\" src=\"images/OBGYN/67672_Doppler_ultrasound_nuchal_cord.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Professor Josef Wisser, MD.</div><div id=\"graphicVersion\">Graphic 67672 Version 2.0</div></div></div>"},"67673":{"type":"graphic_figure","displayName":"2D TTE parasternal short axis view aortic root","title":"Two-dimensional transthoracic echocardiogram (2D TTE) parasternal short axis view of the aortic root","html":"<div class=\"graphic\"><div style=\"width: 646px\" class=\"figure\"><div class=\"ttl\">Two-dimensional transthoracic echocardiogram (2D TTE) parasternal short axis view of the aortic root</div><div class=\"cntnt\"><img style=\"width:626px; height:173px;\" src=\"images/CARD/67673_2DTTEparasteraxisaortic.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A diagram of the transducer position for obtaining a short axis two dimensional image; the short axis is obtained by a 70° to 110° clockwise rotation of the transducer from the parasternal long axis, with superior and inferior transducer manipulations, and the plane is oriented at the base of the heart (left panel).<br />(B and C) The parasternal short axis view from a transthoracic echocardiogram shows the noncoronary (NCC), right coronary (RCC), and left coronary (LCC) leaflets of the aortic valve. Also seen are the left atrium (LA), right atrium (RA), tricuspid valve (TV), right ventricle (RV), and pulmonic valve (PV).</div><div id=\"graphicVersion\">Graphic 67673 Version 5.0</div></div></div>"},"67674":{"type":"graphic_picture","displayName":"Barker method of temporary abdominal closure in situ","title":"Barker method of temporary abdominal closure in situ","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Barker method of temporary abdominal closure in situ</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/SURG/67674_Barker_meth_temp_abd_clos.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 67674 Version 1.0</div></div></div>"},"67675":{"type":"graphic_diagnosticimage","displayName":"Sigmoid volvulus","title":"Sigmoid volvulus","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Sigmoid volvulus</div><div class=\"cntnt\"><img style=\"width:511px; height:497px;\" src=\"images/GAST/67675_Sigmoid_volvulus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plain abdominal radiograph of a patient with a sigmoid volvulus demonstrates a large air-filled sigmoid colon (arrow) extending from the pelvis to the right upper quadrant and the absence of air in the rectum (arrow).</div><div class=\"graphic_reference\">Courtesy of Mukesh Harisinghani, MD, Department of Radiology, Massachusetts General Hospital, Boston, MA.</div><div id=\"graphicVersion\">Graphic 67675 Version 3.0</div></div></div>"},"67676":{"type":"graphic_diagnosticimage","displayName":"CT of heptocellular carcinoma","title":"CT of hepatocellular carcinoma invading the portal vein","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT of hepatocellular carcinoma&nbsp;invading the portal vein</div><div class=\"cntnt\"><img style=\"width:352px; height:288px;\" src=\"images/RADIOL/67676_HepatomaincirrhosisCT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hepatocellular carcinoma. Contrast-enhanced CT of a cirrhotic liver demonstrates multifocal hypervascular masses (arrows)&nbsp;and a mass in&nbsp;the portal vein (arrowhead). The spleen is enlarged due to portal hypertension secondary to cirrhosis.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 67676 Version 4.0</div></div></div>"},"67677":{"type":"graphic_picture","displayName":"Mild FSGS Light","title":"Mild FSGS","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mild FSGS</div><div class=\"cntnt\"><img style=\"width:382px; height:264px;\" src=\"images/NEPH/67677_Mild_FGS_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph shows early changes in focal glomerulosclerosis with segmental capillary collapse (arrows) in areas of epithelial cell injury (small arrowhead).</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 67677 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal glomerulus</div><div class=\"cntnt\"><img style=\"width:396px; height:253px;\" src=\"images/NEPH/75094_Normal_glomerulus_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 75094 Version 4.0</div></div></div>"},"67679":{"type":"graphic_waveform","displayName":"ECG bundle branch reentrant ventricular tachcardia","title":"Surface 12-lead ECG in bundle branch reentrant ventricular tachcardia","html":"<div class=\"graphic\"><div style=\"width: 549px\" class=\"figure\"><div class=\"ttl\">Surface 12-lead ECG in bundle branch reentrant ventricular tachcardia</div><div class=\"cntnt\"><img style=\"width:529px; height:395px;\" src=\"images/CARD/67679_ECG_bundle_branch_reentry_V.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left panel: 12 lead ECG during sinus rhythm; there is a left bundle branch block-type intraventricular conduction delay. Right panel: 12 lead ECG during ventricular tachycardia; there is a remarkable similarity in QRS morphology during VT and sinus rhythm. The HV interval during sinus rhythm was 65 msec, suggesting underlying His-Purkinje conduction disease.</div><div id=\"graphicVersion\">Graphic 67679 Version 4.0</div></div></div>"},"67680":{"type":"graphic_table","displayName":"FUdR dose modifications","title":"MSKCC guidelines for FUDR dose modification","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">MSKCC guidelines for FUDR dose modification</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"3\">&nbsp;</td> <td class=\"subtitle1\">FUDR dose</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">AST</td> </tr> <tr> <td class=\"indent1\">Reference value (ref)*</td> <td>&#8804;50 U/L</td> <td>&#62;50 U/L</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\" rowspan=\"4\">Current value<sup>&#182;</sup></td> <td>0 to &#60;3 x ref</td> <td>0 to &#60;2 x ref</td> <td>100 percent</td> </tr> <tr> <td>3 to &#60;4 x ref </td> <td>2 to &#60;3 x ref </td> <td>80 percent</td> </tr> <tr> <td>4 to &#60;5 x ref</td> <td>3 to &#60;4 x ref</td> <td>50 percent</td> </tr> <tr> <td>&#8805;5 x ref</td> <td>&#8805;4 x ref</td> <td>HOLD</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">If held, restart when:</td> <td>&#60;4 x ref</td> <td>&#60;3 x ref</td> <td>50 percent of last dose given</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Alkaline phosphatase</td> </tr> <tr> <td class=\"indent1\">Reference value (ref)</td> <td>&#8804;90 U/L</td> <td>&#62;90 U/L</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Current value</td> <td>0 to &#60;1.5 x ref</td> <td>0 to &#60;1.2 x ref</td> <td>100 percent</td> </tr> <tr> <td>1.5 to &#62;2 x ref</td> <td>1.2 to 1.5 x ref</td> <td>50 percent</td> </tr> <tr> <td>&#8805;2 x ref</td> <td>&#8805;1.5 x ref</td> <td>HOLD</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">If held, restart when:</td> <td>&#60;1.5 x ref</td> <td>&#60;1.2 x ref</td> <td>25 percent of last dose given</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Total bilirubin</td> </tr> <tr> <td class=\"indent1\">Reference value (ref)</td> <td>&#8804;1.2 mg/dL</td> <td>&#62;1.2 mg/dL</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Current value</td> <td>0 to &#60;1.5 x ref</td> <td>0 to &#60;1.2 x ref</td> <td>100 percent</td> </tr> <tr> <td>1.5 to &#60;2 x ref </td> <td>1.2 to &#60;1.5 x ref</td> <td>50 percent</td> </tr> <tr> <td>&#8805;2 x ref</td> <td>&#8805;1.5 x ref</td> <td>HOLD</td> </tr> <tr> <td class=\"indent1\">If held, restart when:</td> <td>&#60;1.5 x ref</td> <td>&#60;1.2 x ref</td> <td>25 percent of last dose given</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MSKCC: Memorial Sloan Kettering Cancer Center; FUDR: fluorodeoxyuridine; AST: aspartate aminotransaminase.<br />* Reference value is the value obtained on the day patient received last FUDR dose.<br />¶ Current value is the value obtained at pump emptying or on the day of planned treatment (whichever is higher).</div><div class=\"graphic_reference\">Reproduced with permission from: Zalcberg JR, Kemeny NE. Systemic or regional chemotherapy for liver metastases from colorectal cancer: Has the wheel stopped spinning? Cancer J 2004; 10:271. Copyright &copy;2004 MediMedia.</div><div id=\"graphicVersion\">Graphic 67680 Version 3.0</div></div></div>"},"67682":{"type":"graphic_picture","displayName":"Striae in Cushing's disease","title":"Striae in Cushing's disease","html":"<div class=\"graphic\"><div style=\"width: 636px\" class=\"figure\"><div class=\"ttl\">Striae in Cushing's disease</div><div class=\"cntnt\"><img style=\"width:616px; height:462px;\" src=\"images/ENDO/67682_Striae_in_Cushings_disease.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lower abdominal and thigh striae in a female patient with Cushing's syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 67682 Version 4.0</div></div></div>"},"67683":{"type":"graphic_table","displayName":"Triceps skin fold normals","title":"Triceps skin fold - normal values","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Triceps skin fold - normal values</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">Age</td>\n\n      <td class=\"subtitle1\" colspan=\"7\" rowspan=\"1\">Triceps\nskinfold percentiles, mm</td>\n\n    </tr>\n\n    \n\n    <tr>\n\n      \n\n      <td class=\"subtitle2\">5</td>\n\n      <td class=\"subtitle2\">10</td>\n\n      <td class=\"subtitle2\">25</td>\n\n      <td class=\"subtitle2\">50</td>\n\n      <td class=\"subtitle2\">75</td>\n\n      <td class=\"subtitle2\">90</td>\n\n      <td class=\"subtitle2\">95</td>\n\n    </tr>\n\n    <tr><td colspan=\"8\" rowspan=\"1\" class=\"subtitle2_left\">Males</td></tr><tr>\n\n      <td class=\"indent1\">1 - 1.9</td>\n\n      <td>6</td>\n\n      <td>7</td>\n\n      <td>8</td>\n\n      <td>10</td>\n\n      <td>12</td>\n\n      <td>14</td>\n\n      <td>16</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">2 - 2.9</td>\n\n      <td>6</td>\n\n      <td>7</td>\n\n      <td>8</td>\n\n      <td>10</td>\n\n      <td>12</td>\n\n      <td>14</td>\n\n      <td>15</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">3 - 3.9</td>\n\n      <td>6</td>\n\n      <td>7</td>\n\n      <td>8</td>\n\n      <td>10</td>\n\n      <td>11</td>\n\n      <td>14</td>\n\n      <td>15</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">4 - 4.9</td>\n\n      <td>6</td>\n\n      <td>6</td>\n\n      <td>8</td>\n\n      <td>9</td>\n\n      <td>11</td>\n\n      <td>12</td>\n\n      <td>14</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">5 - 5.9</td>\n\n      <td>6</td>\n\n      <td>6</td>\n\n      <td>8</td>\n\n      <td>9</td>\n\n      <td>11</td>\n\n      <td>14</td>\n\n      <td>15</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">6 - 6.9</td>\n\n      <td>5</td>\n\n      <td>6</td>\n\n      <td>7</td>\n\n      <td>8</td>\n\n      <td>10</td>\n\n      <td>13</td>\n\n      <td>16</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">7 - 7.9</td>\n\n      <td>5</td>\n\n      <td>6</td>\n\n      <td>7</td>\n\n      <td>9</td>\n\n      <td>12</td>\n\n      <td>15</td>\n\n      <td>17</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">8 - 8.9</td>\n\n      <td>5</td>\n\n      <td>6</td>\n\n      <td>7</td>\n\n      <td>8</td>\n\n      <td>10</td>\n\n      <td>13</td>\n\n      <td>16</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">9 - 9.9</td>\n\n      <td>6</td>\n\n      <td>6</td>\n\n      <td>7</td>\n\n      <td>10</td>\n\n      <td>13</td>\n\n      <td>17</td>\n\n      <td>18</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">10 - 10.9</td>\n\n      <td>6</td>\n\n      <td>6</td>\n\n      <td>8</td>\n\n      <td>10</td>\n\n      <td>14</td>\n\n      <td>18</td>\n\n      <td>21</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">11 - 11.9</td>\n\n      <td>6</td>\n\n      <td>6</td>\n\n      <td>8</td>\n\n      <td>11</td>\n\n      <td>16</td>\n\n      <td>20</td>\n\n      <td>24</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">12 - 12.9</td>\n\n      <td>6</td>\n\n      <td>6</td>\n\n      <td>8</td>\n\n      <td>11</td>\n\n      <td>14</td>\n\n      <td>22</td>\n\n      <td>28</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">13 - 13.9</td>\n\n      <td>5</td>\n\n      <td>5</td>\n\n      <td>7</td>\n\n      <td>10</td>\n\n      <td>14</td>\n\n      <td>22</td>\n\n      <td>26</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">14 - 14.9</td>\n\n      <td>4</td>\n\n      <td>5</td>\n\n      <td>7</td>\n\n      <td>9</td>\n\n      <td>14</td>\n\n      <td>21</td>\n\n      <td>24</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">15 - 15.9</td>\n\n      <td>4</td>\n\n      <td>5</td>\n\n      <td>6</td>\n\n      <td>8</td>\n\n      <td>11</td>\n\n      <td>18</td>\n\n      <td>24</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">16 - 16.9</td>\n\n      <td>4</td>\n\n      <td>5</td>\n\n      <td>6</td>\n\n      <td>8</td>\n\n      <td>12</td>\n\n      <td>16</td>\n\n      <td>22</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">17 - 17.9</td>\n\n      <td>5</td>\n\n      <td>5</td>\n\n      <td>6</td>\n\n      <td>8</td>\n\n      <td>12</td>\n\n      <td>16</td>\n\n      <td>19</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">18 - 18.9</td>\n\n      <td>4</td>\n\n      <td>5</td>\n\n      <td>6</td>\n\n      <td>9</td>\n\n      <td>13</td>\n\n      <td>20</td>\n\n      <td>24</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">19 - 24.9</td>\n\n      <td>4</td>\n\n      <td>5</td>\n\n      <td>7</td>\n\n      <td>10</td>\n\n      <td>15</td>\n\n      <td>20</td>\n\n      <td>22</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">25 - 34.9</td>\n\n      <td>5</td>\n\n      <td>6</td>\n\n      <td>8</td>\n\n      <td>12</td>\n\n      <td>16</td>\n\n      <td>20</td>\n\n      <td>24</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"8\" rowspan=\"1\" class=\"subtitle2_left\">Females</td>\n\n      \n\n    </tr>\n\n    \n\n    <tr>\n\n      <td class=\"indent1\">1 - 1.9</td>\n\n      <td>6</td>\n\n      <td>7</td>\n\n      <td>8</td>\n\n      <td>10</td>\n\n      <td>12</td>\n\n      <td>14</td>\n\n      <td>16</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">2 - 2.9</td>\n\n      <td>6 </td>\n\n      <td>8</td>\n\n      <td>9</td>\n\n      <td>10</td>\n\n      <td>12</td>\n\n      <td>15</td>\n\n      <td>16</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">3 - 3.9</td>\n\n      <td>7 </td>\n\n      <td>8</td>\n\n      <td>9</td>\n\n      <td>11</td>\n\n      <td>12</td>\n\n      <td>14</td>\n\n      <td>15</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">4 - 4.9</td>\n\n      <td>7</td>\n\n      <td>8</td>\n\n      <td>8 </td>\n\n      <td>10</td>\n\n      <td>12</td>\n\n      <td>14</td>\n\n      <td>16</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">5 - 5.9</td>\n\n      <td>6 </td>\n\n      <td>7</td>\n\n      <td>8 </td>\n\n      <td>10</td>\n\n      <td>12</td>\n\n      <td>15</td>\n\n      <td>14</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">6 - 6.9</td>\n\n      <td>6 </td>\n\n      <td> 6</td>\n\n      <td>8 </td>\n\n      <td>10</td>\n\n      <td>12</td>\n\n      <td>14</td>\n\n      <td>16</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">7 - 7.9</td>\n\n      <td>6</td>\n\n      <td> 7</td>\n\n      <td>9</td>\n\n      <td>11</td>\n\n      <td>13</td>\n\n      <td>16</td>\n\n      <td>18</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">8 - 8.9</td>\n\n      <td>6</td>\n\n      <td>8 </td>\n\n      <td>9 </td>\n\n      <td>12</td>\n\n      <td>15</td>\n\n      <td>18</td>\n\n      <td>24</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">9 - 9.9</td>\n\n      <td>8</td>\n\n      <td>8</td>\n\n      <td>10</td>\n\n      <td>13</td>\n\n      <td>16</td>\n\n      <td>20</td>\n\n      <td>22</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">10 - 10.9</td>\n\n      <td>7 </td>\n\n      <td>8</td>\n\n      <td>10</td>\n\n      <td>12</td>\n\n      <td>17</td>\n\n      <td>23</td>\n\n      <td>27</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">11 - 11.9</td>\n\n      <td>7</td>\n\n      <td>8 </td>\n\n      <td>10</td>\n\n      <td>13</td>\n\n      <td>18</td>\n\n      <td>24</td>\n\n      <td>28</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">12 - 12.9</td>\n\n      <td>8 </td>\n\n      <td>9 </td>\n\n      <td>11</td>\n\n      <td>14</td>\n\n      <td>18</td>\n\n      <td>23</td>\n\n      <td>27</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">13 - 13.9</td>\n\n      <td>8</td>\n\n      <td>8</td>\n\n      <td>12</td>\n\n      <td>15</td>\n\n      <td>21</td>\n\n      <td>26</td>\n\n      <td>30</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">14 - 14.9</td>\n\n      <td>9</td>\n\n      <td>10</td>\n\n      <td>13</td>\n\n      <td>16</td>\n\n      <td>21</td>\n\n      <td>26</td>\n\n      <td>28</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">15 - 15.9</td>\n\n      <td>8</td>\n\n      <td>10</td>\n\n      <td>12</td>\n\n      <td>17</td>\n\n      <td>21</td>\n\n      <td>25</td>\n\n      <td>32</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">16 - 16.9</td>\n\n      <td>10 </td>\n\n      <td>12 </td>\n\n      <td>15</td>\n\n      <td>18</td>\n\n      <td>22</td>\n\n      <td>26</td>\n\n      <td>31</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">17 - 17.9</td>\n\n      <td>10</td>\n\n      <td>12</td>\n\n      <td>13</td>\n\n      <td>19</td>\n\n      <td>24</td>\n\n      <td>30</td>\n\n      <td>37</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">18 - 18.9</td>\n\n      <td>10</td>\n\n      <td>12 </td>\n\n      <td>15</td>\n\n      <td>18</td>\n\n      <td>22</td>\n\n      <td>26</td>\n\n      <td>30</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">19 - 24.9</td>\n\n      <td>10</td>\n\n      <td>11</td>\n\n      <td>14</td>\n\n      <td>18</td>\n\n      <td>24</td>\n\n      <td>30</td>\n\n      <td>34</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">25 - 34.9</td>\n\n      <td>10</td>\n\n      <td>12</td>\n\n      <td>16</td>\n\n      <td>21</td>\n\n      <td>27</td>\n\n      <td>34</td>\n\n      <td>37</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_lgnd\">Percentiles for triceps skinfold for whites of the United States Health and Nutrition Examination Survey 1 of 1971 to 1974.</div><div class=\"graphic_reference\">Adapted from Frisancho, Am J Clin Med 1981; 34:2540.</div><div id=\"graphicVersion\">Graphic 67683 Version 1.0</div></div></div>"},"67684":{"type":"graphic_figure","displayName":"Amiodarone in CAMIAT","title":"Effect of amiodarone in CAMIAT","html":"<div class=\"graphic\"><div style=\"width: 493px\" class=\"figure\"><div class=\"ttl\">Effect of amiodarone in CAMIAT</div><div class=\"cntnt\"><img style=\"width:473px; height:511px;\" src=\"images/CARD/67684_Amiodarone_in_CAMIAT.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Effect of amiodarone versus placebo in 1202 postmyocardial infarction patients with ventricular ectopy in the CAMIAT trial. By an intention to treat analysis, amiodarone produced a significant reduction in arrhythmic death (top panel, p = 0.016) but no change in all-cause mortality (bottom panel).</div><div class=\"graphic_reference\">Data from: Cairns JA, Connolly SJ, Gent M, et al. Lancet 1997; 349:675.</div><div id=\"graphicVersion\">Graphic 67684 Version 2.0</div></div></div>"},"67685":{"type":"graphic_figure","displayName":"Monoclonal pattern on SPEP","title":"Monoclonal pattern on serum protein electrophoresis (SPEP)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Monoclonal pattern on serum protein electrophoresis (SPEP)</div><div class=\"cntnt\"><img style=\"width:278px; height:350px;\" src=\"images/HEME/67685_Monoclonal_pattern_SPEP_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Densitometer tracing of these findings reveals a tall, narrow-based peak (asterisk) of gamma mobility and has been likened to a church spire. The monoclonal band has a densitometric appearance similar to that of albumin (alb) and a reduction in the normal polyclonal gamma band.<br />(B) A dense, localized band (asterisk) representing a monoclonal protein of gamma mobility is seen on serum protein electrophoresis on agarose gel (anode on left).</div><div class=\"graphic_reference\">Reproduced with permission from: Kyle RA, Rajkumar SV. Plasma cell disorders. In: Cecil textbook of medicine, 22nd ed, Goldman L, Ausiello DA (Eds), WB Saunders, Philadelphia 2004. p.1184. Copyright &copy; 2004 Elsevier.</div><div id=\"graphicVersion\">Graphic 67685 Version 8.0</div></div></div>"},"67690":{"type":"graphic_diagnosticimage","displayName":"Chest radiographs with and without thymic shadows","title":"Chest radiographs with and without thymic shadows","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiographs with and without thymic shadows</div><div class=\"cntnt\"><img style=\"width:366px; height:638px;\" src=\"images/ALLRG/67690_Thymic_shadow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The top chest radiograph shows a normal thymic shadow. The bottom radiograph shows absence of the thymic shadow in an infant with severe combined immunodeficiency (SCID).</div><div class=\"graphic_reference\">Courtesy of J Pierre Sasson, MD.</div><div id=\"graphicVersion\">Graphic 67690 Version 4.0</div></div></div>"},"67691":{"type":"graphic_picture","displayName":"Nevus globular pattern","title":"Dermoscopic image of a nevus with a globular pattern","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of a nevus with a globular pattern</div><div class=\"cntnt\"><img style=\"width:504px; height:429px;\" src=\"images/DERM/67691_Nevus_globular_pattern_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Drs. Ashfaq Marghoob and Natalia Jaimes.</div><div id=\"graphicVersion\">Graphic 67691 Version 4.0</div></div></div>"},"67692":{"type":"graphic_picture","displayName":"Black grain direct exam","title":"Eumycetoma: Black grain direct exam","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eumycetoma: Black grain direct exam</div><div class=\"cntnt\"><img style=\"width:396px; height:268px;\" src=\"images/ID/67692_Blackgraindirectexam.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Direct examination of a black grain with 20% potassium hydroxide (KOH) solution. Note the broad, septate, and branching hyphae, with large swollen cells (x400).</div><div class=\"graphic_reference\">Courtesy of Beatriz Bustamante, MD.</div><div id=\"graphicVersion\">Graphic 67692 Version 5.0</div></div></div>"},"67694":{"type":"graphic_picture","displayName":"Ca oxalate monohydrate crystals","title":"Urinary calcium oxalate monohydrate crystals under polarized light","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Urinary calcium oxalate monohydrate crystals under polarized light</div><div class=\"cntnt\"><img style=\"width:378px; height:232px;\" src=\"images/NEPH/67694_Ca_oxalate_monohydrate_crys.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Urine sediment viewed under polarized light showing coarse, needle-shaped calcium oxalate monohydrate crystals. These crystals have a similar appearance to hippurate crystals.</div><div class=\"graphic_reference\">Courtesy of W Merrill Hicks, MD.</div><div id=\"graphicVersion\">Graphic 67694 Version 2.0</div></div></div>"},"67695":{"type":"graphic_figure","displayName":"Changes in PD sodium ratio","title":"Changes in peritoneal dialysis sodium dialysate/plasma ratio over time","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Changes in peritoneal dialysis sodium dialysate/plasma ratio over time</div><div class=\"cntnt\"><img style=\"width:344px; height:431px;\" src=\"images/NEPH/67695_Na_D_div_P_ratios_and_filt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sodium D/P (dialysate/plasma) ratios versus time as measured in 1985 (5/23/85, white curve) and 1992 (7/06/92, black curve) in a patient with progressive loss of ultrafiltration. Values are superimposed upon the standard curves. The initial curve is normal, displaying an initial drop of the ratio; the second curve is abnormal with no decrease at the beginning of dwell. The curve rises steadily after a one hour dwell.</div><div id=\"graphicVersion\">Graphic 67695 Version 2.0</div></div></div>"},"67698":{"type":"graphic_figure","displayName":"Surfaces of the liver","title":"Surfaces of the liver","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Surfaces of the liver</div><div class=\"cntnt\"><img style=\"width:540px; height:720px;\" src=\"images/SURG/67698_Liver-surfaces.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 67698 Version 2.0</div></div></div>"},"67699":{"type":"graphic_diagnosticimage","displayName":"CT cystogram bladder rupture intraperitoneal","title":"CT cystogram of intraperitoneal bladder rupture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT cystogram of intraperitoneal bladder rupture</div><div class=\"cntnt\"><img style=\"width:432px; height:331px;\" src=\"images/EM/67699_Bladder_rupture_ID_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This CT cystogram reveals an intraperitoneal bladder rupture. Contrast outlines several loops of bowel (arrows).</div><div class=\"graphic_reference\">Courtesy of Michael S Runyon, MD, FAAEM.</div><div id=\"graphicVersion\">Graphic 67699 Version 2.0</div></div></div>"},"67700":{"type":"graphic_figure","displayName":"Normal CO2 waveform","title":"Normal CO2 waveform","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal CO2 waveform</div><div class=\"cntnt\"><img style=\"width:387px; height:265px;\" src=\"images/EM/67700_Normal_CO2_waveform.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A - B: Dead space ventilation<br> B - C: Ascending expiratory phase<br> C - D: Alveolar Plateau<br> D: End-tidal CO<sub>2</sub><br> D - E: Descending inspiratory phase</div><div class=\"graphic_reference\">Reproduced with permission from: Krauss B, Deykin A, Lam A, et al. Capnogram shape in obstructive lung disease. Anesth Analg 2005; 100:884. Copyright © 2005 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 67700 Version 11.0</div></div></div>"},"67702":{"type":"graphic_table","displayName":"Presenting symptoms gastric CA","title":"Presenting symptoms of gastric cancer in 18,363 patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Presenting symptoms of gastric cancer in 18,363 patients</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Symptom</td>\n<td class=\"subtitle1\">Percent</td>\n</tr>\n<tr>\n<td>Weight loss</td>\n<td>62</td>\n</tr>\n<tr>\n<td>Abdominal pain</td>\n<td>52</td>\n</tr>\n<tr>\n<td>Nausea</td>\n<td>34</td>\n</tr>\n<tr>\n<td>Dysphagia</td>\n<td>26</td>\n</tr>\n<tr>\n<td>Melena</td>\n<td>20</td>\n</tr>\n<tr>\n<td>Early satiety</td>\n<td>18</td>\n</tr>\n<tr>\n<td>Ulcer-type pain</td>\n<td>17</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Wanebo, HJ, Kennedy, BJ, Chmiel, J, et al, Ann Surg 1993; 218:583.</div><div id=\"graphicVersion\">Graphic 67702 Version 1.0</div></div></div>"},"67704":{"type":"graphic_table","displayName":"Major causes of wheeze","title":"Causes of wheezing based on anatomic site of obstruction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of wheezing based on anatomic site of obstruction</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Extrathoracic upper airway obstruction</td> </tr> <tr> <td class=\"indent1\">Postnasal drip syndrome</td> </tr> <tr> <td class=\"indent1\">Paroxysmal vocal cord motion</td> </tr> <tr> <td class=\"indent1\">Hypertrophied tonsils</td> </tr> <tr> <td class=\"indent1\">Supraglottitis</td> </tr> <tr> <td class=\"indent1\">Laryngeal edema</td> </tr> <tr> <td class=\"indent1\">Laryngostenosis</td> </tr> <tr> <td class=\"indent1\">Postextubation granuloma</td> </tr> <tr> <td class=\"indent1\">Retropharyngeal abscess</td> </tr> <tr> <td class=\"indent1\">Benign airway tumors</td> </tr> <tr> <td class=\"indent1\">Anaphylaxis</td> </tr> <tr> <td class=\"indent1\">Malignancy</td> </tr> <tr> <td class=\"indent1\">Obesity</td> </tr> <tr> <td class=\"indent1\">Klebsiella rhinoscleroma</td> </tr> <tr> <td class=\"indent1\">Mobile supraglottic soft tissue</td> </tr> <tr> <td class=\"indent1\">Relapsing polychondritis</td> </tr> <tr> <td class=\"indent1\">Laryngocele</td> </tr> <tr> <td class=\"indent1\">Abnormal arytenoid movement</td> </tr> <tr> <td class=\"indent1\">Vocal cord hematoma</td> </tr> <tr> <td class=\"indent1\">Bilateral vocal cord paralysis</td> </tr> <tr> <td class=\"indent1\">Cricoarytenoid arthritis</td> </tr> <tr> <td class=\"indent1\">Granulomatosis with polyangiitis (Wegener's)</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Intrathoracic upper airway obstruction</td> </tr> <tr> <td class=\"indent1\">Tracheal stenosis</td> </tr> <tr> <td class=\"indent1\">Foreign body aspiration</td> </tr> <tr> <td class=\"indent1\">Benign airway tumors</td> </tr> <tr> <td class=\"indent1\">Malignancies</td> </tr> <tr> <td class=\"indent1\">Intrathoracic goiter</td> </tr> <tr> <td class=\"indent1\">Tracheobronchomegaly</td> </tr> <tr> <td class=\"indent1\">Acquired tracheomalacia</td> </tr> <tr> <td class=\"indent1\">Herpetic tracheobronchitis</td> </tr> <tr> <td class=\"indent1\">Right-sided aortic arch</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Lower airway obstruction</td> </tr> <tr> <td class=\"indent1\">Asthma</td> </tr> <tr> <td class=\"indent1\">Chronic obstructive pulmonary disease</td> </tr> <tr> <td class=\"indent1\">Pulmonary edema</td> </tr> <tr> <td class=\"indent1\">Aspiration</td> </tr> <tr> <td class=\"indent1\">Pulmonary embolism</td> </tr> <tr> <td class=\"indent1\">Bronchiolitis</td> </tr> <tr> <td class=\"indent1\">Cystic fibrosis</td> </tr> <tr> <td class=\"indent1\">Carcinoid syndrome</td> </tr> <tr> <td class=\"indent1\">Bronchiectasis</td> </tr> <tr> <td class=\"indent1\">Lymphangitic carcinomatosis</td> </tr> <tr> <td class=\"indent1\">Parasitic infections</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 67704 Version 6.0</div></div></div>"},"67705":{"type":"graphic_diagnosticimage","displayName":"Rheumatoid nodule chest xray","title":"Rheumatoid nodule chest x-ray","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rheumatoid nodule chest x-ray</div><div class=\"cntnt\"><img style=\"width:352px; height:322px;\" src=\"images/PULM/67705_Rheumatoid_nodule_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest x-ray demonstrating a cavitating rheumatoid nodule. The patient presented with pleuritic chest pain.</div><div class=\"graphic_reference\">Courtesy of Fiona R Lake, MD.</div><div id=\"graphicVersion\">Graphic 67705 Version 3.0</div></div></div>"},"67706":{"type":"graphic_diagnosticimage","displayName":"Plain film radiography of femoral head osteonecrosis","title":"Plain film radiography of femoral head osteonecrosis (avascular necrosis)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Plain film radiography of femoral head osteonecrosis (avascular necrosis)</div><div class=\"cntnt\"><img style=\"width:504px; height:424px;\" src=\"images/RADIOL/67706_Osteonecrosis_R_hip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Femoral head osteonecrosis. Plain film radiograph frontal view of the pelvis demonstrates collapse of the right femoral head (arrow) from osteonecrosis (avascular necrosis).</div><div class=\"graphic_reference\">Courtesy of Cecilia M Jude, MD, and Shahla Modarresi, MD.</div><div id=\"graphicVersion\">Graphic 67706 Version 4.0</div></div></div>"},"67707":{"type":"graphic_table","displayName":"Nasal ketorolac and oral aspirin challenge protocol","title":"Nasal ketorolac and oral aspirin challenge protocol*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nasal ketorolac and oral aspirin challenge protocol*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Time</td> <td class=\"subtitle1\">Dose of intranasal ketorolac (in sprays) or oral aspirin (in mg)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Day 1</td> </tr> <tr> <td class=\"indent1\">8 AM</td> <td>1 spray (one in one nostril)</td> </tr> <tr> <td class=\"indent1\">8:30 AM</td> <td>2 sprays (one in each nostril)</td> </tr> <tr> <td class=\"indent1\">9 AM</td> <td>4 sprays (two in each nostril)</td> </tr> <tr> <td class=\"indent1\">9:30 AM</td> <td>6 sprays<sup>&#182;</sup> (three in each nostril)</td> </tr> <tr> <td class=\"indent1\">10:30 AM</td> <td>60 mg of aspirin</td> </tr> <tr> <td class=\"indent1\">12 PM</td> <td>60 mg of aspirin</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">1:30 PM</td> <td>Instructions and discharge</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Day 2</td> </tr> <tr> <td class=\"indent1\">8 AM</td> <td>150 mg</td> </tr> <tr> <td class=\"indent1\">11 AM</td> <td>325 mg</td> </tr> <tr> <td class=\"indent1\">2 PM</td> <td>Instructions and discharge</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Clinical and objective evaluation performed every 30 minutes and as needed.<br />&para; Provoking dose is repeated. Symptoms are treated as indicated.</div><div class=\"graphic_reference\">Original figure modified for this publication. Lee RU, White AA, Ding D, et al. Use of intranasal ketorolac and modified oral aspirin challenge for desensitization of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2010; 105:130. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 67707 Version 7.0</div></div></div>"},"67708":{"type":"graphic_movie","displayName":"Midurethral retropubic sling","title":"Midurethral retropubic sling procedure","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Midurethral retropubic sling procedure</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/OBGYN/67708_Midurethretropslingconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:373px; height:390px;\" src=\"images/OBGYN/67708_Midurethralretropubsling.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 67708 Version 2.0</div></div></div>"},"67709":{"type":"graphic_table","displayName":"Thallium v technetium imaging","title":"Comparison of thallium-201 and technetium-99m","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of thallium-201 and technetium-99m</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">&nbsp;</td>\n\n      <td class=\"subtitle1\">Thallium-201</td>\n\n      <td class=\"subtitle1\">Technetium-99m</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Dose</td>\n\n      <td>2-4 mCi</td>\n\n      <td>20-30 mCi</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Photon energy</td>\n\n      <td>69-83 keV</td>\n\n      <td>140 keV</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Half-life</td>\n\n      <td>73 hours</td>\n\n      <td>6 hours</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Availability</td>\n\n      <td>Cyclotron-produced</td>\n\n      <td>Generator produced; often available on site</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Significant redistribution</td>\n\n      <td>Yes</td>\n\n      <td>No</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 67709 Version 1.0</div></div></div>"},"67710":{"type":"graphic_table","displayName":"Repeat hepatic resection CRC","title":"Outcome after repeat hepatic resection for recurrent colorectal metastases","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Outcome after repeat hepatic resection for recurrent colorectal metastases</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Reference, year</td> <td class=\"subtitle1\">Number of patients</td> <td class=\"subtitle1\">Overall survival</td> <td class=\"subtitle1\">Median survival, months</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Nordlinger B; 1994</td> <td>116</td> <td>33 percent, 3 year</td> <td>24</td> </tr> <tr> <td>Fernandez-Trigo V; 1995</td> <td>170</td> <td>32 percent, 5 year</td> <td>34</td> </tr> <tr> <td>Adam R; 1997</td> <td>64</td> <td>41 percent, 5 year</td> <td>46</td> </tr> <tr> <td>Yamamoto J; 1999</td> <td>90</td> <td>31 percent, 5 year</td> <td>31</td> </tr> <tr> <td>Petrowsky H; 2002</td> <td>126</td> <td>34 percent, 5 year</td> <td>37</td> </tr> <tr> <td>Nagakura S; 2002</td> <td>28</td> <td>42 perent, 5 year</td> <td>27</td> </tr> <tr> <td>Tanaka K; 2004</td> <td>26</td> <td>48 percent*, 5 year</td> <td>NR</td> </tr> <tr> <td>Pessaux P; 2006</td> <td>42</td> <td>55, 21, 36<sup>&#182;</sup> percent, 5 year</td> <td>41, 25, 16*</td> </tr> <tr> <td>Ishiguro S; 2006</td> <td>111</td> <td>41 percent, 5 year</td> <td>43 months</td> </tr> <tr> <td>Cunha A; 2007</td> <td>40</td> <td>31 percent, 5 year</td> <td>NR</td> </tr> <tr> <td>Jones N; 2012</td> <td>52</td> <td>34 percent, 2 year</td> <td>22</td> </tr> <tr> <td>Adair RA; 2012</td> <td>195</td> <td>29 percent, 5 year</td> <td>NR</td> </tr> <tr> <td>Wicherts DA; 2013</td> <td>288</td> <td>41 percent, 5 year<sup>&#916;</sup></td> <td>44</td> </tr> <tr> <td>Butte J; 2015</td> <td>160</td> <td>25 percent, 3 year<sup>&#9674;</sup></td> <td>87<sup>&#167;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NR: not reported.<br />* Disease-free survival.<br />¶ Five-year survival and median survival durations reported separately for three groups undergoing second (n = 42), third (n = 11), and fourth (n = 2) hepatectomies.<br />Δ Second hepatectomy only.<br />◊&nbsp;For the 145 patients with at least 36 months of follow-up after salvage, repeat resection.<br />§ Median disease-specific survival, measured from the date of initial liver resection.</div><div id=\"graphicVersion\">Graphic 67710 Version 8.0</div></div></div>"},"67711":{"type":"graphic_table","displayName":"Diagnostic criteria for Kawasaki disease","title":"Diagnostic criteria for Kawasaki disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for Kawasaki disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">The diagnosis of Kawasaki disease requires the presence of fever lasting at least five days* without any other explanation combined with at least four of the five following criteria:</td> </tr> <tr> <td class=\"sublist1\">Bilateral bulbar conjunctival injection</td> </tr> <tr> <td class=\"sublist1\">Oral mucous membrane changes, including injected or fissured lips, injected pharynx, or strawberry tongue</td> </tr> <tr> <td class=\"sublist1\">Peripheral extremity changes, including erythema of palms or soles, edema of hands or feet (acute phase), and periungual desquamation (convalescent phase)</td> </tr> <tr> <td class=\"sublist1\">Polymorphous rash</td> </tr> <tr> <td class=\"sublist1\">Cervical lymphadenopathy (at least one lymph node &#62;1.5 cm in diameter)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* If&nbsp;≥4 of the above criteria are present, Kawasaki disease can be made on day 4 of illness. </div><div id=\"graphicVersion\">Graphic 67711 Version 6.0</div></div></div>"},"67712":{"type":"graphic_picture","displayName":"Laryngeal cleft type 4","title":"Endoscopic view of type 4 laryngeal cleft","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic view of type 4 laryngeal cleft</div><div class=\"cntnt\"><img style=\"width:370px; height:342px;\" src=\"images/PEDS/67712_Laryngeal_cleft_type_4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Type 4 laryngeal clefts involve a major portion of the intrathoracic tracheoesophageal wall. In the image above, the endotracheal tube is displaced into the laryngeal cleft.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 67712 Version 1.0</div></div></div>"},"67713":{"type":"graphic_figure","displayName":"Prone hip exam","title":"Prone examination of the hip","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Prone examination of the hip</div><div class=\"cntnt\"><img style=\"width:505px; height:473px;\" src=\"images/PEDS/67713_Prone_hip_exam.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With the knees flexed to 90 degrees and both feet caused to &quot;fall outward,&quot; subtle asymmetry in internal rotation is readily appreciated.</div><div id=\"graphicVersion\">Graphic 67713 Version 1.0</div></div></div>"},"67714":{"type":"graphic_picture","displayName":"Seborrheic keratosis eyelid","title":"Seborrheic keratosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Seborrheic keratosis</div><div class=\"cntnt\"><img style=\"width:398px; height:256px;\" src=\"images/PC/67714_Seborrheic_keratosis_eyelid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The crust-like lesion is evident on the lower eyelid.</div><div class=\"graphic_reference\">With permission from Slomovits, TL (Ed), Basic and clinical science courses section, American Academy of Ophthalmology, San Francisco 1996.</div><div id=\"graphicVersion\">Graphic 67714 Version 1.0</div></div></div>"},"67715":{"type":"graphic_diagnosticimage","displayName":"Bronchial atresia CT III","title":"Left upper lobe bronchial atresia seen on a coronal CT image","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left upper lobe bronchial atresia seen on a coronal CT image</div><div class=\"cntnt\"><img style=\"width:360px; height:298px;\" src=\"images/PULM/67715_Bronchial_atresia_CT_III.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal multiplanar reformat with mediastinal window settings shows the tubular hilar mass consistent with a mucoid impaction distal to the atretic bronchus. No evidence for an endobronchial tumor is seen, but tubular calcifications are seen in the mucoid impaction.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 67715 Version 3.0</div></div></div>"},"67717":{"type":"graphic_picture","displayName":"Small mycetoma lesion A","title":"Subcutaneous nodule due to mycetoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Subcutaneous nodule due to mycetoma</div><div class=\"cntnt\"><img style=\"width:384px; height:284px;\" src=\"images/ID/67717_Subcutaneous_nodule.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Beatriz Bustamante, MD.</div><div id=\"graphicVersion\">Graphic 67717 Version 2.0</div></div></div>"},"67718":{"type":"graphic_table","displayName":"Classification of systemic reactions to SCIT","title":"Classification of systemic reactions to subcutaneous immunotherapy (SCIT)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of systemic reactions to subcutaneous immunotherapy (SCIT)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">AAAAI/ACAAI surveillance study</td> </tr> <tr> <td class=\"subtitle2_single\">Grade I &#8594; Mild systemic reactions:</td> </tr> <tr> <td class=\"indent1\">Generalized urticaria and/or upper respiratory symptoms (eg, itching of the palate and throat, sneezing)</td> </tr> <tr> <td class=\"subtitle2_single\">Grade 2 &#8594; Moderate systemic reactions:</td> </tr> <tr> <td class=\"indent1\">Asthma (eg, PEFR falls 20 to 40%) with or without generalized urticaria, upper respiratory symptoms, or abdominal symptoms (nausea, cramping)</td> </tr> <tr> <td class=\"subtitle2_single\">Grade 3 &#8594; Severe life-threatening anaphylaxis:</td> </tr> <tr> <td class=\"indent1\">Severe airway compromise due to severe bronchospasm (eg, PEFR falls more than 40%) or upper airway obstruction with stridor, and/or hypotension (with or without loss of consciousness)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AAAAI: American Academy of Allergy, Asthma, and Immunology; ACAAI: American College of Allergy, Asthma, and Immunology; PEFR: peak expiratory flow rate.</div><div id=\"graphicVersion\">Graphic 67718 Version 7.0</div></div></div>"},"67721":{"type":"graphic_table","displayName":"Complications associated with multiple gestation","title":"Problems occurring more often in multiple gestations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Problems occurring more often in multiple gestations</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Maternal</td>\n</tr>\n<tr>\n<td>Early or late fetal loss</td>\n</tr>\n<tr>\n<td>Preeclampsia</td>\n</tr>\n<tr>\n<td>Gestational diabetes</td>\n</tr>\n<tr>\n<td>Hydramnios</td>\n</tr>\n<tr>\n<td>Anemia</td>\n</tr>\n<tr>\n<td>Antepartum bleeding</td>\n</tr>\n<tr>\n<td>Prolonged hospitalization</td>\n</tr>\n<tr>\n<td>Preterm birth</td>\n</tr>\n<tr>\n<td>Cesarean delivery</td>\n</tr>\n<tr>\n<td>Postpartum bleeding</td>\n</tr>\n<tr>\n<td>Parental stress (psychological, economic)</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Fetal or neonatal</td>\n</tr>\n<tr>\n<td>Congenital anomalies</td>\n</tr>\n<tr>\n<td class=\"sublist1_start\">Preterm delivery</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Cerebral palsy</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Intraventricular hemorrhage</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Retinopathy</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Sepsis</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Respiratory problems</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Necrotizing enterocolitis</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Hyperbilirubinemia</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Patent ductus</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Hypoglycemia, hypocalcemia</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Prolonged hospitalization</td>\n</tr>\n<tr>\n<td>Longterm disability</td>\n</tr>\n<tr>\n<td>High medical costs</td>\n</tr>\n<tr>\n<td>Perinatal mortality</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted from: Adamson, D, Baker, V. Fertil Steril 2004; 81:517.</div><div id=\"graphicVersion\">Graphic 67721 Version 2.0</div></div></div>"},"67723":{"type":"graphic_picture","displayName":"US guided carpal tunnel puncture","title":"Ultrasound guided carpal tunnel puncture","html":"<div class=\"graphic\"><div style=\"width: 611px\" class=\"figure\"><div class=\"ttl\">Ultrasound guided carpal tunnel puncture</div><div class=\"cntnt\"><img style=\"width:591px; height:507px;\" src=\"images/RHEUM/67723_US_carpal_tun_pun_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A, B) Patient and paperclip positioning for puncture of carpal tunnel.<br> (C) Transverse US scan showing the reverberation of the paperclip and the median nerve right between the two echoes of the paperclip.</div><div class=\"graphic_reference\">Reproduced with permission from: George AW Bruyn, MD, PhD.</div><div id=\"graphicVersion\">Graphic 67723 Version 2.0</div></div></div>"},"67724":{"type":"graphic_picture","displayName":"Balanoposthitis 2","title":"Balanoposthitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Balanoposthitis</div><div class=\"cntnt\"><img style=\"width:288px; height:213px;\" src=\"images/EM/67724_Balanoposthitis2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This uncircumcised boy developed a moderately severe case of balanoposthitis.</div><div class=\"graphic_reference\">Reproduced with permission from: Genitourinary Emergencies. In: Atlas of Pediatric Emergency Medicine. Fleisher GR, Ludwig S, Baskin MN (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright © 2004 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 67724 Version 11.0</div></div></div>"},"67725":{"type":"graphic_diagnosticimage","displayName":"Buckle fracture radius","title":"Dorsal buckle fracture of distal radius in 5-year-old child","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dorsal buckle fracture of distal radius in 5-year-old child</div><div class=\"cntnt\"><img style=\"width:421px; height:525px;\" src=\"images/EM/67725_Buckle_fx_radius.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this radiograph, buckling of the bony cortex is evident on lateral view (white arrow). This patient had bony tenderness over the fracture site but a relatively intact range of motion.</div><div class=\"graphic_reference\">Courtesy of Paula Schweich, MD.</div><div id=\"graphicVersion\">Graphic 67725 Version 4.0</div></div></div>"},"67726":{"type":"graphic_figure","displayName":"Ogden and Salter-Harris","title":"Comparison of Ogden and Salter-Harris classifications of physeal fractures","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Comparison of Ogden and Salter-Harris classifications of physeal fractures</div><div class=\"cntnt\"><img style=\"width:515px; height:678px;\" src=\"images/EM/67726_Ogden_and_Salter-Harris.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Salter-Harris types I through V are equivalent to Ogden IA through IVA and Ogden V. Refer to UpToDate topics on fracture patterns and description in children for detailed description of the Ogden classification system.</div><div id=\"graphicVersion\">Graphic 67726 Version 3.0</div></div></div>"},"67729":{"type":"graphic_figure","displayName":"Confounding","title":"Confounding","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Confounding</div><div class=\"cntnt\"><img style=\"width:506px; height:329px;\" src=\"images/PC/67729_Confounding.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><span style=\"font-family:times new roman,serif;font-size:12pt\">Confounding occurs when a confounder is associated with the exposure and is a predictor of the outcome. </span></div><div id=\"graphicVersion\">Graphic 67729 Version 4.0</div></div></div>"},"67730":{"type":"graphic_table","displayName":"Techniques of termination phase of Interpersonal Psychotherapy","title":"Techniques of the termination phase of Interpersonal Psychotherapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Techniques of the termination phase of Interpersonal Psychotherapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Technique</td> <td class=\"subtitle1\">Strategy</td> <td class=\"subtitle1\">Comment</td> </tr> <tr> <td>Assess treatment progress and reinforce treatment gains</td> <td>Review serial scores on standardized, self-report depression rating instrument and gains made in interpersonal problem area over the course of therapy.</td> <td>Highlight treatment gains, which are usually considerable, and acknowledge residual symptoms.</td> </tr> <tr> <td>Discuss remaining treatment needs and options</td> <td>Evaluate need for ongoing psychotherapy, augmentation with other treatment modalities such as pharmacotherapy, or change of treatment strategies.</td> <td>Consider ongoing, monthly, maintenance IPT to consolidate and preserve treatment gains.</td> </tr> <tr> <td>Anticipate future vulnerability to recurrence of depression</td> <td>Revisit the link between one's current life events and depression, to help the patient identify periods of risk and strategies to prevent recurrence of symptoms.</td> <td>Establish a plan for seeking treatment in the future if depression recurs, ie, recontact the clinician or contact the primary care physician.</td> </tr> <tr> <td>Discuss feelings associated with termination</td> <td>Normalize feelings of sadness and loss arising at the end of psychotherapy, and differentiate these feelings from symptoms of depression.</td> <td>Probe for feelings associated with termination even if patient does not spontaneously volunteer them.</td> </tr> <tr> <td>Blame the therapy&mdash;and not the patient&mdash;for incomplete remission</td> <td>If therapy has failed to bring about complete resolution of the depressive episode, blame the therapy and not the patient.</td> <td>The clinician should remain optimistic, and encourage the patient to continue treatment of the depressive episode. The availability of numerous pharmacotherapy and psychotherapy options should be emphasized.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 67730 Version 1.0</div></div></div>"},"67731":{"type":"graphic_picture","displayName":"Peripheral IV placement 8","title":"Peripheral IV placement: Completion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peripheral IV placement: Completion</div><div class=\"cntnt\"><img style=\"width:432px; height:288px;\" src=\"images/EM/67731_Peripheral_IV_placement_8.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photograph above shows a peripheral IV catheter in place and secured with tape.</div><div class=\"graphic_reference\">Courtesy of Robert Frank, MD.</div><div id=\"graphicVersion\">Graphic 67731 Version 2.0</div></div></div>"},"67732":{"type":"graphic_table","displayName":"EB-specific monoclonal antibodies","title":"EB-specific monoclonal antibodies and corresponding proteins","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">EB-specific monoclonal antibodies and corresponding proteins</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Antibody*</td> <td class=\"subtitle1\">Target protein (antigen)</td> </tr> <tr> <td>mAb D5/16B4</td> <td>Keratin 5</td> </tr> <tr> <td>mAb LL002</td> <td>Keratin 14</td> </tr> <tr> <td>mAb HD121</td> <td>Plectin</td> </tr> <tr> <td>mAb 123</td> <td>Collagen 17 (BP180)</td> </tr> <tr> <td>mAb GoH3</td> <td>Alpha-6-integrin</td> </tr> <tr> <td>mAb 3E1</td> <td>Beta-4 integrin</td> </tr> <tr> <td>mAb K140</td> <td>Laminin-332 beta 3 chain</td> </tr> <tr> <td>mAb GB3</td> <td>Laminin-332 gamma 2 chain</td> </tr> <tr> <td>mAb BM165</td> <td>Laminin-332 alpha 3 chain</td> </tr> <tr> <td>mAb AE2</td> <td>Type IV collagen</td> </tr> <tr> <td>mAb LH 7-2</td> <td>Type VII collagen</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Monoclonal antibodies can be obtained from several sources and may have different names.</div><div id=\"graphicVersion\">Graphic 67732 Version 2.0</div></div></div>"},"67733":{"type":"graphic_picture","displayName":"Fixed drug eruption with bulla","title":"Fixed drug eruption","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Fixed drug eruption</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/67733_Fixeddrugeruptwbulla.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple violaceous, round&nbsp;plaques are present on the skin. A central bulla is present in one lesion.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 67733 Version 2.0</div></div></div>"},"67734":{"type":"graphic_movie","displayName":"Coyne spoon assisted delivery","title":"Coyne spoon assisted delivery","html":"<div class=\"graphic normal\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Coyne spoon assisted delivery</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/OBGYN/67734_Coynespoonassistdelivery.mp4\" style=\"width:480px;height:288px\"></div><img style=\"width:504px; height:378px;\" src=\"images/OBGYN/67734_Coynespoonassistdelivery.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 67734 Version 1.0</div></div></div>"},"67737":{"type":"graphic_figure","displayName":"Efer Dumon rigid bronchoscope","title":"Efer-Dumon bronchoscopes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Efer-Dumon bronchoscopes</div><div class=\"cntnt\"><img style=\"width:358px; height:148px;\" src=\"images/PULM/67737_Efer_Dumon_rigid_bronchosco.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">12 mm Efer-Dumon bronchoscope (rigid tubes only) for use in bronchi (long tube) or trachea (short tube).</div><div class=\"graphic_reference\">Courtesy of Henri G Colt, MD.</div><div id=\"graphicVersion\">Graphic 67737 Version 1.0</div></div></div>"},"67739":{"type":"graphic_diagnosticimage","displayName":"Malignant thymoma pleural CT","title":"Pleural metastases due to malignant thymoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pleural metastases due to malignant thymoma</div><div class=\"cntnt\"><img style=\"width:360px; height:237px;\" src=\"images/PULM/67739_Malignant_thymoma_pleural_C.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Drop metastases are seen in the left hemithorax, producing three parietal nodules posteromedially (arrows).</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 67739 Version 3.0</div></div></div>"},"67740":{"type":"graphic_picture","displayName":"Nodular episcleritis","title":"Nodular episcleritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nodular episcleritis</div><div class=\"cntnt\"><img style=\"width:350px; height:216px;\" src=\"images/RHEUM/67740_Nodular_episcleritis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nodular episcleritis in a patient with Crohn disease. There is an episcleral nodule with surrounding episcleral vascular engorgement, but normal underlying sclera.</div><div class=\"graphic_reference\">Courtesy of Reza Dana, MD, MSc, MPH.</div><div id=\"graphicVersion\">Graphic 67740 Version 3.0</div></div></div>"},"67741":{"type":"graphic_figure","displayName":"Edinburgh depression scale 1","title":"Appendix A: Edinburgh Postnatal Depression Scale","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Appendix A: Edinburgh Postnatal Depression Scale</div><div class=\"cntnt\"><img style=\"width:445px; height:499px;\" src=\"images/OBGYN/67741_Edinburghdepressionscale.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cox JL, Holden JM, Sagovsky R. Department of Psychiatry, University of Edinburgh.</div><div id=\"graphicVersion\">Graphic 67741 Version 2.0</div></div></div>"},"67744":{"type":"graphic_algorithm","displayName":"Evaluation for hibernation","title":"Sequence of investigation in patients with LV dysfunction and suspected viable myocardium","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sequence of investigation in patients with LV dysfunction and suspected viable myocardium</div><div class=\"cntnt\"><img style=\"width:445px; height:524px;\" src=\"images/CARD/67744_Evaluationforhibernation.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CABG: coronary artery bypass grafting; PET: positron emission tomography; SPECT: single-photon emission computed tomography.</div><div class=\"graphic_reference\">Adapted from: Marwick TH. Lancet 1998; 351:815.</div><div id=\"graphicVersion\">Graphic 67744 Version 3.0</div></div></div>"},"67745":{"type":"graphic_table","displayName":"Laboratory evaluation for inborn errors of metabolism","title":"Laboratory evaluation for suspected inborn errors of metabolism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laboratory evaluation for suspected inborn errors of metabolism</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Initial evaluation*</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Blood tests</td> </tr> <tr> <td class=\"indent2\">CBC with differential</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">Blood glucose</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">Electrolytes, BUN, creatinine, uric acid</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">Arterial blood gas</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">Plasma&nbsp;ammonia</td> <td>Should be obtained from artery or vein without a tourniquet. The tube should be placed on ice for transport to the laboratory and analyzed immediately. If the plasma ammonia concentration is &#62;100 micromol/L (1.7 mcg/mL), the measurement should be repeated immediately.</td> </tr> <tr> <td class=\"indent2\">AST, ALT, bilirubin, PT</td> <td>If the patient has signs of liver disease.</td> </tr> <tr> <td class=\"indent2\">LDH, aldolase, creatine, kinase</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Urine tests</td> </tr> <tr> <td class=\"indent2\">Color, odor</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">Urinalysis</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">Reducing substances</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">Myoglobin</td> <td>If the patient has signs or symptoms of myopathy.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Specialized tests</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Blood tests</td> </tr> <tr> <td class=\"indent2\">Quantitative plasma amino acids</td> <td>Plasma amino acid analysis must be performed quantitatively rather than qualitatively.</td> </tr> <tr> <td class=\"indent2\">Lactate and pyruvate</td> <td>Lactate and pyruvate should be measured in arterial blood and transported on ice.</td> </tr> <tr> <td class=\"indent2\">Acylcarnitine profile</td> <td>Analysis of acylcarnitine conjugates is performed by tandem mass spectrometry and can be measured in a plasma sample or a filter-paper bloodspot. Serum is preferred because of inherent problems in quantitating compounds from a filter-paper blood spot</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Urine tests</td> </tr> <tr> <td class=\"indent2\">Qualitative urine organic acids</td> <td>Minimum of 2 to 5 mL in sterile container without preservative.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CBC: complete blood count; BUN: blood urea nitrogen; AST: aspartate aminotransferase; ALT: alanine aminotransferase; PT: prothrombin time; LDH: lactate dehydrogenase.<br />* If possible, blood and urine samples should be obtained for both the initial and specialized tests at the time of presentation. Samples for specialized tests should be processed and stored appropriately for further testing if indicated.<br /></div><div id=\"graphicVersion\">Graphic 67745 Version 8.0</div></div></div>"},"67746":{"type":"graphic_figure","displayName":"Radiation survey documentation A","title":"Radiation Incident Patient Tag","html":"<div class=\"graphic\"><div style=\"width: 592px\" class=\"figure\"><div class=\"ttl\">Radiation Incident Patient Tag</div><div class=\"cntnt\"><img style=\"width:572px; height:672px;\" src=\"images/PEDS/67746_Radiation_survey_A.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 67746 Version 2.0</div></div></div>"},"67747":{"type":"graphic_picture","displayName":"Gomco bell applied to glans","title":"The Gomco bell is applied to the glans","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The Gomco bell is applied to the glans</div><div class=\"cntnt\"><img style=\"width:432px; height:281px;\" src=\"images/OBGYN/67747_Gomco_bell_applied_to_glans.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of David G Weismiller, MD.</div><div id=\"graphicVersion\">Graphic 67747 Version 1.0</div></div></div>"},"67748":{"type":"graphic_diagnosticimage","displayName":"Posterior needle bx bone tumor","title":"Posterior bone biopsy approach","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Posterior bone biopsy approach</div><div class=\"cntnt\"><img style=\"width:320px; height:320px;\" src=\"images/ONC/67748_Posterior_needle_bx_bone_tu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The CT-guided needle biopsy of this osteosarcoma was performed using a posterior approach. Although targeting the lytic soft tissue component for sampling was appropriate, the posterior needle track would have been difficult to excise with the specimen, and could theoretically have compromised the surgery. In this case, however, amputation was performed.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Daniel Rosenthal, MD.</div><div id=\"graphicVersion\">Graphic 67748 Version 3.0</div></div></div>"},"67750":{"type":"graphic_figure","displayName":"Tympanogram classification","title":"Liden-Jerger classification of tympanometric shapes","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Liden-Jerger classification of tympanometric shapes</div><div class=\"cntnt\"><img style=\"width:538px; height:490px;\" src=\"images/PEDS/67750_Tympanogram_classification.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Type A tympanograms are indicative of normal middle ear pressure. Type A<SUB>D</SUB> (deep) tympanograms demonstrate increased compliance, as seen with ossicular chain discontinuity. Type A<SUB>S</SUB> (shallow) tympanograms show decreased compliance, suggesting&nbsp;a stiff middle ear system, which can be caused by myringosclerosis or otosclerosis. Type B tympanograms with little or no mobility of the tympanic membrane are suggestive of middle ear effusion. Type C tympanograms indicate negative middle-ear pressure and a retracted tympanic membrane.</div><div class=\"graphic_reference\">Data from Feldman AS. Tympanometry: Procedures, interpretation, and variables. In: Feldman AS, Wilber LA (Eds), Acoustic Impedance and Admittance: The Measurement of Middle Ear Function, Williams &amp; Wilkins, Baltimore 1976, p.103.</div><div id=\"graphicVersion\">Graphic 67750 Version 5.0</div></div></div>"},"67751":{"type":"graphic_figure","displayName":"Effect on exercise capacity","title":"Effect of pulmonary rehabilitation on exercise capacity","html":"<div class=\"graphic\"><div style=\"width: 682px\" class=\"figure\"><div class=\"ttl\">Effect of pulmonary rehabilitation on exercise capacity</div><div class=\"cntnt\"><img style=\"width:662px; height:496px;\" src=\"images/PULM/67751_Effect_on_exercise_capacity.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Effect of respiratory rehabilitation on functional exercise capacity.</div><div class=\"graphic_footnotes\">CRQ: Chronic Respiratory Questionnaire.</div><div class=\"graphic_reference\">Data from: McCarthy B, Casey D, Devane D, et al. Pulmonary rehabilitation for chronic obstructive pulmonary disease. The Cochrane Library 2015, 2; 144. Copyright &copy; 2015 The Cochrane Collaboration.</div><div id=\"graphicVersion\">Graphic 67751 Version 3.0</div></div></div>"},"67753":{"type":"graphic_picture","displayName":"Charcot foot","title":"Charcot arthropathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Charcot arthropathy</div><div class=\"cntnt\"><img style=\"width:378px; height:244px;\" src=\"images/ENDO/67753_Charcot_foot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diabetic patient with Charcot arthropathy characterized by collapse of the arch of the midfoot, which is replaced by a bony prominence (arrow). Several factors contribute to this painless condition, including small muscle wasting, decreased sensation, and maldistribution of weightbearing.</div><div class=\"graphic_reference\">Courtesy of David McCulloch, MD.</div><div id=\"graphicVersion\">Graphic 67753 Version 2.0</div></div></div>"},"67755":{"type":"graphic_picture","displayName":"Non Hodgkins lymphoma Endosc","title":"Non-Hodgkin's lymphoma of the colon","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Non-Hodgkin's lymphoma of the colon</div><div class=\"cntnt\"><img style=\"width:222px; height:221px;\" src=\"images/GAST/67755_Non_Hodgkins_lymphoma_Endos.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Colonoscopic view of a friable, indurated mucosa with scattered areas of ulceration suggestive of inflammatory bowel disease. Histology was consistent with a non-Hodgkin's lymphoma.</div><div id=\"graphicVersion\">Graphic 67755 Version 1.0</div></div></div>"},"67756":{"type":"graphic_figure","displayName":"PCI related delay and mortality","title":"Absolute risk reduction in 4- to 6-week mortality rates with primary PCI as function of PCI-related time delay","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Absolute risk reduction in 4- to 6-week mortality rates with primary PCI as function of PCI-related time delay</div><div class=\"cntnt\"><img style=\"width:536px; height:340px;\" src=\"images/CARD/67756_PCI_related_delay_and_morta.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Circles reflect the sample size of the individual study. Values &gt;0 represent benefit and values &lt;0 represent harm.</div><div class=\"graphic_reference\">Reproduced with permission from: Nallamothu BK, Bates ER. Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything? Am J Cardiol 2003; 92:824. Copyright &#169; 2003 Excerpta Media.</div><div id=\"graphicVersion\">Graphic 67756 Version 3.0</div></div></div>"},"67757":{"type":"graphic_picture","displayName":"Calcinosis systemic sclerosis","title":"Calcinosis in scleroderma","html":"<div class=\"graphic\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\">Calcinosis in scleroderma</div><div class=\"cntnt\"><img style=\"width:462px; height:247px;\" src=\"images/RHEUM/67757_Calcinosis_systemic_scleros.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Calcinosis on the fingertip of a patient with limited cutaneous systemic sclerosis.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD, FRCP.</div><div id=\"graphicVersion\">Graphic 67757 Version 1.0</div></div></div>"},"67758":{"type":"graphic_table","displayName":"Normal echocardiography values for prosthetic mitral valves","title":"Normal echocardiography values for prosthetic mitral valves","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Normal echocardiography values for prosthetic mitral valves</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Valve</td> <td class=\"subtitle1\">Size</td> <td class=\"subtitle1\">Peak gradient (mmHg)</td> <td class=\"subtitle1\">Mean gradient (mmHg)</td> <td class=\"subtitle1\">Peak velocity (m/s)</td> <td class=\"subtitle1\">Pressure half-time (ms)</td> <td class=\"subtitle1\">Effective orifice area (cm<sup>2</sup>)</td> </tr> <tr> <td rowspan=\"4\"><strong>Biocor</strong><br /> Stentless bioprosthesis<br /> </td> <td>27</td> <td>13 &#177; 1</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>29</td> <td>14 &#177; 2.5</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>31</td> <td>11.5 &#177; 0.5</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>33</td> <td>12 &#177; 0.5</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\"><strong>Bioflo pericardial</strong><br /> Stented bioprosthesis<br /> </td> <td>25</td> <td>10 &#177; 2</td> <td>6.3 &#177; 1.5</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>2 &#177; 0.1</td> </tr> <tr> <td>27</td> <td>9.5 &#177; 2.6</td> <td>5.4 &#177; 1.2</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>2 &#177; 0.3</td> </tr> <tr> <td>29</td> <td>5 &#177; 2.8</td> <td>3.6 &#177; 1</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>2.4 &#177; 0.2</td> </tr> <tr> <td>31</td> <td>4.0</td> <td>2.0</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>2.3</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\"><strong>Bjork-Shiley</strong><br /> Tilting disc<br /> </td> <td>23</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>1.7</td> <td>115</td> <td>&nbsp;</td> </tr> <tr> <td>25</td> <td>12 &#177; 4</td> <td>6 &#177; 2</td> <td>1.75 &#177; 0.38</td> <td>99 &#177; 27</td> <td>1.72 &#177; 0.6</td> </tr> <tr> <td>27</td> <td>10 &#177; 4</td> <td>5 &#177; 2</td> <td>1.6 &#177; 0.49</td> <td>89 &#177; 28</td> <td>1.81 &#177; 0.54</td> </tr> <tr> <td>29</td> <td>7.83 &#177; 2.93</td> <td>2.83 &#177; 1.27</td> <td>1.37 &#177; 0.25</td> <td>79 &#177; 17</td> <td>2.1 &#177; 0.43</td> </tr> <tr> <td>31</td> <td>6 &#177; 3</td> <td>2 &#177; 1.9</td> <td>1.41 &#177; 0.26</td> <td>70 &#177; 14</td> <td>2.2 &#177; 0.3</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\"><strong>Bjork-Shiley monostrut</strong><br /> Tilting disc</td> <td>23</td> <td>&nbsp;</td> <td>5.0</td> <td>1.9</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>25</td> <td>13 &#177; 2.5</td> <td>5.57 &#177; 2.3</td> <td>1.8 &#177; 0.3</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>27</td> <td>12 &#177; 2.5</td> <td>4.53 &#177; 2.2</td> <td>1.7 &#177; 0.4</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>29</td> <td>13 &#177; 3</td> <td>4.26 &#177; 1.6</td> <td>1.6 &#177; 0.3</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>31</td> <td>14 &#177; 4.5</td> <td>4.9 &#177; 1.6</td> <td>1.7 &#177; 0.3</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\"><strong>Carbomedics</strong><br /> Bileaflet</td> <td>23</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>1.9 &#177; 0.1</td> <td>126 &#177; 7</td> <td>&nbsp;</td> </tr> <tr> <td>25</td> <td>10.3 &#177; 2.3</td> <td>3.6 &#177; 0.6</td> <td>1.3 &#177; 0.1</td> <td>93 &#177; 8</td> <td>2.9 &#177; 0.8</td> </tr> <tr> <td>27</td> <td>8.79 &#177; 3.46</td> <td>3.46 &#177; 1.03</td> <td>1.61 &#177; 0.3</td> <td>89 &#177; 20</td> <td>2.9 &#177; 0.75</td> </tr> <tr> <td>29</td> <td>8.78 &#177; 2.9</td> <td>3.39 &#177; 0.97</td> <td>1.52 &#177; 0.3</td> <td>88 &#177; 17</td> <td>2.3 &#177; 0.4</td> </tr> <tr> <td>31</td> <td>8.87 &#177; 2.34</td> <td>3.32 &#177; 0.87</td> <td>1.61 &#177; 0.29</td> <td>92 &#177; 24</td> <td>2.8 &#177; 1.14</td> </tr> <tr> <td>33</td> <td>8.8 &#177; 2.2</td> <td>4.8 &#177; 2.5</td> <td>1.5 &#177; 0.2</td> <td>93 &#177; 12</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\"><strong>Carpentier-Edwards</strong><br /> Stented bioprosthesis</td> <td>27</td> <td>&nbsp;</td> <td>6 &#177; 2</td> <td>1.7 &#177; 0.3</td> <td>98 &#177; 28</td> <td>&nbsp;</td> </tr> <tr> <td>29</td> <td>&nbsp;</td> <td>4.7 &#177; 2</td> <td>1.76 &#177; 0.27</td> <td>92 &#177; 14</td> <td>&nbsp;</td> </tr> <tr> <td>31</td> <td>&nbsp;</td> <td>4.4 &#177; 2</td> <td>1.54 &#177; 0.15</td> <td>92 &#177; 19</td> <td>&nbsp;</td> </tr> <tr> <td>33</td> <td>&nbsp;</td> <td>6 &#177; 3</td> <td>&nbsp;</td> <td>93 &#177; 12</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\"><strong>Carpentier-Edwards pericardial</strong><br /> Stented bioprosthesis</td> <td>27</td> <td>&nbsp;</td> <td>3.6</td> <td>1.6</td> <td>100</td> <td>&nbsp;</td> </tr> <tr> <td>29</td> <td>&nbsp;</td> <td>5.25 &#177; 2.36</td> <td>1.67 &#177; 0.3</td> <td>110 &#177; 15</td> <td>&nbsp;</td> </tr> <tr> <td>31</td> <td>&nbsp;</td> <td>4.05 &#177; 0.83</td> <td>1.53 &#177; 0.1</td> <td>90 &#177; 11</td> <td>&nbsp;</td> </tr> <tr> <td>33</td> <td>&nbsp;</td> <td>1.0</td> <td>0.8</td> <td>80</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\"><strong>Duromedics</strong><br /> Bileaflet</td> <td>27</td> <td>13 &#177; 6</td> <td>5 &#177; 3</td> <td>1.61 &#177; 0.4</td> <td>75 &#177; 12</td> <td>&nbsp;</td> </tr> <tr> <td>29</td> <td>10 &#177; 4</td> <td>3 &#177; 1</td> <td>1.40 &#177; 0.25</td> <td>85 &#177; 22</td> <td>&nbsp;</td> </tr> <tr> <td>31</td> <td>10.5 &#177; 4.33</td> <td>3.3 &#177; 1.36</td> <td>1.38 &#177; 0.27</td> <td>81 &#177; 12</td> <td>&nbsp;</td> </tr> <tr> <td>33</td> <td>11.2</td> <td>2.5</td> <td>&nbsp;</td> <td>85</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\"><strong>Hancock I</strong> or not specified<br /> Stented bioprosthesis</td> <td>27</td> <td>10 &#177; 4</td> <td>5 &#177; 2</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>1.3 &#177; 0.8</td> </tr> <tr> <td>29</td> <td>7 &#177; 3</td> <td>2.46 &#177; 0.79</td> <td>&nbsp;</td> <td>115 &#177; 20</td> <td>1.5 &#177; 0.2</td> </tr> <tr> <td>31</td> <td>4 &#177; 0.86</td> <td>4.86 &#177; 1.69</td> <td>&nbsp;</td> <td>95 &#177; 17</td> <td>1.6 &#177; 0.2</td> </tr> <tr> <td>33</td> <td>3 &#177; 2</td> <td>3.87 &#177; 2</td> <td>&nbsp;</td> <td>90 &#177; 12</td> <td>1.9 &#177; 0.2</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\"><strong>Hancock II</strong><br /> Stented bioprosthesis</td> <td>27</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>2.21 &#177; 0.14</td> </tr> <tr> <td>29</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>2.77 &#177; 0.11</td> </tr> <tr> <td>31</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>2.84 &#177; 0.1</td> </tr> <tr> <td>33</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>3.15 &#177; 0.22</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\"><strong>Hancock pericardial</strong><br /> Stented bioprosthesis</td> <td>29</td> <td>&nbsp;</td> <td>2.61 &#177; 1.39</td> <td>1.42 &#177; 0.14</td> <td>105 &#177; 36</td> <td>&nbsp;</td> </tr> <tr> <td>31</td> <td>&nbsp;</td> <td>3.57 &#177; 1.02</td> <td>1.51 &#177; 0.27</td> <td>81 &#177; 23</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\"><strong>Ionescu-Shiley</strong><br /> Stented bioprosthesis</td> <td>25</td> <td>&nbsp;</td> <td>4.87 &#177; 1.08</td> <td>1.43 &#177; 0.15</td> <td>93 &#177; 11</td> <td>&nbsp;</td> </tr> <tr> <td>27</td> <td>&nbsp;</td> <td>3.21 &#177; 0.82</td> <td>1.31 &#177; 0.24</td> <td>100 &#177; 28</td> <td>&nbsp;</td> </tr> <tr> <td>29</td> <td>&nbsp;</td> <td>3.22 &#177; 0.57</td> <td>1.38 &#177; 0.2</td> <td>85 &#177; 8</td> <td>&nbsp;</td> </tr> <tr> <td>31</td> <td>&nbsp;</td> <td>3.63 &#177; 0.9</td> <td>1.45 &#177; 0.06</td> <td>100 &#177; 36</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\"><strong>Ionescu-Shiley low profile</strong><br /> Stented bioprosthesis</td> <td>29</td> <td>&nbsp;</td> <td>3.31 &#177; 0.96</td> <td>1.36 &#177; 0.25</td> <td>80 &#177; 30</td> <td>&nbsp;</td> </tr> <tr> <td>31</td> <td>&nbsp;</td> <td>2.74 &#177; 0.37</td> <td>1.33 &#177; 0.14</td> <td>79 &#177; 15</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\"><strong>Labcor-Santiago pericardial</strong><br /> Stented bioprosthesis</td> <td>25</td> <td>8.7</td> <td>4.5</td> <td>&nbsp;</td> <td>97</td> <td>2.2</td> </tr> <tr> <td>27</td> <td>5.6 &#177; 2.3</td> <td>2.8 &#177; 1.5</td> <td>&nbsp;</td> <td>85 &#177; 18</td> <td>2.12 &#177; 0.48</td> </tr> <tr> <td>29</td> <td>6.2 &#177; 2.1</td> <td>3 &#177; 1.3</td> <td>&nbsp;</td> <td>80 &#177; 34</td> <td>2.11 &#177; 0.73</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\"><strong>Lillehei-Kaster</strong><br /> Tilting disc</td> <td>18</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>1.7</td> <td>140</td> <td>&nbsp;</td> </tr> <tr> <td>20</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>1.7</td> <td>67</td> <td>&nbsp;</td> </tr> <tr> <td>22</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>1.56 &#177; 0.09</td> <td>94 &#177; 22</td> <td>&nbsp;</td> </tr> <tr> <td>25</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>1.38 &#177; 0.27</td> <td>124 &#177; 46</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\"><strong>Medtronic-Hall</strong><br /> Tilting disc</td> <td>27</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>1.4</td> <td>78</td> <td>&nbsp;</td> </tr> <tr> <td>29</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>1.57 &#177; 0.1</td> <td>69 &#177; 15</td> <td>&nbsp;</td> </tr> <tr> <td>31</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>1.45 &#177; 0.12</td> <td>77 &#177; 17</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\"><strong>Medtronic intact porcine</strong><br /> Stented bioprosthesis</td> <td>29</td> <td>&nbsp;</td> <td>3.5 &#177; 0.51</td> <td>1.6 &#177; 0.22</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>31</td> <td>&nbsp;</td> <td>4.2 &#177; 1.44</td> <td>1.6 &#177; 0.26</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>33</td> <td>&nbsp;</td> <td>4 &#177; 1.3</td> <td>1.4 &#177; 0.24</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>35</td> <td>&nbsp;</td> <td>3.2 &#177; 1.77</td> <td>1.3 &#177; 0.5</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\"><strong>Mitroflow</strong><br /> Stented bioprosthesis</td> <td>25</td> <td>&nbsp;</td> <td>6.9</td> <td>2.0</td> <td>90</td> <td>&nbsp;</td> </tr> <tr> <td>27</td> <td>&nbsp;</td> <td>3.07 &#177; 0.91</td> <td>1.5</td> <td>90 &#177; 20</td> <td>&nbsp;</td> </tr> <tr> <td>29</td> <td>&nbsp;</td> <td>3.5 &#177; 1.65</td> <td>1.43 &#177; 0.29</td> <td>102 &#177; 21</td> <td>&nbsp;</td> </tr> <tr> <td>31</td> <td>&nbsp;</td> <td>3.85 &#177; 0.81</td> <td>1.32 &#177; 0.26</td> <td>91 &#177; 22</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\"><strong>Omnicarbon</strong><br /> Tilting disc</td> <td>23</td> <td>&nbsp;</td> <td>8.0</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>25</td> <td>&nbsp;</td> <td>6.05 &#177; 1.81</td> <td>1.77 &#177; 0.24</td> <td>102 &#177; 16</td> <td>&nbsp;</td> </tr> <tr> <td>27</td> <td>&nbsp;</td> <td>4.89 &#177; 2.05</td> <td>1.63 &#177; 0.36</td> <td>105 &#177; 33</td> <td>&nbsp;</td> </tr> <tr> <td>29</td> <td>&nbsp;</td> <td>4.93 &#177; 2.16</td> <td>1.56 &#177; 0.27</td> <td>120 &#177; 40</td> <td>&nbsp;</td> </tr> <tr> <td>31</td> <td>&nbsp;</td> <td>4.18 &#177; 1.4</td> <td>1.3 &#177; 0.23</td> <td>134 &#177; 31</td> <td>&nbsp;</td> </tr> <tr> <td>33</td> <td>&nbsp;</td> <td>4 &#177;2</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\"><strong>On-X</strong><br /> Bileaflet</td> <td>25</td> <td>11.5 &#177; 3.2</td> <td>5.3 &#177; 2.1</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>1.9 &#177; 1.1</td> </tr> <tr> <td>27-29</td> <td>10.3 &#177; 4.5</td> <td>4.5 &#177; 1.6</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>2.2 &#177; 0.5</td> </tr> <tr> <td>31-33</td> <td>9.8 &#177; 3.8</td> <td>4.8 &#177; 2.4</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>2.5 &#177; 1.1</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\"><strong>Sorin Allcarbon</strong><br /> Tilting disc<br /> </td> <td>25</td> <td>15 &#177; 3</td> <td>5 &#177; 1</td> <td>2 &#177; 0.2</td> <td>105 &#177; 29</td> <td>2.2 &#177; 0.6</td> </tr> <tr> <td>27</td> <td>13 &#177; 2</td> <td>4 &#177;1</td> <td>1.8 &#177; 0.1</td> <td>89 &#177; 14</td> <td>2.5 &#177; 0.5</td> </tr> <tr> <td>29</td> <td>10 &#177; 2</td> <td>4 &#177;1</td> <td>1.6 &#177; 0.2</td> <td>85 &#177; 23</td> <td>2.8 &#177; 0.7</td> </tr> <tr> <td>31</td> <td>9 &#177; 1</td> <td>4 &#177;1</td> <td>1.6 &#177; 0.1</td> <td>88 &#177; 27</td> <td>2.8 &#177; 0.9</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\"><strong>Sorin Bicarbon</strong><br /> Bileaflet</td> <td>25</td> <td>15 &#177; 0.25</td> <td>4 &#177; 0.5</td> <td>1.95 &#177; 0.02</td> <td>70 &#177; 1</td> <td>&nbsp;</td> </tr> <tr> <td>27</td> <td>11 &#177; 2.75</td> <td>4 &#177; 0.5</td> <td>1.65 &#177; 0.21</td> <td>82 &#177; 20</td> <td>&nbsp;</td> </tr> <tr> <td>29</td> <td>12 &#177; 3</td> <td>4 &#177; 1.25</td> <td>1.73 &#177; 0.22</td> <td>80 &#177; 14</td> <td>&nbsp;</td> </tr> <tr> <td>31</td> <td>10 &#177; 1.5</td> <td>4 &#177; 1</td> <td>1.66 &#177; 0.11</td> <td>83 &#177; 14</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\"><strong>St. Jude Medical</strong><br /> Bileaflet</td> <td>23</td> <td>&nbsp;</td> <td>4.0</td> <td>1.5</td> <td>160</td> <td>1.0</td> </tr> <tr> <td>25</td> <td>&nbsp;</td> <td>2.5 &#177; 1</td> <td>1.34 &#177; 1.12</td> <td>75 &#177; 4</td> <td>1.35 &#177; 0.17</td> </tr> <tr> <td>27</td> <td>11 &#177; 4</td> <td>5 &#177; 1.82</td> <td>1.61 &#177; 0.29</td> <td>75 &#177; 10</td> <td>1.67 &#177; 0.17</td> </tr> <tr> <td>29</td> <td>10 &#177; 3</td> <td>4.15 &#177; 1.8</td> <td>1.57 &#177; 0.29</td> <td>85 &#177; 10</td> <td>1.75 &#177; 0.24</td> </tr> <tr> <td>31</td> <td>12 &#177; 6</td> <td>4.46 &#177; 2.22</td> <td>1.59 &#177; 0.33</td> <td>74 &#177; 13</td> <td>2.03 &#177; 0.32</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\"><strong>Starr-Edwards</strong><br /> Caged ball</td> <td>26</td> <td>&nbsp;</td> <td>10.0</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>1.4</td> </tr> <tr> <td>28</td> <td>&nbsp;</td> <td>7 &#177; 2.75</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>1.9 &#177; 0.57</td> </tr> <tr> <td>30</td> <td>12.2 &#177; 4.6</td> <td>6.99 &#177; 2.5</td> <td>1.7 &#177; 0.3</td> <td>125 &#177; 25</td> <td>1.65 &#177; 0.4</td> </tr> <tr> <td>32</td> <td>11.5 &#177; 4.2</td> <td>5.08 &#177; 2.5</td> <td>1.7 &#177; 0.3</td> <td>110 &#177; 25</td> <td>1.98 &#177; 0.4</td> </tr> <tr> <td>34</td> <td>&nbsp;</td> <td>5.0</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>2.6</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\"><strong>Stentless quadrileaflet bovine pericardial</strong><br /> Stentless bioprosthesis</td> <td>26</td> <td>&nbsp;</td> <td>2.2 &#177; 1.7</td> <td>1.6</td> <td>103 &#177; 31</td> <td>1.7</td> </tr> <tr> <td>28</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>1.58 &#177; 0.25</td> <td>&nbsp;</td> <td>1.7 &#177; 0.6</td> </tr> <tr> <td>30</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>1.42 &#177; 0.32</td> <td>&nbsp;</td> <td>2.3 &#177; 0.4</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\"><strong>Wessex</strong><br /> Stented bioprosthesis</td> <td>29</td> <td>&nbsp;</td> <td>3.69 &#177; 0.61</td> <td>1.66 &#177; 0.17</td> <td>83 &#177; 19</td> <td>&nbsp;</td> </tr> <tr> <td>31</td> <td>&nbsp;</td> <td>3.31 &#177; 0.83</td> <td>1.41 &#177; 0.25</td> <td>80 &#177; 21</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Zoghbi WA, Chambers JB, Bumesnil JG, et al. Recommendations for evaluation of prosthetic valves with echocardiography and doppler ultrasound: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Task Force on Prosthetic Valves, developed in conjunction with the American College of Cardiology Cardiovascular Imaging Committee, Cardiac Imaging Committee of the American Heart Association, the European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography and the Canadian Society of Echocardiography, endorsed by the American College of Cardiology Foundation, American Heart Association, European Association of Echocardiography, a registered branch of the European Society of Cardiology, the Japanese Society of Echocardiography, and Canadian Society of Echocardiography. J Am Soc Echocardiogr 2009; 22:975. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 67758 Version 2.0</div></div></div>"},"67759":{"type":"graphic_picture","displayName":"Subungual hematoma","title":"Subungual hematoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Subungual hematoma</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/67759_Subungual_hematoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blue-black discoloration of the nail plate due to the accumulation of blood beneath the nail plate.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 67759 Version 3.0</div></div></div>"},"67760":{"type":"graphic_table","displayName":"Quick sources of sugar non-diabetes PI","title":"Quick sources of sugar to treat low blood sugar","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Quick sources of sugar to treat low blood sugar</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>3 or 4 glucose tablets</td> </tr> <tr> <td>&#189; cup of juice or regular soda (not sugar-free)</td> </tr> <tr> <td>2 tablespoons of raisins</td> </tr> <tr> <td>4 or 5 saltine crackers</td> </tr> <tr> <td>1 tablespoon of sugar</td> </tr> <tr> <td>1 tablespoon of honey or corn syrup</td> </tr> <tr> <td>6 to 8 hard candies</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These sources of sugar act quickly to treat low blood sugar levels.</div><div id=\"graphicVersion\">Graphic 67760 Version 1.0</div></div></div>"},"67761":{"type":"graphic_picture","displayName":"Variola myocarditis Light","title":"Variola myocarditis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Variola myocarditis</div><div class=\"cntnt\"><img style=\"width:360px; height:236px;\" src=\"images/CARD/67761_Variola_myocarditis_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Autopsy specimen of acute myocarditis associated with variola showing myofiber necrosis and prominent mononuclear infiltrates.</div><div class=\"graphic_reference\">Courtesy of Walter Abelmann, MD.</div><div id=\"graphicVersion\">Graphic 67761 Version 1.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal endomyocardial byopsy</div><div class=\"cntnt\"><img style=\"width:360px; height:232px;\" src=\"images/CARD/80914_Normal_myocardium_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light microscopy from a normal endomyocardial biopsy.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 80914 Version 1.0</div></div></div>"},"67764":{"type":"graphic_figure","displayName":"Auditory canal embryology","title":"Auditory canal embryology","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Auditory canal embryology</div><div class=\"cntnt\"><img style=\"width:416px; height:362px;\" src=\"images/PEDS/67764_Auditory_canal_embryology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The medial-developing external auditory canal becomes filled with the meatal plug, consisting of proliferating ectodermal cells that subsequently recanalize. The tubotympanic recess has deepened to form the tympanic cavity. The otic vesicle forms the endolymphatic duct and sac, early semicircular canals, and cochlear diverticulum. The membranous labyrinth induces surrounding mesenchyme to condense and ultimately form the stapes, incus, and malleus.</div><div id=\"graphicVersion\">Graphic 67764 Version 2.0</div></div></div>"},"67766":{"type":"graphic_diagnosticimage","displayName":"Pulmonary nodules in GPA","title":"Lung nodules in granulomatosis with polyangiitis (Wegener's)","html":"<div class=\"graphic\"><div style=\"width: 667px\" class=\"figure\"><div class=\"ttl\">Lung nodules in granulomatosis with polyangiitis (Wegener's)</div><div class=\"cntnt\"><img style=\"width:647px; height:503px;\" src=\"images/PULM/67766_WegenersgranulomatosisPA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph and CT scans demonstrate bilateral nodules and masses, most&nbsp;extensive at the bases.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 67766 Version 5.0</div></div></div>"},"67767":{"type":"graphic_waveform","displayName":"Permanent junctional tachy","title":"Permanent form of junctional tachycardia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Permanent form of junctional tachycardia</div><div class=\"cntnt\"><img style=\"width:438px; height:228px;\" src=\"images/CARD/67767_Permanentjunctionaltachy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">12-lead ECG and lead II rhythm strip obtained from a patient with junctional tachycardia at a rate of 165 beats/min. The QRS complex is narrow and there are negative P waves with a long RP interval due to slow retrograde conduction via an accessory pathway. The tachycardia tends to terminate spontaneously and recur, as seen in the rhythm strip. Termination is due to retrograde block in the accessory pathway with absence of the retrograde P wave (arrow). An atrial premature beat (*) reinitiates the tachycardia.</div><div id=\"graphicVersion\">Graphic 67767 Version 4.0</div></div></div>"},"67769":{"type":"graphic_table","displayName":"Causes of hypothyroidism","title":"Major causes of hypothyroidism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of hypothyroidism</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Primary hypothyroidism</td> </tr> <tr> <td>Chronic autoimmune thyroiditis</td> </tr> <tr> <td class=\"sublist1_start\">Iatrogenic</td> </tr> <tr> <td class=\"sublist1\">Thyroidectomy</td> </tr> <tr> <td class=\"sublist1\">Radioiodine therapy or external irradiation</td> </tr> <tr> <td>Iodine deficiency or excess</td> </tr> <tr> <td>Drugs - thionamides, lithium, amiodarone, interferon-alfa, interleukin-2,&nbsp;tyrosine kinase inhibitors, checkpoint inhibitor immunotherapy</td> </tr> <tr> <td>Infiltrative diseases - fibrous thyroiditis, hemochromatosis, sarcoidosis</td> </tr> <tr> <td class=\"sublist1_start\">Transient hypothyroidism</td> </tr> <tr> <td class=\"sublist1\">Painless (silent, lymphocytic) thyroiditis </td> </tr> <tr> <td class=\"sublist1\">Subacute granulomatous thyroiditis </td> </tr> <tr> <td class=\"sublist1\">Postpartum thyroiditis </td> </tr> <tr> <td class=\"sublist1\">Subtotal thyroidectomy </td> </tr> <tr> <td class=\"sublist1\">Following radioiodine therapy for Graves' hyperthyroidism</td> </tr> <tr> <td class=\"sublist1\">Following withdrawal of suppressive doses of thyroid hormone in euthyroid patients</td> </tr> <tr> <td>Congenital thyroid agenesis, dysgenesis, or defects in hormone synthesis</td> </tr> <tr> <td class=\"subtitle1_single\">Central hypothyroidism</td> </tr> <tr> <td>TSH deficiency</td> </tr> <tr> <td>TRH deficiency</td> </tr> <tr> <td class=\"subtitle1_single\">Generalized thyroid hormone resistance</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TRH: thyrotropin-releasing hormone; TSH: thyroid-stimulating hormone.</div><div id=\"graphicVersion\">Graphic 67769 Version 4.0</div></div></div>"},"67770":{"type":"graphic_picture","displayName":"Epithelioid giant cell FNA","title":"Epithelioid giant cell: Appearance on fine needle aspirate of the thyroid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Epithelioid giant cell: Appearance on fine needle aspirate of the thyroid</div><div class=\"cntnt\"><img style=\"width:360px; height:237px;\" src=\"images/ENDO/67770_Epithelioid_giant_cell_FNA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fine needle aspirate of a papillary carcinoma of the thyroid showing an epithelioid giant cell.</div><div id=\"graphicVersion\">Graphic 67770 Version 2.0</div></div></div>"},"67772":{"type":"graphic_diagnosticimage","displayName":"Triquetrum fracture lateral radiograph","title":"Triquetrum fracture on plain radiograph lateral view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Triquetrum fracture on plain radiograph lateral view</div><div class=\"cntnt\"><img style=\"width:288px; height:384px;\" src=\"images/EM/67772_Triquetral_fracture_lateral.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this lateral radiograph of the wrist, a fracture of the dorsal surface of the triquetrum is apparent (arrow).</div><div class=\"graphic_reference\">Courtesy of Kevin E Burroughs, MD.</div><div id=\"graphicVersion\">Graphic 67772 Version 6.0</div></div></div>"},"67773":{"type":"graphic_figure","displayName":"Port placement right adrenalectomy","title":"Port placement right adrenalectomy*","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">Port placement right adrenalectomy*</div><div class=\"cntnt\"><img style=\"width:457px; height:587px;\" src=\"images/SURG/67773_Ports_lap_right_adrenalectomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The peritoneal cavity is accessed with a Veress technique through a midclavicular, subcostal site. Three additional 5-mm ports are placed that include a flank port in the midaxillary line between the subcostal margin and the iliac crest, an epigastric port, and a medial subcostal port. One additional port may be needed to retract the liver. Once the adrenal gland is resected, it is captured in a laparoscopic bag that is placed through the 12-mm subcostal port site and removed by extending this incision as needed.</div><div class=\"graphic_footnotes\">* Port placement and technique may vary amongst laparoscopic surgeons.</div><div id=\"graphicVersion\">Graphic 67773 Version 6.0</div></div></div>"},"67775":{"type":"graphic_figure","displayName":"Endotracheal intubation Shikani optical stylet","title":"Endotracheal intubation with the Shikiani optical stylet","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">Endotracheal intubation with the Shikiani optical stylet</div><div class=\"cntnt\"><img style=\"width:470px; height:609px;\" src=\"images/EM/67775_Endotrachintuboptstylet.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The patient's mandible and tongue are retracted anteriorly with the nondominant hand. Using the dominant hand, the operator inserts the scope and endotracheal tube into the center of the patient's mouth and advances them over the tongue.<br> (B) While looking through the eyepiece, the operator advances the stylet and endotracheal tube beneath the epiglottis and into the glottic opening.<br> (C) The endotracheal tube is released from the adjustable stop and passed over the stylet into the proper position.<br> (D) The stylet is carefully removed, with care taken not to dislodge the endotracheal tube.</div><div class=\"graphic_reference\">Reproduced with permission from: King BR, Hagberg CA. Management of the difficult airway. In: Textbook of Pediatric Emergency Procedures, 2nd edition, King C, Henretig FM (Eds). Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 67775 Version 8.0</div></div></div>"},"67776":{"type":"graphic_picture","displayName":"Erythema elevatum diutinum - upper extremities","title":"Erythema elevatum diutinum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythema elevatum diutinum</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/67776_Erythema_elev_diutinum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Violaceous plaques are present on the extremities in this patient with erythema elevatum diutinum.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 67776 Version 3.0</div></div></div>"},"67777":{"type":"graphic_waveform","displayName":"ECG showing changes in VF over time","title":"Continuous electrocardigraphic (ECG) strip during an episode of ventricular fibrillation (VF) that progresses to fine VF and then asystole","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Continuous electrocardigraphic (ECG) strip during an episode of ventricular fibrillation (VF) that progresses to fine VF and then asystole</div><div class=\"cntnt\"><img style=\"width:525px; height:304px;\" src=\"images/CARD/67777_Time_course_VF_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">At the onset of ventricular fibrillation (VF), the QRS complexes are regular, widened, and of tall amplitude, suggesting a more organized ventricular tachyarrhythmia. Over a brief period of time, the rhythm becomes more disorganized with high amplitude fibrillatory waves; this is coarse VF. After a longer period of time, the fibrillatory waves become fine, culminating in asystole.</div><div id=\"graphicVersion\">Graphic 67777 Version 3.0</div></div></div>"},"67778":{"type":"graphic_figure","displayName":"Shirodkar cerclage","title":"Shirodkar cerclage","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Shirodkar cerclage</div><div class=\"cntnt\"><img style=\"width:536px; height:388px;\" src=\"images/OBGYN/67778_Shirodkar_cerclage.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 67778 Version 2.0</div></div></div>"},"67779":{"type":"graphic_picture","displayName":"Anterior polar cataract","title":"Right and left anterior polar cataracts","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Right and left anterior polar cataracts</div><div class=\"cntnt\"><img style=\"width:514px; height:179px;\" src=\"images/PEDS/67779_Anterior_polar_cataract.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anterior polar cataracts. Right eye (A) and left eye (B) of the same patient.</div><div class=\"graphic_reference\">Reproduced with permission from: Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2nd ed. Lippincott Williams &amp; Wilkins, 2001. Copyright &#169; 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 67779 Version 2.0</div></div></div>"},"67780":{"type":"graphic_picture","displayName":"Gianotti-Crosti syndrome extremity","title":"Characteristic eruption of Gianotti-Crosti syndrome (papular acrodermatitis)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Characteristic eruption of Gianotti-Crosti syndrome (papular acrodermatitis)</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/PEDS/67780_Gianotti_Crosti.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The characteristic rash of Gianotti-Crosti syndrome consists of symmetric pink-brown papular or papulovesicular lesions that are flat-topped and range from 1 to 10 mm in diameter. The face, buttocks, extensor aspects of forearms and legs, and feet are predominantly affected.</div><div class=\"graphic_reference\">Courtesy of Moise L Levy, MD.</div><div id=\"graphicVersion\">Graphic 67780 Version 2.0</div></div></div>"},"67781":{"type":"graphic_figure","displayName":"Proximal humeral physis anatomy","title":"The anatomy of the proximal humerus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The anatomy of the proximal humerus</div><div class=\"cntnt\"><img style=\"width:418px; height:380px;\" src=\"images/EM/67781_Proxhumeralphysis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The solid blue line corresponds to the appearance of the physis on radiograph. The dotted line provides the outer limit&nbsp;of the shoulder joint capsule.</div><div class=\"graphic_reference\">Reproduced with permission from: Sarwark JF, King EC, Luhmann SJ. Proximal humerus, scalpula, and clavicle. In: Rockwood and Wilkins' Fractures in Children, 6th edition, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 67781 Version 13.0</div></div></div>"},"67783":{"type":"graphic_table","displayName":"Approach high K RAAS blockers","title":"Approach to patients at risk for hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Approach to patients at risk for hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Estimate glomerular filtration rate to assess specific risk of hyperkalemia</td> </tr> <tr> <td>Discontinue nonsteroidal anti-inflammatory drugs and other drugs that interfere with renal potassium excretion</td> </tr> <tr> <td>Inquire about use of herbal preparations</td> </tr> <tr> <td>Prescribe a low-potassium diet</td> </tr> <tr> <td>Inquire about use of potassium-containing salt substitutes</td> </tr> <tr> <td>Prescribe thiazide or loop diuretics to increase potassium excretion</td> </tr> <tr> <td>Prescribe sodium bicarbonate to correct metabolic acidosis if present</td> </tr> <tr> <td>When initiating ACE inhibitor, angiotensin receptor blocker, or aldosterone receptor blocker therapy, use low doses</td> </tr> <tr> <td>Measure plasma potassium concentration one week after initiating therapy or after increasing dose of these agents</td> </tr> <tr> <td>If plasma potassium increases to &#8804;5.5 mmol/liter, decrease dose of drug and, if combination therapy is being given, discontinue one agent</td> </tr> <tr> <td>In plasma potassium increases to &#62;5.5 mmol/liter despite above measures, discontinue these agents</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACE: angiotensin converting enzyme.</div><div class=\"graphic_reference\">Adapted from: Palmer BF. Managing hyperkalemia caused by inhibitors of the renin- angiotensin-aldosterone system. N Engl J Med 2004; 351:585.</div><div id=\"graphicVersion\">Graphic 67783 Version 4.0</div></div></div>"},"67784":{"type":"graphic_picture","displayName":"Germ tube formation in Candida","title":"Germ tube formation in Candida albicans","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Germ tube formation in Candida albicans</div><div class=\"cntnt\"><img style=\"width:395px; height:252px;\" src=\"images/ID/67784_Germ_tube_formation_in_Cand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rapid presumptive identification of <EM>C. albicans</EM> can be made by observing the formation of germ tubes (the initiation of true hyphal growth) when incubated in proteinaceous liquid (eg, serum) at 36°C for two to three hours. Germ tubes show no constriction at their point of origin from the yeast cell.</div><div class=\"graphic_reference\">Courtesy of Wiley Schell, MS.</div><div id=\"graphicVersion\">Graphic 67784 Version 4.0</div></div></div>"},"67785":{"type":"graphic_figure","displayName":"Benefit carotid endarterectomy","title":"Benefit from carotid endarterectomy is related to sex, age, and degree of stenosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Benefit from carotid endarterectomy is related to sex, age, and degree of stenosis</div><div class=\"cntnt\"><img style=\"width:410px; height:488px;\" src=\"images/NEURO/67785_Benefit_carotid_endarterect.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the European Carotid Surgery trial of 3024 patients, the benefit from carotid endarterectomy varied with sex, age, and degree of carotid stenosis. Men derived more benefit from surgery than women and there was more benefit with increasing severity of stenosis. Younger patients showed definite benefit from surgery over a narrowed range of severe stenosis than did older patients. Curved lines connect points of equal months of major-stroke-free-life expectancy.</div><div class=\"graphic_reference\">Redrawn from European Carotid Sugery Trialists Collaborative Group. Lancet 1998; 351:1379.</div><div id=\"graphicVersion\">Graphic 67785 Version 1.0</div></div></div>"},"67786":{"type":"graphic_table","displayName":"NCI CTCAE v5 acneiform rash","title":"NCI CTCAE v5.0 acneiform rash","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 acneiform rash</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr> <td>Acneiform rash</td> <td>Papules and/or pustules covering &#60;10% of the body surface area, which may or may not be associated with symptoms of pruritus or tenderness</td> <td>Papules and/or pustules covering 10 to 30% of the body surface area, which may or may not be associated with symptoms of pruritus or tenderness; associated with psychosocial impact; limiting instrumental ADL*; papules and/or pustules covering &#62;30% of the body surface area, with or without mild symptoms</td> <td>Papules and/or pustules covering &#62;30% of the body surface area, which may or may with moderate or severe symptoms; limiting self-care ADL*; associated with local superinfection with oral antibiotics indicated</td> <td>Life-threatening consequences; papules and/or pustules covering any percent of the body surface area, which may or may not be associated with symptoms of pruritus or tenderness and are associated with extensive superinfection with intravenous antibiotics indicated</td> <td>Death</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Acneiform rash is characterized by an eruption of papules and pustules, typically appearing in face, scalp, upper chest, and back.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; BSA: body surface area; ADL: activities of daily living.<br />* Instrumental ADLs include preparing meals, shopping, using the telephone, managing money. Self-care ADLs include bathing, dressing/undressing, using the toilet, taking medications, and not bedridden.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <a href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=\"_blank\">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</a> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 67786 Version 13.0</div></div></div>"},"67789":{"type":"graphic_picture","displayName":"Laryngeal inlet","title":"Laryngeal inlet","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Laryngeal inlet</div><div class=\"cntnt\"><img style=\"width:432px; height:352px;\" src=\"images/EM/67789_Laryngeal_inlet.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Joshua Nagler, MD.</div><div id=\"graphicVersion\">Graphic 67789 Version 1.0</div></div></div>"},"67790":{"type":"graphic_picture","displayName":"Herpes esophagitis Light","title":"Herpes simplex esophagitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Herpes simplex esophagitis</div><div class=\"cntnt\"><img style=\"width:447px; height:288px;\" src=\"images/GAST/67790_Herpes_esophagitis_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power view of an esophageal biopsy shows multiple multinucleated cells containing intranuclear clearing and inclusions (arrows).</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD.</div><div id=\"graphicVersion\">Graphic 67790 Version 1.0</div></div></div>"},"67794":{"type":"graphic_table","displayName":"Mechanisms HIE","title":"Mechanisms of neonatal hypoxic-ischemic encephalopathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mechanisms of neonatal hypoxic-ischemic encephalopathy</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t    <td class=\"subtitle1\">Anatomical unit</td>\n\t    <td class=\"subtitle1\">Examples</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle2_left\" colspan=\"2\">Maternal</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\" rowspan=\"3\">Impaired oxygenation</td>\n\t    <td>Asthma</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Pulmonary embolism</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Pneumonia</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\" rowspan=\"4\">Inadequate perfusion of maternal placenta</td>\n\t    <td>Cardiorespiratory arrest</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Maternal hypotension</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Preeclampsia</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Chronic vascular disease</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle2_left\" colspan=\"2\">Placental</td>\n\t  </tr>\n\t  <tr>\n\t\t<td class=\"indent1\" rowspan=\"5\">&nbsp;</td>\n\t    <td>Abruptio placenta</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Tight nuchal cord</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Cord prolapsed</td>\n\t  </tr>\n\t  <tr>\n\t    <td>True knot</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Uterine rupture</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"subtitle2_left\" colspan=\"2\">Fetal</td>\n\t  </tr>\n\t  <tr>\n\t    <td class=\"indent1\" rowspan=\"2\">Impaired fetal oxygenation/perfusion</td>\n\t    <td>Fetomaternal hemorrhage</td>\n\t  </tr>\n\t  <tr>\n\t    <td>Fetal thrombosis</td>\n\t  </tr>\n\n</tbody>\n</table></div><div class=\"graphic_reference\">Sidhartha Tan, MD.</div><div id=\"graphicVersion\">Graphic 67794 Version 2.0</div></div></div>"},"67796":{"type":"graphic_diagnosticimage","displayName":"Alveolar hemorrhage CT","title":"Nonresolving pneumonia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nonresolving pneumonia</div><div class=\"cntnt\"><img style=\"width:360px; height:284px;\" src=\"images/PULM/67796_Alveolar_hemorrhage_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest computed tomography (CT) of a patient with acute myelogenous leukemia, severe thrombocytopenia, and the clinical picture of a nonresolving pneumonia. The diagnosis of diffuse alveolar hemorrhage was made at bronchoscopy.</div><div class=\"graphic_reference\">Courtesy of Alan Fein, MD.</div><div id=\"graphicVersion\">Graphic 67796 Version 4.0</div></div></div>"},"67797":{"type":"graphic_figure","displayName":"Surgical repair of parastomal hernia","title":"Surgical repair of parastomal hernia","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Surgical repair of parastomal hernia</div><div class=\"cntnt\"><img style=\"width:500px; height:634px;\" src=\"images/SURG/67797_PSH_repairs_four.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Operative procedures used for repair of a parastomal hernia.<br> (A) Relocation of the stoma - high risk of failure.<br> (B) Direct repair of the fascial defect - high rate of recurrence.<br> (C) Subcutaneous mesh repair - low recurrence risk but undermining is a risk for ischemic injury to skin.<br> (D) Extraperitoneal mesh repair - most common approach for repair with lower failure rate.</div><div id=\"graphicVersion\">Graphic 67797 Version 3.0</div></div></div>"},"67799":{"type":"graphic_table","displayName":"Etiology balanoposthitis","title":"Etiology of balanoposthitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiology of balanoposthitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Infectious</td> <td class=\"subtitle1\">Irritant</td> <td class=\"subtitle1\">Allergic/immunologic</td> <td class=\"subtitle1\">Traumatic</td> </tr> <tr> <td class=\"subtitle2_single\">Fungal</td> <td rowspan=\"18\"> <p>Poor hygiene (nonspecific balanoposthitis)</p> Soap or other contact irritant</td> <td rowspan=\"18\"> <p>Fixed drug eruption</p> Stevens-Johnson syndrome</td> <td rowspan=\"18\"> <p>Excessive forceful foreskin retraction in young children</p> <p>Friction or entrapment against clothing</p> <p>Hair tourniquet (infant)</p> <p>Masturbation</p> <p>Sexual intercourse</p> Zip-fastener injury</td> </tr> <tr> <td class=\"indent1\">Candida albicans*</td> </tr> <tr> <td class=\"subtitle2_single\">Bacterial</td> </tr> <tr> <td class=\"indent1\">Escheria coli</td> </tr> <tr> <td class=\"indent1\">Group B Streptococcus</td> </tr> <tr> <td class=\"indent1\">Bacteroides species</td> </tr> <tr> <td class=\"indent1\">Group A Streptococcus*</td> </tr> <tr> <td class=\"indent1\">Staphylococcus aureus</td> </tr> <tr> <td class=\"indent1\">Gardnerella vaginalis*</td> </tr> <tr> <td class=\"indent1\">Neiserris gonorrhea<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Chlamydia trachomatis<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Treponema pallidum<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_single\">Viral</td> </tr> <tr> <td class=\"indent1\">Human papillomavirus*</td> </tr> <tr> <td class=\"indent1\"> <p>Herpes simplex, type 1*</p> Herpes simplex, type 2<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_single\">Protozoan</td> </tr> <tr> <td class=\"indent1\">Trichomonas vaginalis<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Entameba histolytica*</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Sexual transmission described.<br />¶ Sexual transmission most likely.</div><div id=\"graphicVersion\">Graphic 67799 Version 3.0</div></div></div>"},"67800":{"type":"graphic_figure","displayName":"Lyme cases by year","title":"Reported cases of Lyme disease by year, United States, 1995-2014","html":"<div class=\"graphic\"><div style=\"width: 725px\" class=\"figure\"><div class=\"ttl\">Reported cases of Lyme disease by year, United States, 1995-2014</div><div class=\"cntnt\"><img style=\"width:705px; height:490px;\" src=\"images/ID/67800_Lyme_cases_year.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The graph displays the number of reported cases of Lyme disease from 1995 through 2014.</div><div class=\"graphic_footnotes\">* National Surveillance case definition revised in 2008 to include probable cases.</div><div class=\"graphic_reference\">Reproduced from: Lyme Disease: Lyme Disease Graphs, 2015. United States Centers for Disease Control and Prevention. Available at: <a href=\"http://www.cdc.gov/lyme/stats/graphs.html\" target=\"_blank\">http://www.cdc.gov/lyme/stats/graphs.html</a> (Accessed July 27, 2016).</div><div id=\"graphicVersion\">Graphic 67800 Version 7.0</div></div></div>"},"67803":{"type":"graphic_diagnosticimage","displayName":"Ultrasound guided amniocentesis","title":"Ultrasound guided amniocentesis","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Ultrasound guided amniocentesis</div><div class=\"cntnt\"><img style=\"width:468px; height:374px;\" src=\"images/OBGYN/67803_U-S_guided_amniocentesis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial image of the uterus demonstrating amniotic fluid. A needle is shown traversing the maternal subcutaneous tissue, uterus, and fetal membranes with the tip of the needle centrally located within the amniotic fluid. The fetus is not visualized in this image.</div><div class=\"graphic_reference\">Courtesy of Thomas Shipp, MD.</div><div id=\"graphicVersion\">Graphic 67803 Version 3.0</div></div></div>"},"67805":{"type":"graphic_table","displayName":"Hereditary periodic fevers","title":"The periodic fever syndromes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The periodic fever syndromes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Disease </td> <td class=\"subtitle1\">Gene Locus </td> <td class=\"subtitle1\">Age of onset </td> <td class=\"subtitle1\">Inheritance </td> <td class=\"subtitle1\">Ethnicity </td> <td class=\"subtitle1\">Length of fevers </td> <td class=\"subtitle1\">Clinical features </td> <td class=\"subtitle1\">Amyloid </td> <td class=\"subtitle1\">Diagnosis </td> <td class=\"subtitle1\">Therapy </td> </tr> <tr> <td>FMF</td> <td>MEFV</td> <td>&#60;20 years</td> <td>AR</td> <td> <p>Sephardic Jews</p> <p>Armenians</p> <p>Turks</p> <p>Arabs</p> <p>Ashkenazi Jews</p> </td> <td>1 to 3 days</td> <td> <p>Abdominal pain</p> <p>Pleurisy</p> <p>Arthralgia/arthritis</p> <p>Scrotal swelling</p> <p>Erysipeloid rash</p> </td> <td>&#62;20%*</td> <td>Mutational testing</td> <td> <p>Colchicine</p> <p>IL-1 blockade</p> </td> </tr> <tr> <td>TRAPS</td> <td>TNFR1</td> <td>&#60;20 years</td> <td>AD</td> <td> <p>Irish Scottish</p> <p>Other</p> </td> <td>&#62;5 days</td> <td> <p>Conjunctivitis</p> <p>Abdominal pain</p> <p>Regional myalgia</p> <p>Arthralgia/arthritis</p> <p>Rash</p> </td> <td>25%</td> <td>Mutational testing</td> <td> <p>Glucocorticoids</p> <p>Etanercept</p> <p>IL-1 blockade</p> </td> </tr> <tr> <td>HIDS</td> <td>MEVK</td> <td>&#60;1 year</td> <td>AR</td> <td> <p>Dutch French</p> <p>Other</p> </td> <td>3 to 7 days</td> <td> <p>Cervical lymphadenopathy</p> <p>Abdominal pain</p> <p>Arthralgia/arthritis</p> <p>Rash</p> <p>Splenomegaly</p> </td> <td>Rare</td> <td> <p>Serum IgD &#62;100 int. units/mL</p> <p>IgA elevated &#62;80%</p> <p>Mutational testing for V377I (&#62;80%)</p> </td> <td> <p>NSAIDs </p> <p>Glucocorticoids</p> <p>IL-1 blockade</p> </td> </tr> <tr> <td>FCAS</td> <td>NLRP3</td> <td>&#60;1 year</td> <td>AD</td> <td>Any</td> <td>&#60;1 day</td> <td> <p>Induced by cold exposure</p> <p>Maculopapular to urticarial rash</p> <p>Conjunctivitis</p> </td> <td>Uncommon</td> <td>Mutational testing</td> <td>IL-1 blockade</td> </tr> <tr> <td>MWS</td> <td>NLRP3</td> <td>Variable</td> <td>AD</td> <td>Any</td> <td>2 to 3 days</td> <td> <p>Urticarial rash</p> <p>Hearing loss</p> <p>Conjunctivitis</p> <p>Amyloidosis</p> </td> <td>25%</td> <td>Mutational testing</td> <td>IL-1 blockade</td> </tr> <tr> <td>NOMID</td> <td>NLRP3</td> <td>&#60;1 year</td> <td>AD</td> <td>Any</td> <td>Variable, but may be continuous</td> <td> <p>Severe generalized inflammation</p> <p>Urticarial rash</p> <p>Conjunctivitis</p> <p>Meningitis</p> <p>Bony overgrowth</p> </td> <td>Variable</td> <td>Mutational testing</td> <td>IL-1 blockade</td> </tr> <tr> <td>PFAPA</td> <td>Unknown</td> <td>&#60;5 years</td> <td>?</td> <td>Any</td> <td>3 to 4 days</td> <td> <p>Cervical lymphadenopathy</p> <p>Aphthous stomatitis</p> </td> <td>No</td> <td>None</td> <td> <p>Glucocorticoids</p> <p>&nbsp;</p> <p>Tonsillectomy</p> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">FCAS, MWS, and NOMID are cryopyrin-associated periodic syndromes (CAPS).</div><div class=\"graphic_footnotes\">FMF: familial Mediterranean fever; MEFV: pyrin/marenostrin gene located on chromosome 16p; AR: autosomal recessive;&nbsp;IL-1: interleukin-1; TRAPS: tumor necrosis factor alpha receptor-1 associated syndrome; TNFR1: tumor necrosis factor alpha receptor-1 gene located on chromosome 12p; AD: autosomal dominant;&nbsp;HIDS: hyperimmunoglobulin D syndrome; MEVK: mevalonate kinase gene located on chromosome 12q; IgD: immunoglobulin D; IgA:&nbsp;immunoglobulin A; NSAIDs:&nbsp;nonsteroidal antiinflammatory drugs;&nbsp;FCAS: familial cold autoinflammatory syndrome; NLRP3: nucleotide-binding domain and leucine rich repeat containing family, pyrin domain containing 3;<FONT color=black> MWS: Muckle-Wells syndrome; NOMID: neonatal-onset multisystem inflammatory disease;</FONT>&nbsp;PFAPA: periodic fever with aphthous stomatitis, pharyngitis, and cervical adenitis.<br />*&nbsp;Sixty percent in an untreated Armenian population with FMF.</div><div id=\"graphicVersion\">Graphic 67805 Version 6.0</div></div></div>"},"67807":{"type":"graphic_picture","displayName":"Vulvar squamous carcinoma","title":"Squamous carcinoma extending close to the clitoris","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Squamous carcinoma extending close to the clitoris</div><div class=\"cntnt\"><img style=\"width:335px; height:432px;\" src=\"images/OBGYN/67807_Vulvar_squamous_carcinoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This case is suitable for anterior horseshoe modified radical vulvectomy.</div><div class=\"graphic_reference\">Courtesy of C. William Helm, MD.</div><div id=\"graphicVersion\">Graphic 67807 Version 1.0</div></div></div>"},"67809":{"type":"graphic_table","displayName":"Clinical manifestations of early congenital syphilis","title":"Clinical manifestations of early congenital syphilis*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical manifestations of early congenital syphilis*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Gestational/perinatal</td> </tr> <tr> <td class=\"indent1\">Stillbirth</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Prematurity</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Birth weight &#60;2500 g</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Nonimmune hydrops fetalis</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Placenta</td> <td>Large, thick, pale (send for pathologic/histologic evaluation)</td> </tr> <tr> <td class=\"indent1\">Umbilical cord</td> <td>Inflamed with abscess-like foci of necrosis within Wharton's jelly, centered around the umbilical vessels (necrotizing funisitis); barber-pole appearance (send for pathologic/histologic evaluation)</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Systemic</td> </tr> <tr> <td class=\"indent1\">Fever</td> <td>May be more prominent in infants born to mothers who are affected late in pregnancy and whose serology is negative at delivery</td> </tr> <tr> <td class=\"indent1\">Hepatomegaly</td> <td>Splenomegaly occurs in approximately one-half of patients with hepatomegaly&#8212;isolated splenomegaly does not occur</td> </tr> <tr> <td class=\"indent1\">Generalized lymphadenopathy</td> <td>May be as large as 1 cm; generally nontender and firm</td> </tr> <tr> <td class=\"indent1\">Failure to thrive</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Edema</td> <td>Due to anemia/hydrops fetalis, nephrotic syndrome, malnutrition</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Mucocutaneous</td> </tr> <tr> <td class=\"indent1\">Syphilitic rhinitis (\"snuffles\")</td> <td>Can be an early feature, developing after the first week of life; <strong>contains spirochetes and is infectious (use contact precautions)</strong></td> </tr> <tr> <td class=\"indent1\">Maculopapular rash</td> <td>Usually appears one to two weeks after rhinitis. Oval lesions, initially red or pink and then coppery brown; may be associated with superficial desquamation or scaling, particularly on the palms or soles; more common on the buttocks, back, posterior thighs, and soles; <strong>contains spirochetes and is infectious (use contact precautions)</strong>.</td> </tr> <tr> <td class=\"indent1\">Vesicular rash (pemphigus syphiliticus)</td> <td>May be present at birth, most often develops in first four weeks; widely disseminated; vesicular fluid <strong>contains spirochetes and is infectious (use contact precautions)</strong></td> </tr> <tr> <td class=\"indent1\">Condylomata lata</td> <td>Single or multiple, flat, wartlike, moist lesions around the mouth, nares, and anus and other areas of the skin where there is moisture or friction; <strong>lesions contain spirochetes and are infectious (use contact precautions)</strong>; frequently present without other signs of infection</td> </tr> <tr> <td class=\"indent1\">Jaundice</td> <td>Hyperbilirubinemia secondary to syphilitic hepatitis and/or hemolysis</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Hematologic</td> </tr> <tr> <td class=\"indent1\">Anemia</td> <td> <p>Newborn period: Hemolytic (Coomb's test [direct antiglobulin test] negative); may persist after effective treatment</p> After one month of age: May be chronic and nonhemolytic</td> </tr> <tr> <td class=\"indent1\">Thrombocytopenia</td> <td>May be associated with bleeding or petechiae; can be the only manifestation of congenital infection</td> </tr> <tr> <td class=\"indent1\">Leukopenia</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Leukocytosis</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Musculoskeletal</td> </tr> <tr> <td class=\"indent1\">Pseudoparalysis of Parrot</td> <td>Lack of movement of an extremity because of pain associated with bone lesion; affects upper extremities more often than lower; usually unilateral; rarely present at birth; poorly correlated with radiographic abnormalities</td> </tr> <tr> <td class=\"sublist2_start\">Radiographic abnormalities:</td> <td class=\"sublist_other_start\">Most frequent abnormality in untreated early congenital syphilis; not usually clinically discernible; typically multiple and symmetric</td> </tr> <tr> <td class=\"sublist2\">Periostitis</td> <td class=\"sublist_other\">Irregular periosteal thickening; usually present at birth, but may appear in the first few weeks of life</td> </tr> <tr> <td class=\"sublist2\">Wegner sign</td> <td class=\"sublist_other\">Metaphyseal serration or \"sawtooth metaphysis\"</td> </tr> <tr> <td class=\"sublist2\">Wimberger sign</td> <td class=\"sublist_other\">Demineralization and osseous destruction of the upper medial tibial</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Neurologic</td> </tr> <tr> <td class=\"indent1\">CSF abnormalities</td> <td>Reactive CSF VDRL; elevated CSF white blood cell count; elevated CSF protein</td> </tr> <tr> <td class=\"indent1\">Acute syphilitic leptomeningitis</td> <td>Onset during the first year of life, usually between 3 and 6 months; presentation similar to bacterial meningitis but CSF findings more consistent with aseptic meningitis (mononuclear predominance); responds to penicillin therapy</td> </tr> <tr> <td class=\"indent1\">Chronic meningovascular syphilis</td> <td>Onset toward the end of the first year; hydrocephalus; cranial nerve palsies; intellectual/neurodevelopmental deterioration; cerebral infarction; protracted course</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Miscellaneous</td> </tr> <tr> <td class=\"indent1\">Pneumonia/pneumonitis/respiratory distress</td> <td>Complete opacification of both lung fields on chest radiograph</td> </tr> <tr> <td class=\"indent1\">Nephrotic syndrome</td> <td>Usually occurs at two to three months of age and manifests with generalized edema and ascites</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CSF: cerebrospinal fluid; VDRL: Venereal Disease Research Laboratory test.<br />* All of these findings may occur in other congenital infections; none is specific for congenital syphilis.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Ingall D, Sanchez PJ, Baker CH. Syphilis. In: Infectious Diseases of the Fetus and Newborn infant, 6th edition, Remington JS, Klein JO, Wilson CB, Baker CJ (Eds), Elsevier Saunders, Philadelphia 2006. p.545. </li>&#xD;&#xA;    <li>Dobson SR, Sanchez PJ. Syphilis. In: Feigin and Cherry's Textbook of Pediatric Infectious Diseases, 7th, Cherry JD, Harrison GJ, Kaplan SL, et al. (Eds), Elsevier Saunders, Philadelphia 2014. p.1761.</li>&#xD;&#xA;    <li>Woods CR. Syphilis in children: congenital and acquired. Semin Pediatr Infect Dis 2005; 16:245. </li>&#xD;&#xA;    <li>Saloojee H, Velaphi S, Goga Y, et al. The prevention and management of congenital syphilis: an overview and recommendations. Bull World Health Organ 2004; 82:424. </li>&#xD;&#xA;    <li>Chakraborty R, Luck S. Syphilis is on the increase: the implications for child health. Arch Dis Child 2008; 93:105. </li>&#xD;&#xA;    <li>Rawstron SA. Treponema pallidum (Syphilis). In: Principles and Practice of Pediatric Infectious Diseases, 3rd edition, Long SS, Pickering LK, Prober CG (Eds), Churchill Livingstone Elsevier, Philadelphia 2008. p.930. </li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 67809 Version 8.0</div></div></div>"},"67810":{"type":"graphic_table","displayName":"Causes of proteinuria in pregnancy","title":"Causes of proteinuria in pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of proteinuria in pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Primary renal diseases</td> </tr> <tr> <td class=\"indent1\">IgA nephropathy</td> </tr> <tr> <td class=\"indent1\">Minimal change disease</td> </tr> <tr> <td class=\"indent1\">Membranous nephropathy</td> </tr> <tr> <td class=\"indent1\">Focal segmental glomerulosclerosis</td> </tr> <tr> <td class=\"indent1\">Primary glomerulonephritis</td> </tr> <tr> <td class=\"indent1\">Allergic interstitial nephritis</td> </tr> <tr> <td class=\"indent1\">Polycystic kidney disease</td> </tr> <tr> <td class=\"subtitle1_single\">Systemic causes</td> </tr> <tr> <td class=\"indent1\">Preeclampsia</td> </tr> <tr> <td class=\"indent1\">Diabetic nephropathy</td> </tr> <tr> <td class=\"indent1\">Lupus nephritis (diffuse proliferative, focal proliferative, membranous)</td> </tr> <tr> <td class=\"indent1\">Hypertensive nephrosclerosis</td> </tr> <tr> <td class=\"indent1\">Thrombotic thrombocytopenic purpura (TTP)</td> </tr> <tr> <td class=\"indent1\">Infection-associated glomerular disease (eg, HIV, hepatitis B/C)</td> </tr> <tr> <td class=\"indent1\">Systemic vasculitis</td> </tr> <tr> <td class=\"indent1\">Multiple myeloma</td> </tr> <tr> <td class=\"indent1\">Chronic vesicoureteral reflux</td> </tr> <tr> <td class=\"indent1\">Antiphospholipid syndrome</td> </tr> <tr> <td class=\"indent1\">Symptomatic urinary tract obstruction</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 67810 Version 3.0</div></div></div>"},"67812":{"type":"graphic_diagnosticimage","displayName":"Acromioclavicular injury Type II","title":"Acromioclavicular injury Type II","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acromioclavicular injury Type II</div><div class=\"cntnt\"><img style=\"width:370px; height:395px;\" src=\"images/EM/67812_AC_type_II_XR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Type II AC injuries represent a complete tear of the AC ligaments and partial injury of the CC ligaments. In this radiograph of a type II injury, note the subtle difference in AC joint position (arrow), and slight increase in CC distance. The patient was nontender over the right CC ligaments, suggesting that only the AC ligaments are significantly injured.</div><div class=\"graphic_footnotes\">AC: acromioclavicular; CC: coracoclavicular.</div><div class=\"graphic_reference\">Courtesy of Scott M. Koehler, MD.</div><div id=\"graphicVersion\">Graphic 67812 Version 5.0</div></div></div>"},"67813":{"type":"graphic_figure","displayName":"Anatomy of the lateral wall of the nasal cavity and nasopharynx","title":"Anatomy of the lateral wall of the nasal cavity and the nasopharynx","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Anatomy of the lateral wall of the nasal cavity and the nasopharynx</div><div class=\"cntnt\"><img style=\"width:542px; height:404px;\" src=\"images/ALLRG/67813_Nose_lat_wall_nasopharynx.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 67813 Version 3.0</div></div></div>"},"67814":{"type":"graphic_figure","displayName":"Neonatal HSV SSx","title":"Signs and symptoms of neonatal herpes simplex virus infection","html":"<div class=\"graphic\"><div style=\"width: 598px\" class=\"figure\"><div class=\"ttl\">Signs and symptoms of neonatal herpes simplex virus infection</div><div class=\"cntnt\"><img style=\"width:578px; height:405px;\" src=\"images/PEDS/67814_Neonatal_HSV_SSx.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Signs and symptoms of neonatal herpes simplex virus infection at diagnosis and initiation of therapy.</div><div class=\"graphic_footnotes\">SEM: skin, eyes, or mouth; CNS: central nervous system; DIC: disseminated intravascular coagulopathy.</div><div class=\"graphic_reference\">Data from: Kimberlin DW, Lin C-Y, Jacobs RF, et al. Natural history of neonatal herpes simplex virus infections in the acyclovir era. Pediatrics 2001; 108:223.</div><div id=\"graphicVersion\">Graphic 67814 Version 2.0</div></div></div>"},"67815":{"type":"graphic_diagnosticimage","displayName":"IPAH angio","title":"Idiopathic pulmonary arterial hypertension","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Idiopathic pulmonary arterial hypertension</div><div class=\"cntnt\"><img style=\"width:290px; height:336px;\" src=\"images/CARD/67815_IPAH_angio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This angiogram, obtained after injection of contrast material into the proximal right pulmonary artery, demonstrates a large central pulmonary artery with marked attenuation of the peripheral pulmonary arteries with no intraluminal filling defects to suggest the presence of emboli.</div><div class=\"graphic_reference\">Photo courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 67815 Version 2.0</div></div></div>"},"67817":{"type":"graphic_table","displayName":"Advantages and disadvantages of HSAT for OSA","title":"Advantages and disadvantages of home sleep apnea testing for obstructive sleep apnea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Advantages and disadvantages of home sleep apnea testing for obstructive sleep apnea</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Advantages </td> </tr> <tr> <td>Increased accessibility</td> </tr> <tr> <td>Patient acceptance</td> </tr> <tr> <td>May be done in the home</td> </tr> <tr> <td>Convenience</td> </tr> <tr> <td>Decreased labor costs</td> </tr> <tr> <td>Can be done for more than one night</td> </tr> <tr> <td class=\"subtitle1_single\">Disadvantages </td> </tr> <tr> <td>Absence of a trained technologist to correct and clarify artifacts, make ongoing equipment adjustments, or intervene in medically unstable patients</td> </tr> <tr> <td>Potential data loss or distortion; higher technical failure rate than polysomnography</td> </tr> <tr> <td>Potential for misinterpretation of the results due to limited data</td> </tr> <tr> <td>Inability to perform subsequent multiple sleep latency testing according to standard protocol</td> </tr> <tr> <td>Varied sensor technology</td> </tr> <tr> <td>Most devices have no&nbsp;measurement of sleep</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 67817 Version 4.0</div></div></div>"},"67818":{"type":"graphic_picture","displayName":"Oropharynx of a snorer II","title":"Oropharynx of a snorer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oropharynx of a snorer</div><div class=\"cntnt\"><img style=\"width:358px; height:253px;\" src=\"images/PULM/67818_Oropharynx_of_a_snorer_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph is from a snoring patient in whom obstructive sleep apnea was excluded by polysomnography. Oropharyngeal narrowing is present in the lateral dimension due to residual tonsilar tissue.</div><div id=\"graphicVersion\">Graphic 67818 Version 2.0</div></div></div>"},"67819":{"type":"graphic_figure","displayName":"Hanging arm cast","title":"Hanging arm cast","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hanging arm cast</div><div class=\"cntnt\"><img style=\"width:277px; height:409px;\" src=\"images/RHEUM/67819_Hanging_arm_cast.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows a hanging arm cast. This type of cast is used for angulated or displaced midshaft humerus fractures. The weight of the cast and forces achived through adjustment of the length of the sling and site of attachment of the sling to the cast at the wrist can help achieve acceptable reduction and healing of the fracture.</div><div id=\"graphicVersion\">Graphic 67819 Version 6.0</div></div></div>"},"67820":{"type":"graphic_table","displayName":"AASLD liver biopsy","title":"American Association for the Study of Liver Diseases (AASLD) liver biopsy recommendations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">American Association for the Study of Liver Diseases (AASLD) liver biopsy recommendations</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Focal disease and mass lesions</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Liver biopsy should be considered in patients in whom diagnosis is in question, and when knowledge of a specific diagnosis is likely to alter the management plan.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Liver histology is an important adjunct in the management of patients with known liver disease, particularly in situations where (prognostic) information about fibrosis stage may guide subsequent treatment; the decision to perform liver biopsy in these situations should be closely tied to consideration of the risks and benefits of the procedure.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Technical issues, contraindications, and complications</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Prior to performance of liver biopsy, patients should be educated about their liver disease and about investigations other than liver biopsy (if any) that may also provide diagnostic and prognostic information.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Prior to performance of liver biopsy, patients must be carefully informed about the procedure itself including alternatives (as above), risks, benefits, and limitations; written informed consent should be obtained.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Management of medications</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Antiplatelet medications should be discontinued several to 10 days before liver biopsy, although there is uncertainty surrounding the need for their discontinuation. Management of specific compounds should be handled on a case-by-case basis, taking into account their clinical indications, as well as the potential bleeding risk associated with their use in the setting of liver biopsy.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Anticoagulant medications should be discontinued prior to liver biopsy. Warfarin should generally be discontinued at least five days prior to liver biopsy. Heparin and related products should be discontinued 12 to 24 hours prior to biopsy. In all patients, the risk of discontinuing anticoagulant medications must be weighed against the (potential) risk of bleeding during/after liver biopsy.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Antiplatelet therapy may be restarted 48 to 72 hours after liver biopsy.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Warfarin may be restarted the day following liver biopsy.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Liver biopsy procedure</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Performance of liver biopsy requires an adequate sized and dedicated physical space suitable for focused physician effort as well as safe patient recovery.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>The use of sedation, preferably light sedation, is safe and does not lead to increased procedural risk.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Vital signs must be frequently monitored (at least every 15 minutes for the first hour) after liver biopsy.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>The recommended observation time after biopsy is between two to four hours and will vary depending on local expertise and practice.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Ultrasound guidance with marking of the optimal biopsy site performed immediately preceding biopsy, by the individual performing the biopsy, is preferred, though not mandatory, because it likely reduces the risk of complications from liver biopsy.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Contraindications</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Percutaneous liver biopsy with or without image guidance is appropriate only in cooperative patients, and this technique should not be utilized in uncooperative patients.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Uncooperative patients who require liver biopsy should undergo the procedure under general anesthesia or via the transvenous route.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>In patients with clinically evident ascites requiring a liver biopsy, a transvenous approach is generally recommended, although percutaneous biopsy (after removal of ascites) or laparoscopic biopsy are acceptable alternatives.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Patients who require liver biopsy and who have a large vascular lesion identified on imaging should undergo the procedure using real-time image guidance.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>The decision to perform liver biopsy in the setting of abnormal laboratory parameters of hemostasis should continue to be reached as the result of local practice(s) and consideration of the risks and benefits of liver biopsy because there is no specific PT-INR and/or platelet count cutoff at or above which potentially adverse bleeding can be reliably predicted.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Complications</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Those performing liver biopsy must be cognizant of multiple potential complications (including death) that may occur after liver biopsy and discuss these appropriately with their patients beforehand.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Platelet transfusion should be considered when levels are less than 50,000 to 60,000/mL (this applies whether one is attempting biopsy transcutaneously or transvenously).</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>The use of prophylactic or rescue strategies such as plasma, fibrinolysis inhibitors, or recombinant factors should be considered in specific situations, although their effectiveness remains to be established.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>In patients with renal failure or on hemodialysis, desmopressin (DDAVP) may be considered, although its use appears to be unnecessary in patients on stable dialysis regimens.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Patients on chronic hemodialysis should be well dialyzed prior to liver biopsy, and heparin should be avoided if at all possible.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Radiological considerations</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Image-guided liver biopsy is recommended in certain clinical situations including in patients with known intrahepatic lesions (real-time imaging is strongly preferred) and in those with previous intraabdominal surgery who may have adhesions. Image-guided liver biopsy should also be considered in the following situations: patients with small livers that are difficult to percuss, obese patients, and patients with clinically evident ascites.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Pathological considerations</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Because diagnosis, grading, and staging of nonneoplastic, diffuse parenchymal liver disease is dependent on an adequate sized biopsy, a biopsy of at least 2 to 3 cm in length and 16-gauge in caliber is recommended.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>It is recommended that if applicable, the presence of fewer than 11 complete portal tracts be noted in the pathology report, with recognition that diagnosis, grading, and staging may be incorrect due to an insufficient sample size.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>If cirrhosis is suspected, a cutting rather than a suction needle is recommended.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>In clinical practice, use of a simple (eg, Metavir or Batts-Ludwig) rather than complex (eg, Ishak) scoring system is recommended.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Noninvasive alternatives to liver biopsy</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Liver biopsy is currently a fundamentally important tool in the management of patients with liver disease, important for diagnosis as well as staging of liver disease and its use is recommended until clearly superior methodologies are developed and validated.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Training for liver biopsy</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Specific training for liver biopsy is essential and is recommended for those who perform it.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Liver biopsy should be taught to trainees by experts, highly experienced in the practice of liver biopsy and management of its potential complications.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Although the number of biopsies required to become adequately trained is unknown, it is recommended that operators perform at least 40 biopsies.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Training in percutaneous liver biopsy should include specific training in ultrasound interpretation of fundamental liver anatomy and other landmarks.</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Image-guided liver biopsy should be taught to trainees by experts who themselves have adequate training and experience with the technique.</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div class=\"graphic_reference\">Data from: Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. Hepatology 2009; 49:1017.</div><div id=\"graphicVersion\">Graphic 67820 Version 2.0</div></div></div>"},"67821":{"type":"graphic_table","displayName":"Protein biological value","title":"Table of the biological value of common foods","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Table of the biological value of common foods</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Food item</td> <td class=\"subtitle1\">Biological value</td> </tr> <tr> <td>Egg protein</td> <td class=\"centered\">100</td> </tr> <tr> <td>Whole bean</td> <td class=\"centered\">96</td> </tr> <tr> <td>Whole soy bean</td> <td class=\"centered\">96</td> </tr> <tr> <td>Human milk</td> <td class=\"centered\">95</td> </tr> <tr> <td>Cow milk</td> <td class=\"centered\">90</td> </tr> <tr> <td>Cheese</td> <td class=\"centered\">84</td> </tr> <tr> <td>Rice, unpolished</td> <td class=\"centered\">83</td> </tr> <tr> <td>Chicken</td> <td class=\"centered\">79</td> </tr> <tr> <td>Fish</td> <td class=\"centered\">76</td> </tr> <tr> <td>Beef</td> <td class=\"centered\">74</td> </tr> <tr> <td>Soybean curd</td> <td class=\"centered\">72</td> </tr> <tr> <td>Rice, polished</td> <td class=\"centered\">64</td> </tr> <tr> <td>Corn</td> <td class=\"centered\">60</td> </tr> <tr> <td>Kidney bean</td> <td class=\"centered\">49</td> </tr> <tr> <td>White flour</td> <td class=\"centered\">41</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table depicts common food items with their BV values. Biological value (BV) is a measure of the proportion of absorbed protein that is incorporated into the proteins of the body. One method of determining biological value measures absorbed and excreted nitrogen and determines the ratio of incorporated nitrogen to absorbed nitrogen:<br />&bull; BV = (Nr/Na) x 100.<br />&bull; Nr = nitrogen retained in the body (measured indirectly by nitrogen excretion in the urine and feces).<br />&bull; Na = absorbed nitrogen from dietary protein.<br />&bull; A BV of 100 suggests complete utilization of protein from a particular food. Egg protein has a BV of 100.<br />&bull; BV does not take into account how readily the protein can be digested and absorbed.</div><div class=\"graphic_reference\">Data from: Jolliet P, Pichard C, Biolo G. Enteral nutrition in intensive care patients: a practical approach. Intensive Care Med 1998; 24:848.</div><div id=\"graphicVersion\">Graphic 67821 Version 3.0</div></div></div>"},"67822":{"type":"graphic_picture","displayName":"Circumvallate placenta","title":"Circumvallate placenta","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Circumvallate placenta</div><div class=\"cntnt\"><img style=\"width:432px; height:286px;\" src=\"images/OBGYN/67822_Circumvallate_placenta.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A double layer of amnion and chorion, as well as necrotic villi and fibrin, form a raised white ring around the surface of the placental disk at a variable distance from the umbilical cord insertion site; the fetal vessels do not extend beyond this ring</div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 67822 Version 1.0</div></div></div>"},"67823":{"type":"graphic_table","displayName":"Mgmt interleukin 2 toxicity I","title":"Management of IL-2 toxicity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Management of IL-2 toxicity</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Hypotension </td> </tr> <tr> <td>1. Minimal fluid resuscitation to avoid fluid overload.</td> </tr> <tr> <td>2. Normally systolic blood pressure (SBP) is 20 to 30 mmHg lower than baseline but patient is asymptomatic. In younger patients, may tolerate SBP 80 mmHg; in older patients, may tolerate SBP 85 to 90mmHg, depending on baseline. If baseline is higher, may maintain SBP at 100 mmHg.</td> </tr> <tr> <td>3. Although saline may be utilized initially, it should be used judiciously to avoid fluid overload and extensive capillary leak.</td> </tr> <tr> <td>4. Colloid administration may be necessary if SBP is lower, for symptomatic hypotension, or if urine output declines.</td> </tr> <tr> <td>5. Pressors, either dopamine, 1 to 6 mcg/kg/min (if not tachycardic) or phenylephrine, 0.1 to 2.0 mcg/kg/min, may be used to stabilize blood pressure.</td> </tr> <tr> <td>6. Patients routinely gain 4.5 kg (10 lbs) in water weight.</td> </tr> <tr> <td class=\"subtitle1_single\">Cardiac arrhythmia </td> </tr> <tr> <td>1. Sinus tachycardia is common and may reflect maximal toxicity between doses, or a reaction to hypotension or dopamine administration. Extension of time between doses may control this.</td> </tr> <tr> <td>2. Supraventricular tachycardia may occur with therapy and may require treatment depending on rate. Therapy can be continued once this is controlled, by extending time between doses. If this occurs near the end of the course of treatment, treatment should probably be discontinued.</td> </tr> <tr> <td>3. IL-2 doses should be withheld for atrial fibrillation, but may be resumed when conversion to sinus rhythm is accomplished and the patient is hemodynamically stable.</td> </tr> <tr> <td>4. If significant (ventricular) arrhythmias occur during treatment, IL-2 should be held and an evaluation for cardiac damage must be undertaken, for ischemia or infarction.</td> </tr> <tr> <td>5. Although isolated premature ventricular contractions may not signal discontinuation of IL-2, if they increase in frequency or become sustained, IL-2 therapy should be stopped.</td> </tr> <tr> <td class=\"subtitle1_single\">Metabolic acidosis </td> </tr> <tr> <td>1. Metabolic acidosis may occur with reductions in serum bicarbonate.</td> </tr> <tr> <td>2. Sodium bicarbonate should be utilized to maintain serum HCO3 above 18 mEq/L.</td> </tr> <tr> <td>3. If bicarbonate is persistently low, IL-2 should be held.</td> </tr> <tr> <td class=\"subtitle1_single\">Fevers/chills </td> </tr> <tr> <td>1. These can be prevented to some extent by premedication with acetaminophen, 650 mg orally every 4 hours, and indomethacin, 25 mg orally every 6 hours throughout IL-2 administration. H-2 blockers should be administered to protect the gastric mucosa.</td> </tr> <tr> <td>2. Patients who develop dose-related significant shaking chills, usually 30 to 90 minutes following the dose, should receive intravenous meperidol (pethidine) 25 to 50 mg to stop them. They may then need prochlorperazine for nausea.</td> </tr> <tr> <td class=\"subtitle1_single\">Nausea/vomiting </td> </tr> <tr> <td>1. Although not occurring in all patients, we routinely provide premedication daily with 5HT3 antagonists (eg, ondansetron), as well as prochlorperazine for dose-relate nausea. Dexamethasone is not routinely given.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Dutcher J, Atkins MB, Margolin K, et al for the Cytokine Working Group. Kidney Cancer: The Cytokine Working Group Experience (1986-2001), part II. Management of IL-2 toxicity and studies with other cytokines. Med Oncol 2001; 18:209. Copyright © 2001 Humana Press.</div><div id=\"graphicVersion\">Graphic 67823 Version 3.0</div></div></div>"},"67824":{"type":"graphic_table","displayName":"Foods with calcium PI","title":"Foods and drinks with calcium","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Foods and drinks with calcium</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Food</td> <td class=\"subtitle1\">Calcium, milligrams</td> </tr> <tr> <td>Milk (skim, 2 percent, or whole, 8 oz [240 mL])</td> <td>300</td> </tr> <tr> <td>Yogurt (6 oz [168 g])</td> <td>250</td> </tr> <tr> <td>Orange juice (with calcium, 8 oz [240 mL])</td> <td>300</td> </tr> <tr> <td>Tofu with calcium (1/2 cup [113 g])</td> <td>435</td> </tr> <tr> <td>Cheese (1 oz [28 g])</td> <td>195 to 335 (hard cheese = higher calcium)</td> </tr> <tr> <td>Cottage cheese (1/2 cup [113 g])</td> <td>130</td> </tr> <tr> <td>Ice cream or frozen yogurt (1/2 cup [113 g])</td> <td>100</td> </tr> <tr> <td>Soy milk (8 oz [240 mL])</td> <td>300</td> </tr> <tr> <td>Beans (1/2 cup cooked [113 g])</td> <td>60 to 80</td> </tr> <tr> <td>Dark, leafy green vegetables (1/2 cup cooked [113 g])</td> <td>50 to 135</td> </tr> <tr> <td>Almonds (24 whole)</td> <td>70</td> </tr> <tr> <td>Orange (1 medium)</td> <td>60</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 67824 Version 5.0</div></div></div>"},"67826":{"type":"graphic_figure","displayName":"Parks classification fistulas","title":"The Parks' classification of anal fistulas","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The Parks' classification of anal fistulas</div><div class=\"cntnt\"><img style=\"width:331px; height:358px;\" src=\"images/OBGYN/67826_Parks_classification_fistul.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A superficial fistula tracks below both the internal and external anal sphincter (EAS) complexes. (B) An intersphincteric fistula tracks between the internal anal sphincter and the EAS in the intersphincteric space. (C) A transsphincteric fistula tracks from the intersphincteric space through the EAS. (D) A suprasphincteric fistula leaves the intersphincteric space over the top of the puborectalis and penetrates the levator muscle before tracking down to the skin. (E) An extrasphincteric fistula tracks outside of the internal and external anal sphincters and penetrates the levator muscle into the rectum.</div><div class=\"graphic_reference\">Reproduced with permission from: Parks, AG, Hardcastle, JD, Gordon, PH. A classification of fistula-in-ano. British Journal of Surgery 1976; 63:1. Copyright &#169; 1976 Blackwell Publishing.</div><div id=\"graphicVersion\">Graphic 67826 Version 1.0</div></div></div>"},"67827":{"type":"graphic_figure","displayName":"Tompkins metroplasty AB","title":"Tompkins metroplasty (A and B)","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">Tompkins metroplasty (A and B)</div><div class=\"cntnt\"><img style=\"width:470px; height:615px;\" src=\"images/OBGYN/67827_Tompkins_metroplasty_AB.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) In the Tompkins procedure, the septum is incised, but not removed. An initial incision is made down the middle of the septum until the common cavity is reached. (B) The septal tissue is incised bilaterally to unroof the two cavities.</div><div id=\"graphicVersion\">Graphic 67827 Version 1.0</div></div></div>"},"67828":{"type":"graphic_picture","displayName":"Primary lymphoma bone","title":"Primary lymphoma of bone","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Primary lymphoma of bone</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/HEME/67828_Primary_lymphoma_bone.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histologic evaluation of a femoral resection in a case of diffuse large B cell lymphoma involving the bone. The photomicrograph demonstrates an infiltration of large pleomorphic cells, many of which contain highly convoluted, polylobated nuclear membranes with smudged chromatin and one to two inconspicuous nucleoli (&quot;floret cells,&quot; black arrows).</div><div class=\"graphic_reference\">Kindly provided by Julia M. Braza, MD, MS, German Pihan, MD, and Rajan Mariappan, MD, Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA.</div><div id=\"graphicVersion\">Graphic 67828 Version 1.0</div></div></div>"},"67829":{"type":"graphic_table","displayName":"Medications for PCOS","title":"Medications for polycystic ovary syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medications for polycystic ovary syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"14%\"></colgroup><colgroup span=\"3\" width=\"5%\"></colgroup><colgroup span=\"2\" width=\"14%\"></colgroup> <tbody> </tbody> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Drug type</td> <td class=\"subtitle1\" rowspan=\"2\">Active ingredient</td> <td class=\"subtitle1\" rowspan=\"2\">Examples</td> <td class=\"subtitle1\" rowspan=\"2\">Major mechanism</td> <td class=\"subtitle1\" colspan=\"3\">Efficacy</td> <td class=\"subtitle1\" rowspan=\"2\">Indications</td> <td class=\"subtitle1\" rowspan=\"2\">Comments</td> </tr> <tr> <td class=\"subtitle2\">Hirsutism</td> <td class=\"subtitle2\">Menstrual irregularity</td> <td class=\"subtitle2\">Insulin-lowering</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"9\">First-line treatment for menstrual irregularity and hyperandrogenism:</td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">Oral contraceptive pills</td> <td>Ethinyl estradiol 30 mcg + drospirenone</td> <td> <p>Yasmin</p> Yaz</td> <td rowspan=\"3\">Suppress ovarian function</td> <td class=\"centered\" rowspan=\"3\">+</td> <td class=\"centered\" rowspan=\"3\">+</td> <td class=\"centered\" rowspan=\"3\">&nbsp;</td> <td rowspan=\"3\">Menstrual irregularity, hirsutism</td> <td rowspan=\"3\">Contraindicated in patients with venous thrombosis, uncontrolled hypertension</td> </tr> <tr> <td>Ethinyl estradiol 35 mcg + norgestimate</td> <td>Ortho Cyclen</td> </tr> <tr> <td>Ethinyl estradiol 50 mcg + ethynodiol diacetate</td> <td> <p>Demulen 1/50</p> Zovia 1/50</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Progestin</td> <td>Micronized progesterone</td> <td>Prometrium</td> <td rowspan=\"2\">Normalizes endometrial cycle</td> <td class=\"centered\" rowspan=\"2\">&nbsp;</td> <td class=\"centered\" rowspan=\"2\">+</td> <td class=\"centered\" rowspan=\"2\">&nbsp;</td> <td rowspan=\"2\">Menstrual irregularity</td> <td rowspan=\"2\">Less efficacious than oral contraceptive pills</td> </tr> <tr> <td>Medroxyprogesterone acetate</td> <td>Provera</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"9\">Other options occasionally used for selected patients:</td> </tr> <tr> <td class=\"indent1\">Cell cycle inhibitor</td> <td>Eflornithine HCl 13.9 percent (topical)</td> <td>Vaniqa</td> <td>Irreversible inhibitor of ornithine decarboxylase</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td>Focal hirsutism</td> <td>Contraindicated in pregnancy and lactation</td> </tr> <tr> <td class=\"indent1\">GnRH agonist*</td> <td>Leuprolide acetate depot</td> <td>Depot Lupron</td> <td>Suppress gonadotropins</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td>Oral contraceptive alternative</td> <td>Contraindicated in patients with osteoporosis without add-back estrogen</td> </tr> <tr> <td class=\"indent1\">Glucocorticoid*</td> <td>Glucocorticoid</td> <td>Prednisone</td> <td>Suppress adrenal androgen</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td>Isolated functional adrenal hyperandrogenism</td> <td>Poor efficacy. Contraindicated in obese or glucose-intolerant patients.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"9\">For patients with hirsutism that is not controlled satisfactorily within six months by the above treatments:</td> </tr> <tr> <td class=\"indent1\" rowspan=\"4\">Antiandrogens</td> <td>Spironolactone</td> <td> <p>Spironolactone</p> Aldactone</td> <td>Competitive inhibitor of androgen binding to the androgen receptor</td> <td class=\"centered\">+</td> <td class=\"centered\">&#177;</td> <td class=\"centered\">&nbsp;</td> <td>Severe hirsutism</td> <td>Use only with appropriate contraception because of adverse effects on fetus. Contraindicated in kidney or liver failure.</td> </tr> <tr> <td>Cyproterone acetate*</td> <td> <p>Cyproterone acetate</p> Androcur</td> <td>Competitive inhibitor of androgen binding to the androgen receptor</td> <td class=\"centered\">+</td> <td class=\"centered\">&#177;</td> <td class=\"centered\">&nbsp;</td> <td>Severe hirsutism</td> <td>Use only with appropriate contraception because of adverse effects on fetus</td> </tr> <tr> <td>Flutamide*</td> <td> <p>Flutamide</p> <p>Apo-flutamide</p> <p>Euflex</p> Eulexin</td> <td>Nonsteroidal competitive inhibitor of androgen binding to the androgen receptor</td> <td class=\"centered\">+</td> <td class=\"centered\">&#177;</td> <td class=\"centered\">&nbsp;</td> <td>Severe hirsutism</td> <td>Use only with appropriate contraception because of adverse effects on fetus. Monitor for liver failure. Contraindicated in liver disease.</td> </tr> <tr> <td>Finasteride*</td> <td>Proscar</td> <td>Competitive 5&#945;-reductase inhibitor</td> <td class=\"centered\">+</td> <td class=\"centered\">&#177;</td> <td class=\"centered\">&nbsp;</td> <td>Severe hirsutism</td> <td>Use only with appropriate contraception because of adverse effects on fetus</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"9\">For patients with obesity and marked insulin resistance:</td> </tr> <tr> <td class=\"indent1\">Biguanide</td> <td>Metformin</td> <td>Glucophage, Glucophage XR, Glumetza</td> <td>Reduces hepatic glucose production</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&#177;</td> <td class=\"centered\">&#177;</td> <td>Obesity and insulin resistance; type 2 diabetes</td> <td>Efficacy poor unless weight control is achieved</td> </tr> <tr> <td class=\"indent1\">Thiazolidinedione*</td> <td>Pioglitazone</td> <td>Actos</td> <td>Peroxisome proliferator-activated receptor agonist</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&#177;</td> <td class=\"centered\">+</td> <td>Type 2 diabetes</td> <td>Contraindicated in patients with hepatic or cardiac disease</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">+: usually effective; &plusmn;: marginally effective.</div><div class=\"graphic_footnotes\">* These medications are second- or third-line options as compared with other medications in this grouping.</div><div id=\"graphicVersion\">Graphic 67829 Version 9.0</div></div></div>"},"67831":{"type":"graphic_picture","displayName":"Porokeratosis histopathology 3","title":"Porokeratosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Porokeratosis</div><div class=\"cntnt\"><img style=\"width:504px; height:491px;\" src=\"images/DERM/67831_Porokeratosis_histopath_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A column of porokeratosis consistent with a cornoid lamella is present in the center of this specimen.</div><div id=\"graphicVersion\">Graphic 67831 Version 2.0</div></div></div>"},"67832":{"type":"graphic_table","displayName":"NTCTCSG staging","title":"Registry staging classification","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Registry staging classification</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"2\">Papillary carcinoma</td> <td class=\"subtitle1\" colspan=\"2\">Follicular carcinoma</td> </tr> <tr> <td class=\"subtitle2\">Age &#60;45</td> <td class=\"subtitle2\">Age &#8805;45</td> <td class=\"subtitle2\">Age &#60;45</td> <td class=\"subtitle2\">Age &#8805;45</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"3\">Primary tumor size, cm</td> <td>&#60;1</td> <td>I</td> <td>I</td> <td>I</td> <td>II</td> </tr> <tr> <td>1 to 4</td> <td>I</td> <td>II</td> <td>I</td> <td>III</td> </tr> <tr> <td>&#62;4</td> <td>II</td> <td>III</td> <td>II</td> <td>III</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"5\">Primary tumor description</td> <td>Microscopic multifocal</td> <td>I</td> <td>II</td> <td>I</td> <td>III</td> </tr> <tr> <td>Macroscopic multifocal or macroscopic tumor capsule invasion</td> <td>I</td> <td>II</td> <td>II</td> <td>III</td> </tr> <tr> <td>Microscopic extraglandular invasion</td> <td>I</td> <td>II</td> <td>I</td> <td>III</td> </tr> <tr> <td>Macroscopic extraglandular invasion</td> <td>II</td> <td>III</td> <td>II</td> <td>III</td> </tr> <tr> <td>Poor differentiation</td> <td>N/A</td> <td>N/A</td> <td>III</td> <td>III</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"2\">Metastases</td> <td>Cervical lymph node metastases</td> <td>I</td> <td>III</td> <td>I</td> <td>III</td> </tr> <tr> <td>Extracervical metastases</td> <td>III</td> <td>IV</td> <td>III</td> <td>IV</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Jonklaas J, Sarlis NJ, Litofsky D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006; 16:1229. Copyright ©2006 Mary Ann Liebert Publishers.</div><div id=\"graphicVersion\">Graphic 67832 Version 3.0</div></div></div>"},"67833":{"type":"graphic_table","displayName":"Treatment of Graves' hyperthyroidism","title":"Treatment of Graves' hyperthyroidism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of Graves' hyperthyroidism</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Therapy</td> <td class=\"subtitle1\">Advantages</td> <td class=\"subtitle1\">Disadvantages</td> </tr> <tr> <td>Thionamides</td> <td> <p>Chance of permanent remission</p> <p>Some patients avoid permanent hypothyroidism</p> <p>Lower initial cost</p> </td> <td> <p>Minor side effects: rash, hives, arthralgias, transient granulocytopenia, gastrointestinal symptoms</p> <p>Major side effects: agranulocytosis, vasculitis (lupus-like syndrome), hepatitis</p> <p>Risk of fetal goiter, hypothyroidism,&nbsp;and&nbsp;birth defects&nbsp;if pregnant</p> <p>Requires more frequent monitoring</p> </td> </tr> <tr> <td>Radioiodine</td> <td>Permanent resolution of hyperthyroidism</td> <td> <p>Permanent hypothyroidism</p> <p>Patient must take radiation precautions for several days after treatment, avoiding contact with young children and pregnant women</p> <p>Development or worsening of&nbsp;Graves' ophthalmopathy&nbsp;</p> <p>Rare radiation thyroiditis</p> <p>Patient concerns about long-term oncogenic effects of radiation</p> </td> </tr> <tr> <td>Surgery</td> <td>Rapid, permanent cure of hyperthyroidism</td> <td> <p>Permanent hypothyroidism</p> <p>Risks&nbsp;for&nbsp;iatrogenic&nbsp;hypoparathyroidism and recurrent laryngeal nerve damage</p> <p>Risks associated with general anesthesia</p> <p>High cost</p> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Summary of the advantages and disadvantages of the three major therapeutic modalities used in the treatment of Graves' hyperthyroidism.</div><div id=\"graphicVersion\">Graphic 67833 Version 4.0</div></div></div>"},"67835":{"type":"graphic_picture","displayName":"Multiple nerve plexuses B","title":"Multiple nerve plexuses are found in the lower airways","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Multiple nerve plexuses are found in the lower airways</div><div class=\"cntnt\"><img style=\"width:540px; height:211px;\" src=\"images/PULM/67835_multiple_nerve_plexuses_B.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">a) Luminal view of the airway mucosa of a 39-year old nonsmoker reveals that nerves, almost certainly vagal afferent nerves, project to the airway mucosa and epithelium. Many of these epithelial nerve fibers have varicosities (arrowhead), suggesting they may be able to release neurotransmitters locally in an axon reflex response. b) Cross-sectional confocal image of the photomicrograph in panel a reveals that axons of these sensory nerves occupy a plexus immediately below the luminal surface. c) Airway smooth muscle (stained in red with antisera to a-actin) as well as glands and bronchial vasculature (neither visible in this photomicrograph) are innervated by postganglionic autonomic nerve fibers (stained green with antisera to PGP 9.5).</div><div class=\"graphic_reference\">Figures a) and b) reproduced with permission from: Reproduced with permission from: Sparrow MP, Weichselbaum M, McCray PB. Development of the innervation and airway smooth muscle in human fetal lung. Am J Respir Cell Mol Biol. 1999; 20:550. Figure c) reproduced from Sparrow MP, Weichselbaum M, McCray PB. Development of the innervation and airway smooth muscle in human fetal lung. Am J Respir Cell Mol Biol. 1999; 20:550.</div><div id=\"graphicVersion\">Graphic 67835 Version 3.0</div></div></div>"},"67837":{"type":"graphic_picture","displayName":"Transbronchial biopsy sarcoid","title":"Sarcoidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sarcoidosis</div><div class=\"cntnt\"><img style=\"width:360px; height:234px;\" src=\"images/PULM/67837_Transbronchial_biopsy_sarco.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transbronchial biopsy findings are consistent with the clinical diagnosis of sarcoidosis. The histopathologic specimen shows granulomatous inflammation.</div><div class=\"graphic_reference\">Courtesy of Talmadge E King Jr, MD.</div><div id=\"graphicVersion\">Graphic 67837 Version 2.0</div></div></div>"},"67838":{"type":"graphic_figure","displayName":"Mechanisms of ACEI versus ARBs","title":"Actions of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on angiotensin and kinin pathways","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Actions of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on angiotensin and kinin pathways</div><div class=\"cntnt\"><img style=\"width:498px; height:243px;\" src=\"images/ALLRG/67838_ACEI_v_ARBs_in_AE_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left side of figure: ACE normally converts angiotension I to angiotension II, and ACE inhibitors (ACEIs) inhibit this reaction.<br />Right side of figure: In the presence of ACEIs, bradykinin is not degraded and binds to bradykinin B<SUB>2</SUB> receptors.</div><div class=\"graphic_footnotes\">ACE: angiotensin-converting enzyme; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin II receptor blocker.</div><div id=\"graphicVersion\">Graphic 67838 Version 4.0</div></div></div>"},"67840":{"type":"graphic_figure","displayName":"Dorsal onlay repair of urethral stricture","title":"Dorsal onlay repair of urethral stricture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dorsal onlay repair of urethral stricture</div><div class=\"cntnt\"><img style=\"width:395px; height:558px;\" src=\"images/SURG/67840_Dorsal-onlay-repair-of-urethral-stricture.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 67840 Version 1.0</div></div></div>"},"67841":{"type":"graphic_table","displayName":"Causes of cardiogenic and obstructive shock in children","title":"Causes of cardiogenic shock and obstructive shock in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of cardiogenic shock and obstructive shock in children</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Trauma</td> </tr> <tr> <td class=\"indent1\">Hemopericardium with tamponade*</td> </tr> <tr> <td class=\"sublist2_start\">Blunt cardiac injury</td> </tr> <tr> <td class=\"sublist2\">Myocardial contusion</td> </tr> <tr> <td class=\"sublist2\">Traumatic aneurysm</td> </tr> <tr> <td class=\"sublist2\">Traumatic septal defect</td> </tr> <tr> <td class=\"sublist2\">Chamber rupture</td> </tr> <tr> <td class=\"sublist2\">Valvular rupture</td> </tr> <tr> <td class=\"indent1\">Tension pneumothorax*</td> </tr> <tr> <td class=\"indent1\">Tension pneumopericardium*</td> </tr> <tr> <td class=\"subtitle1_single\">Congenital heart disease</td> </tr> <tr> <td class=\"indent1\">Critical aortic stenosis*</td> </tr> <tr> <td class=\"indent1\">Critical coarctation of the aorta*</td> </tr> <tr> <td class=\"indent1\">Mitral stenosis*</td> </tr> <tr> <td class=\"indent1\">Mitral atresia*</td> </tr> <tr> <td class=\"indent1\">Interrupted aortic arch*</td> </tr> <tr> <td class=\"indent1\">Hypoplastic left heart*</td> </tr> <tr> <td class=\"indent1\">Pulmonary hypotension</td> </tr> <tr> <td class=\"indent1\">Severe heart failure secondary to congenital heart disease</td> </tr> <tr> <td class=\"indent1\">Postoperative cardiac surgery</td> </tr> <tr> <td class=\"subtitle1_single\">Dysrhythmias</td> </tr> <tr> <td class=\"indent1\">Supraventricular tachycardia</td> </tr> <tr> <td class=\"indent1\">Ventricular tachycardia</td> </tr> <tr> <td class=\"indent1\">Atrioventricular block</td> </tr> <tr> <td class=\"indent1\">Junctional ectopic tachycardia</td> </tr> <tr> <td class=\"indent1\">Bradycardia</td> </tr> <tr> <td class=\"subtitle1_single\">Massive pulmonary embolus*</td> </tr> <tr> <td class=\"subtitle1_single\">Drug toxicity</td> </tr> <tr> <td class=\"indent1\">Beta blockers</td> </tr> <tr> <td class=\"indent1\">Barbiturates</td> </tr> <tr> <td class=\"indent1\">Chemotherapeutic agents</td> </tr> <tr> <td class=\"indent1\">Calcium channel blockers</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Radiation</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Metabolic derangements</td> </tr> <tr> <td class=\"indent1\">Acidosis</td> </tr> <tr> <td class=\"indent1\">Hyperkalemia</td> </tr> <tr> <td class=\"indent1\">Hypocalcemia</td> </tr> <tr> <td class=\"indent1\">Congenital organic acidemias</td> </tr> <tr> <td class=\"subtitle1_single\">Late septic shock</td> </tr> <tr> <td class=\"subtitle1_single\">Hypoxic or anoxic/ischemic injury</td> </tr> <tr> <td class=\"subtitle1_single\">Hypothermia</td> </tr> <tr> <td class=\"subtitle1_single\">Viral myocarditis</td> </tr> <tr> <td class=\"subtitle1_single\">Cardiomyopathies</td> </tr> <tr> <td class=\"indent1\">Dilated cardiomyopathies</td> </tr> <tr> <td class=\"sublist2_start\">Infiltrative cardiomyopathies</td> </tr> <tr> <td class=\"sublist2\">Mucopoylsaccharidosis</td> </tr> <tr> <td class=\"sublist2\">Glycogen storage diseases</td> </tr> <tr> <td class=\"subtitle1_single\">Ischemic heart disease</td> </tr> <tr> <td class=\"indent1\">Anomalous left coronary artery</td> </tr> <tr> <td class=\"indent1\">Kawasaki disease</td> </tr> <tr> <td class=\"indent1\">Myocardial infarction</td> </tr> <tr> <td class=\"subtitle1_single\">Thyrotoxicosis</td> </tr> <tr> <td class=\"subtitle1_single\">Pheochromocytoma</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">*Denotes that the condition primarily causes obstructive shock. All other conditions primarily cause cardiogenic shock. </div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Witte MK, Hill JH, Blumer JL. Adv Pediatr 1987; 34:139.</li>&#xD;&#xA;    <li>Perkin RM, Levin DL. Shock. In: Essentials of Pediatric Intensive Care, Levin DL, Morriss FC (Eds), Quality Medical Pub, St. Louis, MO 1990. p.78.</li>&#xD;&#xA;    <li>Tobias JD. Shock in children: The first 60 minutes. Pediatr Ann 1996; 25:330.</li>&#xD;&#xA;    <li>Bengur AR, Meliones JN. Cardiogenic shock. New Horiz 1998; 6:139.</li>&#xD;&#xA;    <li>Bell LM. Shock. In: Textbook of Pediatric Emergency Medicine, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2000. p.47.</li>&#xD;&#xA;    <li>Williams TM. Indiana Med 1988; 81:18.</li>&#xD;&#xA;    <li>Hazinski MF, Barkin RM. Shock. In: Pediatric Emergency Medicine: Concepts and Clinical Practice, Barkin RM (Ed), Mosby-Yearbook Inc, St. Louis, MO 1997. p.118.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 67841 Version 7.0</div></div></div>"},"67844":{"type":"graphic_figure","displayName":"Diagram of human eye","title":"Anatomy of the eye","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Anatomy of the eye</div><div class=\"cntnt\"><img style=\"width:511px; height:590px;\" src=\"images/PC/67844_Diagram_of_human_eye.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 67844 Version 2.0</div></div></div>"},"67845":{"type":"graphic_picture","displayName":"Palpation radial styloid","title":"Palpation of the radial styloid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Palpation of the radial styloid</div><div class=\"cntnt\"><img style=\"width:379px; height:267px;\" src=\"images/EM/67845_Palpation_radial_styloid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The wrist is placed in a neutral position with the radial side up. The most distal portion of the radial styloid is identified, marked, and palpated for local tenderness.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 67845 Version 2.0</div></div></div>"},"67846":{"type":"graphic_diagnosticimage","displayName":"Loculated pleural effusion","title":"Loculated pleural effusion","html":"<div class=\"graphic normal\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Loculated pleural effusion</div><div class=\"cntnt\"><img style=\"width:509px; height:266px;\" src=\"images/PULM/67846_Loculated_pleural_effusion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiographs show a loculated pleural effusion in the left major fissure. The mass-like appearance on the&nbsp;frontal view (left) forms a pseudotumor. The lateral view (right) clearly localizes the mass to the major fissure.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 67846 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"67848":{"type":"graphic_picture","displayName":"Chlamydia cervicitis","title":"Chlamydia cervicitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chlamydia cervicitis</div><div class=\"cntnt\"><img style=\"width:288px; height:346px;\" src=\"images/ID/67848_Chlamydia_cervicitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mucopurulent discharge is visible coming from the os in a patient with Chlamydia cervicitis. The cervix is erythematous and friable.</div><div class=\"graphic_reference\">Reproduced from the Centers for Disease Control and Prevention.</div><div id=\"graphicVersion\">Graphic 67848 Version 2.0</div></div></div>"},"67850":{"type":"graphic_picture","displayName":"Truncal rash of RMSF","title":"Rocky Mountain spotted fever","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rocky Mountain spotted fever</div><div class=\"cntnt\"><img style=\"width:385px; height:252px;\" src=\"images/ID/67850_Truncal_rash_of_RMSF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Extensive maculopapular and petechial lesions on the trunk and thigh in a patient with Rocky Mountain spotted fever. The rash characteristically begins on the wrists and ankles and spreads centripetally.</div><div class=\"graphic_reference\">Courtesy of Harold G Muchmore. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp;Wilkins, Baltimore, 1995.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 67850 Version 6.0</div></div></div>"},"67851":{"type":"graphic_table","displayName":"Causes of pericardial disease","title":"Causes of pericardial disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of pericardial disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Idiopathic (presumed to be viral, postviral, or immune-mediated)</td> </tr> <tr> <td class=\"indent1\">In most case series, the majority of patients are not found to have an identifiable cause of pericardial disease. Frequently such cases are presumed to have a viral or autoimmune etiology.</td> </tr> <tr> <td class=\"subtitle1_single\">Infectious</td> </tr> <tr> <td class=\"indent1\">Viral - Coxsackievirus, echovirus, adenovirus, Epstein-Barr virus, cytomegalovirus, influenza, varicella, rubella, HIV, hepatitis B, mumps, parvovirus B19, vaccina (smallpox vaccine)</td> </tr> <tr> <td class=\"indent1\">Bacterial - <em>Mycobacterium tuberculosis </em>(most common cause in countries where tuberculosis is endemic), <em>Staphylococcus, Streptococcus, Haemophilus, Neisseria </em>(<em>N. gonorrhoeae or N. meningitidis</em>), <em>Chlamydia </em>(<em>C. psittaci or C. trachomatis</em>), <em>Legionella, Salmonella, Borrelia burgdorferi </em>(the cause of Lyme disease), <em>Mycoplasma, Actinomyces, Nocardia, Tropheryma whippelii, Treponema, Rickettsia</em></td> </tr> <tr> <td class=\"indent1\">Fungal - <em>Histoplasma, Aspergillus, Blastomyces, Coccidioides, Candida</em></td> </tr> <tr> <td class=\"indent1\">Parasitic - <em>Echinococcus</em>, amebic, <em>Toxoplasma</em></td> </tr> <tr> <td class=\"indent1\">Infective endocarditis with valve ring abscess</td> </tr> <tr> <td class=\"subtitle1_single\">Noninfectious</td> </tr> <tr> <td class=\"subtitle2_single\">Autoimmune and autoinflammatory</td> </tr> <tr> <td class=\"indent1\">Systemic inflammatory diseases, especially lupus, rheumatoid arthritis, scleroderma, Sj&#246;gren syndrome, vasculitis, mixed connective disease</td> </tr> <tr> <td class=\"indent1\">Autoinflammatory diseases (especially familial Mediterranean fever and tumor necrosis factor associated periodic syndrome [TRAPS], IgG4-related disease)</td> </tr> <tr> <td class=\"indent1\">Postcardiac injury syndromes (immune-mediated after cardiac trauma in predisposed individuals)</td> </tr> <tr> <td class=\"indent1\">Other - Granulomatosis with polyangiitis (Wegener's), polyarteritis nodosa, sarcoidosis, inflammatory bowel disease (Crohn's, ulcerative colitis), Whipple's, giant cell arteritis, Beh&#231;et's disease, rheumatic fever</td> </tr> <tr> <td class=\"subtitle2_single\">Neoplasm</td> </tr> <tr> <td class=\"indent1\">Metastatic - Lung or breast cancer, Hodgkin's disease, leukemia, melanoma</td> </tr> <tr> <td class=\"indent1\">Primary - Rhabdomyosarcoma, teratoma, fibroma, lipoma, leiomyoma, angioma</td> </tr> <tr> <td class=\"indent1\">Paraneoplastic</td> </tr> <tr> <td class=\"subtitle2_single\">Cardiac</td> </tr> <tr> <td class=\"indent1\">Early infarction pericarditis</td> </tr> <tr> <td class=\"indent1\">Late postcardiac injury syndrome (Dressler's syndrome), also seen in other settings (eg, post-myocardial infarction and post-cardiac surgery)</td> </tr> <tr> <td class=\"indent1\">Myocarditis</td> </tr> <tr> <td class=\"indent1\">Dissecting aortic aneurysm</td> </tr> <tr> <td class=\"subtitle2_single\">Trauma</td> </tr> <tr> <td class=\"indent1\">Blunt</td> </tr> <tr> <td class=\"indent1\">Penetrating</td> </tr> <tr> <td class=\"indent1\">Iatrogenic - Catheter and pacemaker perforations, cardiopulmonary resuscitation, post-thoracic surgery</td> </tr> <tr> <td class=\"subtitle2_single\">Metabolic</td> </tr> <tr> <td class=\"indent1\">Hypothyroidism - Primarily pericardial effusion</td> </tr> <tr> <td class=\"indent1\">Uremia</td> </tr> <tr> <td class=\"indent1\">Ovarian hyperstimulation syndrome</td> </tr> <tr> <td class=\"subtitle2_single\">Radiation</td> </tr> <tr> <td class=\"subtitle2_single\">Drugs (rare)</td> </tr> <tr> <td class=\"indent1\">Procainamide, isoniazid, or hydralazine as part of drug-induced lupus</td> </tr> <tr> <td class=\"indent1\">Other - Cromolyn sodium, dantrolene, methysergide, anticoagulants, thrombolytics, phenytoin, penicillin, phenylbutazone, doxorubicin</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References: <br /><OL>&#xD;&#xA;<LI>LeWinter M. Clinical practice. Acute pericarditis. N Engl J Med 2014; 371:2410.</LI>&#xD;&#xA;<LI>Imazio M, Gaita F. Diagnosis and treatment of pericarditis. Heart 2015; 101:1159.</LI>&#xD;&#xA;<LI>Imazio M. Contemporary management of pericardial diseases. Curr Opin Cardiol 2012; 27:308.</LI></OL></div><div id=\"graphicVersion\">Graphic 67851 Version 8.0</div></div></div>"},"67856":{"type":"graphic_picture","displayName":"Burns from a hot coffee mug in leprosy","title":"Ulcers from burns due to a hot coffee mug in a leprosy patient","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Ulcers from burns due to a hot coffee mug in a leprosy patient</div><div class=\"cntnt\"><img style=\"width:480px; height:423px;\" src=\"images/ID/67856_Burns_coffee_leprosy.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 67856 Version 1.0</div></div></div>"},"67857":{"type":"graphic_figure","displayName":"Excision and clot evacuation of a thrombosed hemorrhoid","title":"Excision and clot evacuation of a thrombosed hemorrhoid","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Excision and clot evacuation of a thrombosed hemorrhoid</div><div class=\"cntnt\"><img style=\"width:541px; height:643px;\" src=\"images/SURG/67857_Hemorrhoid-excision.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the procedure for an excision of a thrombosed hemorrhoid and evacuation of the clot.<br />Figure A: Injection of local anesthetic at the base of the thrombosed hemorrhoid.<br />Figure B: Excision of an ellipse of skin with iris scissors. Do&nbsp;not excise deep into the anal sphincter.<br />Figure C: Excised skin ellipse and clot evacuated.<br />Figure D: Hemorrhoid excised, clot evacuated, wound left open to heal. Note underlying anal sphincter.</div><div id=\"graphicVersion\">Graphic 67857 Version 4.0</div></div></div>"},"67858":{"type":"graphic_picture","displayName":"Corneal alkali burn","title":"Corneal alkali burn","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Corneal alkali burn</div><div class=\"cntnt\"><img style=\"width:342px; height:232px;\" src=\"images/EM/67858_Corneal_alkali_burn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Alkali burn. Significant corneal, conjunctival, and scleral damage occurred after a severe alkali injury. Notice the opacified cornea and the conjunctival and scleral blanching, indicating severe damage to the surrounding blood vessels.</div><div class=\"graphic_reference\">Reproduced with permission from: Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2e. Lippincott Williams &amp; Wilkins, 2001. Copyright &#169; 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 67858 Version 3.0</div></div></div>"},"67861":{"type":"graphic_diagnosticimage","displayName":"Abdominal aortic aneurysm long and short axis","title":"Abdominal aortic aneurysm long and short axis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Abdominal aortic aneurysm long and short axis</div><div class=\"cntnt\"><img style=\"width:435px; height:216px;\" src=\"images/CARD/67861_Abdominal_aorta_aneurysm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The long axis view shows an aneurysm of the abdominal aorta (A Ao An) as the aorta crosses the diaphragm. Prominent plaques just beyond the aneurysm can be appreciated.<br> (B) The short axis through the aneurysm (An) also shows the inferior vena cava (IVC).</div><div id=\"graphicVersion\">Graphic 67861 Version 5.0</div></div></div>"},"67862":{"type":"graphic_figure","displayName":"Cytokines in scleroderma","title":"Paracrine interactions between cells involved in scleroderma","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Paracrine interactions between cells involved in scleroderma</div><div class=\"cntnt\"><img style=\"width:542px; height:277px;\" src=\"images/RHEUM/67862_Cytokines_in_scleroderma.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Activated cells of the immune system, endothelial cells, and fibroblasts are all capable of releasing cytokines and growth factors which might exert a paracrine or autocrine influence on other cells. This could in turn modulate celluar properties and induce production of the same or other factors. Thus, there is the potential for local cytokine loops to initiate and perpetuate the immunologic, vascular, and fibrotic components of scleroderma.</div><div id=\"graphicVersion\">Graphic 67862 Version 1.0</div></div></div>"},"67863":{"type":"graphic_picture","displayName":"Reactive arthritis of knee","title":"Asymmetical arthritis of the knees","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Asymmetical arthritis of the knees</div><div class=\"cntnt\"><img style=\"width:322px; height:504px;\" src=\"images/RHEUM/67863_Reactive_arthritis_of_knee.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Asymmetrical swelling due to reactive arthritis is apparent in this photograph. The patellar borders are effaced and there is suprapatellar fullness of the left knee.</div><div class=\"graphic_reference\">Courtesy of Filip de Keyser.</div><div id=\"graphicVersion\">Graphic 67863 Version 1.0</div></div></div>"},"67864":{"type":"graphic_table","displayName":"Treatment of reflex syncope","title":"Treatment of reflex syncope","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of reflex syncope</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"80%\"></colgroup><colgroup span=\"2\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Recommendations</td> <td class=\"subtitle1\">Class*</td> <td class=\"subtitle1\">Level<sup>&#182;</sup></td> </tr> <tr> <td>Explanation of the diagnosis, provision of reassurance, and explanation of risk recurrence are indicated in all patients</td> <td>I</td> <td>C</td> </tr> <tr> <td>Isometric PCMs are indicated in patients with prodrome</td> <td>I</td> <td>B</td> </tr> <tr> <td>Cardiac pacing should be considered in patients with dominant cardioinhibitory CSS</td> <td>IIa</td> <td>B</td> </tr> <tr> <td>Cardiac pacing should be considered in patients with frequent recurrent reflex syncope, age &#62;40 years, and documented spontaneous cardioinhibitory response during monitoring</td> <td>IIa</td> <td>B</td> </tr> <tr> <td>Midodrine may be indicated in patients with VVS refractory to lifestyle measures</td> <td>IIb</td> <td>B</td> </tr> <tr> <td>Tilt training may be useful for education of patients but long-term benefit depends on compliance</td> <td>IIb</td> <td>B</td> </tr> <tr> <td>Cardiac pacing may be indicated in patients with tilt-induced cardioinhibitory response with recurrent frequent unpredictable syncope and age &#62;40 after alternative therapy has failed</td> <td>IIb</td> <td>C</td> </tr> <tr> <td>Cardiac pacing is not indicated in the absence of a documented cardioinhibitory reflex</td> <td>III</td> <td>C</td> </tr> <tr> <td>&#946;-adrenergic blocking drugs are not indicated</td> <td>III</td> <td>A</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CSS: carotid sinus syndrome; PCM: physical isometric counterpressure manoeuvre; VVS: vasovagal syncope.<br />* Class of recommendation.<br />¶ Level of evidence.</div><div class=\"graphic_reference\">Reproduced with permission from: European Heart Rhythm Association (EHRA), Heart Failure Association (HFA), Heart Rhythm Society (HRS), et al. Guidelines for the diagnosis and management of syncope (version 2009): the Task Force for the Diagnosis and Management of Syncope of the European Society of Cardiology (ESC). Eur Heart J 2009; 30:2631. Copyright © 2009 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 67864 Version 8.0</div></div></div>"},"67865":{"type":"graphic_waveform","displayName":"ECG LAD ischemia or infarct deep T-wave inversion pattern","title":"ECG LAD deep T-wave (wellens) inversion pattern","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">ECG LAD deep T-wave (wellens) inversion pattern</div><div class=\"cntnt\"><img style=\"width:526px; height:214px;\" src=\"images/CARD/67865_LAD_ischemia_infarct_Twave.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Dr. Ary Goldberger.</div><div id=\"graphicVersion\">Graphic 67865 Version 4.0</div></div></div>"},"67866":{"type":"graphic_picture","displayName":"Male LGV","title":"Male lymphogranuloma venereum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Male lymphogranuloma venereum</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/ID/67866_Male_LGV.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 67866 Version 3.0</div></div></div>"},"67867":{"type":"graphic_diagnosticimage","displayName":"Unstable comminuted proximal phalangeal shaft fracture","title":"Unstable comminuted proximal phalangeal shaft fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Unstable comminuted proximal phalangeal shaft fracture</div><div class=\"cntnt\"><img style=\"width:274px; height:477px;\" src=\"images/SURG/67867_Unstable_com_prox_phal_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Unstable fractures need to be reduced and the stability of the reduction assessed by radiograph.</div><div id=\"graphicVersion\">Graphic 67867 Version 7.0</div></div></div>"},"67870":{"type":"graphic_figure","displayName":"MI location PI","title":"Location of heart attacks","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Location of heart attacks</div><div class=\"cntnt\"><img style=\"width:530px; height:534px;\" src=\"images/PI/67870_MI_location_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The heart pumps oxygen-rich blood through the huge network of arteries that extend throughout the body, including the vessels that supply oxygen to the heart muscle itself. These vessels, called coronary arteries, lie on the surface of the heart muscle before entering the heart muscle itself. Depending upon which coronary arteries are obstructed, different areas of the heart can suffer damage during an MI.</div><div id=\"graphicVersion\">Graphic 67870 Version 3.0</div></div></div>"},"67871":{"type":"graphic_picture","displayName":"Bronchiolitis obliterans I","title":"Bronchiolitis obliterans","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bronchiolitis obliterans</div><div class=\"cntnt\"><img style=\"width:360px; height:237px;\" src=\"images/PULM/67871_Bronchiolitis_obliterans_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bronchiolitis obliterans in chronic lung transplant rejection. Photomicrograph of early lesion of chronic lung transplant rejection, demonstrating inflammation and disruption of the epithelium of small airways.</div><div class=\"graphic_reference\">Courtesy of L Kobzik, MD.</div><div id=\"graphicVersion\">Graphic 67871 Version 1.0</div></div></div>"},"67873":{"type":"graphic_table","displayName":"Pneumonectomy complications","title":"Complications associated with pneumonectomy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Complications associated with pneumonectomy</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"container\"><table cellspacing=\"0\"><tbody><tr><td class=\"subtitle1_single\">Pulmonary</td></tr>\n\t\t\t\t\t\t<tr><td>Postpneumonectomy pulmonary edema</td></tr>\n\t\t\t\t\t\t<tr><td>Postpneumonectomy syndrome</td></tr>\n\t\t\t\t\t\t<tr><td>Intraoperative spillage</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Pleural space</td></tr>\n\t\t\t\t\t\t<tr><td>Postpneumonectomy space empyema</td></tr>\n\t\t\t\t\t\t<tr><td>Bronchopleural fistula</td></tr>\n\t\t\t\t\t\t<tr><td>Esophagopleural fistula</td></tr>\n\t\t\t\t\t\t<tr><td>Chylothorax</td></tr>\n\t\t\t\t\t\t<tr><td>Contralateral pneumothorax</td></tr>\n\t\t\t\t\t\t<tr><td>Acute hemothorax</td></tr></tbody></table></td>\n\n      <td class=\"container\"><table cellspacing=\"0\"><tbody><tr><td class=\"subtitle1_single\">Cardiovascular</td></tr>\n\t\t\t\t\t\t<tr><td>Arrhythmias</td></tr>\n\t\t\t\t\t\t<tr><td>Myocardial infarction</td></tr>\n\t\t\t\t\t\t<tr><td>Intracardiac right-to-left shunt</td></tr>\n\t\t\t\t\t\t<tr><td>Cardiac hernation</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1_start\">Embolism</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Thromboembolism</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\"> Tumor embolism </td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Air embolism</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Miscellaneous</td></tr>\n\t\t\t\t\t\t<tr><td>Esophageal motility disorders</td></tr>\n\t\t\t\t\t\t<tr><td>Gastric volvulus</td></tr>\n\t\t\t\t\t\t<tr><td>Lactation</td></tr>\n\t\t\t\t\t\t<tr><td>Pneumopericardium</td></tr>\n\t\t\t\t\t\t<tr><td>Postpneumonectomy paralysis</td></tr>\n\t\t\t\t\t\t<tr><td>Postpneumonectomy scoliosis</td></tr></tbody></table></td>\n\n    </tr>\n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n    \n    \n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n    \n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 67873 Version 1.0</div></div></div>"},"67875":{"type":"graphic_picture","displayName":"Papillitis","title":"Papillitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Papillitis</div><div class=\"cntnt\"><img style=\"width:432px; height:321px;\" src=\"images/NEURO/67875_Papillitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Don C Bienfang, MD.</div><div id=\"graphicVersion\">Graphic 67875 Version 1.0</div></div></div>"},"67876":{"type":"graphic_table","displayName":"CBTRUS incidence CNS neuroepithelial tumors children","title":"Distribution of neuroepithelial primary brain tumors by histology in children and adolescents (0 to 19 years)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Distribution of neuroepithelial primary brain tumors by histology in children and adolescents (0 to 19 years)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Histology</td> <td class=\"subtitle1\">Percent of total&nbsp;</td> <td class=\"subtitle1\">Annual incidence rate*&nbsp;</td> </tr> <tr> <td>Pilocytic astrocytoma</td> <td>24.1</td> <td>0.97</td> </tr> <tr> <td>Embryonal tumors<sup>&#182;</sup></td> <td>19.5</td> <td>0.78</td> </tr> <tr> <td>Glioma malignant, NOS</td> <td>19.2</td> <td>0.77</td> </tr> <tr> <td>Neuronal and mixed neuronal-glial tumors</td> <td>8.7</td> <td>0.35</td> </tr> <tr> <td>Ependymal tumors</td> <td>7.6</td> <td>0.30</td> </tr> <tr> <td>Diffuse astrocytoma</td> <td>6.6</td> <td>0.27</td> </tr> <tr> <td>Glioblastoma</td> <td>3.7</td> <td>0.15</td> </tr> <tr> <td>Choroid plexus tumors</td> <td>2.9</td> <td>0.12</td> </tr> <tr> <td>Unique astrocytoma variants</td> <td>2.5</td> <td>0.10</td> </tr> <tr> <td>Tumors of the pineal region</td> <td>1.1</td> <td>0.05</td> </tr> <tr> <td>Oligodendroglioma&nbsp;</td> <td>0.9</td> <td>0.04&nbsp;</td> </tr> <tr> <td>Oligoastrocytic tumors&nbsp;</td> <td>0.6&nbsp;</td> <td>0.02&nbsp;</td> </tr> <tr> <td>Other neuroepithelial tumors&nbsp;</td> <td>0.3&nbsp;</td> <td>0.01&nbsp;</td> </tr> <tr> <td><strong>Total</strong></td> <td><strong>100.0</strong></td> <td><strong>4.00</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">CBTRUS Statistical Report: NPCR and SEER Data from 2008-2012.<br /><SUP>* </SUP>Average annual age-adjusted incidence rate<br /><SUP>¶</SUP> Includes medulloblastoma, primitive neuroectodermal tumor, atypical teratoid/rhabdoid tumor, and other emryonal histologies.</div><div class=\"graphic_footnotes\">NOS: not otherwise specified. </div><div class=\"graphic_reference\">Data from: Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. Neuro Oncol 2015; 17 Suppl 4:iv1.</div><div id=\"graphicVersion\">Graphic 67876 Version 2.0</div></div></div>"},"67877":{"type":"graphic_figure","displayName":"CF nasal PD","title":"Nasal potential difference measurements in cystic fibrosis","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Nasal potential difference measurements in cystic fibrosis</div><div class=\"cntnt\"><img style=\"width:538px; height:366px;\" src=\"images/PEDS/67877_CF_nasal_PD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Examples of nasal potential difference tracings in a normal patient (Panel A) and a patient with cystic fibrosis (Panel B). The x-axis is time (min) as described, and the y-axis is nasal potential difference (PD) (mV, upward is polarizing). The normal phenotype includes a lower (less polarized) baseline PD in Solution #1, a small depolarizing change in PD after amiloride perfusion (Solution #2), and a repolarizing PD after perfusion with low-chloride (0 [CI-]) and low-chloride + isoproterenol (Solutions #3 and #4 - continued presence of amiloride). The cystic fibrosis phenotype includes a higher (more polarized) baseline PD, a large depolarizing change in PD after amiloride perfusion, and absent repolarization after perfusion with 0 [CI-] and 0 [CI-] + isoproterenol. ATP-stimulated PD (Solution #5, reflecting stimulation of calcium activated chloride conductance) is retained in normal subjects and in subjects with cystic fibrosis.</div><div class=\"graphic_reference\">Reproduced with permission from: Clancy JP, Rowe SM, Bebok Z, et al. No Detectable Improvements in Cystic Fibrosis Transmembrane Conductance Regulator by Nasal Aminoglycosides in Patients with Cystic Fibrosis with Stop Mutations. Am J Respir Cell Mol Biol 2007; 37:59. Official Journal of the American Thoracic Society. Copyright ©2007 American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 67877 Version 2.0</div></div></div>"},"67878":{"type":"graphic_diagnosticimage","displayName":"Epiglottitis - Lateral radiograph","title":"Epiglottitis: Lateral radiograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Epiglottitis: Lateral radiograph</div><div class=\"cntnt\"><img style=\"width:287px; height:340px;\" src=\"images/PEDS/67878_Epiglottitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral neck radiograph demonstrating swollen epiglottis (arrow) and aryepiglottic folds (asterisks) in a child with epiglottitis due to <EM>Haemophilus influenzae</EM> type b. The swollen epiglottis is often called a \"thumb sign.\"</div><div class=\"graphic_reference\">Courtesy of Evelyn Y Anthony, MD, Wake Forest University School of Medicine.</div><div id=\"graphicVersion\">Graphic 67878 Version 7.0</div></div></div>"},"67879":{"type":"graphic_picture","displayName":"Perichondritis","title":"Perichondritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Perichondritis</div><div class=\"cntnt\"><img style=\"width:300px; height:339px;\" src=\"images/PEDS/67879_Perichondritis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Perichondritis is characterized by swelling and erythema of the outer ear.</div><div class=\"graphic_reference\">Reproduced with permission from: Handler SD, Myer CM. Atlas of ear, nose and throat disorders in children. Ontario, Canada: BC Decker; 1998:12. Copyright &#169; 1998 PMPH-USA, Ltd.</div><div id=\"graphicVersion\">Graphic 67879 Version 4.0</div></div></div>"},"67880":{"type":"graphic_table","displayName":"Inherited metabolic disease","title":"Transplantation of allogeneic hepatocytes in patients with inherited metabolic diseases","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Transplantation of allogeneic hepatocytes in patients with inherited metabolic diseases</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"15%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Diagnosis [reference]</td> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">Procedure and outcome</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Alpha-1 antitrypsin deficiency</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">[1,2]</td> <td class=\"centered\">4.5 months</td> <td>Orthotopic liver transplantation (OLT) 2 days after hepatocyte transplantation. Explanted liver showed cirrhosis.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Crigler-Najjar syndrome type 1</td> </tr> <tr> <td class=\"centered\">[3]</td> <td class=\"centered\">10 years</td> <td>Total bilirubin reduced by 50%. Bilirubin glucuronide demonstrated in bile up to 3.5 years. Auxilliary liver transplantation (ALTx) after 4 years.</td> </tr> <tr> <td class=\"centered\">[4]</td> <td class=\"centered\">3.5 years</td> <td>Nine infusions were given. Serum bilirubin was reduced by 40% for at least 9 months. Ultimate outcome not reported.</td> </tr> <tr> <td class=\"centered\">[5]</td> <td class=\"centered\">9 years</td> <td>Serum bilirubin was reduced by 32%. OLT after 4.6 months.</td> </tr> <tr> <td class=\"centered\">[6]</td> <td class=\"centered\">8 years</td> <td>Serum bilirubin reduced by 30%. OLT after 11 months.</td> </tr> <tr> <td class=\"centered\">[7]</td> <td class=\"centered\">8 years</td> <td>Hepatocyte transplantation by one percutaneous infusion and&nbsp;eight infusions through an implanted mesenteric Port-a-Cath (PAC) over 5 months. Serum bilirubin was reduced by 40%. OLT after 20 months.</td> </tr> <tr> <td class=\"centered\">[8]</td> <td class=\"centered\">1.5 years</td> <td>Serum bilirubin was reduced by 40%. OLT after 8 months.</td> </tr> <tr> <td class=\"centered\">[8]</td> <td class=\"centered\">3.5 years</td> <td>No clear benefit.</td> </tr> <tr> <td class=\"centered\">[9]</td> <td class=\"centered\">2 years</td> <td>Hepatic progenitor cells were infused through the hepatic artery. Serum bilirubin was reduced by 50%. Ultimate outcome was not reported.</td> </tr> <tr> <td class=\"centered\">[10]</td> <td class=\"centered\">11 years</td> <td>Serum bilirubin was reduced by 20%. On waiting list for OLT.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">[11]</td> <td class=\"centered\">7 months</td> <td>Serum bilirubin was reduced by 50%, bilirubin levels stable after 1 year. Improvement of psychomotor parameters.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Factor VII deficiency</td> </tr> <tr> <td class=\"centered\">[12]</td> <td class=\"centered\">3 months</td> <td>Requirement of rFVII was reduced by 70%. OLT after 7 months.</td> </tr> <tr> <td class=\"centered\">[12]</td> <td class=\"centered\">35 months</td> <td>Requirement of rFVII was reduced by 70%. OLT after 8 months.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">[13]</td> <td class=\"centered\">4 months</td> <td>Requirement of rFVII was reduced. Ultimate outcome not reported.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Glycogen storage disease type 1a</td> </tr> <tr> <td class=\"centered\">[11]</td> <td class=\"centered\">6 years</td> <td>Hypoglycemic episodes were reduced. No admission for hypoglycemia at 1 year follow up after hepatocyte transplantation.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">[14]</td> <td class=\"centered\">47 years</td> <td>No hypoglycemia on a normal diet on a 9-month follow up. Long-term outcome not reported.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Glycogen storage disease type 1b</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">[15]</td> <td class=\"centered\">18 years</td> <td>Normal glucose-6-phosphatase activity for 7 months. Ultimate outcome not reported.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Infantile Refsum's disease</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">[16]</td> <td class=\"centered\">4 years</td> <td>Pipecholic acid decreased by 40% and c26:c22 fatty acid ratio by 36% after 18 months. Ultimate outcome not reported.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Phenylketonuria</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">[17]</td> <td class=\"centered\">6 years</td> <td>Patient received hepatocytes from the explanted liver of a patient with glucogen storage disease 1a, and a second transplantation from a deceased donor 7.5 months later. Plasma phenylalanine levels were normalized for 3 months after the second infusion. The therapeutic effect waned after that and patient had to be reinstated on phenylalanine-restricted diet.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Primary hyperoxaluria type 1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">[18]</td> <td class=\"centered\">33 months</td> <td>Reduction of plasma oxalate levels by 25 to 33%. OLT and kidney transplantation after 12 months.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Progressive familial intrahepatic cholestasis type 2</td> </tr> <tr> <td class=\"centered\">[4,8]</td> <td class=\"centered\">32 months</td> <td>Patient had cirrhosis of the liver. No benefit was demonstrated by hepatocyte transplantation. OLT after 5 months.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">[4,8]</td> <td class=\"centered\">16 months</td> <td>Patient had cirrhosis of the liver. No benefit was demonstrated by hepatocyte transplantation. OLT after 14 months.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Tyrosinemia type 1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">[11]</td> <td class=\"centered\">45 days</td> <td>Serum bilirubin levels decreased and there was improvement of coagulopathy. OLT after 45 days. Explanted liver had established cirrhosis.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Urea cycle disorders</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Ornithine transcarbamylase (OTC) deficiency</td> </tr> <tr> <td class=\"centered\">[19]</td> <td class=\"centered\">5 years</td> <td>Blood ammonia level decreased. Biopsy on day 28 showed 0.5% of the OTC activity in normal liver. Patient died of sepsis 42 days after hepatocyte transplantation.</td> </tr> <tr> <td class=\"centered\">[20]</td> <td class=\"centered\">10 hours</td> <td>Blood ammonia level decreased. Protein tolerance improved. OLT after 6 months.</td> </tr> <tr> <td class=\"centered\">[21]</td> <td class=\"centered\">Newborn</td> <td>Hepatocytes were infused through the umbilical vein. Blood ammonia level was normal on normal diet. No neurological abnormality developed. OLT after 7 months.</td> </tr> <tr> <td class=\"centered\">[7]</td> <td class=\"centered\">14 months</td> <td>Catheter was malpositioned. Effect of hepatocyte transplantation was not reported. OLT after 6 months.</td> </tr> <tr> <td class=\"centered\">[22]</td> <td class=\"centered\">14 months</td> <td>Blood ammonia was reduced and urea production was increased. There was psychomotor improvement. OLT after 6 months.</td> </tr> <tr> <td class=\"centered\">[23]</td> <td class=\"centered\">1 day</td> <td>Blood ammonia was reduced and urea production was increased. Protein tolerance was improved. ALTx after 7 months.</td> </tr> <tr> <td class=\"centered\">[24]</td> <td class=\"centered\">6 hours</td> <td>Blood ammonia was reduced, urea production was increased, and urinary orotic acid excretion became normal. Patient died 4 months after hepatocyte transplantation.</td> </tr> <tr> <td class=\"centered\">[24]</td> <td class=\"centered\">9 days</td> <td>Blood ammonia was reduced, protein tolerance improved and urinary orotic acid excretion became normal. On waiting list for OLT 6 months after hepatocyte transplantation.</td> </tr> <tr> <td class=\"centered\">[25]</td> <td class=\"centered\">5 years</td> <td>Blood ammonia was reduced, and glutamine levels were normal. Patient died 45 days after hepatocyte transplantation.</td> </tr> <tr> <td class=\"centered\">[21]</td> <td class=\"centered\">1 day</td> <td>Blood ammonia was reduced, urea production increased, and protein tolerance improved. ALTx after 7 months. Patient remained neurologically normal.</td> </tr> <tr> <td class=\"centered\">[11]</td> <td class=\"centered\">12 years</td> <td>Blood ammonia was reduced, urea production increased, and glutamine levels were normal. Patient died of septicemia 30 days after hepatocyte transplantation.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">[26]</td> <td class=\"centered\">11 days</td> <td>Blood ammonia was reduced and the patient remained neurologically normal 3 months after hepatocyte transplantation.</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Arginosuccinate lyase deficiency</td> </tr> <tr> <td class=\"centered\">[27]</td> <td class=\"centered\">42 months</td> <td>Blood ammonia was reduced and there was psychomotor improvement. OLT after 18 months.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">[7]</td> <td class=\"centered\">3 years</td> <td>Blood ammonia was reduced. Ultimate outcome was not reported.</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Carbomoyl phosphate synthase I deficiency</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">[28]</td> <td class=\"centered\">2.5 months</td> <td>Blood ammonia was reduced and urea production increased. Patient was on waiting list for OLT 11 months after hepatocyte transplantation.</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">Citrulinemia</td> </tr> <tr> <td class=\"centered\">[28]</td> <td class=\"centered\">3 years</td> <td>Blood ammonia was reduced, urea production was increased, and protein tolerance was improved. Ultimate outcome was not reported.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Fisher RA, Strom SC. Human hepatocyte transplantation: Worldwide results. Transplantation 2006; 82:441.</LI>&#xD;&#xA;<LI>Strom SC, Roy-Chowdhury J, Fox IJ. Hepatocyte transplantation for the treatment of human diseases. Semin Liver Dis 1999; 19:39.</LI>&#xD;&#xA;<LI>Fox IJ, Roy-Chowdhury J, Kaufman SS, et al. Treatment of Crigler-Najjar syndrome type 1 with hepatocyte transplantation. N Eng J Med 1998; 338:1422.</LI>&#xD;&#xA;<LI>Hughes RS, Mitry RR, Dhawan A. Hepatocyte transplantation for metabolic liver disease: UK experience. J Royal Soc Med 2005; 98:341.</LI>&#xD;&#xA;<LI>Ambrosino G, Varotto S, Strom SC, et al. Isolated hepatocyte transplantation for Crigler-Najjar syndrome type 1. Cell Transplant 2005; 14:151.</LI>&#xD;&#xA;<LI>Allen KJ, Mifsud NA, Williamson R, et al. Cell-mediated rejection results in allograft loss after liver cell transplantation. Liver Transpl 2008; 14:688.</LI>&#xD;&#xA;<LI>Darwish AA, Sokal E, Stephenne X, et al. Permanent access to the portal system for cellular transplantation using an implantable port device. Liver Transpl 2004; 10:1213.</LI>&#xD;&#xA;<LI>Dhawan A, Mitry RR, Hughes RD. Hepatocyte transplantation for liver-based metabolic disorders. J Inherit Metab Dis 2006; 29:431.</LI>&#xD;&#xA;<LI>Khan AA, Parveen N, Mahaboob VS, et al. Treatment of Crigler-Najjar syndrome type 1 by hepatic progenitor cell transplantation: A simple procedure for management of hyperbilirubinemia. Transplant Proc 2008; 40:1148.</LI>&#xD;&#xA;<LI>Meyburg J, Hoerster F, Schmidt J, et al. Monitoring of intraportal liver cell application in children. Cell Transplant 2010; 19:629.</LI>&#xD;&#xA;<LI>Ribes-Koninckx C, Ibars EP, Calzado Agrasot MA, et al. Clinical outcome of hepatocyte transplantation in four pediatric patients with inherited metabolic diseases. Cell Transplant 2012; 21:2267.</LI>&#xD;&#xA;<LI>Dhawan A, Mitry RR, Hughes RD, et al. Hepatocyte transplantation for inherited Factor VII deficiency. Transplantation 2004; 78:1812.</LI>&#xD;&#xA;<LI>Hughes RD, Mitry RR, Dhawan A, et al. Isolation of hepatocytes from livers from non-heart-beating donors for cell transplantation. Cell Transpl 2006; 12:713.</LI>&#xD;&#xA;<LI>Muraca M, Gerunda G, Neri D, et al. Hepatocyte transplantation as a treatment of glycogen storage disease type 1a. Lancet 2002; 359:317.</LI>&#xD;&#xA;<LI>Lee KW, Lee JH, Shin SW, et al. Hepatocyte transplantation for glycogen storate disease type Ib. Cell Transplant 2007; 16:629.</LI>&#xD;&#xA;<LI>Sokal EM, Smets F, Bourgois A, et al. Hepatocyte transplantation in a 4-year-old girl with peroxisomal biogenesis disease: Technique, safety and metabolic follow-up. Transplantation 2003; 76:735.</LI>&#xD;&#xA;<LI>Stephenne X, Debray FG, Smets F, et al. Hepatocyte Transplantation Using the Domino Concept in a Child With Tetrabiopterin Nonresponsive Phenylketonuria. Cell Transplant 2012; 21:2765.</LI>&#xD;&#xA;<LI>Beck BB, Habbig S, Dittrich K, et al. Liver cell transplantation in severe infantile oxalosis - a potential bridging procedure to orthotopic liver transplantation? Nephrol Dial Transplant 2012; 27:2984.</LI>&#xD;&#xA;<LI>Strom SC, Fisher RA, Rubinstein WS, et al. Transplantation of human hepatocytes. Transplant Proc 1997; 29:2101.</LI>&#xD;&#xA;<LI>Horslen SP, McCowan TC, Goertzen TC, et al. Isolated hepatocyte transplantation in an infant with a severe urea cycle disorder. Pediatrics 2003; 111:1262.</LI>&#xD;&#xA;<LI>Mitry RR, Dhawan A, Hughes RD, et al. One liver, three recipients - Segment 4 from split liver procedure as a source of hepatocytes for cell transplantation. Transplantation 2004; 77:1624.</LI>&#xD;&#xA;<LI>Stephenne X, Najimi M, Smets F, et al. Cryopreserved liver cell transplantation controls ornithine transcarbamylase deficient patient while awaiting liver transplantation. Am J Transplant 2005; 5:2058.</LI>&#xD;&#xA;<LI>Puppi J, Tan N, Mitry RR, et al. Hepatocyte transplantation followed by auxiliary liver transplantation - a novel treatment for ornithine transcarbamylase deficiency. Am J Transplant 2008; 8:452.</LI>&#xD;&#xA;<LI>Meyburg J, Das AM, Hoerster F, et al. One liver for four children: First clinical series of liver cell transplantation for severe neonatal urea cycle defects. Transplantation 2009; 87:636.</LI>&#xD;&#xA;<LI>Bohnen NI, Carron M, Reyes J, et al. Use of Indium-111-labeled hepatocytes to determine the biodistribution of transplanted hepatocytes through portal ven infusion. Clin Nucl Med 2000; 25:447.</LI>&#xD;&#xA;<LI>Ensawa S, Horikwa R, Yamamoto A, et al. Hepatocyte transplantation using a living donor reduced graft in a baby with ornithine transcarbamylase deficiency: a novel source of hepatocytes. Liver Transpl 2014; 20:391.</LI>&#xD;&#xA;<LI>Stephenne X, Najimi M, Sibille EM. Sustained engraftment and tissue enzyme activity after liver cell transplantation for arginosuccinate lyase deficiency. Gastroenterology 2006; 130:1317.</LI>&#xD;&#xA;<LI>Meyburg K. Alexandrova K, Barthold M, et al. Liver cell transplantation: Basic investigations for safe application in infants and small children. Cell Transplant 2009; 18:777.</LI></OL></div><div id=\"graphicVersion\">Graphic 67880 Version 3.0</div></div></div>"},"67882":{"type":"graphic_waveform","displayName":"ECG first degree AV block I","title":"Single-lead electrocardiogram (ECG) showing first degree atrioventricular (AV) block I","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Single-lead electrocardiogram (ECG) showing first degree atrioventricular (AV) block I</div><div class=\"cntnt\"><img style=\"width:360px; height:113px;\" src=\"images/CARD/67882_First_degree_AV_block_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram of lead II showing normal sinus rhythm, first degree atrioventricular block with a prolonged PR interval of 0.30 sec, and a QRS complex of normal duration. The tall P waves and P wave duration of approximately 0.12 sec suggest concurrent right atrial enlargement.</div><div class=\"graphic_reference\">Courtesy of Morton Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 67882 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"67884":{"type":"graphic_table","displayName":"Spleen injury scale","title":"Spleen injury scale (1994 revision)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Spleen injury scale (1994 revision)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Grade*</td> <td class=\"subtitle1\">Injury type</td> <td class=\"subtitle1\">Injury description</td> </tr> <tr> <td rowspan=\"2\">I</td> <td>Hematoma</td> <td>Subcapsular, &#60;10 percent surface area</td> </tr> <tr> <td>Laceration</td> <td>Capsular tear, &#60;1 cm parenchymal depth</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">II</td> <td>Hematoma</td> <td>Subcapsular, 10-50 percent surface area; intraparenchymal, &#60;5 cm in diameter</td> </tr> <tr> <td>Laceration</td> <td>1-3 cm parenchymal depth which does not involve a trabecular vessel</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">III</td> <td rowspan=\"2\">Hematoma</td> <td>Subcapsular, &#62;50 percent surface area or expanding; ruptured subcapsular or parenchymal hematoma</td> </tr> <tr> <td>Intraparenchymal hematoma &#62;5 cm or expanding</td> </tr> <tr> <td>Laceration</td> <td>&#62;3 cm parenchymal depth or involving trabecular vessels</td> </tr> <tr class=\"divider_top\"> <td>IV</td> <td>Laceration</td> <td>Laceration involving segmental or hilar vessels producing major devascularization (&#62;25 percent of spleen)</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">V</td> <td>Laceration</td> <td>Completely shattered spleen</td> </tr> <tr> <td>Vascular</td> <td>Hilar vascular injury which devascularizes spleen</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Advance one grade for multiple injuries, up to grade III.</div><div class=\"graphic_reference\">Adapted from: Moore, EE, Cogbill, TH, Jurkovich, GJ, et al. Organ injury scaling: spleen and liver (1994 revision). J Trauma 1995; 38:323.</div><div id=\"graphicVersion\">Graphic 67884 Version 4.0</div></div></div>"},"67885":{"type":"graphic_picture","displayName":"Treatment of necrotic tissue with maggots","title":"Treatment of necrotic tissue with maggots","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Treatment of necrotic tissue with maggots</div><div class=\"cntnt\"><img style=\"width:514px; height:488px;\" src=\"images/PC/67885_Maggot_treatment.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Infection of necrotic skin associated with ulcerated cancer.<br> (B) After treatment with maggots.<br> (C) Maggots in a tea bag.</div><div class=\"graphic_reference\">Courtesy of Michael J Dixon, MD.</div><div id=\"graphicVersion\">Graphic 67885 Version 3.0</div></div></div>"},"67886":{"type":"graphic_form","displayName":"Colposcopy form BWH","title":"Colposcopy form","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Colposcopy form</div><div class=\"cntnt\"><img style=\"width:546px; height:672px;\" src=\"images/OBGYN/67886_Colposcopy_form_BWH.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 67886 Version 2.0</div></div></div>"},"67887":{"type":"graphic_picture","displayName":"Towel stretch","title":"Towel stretch","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Towel stretch</div><div class=\"cntnt\"><img style=\"width:311px; height:323px;\" src=\"images/RHEUM/67887_Towel_stretch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Take a three-foot-long towel, grasp it with both hands, and hold it in the horizontal position. Use the upper, good arm to pull the affected arm toward the lower back. This can be repeated with the towel at a 45-degree angle. Perform sets of 10 to 20 stretches at each session.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 67887 Version 6.0</div></div></div>"},"67889":{"type":"graphic_table","displayName":"Features of systemic sclerosis","title":"Clinical features of the major systemic Sclerosis subsets","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of the major systemic Sclerosis subsets</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Diffuse cutaneous</td>\n<td class=\"subtitle1\">Early (&#60;3 years after onset)</td>\n<td class=\"subtitle1\">Late (&#62;3 years after onset)</td>\n</tr>\n<tr>\n<td>Constitutional</td>\n<td>Fatigue and weight loss</td>\n<td>Minimal, weight gain typical</td>\n</tr>\n<tr>\n<td>Vascular</td>\n<td>Raynaud's often relatively mild</td>\n<td>Raynaud's more severe, more telangiectasia</td>\n</tr>\n<tr>\n<td>Cutaneous</td>\n<td>Rapid progression involving arms, trunk, face</td>\n<td>Stable or regression</td>\n</tr>\n<tr>\n<td>Musculoskeletal</td>\n<td>Prominent arthralgia, stiffness, myalgia, muscle weakness, tendon friction rubs</td>\n<td>Flexion contractures and deformities, joint/muscle symptoms less prominent</td>\n</tr>\n<tr>\n<td>Gastrointestinal</td>\n<td>Dysphagia, heartburn</td>\n<td>More pronounced symptoms, midgut and anorectal complications more common</td>\n</tr>\n<tr>\n<td>Cardiopulmonary</td>\n<td>Maximum risk for myocarditis, pericardial effusion, intersitital pulmonary fibrosis</td>\n<td>Reduced risk of new involvement but progression of existing established visceral fibrosis</td>\n</tr>\n<tr>\n<td>Renal</td>\n<td>Maximum risk period for scleroderma after 5 years</td>\n<td>Renal crisis less frequent, uncommon after 5 years</td>\n</tr>\n<tr>\n<td class=\"subtitle1\">Limited cutaneous</td>\n<td class=\"subtitle1\">Early (&#60;10 years after onset)</td>\n<td class=\"subtitle1\">Late (&#62;10 years after onset)</td>\n</tr>\n<tr>\n<td>Constitutional</td>\n<td>None</td>\n<td>Only secondary to visceral complications</td>\n</tr>\n<tr>\n<td>Vascular</td>\n<td>Raynaud's typically severe and longstanding telangiectasia</td>\n<td>Raynaud's persists, often causing digital ulceration or gangrene</td>\n</tr>\n<tr>\n<td>Cutaneous</td>\n<td>Mild sclerosis with little progression on trunk, face</td>\n<td>Stable, calcinosis more prominent</td>\n</tr>\n<tr>\n<td>Musculoskeletal</td>\n<td>Occasional joint stiffness</td>\n<td>Mild flexion contractures</td>\n</tr>\n<tr>\n<td>Gastrointestinal</td>\n<td>Dysphagia, heartburn</td>\n<td>More pronounced symptoms, midgut and anorectal complications more common</td>\n</tr>\n<tr>\n<td>Cardiopulmonary</td>\n<td>Usually no involvement</td>\n<td>Lung fibrosis may develop, but often progresses slowly, Anti-SCL-70 predicts increased risk of severe fibrosis. Maximum risk for developing isolated pulmonary hypertension and secondary right ventricular failure.</td>\n</tr>\n<tr>\n<td>Renal</td>\n<td>No involvement</td>\n<td>Rarely involved, anti-RNA polymerase predicts increased risk of renal involvement.</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 67889 Version 1.0</div></div></div>"},"67890":{"type":"graphic_picture","displayName":"Rosacea papules","title":"Rosacea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rosacea</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/67890_Rosaceapapules.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous papules on the cheek.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 67890 Version 5.0</div></div></div>"},"67891":{"type":"graphic_figure","displayName":"Epidermal basement membrane zone","title":"The epidermal basement membrane zone","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">The epidermal basement membrane zone</div><div class=\"cntnt\"><img style=\"width:524px; height:513px;\" src=\"images/DERM/67891_BM_zone.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 67891 Version 3.0</div></div></div>"},"67892":{"type":"graphic_picture","displayName":"DIP stack splint","title":"Stack splint for DIP joint","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Stack splint for DIP joint</div><div class=\"cntnt\"><img style=\"width:432px; height:288px;\" src=\"images/EM/67892_DIP_stack_splint.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD.</div><div id=\"graphicVersion\">Graphic 67892 Version 2.0</div></div></div>"},"67894":{"type":"graphic_table","displayName":"Empiric therapy gram negatives and anaerobes","title":"Empiric antibiotic therapy for gram-negative and anaerobic pathogens","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Empiric antibiotic therapy for gram-negative and anaerobic pathogens</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Regimen</td> <td class=\"subtitle1\">Dose (adult)*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">First choice</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\">Monotherapy with a beta-lactam/beta-lactamase inhibitor:</td> </tr> <tr> <td class=\"sublist2\">Ampicillin-sulbactam<sup>&#182;</sup></td> <td class=\"sublist_other\">3 g IV every six hours</td> </tr> <tr> <td class=\"sublist2\">Piperacillin-tazobactam<sup>&#916;</sup></td> <td class=\"sublist_other\">3.375 or 4.5 g IV every six hours</td> </tr> <tr> <td class=\"sublist2\">Ticarcillin-clavulanate</td> <td class=\"sublist_other\">3.1 g IV every four hours</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\">Combination third generation cephalosporin <strong>PLUS</strong> metronidazole:</td> </tr> <tr> <td class=\"sublist2\">Ceftriaxone <strong>plus</strong></td> <td class=\"sublist_other\">1 g IV every 24 hours (or 2 g IV every 12 hours for CNS infections)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist2\">Metronidazole</td> <td class=\"sublist_other\">500 mg IV every eight hours</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Alternative empiric regimens</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\">Combination fluoroquinolone<sup>&#9674;</sup> <strong>PLUS</strong> metronidazole:</td> </tr> <tr> <td class=\"sublist2\">Ciprofloxacin <strong>or</strong></td> <td class=\"sublist_other\">400 mg IV every 12 hours</td> </tr> <tr> <td class=\"sublist2\">Levofloxacin <strong>plus</strong></td> <td class=\"sublist_other\">500 or 750 mg IV once daily</td> </tr> <tr> <td class=\"sublist2\">Metronidazole</td> <td class=\"sublist_other\">500 mg IV every eight hours</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\">Monotherapy with a carbapenem<sup>&#167;</sup>:</td> </tr> <tr> <td class=\"sublist2\">Imipenem-cilastatin</td> <td class=\"sublist_other\">500 mg IV every six hours</td> </tr> <tr> <td class=\"sublist2\">Meropenem</td> <td class=\"sublist_other\">1 g IV every eight hours</td> </tr> <tr> <td class=\"sublist2\">Doripenem</td> <td class=\"sublist_other\">500 mg IV every eight hours</td> </tr> <tr> <td class=\"sublist2\">Ertapenem<sup>&#165;</sup></td> <td class=\"sublist_other\">1 g IV once daily</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CNS: central nervous system; IV: intravenous; MIC: minimum inhibitory concentration.<br />* Antibiotic doses should be adjusted appropriately for patients with renal insufficiency or other dose-related considerations.<br />¶ <EM>E. coli</EM> resistance to ampicillin-sulbactam is emerging in some areas; check local susceptibility data.<br />Δ Some clinicians use 4.5 g every eight hours for empiric therapy since the percent time above the MIC is similar between the regimens for most pathogens; however, this regimen is NOT recommended for nosocomial pneumonia or <EM>Pseudomonas</EM> coverage. Please refer to UpToDate&nbsp;content on the treatment of health care-associated pneumonia and treatment of&nbsp;<EM>Pseudomonas aeruginosa</EM> infections.<br /><FONT class=lozenge>◊</FONT> Fluoroquinolones are generally avoided in pregnant women due to potential fetal toxicity.<br />§ Use carbapenems cautiously in patients with immediate-type hypersensitivity to beta-lactams.<br />¥ Ertapenem lacks activity against <EM>Acinetobacter</EM> and <EM>Pseudomonas</EM> and is not an appropriate choice for severe or nosocomial infection.</div><div id=\"graphicVersion\">Graphic 67894 Version 16.0</div></div></div>"},"67896":{"type":"graphic_movie","displayName":"Phonocardiogram calcific AS 3rd left ICS ","title":"Phonocardiogram showing paradoxical splitting of S2 in aortic stenosis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Phonocardiogram showing paradoxical splitting of S2 in aortic stenosis</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/67896_asc3licsconv.mp4\" style=\"width:396px;height:488px\"></div><img style=\"width:403px; height:253px;\" src=\"images/CARD/67896_asc3lics.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram and phonocardiogram of aortic stenosis due to valvular calcification as heard at the third left intercostal space. S1 (mitral and tricuspid valve closure) is followed by a mild systolic ejection murmur of aortic stenosis. In contrast to normal, aortic valve closure is very delayed and it occurs after closure of the pulmonic valve, accounting for the paradoxical splitting (S2 becomes single with inspiration).</div><div class=\"graphic_reference\">Provided by John M Criley, MD, The Physiological Origins of Heart Sounds and Murmurs, Little, Brown, Boston, 1996, 1-800-527-0145. This program contains a complete interactive tutorial integrating over 200 heart sounds and murmurs with cineangiographic, echo-Doppler, and hemodynamic motion picture sequences.</div><div id=\"graphicVersion\">Graphic 67896 Version 5.0</div></div></div>"},"67899":{"type":"graphic_picture","displayName":"RTT unique hand pattern","title":"Rett syndrome, unique hand pattern","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rett syndrome, unique hand pattern</div><div class=\"cntnt\"><img style=\"width:252px; height:378px;\" src=\"images/PEDS/67899_RS_unique_hand_pattern.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">As typically happens from age one to four years in RTT, this girl had onset of midline hand stereotypes that occur incessantly during wakefulness but cease during sleep.</div><div class=\"graphic_reference\">Reproduced with permission from: Glaze DG, Schultz RJ. Rett syndrome: meeting the challenge of this gender-specific neurodevelopmental disorder. Medscape Women's Health 1997; 2. Copyright © 1997 Medscape.</div><div id=\"graphicVersion\">Graphic 67899 Version 5.0</div></div></div>"},"67901":{"type":"graphic_table","displayName":"Somatization","title":"Somatization","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Somatization</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">A. Somatic symptoms and related disorders in DSM-5</td> </tr> <tr> <td class=\"indent1\">1. Somatic symptom disorder</td> </tr> <tr> <td class=\"indent1\">2. Illness anxiety</td> </tr> <tr> <td class=\"indent1\">3. Conversion disorder</td> </tr> <tr> <td class=\"indent1\">4. Psychological factors affecting other medical conditions</td> </tr> <tr> <td class=\"subtitle1_single\">B. Somatoform disorders</td> </tr> <tr> <td class=\"sublist2_start\">1. Somatoform disorders common to the American Psychiatric Association's Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR) and World Health Organization's International Classification of Diseases-10th Revision (ICD-10)</td> </tr> <tr> <td class=\"sublist2\">a. Somatization disorder</td> </tr> <tr> <td class=\"sublist2\">b. Undifferentiated somatoform disorder</td> </tr> <tr> <td class=\"sublist2\">c. Pain disorder</td> </tr> <tr> <td class=\"sublist2\">d. Hypochondriasis</td> </tr> <tr> <td class=\"sublist2\">e. Somatoform disorder not otherwise specified</td> </tr> <tr> <td class=\"sublist2_start\">2. Somatoform disorders unique to DSM-IV-TR</td> </tr> <tr> <td class=\"sublist2\">a. Conversion disorder</td> </tr> <tr> <td class=\"sublist2\">b. Body dysmorphic disorder</td> </tr> <tr> <td class=\"sublist2_start\">3. Somatoform disorders unique to ICD-10</td> </tr> <tr> <td class=\"sublist2\">a. Somatoform autonomic dysfunction</td> </tr> <tr> <td class=\"sublist2\">b. Other somatoform disorders</td> </tr> <tr> <td class=\"subtitle1_single\">C. Other specific types of somatization common to DSM-5 and ICD-10</td> </tr> <tr> <td class=\"indent1\">1. Factitious disorder</td> </tr> <tr> <td class=\"indent1\">2. Malingering</td> </tr> <tr> <td class=\"subtitle1_single\">Additional categories that are not recognized by DSM-5, DSM-IV-TR, or ICD-10:</td> </tr> <tr> <td class=\"indent1\">1. Abridged somatization</td> </tr> <tr> <td class=\"indent1\">2. Multisomatoform disorder</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from:<br /><ol>&#xD;&#xA;    <li>American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, VA, American Psychiatric Association, 2013.</li>&#xD;&#xA;    <li>World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 10th Revision, Version for 2007. http://www.who.int/classifications/apps/icd/icd10online/ (Accessed on November 22, 2009).</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 67901 Version 4.0</div></div></div>"},"67902":{"type":"graphic_table","displayName":"Asbestosis and job risk","title":"Occupations and industries associated with asbestosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Occupations and industries associated with asbestosis</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"container\"><table cellspacing=\"0\"><tbody><tr><td class=\"subtitle1_single\">Occupations</td></tr>\n\t\t\t\t\t\t<tr><td>Plumbers</td></tr>\n\t\t\t\t\t\t<tr><td>Pipefitters</td></tr>\n\t\t\t\t\t\t<tr><td>Steamfitters</td></tr>\n\t\t\t\t\t\t<tr><td>Electricians</td></tr>\n\t\t\t\t\t\t<tr><td>Insulation workers</td></tr>\n\t\t\t\t\t\t<tr><td>Carpenters</td></tr>\n\t\t\t\t\t\t<tr><td>Laborers</td></tr>\n\t\t\t\t\t\t<tr><td>Boilermakers</td></tr>\n\t\t\t\t\t\t<tr><td>Welders and cutters</td></tr>\n\t\t\t\t\t\t<tr><td>Janitors</td></tr></tbody></table></td>\n<td class=\"container\"><table cellspacing=\"0\"><tbody><tr><td class=\"subtitle1_single\">Industries</td></tr>\n\t\t\t\t\t\t<tr><td>Construction</td></tr>\n\t\t\t\t\t\t<tr><td>Shipbuilding and repairing</td></tr>\n\t\t\t\t\t\t<tr><td>Chemicals and other manufacturing</td></tr>\n\t\t\t\t\t\t<tr><td>Nonmetallic mineral stone products</td></tr>\n\t\t\t\t\t\t<tr><td>Railways</td></tr>\n\t\t\t\t\t\t<tr><td>Yarn, thread, and fabric mills</td></tr>\n\t\t\t\t\t\t<tr><td>Trucking</td></tr>\n\t\t\t\t\t\t<tr><td>Plastic and rubber manufacture</td></tr></tbody></table></td>\n</tr>\n\n\n\n\n\n\n\n\n\n\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Wagner, GR, Lancet 1997; 349:1311.</div><div id=\"graphicVersion\">Graphic 67902 Version 1.0</div></div></div>"},"67903":{"type":"graphic_picture","displayName":"Nodular sarcoidosis","title":"Nodular sarcoidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nodular sarcoidosis</div><div class=\"cntnt\"><img style=\"width:356px; height:234px;\" src=\"images/PULM/67903_Nodular_sarcoidosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The histopathologic specimen shows a confluent mass of granulomas that have coalesced to form nodules several centimeters in size that are identifiable on chest radiograph. Multiple multinucleated giant cells are present.</div><div class=\"graphic_reference\">Courtesy of Talmadge E King Jr, MD.</div><div id=\"graphicVersion\">Graphic 67903 Version 2.0</div></div></div>"},"67905":{"type":"graphic_figure","displayName":"Chylomicron metabolism","title":"Exogenous pathway of lipid metabolism","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Exogenous pathway of lipid metabolism</div><div class=\"cntnt\"><img style=\"width:438px; height:265px;\" src=\"images/CARD/67905_Chylomicron_metabolism.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the intestinal cell, absorbed free fatty acids combine with glycerol to form triglycerides, and, to a lesser degree, absorbed cholesterol is esterified to form cholesteryl esters. These lipids are assembled as chylomicrons; the main apolipoprotein (apo) is B-48, but apo C-II and E are acquired as the chylomicrons enter the circulation. Apo C-II is a cofactor for lipoprotein lipase which makes the chylomicrons progressively smaller in part by hydrolyzing the core triglycerides and releasing free fatty acids. The chylomicron remnants that are cleared from the circulation by hepatic chylomicron remnant receptors for which apo E is a high-affinity ligand.</div><div id=\"graphicVersion\">Graphic 67905 Version 1.0</div></div></div>"},"67908":{"type":"graphic_picture","displayName":"Congenital leukemia","title":"Congenital leukemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Congenital leukemia</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/67908_Congenital_leukemia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Red-brown nodules are present on the skin of this neonate with congenital leukemia.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 67908 Version 4.0</div></div></div>"},"67909":{"type":"graphic_picture","displayName":"Autoimmune hepatitis Low","title":"Autoimmune hepatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Autoimmune hepatitis</div><div class=\"cntnt\"><img style=\"width:376px; height:251px;\" src=\"images/GAST/67909_Autoimmune_hepatitis_Low.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Liver biopsy in autoimmune hepatitis showing portal and periportal mononuclear cell infiltration.</div><div class=\"graphic_reference\">Courtesy of Edward L Krawitt, MD</div><div id=\"graphicVersion\">Graphic 67909 Version 1.0</div></div></div>"},"67910":{"type":"graphic_table","displayName":"CPA underlying diseases","title":"Underlying diseases in patients with chronic pulmonary aspergillosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Underlying diseases in patients with chronic pulmonary aspergillosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Common underlying diseases</td> </tr> <tr> <td class=\"indent1\">Pulmonary tuberculosis</td> </tr> <tr> <td class=\"indent1\">Nontuberculous mycobacterial infection</td> </tr> <tr> <td class=\"indent1\">Allergic bronchopulmonary aspergillosis</td> </tr> <tr> <td class=\"indent1\">Treated lung cancer</td> </tr> <tr> <td class=\"indent1\">Pneumothorax (often related to a bulla)</td> </tr> <tr> <td class=\"indent1\">Chronic obstructive pulmonary disease</td> </tr> <tr> <td class=\"indent1\">Sarcoidosis (stage II/III)</td> </tr> <tr> <td class=\"subtitle1_single\">Uncommon underlying diseases</td> </tr> <tr> <td class=\"indent1\">Rheumatoid arthritis with pulmonary nodules</td> </tr> <tr> <td class=\"indent1\">Ankylosing spondylitis</td> </tr> <tr> <td class=\"indent1\">Thoracic surgery</td> </tr> <tr> <td class=\"indent1\">Asthma</td> </tr> <tr> <td class=\"indent1\">Radiotherapy to the thorax or chest wall</td> </tr> <tr> <td class=\"indent1\">Community-acquired pneumonia</td> </tr> <tr> <td class=\"indent1\">Invasive pulmonary aspergillosis</td> </tr> <tr> <td class=\"indent1\">Cannabis lung</td> </tr> <tr> <td class=\"indent1\">Pneumoconiosis</td> </tr> <tr> <td class=\"indent1\">Histoplasmosis</td> </tr> <tr> <td class=\"indent1\">Silicosis</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 67910 Version 3.0</div></div></div>"},"67911":{"type":"graphic_movie","displayName":"Pulmonary hypertension short axis echo","title":"Pulmonary hypertension short axis echocardiographic view","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary hypertension short axis echocardiographic view</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/67911_shaxpuhyconv.mp4\" style=\"width:328px;height:248px\"></div><img style=\"width:243px; height:417px;\" src=\"images/CARD/67911_shaxpuhy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The short axis view from a 2-D echocardiogram shows significant right ventricular&nbsp;pressure and volume overload&nbsp;as a result of pulmonary hypertension.</div><div class=\"graphic_reference\">Provided by Thomas Binder, MD, et al. Interactive Echocardiography. A Clinical Atlas. Futura, 1997.</div><div id=\"graphicVersion\">Graphic 67911 Version 4.0</div></div></div>"},"67913":{"type":"graphic_table","displayName":"Axial signs symptoms ALS","title":"Axial signs and symptoms associated with amyotrophic lateral sclerosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Axial signs and symptoms associated with amyotrophic lateral sclerosis</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\t<tbody>\n\t\t<tr>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Upper motor neuron signs</td></tr>\n\t\t\t\t\t\t<tr><td>Absent abdominal reflexes</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Lower motor neuron signs</td></tr>\n\t\t\t\t\t\t<tr><td>Neck extension weakness</td></tr>\n\t\t\t\t\t\t<tr><td>Truncal extension weakness; bent spine</td></tr>\n\t\t\t\t\t\t<tr><td>Abdominal protuberance</td></tr>\n\t\t\t\t\t\t<tr><td>Increased lumbar lordosis</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tbody>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Upper motor neuron symptoms</td></tr>\n\t\t\t\t\t\t<tr><td>Stiffness and imbalance</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Lower motor neuron symptoms</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1_start\">Neck extensors</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Difficulty holding up the head</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">When severe produces head drop</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1_start\">Truncal extensors</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Difficulty maintaining an erect posture</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1_start\">Lumbar extensors</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Increased lumbar lordosis</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1_start\">Abdominal wall muscles</td></tr>\n\t\t\t\t\t\t<tr><td class=\"sublist1\">Abdominal protuberance</td></tr>\n\t\t\t\t\t\t<tr><td>Cramps</td></tr>\n\t\t\t\t\t</tbody>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t</tr>\n\t</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 67913 Version 1.0</div></div></div>"},"67914":{"type":"graphic_figure","displayName":"Kaplan-Meier survival curves","title":"Kaplan-Meier survival curves","html":"<div class=\"graphic\"><div style=\"width: 486px\" class=\"figure\"><div class=\"ttl\">Kaplan-Meier survival curves</div><div class=\"cntnt\"><img style=\"width:466px; height:350px;\" src=\"images/PC/67914_Kaplan_meier_curves.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The two curves illustrate the effect of an intervention (dashed red line) on survival compared to placebo (solid blue line). Each downward step corresponds to a death.</div><div id=\"graphicVersion\">Graphic 67914 Version 3.0</div></div></div>"},"67917":{"type":"graphic_table","displayName":"Immunosuppressive agents","title":"Immunosuppressive agents in liver transplantation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Immunosuppressive agents in liver transplantation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Mechanism of action</td> <td class=\"subtitle1\">Selected adverse effects*</td> </tr> <tr class=\"divider_bottom\"> <td>Prednisone</td> <td> <p>Suppresses leukocyte, macrophage, and cytotoxic T-cell activity</p> Decreases cytokines, prostaglandins, and leukotrienes</td> <td> <p>Hypertension</p> <p>Dyslipidemia</p> <p>Glucose intolerance</p> <p>Bone abnormalities</p> <p>Peptic ulcers</p> Psychiatric disorders</td> </tr> <tr class=\"divider_bottom\"> <td>Cyclosporine</td> <td> <p>Inactivates calcineurin</p> <p>Decreases IL-2 production</p> Inhibits T-cell activation</td> <td> <p>Hypertension</p> <p>Renal insufficiency</p> <p>Neuropathy</p> <p>Hyperlipidemia</p> <p>Gingival hyperplasia</p> <p>Hirsutism</p> Insulin resistance</td> </tr> <tr class=\"divider_bottom\"> <td>Tacrolimus</td> <td> <p>Inactivates calcineurin</p> <p>Decreases IL-2 production</p> Inhibits T-cell activation</td> <td> <p>Hypertension</p> <p>Renal insufficiency</p> <p>Insulin resistance</p> <p>Neuropathy</p> Hyperlipidemia</td> </tr> <tr class=\"divider_bottom\"> <td>Azathioprine or 6-mercaptopurine</td> <td> <p>Inhibits adenosine and guanine production</p> Inhibits DNA and RNA synthesis in rapidly proliferating T cells</td> <td> <p>Leukopenia</p> <p>Anemia</p> <p>Thrombocytopenia</p> Pancreatitis</td> </tr> <tr class=\"divider_bottom\"> <td>Mycophenolate mofetil or mycophenolic acid</td> <td> <p>Inhibits production of inosine monophosphate dehydrogenase (IMPDH)</p> Prevents T and B cell proliferation</td> <td> <p>Leukopenia</p> <p>Anemia</p> <p>Thrombocytopenia</p> GI side effects</td> </tr> <tr> <td>Sirolimus or everolimus</td> <td> <p>Inhibits mTOR, (target of Rapamycin)</p> Prevents T-cell replication</td> <td> <p>Leukopenia</p> <p>Thrombocytopenia</p> <p>Anemia (microcytic)</p> <p>Hyperlipidemia</p> <p>Hepatic artery thrombosis</p> <p>Inhibited wound healing</p> <p>Peripheral edema</p> Pulmonary toxicity</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Not a complete list of adverse effects. See individual Lexicomp drug monographs for additional information.</div><div id=\"graphicVersion\">Graphic 67917 Version 9.0</div></div></div>"},"67918":{"type":"graphic_table","displayName":"VIN grading","title":"Histological grades of squamous vulvar intrapeithelial neoplasia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Histological grades of squamous vulvar intrapeithelial neoplasia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Condyloma acuminatum (formerly VIN 1)</td> </tr> <tr> <td>Cytologic atypia is most often represented by koilocytosis or basal cell hyperplasia and increased mitotic activity, with squamous maturation occurring in the upper two-thirds of the epithelium.</td> </tr> <tr> <td class=\"subtitle1_single \">VIN 2</td> </tr> <tr> <td>Loss of maturation is confined to the lower two thirds of the epithelium with some surface maturation present.</td> </tr> <tr> <td class=\"subtitle1_single \">VIN 3</td> </tr> <tr> <td>Full thickness loss of squamous maturation of the squamous epithelium is present. Cytological changes may be significant with bizarre mitotic figures and significant pleomorphism. Stromal invasion is not present.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 67918 Version 2.0</div></div></div>"},"67919":{"type":"graphic_picture","displayName":"Xanthelasma","title":"Xanthelasma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Xanthelasma</div><div class=\"cntnt\"><img style=\"width:432px; height:234px;\" src=\"images/PC/67919_Xanthelasma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Yellow plaques are present bilaterally.</div><div class=\"graphic_reference\">With permission from: Slomovits TL (Ed), Basic and clinical science courses section, American Academy of Ophthalmology, San Francisco 1996.</div><div id=\"graphicVersion\">Graphic 67919 Version 2.0</div></div></div>"},"67921":{"type":"graphic_table","displayName":"Tumor embolism malignancies","title":"Malignancies associated with tumor embolism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Malignancies associated with tumor embolism</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Renal cell</td> </tr> <tr> <td>Hepatocellular</td> </tr> <tr> <td>Breast</td> </tr> <tr> <td>Gastric</td> </tr> <tr> <td>Pancreatic</td> </tr> <tr> <td>Lung</td> </tr> <tr> <td>Prostate</td> </tr> <tr> <td>Choriocarcinoma</td> </tr> <tr> <td>Colorectal</td> </tr> <tr> <td>Cervical</td> </tr> <tr> <td>Mesothelioma</td> </tr> <tr> <td>Ovarian</td> </tr> <tr> <td>Bladder</td> </tr> <tr> <td>Skin</td> </tr> <tr> <td>Parotid</td> </tr> <tr> <td>Thyroid</td> </tr> <tr> <td>Atrial myxoma</td> </tr> <tr> <td>Wilms' tumor</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from:&nbsp;Roberts KE, Hamele-Bena D, Saqi A, et al. Pulmonary tumor embolism: a review of the literature. Am J Med 2003; 115:228.</div><div id=\"graphicVersion\">Graphic 67921 Version 2.0</div></div></div>"},"67922":{"type":"graphic_picture","displayName":"Skin vasculitis in lupus","title":"Lupus vasculitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lupus vasculitis</div><div class=\"cntnt\"><img style=\"width:335px; height:312px;\" src=\"images/RHEUM/67922_Skin_vasculitis_in_lupus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Palpable purpuric lesions on the shins in a patient with lupus and necrotizing vasculitis of the skin, kidney, and brain.</div><div class=\"graphic_reference\">Courtesy of Samuel Moschella, MD.</div><div id=\"graphicVersion\">Graphic 67922 Version 1.0</div></div></div>"},"67923":{"type":"graphic_picture","displayName":"Sweat gland innervation","title":"Sweat gland innervation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sweat gland innervation</div><div class=\"cntnt\"><img style=\"width:340px; height:583px;\" src=\"images/NEURO/67923_Sweatglandinnervation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Skin biopsy from a patient showing normal innervation of two sweat glands.<br> (B) Skin biopsy from a patient with congenital insensitivity to pain due to a mutation of the tyrosine kinase A receptor showing absent innervation of sweat glands.</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 112, Pages e237-241, Copyright &copy; 2003 by the AAP.</div><div id=\"graphicVersion\">Graphic 67923 Version 12.0</div></div></div>"},"67924":{"type":"graphic_table","displayName":"NKPI for extranodal NK-T cell lymphoma nasal type","title":"NK/T cell lymphoma prognostic index (NKPI) for extranodal NK/T cell lymphoma, nasal type","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NK/T cell lymphoma prognostic index (NKPI) for extranodal NK/T cell lymphoma, nasal type</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td colspan=\"3\">Presence of systemic B symptoms*</td> </tr> <tr> <td colspan=\"3\">Ann Arbor stage III or IV disease</td> </tr> <tr> <td colspan=\"3\">Elevated lactate dehydrogenase</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"3\">Regional lymph node involvement<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"3\">One point is given for each of the above characteristics present in the patient, for a total score ranging from zero to four. When applied to retrospective series of patients with extranodal NK/T cell lymphoma, five-year overall survival (OS) and rates of central nervous system (CNS) involvement without prophylaxis according to score were as follows:</td> </tr> <tr> <td class=\"subtitle2_left\">Score</td> <td class=\"subtitle2_left\">OS, percent<sup>[1]</sup></td> <td class=\"subtitle2_left\">CNS involvement, percent<sup>[2]</sup></td> </tr> <tr> <td class=\"indent1\">0</td> <td class=\"indent1\">81</td> <td class=\"indent1\">&#60;2</td> </tr> <tr> <td class=\"indent1\">1</td> <td class=\"indent1\">64</td> <td class=\"indent1\">&#60;2</td> </tr> <tr> <td class=\"indent1\">2</td> <td class=\"indent1\">34</td> <td class=\"indent1\">&#60;2</td> </tr> <tr> <td class=\"indent1\">3 or 4</td> <td class=\"indent1\">7</td> <td class=\"indent1\">10</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Systemic B symptoms are defined as temperature &gt;38°C (&gt;100.4°F), unexplained weight loss of &gt;10 percent of body weight over the past six months, and/or the presence of drenching night sweats.<br />¶ Regional lymph node involvement was defined as the invasion of lymph nodes corresponding to N1, N2, or N3 of the primary lesion in the American Joint Committee on Cancer tumor (T), nodes (N), metastasis (M) staging system. An example of regional lymph node involvement is the involvement of cervical nodes for patients with NK/T cell lymphoma of the upper aerodigestive tract.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 2006; 24:612. </LI>&#xD;&#xA;<LI>Kim SJ, Oh SY, Hong JY. When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type? Ann Oncol 2010; 21:1058. </LI></OL></div><div id=\"graphicVersion\">Graphic 67924 Version 3.0</div></div></div>"},"67925":{"type":"graphic_table","displayName":"Causes of ALF","title":"Mnemonic for causes of acute liver failure: The ABCs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mnemonic for causes of acute liver failure: The ABCs</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"centered\">A</td> <td>Acetaminophen, hepatitis A, autoimmune hepatitis, <em>Amanita phalloides</em> (mushroom poisoning), adenovirus</td> </tr> <tr> <td class=\"centered\">B</td> <td>Hepatitis B, Budd-Chiari syndrome</td> </tr> <tr> <td class=\"centered\">C</td> <td>Cryptogenic, hepatitis C, CMV</td> </tr> <tr> <td class=\"centered\">D</td> <td>Hepatitis D, drugs and toxins</td> </tr> <tr> <td class=\"centered\">E</td> <td>Hepatitis E, EBV</td> </tr> <tr> <td class=\"centered\">F</td> <td>Fatty infiltration - acute fatty liver of pregnancy, Reye's syndrome</td> </tr> <tr> <td class=\"centered\">G</td> <td>Genetic - Wilson disease</td> </tr> <tr> <td class=\"centered\">H</td> <td>Hypoperfusion (ischemic hepatitis, SOS, sepsis), HELLP syndrome, HSV, heat stroke, hepatectomy, hemophagocytic lymphohistiocytosis</td> </tr> <tr> <td class=\"centered\">I</td> <td>Infiltration by tumor</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CMV: cytomegalovirus; EBV: Epstein-Barr virus; SOS: sinusoidal obstruction syndrome&nbsp;(veno-occlusive disease); HELLP: hemolysis, elevated liver enzymes, low platelets; HSV: herpes simplex virus.</div><div id=\"graphicVersion\">Graphic 67925 Version 6.0</div></div></div>"},"67928":{"type":"graphic_movie","displayName":"Impaired TM mobility","title":"Tympanic membrane with impaired mobility","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tympanic membrane with impaired mobility</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/67928_pneumat2conv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:360px; height:250px;\" src=\"images/CARD/67928_pneumat2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A maximally retracted tympanic membrane may be unable to move away from the observer with positive pressure.</div><div class=\"graphic_reference\">Courtesy of Ellen R Wald, MD.</div><div id=\"graphicVersion\">Graphic 67928 Version 2.0</div></div></div>"},"67929":{"type":"graphic_diagnosticimage","displayName":"Doppler of tricuspid regurgitation","title":"Color Doppler echocardiogram of tricuspid regurgitation","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Color Doppler echocardiogram of tricuspid regurgitation</div><div class=\"cntnt\"><img style=\"width:528px; height:174px;\" src=\"images/CARD/67929_Doppler_tricuspid_regurgita.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The color Doppler echocardiogram&nbsp;of a patient with mild tricuspid regrugitation (TR) due to moderate pulmonary hypertension shows a TR jet; although the jet entrains along the interatrial septum (IAS), it has a narrow vena contracta and proximal acceleration region (PISA), suggesting that TR is mild (panel A). Panel P is a continuous wave (cw) Doppler which shows that the jet is low density, has an incomplete envelope, and a parabolic shape. These features of mild tricuspid insufficiency co-exist with and are unaffected by pulmonary hypertension. Pulmonary hypertension is identified by a peak TR velocity of 3.7 meter/sec.</div><div id=\"graphicVersion\">Graphic 67929 Version 2.0</div></div></div>"},"67930":{"type":"graphic_picture","displayName":"Recoverin and photoreceptors","title":"Anti-recoverin antibodies","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anti-recoverin antibodies</div><div class=\"cntnt\"><img style=\"width:360px; height:247px;\" src=\"images/ONC/67930_Recoverin_and_photoreceptor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Section of bovine retina incubated with the serum of a patient with cancer-associated retinopathy and anti-recoverin antibodies that are targeted against the photoreceptors. The antibodies specifically react with the photoreceptors (seen in brown).</div><div class=\"graphic_reference\">Courtesy of Josep Dalmau, MD, PhD.</div><div id=\"graphicVersion\">Graphic 67930 Version 1.0</div></div></div>"},"67932":{"type":"graphic_picture","displayName":"Traumatic perforation of TM","title":"Otoscopic view of traumatic perforation of the tympanic membrane from a cotton-tipped applicator","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Otoscopic view of traumatic perforation of the tympanic membrane from a cotton-tipped applicator</div><div class=\"cntnt\"><img style=\"width:334px; height:345px;\" src=\"images/ALLRG/67932_Otoscopic_traum_perfor_cott.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 67932 Version 2.0</div></div></div>"},"67933":{"type":"graphic_picture","displayName":"Bunny line botulinum toxin injection sites","title":"Example of botulinum toxin injection sites for \"bunny lines\"","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Example of botulinum toxin injection sites for &quot;bunny lines&quot;</div><div class=\"cntnt\"><img style=\"width:502px; height:326px;\" src=\"images/DERM/67933_Bunnylineinjectionsites.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 67933 Version 3.0</div></div></div>"},"67934":{"type":"graphic_picture","displayName":"Eccentric exercise for elbow epicondylitis","title":"Eccentric exercise for elbow epicondylitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eccentric exercise for elbow epicondylitis</div><div class=\"cntnt\"><img style=\"width:396px; height:321px;\" src=\"images/EM/67934_Epicondy_eccentric_rehab.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph demonstrates an eccentric exercise for the wrist extensor muscles. Eccentric exercise involves the application of a load during the lengthening of a muscle and may assist with healing of a tendinopathy. Here the wrist extensors are contracting eccentrically against the resistance of an exercise band.</div><div class=\"graphic_reference\">Courtesy of Neeru Jayanthi, MD.</div><div id=\"graphicVersion\">Graphic 67934 Version 2.0</div></div></div>"},"67935":{"type":"graphic_table","displayName":"Assessment of thyroid function","title":"Patterns of thyroid function tests during assessment of thyroid function","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Patterns of thyroid function tests during assessment of thyroid function</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Serum TSH</td> <td class=\"subtitle1\">Serum free T4</td> <td class=\"subtitle1\">Serum T3</td> <td class=\"subtitle1\">Assessment</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Normal hypothalamic-pituitary function</td> </tr> <tr> <td class=\"indent1\">Normal</td> <td>Normal</td> <td>Normal</td> <td>Euthyroid</td> </tr> <tr> <td class=\"indent1\">Normal</td> <td>Normal or high</td> <td>Normal or high</td> <td>Euthyroid hyperthyroxinemia</td> </tr> <tr> <td class=\"indent1\">Normal</td> <td>Normal or low</td> <td>Normal or low</td> <td>Euthyroid hypothyroxinema</td> </tr> <tr> <td class=\"indent1\">Normal</td> <td>Low</td> <td>Normal or high</td> <td>Euthyroid: T3 therapy</td> </tr> <tr> <td class=\"indent1\">Normal</td> <td>Low-normal or low</td> <td>Normal or high</td> <td>Euthyroid: thyroid extract therapy</td> </tr> <tr> <td class=\"indent1\">High</td> <td>Low</td> <td>Normal or low</td> <td>Primary hypothyroidism</td> </tr> <tr> <td class=\"indent1\">High</td> <td>Normal</td> <td>Normal</td> <td>Subclinical hypothyroidism</td> </tr> <tr> <td class=\"indent1\">Low</td> <td>High or normal</td> <td>High</td> <td>Hyperthyroidism</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Low</td> <td>Normal</td> <td>Normal</td> <td>Subclinical hyperthyroidism</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Abnormal hypothalamic-pituitary function</td> </tr> <tr> <td class=\"indent1\">Normal or high</td> <td>High</td> <td>High</td> <td>TSH-mediated hyperthyroidism</td> </tr> <tr> <td class=\"indent1\">Normal or low*</td> <td>Low or low-normal</td> <td>Low or normal</td> <td>Central hypothyroidism</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">T3: triiodothyronine; T4: thyroxine; TSH: thyroid-stimulating hormone.<br />* In central hypothyroidism, serum TSH may be low, normal, or slightly high.</div><div id=\"graphicVersion\">Graphic 67935 Version 4.0</div></div></div>"},"67936":{"type":"graphic_picture","displayName":"Actinomyces infection endosc","title":"<EM>Actinomyces</EM> infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Actinomyces</EM> infection</div><div class=\"cntnt\"><img style=\"width:329px; height:311px;\" src=\"images/GAST/67936_Actinomyces_infection_Endos.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Colonoscopy showing button-like elevation of the inverted appendiceal orifice in the cecum due to inflammatory infiltration by actinomycosis.</div><div class=\"graphic_reference\">Reproduced with permission from Yang SH, et al. Colonoscopy in abdominal actinomycosis. Gastrointest Endosc 2000; 51:236. Copyright © 2000 Mosby, Inc.</div><div id=\"graphicVersion\">Graphic 67936 Version 3.0</div></div></div>"},"67939":{"type":"graphic_picture","displayName":"Uvular edema and erythema","title":"Uvular edema and erythema","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Uvular edema and erythema</div><div class=\"cntnt\"><img style=\"width:503px; height:180px;\" src=\"images/PEDS/67939_Uvulitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inflammation of the uvula in association with tonsillar and posterior pharyngeal involvement.<br />(A) Redness and vascularity of the tonsillar pillars and uvula are mild to moderate. The uvula is moderately swollen.<br />(B) Redness is diffuse and intense.</div><div class=\"graphic_reference\">Reproduced with permission from: Bickley LS, Szilagyi PG. Bates' guide to physical examination and history taking (8th ed.). Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 67939 Version 5.0</div></div></div>"},"67940":{"type":"graphic_picture","displayName":"Intraarticular injection","title":"Intraarticular shoulder injection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intraarticular shoulder injection</div><div class=\"cntnt\"><img style=\"width:436px; height:346px;\" src=\"images/RHEUM/67940_Intraarticular_injection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fluoroscopy is recommended to perform this procedure in obese patients. The patient assumes a sitting position with the shoulder relaxed. The humeral head, coracoid process, and acromioclavicular (AC) joint are located and marked. The point of entry is 1/2&quot; below the coracoid process. The angle of entry is 10 to 20 degrees up and out, aligned with the AC joint. A 3 1/2&quot;, 22-gauge needle is used to a depth of 2 to 2 1/2&quot;. Ethyl chloride is sprayed on the skin. Local anesthetic is placed at the pectoralis fascia (1 mL) and, the subscapularis fascia (1 mL), and intraarticularly (1 to 2 mL). 1 mL of triamcinolone acetonide (40 mg/mL) is then injected intraarticularly.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 67940 Version 4.0</div></div></div>"},"67943":{"type":"graphic_table","displayName":"Ddx cavitary lung lesions","title":"Differential diagnosis of cavitary lung lesions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of cavitary lung lesions</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Infections</td> </tr> <tr> <td class=\"subtitle2_single\">Necrotizing infections</td> </tr> <tr> <td class=\"indent2\">Anaerobic bacteria, often mixed with aerobic and microaerophilic streptococci</td> </tr> <tr> <td class=\"indent2\">Other bacteria</td> </tr> <tr> <td class=\"indent3\"><em>Staphylococcus aureus</em>, <em>Klebsiella pneumoniae</em>, Enterobacteriaceae, <em>Pseudomonas aeruginosa</em>, <em>Legionella</em> spp, <em>Haemophilus influenzae</em> type B, <em>Nocardia</em> spp, <em>Actinomyces</em> spp, <em>Burkholderia pseuomallei</em></td> </tr> <tr> <td class=\"indent2\">Mycobacteria</td> </tr> <tr> <td class=\"indent3\"><em>Mycobacterium tuberculosis</em>, <em>M. avium</em>, <em>M. kansasii</em>, other nontuberculous mycobacteria</td> </tr> <tr> <td class=\"indent2\">Fungi</td> </tr> <tr> <td class=\"indent3\"><em>Aspergillus</em> spp, <em>Coccidioides</em> spp, <em>Histoplasma</em> spp, <em>Blastomyces dermatitidis</em>, <em>Cryptococcus</em> spp, agents of mucormycosis, <em>Pneumocystis jirovecii</em> (formerly <em>P. carinii</em>)</td> </tr> <tr> <td class=\"indent2\">Parasites</td> </tr> <tr> <td class=\"indent3\"><em>Entamoeba histolytica</em></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent3\"><em>Paragonimus westermani</em></td> </tr> <tr> <td class=\"subtitle2_single\">Empyema with air-fluid level (hydropneumothorax)</td> </tr> <tr> <td class=\"subtitle2_single\">Septic pulmonary emboli</td> </tr> <tr> <td class=\"subtitle1_single\">Non-infectious diseases</td> </tr> <tr> <td class=\"indent1\">Pulmonary embolism with infarction</td> </tr> <tr> <td class=\"indent1\">Vasculitis (eg, granulomatosis with polyangiitis)</td> </tr> <tr> <td class=\"indent1\">Neoplasm</td> </tr> <tr> <td class=\"indent1\">Pulmonary sequestration</td> </tr> <tr> <td class=\"indent1\">Bullae or cysts with air fluid level</td> </tr> <tr> <td class=\"indent1\">Bronchiectasis</td> </tr> <tr> <td class=\"indent1\">Cryptogenic organizing pneumonia</td> </tr> <tr> <td class=\"indent1\">Sarcoidosis</td> </tr> <tr> <td class=\"indent1\">Rheumatoid nodules</td> </tr> <tr> <td class=\"indent1\">Pulmonary Langerhans histiocytosis</td> </tr> <tr> <td class=\"indent1\">Foreign body aspiration</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 67943 Version 4.0</div></div></div>"},"67947":{"type":"graphic_picture","displayName":"Lobular carcinoma in situ of the breast","title":"Lobular carcinoma in situ of the breast","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lobular carcinoma in situ of the breast</div><div class=\"cntnt\"><img style=\"width:405px; height:251px;\" src=\"images/SURG/67947_LobularCISLightII.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power photomicrograph of a hematoxylin and eosin-stained section of a breast biopsy specimen from a 43-year-old woman showing classic calcifications (double-headed arrows) in an area of lobular carcinoma in situ, and similar-appearing calcifications (single arrow) in an adjacent focus of adenosis.</div><div class=\"graphic_reference\">From: Georgian-Smith D, Lawton TJ. Calcifications of lobular carcinoma in situ of the breast: Radiologic-pathologic correlation. AJR Am J Roentgenol 2001; 176:1255. Reprinted with permission from: the American Journal of Roentgenology.</div><div id=\"graphicVersion\">Graphic 67947 Version 13.0</div></div></div>"},"67948":{"type":"graphic_table","displayName":"Diagnosis of SCID","title":"Diagnostic criteria for severe combined immunodeficiency (SCID)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for severe combined immunodeficiency (SCID)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Definitive diagnosis*</td> </tr> <tr> <td class=\"indent1\">Patient less than two years of age with either (a) an absolute CD3 T cell count of less than 300/mm<sup>3</sup>, or (b) an absolute CD3 T cell count of greater than 300/mm<sup>3</sup> with absent na&#239;ve CD3/CD45RA T cells, and at least one of the following:</td> </tr> <tr> <td class=\"indent1\"> <ol> <li>Male with deleterious mutation in the X-linked <em>IL2RG</em> gene encoding the cytokine receptor common gamma chain (gamma-c). </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol start=\"2\"> <li>Male or female patient with deleterious homozygous or compound heterozygous mutations in any of the genes listed in the Gene Defects table other than <em>IL2RG</em>. </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ol start=\"3\"> <li>ADA activity of less than 2% of control or mutations in both alleles of the <em>ADA</em> gene. </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ol start=\"4\"> <li>Engraftment of transplacentally acquired maternal T cells. </li> </ol> </td> </tr> <tr> <td class=\"subtitle1_single\">Probable diagnosis*</td> </tr> <tr> <td class=\"indent1\">Male or female patient less than two years of age with (a) less than 20% CD3+ T cells, an absolute lymphocyte count of less than 3000/mm<sup>3</sup>, and proliferative responses to mitogens less than 10% of control or (b) the presence of maternal lymphocytes in the circulation.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IL2RG: interleukin 2 receptor gamma chain, also called the cytokine receptor common gamma chain; ADA: adenosine deaminase.<br />* Patients with a definitive or probable diagnosis are assumed to have a greater than 98 and 85% probability, respectively, that in 20 years they will still have the same diagnosis.</div><div class=\"graphic_reference\">Data from: Picard C, Al-Herz W, Bousfiha A, et al. Primary immunodeficiency diseases: An update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015. J Clin Immunol 2015; 35:696.</div><div id=\"graphicVersion\">Graphic 67948 Version 5.0</div></div></div>"},"67949":{"type":"graphic_picture","displayName":"Physalia physalis print","title":"Physalia physalis print","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Physalia physalis print</div><div class=\"cntnt\"><img style=\"width:288px; height:485px;\" src=\"images/PC/67949_Physalia_physalis_print.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Print from a Physalia physalis tentacle.</div><div class=\"graphic_reference\">Reproduced with permission from Junghanss, T, Bodio, M. Medically important venomous animals: Biology, prevention, first aid, and clinical management. CID 2006; 32:1309. Copyright &#169; 2006 University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 67949 Version 1.0</div></div></div>"},"67950":{"type":"graphic_figure","displayName":"WHO length for age boys 0 to 24 months","title":"Length-for-age percentiles, boys birth to 24 months, WHO growth standards","html":"<div class=\"graphic\"><div style=\"width: 587px\" class=\"figure\"><div class=\"ttl\">Length-for-age percentiles, boys birth to 24 months, WHO growth standards</div><div class=\"cntnt\"><img style=\"width:567px; height:459px;\" src=\"images/PEDS/67950_WHO_length_boy_0_to_24.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">WHO: World Health Organization.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention based on data from the WHO Child Growth Standards.</div><div id=\"graphicVersion\">Graphic 67950 Version 3.0</div></div></div>"},"67951":{"type":"graphic_figure","displayName":"Montgomery-Asberg Depression Rating Scale - page 2","title":"Montgomery-Asberg Depression Rating Scale, page 2","html":"<div class=\"graphic\"><div style=\"width: 631px\" class=\"figure\"><div class=\"ttl\">Montgomery-Asberg Depression Rating Scale, page 2</div><div class=\"cntnt\"><img style=\"width:611px; height:749px;\" src=\"images/PSYCH/67951_Montgomery_p2.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Montgomery, SA. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382.</div><div id=\"graphicVersion\">Graphic 67951 Version 2.0</div></div></div>"},"67952":{"type":"graphic_figure","displayName":"Latissimus flap breast reconstruction","title":"Latissimus flap breast reconstruction","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Latissimus flap breast reconstruction</div><div class=\"cntnt\"><img style=\"width:525px; height:526px;\" src=\"images/SURG/67952_Latissimus-flap-breast-reconstruction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The latissimus dorsi (LD)&nbsp;flap is a reliable option for autologous tissue reconstruction. The flap is tunneled through the axilla, leaving its vascular pedicle, the thoracodorsal artery and vein, intact. Because the LD is not a bulky flap, it usually is used in combination with a saline or silicone implant to provide sufficient breast volume and projection.</div><div id=\"graphicVersion\">Graphic 67952 Version 3.0</div></div></div>"},"67953":{"type":"graphic_figure","displayName":"Blood pressure AR with dexfen","title":"The incidence of aortic regurgitation with dexfenfluramine is associated with diastolic blood pressure","html":"<div class=\"graphic\"><div style=\"width: 496px\" class=\"figure\"><div class=\"ttl\">The incidence of aortic regurgitation with dexfenfluramine is associated with diastolic blood pressure</div><div class=\"cntnt\"><img style=\"width:476px; height:254px;\" src=\"images/CARD/67953_BloodpressureARwithdexf.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The frequency of any degree of aortic regurgitation (AR) in dexfenfluramine patients increases progressively with higher diastolic blood pressures (p = 0.03); there is no effect of diastolic pressure on the incidence of AR in control subjects.</div><div class=\"graphic_reference\">Data from Shively BK, Roldan CA, Gill EA, et al. Circulation 1999; 100:2161.</div><div id=\"graphicVersion\">Graphic 67953 Version 2.0</div></div></div>"},"67954":{"type":"graphic_diagnosticimage","displayName":"TB Ghon complex","title":"Classic Ghon complex in a child infected with <EM>Mycobacterium tuberculosis</EM>","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Classic Ghon complex in a child infected with <EM>Mycobacterium tuberculosis</EM></div><div class=\"cntnt\"><img style=\"width:281px; height:432px;\" src=\"images/ID/67954_TB_Ghon_complex.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This radiograph shows a classic Ghon complex in a child infected with <EM>Mycobacterium tuberculosis</EM> about&nbsp;six months previously, based on results of a contact investigation. There is a calcifed parenchymal lesion and calcification of the regional hilar lymph node. Although a Ghon complex contains live organisms, the number is small (as seen in infection rather than disease), so management with isoniazid alone as for latent infection is sufficient.</div><div class=\"graphic_reference\">Courtesy of Jeffrey R Starke, MD.</div><div id=\"graphicVersion\">Graphic 67954 Version 4.0</div></div></div>"},"67956":{"type":"graphic_figure","displayName":"Nutrition label fat PI","title":"Nutrition label fat","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nutrition label fat</div><div class=\"cntnt\"><img style=\"width:222px; height:443px;\" src=\"images/PI/67956_Nutrition_label_fat_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The percentage of calories from fat can be calculated by dividing the calories from fat (90 in this example) by the total calories (320 in this example).<br>90 / 320 = 0.28 = 28 percent of calories from fat.<br>It is important to pay attention to serving size; these numbers apply to 1 serving, which in this example is 1 cup.</div><div id=\"graphicVersion\">Graphic 67956 Version 1.0</div></div></div>"},"67957":{"type":"graphic_figure","displayName":"Levels TNF and NYHA class","title":"Levels of tumor necrosis factor alpha correlate with NYHA functional","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Levels of tumor necrosis factor alpha correlate with NYHA functional</div><div class=\"cntnt\"><img style=\"width:434px; height:316px;\" src=\"images/CARD/67957_Levels_TNF_and_NYHA_class.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Circulating levels of tumor necrosis factor alpha (TNFa) are significantly higher in patients with heart failure compared to normals (1.95 versus 0.75 pg/mL). Levels were progressively elevated in relationship to decreasing functional status of the patient; levels were highest in those with NYHA class III compared to those with NYHA class I heart failure or controls.</div><div class=\"graphic_footnotes\">* p = 0.001.</div><div class=\"graphic_reference\">Data from Torre-Amione G, Kapadia S, Benedict C, et al. J Am Coll Cardiol 1996; 27:1201.</div><div id=\"graphicVersion\">Graphic 67957 Version 2.0</div></div></div>"},"67959":{"type":"graphic_picture","displayName":"Interface hepatitis AASLD","title":"Interface hepatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Interface hepatitis</div><div class=\"cntnt\"><img style=\"width:384px; height:267px;\" src=\"images/GAST/67959_Interface_hepatitis_AASLD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The portal tract is expanded by a mononuclear infiltrate; the limiting plate is disrupted; and the inflammatory process extends into the acinus. Staining by hematoxylin-eosin; original magnification x 200.</div><div class=\"graphic_reference\">Reproduced with permission from the American Association for the Study of Liver Diseases. Hepatology 2002; 36:479.</div><div id=\"graphicVersion\">Graphic 67959 Version 1.0</div></div></div>"},"67963":{"type":"graphic_table","displayName":"Classification of DCIS","title":"Proposed classification systems for ductal carcinoma in situ","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Proposed classification systems for ductal carcinoma in situ</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">Lagios*</td>\n\n      <td class=\"subtitle1\">Van Nuys&#8226;</td>\n\n      <td class=\"subtitle1\">European&#916;</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Low grade</td>\n\n      <td>Non-high grade without necrosis</td>\n\n      <td>Well differentiated</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Intermediate grade</td>\n\n      <td>Non-high grade with necrosis</td>\n\n      <td>Intermediately differentiated</td>\n\n    </tr>\n\n    <tr>\n\n      <td>High grade</td>\n\n      <td>High grade</td>\n\n      <td>Poorly differentiated</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">* Adapted from Lagios MD, Margolin FR, Westdahl PR, Rose MR. Cancer 1989; 63:618.<BR>• Silverstein MJ, Poller DN, Waisman JR, et al. Lancet 1995; 345:1154.<BR>Δ Holland R, Peterse JL, Millis RR, et al. Semin Diagn Pathol 1994; 11:167.</div><div id=\"graphicVersion\">Graphic 67963 Version 2.0</div></div></div>"},"67964":{"type":"graphic_figure","displayName":"NASCET endarterectomy stroke death","title":"Carotid endarterectomy reduces major stroke and death in symptomatic patients with severe stenosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Carotid endarterectomy reduces major stroke and death in symptomatic patients with severe stenosis</div><div class=\"cntnt\"><img style=\"width:359px; height:256px;\" src=\"images/NEURO/67964_Endarter_stroke_death_edt2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The NASCET&nbsp;included 659 patients with a recent TIA or nondisabling stroke and a 70 to 99 percent carotid stenosis who were randomly assigned to carotid endarterectomy or medical therapy. At two-year follow-up, the cumulative risk of a major stroke or death was significantly lower in the endarterectomy group compared with the medical treatment group (8.0 versus 19.1 percent). The Kaplan-Meier survival curve shows the probability of event-free survival after randomization at six-month intervals.</div><div class=\"graphic_footnotes\">NASCET: North American Symptomatic Carotid Endarterectomy Trial; TIA: transient ischemic attack.</div><div class=\"graphic_reference\">Data from: North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 1991; 325:445.</div><div id=\"graphicVersion\">Graphic 67964 Version 12.0</div></div></div>"},"67965":{"type":"graphic_table","displayName":"Contraception guide PI","title":"Questions to guide a woman's choice of birth control","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Questions to guide a woman's choice of birth control</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr><td>1. Do you plan to become pregnant? When?</td></tr>\n<tr><td>2. Are you currently having sex with a male partner?</td></tr>\n<tr><td>3. What have you used before to prevent pregnancy? </td></tr>\n<tr><td>4. What did you like/dislike about the method(s)?</td></tr>\n<tr><td>5. Are you a good pill taker?</td></tr>\n<tr><td>6. How often did you forget to use the method?</td></tr>\n<tr><td>7. Are there any methods you have heard about and would like to try?</td></tr>\n<tr><td>8. Is sex usually planned or spontaneous?</td></tr>\n<tr><td>9. Is protection from sexually transmitted infections important considering your life situation?</td></tr>\n<tr><td>10. Is cost an issue? Does your health insurance plan cover any birth control method?</td></tr>\n\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted from: Association of Reproductive Health Professionals. Clinical Proceedings: Periodic Well-Woman Visit: Individualized Contraceptive Care. Washington, DC; April 2004. Copyright &#169; Association of Reproductive Health Professionals (ARHP).</div><div id=\"graphicVersion\">Graphic 67965 Version 1.0</div></div></div>"},"67966":{"type":"graphic_figure","displayName":"Stress MPI after CABG","title":"Stress MPI provides prognostic information after CABG","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">Stress MPI provides prognostic information after CABG</div><div class=\"cntnt\"><img style=\"width:523px; height:351px;\" src=\"images/CARD/67966_Stress_MPI_after_CABG.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In 1544 patients who had previously undergone coronary artery bypass grafting (CABG), stress myocardial perfusion imaging (MPI) was predictive of the subsequent annual cardiac death rate. Cardiac death rates were significantly higher for patients with who had a higher summed stress score (SSS) on MPI; they were also higher in patients evaluated &gt;5 years, as opposed to &#8804;5 years, after CABG.</div><div class=\"graphic_reference\">Data from: Zellweger, MJ, Lewin, HC, Lai, S, et al. J Am Coll Cardiol 2001; 37:144.</div><div id=\"graphicVersion\">Graphic 67966 Version 1.0</div></div></div>"},"67967":{"type":"graphic_table","displayName":"Monitoring of MTF transgender persons on cross-hormone therapy","title":"Monitoring of male-to-female transgender persons on cross-hormone therapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Monitoring of male-to-female transgender persons on cross-hormone therapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>1. Evaluate patient every two to three months in the first year and then one to two times per year afterward to monitor for appropriate signs of feminization and for development of adverse reactions.</td> </tr> <tr> <td class=\"sublist1_start\">2. Measure serum testosterone and estradiol every three months.</td> </tr> <tr> <td class=\"sublist2\">a. Serum testosterone levels should be &#60;55 ng/dL.</td> </tr> <tr> <td class=\"sublist2\">b. Serum estradiol should not exceed the peak physiological range for young, healthy females, with ideal levels &#60;200 pg/mL.</td> </tr> <tr> <td class=\"sublist2\">c. Doses of estrogen should be adjusted according to the serum levels of estradiol.</td> </tr> <tr> <td>3. For individuals on spironolactone, serum electrolytes (particularly potassium) should be monitored every two to three months initially in the first year.</td> </tr> <tr> <td>4. Routine cancer screening should be performed for colon and prostate cancer, as well as breast cancer (because of high dose estrogen).</td> </tr> <tr> <td>5. Consider BMD testing at baseline if risk factors for osteoporotic fracture are present (eg, previous fracture, family history, glucocorticoid use, prolonged hypogonadism). In individuals at low risk, screening for osteoporosis should be conducted at age 60 and in those who are not compliant with hormone therapy.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BMD: bone mineral density.</div><div class=\"graphic_reference\">Modified with permission from: Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2009; 94:3132. Copyright &copy; 2009 The Endocrine Society.</div><div id=\"graphicVersion\">Graphic 67967 Version 8.0</div></div></div>"},"67968":{"type":"graphic_picture","displayName":"Pincer nails 2","title":"Pincer nails deformity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pincer nails deformity</div><div class=\"cntnt\"><img style=\"width:432px; height:265px;\" src=\"images/DERM/67968_Pincernails2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transverse overcurvature of the nail is seen in pincer nail deformity. The disorder may be hereditary or acquired. In cases of acquired pincer nails, poorly fitting shoes are often responsible. The condition can be painful.</div><div class=\"graphic_reference\">Reproduced with permission from: Stedman's Medical Dictionary. Copyright © 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 67968 Version 2.0</div></div></div>"},"67969":{"type":"graphic_figure","displayName":"Metformin in type 2 DM II","title":"Metformin in overweight patients with type 2 diabetes mellitus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Metformin in overweight patients with type 2 diabetes mellitus</div><div class=\"cntnt\"><img style=\"width:427px; height:299px;\" src=\"images/ENDO/67969_Metformin_in_type_2_DM_II.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier plots of any diabetes-related death in 753 overweight patients with type 2 diabetes mellitus in the United Kingdom Prospective Diabetes Study who were randomly assigned to either intensive therapy with metformin or to conventional treatment with diet; drugs were added if there were hyperglycemic symptoms or if the fasting blood glucose concentration was greater than 270 mg/dL (15 mmol/L). Another 951 overweight patients received intensive therapy with a sulfonylurea or insulin and are included in the analysis. Metformin was associated with a 42 percent reduction in any diabetes-related endpoint compared to conventional therapy (P = 0.02).</div><div class=\"graphic_reference\">Data from UK Prospective Diabetes Study (UKPDS) Group, Lancet 1998; 352:854.</div><div id=\"graphicVersion\">Graphic 67969 Version 1.0</div></div></div>"},"67971":{"type":"graphic_waveform","displayName":"MRS of hypoxic-ischemic brain injury","title":"Magnetic resonance spectroscopy of hypoxic-ischemic brain injury","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance spectroscopy of hypoxic-ischemic brain injury</div><div class=\"cntnt\"><img style=\"width:468px; height:350px;\" src=\"images/PEDS/67971_MR_spectroscopy_HIE.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnetic resonance spectroscopy (MRS) of the basal ganglia in a term newborn with hypoxic-ischemic injury. The prominent inverted lactate doublet peak (L) is characteristic of lactic acidosis.</div><div class=\"graphic_footnotes\">N: N-acetyl-aspartate; G: glutamate; Cr: creatine 1 &amp;2; Ch: choline; I: myoinisitol.</div><div id=\"graphicVersion\">Graphic 67971 Version 3.0</div></div></div>"},"67972":{"type":"graphic_table","displayName":"ROS overweight child","title":"Important aspects of the review of systems in overweight or obese children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Important aspects of the review of systems in overweight or obese children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Symptom</td> <td class=\"subtitle1\">Potential significance</td> <td class=\"subtitle1\">Additional studies or referral <br /> (consider)</td> </tr> <tr> <td>Delayed development</td> <td>Genetic syndrome</td> <td>Pediatric geneticist and/or neurologist</td> </tr> <tr> <td rowspan=\"2\">Short stature or reduced height velocity</td> <td>Genetic syndrome</td> <td>Pediatric geneticist</td> </tr> <tr> <td>Endocrinologic etiology (eg, Cushing syndrome, hypothyroidism, ROHHADNET syndrome [rapid onset obesity with hypothalamic dysfunction, hypoventilation, autonomic dysregulation, and neural crest tumor])</td> <td>24 hour urine collection for free cortisol, thyroid function tests; pediatric endocrinologist</td> </tr> <tr> <td> <p>Headaches (especially morning)</p> </td> <td rowspan=\"3\">Pseudotumor cerebri</td> <td rowspan=\"3\">Pediatric neurologist</td> </tr> <tr> <td> <p>Nausea/vomiting</p> &nbsp;</td> </tr> <tr> <td> <p>Blurred or decreased vision&nbsp;</p> </td> </tr> <tr> <td>Snoring</td> <td rowspan=\"3\">Sleep apnea, obesity hypoventilation syndrome<br /> </td> <td rowspan=\"3\">Polysomnogram (sleep study) and/or referral to a pediatric sleep medicine, pulmonologist,&nbsp;or ENT specialist<br /> </td> </tr> <tr> <td>Daytime sleepiness</td> </tr> <tr> <td>Nocturnal enuresis&nbsp;</td> </tr> <tr> <td rowspan=\"2\">Abdominal pain</td> <td>Gall bladder disease</td> <td>AST, ALT, abdominal ultrasonography</td> </tr> <tr> <td>Nonalcoholic fatty liver disease</td> <td>AST, ALT, pediatric gastroenterologist</td> </tr> <tr> <td>Hip pain, knee pain, limp</td> <td>Slipped capital femoral epiphysis (SCFE) or Blount disease (tibia vara)</td> <td>Radiographs; pediatric orthopedist</td> </tr> <tr> <td>Right upper quadrant abdominal pain&nbsp;</td> <td>Cholelithiasis or non-alcoholic fatty liver disease</td> <td>Abdominal ultrasonography</td> </tr> <tr> <td rowspan=\"2\">Oligomenorrhea or amenorrhea</td> <td>Polycystic ovary syndrome (PCOS)</td> <td>Pediatric endocrinologist or adolescent specialist</td> </tr> <tr> <td>Prader-Willi syndrome</td> <td>Pediatric geneticist</td> </tr> <tr> <td>Urinary frequency, nocturia, polydipsia, polyuria</td> <td>Type 2 diabetes</td> <td>Urinalysis, fasting blood glucose, hemoglobin A1c, glucose tolerance test; pediatric endocrinologist</td> </tr> <tr> <td>Binge eating or purging</td> <td>Eating disorder</td> <td>Specialist in eating disorders</td> </tr> <tr> <td>Insomnia</td> <td rowspan=\"2\">Depression<br /> </td> <td rowspan=\"2\">Pediatric psychologist or psychiatrist<br /> </td> </tr> <tr> <td>Anhedonia</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ENT: ear/nose/throat; AST: aspartate aminotransferase; ALT: alanine aminotransferase.</div><div class=\"graphic_reference\">Adapted from: Barlow SE, Dietz WH. Obesity evaluation and treatment: Expert Committee recommendations. The Maternal and Child Health Bureau, Health Resources and Services Administration and the Department of Health and Human Services. Pediatrics 1998; 102:E29 and Dietz WH, Robinson TN. Clinical practice. Overweight children and adolescents. N Engl J Med 2005; 352:2100.</div><div id=\"graphicVersion\">Graphic 67972 Version 13.0</div></div></div>"},"67973":{"type":"graphic_picture","displayName":"Jugulotympanic paraganglioma of the middle ear","title":"Jugulotympanic paraganglioma (glomus tympanicum) of the middle ear","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Jugulotympanic paraganglioma (glomus tympanicum) of the middle ear</div><div class=\"cntnt\"><img style=\"width:396px; height:396px;\" src=\"images/PC/67973_Glomus_tympanicum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Picture of a left tympanic membrane with a pulsating red mass occupying the inferior portion of the middle ear space. The rest of the tympanic membrane is normal.</div><div class=\"graphic_reference\">Reproduced with permission from: Bechara Y Ghorayeb, MD. www.ghorayeb.com.</div><div id=\"graphicVersion\">Graphic 67973 Version 3.0</div></div></div>"},"67975":{"type":"graphic_picture","displayName":"Normal parathyroid glands","title":"Normal parathyroid glands","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal parathyroid glands</div><div class=\"cntnt\"><img style=\"width:440px; height:613px;\" src=\"images/SURG/67975_Normal_parathyroid_glands.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Four normal parathyroid glands removed at autopsy from a 53-year-old man.</div><div class=\"graphic_reference\">Reproduced with permission from: Mills, SE. Histology For Pathologists, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2007. Copyright &#169; 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 67975 Version 2.0</div></div></div>"},"67976":{"type":"graphic_figure","displayName":"Nutcracker esophagus HREPT and manometry","title":"High-resolution esophageal pressure topography and conventional manometry in a patient with nutcracker esophagus","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">High-resolution esophageal pressure topography and conventional manometry in a patient with nutcracker esophagus</div><div class=\"cntnt\"><img style=\"width:464px; height:604px;\" src=\"images/GAST/67976_Nutcracker_eso_HREPT_mano.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-resolution esophageal pressure topography (panel A) and conventional manometry (panel B) from a patient with nutcracker esophagus. High-resolution esophageal pressure topography reveals vigorous contractions (indicated by the dark red color) with normal relaxation of the hypertensive lower esophageal sphincter and normal propagation velocity. Vigorous contractions are also demonstrated on the conventional manometric tracing that reveals high pressure amplitudes (tracing to the right of the arrow). Normal bolus transit by impedance is seen at the top of both panels.</div><div id=\"graphicVersion\">Graphic 67976 Version 3.0</div></div></div>"},"67977":{"type":"graphic_diagnosticimage","displayName":"Apical 4 chamber ASD","title":"Atrial septal defect","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atrial septal defect</div><div class=\"cntnt\"><img style=\"width:288px; height:288px;\" src=\"images/CARD/67977_Apical_4_chamber_ASD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Apical four chamber view showing a defect in the secundum atrial septum (red arrow). The right heart chambers (RV and RA) are enlarged, demonstrating right heart volume overload from left-to-right shunting at atrial level.</div><div class=\"graphic_reference\">RA: right atrium; RV: right ventricle; LA: left atrium; LV: left ventricle.</div><div id=\"graphicVersion\">Graphic 67977 Version 2.0</div></div></div>"},"67978":{"type":"graphic_figure","displayName":"Compliance with diet in hypertension","title":"Diminished compliance with nonpharmacologic antihypertensive therapy over time","html":"<div class=\"graphic\"><div style=\"width: 592px\" class=\"figure\"><div class=\"ttl\">Diminished compliance with nonpharmacologic antihypertensive therapy over time</div><div class=\"cntnt\"><img style=\"width:572px; height:228px;\" src=\"images/NEPH/67978_Compliance_with_diet_in_HTN.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Changes in weight, sodium intake (as estimated from urine sodium excretion), and exercise (measured by physical activity points) in patients with mild diastolic hypertension treated with combined dietary modification. Despite initial compliance, patients tended to return toward but not to baseline levels over a 48-month period. Although not shown, there was a persistent reduction in the number of alcoholic drinks from 3.6 to 2.5 drinks per week.</div><div class=\"graphic_reference\">Data from Neaton JD, Grimm RH Jr, Prineas RJ, et al. Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA 1993; 270:713.</div><div id=\"graphicVersion\">Graphic 67978 Version 3.0</div></div></div>"},"67980":{"type":"graphic_picture","displayName":"PUPPP striae","title":"PUPPP striae","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">PUPPP striae</div><div class=\"cntnt\"><img style=\"width:392px; height:260px;\" src=\"images/ALLRG/67980_PUPPP_striae.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PUPPP: pruritic urticarial papules and plaques of pregnancy.</div><div id=\"graphicVersion\">Graphic 67980 Version 3.0</div></div></div>"},"67982":{"type":"graphic_table","displayName":"Bulb syringe PI","title":"Instructions on using a bulb syringe","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Instructions on using a bulb syringe</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Nasal congestion from a cold can make it difficult for a young infant to breathe while eating. Mucus can be removed from the infant's nose with a bulb syringe.</td> </tr> <tr> <td class=\"sublist1_start\">Before using a bulb syringe, saline nose drops can be used to thin the mucus. Saline nose drops can be purchased in most pharmacies or can be made at home by adding 1/4 teaspoon salt to 8 ounces (1 cup) of warm (not hot) water. Stir to dissolve the salt, and store the solution for up to&nbsp;one week in a clean container with a cover. </td> </tr> <tr> <td class=\"sublist1\">Place the infant on his or her back. Using a clean nose dropper, place&nbsp;one to&nbsp;two drops of saline solution in each nostril. Wait a short period. </td> </tr> <tr> <td class=\"sublist1\">Squeeze and hold the bulb syringe to remove the air. Gently insert the tip of the bulb syringe into one nostril, and release the bulb. The suction will draw mucus out of the nostril into the bulb. </td> </tr> <tr> <td class=\"sublist1\">Squeeze the mucus out of the bulb into a tissue. </td> </tr> <tr> <td class=\"sublist1\">Repeat suction process several times in each nostril until most mucus is removed. </td> </tr> <tr> <td class=\"sublist1\">Wash the dropper and bulb syringe in warm, soapy water. Rinse well, and squeeze to remove any water. </td> </tr> <tr> <td>The bulb syringe can be used two to three times per day as needed to remove mucus. It is best to do this before feeding; the saline and suction process can cause vomiting after feeding.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Information from <A href=\"http://www.cincinnatichildrens.org/health/info/newborn/home/suction.htm\">www.cincinnatichildrens.org/health/info/newborn/home/suction.htm</A>.</div><div id=\"graphicVersion\">Graphic 67982 Version 2.0</div></div></div>"},"67983":{"type":"graphic_figure","displayName":"Technique of ray amputation","title":"Technique of ray amputation","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Technique of ray amputation</div><div class=\"cntnt\"><img style=\"width:502px; height:691px;\" src=\"images/SURG/67983_Ray-amputation.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 67983 Version 2.0</div></div></div>"},"67985":{"type":"graphic_table","displayName":"AIM 75_9","title":"Doxorubicin (Adriamycin), ifosfamide, and mesna (AIM 75/9) for advanced soft tissue sarcoma and as neoadjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Doxorubicin (Adriamycin), ifosfamide, and mesna (AIM 75/9) for advanced soft tissue sarcoma and as neoadjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 21 days.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Doxorubicin</td> <td>25 mg/m<sup>2</sup> per day IV</td> <td>Dilute with 50 mL normal saline (NS) or 5% dextrose in water (D5W) and administer over one to five minutes.</td> <td>Days 1, 2, and 3</td> </tr> <tr> <td>Ifosfamide</td> <td>2000 to 3000 mg/m<sup>2</sup> per day IV*</td> <td>Dilute with 250 to 500 mL of NS or D5W to a final concentration of 0.6 to 20 mg/mL and administer over three hours daily.</td> <td>Days 1, 2, and 3</td> </tr> <tr class=\"divider_bottom\"> <td>Mesna<sup>&#182;</sup></td> <td>1200 to 1800 mg/m<sup>2</sup> per day IV (60% of the total daily ifosfamide dose), given in three divided doses</td> <td>Dilute one-third of the total daily dose in NS or D5W (total concentration of mesna should not exceed 20 mg/mL) and administer over 15 minutes prior to each daily dose of ifosfamide. Repeat at four and eight hours after the initiation of each dose of ifosfamide daily.</td> <td>Days 1, 2, and 3</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Hydration</strong></td> <td colspan=\"3\"> <ul> <li>Adequate hydration (at least two liters of oral or IV fluids per day) should be maintained with ifosfamide to reduce the risk of bladder toxicity.<sup>[2]</sup> </li> <li>Refer to UpToDate topic on \"Cystitis in patients with cancer\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>HIGH (&#62;90% risk of emesis).<sup>&#182;</sup> </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> <li>Concomitant administration of aprepitant may increase the risk of ifosfamide neurotoxicity;<sup>[3-5]</sup> its use is avoided at some institutions. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>There is no standard premedication regimen. </li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Doxorubicin is a vesicant; avoid extravasation. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>The incidence of febrile neutropenia was not reported in the study; however, severe neutropenia is a frequent adverse event.<sup>[1]</sup> Primary prophylaxis with hematopoietic growth factors should be considered on an individual basis, particularly for high-risk patients such as those with preexisting neutropenia, advanced disease, poor performance status, or age over 50 years. </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>A lower initial ifosfamide dose may be needed for patients with preexisting renal or liver impairment. A lower starting dose of doxorubicin may be needed for patients with preexisting liver impairment.<sup>[6]</sup> </li> <li>Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\".</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Cardiac issues</strong></td> <td colspan=\"3\"> <ul> <li>Doxorubicin is associated with cardiomyopathy, the incidence of which is related to the cumulative dose. Assess baseline LVEF prior to administration. Doxorubicin is contraindicated for patients with recent myocardial infarction, severe myocardial dysfunction, severe arrhythmia, or previous therapy with high cumulative doses of doxorubicin or any other anthracyclines.<sup>[6]</sup> </li> <li>Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count weekly during treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Ifosfamide is associated with cumulative nephrotoxicity, mostly at a total dose above 60 g/m<sup>2</sup>. Clinical manifestations may include hypophosphatemia, renal potassium wasting, metabolic acidosis with a normal ion gap, and rarely, polyuria due to nephrogenic diabetes insipidus. Assess creatinine and electrolytes, including potassium and phosphate, daily during treatment and prior to each subsequent treatment cycle. </li> <li>Refer to UpToDate topic on \"Ifosfamide nephrotoxicity\". </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Mesna does not prevent hemorrhagic cystitis in all patients.<sup>[7]</sup> Monitor a morning specimen of urine for hematuria daily, on days 1 through 3. </li> <li>Refer to UpToDate topic on \"Cystitis in patients with cancer\". </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for ifosfamide neurotoxicity (confusion, coma, rarely seizures, weakness, neuropathy, ataxia, cranial nerve dysfunction) daily on days 1 to 3. Central nervous system side effects may be especially problematic for those over age 60. </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of non-platinum cancer chemotherapy\". </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess liver function tests prior to each treatment cycle. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor cumulative doxorubicin dose. Reassess LVEF periodically during therapy as clinically indicated. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>No defined dose alterations for myelosuppression were outlined in this study.<sup>[1]</sup> However, treatment should be delayed until white blood cell count is &#62;4000 cells/microL and platelet count is &#62;100,000/microL. Reduce doses of ifosfamide and doxorubicin by 25% for failure to recover platelets to &#62;100,000/microL by day 28, or for grade 4 neutropenia or febrile neutropenia despite prophylaxis with hematopoietic growth factors, or for platelet count &#60;50,000/microL during any cycle. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurologic toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Although formal guidelines are not provided by the manufacturer, ifosfamide dose adjustment (lower dose, or administering the same dose over a greater number of days) should be considered for patients with reversible grade 2 or 3 neurologic toxicity.<sup>[2]</sup> Discontinue for &#8805;grade 3 toxicity. </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of non-platinum cancer chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Bladder toxicity</strong></td> <td colspan=\"3\"> <ul> <li>For microscopic hematuria (greater than 10 RBC per high power field), withhold ifosfamide until complete resolution. Although formal guidelines are not available, ifosfamide dose adjustment may be needed for patients with grade 3 or worse urotoxicity that has not responded to increases in IV fluids or mesna.<sup>[2]</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Renal toxicity</strong></td> <td colspan=\"3\"> <ul> <li>A 50% reduction in ifosfamide dose is suggested for creatinine increase up to 1.5 times ULN during therapy, with treatment discontinuation for any increase &#62;1.5 times ULN.<sup>[8]</sup> In addition, for patients with a normal baseline serum creatinine level, reduce ifosfamide dose for a day 1 serum creatinine of 1.8 mg/dL or greater. </li> <li>Refer to UpToDate topic on \"Ifosfamide nephrotoxicity\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; LVEF: left ventricular ejection fraction; CBC: complete blood count; RBC: red blood cells; ULN: upper limit of normal.<br />* The ifosfamide dose (6000 or 9000 mg/m<SUP>2</SUP> per cycle) should be chosen based upon clinical judgment. While generally well tolerated, AIM chemotherapy may be associated with severe, potentially fatal neutropenia, thrombocytopenia, and anemia as well as nephrotoxicity and neurotoxicity. A lower dose of ifosfamide may be preferred for patients over the age of 60.<SUP>[2]</SUP><br />¶ If necessary, oral mesna may be used; however, oral mesna is not recommended for the initial dose.<SUP>[9]</SUP> If the oral route is chosen, patients should receive an initial IV dose of mesna (at 20% of the daily dose of ifosfamide) prior to the day 1 ifosfamide administration, followed by oral mesna tablets at 40% of the daily ifosfamide dose per dose, administered at two and six hours after the initiation of each dose of ifosfamide. This same dosing schedule is repeated on each day that ifosfamide is administered. The total daily mesna dose is 100% of the ifosfamide dose when the oral route is used. If patients vomit within two hours of taking a dose of mesna, they should repeat the dose or receive an IV dose of mesna.<SUP>[10]</SUP></div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Grobmyer SR, et al. Ann Oncol 2004; 15:1667.</li>&#xD;&#xA;    <li>Ifosfamide injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed January 3, 2012).</li>&#xD;&#xA;    <li>Durand JP, et al. Ann Oncol 2007; 18:808.</li>&#xD;&#xA;    <li>Jarkowski A. Am J Health-Syst Pharm 2008; 65:2229.</li>&#xD;&#xA;    <li>Howell JE, et al. J Oncol Pharm Practice 2008; 14:157.</li>&#xD;&#xA;    <li>Doxorubicin hydrochloride injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed January 3, 2012).</li>&#xD;&#xA;    <li>MESNA injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed January 3, 2012).</li>&#xD;&#xA;    <li>Worden FP, et al. J Clin Oncol 2005; 23:105.</li>&#xD;&#xA;    <li>Hensley ML, et al. J Clin Oncol 2009; 27:127.</li>&#xD;&#xA;    <li>Mesna tablets. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed January 3, 2012).</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 67985 Version 14.0</div></div></div>"},"67986":{"type":"graphic_table","displayName":"Mortality in acromegaly","title":"Survival determinants and causes of death in acromegaly","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Survival determinants and causes of death in acromegaly</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Survival determinants</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Last known GH level</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hypertension</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cardiac disease</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Diabetes mellitus</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Symptom duration</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Causes of death</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cardiovascular - 38 to 62 percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Respiratory - 0 to 25 percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Malignancy - 9 to 25 percent</td>\n\n    </tr>\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">4.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=15456&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Mortality_in_acromegaly.htm</title></head></div><div class=\"graphic_footnotes\">GH: growth hormone.</div><div id=\"graphicVersion\">Graphic 67986 Version 2.0</div></div></div>"},"67987":{"type":"graphic_picture","displayName":"Glycogen acanthosis Light","title":"Glycogen acanthosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Glycogen acanthosis</div><div class=\"cntnt\"><img style=\"width:360px; height:280px;\" src=\"images/GAST/67987_Glycogen_acanthosis_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Medium power view of a biopsy specimen from the upper and mid esophagus revealed glycogen filled squamous cells, known as glycogenic acanthosis, a benign condition with no clinical significance.</div><div class=\"graphic_reference\">Courtesy of Donald Antonioli, MD.</div><div id=\"graphicVersion\">Graphic 67987 Version 1.0</div></div></div>"},"67988":{"type":"graphic_picture","displayName":"Peutz Jeghers colonic polyp","title":"Peutz-Jeghers polyp","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Peutz-Jeghers polyp</div><div class=\"cntnt\"><img style=\"width:366px; height:283px;\" src=\"images/GAST/67988_Peutz_Jeghers_col_polyp_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gross picture of an intestinal polyp (arrow) removed from a patient with the Peutz-Jeghers syndrome.</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD.</div><div id=\"graphicVersion\">Graphic 67988 Version 3.0</div></div></div>"},"67990":{"type":"graphic_diagnosticimage","displayName":"Recurrent bc postmastectomy","title":"Recurrent breast cancer in post mastectomy patient","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Recurrent breast cancer in post mastectomy patient</div><div class=\"cntnt\"><img style=\"width:329px; height:582px;\" src=\"images/PC/67990_Recurrent_breast_cancer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CC and MLO views (Panels A and B) of a TRAM flap in a woman with a palpable lump. An irregular nodule with spiculated margins is seen in the lower inner quadrant of the reconstructed breast, corresponding to the palpable lump marked on the skin with a BB marker. Ultrasound (Panel C) shows a solid nodule at the area of clinical lump. The ill defined and angulated margins on ultrasound correspond to the spiculations on mammogram.</div><div class=\"graphic_footnotes\">CC: craniocaudal; MLO: mediolateral oblique; TRAM: transverse rectus abdominis myocutaneous.</div><div id=\"graphicVersion\">Graphic 67990 Version 2.0</div></div></div>"},"67991":{"type":"graphic_figure","displayName":"Diagram of laser components","title":"Diagram of laser components","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Diagram of laser components</div><div class=\"cntnt\"><img style=\"width:511px; height:284px;\" src=\"images/PULM/67991_Diagram_of_laser_components.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 67991 Version 2.0</div></div></div>"},"67993":{"type":"graphic_figure","displayName":"RB ILD versus IPF","title":"Symptoms and signs in RB-ILD versus IPF","html":"<div class=\"graphic\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Symptoms and signs in RB-ILD versus IPF</div><div class=\"cntnt\"><img style=\"width:519px; height:275px;\" src=\"images/PULM/67993_RB_ILD_versus_IPF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Clinical symptoms and signs at presentation in 18 patients with respiratory bronchiolitis-associated interstitial lung disease (RB-ILD) compared to 59 patients with idiopathic pulmonary fibrosis (IPF). Cough and dyspnea were the most common presenting symptoms in both patient groups. Rales were common findings on physical examination in RB-ILD, whereas clubbing was rarely seen.</div><div class=\"graphic_reference\">Redrawn from King, TE Jr, Mortenson, RL, Immunol Allergy Clin North Am 1992; 12:461.</div><div id=\"graphicVersion\">Graphic 67993 Version 1.0</div></div></div>"},"67994":{"type":"graphic_picture","displayName":"Ankle fracture complicated by complex regional pain syndrome","title":"Ankle fracture complicated by complex regional pain syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ankle fracture complicated by complex regional pain syndrome</div><div class=\"cntnt\"><img style=\"width:432px; height:332px;\" src=\"images/EM/67994_Ankle_frac_comp_CRPS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Early Complex Regional Pain Syndrome (CRPS) in a patient with a lateral avulsion fracture. The patient had been treated with weight bearing as tolerated in a walking cast boot. The patient presented with increased pain, swelling, warmth, and skin changes 23 days after the injury. He responded to gabapentin, early motion, tactile stimulation and sympathetic nerve blockade.</div><div class=\"graphic_reference\">Courtesy of Scott M Koehler, MD.</div><div id=\"graphicVersion\">Graphic 67994 Version 4.0</div></div></div>"},"67995":{"type":"graphic_picture","displayName":"Xanthrogranulomatous chol gross","title":"Xanthogranulomatous cholecystitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Xanthogranulomatous cholecystitis</div><div class=\"cntnt\"><img style=\"width:216px; height:330px;\" src=\"images/GAST/67995_Xanthrogranulomatous_chol_g.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Surgical specimen of a gallbladder with xanthogranulomatous cholecystitis showing extensive necrosis, fibrosis, and gallstones.</div><div class=\"graphic_reference\">Courtesy of Salam F Zakko, MD, FACP. </div><div id=\"graphicVersion\">Graphic 67995 Version 2.0</div></div></div>"},"67999":{"type":"graphic_picture","displayName":"MPGN Light I","title":"Membranoproliferative glomerulonephritis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Membranoproliferative glomerulonephritis</div><div class=\"cntnt\"><img style=\"width:378px; height:259px;\" src=\"images/NEPH/67999_MPGN_Light_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph in membranoproliferative glomerulonephritis showing a lobular appearance of the glomerular tuft with focal areas of increased glomerular cellularity (large arrows), mesangial expansion (*), narrowing of the capillary lumens, and diffuse thickening of the glomerular capillary walls (small arrows).</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 67999 Version 1.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal glomerulus</div><div class=\"cntnt\"><img style=\"width:396px; height:253px;\" src=\"images/NEPH/75094_Normal_glomerulus_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 75094 Version 4.0</div></div></div>"}};